quinazolines has been researched along with gefitinib in 4040 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1879 (46.51) | 29.6817 |
| 2010's | 2100 (51.98) | 24.3611 |
| 2020's | 61 (1.51) | 2.80 |
| Authors | Studies |
|---|---|
| Ciardiello, F | 1 |
| Averbuch, SD; Baselga, J | 1 |
| Chabner, BA; Ryan, PD | 1 |
| Kris, MG; Miller, VA; Scher, HI; Sirotnak, FM; Zakowski, MF | 1 |
| Adi Vago, N; Armand, JP; Faivre, S; Le Chevalier, T; Meric, JB; Monnerat, C; Raymond, E | 1 |
| Bundred, NJ; Chan, KC; Gandhi, A; Knox, WF; Potten, CS; Slamon, DJ | 1 |
| Solignac, M | 1 |
| Kinoshita, S; Nakamura, Y; Sotozono, C | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Cuccato, S; Damiano, V; De Placido, S; Fontanini, G; Tortora, G | 1 |
| Dane, A; Jones, H; Laight, A; Morris, C; Stafford, L; Swaisland, H; Yates, R | 1 |
| Kuwano, M; Ono, M | 2 |
| Nakagawa, K | 4 |
| Barrow, D; Dutkowski, CM; Gee, JM; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Pamment, J | 1 |
| Baselga, J; Mendelsohn, J | 2 |
| Dancey, JE; Schoenfeldt, M | 1 |
| Ashton, SE; Barker, AJ; Barlow, JJ; Curry, BJ; Gibson, KH; Godfrey, AA; Grundy, W; Healy, MP; Henthorn, L; Richards, L; Scarlett, L; Woodburn, JR | 1 |
| Klar, U; Lichtner, RB; Menrad, A; Schneider, MR; Sommer, A | 1 |
| Barton, J; Blackledge, G; Wakeling, A | 1 |
| Albanell, J; Anido, J; Baselga, J; Codony-Servat, J; Del Campo, JM; Giralt, J; Mendelsohn, J; Nicholson, RI; Raspall, G; Rojo, F; Roselló, J; Sauleda, S | 1 |
| Norman, P | 1 |
| Averbuch, SD; Basso, A; Moasser, MM; Rosen, N | 1 |
| Ciardiello, F; Tortora, G | 1 |
| Arteaga, CL; Johnson, DH | 2 |
| Harari, PM; Huang, SM | 1 |
| Albanell, J; Baselga, J; Rojo, F | 1 |
| Fry, DW; Slichenmyer, WJ | 1 |
| Ahmad, T; Anderson, NG; Bundred, NJ; Chan, K; Dobson, R | 1 |
| Arteaga, CL; Bianco, R; Moulder, SL; Muthuswamy, SK; Simpson, JF; Yakes, FM | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM; Zunino, F | 1 |
| Chan, E; Cherrington, JM; Christensen, JG; Cui, J; Liu, L; Mendel, DB; Schreck, RE; Sun, L; Wang, X; Wei, J; Yang, C | 1 |
| Albanell, J; Averbuch, S; Baselga, J; Feyereislova, A; Gee, J; Herbst, R; LoRusso, P; Mascaro, JM; Nicholson, RI; Rischin, D; Rojo, F; Sauleda, S | 1 |
| Arteaga, CL; Carter, MB; Chinratanalab, W | 1 |
| Bundred, NJ; Chan, KC; Gee, JM; Knox, WF; Morris, J; Nicholson, RI; Potten, CS | 1 |
| Ao, Y; Fukumoto, H; Kuroki, T; Mori, M; Naruse, I; Nishio, K; Ohmori, T; Saijo, N | 1 |
| Campiglio, M; Ciardiello, F; De, LA; Gianni, L; Maiello, M; Menard, S; Normanno, N; Salomon, DS; Somenzi, G | 1 |
| Baselga, J | 5 |
| Langdon, SP; Macleod, KG; Ritchie, A; Sewell, JM; Smyth, JF | 1 |
| Dubreuil, A; Fischel, JL; Formento, P; Lagrange, JL; Magné, N; Marcié, S; Milano, G | 1 |
| Bunn, PA; Chan, D; Helfrich, BA; Johnson, G; Raben, D | 1 |
| Bakanauskas, VJ; Bernhard, EJ; Cerniglia, GJ; Feldman, MD; Goldsmith, JD; Gupta, AK; Machtay, M; McKenna, WG; Mick, R; Muschel, RJ; Rosenthal, DI; Weber, CN; Weber, RS | 1 |
| Kobayashi, K | 2 |
| Tamura, T | 2 |
| Gee, JM; Nicholson, RI; Wakeling, AE | 1 |
| Bianco, AR; Biroccio, A; Borriello, G; Caputo, R; Ciardiello, F; Del Bufalo, D; Tortora, G; Zupi, G | 1 |
| Stratford, IJ; Telfer, BA; Wedge, SR; Williams, KJ | 1 |
| Hirata, A; Kometani, T; Kuwano, M; Kuwano, T; Naito, S; Ogawa, S; Ono, M | 1 |
| Averbuch, S; Ferry, D; Feyereislova, A; Hammond, LA; Kris, M; Miller, V; Morris, C; Murray, PI; Ochs, J; Ranson, M; Rowinsky, EK; Swaisland, H; Tullo, A | 1 |
| Dubreuil, A; Fischel, JL; Formento, P; Laurent-Puig, P; Magné, N; Milano, G; Poupon, MF | 1 |
| Fukuoka, M | 1 |
| Bunn, PA; Chan, DC; Chan, KK; Covey, JM; Feng, WY; Gera, L; Helfrich, B; Stewart, JM; Zhao, TL | 1 |
| Bundred, N; Gilmore, AP; Korsmeyer, SJ; O'Hare, MJ; Ranger, AM; Streuli, CH; Valentijn, AJ; Wakeling, A; Wang, P | 1 |
| Herbst, RS | 4 |
| Albanell, J; Baselga, J | 2 |
| Daud, A; Munster, P; Spriggs, DR | 1 |
| Jones, HK; Payne, R; Stafford, LE; Swaisland, HC | 1 |
| Sobel, RK | 1 |
| Erwin, CR; Kemp, CJ; Nelson, LA; O'Brien, DP; Warner, BW; Williams, JL | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| Kubota, K; Yoh, K | 1 |
| Kawate, N | 1 |
| Kudoh, S; Yamauchi, S | 1 |
| Jayson, G; Mansoor, W; Ranson, M | 1 |
| Fujimura, M; Hidaka, T; Saito, S | 1 |
| Fischer, DC; Gabriel, B; Kieback, DG | 1 |
| Wakeling, AE | 1 |
| Arteaga, CL; Moulder, SL; Yakes, FM | 1 |
| Armstrong, EA; Harari, PM; Huang, SM; Li, J | 1 |
| Sánchez De Cos Escuín, J | 1 |
| Herbst, RS; Kies, MS | 2 |
| Ranson, M | 1 |
| Natale, RB; Zaretsky, SL | 1 |
| Arteaga, CL | 2 |
| Giaccone, G; Kirtschig, G; Scheffer, E; Stoof, TJ; Van Doorn, R | 1 |
| Erwin, CR; Juno, RJ; Knott, AW; O'brien, DP; Warner, BW; Williams, JL | 1 |
| Averbuch, SD; Baselga, J; Herbst, RS; Hong, WK; LoRusso, PM; Maddox, AM; Ochs, J; Rojo, F; Rothenberg, ML; Rubin, EH; Small, EJ; Swaisland, H | 1 |
| Jänne, PA; Johnson, BE; Salgia, R; Taffaro, ML | 1 |
| Morris, C | 1 |
| Coll, JL; Dubrez, L; Favrot, MC; Hurbin, A | 1 |
| Wilkinson, E | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Fontanini, G; Pepe, S; Raben, D; Tortora, G; Troiani, T; Veneziani, BM | 1 |
| Culy, CR; Faulds, D | 1 |
| Ashton, SE; Barker, AJ; Curry, BJ; Gibson, KH; Guy, SP; Wakeling, AE; Woodburn, JR | 1 |
| Couzin, J | 2 |
| Rowinsky, EK; Takimoto, CH; Tolcher, AW | 1 |
| Albanell, J; Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Kaye, SB; Kieback, DG; Ranson, M; Raymond, E; Rischin, D; Rojo, F; Swaisland, H | 1 |
| Twombly, R | 3 |
| Baselga, J; Hammond, LA | 1 |
| Benson, AB; O'dwyer, PJ | 1 |
| Bunn, PA; Franklin, W | 1 |
| Archer, GE; Bigner, DD; Chewning, TA; Friedman, AH; Friedman, HS; Heimberger, AB; Learn, CA; McLendon, RE; Pracyk, JB; Sampson, JH; Tuck, FL | 1 |
| Garber, K | 3 |
| Baldwin, J | 1 |
| Castro, M | 1 |
| Burton, A | 1 |
| Chen, J; Lee, F; Scher, HI; She, Y; Sirotnak, FM | 1 |
| Chu, E; Copur, S; DeGrendele, HC; Jain, VK; Lee, D; Maung, K; Schilsky, R | 1 |
| Workman, P | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigues, S; Thim, L; Van Aken, E; Van Bocxlaer, S; Westley, BR | 1 |
| Ebina, M; Gomi, K; Inoue, A; Kikuchi, T; Kimura, Y; Maemondo, M; Moriya, T; Nukiwa, T; Saijo, Y; Tokue, Y | 1 |
| Thomas, M | 2 |
| Hynes, NE; Motoyama, AB | 1 |
| Fischman, J | 2 |
| Cullinane, C; Hagekyriakou, J; McArthur, GA; Solomon, B; Stacker, SA; Trivett, MK | 1 |
| Bianco, AR; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Tortora, G; Troiani, T; Veneziani, BM; Zangemeister-Wittke, U | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jones, HE; Knowlden, JM; Madden, T; Nicholson, RI; Wakeling, AE | 1 |
| Dummer, R; Follath, F; Jacky, E; Trojan, A | 1 |
| Abbruzzese, A; Avallone, A; Barbarino, M; Bruzzese, F; Budillon, A; Caponigro, F; Caraglia, M; Comella, P; De Lorenzo, S; Di Gennaro, E; Pepe, S | 1 |
| Cohen, RB | 1 |
| Glisson, BS | 1 |
| Arteaga, CL; Ritter, CA | 1 |
| Sirotnak, FM | 1 |
| Lorusso, PM | 1 |
| Cella, D | 1 |
| Schiller, JH | 2 |
| Bianco, C; Ciardiello, F; Harari, P; Helfrich, B; Raben, D; Weng, E | 1 |
| Mauer, AM; Villano, JL; Vokes, EE | 1 |
| Muguruma, H; Sone, S; Yano, S | 2 |
| Bianco, C; De Luca, A; Maiello, MR; Normanno, N; Salomon, DS | 1 |
| Fujiwara, K; Hamasaki, S; Kiura, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ranson, M; Thatcher, N | 1 |
| Lavelle, F | 1 |
| Albanell, J; Anido, J; Arribas, J; Averbuch, S; Baselga, J; Guzmán, M; Matar, P; Rojo, F | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM | 1 |
| Nakamura, M; Nakano, J | 1 |
| Schultz, J | 1 |
| Giaccone, G; Lobbezoo, MW; Van Kalken, C | 1 |
| Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; Hong, WK; Kumar, R; Mandal, M; Yang, Z | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Marronaro, A; Vicentini, C | 1 |
| Almqvist, Y; Carlsson, J; Sundberg, AL; Tolmachev, V | 1 |
| Dyer, O | 1 |
| Cohen, EE; Huo, D; Recant, W; Rosen, F; Stadler, WM; Stenson, K; Vokes, EE | 1 |
| Averbuch, S; Baselga, J; Dong, RP; Douillard, JY; Eek, R; Feyereislova, A; Fukuoka, M; Giaccone, G; Horai, T; Kudoh, S; Macleod, A; Nakagawa, K; Nishiwaki, Y; Noda, K; Rischin, D; Smit, E; Takata, I; Tamura, T; Vansteenkiste, J; Yano, S | 1 |
| Cyranoski, D | 1 |
| Carbone, D; Heelan, RT; Johnson, DH; Kris, MG; Krozely, P; Krug, LM; Miller, VA; Ochs, J; Perez, W; Pizzo, B; Sandler, A; Smith, R; Tyson, L | 1 |
| Androulakis, N; Bozionelou, V; Georgoulias, V; Kouroussis, C; Mavroudis, D; Pallis, AG; Souglakos, J; Vlachonikolis, IG | 1 |
| Fujii, K; Kihara, N; Kohrogi, H; Matsumoto, M; Okamoto, I; Suga, M; Terasaki, Y | 1 |
| Arteaga, CL; Barbieri, CE; Matheny, KE; Pietenpol, JA; Sniezek, JC | 1 |
| Daigo, Y; Hirata, K; Kakiuchi, S; Katagiri, T; Kikuchi, T; Nakamura, Y; Nishime, C; Ohnishi, Y; Zembutsu, H | 1 |
| Dong, RP; Fukuoka, M; Hirose, M; Kudoh, S; Nakagawa, K; Nakatani, I; Negoro, S; Swaisland, H; Takeda, K; Tamura, T; Yamamoto, N | 1 |
| Patrick-Miller, LJ | 1 |
| Blanco, Cdel V; Caputo, R; Ciardiello, F; Manzo, BA; Ricci, V; Romano, M; Tortora, G; Tuccillo, C; Zarrilli, R | 1 |
| Averbuch, SD; Baselga, J; Bjork, T; Calvert, H; Feyereislova, A; Gianni, L; Harris, A; Herbst, RS; Heyes, A; Kaye, S; Kieback, D; LoRusso, PM; Maddox, AM; Ochs, J; Ranson, M; Raymond, E; Rischin, D; Rothenberg, ML; Rubin, EH; Small, EJ | 1 |
| Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Ouchi, Y; Teramoto, S; Yamamoto, H | 1 |
| Hanajiri, K; Maruyama, T; Mitsui, H; Nakajima, J; Omata, M | 1 |
| Douglass, EC | 1 |
| Matsuo, M; Saiki, I; Sakurai, H | 1 |
| Grünwald, V; Hidalgo, M | 1 |
| Mitka, M | 1 |
| Aono, Y; Azuma, M; Kanematsu, T; Miki, T; Sone, S; Uehara, H; Yamamoto, A; Yano, S | 1 |
| Dufresne, A; Gainet, M; Guardiola, E; Pivot, X | 1 |
| Graham, J; Kirkpatrick, P; Muhsin, M | 1 |
| Seymour, L; Shepherd, FA; Sridhar, SS | 1 |
| Dancey, JE; Freidlin, B | 1 |
| Batist, G; Daneshmand, M; Goss, G; Hirte, HW; Lorimer, IA; Major, P; Matthews, S; Miller, WH; Parolin, DA; Seymour, L; Stewart, D | 1 |
| Bartolini, S; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, G; Crino, L; de Rosa, M; Gregorc, V; Lombardo, L; Magrini, E; Paties, CT; Rossi, E; Villa, E | 1 |
| Arteaga, CL; Moulder, SL | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L | 1 |
| Bunn, PA; Ciardiello, F; Helfrich, B; Raben, D | 1 |
| Johnson, DH | 1 |
| Ardizzoni, A; Bartolini, S; Calandri, C; Cappuzzo, F; Crinò, L; Gridelli, C; Maione, P; Santoro, A; Soto-Parra, H; Tiseo, M | 1 |
| Behnken, D; Govindan, R; McLeod, H; Read, W | 1 |
| Attoub, S; Bruyneel, E; Emami, S; Gespach, C; Mareel, M; May, FE; Nguyen, QD; Rodrigue, CM; Rodrigues, S; Thim, L; Westley, BR | 1 |
| Ieki, R; Saitoh, E; Shibuya, M | 1 |
| Avitto, FM; Beltrami, V; Cirolla, VA; Conte, S; Covotta, A; Covotta, L; Giarnieri, E; Luzzatto, L; Marino, G; Midiri, G; Vecchione, A | 1 |
| Kelly, K | 1 |
| Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Francoual, M; Magné, N; Milano, G; Renée, N; Tiffon, C | 1 |
| Goto, H; Hashimoto, E; Ieki, R; Iguchi, M; Moriyama, S; Ohta, T; Okamura, T; Saitoh, E; Shibuya, M; Yuasa, K | 1 |
| Chen, G; Cohen, MH; Pazdur, R; Sridhara, R; Williams, GA | 1 |
| Azzariti, A; Colucci, G; Lu, B; Paradiso, A; Severino, M; Xu, JM | 1 |
| Manegold, C | 1 |
| Brown, H | 1 |
| Chang, GC; Chiang, CD; Huang, CM; Wang, NS; Yang, TY | 1 |
| Genma, A; Kudo, S; Yoshimura, A | 1 |
| Almqvist, Y; Blomquist, E; Carlsson, J; Gedda, L; Jensen, HJ; Orlova, A; Sundberg, AL; Tolmachev, V | 1 |
| Gemma, A; Kudoh, S; Yoshimura, A | 1 |
| Gill, S; Goldberg, RM; Thomas, RR | 1 |
| Aoshiba, K; Nagai, A; Suzuki, H; Yokohori, N | 1 |
| Barrow, D; Gee, JM; Harper, ME; Hutcheson, IR; Jordan, N; Knowlden, JM; Madden, TA; McClelland, RA; Nicholson, RI; Wakeling, AE | 1 |
| George, SL | 1 |
| Azzariti, A; Colucci, G; Paradiso, A; Xu, JM | 1 |
| Herchenhorn, D; Rabinowits, G; Rabinowits, M; Torres, W; Weatge, D | 1 |
| Goya, T; Koshiishi, Y; Miya, T; Ono, Y; Tanaka, H | 1 |
| Chen, J; Haimovitz-Friedman, A; Kris, MG; Lee, F; Miller, VA; Rusch, VR; She, Y; Sirotnak, FM | 1 |
| Endo, H; Hida, T; Masuda, A; Mitsudomi, T; Nakagawa, T; Sugiura, T; Suzuki, T; Takahashi, T; Yatabe, Y | 1 |
| Hamakawa, H; Kayahara, H; Kiyota, A; Mihara, M; Nakashiro, K; Shintani, S; Sumida, T | 1 |
| Barrow, D; Gee, JM; Hutcheson, I; Knowlden, J; Madden, TA; McClelland, R; Nicholson, RI | 1 |
| Basso, A; Moasser, MM; She, QB; Solit, D | 1 |
| Liu, CY; Seen, S | 1 |
| Albain, KS; Averbuch, SD; Belani, CP; Cella, D; Herbst, RS; Kay, AC; Kelly, K; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JJ; Prager, D; Sandler, A; Schiller, JH; Spiridonidis, H; Wolf, MK | 1 |
| Dainichi, T; Furue, M; Noda, K; Tanaka, M; Tsuruta, N | 1 |
| Yamada, K; Yamaguchi, S; Yamamura, T | 1 |
| Bacik, J; Drucker, B; Ginsberg, M; Marion, S; Mazumdar, M; Motzer, R; Russo, P | 1 |
| Ciccolini, J; Dubreuil, A; Etienne, MC; Fischel, JL; Formento, JL; Formento, P; Magné, N; Marchetti, S; Milano, G; Renée, N; Tiffon, C | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Mottolese, M; Vocaturo, A | 1 |
| Gerst, B; Höpfner, M; Scherübl, H; Sutter, AP; Zeitz, M | 1 |
| Ahmad, T; Anderson, NG; Bundred, NJ; Farnie, G | 1 |
| DeGrendele, H | 1 |
| Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S; Terakado, N; Yano, J | 2 |
| Campiglio, M; Fumagalli, M; Gianni, L; Locatelli, A; Ménard, S; Normanno, N; Olgiati, C; Somenzi, G; Viganò, L | 1 |
| Okamoto, I; Suga, M | 1 |
| Hamakawa, H; Li, C; Mihara, M; Nakashiro, K; Shintani, S | 1 |
| Blackledge, G | 1 |
| Chang, CM; Li, B; McKenna, WG; Shu, HK; Yuan, M | 1 |
| Castaldo, V; Gridelli, C; Maione, P; Rossi, A | 1 |
| Maruyama, S; Sukegawa, Y; Yagita, A | 1 |
| Goldman, B | 1 |
| Calvo, F; Ma, L; Menashi, S; Mourah, S; Serova, M; Vignot, S | 1 |
| Basso, A; Chung, EJ; Jung, YJ; Neckers, L; Rosen, N; Trepel, J; Xu, W; Yang, Y; Yuan, X | 1 |
| Ahmed Rasheed, BK; Bigner, DD; Dancey, JE; Dowell, JM; Friedman, AH; Friedman, HS; Herndon, JE; Kao, JC; McLendon, RE; Peery, T; Penne, KL; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Stenzel, TT; Tourt-Uhlig, SE; Van Duyn, LB; Vredenburgh, JJ; Wikstrand, CJ | 1 |
| Dong, RP; Yamaguchi, M; Yano, S | 1 |
| Averbuch, SD | 1 |
| Natale, RB | 3 |
| Hammond, LA | 1 |
| Sandler, AB | 3 |
| Khuri, FR | 1 |
| Ambrad, AA; Carey, S; Falsey, R; Glanzberg, H; Kislin, K; Martinez, JD; Meuillet, EJ; Patel, J; Stea, B | 1 |
| Fayette, J; Soria, JC | 1 |
| Kanzawa, F; Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T; Tsukiyama, S; Ueda, Y | 1 |
| Shiotsu, Y | 1 |
| Giaccone, G; Janmaat, ML | 1 |
| Cortes-Funes, H; Soto Parra, H | 1 |
| van Zandwijk, N | 1 |
| Katz, A; Zalewski, P | 1 |
| Bernardo, MM; de Braud, F; Gridelli, C; Kosimidis, P; Parra, HS; Petruzelka, L; Rossi, A; Souquet, PJ; Stahel, R | 1 |
| Ciardiello, F; De Placido, S; De Vita, F; Orditura, M; Tortora, G | 1 |
| Janas, M; Renee Bailey, L | 1 |
| Miller, VA; Shah, NT | 1 |
| Bunn, PA; Herbst, RS | 1 |
| Alloisio, M; Campagnoli, E; Cavina, R; Ferrari, B; Ginanni, V; Latteri, F; Morenghi, E; Pedicini, V; Ravasi, G; Roncalli, M; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Asai Go, Go; Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Nogami, T; Tamura, K; Uejima, H | 1 |
| Konecny, GE; Slamon, DJ; Wilson, CA | 1 |
| Randal, J | 1 |
| Brown, PH; Celestino, J; Hill, J; Hilsenbeck, S; Kim, H; Lu, C; Mohsin, SK; Osborne, CK; Shen, Q; Speers, C; Steinbis, E; Wakeling, A; Xu, X; Zhang, Y | 1 |
| Gatzemeier, U | 1 |
| Pérez-Soler, R | 3 |
| Fan, QW; Goldenberg, DD; Shokat, KM; Specht, KM; Weiss, WA; Zhang, C | 1 |
| Bartolini, S; Calandri, C; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Lombardo, L; Spreafico, A; Tamberi, S; Toschi, L; Villa, E | 1 |
| Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Mikami, O; Tsukagoshi, S | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Sumitomo, M | 1 |
| Jones, S | 1 |
| Bonomi, PD | 1 |
| Kurebayashi, J; Okubo, S; Sonoo, H; Yamamoto, Y | 1 |
| Vansteenkiste, J | 1 |
| Nakata, H; Ohsaki, Y; Tuji, T | 1 |
| Kris, MG; Miller, VA; Pao, W | 1 |
| Hussar, DA | 1 |
| Gray, ML; Khan, S; Zimmerman, R | 1 |
| Adam, L; Bagheri-Yarmand, R; Barnes, CJ; Clayman, GL; El-Naggar, A; Hong, WK; Kumar, R; Lotan, R; Papadimitrakopoulou, VV; Wang, RA; Yang, Z | 1 |
| Asakuma, J; Asano, T; Hayakawa, M; Horiguchi, A; Sumitomo, M | 1 |
| Averbuch, S; Blackledge, G | 1 |
| Azria, D; Culine, S; Dubois, JB; Larbouret, C; Pèlegrin, A; Robert, B; Verrelle, P; Ychou, M | 1 |
| Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J | 1 |
| Adenis, A; Peyrat, JP | 1 |
| Fayette, J; Le Chevalier, T; Soria, JC | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Kita, T; Nakao, S; Yoshimoto, A | 1 |
| Haraguchi, N; Kikuchi, N; Kodama, T; Satoh, H; Sekizawa, K | 1 |
| Belani, CP; Ramalingam, S | 2 |
| Ochs, JS | 1 |
| Langer, CJ | 2 |
| Dancey, J | 1 |
| Abraham, S; Baird, A; Chen, G; Cohen, MH; Liang, C; Lostritto, R; McGuinn, WD; Morse, D; Pazdur, R; Rahman, A; Sridhara, R; Williams, GA | 1 |
| Glover, KY; Papadimitradopoulou, VA; Perez-Soler, R | 1 |
| Averbuch, S; Kelly, K | 1 |
| España, A; Fernandez-Galar, M; López-Picazo, JM | 1 |
| Averbuch, SD; Fandi, A; Gatzemeier, U; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Pluzanska, A; Rennie, P; Rosell, R; Scagliotti, G; Schiller, JH; Von Pawel, J; Wolf, MK | 1 |
| Averbuch, SD; Fandi, A; Giaccone, G; Grous, J; Herbst, RS; Johnson, DH; Krebs, AD; Manegold, C; Miller, V; Natale, RB; Ochs, JS; Oliff, I; Reeves, JA; Rosell, R; Scagliotti, G; Schiller, JH; Wolf, MK | 1 |
| Benowitz, S | 1 |
| Hasegawa, S; Ishibashi, O; Kambayashi, T; Tanaka, F; Wada, H; Yanagihara, K | 1 |
| Aulmann, S; Bastert, G; Koehler, M; Kolay, S; Schneeweiss, A; Torode, J; Von Minckwitz, G | 1 |
| Azzoli, C; Ben-Porat, L; Gomez, J; Heelan, RT; Kris, MG; Krug, LM; Memoli, N; Miller, VA; Pao, W; Patel, J; Pizzo, B; Rizvi, N; Rusch, V; Shah, N; Tyson, L; Venkatraman, E; Zakowski, M | 1 |
| Chansel, D; Chatziantoniou, C; Dussaule, JC; Flamant, M; François, H; Placier, S; Tharaux, PL | 1 |
| Choi, JH; Kim, SW; Koh, JK; Lee, HW; Lee, MW; Moon, KC; Seo, CW; Yang, HJ | 1 |
| Kim, R; Toge, T | 1 |
| Arteaga, CL; Truica, CI | 1 |
| Shimizu, E | 1 |
| Caponigro, F | 1 |
| Grandis, JR; Thomas, SM | 1 |
| Ranson, M; Wardell, S | 1 |
| Ardizzoni, A; Tiseo, M | 1 |
| Griffiths, TR; Kriajevska, M; McHugh, LA; Mellon, JK; Symonds, RP | 1 |
| Bally, MB; Chia, S; Denyssevych, T; Dragowska, WH; Gelmon, K; Masin, D; Wallis, AE; Warburton, C; Yan, H | 1 |
| Fujii, T; Hirata, A; Kinoshita, H; Kometani, T; Kuwano, M; Miyagawa, M; Ono, M; Ueda, S | 1 |
| Lazarowicz, HP; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Fidias, P; Gurubhagavatula, S; Jänne, PA; Johnson, BE; Lucca, J; Lynch, TJ; Ostler, P; Skarin, AT; Yeap, BY | 1 |
| Hu, B; Wei, YQ | 1 |
| Krozely, P | 1 |
| Baas, P; Haringhuizen, A; Vaessen, HF; van Tinteren, H; van Zandwijk, N | 1 |
| Alfonso, R; Averbuch, S; Fandi, A; Giaccone, G; González-Larriba, JL; Martens, M; Peters, GJ; Smit, EF; Smith, R; van der Vijgh, WJ; van Oosterom, AT | 1 |
| Ono, M | 1 |
| Hayakawa, Y | 1 |
| Fukuoka, M; Horai, T; Imamura, F; Katakami, N; Kiura, K; Kudoh, S; Matsui, K; Nakagawa, K; Nishiwaki, Y; Noda, K; Saka, H; Sawa, Y; Sugiura, T; Takada, M; Takata, I; Takeda, K; Tamura, T; Uchida, H; Watanabe, K; Yano, S; Yokoyama, A | 1 |
| Green, MR | 1 |
| Bell, DW; Brannigan, BW; Christiani, DC; Gurubhagavatula, S; Haber, DA; Haluska, FG; Harris, PL; Haserlat, SM; Louis, DN; Lynch, TJ; Okimoto, RA; Settleman, J; Sordella, R; Supko, JG | 1 |
| Boggon, TJ; Eck, MJ; Fujii, Y; Gabriel, S; Greulich, H; Herman, P; Jänne, PA; Johnson, BE; Kaye, FJ; Lee, JC; Lindeman, N; Meyerson, M; Naoki, K; Paez, JG; Sasaki, H; Sellers, WR; Tracy, S | 1 |
| Marx, J | 1 |
| Campiglio, M; Ménard, S; Normanno, N | 1 |
| Hao, LH; Li, X; Li, Y; Xu, JM; Yuan, SJ; Zhao, QC; Zhu, BD | 1 |
| Archer, GE; Bigner, DD; Friedman, AH; Friedman, HS; Hartzell, TL; Learn, CA; Rich, JN; Sampson, JH; Wikstrand, CJ | 1 |
| Damjanov, N; Meropol, NJ | 1 |
| Kawashima, H; Kurisu, T; Nakatani, T; Sugimura, K; Sugita, S; Tanaka, T | 1 |
| Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Zhang, L | 1 |
| Choy, H; Kim, DW | 1 |
| Campiglio, M; Di Maio, M; Normanno, N; Perrone, F | 1 |
| Dancey, JE | 2 |
| Marmé, D | 1 |
| Cersosimo, RJ | 2 |
| Broxterman, HJ; Georgopapadakou, NH | 1 |
| Siegfried, JM; Stabile, LP | 1 |
| Argiris, A; Mittal, N | 1 |
| Congleton, J; Harper-Wynne, C; O'Brien, M; Sumpter, K | 1 |
| Ebihara, S; Ohrui, T; Sasaki, H; Takahashi, H; Yamada, M | 1 |
| Abe, S; Inomata, S; Nagata, M; Saitoh, T; Sato, T; Satoh, M; Shiratori, M; Takahashi, H; Tanaka, H; Yamada, G | 1 |
| Chabner, BA | 1 |
| Baker, M | 1 |
| Cavanaugh, SX; Hammond, LA; Thomas, CR | 1 |
| Gazdar, AF; Herz, J; Minna, JD; Sprang, SR | 1 |
| Nukiwa, T | 2 |
| Azzariti, A; Paradiso, A; Porcelli, L; Xu, JM | 1 |
| Campagnoli, E; Cavina, R; Grimaldi, GC; Latteri, F; Morenghi, E; Parra, HS; Roncalli, M; Santoro, A; Zucali, PA | 1 |
| Kodama, T; Kunitoh, H; Kusumoto, M; Nokihara, H; Ohe, Y; Saijo, N; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Yamamoto, N; Yamamoto, S | 1 |
| Igarashi, T; Imamura, F; Nakamura, S; Ueno, K; Yamamoto, S; Yoshimura, M | 1 |
| Hasegawa, Y; Kumasaka, R; Nakamura, M; Nakamura, N; Okumura, K; Osawa, H; Shirato, K; Takanashi, S; Tamura, M; Yamabe, H | 1 |
| Blagosklonny, MV | 1 |
| Hayes, DF | 1 |
| Ali, S; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Wakeling, AE; Weiss, H | 1 |
| Büchler, MW; Friess, H; Giese, N; Kleeff, J; Korc, M; Li, J | 1 |
| Castillo, L; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Magné, N; Milano, G | 1 |
| Bartolini, S; Cappuzzo, F; Ceresoli, GL; Crinò, L; Gregorc, V; Villa, E | 1 |
| Purdom, M | 1 |
| Belani, CP | 1 |
| Chansky, K; Crowley, J; Davies, AM; Franklin, WA; Gandara, DR; Gumerlock, PH; Hirsch, FR; Lau, DH; West, H | 1 |
| Giaccone, G | 3 |
| Capriotti, T | 1 |
| Aderka, D; Levitt, ML; Pfeffer, MR | 1 |
| Hirano, A; Kawata, N; Kimura, G; Okada, C; Shibayama, T; Soda, R; Tada, A; Takahashi, K; Takigawa, N; Yamadori, I | 1 |
| Futreal, PA; Stratton, MR | 1 |
| El-Rayes, BF; LoRusso, PM | 1 |
| Golsteyn, RM | 2 |
| Im, YH; Jung, CW; Kang, WK; Kim, HY; Kim, JH; Kim, JY; Kim, K; Lee, KE; Lee, MH; Lee, SH; Lee, SI; Park, BB; Park, J; Park, JO; Park, K; Park, SH; Park, YS | 1 |
| Hirata, A; Izumi, K; Kuwano, M; Naito, S; Ono, M; Uehara, H | 1 |
| Behnken, D; Coplin, MA; Gao, F; Govindan, R; Kommareddy, A; Read, W; Romvari, E | 1 |
| Druker, BJ | 1 |
| Figg, WD; Price, DK | 1 |
| Baldi, E; Bonaccorsi, L; Forti, G; Marchiani, S; Muratori, M | 1 |
| Bayle, S; Daniel, C; Descourt, R; Gouva, S; Robinet, G | 1 |
| McNeil, C | 1 |
| Cheng, ZW; Gao, JM; Zhang, L | 1 |
| Li, LY; Wang, SL; Zhang, XT | 1 |
| Averbuch, S; Swaisland, H; Wolf, M | 1 |
| Agrawal, S; Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Ficorella, C; Tortora, G | 1 |
| Davies, BR; Dominguez-Escrig, JL; Kelly, JD; King, SM; Neal, DE | 1 |
| Eccles, SA; Harrington, KJ; Nutting, CM; Rogers, SJ | 1 |
| Bessis, D; Fabbro, M; Guillot, B; Jacot, W; Jorda, E; Pujol, JL; Ychou, M | 1 |
| Ardito, R; Bianchino, G; Boninsegna, A; Camerini, A; Cittadini, A; Faraglia, B; Sgambato, A; Spada, D; Valentini, V | 1 |
| Uehara, Y | 1 |
| Akiyama, S | 2 |
| Nishio, K | 1 |
| Bell, DW; Haber, DA; Settleman, J; Sordella, R | 1 |
| Armstrong, EA; Benavente, S; Chinnaiyan, P; Harari, PM; Huang, S | 1 |
| Alimonti, A; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Martinelli, E; Matar, P; Milella, M; Papaldo, P | 1 |
| Fujiwara, M; Ishikawa, H; Nakayama, M; Ohtsuka, M; Satoh, H; Sekizawa, K | 1 |
| Kris, MG; Miller, VA; Pao, W; Venkatraman, E | 1 |
| Bartolini, S; Bellezza, G; Calandri, C; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crinò, L; Damiani, S; Gregorc, V; Ligorio, C; Lombardo, L; Ludovini, V; Magrini, E; Paties, CT; Rossi, E; Spreafico, A; Tonato, M | 1 |
| Bianco, AR; Bianco, C; Bianco, R; Bunn, P; Ciardiello, F; Cionini, L; D'Armiento, FP; Damiano, V; Melisi, D; Mignogna, C; Raben, D; Tortora, G | 1 |
| Li, LY; Mu, XL; Wang, MZ; Wang, SL; Zhang, XT | 2 |
| Doherty, J; Fulton, L; Heelan, R; Kris, M; Kupfer, D; Mardis, E; Miller, V; Pao, W; Politi, K; Rusch, V; Sarkaria, I; Singh, B; Varmus, H; Wilson, R; Zakowski, M | 1 |
| Amano, H; Hoshi, S; Kono, C; Yamada, Y; Yamaguchi, T | 1 |
| Bamias, A; Efstathiou, E; Stratigos, A; Zorzou, MP | 1 |
| Camus, P; Ebina, M; Kudoh, S | 1 |
| Sipp, D | 1 |
| Chang, GC; Chen, CY; Hsu, SL; Liang, FP; Lin, SY; Sheu, GT; Tsai, JR | 1 |
| Pizzo, B | 1 |
| Chen, Z; Grandis, JR; Li, M; Shin, DM; Wang, Z; Wieand, HS; Zhang, X | 1 |
| Hosoi, H; Iehara, T; Kita, M; Kuroda, H; Kuwahara, Y; Osone, S; Sugimoto, T | 1 |
| Vastag, B | 1 |
| Asada, S; Imai, Y; Ishikawa, E; Sugimoto, Y; Tsukahara, S; Yanase, K | 1 |
| Sorscher, SM | 1 |
| Longo, L; Marchioni, A; Rossi, G | 1 |
| Rasheed, BK; Rich, JN; Yan, H | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, NK; Kim, TY; Kim, YT | 1 |
| Barrow, D; Dutkowskil, C; Hiscox, S; Morgan, L; Nicholson, RI; Wakeling, A | 1 |
| Depreux, P; Hénichart, JP; Jouy, N; Mimeault, M | 1 |
| Zhang, L | 1 |
| Bencardino, KB; Cappuzzo, F; Ceresoli, GL; Crinò, L; Ferraldeschi, M; Floriani, I; Gregorc, V; Ludovini, V; Mihaylova, Z; Pistola, L; Spreafico, A; Tofanetti, FR; Tonato, M; Torri, V; Villa, E | 1 |
| del Giglio, A; Ito, C | 1 |
| Barthorpe, A; Bignell, G; Blow, M; Brackenbury, L; Brasseur, F; Butler, A; Chenevix-Trench, G; Clarke, O; Cole, J; Cooper, CS; Davies, H; Dicks, E; Dike, A; Drozd, A; Edkins, S; Edwards, K; Flanagan, AM; Forbes, S; Foster, R; Futreal, PA; Goldstraw, P; Gray, K; Greenman, C; Halliday, K; Harris, G; Hills, K; Hunter, C; Knowles, M; Kosmidou, V; Leung, SY; Looijenga, LH; Louis, DN; Lugg, R; Malkowicz, B; Menzies, A; Nicholson, AG; O'Meara, S; Parker, A; Perry, J; Petty, R; Pierotti, MA; Raine, K; Ratford, L; Shepherd, R; Small, A; Smith, R; Stephens, P; Stephens, Y; Stevens, C; Stratton, MR; Teague, J; Teh, B; Tofts, C; Varian, J; Weber, BL; West, S; Widaa, S; Wooster, R; Yates, A; Yuen, ST | 1 |
| Ishida, A; Iwamoto, Y; Kanoh, K; Kohno, N; Miyazawa, T; Miyazu, Y; Nishisaka, T | 1 |
| Fukuoka, M; Kaneda, H; Kurata, T; Nakagawa, K; Tamura, K; Uejima, H | 1 |
| Fujiwara, K; Hisamoto, A; Hotta, K; Kiura, K; Kozuki, T; Okada, T; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Caplin, M; Friedmann, B; Hartley, JA; Hochhauser, D | 1 |
| Arribas, J; Baselga, J; Cassia, R; Di Cosimo, S; Guzmán, M; Matar, P; Moreno-Bueno, G; Palacios, J; Rodriguez, S; Rojo, F; Tabernero, J | 1 |
| Ito, M; Iwasaki, T; Kawamura, S; Kijima, T; Kimura, H; Maeda, H; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Okumura, Y; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Easthope, SE; Frampton, JE | 2 |
| Ginsburg, GS; Hortobagyi, GN; Linette, GP; Pietrusko, R; Pusztai, L; Rolfe, M; Ross, JS; Schenkein, DP; Stagliano, NE; Stec, J; Symmans, WF | 1 |
| Hansen, M; Jänne, PA; Johnson, BE; Meyerson, M; Mukohara, T; Tracy, S | 1 |
| Cheshire, PJ; Daw, N; Germain, GS; Gilbertson, R; Harwood, FC; Houghton, PJ; Jenkins, JJ; Leggas, M; Panetta, JC; Peterson, J; Schuetz, JD; Stewart, CF | 1 |
| Kikuchi, K; Nakanishi, K; Ohsaki, Y; Tanno, S; Toyoshima, E | 1 |
| Kang, JH; Kuh, HJ; Lee, SH; Nishio, K; Park, JK; Saijo, N | 1 |
| Daigo, Y; Fukuoka, M; Furukawa, C; Ishikawa, N; Kakiuchi, S; Kohno, N; Nakagawa, K; Nakamura, Y; Sone, S; Tsunoda, T; Tsuruo, T; Yano, S | 1 |
| Bando, M; Hosono, T; Nakazawa, S; Ohno, S; Oshikawa, K; Sohara, Y; Sugiyama, Y | 1 |
| Lyle, J | 1 |
| Saeed, M | 1 |
| Bronk, SF; Gores, GJ; Gwak, GY; Lee, HS; Werneburg, NW; Yoon, JH | 1 |
| Chang, GC; Chen, KC; Hsu, JY; Kuo, BI; Lin, CP; Yang, TY; Yin, MC | 1 |
| Goto, K; Ishii, G; Kim, YH; Kodama, T; Nagai, K; Nishiwaki, Y; Nitadori, J; Ochiai, A; Shiono, S; Tsuta, K | 1 |
| Senior, K | 1 |
| Fujimoto, N; Fujiwara, K; Hamazaki, S; Kiura, K; Kozuki, T; Mizobuchi, K; Shiomi, K; Tabata, M; Tanimoto, M; Ueoka, H | 1 |
| Ho, SS; Mok, TS; Poon, AN; Yeo, W | 1 |
| Settleman, J | 1 |
| Bañuls, J; Belinchon, I; Blanes, M; Massuti, B; Pascual, JC | 1 |
| Chang, GC; Chen, KC; Lin, YC; Wang, RC; Yang, TY; Yin, MC | 1 |
| Defrance, R; Favaudon, V; Giocanti, N; Hennequin, C; Rouillard, D | 1 |
| Antonaci, S; Azzariti, A; Fransvea, E; Giannelli, G; Paradiso, A; Porcelli, L | 1 |
| Ando, Y; Nagashima, F; Narabayashi, M; Ohyanagi, F; Sasaki, Y | 1 |
| Faulkner, K; Forsythe, B | 1 |
| Adjei, A; Belani, CP | 1 |
| Ben-Porat, L; Heelan, RT; Heinemann, MH; Kris, MG; Miller, VA; Pao, W; Pizzo, BM; Sachs, DL; Shah, NT; Tyson, LB | 1 |
| Feinstein, MB; Gomez, JE; Kris, MG; Milton, DT | 1 |
| Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P | 1 |
| Guan, ZZ; Jiang, WQ; Lin, TY; Wang, SS; Xiang, YQ; Zhang, L | 1 |
| Cole, IE; Gallagher, RM; Kalish, LH; Kwong, RA; Musgrove, EA; Sutherland, RL | 1 |
| Dennis, PA; Tsurutani, J | 1 |
| Baselga, J; Fukuoka, M; Herbst, RS | 1 |
| Höpfner, M; Huether, A; Scherübl, H; Schuppan, D; Sutter, AP; Zeitz, M | 1 |
| Von Pawel, J | 1 |
| Nakanishi, Y | 2 |
| Dawson, NA; Dorsey, B; Guo, C; Hussain, A; Smoot, J; Wong, J; Zak, R | 1 |
| Koh, Y; Koizumi, F; Nishio, K; Saijo, N; Taguchi, F; Tamura, T | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Kleisbauer, JP; Tchouhadjian, C; Torre, JP | 1 |
| Bailey, C; Cantarini, MV; Marshall, AL; McFarquhar, T; Smith, RP | 1 |
| Chen, YM; Chiang, SC; Chiu, CH; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Arao, T; Fukumoto, H; Nishio, K; Saijo, N; Takeda, M; Tamura, T | 1 |
| Amador, ML; Ashfaq, R; Baker, SD; Cusati, G; Cusatis, G; Forastiere, A; Hidalgo, M; Iacobuzio-Donahue, C; Maitra, A; Oppenheimer, D; Perea, S; Takimoto, C | 1 |
| Aoe, M; Doihara, H; Hara, H; Ishibe, Y; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Teramoto, J; Yoshitomi, S | 1 |
| Alfaro, V; Tanović, A | 1 |
| Birnbaum, A; Ready, N | 1 |
| Bryant, JA; Charles, AC; Cloughesy, TF; Finn, RS; Slamon, DJ | 1 |
| Clarke, NW; Hendry, JH; Maddineni, SB; Margison, GP; Sangar, VK | 1 |
| Bowman, R; Fong, KM | 1 |
| Harari, PM | 1 |
| Barrow, D; Gee, JM; Goddard, L; Hiscox, S; Jones, HE; Knowlden, JM; Nicholson, RI; Rubini, M; Wakeling, AE; Williams, S | 1 |
| Carpentier, AF | 1 |
| Cadranel, J; Madelaine, J; Zalcman, G | 1 |
| Blandin, S; Gérinière, L; Girard, N; Perrot, E; Souquet, PJ | 1 |
| Chang, WC; Chen, YR; Chen, YT; Fu, YN; Huang, SF; Ku, YC; Kuo, HP; Li, LH; Lin, YF; Liu, HP; Tsai, HY; Tsai, SF; Wu, YC | 1 |
| Barnard, GF; Inoue, H; Ishii, H; Ishikawa, K; Mimori, K; Mori, M; Ohta, M; Utsunomiya, T; Yamashita, K; Yoshinaga, K | 1 |
| Brave, S; Kendrew, J; Stratford, IJ; Telfer, BA; Wedge, SR; Whittaker, L; Williams, KJ | 1 |
| Bekele, BN; Doan, D; El-Naggar, AK; Holsinger, FC; Jasser, SA; Kim, S; Mandal, M; McMurphy, AB; Myers, JN; Schiff, BA; Sherman, SI; Yeung, SC; Yigitbasi, OG; Younes, MN; Zhou, G | 1 |
| Arnheim, K | 2 |
| Barber, TD; Kinzler, KW; Velculescu, VE; Vogelstein, B | 1 |
| Cho, D; Halmos, B; Janne, PA; Kocher, O; Lee, JC; Meyerson, ML; Tenen, DG | 1 |
| Hoang-Xuan, K; Sanson, M; Thillet, J | 1 |
| Patel, JD | 1 |
| Bremer, E; de Leij, LF; Dijkstra, MH; Helfrich, W; Kroesen, BJ; Samplonius, DF; van Genne, L | 1 |
| Baldi, E; Bonaccorsi, L; Carloni, V; Forti, G; Marchiani, S; Muratori, M | 1 |
| Hansen, FD; Nexø, E; Sørensen, BS; Tørring, N; Ørntoft, TF | 1 |
| Bostrom, B; Drehner, D; Lander, T; Marker, S; Sidman, J | 1 |
| Bakoyannis, C; Briasoulis, E; Dimopoulos, M; Efstathiou, H; Fountzilas, G; Kopterides, P; Kosmidis, P; Lambropoulos, S; Makatsoris, T; Papadopoulos, S; Pectasides, D; Razis, E; Rigatos, S; Skarlos, D; Tzamakou, E; Varthalitis, G | 1 |
| Baetz, T; Berry, S; Brundage, M; Canil, CM; Chi, KN; Douglas, L; Ernst, DS; Fisher, B; McKenna, A; Moore, MJ; Pollak, M; Seymour, L; Winquist, E | 1 |
| Barbu, V; Cacheux, W; Clergue, F; Desbois-Mouthon, C; Housset, C; Poupon, R; Rey, C; Rosmorduc, O; Schiffer, E; Wendum, D | 1 |
| Carminati, O; De Giorgi, U; Kopf, B; Marangolo, M; Rosti, G; Zago, S | 1 |
| Akita, H | 1 |
| Aikawa, A; Hanawa, Y; Hashizume, M; Itou, S; Katou, K; Kidokoro, T; Kimura, B; Okano, Y; Takano, T; Takaoka, K; Tokimitsu, S; Uchikado, M; Yagi, M; Yamagishi, M | 1 |
| Favaudon, V; Hennequin, C | 1 |
| Curigliano, G; De Braud, F; De Pas, T; Dodaro, L; Manzoni, S; Noberasco, C; Pelosi, G; Spaggiari, L | 1 |
| Normanno, N | 1 |
| Vanchieri, C | 1 |
| Bristow, E; Esmaeli, B; Faulkner, K; Forsythe, BJ; Murray, PI; Tullo, AB | 1 |
| Attard, G; De Bono, J; Kaye, S; Vidal, L | 1 |
| Endo, K; Hirabayashi, M; Kurokawa, I | 1 |
| Beex, L; Come, SE; Jones, SE; Kaufmann, M; Makris, A; Nortier, JW; Possinger, K; Robertson, JF; Rutqvist, LE | 1 |
| Singer, E | 1 |
| du Bois, A; Eiermann, W; Fasching, P; Hilfrich, J; Jonat, W; Kettner, E; Kleeberg, U; Lück, HJ; Schneeweiss, A; Torode, J; von Minckwitz, G | 1 |
| Belani, C; Price, N | 1 |
| Blencke, S; Brehmer, D; Cotten, M; Daub, H; Godl, K; Greff, Z; Kéri, G; Klebl, B; Kurtenbach, A; Müller, S; Weber, M; Wissing, J | 1 |
| Heelan, RT; Kris, MG; Ladanyi, M; Miller, VA; Pan, Q; Pao, W; Riely, GJ; Varmus, HE; Wang, TY; Zakowski, MF | 1 |
| Belani, CP; Cella, D; Herbst, RS; Heyes, A; Kay, AC; Kris, MG; Lynch, TJ; Natale, RB; Ochs, JS; Prager, D; Schiller, JH; Wolf, MK | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Boyer, M; Clarke, S; Millward, M; Sharma, R | 1 |
| Aoe, M; Date, H; Gazdar, AF; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, N; Tabata, M; Tanimoto, M; Tokumo, M; Tomii, K; Toyooka, S; Tsuda, T; Tsukuda, K; Ueoka, H; Yano, M | 1 |
| Bang, YJ; Choi, IS; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeong, S; Kim, DW; Kim, J; Kim, JH; Kim, NK; Kim, TY; Kim, YT; Lee, JS; Oh, DY | 1 |
| Castaldo, V; Del Gaizo, F; Gridelli, C; Guerriero, C; Maione, P; Rossi, A | 1 |
| Kishida, O; Kiyohara, T; Miyazaki, T; Miyazaki, Y; Murayama, Y; Ogasa, M; Shimomura, I; Shinomura, Y; Tsutsui, S; Watabe, K; Yamamoto, T | 2 |
| Berlin, JD; Lockhart, AC; Lockhart, C | 1 |
| Belani, CP; Gooding, W; Lin, Y; Mohamed, MK; Ramalingam, S | 1 |
| Boggon, TJ; Dayaram, T; Eck, MJ; Halmos, B; Jänne, PA; Johnson, BE; Kobayashi, S; Kocher, O; Meyerson, M; Tenen, DG | 1 |
| Dowell, JE; Minna, JD | 3 |
| Matsuo, K; Tanimoto, M; Uchida, A | 1 |
| Cantley, LC; Cichowski, K; Engelman, JA; Fleet, C; Jänne, PA; Johnson, BE; Mermel, C; Mukohara, T; Pearlberg, J | 1 |
| Chang, KL; Lau, SK | 1 |
| Chu, DT; Wang, B; Zhang, XR | 2 |
| Gatzemeier, U; Reck, M | 3 |
| Kaplow, R | 1 |
| Grandis, JR; Gubish, CT; Lyker, JS; Siegfried, JM; Stabile, LP; Zhang, W | 1 |
| Doi, S; Ikegami, Y; Itoh, A; Kitazaki, T; Kohno, S; Nakamura, Y; Nakatomi, K; Oka, M; Shiozawa, K; Soda, H; Tsurutani, J; Yoshida, H; Yoshikawa, M | 1 |
| Baudard, M; Cremer, FW; De Vos, J; Fiol, G; Goldschmidt, H; Grau, V; Hose, D; Jourdan, E; Jourdan, M; Klein, B; Mahtouk, K; Moos, M; Moreaux, J; Raab, M; Rème, T; Rossi, JF | 1 |
| Antonella, P; Augusto, P; Busi, G; Giancarla, B; Palumbo, A; Pedrazzini, A; Roggero, E | 1 |
| Kris, MG; Miller, VA; Pao, W; Politi, KA; Riely, GJ; Somwar, R; Varmus, H; Zakowski, MF | 1 |
| Endoh, H; Hatooka, S; Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Mori, S; Shinoda, M; Takahashi, T; Yatabe, Y | 1 |
| Batist, G; Douglas, L; Friedmann, J; Goss, G; Hanna, P; Hirte, H; Lorimer, IA; Mathews, S; Miller, WH; Parolin, DA; Seymour, LK; Stafford, S; Stewart, D; Walsh, W | 1 |
| Batist, G; Douglas, L; Glenwood, G; Goel, R; Hirte, HW; Jean, M; Lorimer, IA; Mackenzie, MJ; Major, PP; Matthews, S; Miller, WH; Panasci, L; Seymour, L | 1 |
| Apáti, A; Buday, L; Elkind, NB; Homolya, L; Kéri, G; Német, K; Ozvegy-Laczka, C; Sarkadi, B; Szabó, K; Szentpétery, Z; Ujhelly, O; Váradi, A; Várady, G | 1 |
| Coppola, D; Cress, D; Haura, EB; Livingston, S; Song, L | 1 |
| Kris, MG; Lobo, J; Rosen, N; Scher, HI; She, Y; Sirotnak, FM; Solit, DB | 1 |
| Fischel, JL; Formento, P; Milano, G | 1 |
| Burdak-Rothkamm, S; Feldmann, K; Ludwig, D; Nguyen, TP; Rübe, C; Rübe, CE; Wiegel, T | 1 |
| Frantz, S | 2 |
| Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Taguchi, F | 1 |
| Li, X; Li, Y; Lu, QY; Yuan, SJ; Zhao, QC; Zhu, BD | 1 |
| Bardsley, J; Hutchison, M; McKillop, D; Parry, AC; Partridge, EA; Rhead, SA; Swaisland, HC; Woodman, HM | 1 |
| Bushby, N; Clarkson-Jones, JA; Cooper, CM; Herron, W; Hutchison, M; McKillop, D; Partridge, EA; Swaisland, HC | 1 |
| del Valle, ML; Sanz, A | 1 |
| Miller, VA; Pao, W | 1 |
| Curigliano, G; de Braud, F; De Pas, T; Noberasco, C; Pelosi, G; Spaggiari, L; Veronesi, G | 1 |
| Yatabe, Y | 1 |
| Araki, J; Ichikawa, Y; Okamoto, I; Sasaki, J; Suto, R | 1 |
| Lanzi, C; Supino, R; Zanchi, C; Zuco, V; Zunino, F | 1 |
| Hirakawa, K; Ishikawa, T; Nobuhara, Y; Ogisawa, K; Onoda, N; Takashima, T; Yamasaki, M; Yamashita, Y | 1 |
| Jänne, PA | 4 |
| Karjalainen, EM; Knuuttila, A; Mali, P; Rouhos, A | 1 |
| Hutchison, M; McCormick, AD; McKillop, D; Miles, GS; Millar, A; Phillips, PJ | 1 |
| Ahn, SJ; Baek, SM; Jeong, JY; Kim, KS; Kim, YC; Kim, YH; Kim, YI; Lim, SC; Na, KJ; Park, CM; Park, CS; Park, KO | 1 |
| Govindan, R; Green, MR; Herndon, JE; Kindler, HL; Kratzke, RA; Niehans, GA; Vollmer, R; Watson, D | 1 |
| Dimitroulakos, J; Goss, G; Hanson, JE; Lagarde, AE; Lorimer, IA; Mantha, AJ | 1 |
| Baker, SD; Hartke, C; He, P; Hidalgo, M; Jimeno, A; Li, J; Zabelina, Y; Zhao, M | 1 |
| Choe, JK; Cogswell, J; Kasimis, B; Nagaria, NC | 1 |
| Desai, AA; Ratain, MJ | 1 |
| Barnett, S; Bichat, F; Giles, PB; Guilbaud, N; Kemp, JV; Kendrew, J; McKillop, D; Partridge, EA; Patterson, AB; Spence, MP; Stephens, TC; Wood, PG | 1 |
| Earp, HS; Gregory, CW; Liu, Y; Majumder, S; McCall, W; Mohler, JL; Sartor, CI; Whang, YE | 1 |
| Endo, K; Fujii, Y; Fukai, I; Iuchi, K; Kawaguchi, T; Kawahara, M; Konishi, A; Matsumura, A; Okumura, M; Sasaki, H; Shimizu, T; Takada, M; Takeuchi, H; Tanaka, H; Yano, M | 1 |
| Han, JY; Hong, EK; Kim, HK; Kim, HY; Lee, DH; Lee, EK; Lee, HG; Lee, JJ; Lee, JS | 1 |
| Blankenburg, T; Brust, D; Nagel, S; Schaedlich, S; Schütte, W | 1 |
| Choo, MK; Koizumi, K; Matsuo, M; Saiki, I; Sakurai, H; Ueno, Y | 1 |
| Al-Hazzaa, A; Birchall, MA; Bowen, ID; Randerson, P | 1 |
| Bell, DW; Haber, DA; Louis, DN; Riemenschneider, MJ | 1 |
| Abrey, LE; Franceschi, E; Kris, MG; Miller, VA; Milton, DT; Omuro, AM; Shah, N | 1 |
| Coulon, C; Gandara, D; Geraghty, E; Laptalo, L; Lau, D; Seibert, A | 1 |
| Yang, CH | 2 |
| Chiu, CH; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Alberola, V; Camps, C; Cardenal, F; Castellanos, D; Cortes-Funes, H; Diz, P; Garcia-Giron, C; Gomez, C; Gonzalez-Larriba, JL; Izquierdo, A; Maeztu, I; Mayo, C; Mendez, P; Moran, T; Queralt, C; Rosell, R; Sanchez, JJ; Taron, M; Valero, P; Velasco, A; Vieitez, JM | 1 |
| Carpentier, AF; Delattre, JY; Hoang-Xuan, K; Marie, Y; Omuro, AM; Sanson, M; Thillet, J | 1 |
| Hampton, T | 1 |
| Albanell, J; Gascón, P | 1 |
| Kaye, FJ | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Danenberg, K; Doglioni, C; Domenichini, I; Franklin, WA; Gregorc, V; Haney, J; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Sidoni, A; Tonato, M; Varella-Garcia, M; Witta, S | 1 |
| Horai, T; Horiike, A; Ishikawa, Y; Nakagawa, K; Nishio, K; Nishio, M; Ohyanagi, F; Okumura, S; Satoh, Y | 1 |
| Berlin, J; Davis, L; Giantonio, B; Haller, DG; O'Dwyer, PJ; Shults, J; Sun, W; Veronese, ML | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Shibuya, M; Yoshimura, A | 1 |
| Lenz, HJ; Vallbohmer, D | 1 |
| Fujimura, M; Hourai, T; Kasahara, K; Kimura, H; Nakao, S; Nishio, M; Sone, T; Yoshimoto, A | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Vicentini, C | 1 |
| Ciardiello, F; Di Maio, M; Gridelli, C; Normanno, N; Perrone, F | 1 |
| Bell, DW; Brannigan, BW; Driscoll, DR; Fidias, P; Godin-Heymann, N; Haber, DA; Harris, PL; Isselbacher, KJ; Kwak, EL; Lynch, TJ; McGinnis, JP; Okimoto, RA; Rabindran, SK; Settleman, J; Sharma, SV; Sordella, R; Wissner, A | 1 |
| Magné, N; Milano, G | 1 |
| Fujii, T; Hirata, A; Hosoi, F; Kuwano, M; Miyagawa, M; Naito, S; Ono, M; Ueda, S | 1 |
| Kiura, K; Mitsudomi, T; Toyooka, S | 1 |
| Dietrich, GM; Fischer, JR; Geiger, D; Haffner, U; Lahm, H; Spahlinger, B | 1 |
| Astoul, P; Barlési, F; Doddoli, C; Greillier, L; Kleisbauer, JP; Tchouhadjian, C; Thomas, P; Villani, P | 1 |
| Jeng, YM; Lien, HC; Su, MC | 1 |
| Hsu, HS; Huang, BS; Huang, MJ; Lim, KH; Tzen, CY; Yen, Y | 1 |
| Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Gérard, F; Gugenheim, J; Hannoun-Levi, JM; Mazeau, C; Milano, G | 1 |
| Gasparini, G; Longo, R; Morabito, A; Torino, F | 1 |
| Cascone, T; Ciardiello, F; De Vita, F; Eckhardt, SG; Laus, G; Morelli, MP; Orditura, M; Pepe, S; Tortora, G; Troiani, T | 1 |
| Kanazawa, S; Kinoshita, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 2 |
| Anderson, H; Bebb, G; Ho, C; Laskin, J; Melosky, B; Murray, N | 1 |
| Ali, S; Barrett, N; Beresford, E; Coombes, RC; Hadjiminas, D; Jiang, J; Mansi, JL; Morrison, K; Peston, D; Polychronis, A; Shivapatham, D; Shousha, S; Singhal, H; Sinnett, HD; Slade, MJ; Vigushin, D | 1 |
| Heymach, JV | 1 |
| Blum, HE; Geissler, M; Grimm, CF | 1 |
| Campagnoli, E; Cavina, R; De Vincenzo, F; Latteri, F; Santoro, A; Soto Parra, HJ; Zucali, PA | 1 |
| Ichinose, Y; Ikeda, J; Maruyama, R; Miyake, T; Nakamura, T; Okamoto, T; Shoji, F; Wataya, H | 1 |
| Albanell, J; Baselga, J; Gascón, P; González, S; Guillém, V; Koehler, MT; Lluch, A; Marimón, I; Rojo, F; Ruiz, A; Sauleda, S; Tabernero, JM | 1 |
| Chuah, KL; Leong, SS; Lim, ST; Lim, WT; Tan, EH; Tay, MH; Toh, CK; Wong, EH | 1 |
| Reddy, GK | 2 |
| Tyagi, P | 1 |
| Buchholz, E; Fandi, A; Gatzemeier, U; Manegold, C; Smith, RP | 1 |
| Byrne, BJ; Garst, J | 1 |
| Aldinucci, D; D'Antonio, A; De Filippi, R; De Luca, A; Maiello, MR; Mancino, M; Normanno, N; Pinto, A | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Soda, H | 1 |
| Costello, G; Holloway, B; Speake, G | 1 |
| Fukuoka, M; Tamura, K | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Oka, M; Soda, H; Takemura, M; Tsurutani, J; Yabuuchi, H; Yasunaga, M | 1 |
| Chang, XY; Cui, QC; Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Bukowski, RM; Costa, L; Drabkin, HA; Gemmill, RM; Korch, C; Zhou, M | 1 |
| Buter, J; Giaccone, G | 2 |
| Cui, QC; Feng, RE; Guo, BQ; Li, LY; Mu, XL; Wang, MZ; Zhang, XT; Zhou, HS | 1 |
| Brandt, R; Hynes, NE; Littlewood, A; O'Reilly, T; Schnell, C; Sini, P; Wood, J; Wyder, L | 1 |
| Lilenbaum, R; Lopes, G; Raez, LE | 1 |
| Gooding, WE; Grandis, JR; Lui, VW; Siegfried, JM; Thomas, SM; Wentzel, AL | 1 |
| Haber, DA; Settleman, J | 1 |
| Wadman, M | 1 |
| Bafaloukos, D; Briasoulis, E; Fountzilas, G; Gogas, H; Kalofonos, HP; Kalogera-Fountzila, A; Kosmidis, P; Kourea, H; Lambropoulos, S; Linardou, H; Markopoulos, C; Mavroudis, D; Papadimitriou, C; Papadopoulos, S; Pavlidis, N; Pectasides, D; Razis, E; Skarlos, D | 1 |
| Endoh, H; Kosaka, T; Mitsudomi, T; Yatabe, Y | 1 |
| Masuda, N; Yanase, N; Yokoba, M | 1 |
| Camirand, A; Pollak, M; Young, F; Zakikhani, M | 1 |
| Corsello, SM; Deangelo, DJ; Golub, TR; Ross, KN; Stegmaier, K; Wong, JS | 1 |
| Bunn, PA; Crowley, J; Franklin, WA; Gandara, DR; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sakiyama, T; Sekine, I; Shibata, T; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yamamoto, S; Yoshida, T | 1 |
| Gallegos-Ruiz, M; Giaccone, G; Janmaat, ML; Kruyt, FA; Rodriguez, JA | 1 |
| Aoe, M; Doihara, H; Hara, F; Ohta, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Toyooka, S; Tsukuda, K; Yoshitomi, S | 1 |
| Abe, T; Hagiri, S; Ishii, K; Katagiri, M; Kato, E; Kobayashi, H; Kuboto, M; Masuda, N; Mitsufuji, H; Onoda, S; Ryuge, S; Takada, N; Tanaka, N; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Brom, R; Candelaria, M; Duenas-Gonzalez, A; Meza, F; Taja-Chayeb, L; Trejo-Becerril, C | 1 |
| Doi, S; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Soda, H | 1 |
| Besse, B; Cirauqui, B; Ichinose, Y; Mate, JL; Mendez, P; Moran, T; Nishiyama, K; Perez, M; Queralt, C; Reguart, N; Rosell, R; Sanchez, JJ; Sanchez, JM; Sarries, C; Taron, M | 1 |
| Artale, S; Bardelli, A; Benvenuti, S; Moroni, M; Sartore-Bianchi, A; Siena, S | 1 |
| Gow, CH; Shih, JY; Yang, PC | 1 |
| Ames, MM; Gilbert, JA; Lloyd, RV | 1 |
| Ready, N | 1 |
| Ettinger, DS | 1 |
| Fujiwara, T; Kagawa, S; Kawashima, T; Nisizaki, M; Tanaka, N; Tango, Y; Teraishi, F; Umeoka, T; Watanabe, T | 1 |
| Choi, JH; Hyun, MS; Kim, MK; Lee, JK; Lee, KH | 1 |
| Cheng, AL; Shen, YC; Wan, JP; Yeh, KH; Yeh, SH | 1 |
| Hiddemann, W; Krych, M; Ostermann, H; Schoenberg, SO; Stemmler, HJ; Weigert, O | 1 |
| Baltaci, M; Derler, AM; Fritsch, P; Höpfl, R; Sögner, P; Tzankov, A; Weber, F | 1 |
| Tuma, RS | 1 |
| De Boeck, G; de Bruijn, EA; Esmans, E; Guetens, G; Lemière, F; Prenen, H; Schöffski, P; Van Dongen, W; van Oosterom, AT | 1 |
| Bailey, CJ; Cantarini, MV; Macpherson, MP; Marshall, AL; Robinson, AV | 1 |
| Figlin, R; Fishbein, MC; Truell, JS | 1 |
| Bartolini, S; Bunn, PA; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Gazdar, AF; Gregorc, V; Hirsch, FR; Ludovini, V; Rossi, E; Shigematsu, H; Toschi, L; Varella-Garcia, M | 1 |
| Bauer, JA; Cerny, T; Egli, F; Gillessen, S; Jermann, M; Joerger, M; Morant, R; Pless, M; Rhyner, K; Salzberg, M; Stahel, RA | 1 |
| Engelman, JA; Jänne, PA | 1 |
| Cortese, JF; Eliason, JF; Everson, RB; Gowda, AL; Pass, HI; Wali, A | 1 |
| Cheng, AL; Chu, YC; Huang, CJ; Whang-Peng, J; Yang, CH; Yang, CS; Yang, PC | 1 |
| Arciero, CA; Chen, X; Darcy, KM; Decesare, SL; Godwin, AK; Lee, RB; Lewandowski, G; Schilder, RJ; Sill, MW; Wu, H | 1 |
| Ajiki, T; Digiovanni, J; Kawamoto, T; Kiguchi, K; Ruffino, L | 1 |
| Kwan, W; Liu, S; Lubieniecka, JM; Nielsen, TO; Terry, J | 1 |
| Friberg, G; Kindler, HL; Skoog, L; Vokes, EE; Wade-Oliver, K | 1 |
| Raizer, JJ | 1 |
| Comis, RL | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Chu, DT; Guan, ZZ; Jiang, GL; Li, LY; Li, W; Liu, XY; Zhang, L; Zhao, HY | 1 |
| Bradley, J; Govindan, R; Hope, A; Kreisel, D; Krupnick, AS; Meyers, B | 1 |
| Afar, DE; Agus, DB; Aronson, N; Curran, J; Galkin, A; Hunter, JB; Jain, A; Laux, I; Natale, RB; Shak, S; Tindell, CA | 1 |
| Alavi, J; Algazy, K; Bearn, L; Eaby, B; Evans, T; Shults, J; Stevenson, JP; Veronese, ML | 1 |
| Bearz, A; Berretta, M; Spazzapan, S; Tirelli, U; Vaccher, E | 1 |
| Altundag, K; Altundag, O; Boruban, C; Silay, YS | 1 |
| Halmos, B; Ji, H; Kobayashi, S; Meyerson, M; Tenen, DG; Wong, KK; Yuza, Y | 1 |
| Fukuyama, S; Hagiwara, K; Kanazawa, M; Kato, M; Kobayashi, K; Miyazawa, H; Nagai, Y; Tanaka, T; Udagawa, K; Yokote, A | 1 |
| Gazdar, AF; Minna, JD; Peyton, MJ | 1 |
| Cantley, LC; Engelman, JA; Halmos, B; Hanna, NH; Jänne, PA; Johnson, BE; Kobayashi, S; Lindeman, N; Mukohara, T; Pearlberg, J; Tenen, DG; Tsuchihashi, Z; Yeap, BY | 1 |
| Branca, MA | 1 |
| Amici, S; Gasparini, G; Gattuso, D; Gion, M; Longo, R; Sarmiento, R; Zancan, M | 1 |
| Batra, SK; Depreux, P; Hénichart, JP; Lin, MF; Mimeault, M; Moniaux, N; Moore, E | 1 |
| Blanke, CD | 1 |
| Advani, RH; Cho, CD; Fisher, GA; Ford, JM; Halsey, J; Kuo, T; Sikic, BI; Wakelee, HA | 1 |
| Agrawal, A; Gee, JM; Gutteridge, E; Nicholson, RI; Robertson, JF | 1 |
| Barrow, D; Gee, JM; Jones, HE; Nicholson, RI; Rubini, M; Taylor, KM; Williams, HD | 1 |
| Harper, P; Spicer, J | 1 |
| Lindner, H; Loeffler-Ragg, J; Mueller, D; Sarg, B; Skvortsov, S; Skvortsova, I; Witsch-Baumgartner, M; Zwierzina, H | 1 |
| Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Hsue, V; Ichinose, Y; Jablons, D; Jahan, T; Manegold, C; Massuti, B; Mate, JL; Mok, T; Moran, T; Ono, M; Queralt, C; Rosell, R; Sanchez, JJ; Sanchez, JM; Sanchez-Ronco, M; Taron, M; Zamora, L | 1 |
| Edakuni, N; Inayama, M; Kakiuchi, S; Muguruma, H; Nakataki, E; Nishikubo, N; Ohtsuka, S; Sone, S; Tomimoto, H; Yano, S | 1 |
| Ganti, AK; Potti, A | 1 |
| Ando, Y; Araki, K; Endo, H; Fujita, K; Kodama, K; Miya, T; Nagashima, F; Narabayashi, M; Sasaki, Y; Yamamoto, W | 1 |
| Hong, SJ; Jae, YW; Kim, SI; Kwon, SM; Oh, HY | 1 |
| Govindan, R; Pillot, G; Viswanathan, A | 1 |
| Bartolini, S; Cappuzzo, F; Crinò, L; Finocchiaro, G; Metro, G; Toschi, L; Trisolini, R | 1 |
| Adamson, PC; Bernstein, ML; Blaney, SM; Croop, JM; Dancey, JE; Daw, NC; Furman, WL; Iacono, LC; Krailo, M; Reaman, GH; Speights, RA; Stewart, CF | 1 |
| Hasegawa, Y; Imaizumi, K; Kataoka, K; Kawabe, T; Kimura, T; Kondoh, Y; Kume, H; Nishiyama, O; Shimokata, K; Taniguchi, H | 1 |
| Goldstein, D; Qu, XJ; Russell, PJ; Yang, JL | 1 |
| Fukui, T; Hasegawa, Y; Imaizumi, K; Kondo, M; Kume, H; Nagasaka, T; Sekido, Y; Shimokata, K; Yokoi, K; Yokoyama, T; Yoshioka, H | 1 |
| Dannenberg, AJ; Gibson, N; Lippman, SM; Subbaramaiah, K | 1 |
| Chen, A; Chen, ZG; Choe, MS; Khuri, FR; Lin, Y; Shin, DM; Shin, HJ; Sun, SY; Wieand, HS; Zhang, X | 1 |
| Burt, PA; Lee, LW | 1 |
| Campiglio, M; De Luca, A; Menard, S; Normanno, N; Perrone, F | 1 |
| Fox, JL | 1 |
| Lindner, H; Loeffler-Ragg, J; Lukas, P; Sarg, B; Skvortsov, S; Skvortsova, I; Tabernero, J; Zwierzina, H | 1 |
| Chang, YL; Chen, KY; Gow, CH; Hsu, YC; Shih, JY; Su, WP; Tsai, MF; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Bidart, JM; Duvillard, P; Lacroix, L; Motté, N; Pautier, P; Saulnier, P; Soria, JC | 1 |
| Kasahara, K; Kimura, H; Nishio, K; Sekijima, M; Tamura, T | 1 |
| Hotta, K; Inoue, A; Kiura, K; Nukiwa, T; Tanimoto, M; Ueoka, H | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Fujikawa, T; Ito, M; Iwasaki, T; Kawamura, T; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Namba, Y; Niinaka, M; Okada, T; Takeda, Y; Yamaguchi, T; Yokota, S | 1 |
| Arnold, D; Mueller, T; Pfeiffer, C; Pickan, V; Simon, H; Voigt, W | 1 |
| Edelman, MJ | 1 |
| Lawrence, TS | 1 |
| Cooney, MM; Remick, SC; Vogelzang, NJ | 1 |
| Aul, C; Schroeder, M | 1 |
| Brahmandam, M; Cantor, M; Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kinsella, K; Kulke, MH; Loda, M; Meyerhardt, JA; Michelini, AL; Namgyal, C; Ogino, S; Ryan, DP | 1 |
| Abraham, RT; Baker, A; Berggren, MI; Ihle, NT; Kirkpatrick, DL; Paine-Murrieta, G; Powis, G; Tate, WR; Wipf, P | 1 |
| Binns, D; Cullinane, C; Hicks, RJ; McArthur, GA; Roselt, P; Solomon, B; Weibe, LI | 1 |
| Haddad, RI; Joshi, VA; Lee, JC; Lindeman, NI; Norris, CM; Posner, MR; Wirth, LJ; Zhao, X | 1 |
| Chang, YL; Gow, CH; Shih, JY; Yu, CJ | 1 |
| Laight, A; Leadbetter, J; McKillop, D; Ranson, M; Smith, RP; Swaisland, HC; Wild, MJ | 1 |
| Beijnen, JH; Schellens, JH; Siegel-Lakhai, WS | 1 |
| Lee, D | 1 |
| Bradof, JE; Brierre, JE; Burkett, ER; Burris, HA; Dickson, NR; Greco, FA; Hainsworth, JD; Jones, SF; Rubinsak, JR; Scullin, DC; Spigel, DR; Thomas, M; Yardley, DA | 1 |
| Garcia-Foncillas, J; Gurpide, A; Lopez-Picazo, JM; Martin-Algarra, S; Moreno, M; Perez-Gracia, JL; Zubieta, JL | 1 |
| Ceribelli, A; Cognetti, F; Gelibter, A; Milella, M; Moscetti, L; Pollera, CF; Sperduti, I | 1 |
| Alvarez, JV; Bulmer, SE; Chen, TH; Feng, W; Frank, DA; Greulich, H; Hahn, WC; Jänne, PA; Meyerson, M; Sellers, WR; Zappaterra, M | 1 |
| Leighl, NB; Nematollahi, M; Shepherd, FA; Tsao, WS; Zawisza, DL | 1 |
| Eicke, N; Emons, G; Gründker, C; Günthert, AR; Läsche, J; Olota, A | 1 |
| Ottesen, LH; Pedersen, MW; Pedersen, N; Poulsen, HS | 1 |
| Hsu, C; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Hanagiri, T; Morita, M; Ono, K; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K; Yoshimatsu, T | 1 |
| Endo, K; Fujii, Y; Fukai, I; Haneda, H; Iuchi, K; Kawahara, M; Kobayashi, Y; Konishi, A; Kuwabara, Y; Matsumura, A; Mizuno, K; Okumura, M; Sasaki, H; Sugiura, H; Suzuki, E; Takada, M; Tanaka, H; Yano, M | 1 |
| Kurisu, K; Okamura, T | 1 |
| Dobashi, K; Iijima, H; Ishizuka, T; Minna, JD; Mori, M; Nakajima, T; Otani, Y; Saito, R; Sato, K; Suga, T; Sunaga, N; Takise, A; Tanaka, S; Tomizawa, Y | 1 |
| Baselga, J; Bell, DW; Brannigan, BW; Fukuoka, M; Giaccone, G; Haber, DA; Harris, PL; Haserlat, SM; Herbst, RS; Iacona, RB; Johnson, DH; Krebs, AD; Kris, MG; Lynch, TJ; Manegold, C; Muir, B; Ochs, JS; Okimoto, RA; Riemenschneider, MJ; Sgroi, DC | 1 |
| Greulich, H; Griffin, JD; Jänne, PA; Jiang, J; Meyerson, M; Sellers, WR | 1 |
| Fujito, H; Mori, M; Saita, T | 1 |
| Chen, YR; Chen, YT; Fu, YN; Hu, SF; Huang, SF; Lin, CH; Tsai, SF; Yang, ST | 1 |
| Elsner, J; Gutzmer, R; Kapp, A; Werfel, T | 1 |
| Donson, AM; Foreman, NK; Gore, L; Heideman, R; Straessle, J; Wells, D | 1 |
| Date, M; Fujise, K; Matsumoto, K; Nakamura, T; Namiki, T; Namiki, Y; Satoi, J; Tada, N; Yanagihara, K; Yashiro, M; Yoshida, H | 1 |
| Braun, AH; Dirsch, O; Hilger, RA; Seeber, S; Stark, K; Vanhoefer, U | 1 |
| Fukuoka, M; Ichinose, Y; Jiang, H; Kato, H; Nagai, K; Tada, H; Tsuboi, M; Tsuchiya, R; Wada, H | 1 |
| Kakiuchi, S; Sone, S; Yano, S | 1 |
| Bessho, A; Gemba, K; Harita, S; Hotta, K; Kiura, K; Maeda, T; Ogino, A; Tabata, M; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T | 1 |
| Ariyama, H; Baba, E; Harada, M; Mitsugi, K; Nakano, S; Qin, B; Tanaka, R | 1 |
| Daigo, Y; Hayama, S; Inai, K; Ishikawa, N; Kato, T; Kohno, N; Murakami, H; Nakamura, Y; Nishimura, H; Takano, A; Takeshima, Y; Taniwaki, M; Tsuchiya, E | 1 |
| Duvauchelle, T; Kerr, DJ; Laight, A; Ranson, M; Smith, RP; Swaisland, HC; Wilder-Smith, CH | 1 |
| Li, LY; Mu, XL; Song, W; Wang, MZ; Wang, SL; Zhang, XT | 1 |
| Garfield, DH | 2 |
| Ohe, Y; Takano, T | 1 |
| Bates, SE; Fojo, T | 1 |
| Galligan, L; Johnston, P; Karaiskou-McCaul, A; Kelly, D; Longley, D; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Kanazawa, S; Kinoshita, Y; Komiyama, Y; Muramatsu, M; Nomura, S; Yamaguchi, K | 3 |
| Fujii, T; Kuwano, M; Nakamura, H; Ono, M; Shirouzu, K; Takamori, S; Yamana, H | 1 |
| D'Amico, TA | 1 |
| Hotta, K; Kanehiro, A; Kishino, D; Kiura, K; Nishii, K; Notohara, K; Tabata, M; Tanimoto, M; Tanimoto, Y; Ueoka, H; Umemura, S | 1 |
| Carbone, DP | 1 |
| Ciardiello, F; De Vita, F | 1 |
| Brodeur, GM; Cnaan, A; Evans, AE; Hishiki, T; Ho, R; Maris, J; Minturn, JE; Wang, Q; Zhao, H | 1 |
| Berdel, WE; Hoffknecht, P; Lange, T; Müller-Tidow, C; Serve, H; Thomas, M | 1 |
| Abrey, LE; Chang, S; Cowell, JK; DeAngelis, LM; Gilbert, MR; Grefe, CN; Holland, EC; Kuhn, JG; Lamborn, K; Lassman, AB; Lieberman, FS; Nowak, NJ; Pao, W; Prados, M; Raizer, JJ; Razier, JR; Rossi, MR; Shih, AH; Wen, P; Wilson, R; Yung, WA | 1 |
| Kris, M | 1 |
| Bigner, DD; Friedman, HS | 1 |
| Beroukhim, R; Cavenee, WK; Chute, DJ; Cloughesy, TF; Dia, EQ; Haas-Kogan, DA; Horvath, S; Huang, JH; Lee, JC; Liau, LM; Lu, KV; Mellinghoff, IK; Mischel, PS; Peck, TC; Prados, M; Rao, PN; Riggs, BL; Sawyers, CL; Sellers, WR; Stokoe, D; Vivanco, I; Wang, MY; Yoshimoto, K; Zhu, S | 1 |
| Horio, Y; Mitsudomi, T; Shimizu, J | 1 |
| Hirashima, T; Kawahara, K; Kawase, I; Kobayashi, M; Matsui, K; Nakamura, Y; Nitta, T; Sasada, S; Takimoto, T | 1 |
| Kabasawa, K; Kawasaki, N; Nakamura, H; Taguchi, M | 1 |
| Macarulla, T; Tabernero, J | 1 |
| Treudler, R; Zouboulis, CC | 1 |
| Adam, L; Bar-Eli, M; Brown, G; Diehl, AJ; Dinney, CP; Kassouf, W; McConkey, DJ | 1 |
| Bartolini, S; Bemis, L; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Franklin, WA; Hirsch, FR; Ludovini, V; Magrini, E; Rossi, E; Toschi, L; Varella-Garcia, M | 1 |
| Dudek, AZ; Keshtgarpour, M; Kmak, KL; Koopmeiners, J | 1 |
| Anderson, F; Bebb, G; Davis, J; Ho, C; Murray, N | 1 |
| Pao, W; Riely, GJ | 1 |
| Bell, DW; Brannigan, BW; Clark, JR; Cohen, EE; Dahiya, S; Haber, DA; Harris, PL; Haserlat, SM; Lingen, MW; Martin, LE; Muir, B; Okimoto, RA; Rocco, JW; Sgroi, DC; Vokes, EE | 1 |
| Christoffersen, T; Dajani, O; Guren, TK; Thoresen, GH; Tveit, KM; Wisløff, F | 1 |
| Bunn, PA; Hirsch, FR | 1 |
| Agus, DB; Jain, A; Laux, I; Singh, S | 1 |
| Belinchón, I; Pascual, JC; Sivera, F; Yuste, A | 1 |
| Endo, K; Fujii, Y; Fukai, I; Mizuno, K; Sasaki, H; Yamakawa, Y; Yano, M | 1 |
| Jazieh, AR; Nahleh, ZA | 1 |
| Bepler, G; Cantor, A; Haura, EB; Song, L; Zheng, Z | 1 |
| Brockstein, BE; Cohen, EE; Dekker, A; Huo, D; Kane, MA; List, MA; Mauer, AM; Mehrotra, B; Pierce, C; Vokes, EE | 1 |
| Angelucci, A; Biordi, L; Bologna, M; Dolo, V; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Speca, S; Vicentini, C | 1 |
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Melisi, D; Tortora, G; Veneziani, BM | 1 |
| Apolone, G; Garattini, S; La Vecchia, C | 1 |
| Altundag, K; Altundag, O; Atik, MA; Baptista, MZ; Turen, S | 1 |
| Barrow, D; Gee, J; Green, TP; Hiscox, S; Morgan, L; Nicholson, RI | 1 |
| Jacobson, JW; Lively, TG; Taube, SE | 1 |
| Chai, RL; Grandis, JR | 1 |
| Barnard, GF; Ishii, H; Mimori, K; Mori, M; Nagahara, H; Sudo, T; Yamashita, K | 1 |
| Rivera, MP; Silvestri, GA | 1 |
| Araki, J; Fukuoka, M; Nakagawa, K; Okamoto, I; Shimada, M; Suto, R | 1 |
| Cody, DD; Dackor, J; Fujimoto, N; Hanna, AE; Herbst, R; Iwanaga, K; Kalyankrishna, S; Kurie, JM; Massarelli, E; Minna, JD; Peyton, M; Price, RE; Sato, M; Shay, JW; Tang, X; Threadgill, DW; Wislez, M; Wistuba, II; Zhang, J | 1 |
| Guo, M; Herman, JG; Liu, S; Lu, F; Zhuang, H | 1 |
| Adachi, M; Ando, K; Hirose, T; Horichi, N; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kuroki, T; Nishio, K; Ohmori, T; Okuda, K; Saijo, N; Shirai, T | 1 |
| Benson, AB; Berlin, JD; Coffey, RJ; LaFleur, B; Levy, DE; Morgan-Meadows, SL; Ramanathan, RK; Rothenberg, ML; Washington, MK | 1 |
| Fukuoka, M; Hirata, K; Kimura, T; Kudoh, S; Matsui, K; Matsuura, K; Mitsuoka, S; Nakagawa, K; Negoro, S; Yoshimura, N | 1 |
| Chan, SK; Gullick, WJ; Hill, ME | 2 |
| Goto, H; Imao, M; Kato, T; Nakashima, M; Sano, K; Yasuda, S; Yoshimura, K | 1 |
| Arao, T; Kaji, N; Murofushi, K; Nishio, K; Saijo, N; Sakai, K; Sekijima, M; Shimoyama, T; Tamura, T | 1 |
| Abdallah, R; Albitar, L; Laidler, LL; Leslie, KK | 1 |
| Bozec, A; Ciccolini, J; Fanciullino, R; Fischel, JL; Formento, P; Milano, G; Murraciole, X; Padovani, L | 1 |
| Harari, PM; Huang, S | 1 |
| Goto, K; Kakinuma, R; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Hur, GY; In, KH; Jung, HC; Jung, KH; Kang, KH; Kim, JH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Baldwin, PD; Lundberg, AS; Tammaro, KA | 1 |
| Choong, NW; Davies, GC; Dietrich, S; Husain, AN; Lipkowitz, S; Ma, PC; Nallasura, V; Salgia, R; Seiwert, TY; Tretiakova, MS | 1 |
| Akizawa, T; Hatamura, I; Negi, S; Orita, H; Saji, F; Sakaguchi, T; Shibata, M; Shiizaki, K | 1 |
| Guan, JY; Hour, TC; Hsieh, MW; Huang, CY; Lin, CC; Lin, SR; Liu, GY; Pu, YS; Wang, CW | 1 |
| Lawrence, TS; Nyati, MK | 1 |
| Campiglio, M; Carotenuto, A; De Luca, A; Maiello, MR; Mancino, M; Menard, S; Napolitano, M; Normanno, N; Viglietto, G | 1 |
| Eguchi, K; Koboyashi, T; Seki, N; Seto, T; Shioya, S; Tanigaki, T; Uematsu, K; Umemura, S | 1 |
| Baron, A; Bunn, PA; Chan, DC; Chan, Z; Coldren, CD; Drabkin, HA; Dziadziuszko, R; Franklin, W; Gazdar, AF; Gemmill, RM; Girard, L; Hedman, K; Helfrich, B; Hirsch, FR; Minna, JD; Ravdel, L; Sugita, M; Witta, SE | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Nyati, MK; Scheurer, AM | 1 |
| Adamson, P; Amador, ML; Blaney, SM; Cusatis, G; Daw, NC; Hidalgo, M; Ingle, AM; Jimeno, A; Krailo, M; Kulesza, P | 1 |
| Arra, C; Avallone, A; Bruzzese, F; Budillon, A; Caraglia, M; Di Gennaro, E; Pepe, S; Tagliaferri, P | 1 |
| Chen, YM; Perng, RP; Tsai, CM | 1 |
| Ikeda, M; Kurebayashi, J; Okubo, S; Otsuki, T; Sonoo, H; Tanaka, K; Yamamoto, Y | 1 |
| Song, ST; Wang, Y; Xu, JM | 1 |
| Sun, Y; Wang, Y | 1 |
| Li, Zi; Lu, S; Yu, YF | 1 |
| Matsuo, M; Ohtani, O; Saiki, I; Sakurai, H; Ueno, Y | 1 |
| Kim, TY; Moriguchi, H; Sato, C | 1 |
| Ballas, M; Dennis, PA; Egilsson, V; Steinberg, SM; Tsurutani, J | 1 |
| Bendell, JC; Blobe, GC; Clary, BM; Czito, BG; Fernando, NH; Honeycutt, W; Hurwitz, HI; Ludwig, KA; Mantyh, CR; Morse, MA; Pappas, TN; Tyler, DS; Willett, CG; Yu, D | 1 |
| Abrey, LE; Gilbert, MR; Lassman, AB | 1 |
| Gatzemeier, U; Kranich, AL; Reck, M; Steinbach, AK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Borras, AM; Distel, RJ; Halmos, B; Jänne, PA; Johnson, BE; Joshi, VA; Kuang, Y; Lee, JC; Lindeman, N; Liyanage, H; Maher, EA; Meyerson, M; Rogers, AM | 1 |
| Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rizvi, N; Venkatraman, ES; Zakowski, MF | 1 |
| Bigner, DD; Desjardins, A; Dowell, JM; Friedman, AH; Friedman, HS; Gururangan, S; Herndon, JE; Lyons, P; McLendon, RE; Ochs, JS; Provenzale, JM; Quinn, JA; Reardon, DA; Rich, JN; Sampson, JH; Sathornsumetee, S; Smith, RP; Swaisland, AJ; Tourt-Uhlig, S; Vredenburgh, JJ | 1 |
| Akaza, H; Hattori, K; Iida, K; Joraku, A; Oyasu, R; Tsukamoto, S | 1 |
| Amjad, EH; Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH | 1 |
| Acebo, E; Díaz-Pérez, JL; Lasa, O; Martínez de Lagrán, Z; Ratón, JA | 1 |
| Cho, C; Ding, Q; Gao, F; Gray, N; Hur, W; Jin, Y; Joazeiro, CA; Liu, Y; Uno, T; Zhang, Q | 1 |
| Bellezza, I; Bracarda, S; Caserta, C; Minelli, A | 1 |
| Axelson, J; Breen, TE; Einhorn, LH; Estes, D; Govindan, R; Hanna, NH; Moore, AM; Vinson, J; Yu, M | 1 |
| Behnke-Mursch, J; Halatsch, ME; Schmidt, U; Unterberg, A; Wirtz, CR | 1 |
| Bonde, P; Broor, A; Dhara, S; Duncan, M; Feldmann, G; Harmon, JW; Maitra, A; Marti, G; Montgomery, E; Sui, G; Wang, J | 1 |
| Gazdar, AF; Girard, L; Lee, W; Minna, JD; Peyton, M; Ramirez, RD; Sato, M; Shames, DS; Shay, JW; Sunaga, N; Vaughan, MB | 1 |
| Bouaroud, N; Brahmer, J; Chan, A; Clark, DP; Forastiere, A; Hidalgo, M; Jimeno, A; Kincaid, E; Kulesza, P | 1 |
| A'Hern, RP; Box, C; D'Ambrosio, C; Eccles, SA; Harrington, KJ; Kirby, AM; Nutting, CM; Rogers, SJ; Syrigos, KN; Tanay, M | 1 |
| Baker, SD; Brahmer, J; Hidalgo, M; Li, J; Messersmith, W | 1 |
| Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Matsuo, K; Tabata, M; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S | 1 |
| Ashworth, A; Caplin, M; Friedmann, BJ; Hartley, JA; Hochhauser, D; Lord, CJ; Savic, B; Shah, T | 1 |
| Chuai, S; Kris, MG; Ladanyi, M; McDonough, T; Miller, VA; Pao, W; Pham, D; Riely, GJ; Rusch, VW; Sarkaria, IS; Singh, B; Venkatraman, ES; Wilson, RK | 1 |
| Barnett, S; Bushby, N; Guy, SP; Hutchison, M; Kemp, JV; Kendrew, J; McKillop, D; Spence, MP; Wood, PG | 1 |
| Doihara, H; Hara, F; Ishibe, Y; Oota, T; Shien, T; Shimizu, N; Taira, N; Takahashi, H; Yoshitomi, S | 1 |
| Hatano, H; Ishii, D; Kosaka, T; Mitsudomi, T; Mizuno, M; Nakahara, N; Natsume, A; Shimato, S; Wakabayashi, T; Yatabe, Y; Yoshida, J | 1 |
| Fukuda, M; Kitazaki, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Shiozawa, K; Soda, H; Takemura, M; Tsukamoto, K; Yabuuchi, H | 1 |
| Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Trisolini, R | 1 |
| Ariyama, H; Baba, E; Harada, M; Kusaba, H; Nakano, S; Qin, B; Tanaka, R | 1 |
| Amino, N; Hisamichi, H; Ideyama, Y; Kudoh, M; Kuromitsu, S; Matsuhisa, A; Samizu, K; Shibasaki, M; Shirasuna, K; Tajinda, K; Yamano, M | 1 |
| He, YM; Lai, RS; Shen, LS; Xie, L; Zhu, CL | 1 |
| Schwartz, LM; Woloshin, S | 1 |
| Cerniglia, G; Gupta, A; Jiang, Z; Kao, GD; Maity, A; Pore, N | 1 |
| Aguilera, J; Altuna, X; Chen, JS; Chu, TS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J; Weisman, RA | 1 |
| Iwashige, A; Kagami, S; Tsukada, J; Uramoto, H | 1 |
| Fontana, JA; Jiang, Y; Levi, E; Majumdar, APN; Nautiyal, J; Rishi, AK; Wali, A; Yu, Y; Zhang, L | 1 |
| Hennemann, B | 1 |
| Abe, S; Harada, K; Inomata, S; Kanai, A; Kitajima, H; Saikai, T; Takahashi, H; Taniguchi, H | 1 |
| Cufer, T; Erensoy, I; Gaafar, R; Pemberton, K; Vrdoljak, E | 1 |
| Arnold, B; Pollack, IF; Premkumar, DR | 1 |
| Kris, MG; Moryl, N; Obbens, EA; Ozigbo, OH | 1 |
| Hayashi, T; Kitazaki, T; Kohno, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Tsukamoto, K; Uchida, K; Urabe, S | 1 |
| Chen, YM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Febbo, PG; Riedel, RF | 1 |
| Khuri, FR; Saba, NF; Shin, DM | 1 |
| Al-Dayel, F; Al-Jommah, N; Al-Kuraya, K; Amr, S; Bavi, P; Ezzat, A; Guido, S; Sheikh, S; Simon, R; Siraj, AK | 1 |
| Matsumoto, K; Murawaki, Y; Nagahara, T; Okano, J | 1 |
| Das-Gupta, A; Small, E; Soulie, P; Trump, D; Wilding, G | 1 |
| Goto, K; Park, K | 1 |
| Endo, M; Johkoh, T; Kimura, K; Yamamoto, N | 1 |
| Gallegos-Ruiz, MI; Giaccone, G; Janmaat, ML; Meijer, GA; Richel, DJ; Rodriguez, JA; Van Groeningen, C; Vervenne, WL | 1 |
| Frei, K; Hofer, S; Rutz, HP | 1 |
| Abbruzzese, JL; Baker, CH; Cognetti, F; McConkey, DJ; Pino, MS; Shrader, M; Xiong, HQ | 1 |
| Bartralot, R; Bodet, D; García-Patos, V; Heras, C; Mollet, J | 1 |
| Bartolini, S; Bunn, PA; Cancellieri, A; Cappuzzo, F; Ceresoli, GL; Crino, L; Domenichini, I; Finocchiaro, G; Franklin, WA; Hirsch, FR; Magrini, E; Metro, G; Santoro, A; Tallini, G; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Gullick, WJ; Normanno, N | 1 |
| Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Rucci, N; Teti, A; Vicentini, C | 1 |
| Balsari, A; Campiglio, M; Castiglioni, F; Ménard, S; Pupa, SM; Tagliabue, E | 1 |
| Ariazi, E; Bertucci, A; Grigg, R; Jordan, VC; Lee, ES; Meeke, K; Morris, C; O'Regan, RM; Osipo, C; Sarker, MA | 1 |
| Hashizume, T; Kobayashi, N; Kozawa, S; Miyazawa, N; Ogura, T; Tagawa, A; Takahashi, H; Watanuki, Y | 1 |
| Fujii, Y; Kuga, T; Matsuoka, T; Morikage, N; Nakayama, T | 1 |
| Li, JQ; Lin, XJ; Xu, L; Zhang, YJ | 1 |
| Fish-Steagall, A; Searcy, P; Sipples, R | 1 |
| Sipples, R | 1 |
| Garfield, D | 2 |
| Chansky, K; Crowley, JJ; Franklin, WA; Gandara, DR; Gumerlock, PH; Lau, DH; McCoy, J; Vance, R; West, HL | 1 |
| Murakami-Murofushi, K; Nishio, K; Saijo, N; Sakai, K; Tamura, T; Yokote, H | 1 |
| Fujiwara, Y; Hotta, K; Ishimaru, F; Kiura, K; Kubonishi, S; Matsuo, K; Nakajima, H; Niiya, D; Ogino, A; Shinagawa, K; Tabata, M; Tanimoto, M; Uchida, A; Ueoka, H | 1 |
| Furukawa, M; Greene, MI; Inoue, K; Kawase, I; Kijima, T; Kumagai, T; Nagatomo, I; Ogata, Y; Osaki, T; Saito, Y; Tachibana, I; Takahashi, R; Yamadori, T; Yano, Y; Yoneda, T; Yoshida, M | 1 |
| Leow, CH; Liam, CK; Pang, YK | 1 |
| Bakri, K; Bůzková, P; Choksi, J; Gillenwater, H; Jones, PE; Mears, A; Socinski, MA; Stinchcombe, TE; Taylor, M; Tynan, M | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, JH; Kim, NK; Kim, TY; Lee, KH | 1 |
| Kawase, I | 1 |
| Blumenschein, GR; Fossella, FV; Glisson, BS; Herbst, RS; Kies, MS; Lee, JJ; Liu, D; Pisters, KM; Schaerer, R; Thomas, SK; Tsao, AS; Zinner, RG | 1 |
| Amann, K; Fässler, R; Ferby, I; Klein, R; Knyazev, P; Kraut, N; Kudlacek, O; Pantè, G; Reschke, M; Sommergruber, W; Ullrich, A | 1 |
| Bai, F; Houghton, PJ; Johnston, B; Leggas, M; Panetta, JC; Schuetz, JD; Sorrentino, B; Stewart, CF; Zhou, S; Zhuang, Y | 1 |
| Baba, K; Hasegawa, Y; Imaizumi, K; Kato, K; Matsumoto, S; Oishi, T; Saito, H; Saka, H; Shimokata, K; Suzuki, R; Taniguchi, H; Yamamoto, M | 1 |
| Al-Hashem, R; Bronson, RT; Discafani, CM; Eck, M; Glatt, KA; Horner, JW; Ji, H; Jung, BL; Li, D; Maher, E; McNamara, K; Meyerson, M; Mitchell, A; Protopopov, A; Rabindran, SK; Sasaki, H; Shapiro, GI; Shimamura, T; Sun, Y; Thomas, RK; Wong, KK; Xia, H; Yuza, Y; Zhao, X | 1 |
| Adams, D; Fernanadez, EM; Seiverling, EV | 1 |
| Abbou, CC; Bakkar, A; Chopin, DK; Daher, A; de Medina, SG; Loric, S; Maillé, P; Nicolle, G; Radvanyi, F; Thiery, JP; Vacherot, F; Van der Kwast, T; Vermey, M; Vordos, D; Wallerand, H | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Sikic, BI | 1 |
| Bianco, AR; Caputo, F; Catalano, G; Ciardiello, F; Colantuoni, G; De Laurentiis, M; De Placido, S; De Vita, F; Diadema, MR; Gridelli, C; Orditura, M; Palmieri, G; Tortora, G; Troiani, T | 1 |
| Hirata, H; Iizuka, N; Inoue, R; Matsumoto, H; Matsuyama, H; Miura, K; Naito, K; Ohmi, C; Shirai, M; Yano, S | 1 |
| Katoh, M; Katoh, Y | 1 |
| Bianco, R; Cascone, T; Ciardiello, F; De Pacido, S; Eckhardt, SG; Fontanini, G; Morelli, MP; Normanno, N; Romano, M; Tortora, G; Troiani, T; Tuccillo, C; Veneziani, BM | 1 |
| Borner, MM | 1 |
| Gao, M; Miller, KD; Sledge, GW; Wang, JQ; Zheng, QH | 1 |
| Million, RP | 1 |
| Goto, K; Kim, YH; Kubota, K; Niho, S; Nishiwaki, Y; Ohmatsu, H; Saijo, N; Yoh, K | 1 |
| Basaki, Y; Kuwano, M; Ogawa, K; Ono, M; Sakisaka, S; Ueda, S; Yoshie, M | 1 |
| Barón, AE; Bunn, PA; Cappuzzo, F; Crino, L; Danenberg, KD; Danenberg, PV; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Park, S; Tanaka, K; Varella-Garcia, M; Witta, SE | 1 |
| Guo, M; Liu, S; Lu, F | 1 |
| Fukumoto, H; Kiura, K; Koizumi, F; Nishio, K; Saijo, N; Shimoyama, T; Tanimoto, M | 1 |
| Pérol, M | 1 |
| Cantarini, MV; Fuhr, R; Holt, A; Swaisland, HC | 1 |
| Le Chevalier, T; Tsuboi, M | 1 |
| Costa, DB; Schumer, ST | 1 |
| Brink, C; Carter, CA; Chen, C; Gilbert, KS; Maxuitenko, YY; Vincent, P; Waud, WR; Zhang, X | 1 |
| Aoe, M; Date, H; Ichihara, S; Ichimura, K; Kiura, K; Ohashi, K; Sano, Y; Shimizu, N; Tabata, M; Tokumo, M; Toyooka, S; Tsukuda, K | 1 |
| Johnston, PG; Karaiskou-McCaul, A; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, SA; Van Cutsem, E; Van Schaeybroeck, S | 1 |
| Becker, JC; Domschke, W; Muller-Tidow, C; Pohle, T; Serve, H | 1 |
| Ando, M; Ariyoshi, Y; Fukuoka, M; Okamoto, I; Seto, T; Takeda, K; Tamura, K; Yamamoto, N | 1 |
| Fujimoto, S; Fukuda, T; Ishii, Y | 1 |
| Blackhall, F; Ranson, M; Thatcher, N | 1 |
| Stummer, W | 1 |
| Filov, VA; Gershanovich, ML; Imianitov, EN; Stukov, AN | 1 |
| Levitzki, A; Mishani, E | 1 |
| Aksoy, S; Altundag, K; Dincer, M; Kilickap, S | 1 |
| Cohen, EE | 1 |
| Cecere, F; Reguart, N; Rosell, R; Santarpia, M; Taron, M | 1 |
| von Eyben, FE | 1 |
| Goto, H; Matsumori, Y; Nakataki, E; Ryan, AJ; Sone, S; Wedge, SR; Yano, S | 1 |
| Fukuhara, T; Inoue, A; Kimura, Y; Maemondo, M; Morikawa, N; Nukiwa, T; Saijo, Y; Suzuki, T; Watanabe, H | 1 |
| Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Breau, JL; Brechot, JM; Chouahnia, K; Des-Guetz, G; Morere, JF; Saintigny, P | 1 |
| Bogeschdorfer, F; Gronau, S; Riechelmann, H | 1 |
| Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Heseltine, D; Meyerhardt, JA; Ogino, S; Ryan, DP; Zhu, AX | 1 |
| Aldanondo, I; Fernández-Guarino, M; Garrido, P; González-García, C; Jaén, P; Marquet, A; Pérez-García, B | 1 |
| Belani, CP; Govindan, R; Hensing, T; Herbst, R; Kelly, K; Krebs, A; Natale, R; Ochs, J; Reiling, R; Wade, J; Wozniak, A | 1 |
| Bremer, E; de Leij, L; Helfrich, W; Kroesen, BJ; van Dam, G | 1 |
| Buchholz, E; Gatzemeier, U; Krutzfeldt, K; Manegold, C; Reck, M; Romer, KS | 1 |
| Chang, JW; Cheung, YC; Chou, WC; Hsieh, JJ; Huang, SF; Liu, MY; Wang, HM; Yeh, KY | 1 |
| Eng, C; Shalan, N | 1 |
| Ballard, P; Bradbury, RH; Harris, CS; Hennequin, LF; Hickinson, M; Kendrew, J; Kettle, JG; Klinowska, T; Ogilvie, DJ; Pearson, SE; Williams, EJ; Wilson, I | 1 |
| Eguchi, K; Seki, N; Shibakuki, R; Uematsu, K | 1 |
| Adam, L; Brown, G; Dinney, CP; Kassouf, W; Luongo, T | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Kim, DW; Kim, TY; Lee, KH; Oh, DY | 1 |
| Bell, DW; Haber, DA; Halmos, B; Holmes, AJ; Huberman, MS; Jackman, DM; Jänne, PA; Johnson, BE; Joshi, VA; Lindeman, N; Lynch, TJ; Meyerson, M; Rabin, MS; Sequist, LV; Yeap, BY | 1 |
| Holloway, B; Kasahara, K; Kawaishi, M; Kimura, H; Kunitoh, H; Nishio, K; Tamura, T | 1 |
| Elenius, K; Erjala, K; Grenman, R; Junttila, TT; Kulmala, J; Mali, P; Pulkkinen, J; Savisalo, M; Sundvall, M; Zhang, N | 1 |
| Barrow, D; Gee, JM; Holloway, B; Jones, HE; Nicholson, RI; Tonge, D | 1 |
| Pedersen, MW; Poulsen, HS | 1 |
| Hasegawa, Y; Hashimoto, N; Honda, T; Imaizumi, K; Kawabe, T; Nagasaka, T; Shimokata, K | 1 |
| Han, JY; Kim, HT; Lee, DH; Lee, JS | 1 |
| Hida, T; Horio, Y; Kosaka, T; Mitsudomi, T; Takahashi, T; Yatabe, Y | 1 |
| Kudoh, S; Yoshimura, A | 1 |
| Arteaga, CL; Carpenter, G; Gazdar, AF; Muthuswamy, SK; Narasanna, A; Perez-Torres, M; Wang, SE; Wu, FY; Xiang, B; Yang, S | 1 |
| Baribaud, F; Caudler, E; Fridman, JS; Friedman, SM; Gazdar, AF; Girard, L; He, B; Jablons, DM; Li, Y; Liu, C; Lo, Y; Mikami, I; Minna, JD; Newton, RC; Peyton, M; Reguart, N; Scherle, PA; Vaddi, K; Yang, G; Yao, W; Zhou, BB | 1 |
| Graves, JE; Heffernan, MP; Jones, BF; Lind, AC | 1 |
| Shiratori, M; Takahashi, H | 1 |
| Kudo, S | 1 |
| Chida, K; Miyazaki, K; Ogura, T; Sugiyama, Y; Yamaguchi, T | 1 |
| High, WA | 1 |
| Hoshinaga, K; Kuwahara, Y; Maruyama, T; Sakurai, T; Shiroki, R | 1 |
| Nakayama, M; Nishimura, K; Nonomura, N; Okuyama, A; Takayama, H | 1 |
| Auberger, J; Hilbe, W; Loeffler-Ragg, J; Wurzer, W | 1 |
| Chon, HS; Hu, W; Kavanagh, JJ | 1 |
| Ichinose, Y; Maehara, Y; Oda, S; Okamoto, T; Yamanaka, T | 1 |
| Kosaka, T; Mitsudomi, T; Yatabe, Y | 1 |
| Ishikawa, S; Ito, H; Onizuka, M; Ozawa, Y; Sakai, M; Sakakibara, Y; Yamamoto, T | 1 |
| Charoentum, C | 1 |
| Endo, K; Fujii, Y; Haneda, H; Kawano, O; Kobayashi, Y; Sasaki, H; Suzuki, E; Yano, M; Yukiue, H | 1 |
| Becker, JC; Berdel, WE; Brandts, C; Domschke, W; Fujimori, T; Ilea, AM; Müller-Tidow, C; Pohle, T; Serve, H; Stolte, M; Tickenbrock, L; Tidow, N | 1 |
| Bell, DW; Godin-Heymann, N; Haber, DA; Kwak, EL; Lynch, TJ; Settleman, J; Sharma, SV; Sordella, R | 1 |
| Amler, LC; Goddard, AD; Hillan, KJ | 1 |
| Hirsch, FR | 1 |
| Chang, WC; Chang, YH; Chen, HC; Chen, YT; Fang, YF; Hsi, BL; Hsieh, MH; Huang, SF; Ku, YC; Kuo, HP; Lin, SY; Liu, CL; Liu, HP; Tsai, SF | 1 |
| Barón, A; Bunn, PA; Coldren, CD; Franklin, WA; Geraci, MW; Helfrich, BA; Hirsch, FR; Lapadat, R; Sugita, M; Witta, SE; Zeng, C | 1 |
| Itoh, Y; Oishi, R; Sendo, T | 1 |
| Cunningham, MP; Fan, Z; Modjtahedi, H; Thomas, H | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kitahara, N; Kobayashi, Y; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yukiue, H | 1 |
| Altiok, S; Amador, ML; Chan, A; Hidalgo, M; Jimeno, A; Maitra, A; Mezzadra, H; Nielsen, ME; Patel, P | 1 |
| Azzoli, CG; Fury, MG; Gomez, JE; Henry, R; Kris, MG; Miller, VA; Pfister, DG; Pizzo, BA; Rizvi, NA; Rosen, N; Sirotnak, FM; Smith, RP; Solit, DB; Su, YB | 1 |
| Borrás, AM; Cantley, LC; Engelman, JA; Gale, CM; Heymach, JV; Jänne, PA; Jarrell, E; Johnson, BE; Lifshits, E; Mukohara, T; Naumov, GN; Sun, J; Tracy, S; Yeap, BY; Zejnullahu, K; Zhao, X | 1 |
| Iijima, M; Kitami, A; Nakada, T; Sagara, R | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Ichihara, S; Inukai, M; Ito, S; Kiura, K; Ouchida, M; Shimizu, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Katakami, N | 1 |
| Cho, KH; Cho, MJ; Jun, HJ; Lee, JS; Park, JS; Pyo, H; Zo, JI | 1 |
| Nieder, C | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Hiraki, A; Ichihara, S; Katayama, H; Kiura, K; Sano, Y; Shimizu, N; Soh, J; Sugi, K; Toyooka, S | 1 |
| Morse, L | 1 |
| Blüthner, T; Caca, K; Feisthammel, J; Kamenz, T; Kluge, A; Mössner, J; Tannapfel, A; Wiedmann, M | 1 |
| Bernard, B; Liu, B; Wu, JH | 1 |
| Azzariti, A; Paradiso, A; Porcelli, L; Simone, GM; Xu, JM | 1 |
| Bozec, A; Fischel, JL; Formento, P; Gugenheim, J; Hofman, P; Lassalle, S; Milano, G | 1 |
| Choi, SH; Lemmon, MA; Mendrola, JM | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Albanell, J; Baselga, J; Doi, T; Koizumi, W; Ohtsu, A; Ramon Cajal, S; Ramon y Cajal, S; Rojo, F; Shirao, K; Tabernero, J; Takiuchi, H; Van Cutsem, E | 1 |
| Augé, JM; Ayuso, C; Cajal, R; Conill, C; Fernández-Cruz, L; Gallego, R; Gascón, P; Ginès, A; Marmol, M; Martin-Richard, M; Maurel, J; Miquel, R; Nadal, C; Navarro, S; Petriz, L; Sánchez, M | 1 |
| Fukutome, M; Maebayashi, K; Mitsuhashi, N; Nasu, S; Seki, K | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Segawa, Y; Shinkai, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S | 1 |
| Asada, K; Chida, K; Hasegawa, H; Naito, T; Suda, T | 1 |
| Curtiss, FR | 1 |
| Bailey, C; Borras, AM; de Jong, F; Holmes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Kesari, S; Lindeman, N; Wen, PY | 1 |
| Hirata, K; Iwao, H; Kimura, T; Kudoh, S; Matsuura, K; Mitsuoka, S; Yoshikawa, J; Yoshimura, N | 1 |
| Barbu, V; Blivet-Van Eggelpoël, MJ; Cacheux, W; Desbois-Mouthon, C; Fartoux, L; Housset, C; Poupon, R; Rosmorduc, O | 1 |
| Chang, GC; Chen, KC; Gow, CH; Hsu, C; Lin, CP; Shih, JY; Su, WP; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Chiu, CH; Lin, WC; Liou, JL; Perng, RP; Tsai, CM | 1 |
| Furubo, S; Harada, K; Isse, K; Kizawa, K; Nakanuma, Y; Ozaki, S; Sanzen, T; Sasaki, M; Sato, Y; Yasoshima, M | 1 |
| Carotenuto, A; Cito, L; D'Alessio, A; De Luca, A; Guzzo, A; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM | 1 |
| Azerad, MA; Bosquée, L; Canon, JL; Collard, P; De Greve, J; Duplaquet, F; Galdermans, D; Germonpré, P; Goeminne, JC; Meert, AP; Nackaerts, K; Schallier, D; Tits, G; van Puijenbroek, R; Vandenhoven, G; Vansteenkiste, J | 1 |
| Frei, K; Hofer, S | 1 |
| Agero, AL; Benvenuto-Andrade, C; Busam, KJ; Dusza, SW; Halpern, AC; Myskowski, P | 1 |
| Burkhart, C; Matheis, P; Socinski, MA; Thomas, NE; Warren, S | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Venkatraman, G | 1 |
| Antonaci, S; Giannelli, G | 1 |
| Chen, B; Cheng, D; Jordan, VC; Liu, H; Louis, TE; Osipo, C; Weichel, AK; Wing, LK | 1 |
| Das, AK; Gazdar, AF; Girard, L; Graves, R; Minna, JD; Nirodi, CS; Peyton, M; Redpath, S; Sato, M; Shay, JW; Story, MD | 1 |
| Ennishi, D; Hatake, K; Hino, N; Senoo, T; Sezaki, N; Terui, Y | 1 |
| Krohn, KA; Linden, HM; Livingston, RB; Mankoff, DA | 1 |
| Bodenstein, C; Czernin, J; Dubinett, S; Dumont, RA; Herschman, H; Phelps, ME; Seimbille, Y; Su, H; Weber, W | 1 |
| Endoh, H; Hida, T; Kosaka, T; Kuwano, H; Mitsudomi, T; Tada, H; Tsuboi, M; Yatabe, Y; Yoshida, K | 1 |
| Erjala, K; Grénman, R; Kulmala, J; Raitanen, M | 1 |
| Battu, S; Blaszkowsky, L; Clark, JW; Earle, CC; Enzinger, PC; Fuchs, CS; Meyerhardt, JA; Ryan, DP; Wolpin, BM; Zhu, AX | 1 |
| Fujiwara, M; Ito, M; Kakemizu, N; Kido, Y; Kusano, N; Momiyama, M; Nishikawa, M; Nozaki, M; Yoshimoto, N | 1 |
| Hsiao, YP; Shih, HC; Wu, MF; Yang, JH | 1 |
| Azim, HA; Ganti, AK | 1 |
| Doihara, H; Fujita, T; Ishibe, Y; Kawasaki, K; Ogasawara, Y; Shien, T; Taira, N; Takabatake, D; Takahashi, H; Yoshitomi, S | 1 |
| Arimura, K; Higashimoto, I; Machida, K; Matsuyama, W; Mitsuyama, H; Osame, M; Watanabe, M; Yamamoto, M | 1 |
| Asahina, H; Dosaka-Akita, H; Kinoshita, I; Nishimura, M; Yamazaki, K; Yokouchi, H | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Kojima, T; Nishimura, M; Ogura, S; Okamoto, Y; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Kameda, Y; Matsukuma, S; Miyagi, Y; Ohgane, N; Oshita, F; Saito, H; Sakuma, Y; Tsuchiya, E; Yamada, K; Yoshihara, M | 1 |
| Agelaki, S; Argiraki, A; Christofillakis, Ch; Georgoulias, V; Kalykaki, A; Kotsakis, A; Mavroudis, D; Pallis, AG; Souglakos, J; Tselepatiotis, E; Vamvakas, L; Vardakis, N | 1 |
| Heelan, RT; Kris, MG; Miller, VA; Milton, DT; Pao, W; Riely, GJ | 1 |
| Gaya, A; Khorshid, M; Plowman, PN; Walther, JC | 1 |
| Ahmed, SM; Salgia, R | 1 |
| Kato, T; Nishio, K | 1 |
| Kagohashi, K; Ohtsuka, M; Satoh, H | 1 |
| Burchert, A; Dietrich, C; Gläser, S; Hoffmann, S; Lingelbach, S; Müller, H; Rothmund, M; Wunderlich, A; Zielke, A | 1 |
| Baas, P; Boerrigter, L; Burgers, S; de Jong, D; Mathy, A; Nederlof, P; Ruijter, H; Tielen, I; van Zandwijk, N | 1 |
| Fujiwara, Y; Kasahara, K; Kimura, H; Kunitoh, H; Nishio, K; Sone, T; Tamura, T | 1 |
| Fujimoto, K; Kawai, S; Masui, K; Nishi, N; Yonezawa, T | 1 |
| Bearz, A; Berretta, M; Fratino, L; Giacalone, A; Simonelli, C; Spazzapan, S; Tirelli, U | 1 |
| Aldanondo Fernández de la Mora, I; Fernández-Guarino, M; García-Millán, C; Garrido López, P; Jaén Olasolo, P; Pérez García, B | 1 |
| Giaccone, G; Hoekman, K; Kater, M; Manoliu, RA; Meijerink, MR; van Cruijsen, H; van Schaik, C; van Waesberghe, JH | 1 |
| Botwood, N; Bunn, PA; Chang, A; Ciuleanu, T; Donald, E; Dziadziuszko, R; Ellison, G; Flannery, A; Franklin, WA; Hirsch, FR; Holloway, B; Knight, L; Parikh, P; Parums, D; Pereira, JR; Thatcher, N; Varella-Garcia, M; von Pawel, J; Watkins, C | 1 |
| Desbois-Mouthon, C; Fartoux, L; Poupon, R; Rosmorduc, O | 1 |
| Balak, MN; Chiang, A; Gong, Y; Kris, MG; Ladanyi, M; Li, AR; Miller, VA; Ouerfelli, O; Pao, W; Riely, GJ; Somwar, R; Yang, G; Zakowski, MF | 1 |
| Fujiwara, M; Ikehara, S; Ikehara, Y; Kodera, Y; Koike, M; Mochizuki, Y; Nakanishi, H; Nakao, A; Tatematsu, M; Yatabe, Y; Yokoyama, H | 1 |
| Memon, AA; Munk, M; Nexo, E; Sorensen, BS | 1 |
| Pao, W | 1 |
| Arslan, MA; Basaga, H; Kutuk, O | 1 |
| Memon, AA; Nexo, E; Sorensen, SB | 1 |
| Cappuzzo, F | 1 |
| Hagiwara, K; Kanazawa, M; Kobayashi, K; Koyama, N; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Sutani, A; Tanaka, T; Uchida, Y; Udagawa, K | 1 |
| Ahmad, B; Anuar, D; Chin, TM; Goh, BC; Iacopetta, B; Kawakami, K; Lee, SC; Li, WQ; Salto-Tellez, M; Segal, A; Soo, R; Soong, R | 1 |
| Emdad, L; Fisher, PB; Gupta, P; Lebedeva, IV; Sarkar, D; Settleman, J; Su, ZZ | 1 |
| Nexo, E; Ornskov, D; Sorensen, BS | 1 |
| Pujol, JL | 1 |
| Personeni, N | 1 |
| Honmura, Y; Komagata, H; Kurimoto, F; Sakai, H; Sudo, J; Yoneda, S | 1 |
| Barón, A; Bemis, L; Bunn, PA; Chan, DC; Coldren, C; Franklin, WA; Gazdar, A; Gustafson, D; Helfrich, BA; Hirsch, FR; Minna, J; Raben, D; Varella-Garcia, M; Zeng, C | 1 |
| Fraga, CH; Hagedorn, N; Hubbard, KE; Panetta, JC; Stewart, CF; Waters, CM; Zhuang, Y | 1 |
| Golub, T; Halmos, B; Hetherington, CJ; Kobayashi, S; Lowell, AM; Meyerson, M; Monti, S; Shapiro, GI; Shimamura, T; Steidl, U; Tenen, DG | 1 |
| Yu, SY; Zhang, L | 1 |
| Baker, SD; Brahmer, J; Hidalgo, M; Karlsson, MO; Li, J; Spitz, A; Zhao, M | 1 |
| Baker, SD; Cusatis, G; Gregorc, V; Hidalgo, M; Ingersoll, RG; Li, J; Ludovini, V; Sparreboom, A; Spreafico, A; Verweij, J; Villa, E | 1 |
| Chen, M; Gemma, A; Kataoka, K; Kokubo, Y; Kosaihira, S; Kudoh, S; Matsuda, K; Minegishi, Y; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| An, TT; Fang, J; Liu, XY; Wu, MN; Yang, L | 1 |
| Carlini, P; Ciccarese, M; Cognetti, F; Fabi, A; Felici, A; Ferretti, G; Milella, M; Nuzzo, C; Papaldo, P; Ruggeri, EM | 1 |
| Chang, A; Zhang, X | 1 |
| du Bois, A; Gropp, M; Huober, J; Jackisch, C; Loibl, S; Lück, HJ; Meier, W; Pfisterer, J; Schmalfeldt, B; Sehouli, J; Stähle, A; Wagner, U | 1 |
| Guan, ZZ; Pan, ZK; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Han, Y; Li, YM; Paradiso, A; Wang, Y; Xu, JM; Zhao, CH | 1 |
| Hanagiri, T; Oyama, T; Sugaya, M; Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Beck, S; Benson, R; Beusmans, JM; de Graaf, D; Griffiths, GJ; Hendriks, BS; Hickinson, M; Kenyon, D; Lauffenburger, D; Lazzara, M; Swinton, J | 1 |
| Lu, Y; Lubet, RA; Vikis, H; Wang, M; Wang, Y; Yan, Y; Yao, R; You, M | 1 |
| Aoe, K; Aoe, M; Asano, H; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Shigematsu, H; Shimizu, K; Shimizu, N; Soh, J; Tokumo, M; Toyooka, S | 1 |
| Chen, G; Huang, YJ; Liao, RQ; Lin, JY; Wang, K; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Yang, XN; Zhang, GC; Zhou, Q | 1 |
| Arnold, D; Hochhaus, A; Hofheinz, RD; Kubicka, S; Wollert, J | 1 |
| Debus, J; Hof, H; Welzel, T | 1 |
| Fujimoto, N; Fujiwara, K; Hisamoto, A; Hotta, K; Katayama, H; Kiura, K; Kozuki, T; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Boye, K; Bras-Gonçalves, RA; Chapelier, A; de Cremoux, P; Defrance, R; Judde, JG; Livartowski, A; Poupon, MF; Rebucci, M; Tran-Perennou, C; Vogt, N | 1 |
| Briand, O; Depreux, P; Desroses, M; Farce, A; Hénichart, JP; Laconde, G; Lemoine, A; Pommery, N; Telliez, A | 1 |
| Hanada, M; Noguchi, T; Yamaoka, T | 1 |
| Clark, JW; D'Amato, F; Dancey, J; Earle, CC; Eder, JP; Enzinger, PC; Fuchs, CS; Kinsella, K; Mayer, RJ; Meyerhardt, JA; Michelini, A; Ogino, S; Ryan, DP; Stewart, CF; Supko, JG; Zhu, AX | 1 |
| Eckardt, A; Morgan, MA; Reuter, CW | 1 |
| Pühringer-Oppermann, FA; Sarbia, M; Stein, HJ | 1 |
| Abe, T; Haraguchi, M; Hayashi, M; Ito, K; Tsutsui, N | 1 |
| Aglietta, M; Montemurro, F; Valabrega, G | 1 |
| Bissonnette, M; Cerda, S; Cohen, G; Dougherty, U; Fichera, A; Gong, C; Hart, J; Jagadeeswaran, S; Joseph, L; Khare, S; Little, N; Mustafi, R; Sehdev, A; Tallerico, M; Tretiakova, M; Turner, JR; Yuan, W | 1 |
| Azzariti, A; Han, Y; Li, YM; Li, ZQ; Paradiso, A; Wang, Y; Xu, JM; Yang, WW; Yuan, SJ; Zhao, CH | 1 |
| Grenier, J; Soria, JC | 1 |
| Adam, L; Bar-Eli, M; Black, P; Brown, G; Dinney, CP; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Botwood, N; Chau, I; Cunningham, D; Hickish, T; Higgins, L; Massey, A; Osborne, R; Swaisland, A | 1 |
| Chou, LS; Garey, J; Kim, E; Oishi, K | 1 |
| Bréchot, JM | 1 |
| Bergh, A; Hammarsten, P; Henriksson, R; Rudolfsson, SH; Wikström, P | 1 |
| Barrow, D; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; Nicholson, RI | 2 |
| Barrow, D; Burmi, RS; Gee, JM; Hutcheson, IR; Jones, HE; Knowlden, JM; McClelland, RA; Nicholson, RI | 1 |
| Scagliotti, GV; Selvaggi, G | 1 |
| Hirano, S; Kitao, H; Kiura, K; Ogino, A; Rai, K; Tabata, M; Takata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Uchida, A | 1 |
| Iwanaga, K; Tohda, Y | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Gong, SJ; Gong, YF; Hu, XH; Jiang, B; Liu, F; Wang, ML; Yao, BD; Zhang, WY; Zhu, GS; Zhu, ZZ | 1 |
| Fidias, P; Haber, DA; Jänne, PA; Johnson, BE; Joshi, VA; Kucherlapati, R; Lynch, TJ; Meyerson, M; Muzikansky, A; Sequist, LV | 1 |
| Gaiger, A; Grunt, TW; Kainz, B; Köhler, G; Puckmair, K; Rünzler, D; Tomek, K; Wagner, R; Zielinski, CC | 1 |
| Fujii, K; Gemma, A; Hirohashi, S; Kato, H; Kondo, T; Kudoh, S; Matsuno, Y; Nishimura, T; Ohe, Y; Okano, T; Takano, T; Tsuta, K | 1 |
| Bell, DW; Haber, DA; Lynch, TJ; Sequist, LV | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; De Pas, T; Manzotti, M; Pelosi, G; Renne, G; Spitaleri, G | 1 |
| Bonn, GK; Huber, LA; Peränen, J; Schiefermeier, N; Skvortsov, S; Stasyk, T; Zwierzina, H | 1 |
| Adam, L; Bar-Eli, M; Dinney, CP; Lashinger, L; McConkey, DJ; Pino, MS; Shrader, M | 1 |
| Foster, PA; Lunec, J; Mellon, JK; Nutt, JE | 1 |
| Baker, SD; Bates, SE; Brahmer, J; Cusatis, G; Hidalgo, M; Li, J; Robey, RW; Sparreboom, A | 1 |
| Ashitani, J; Imai, K; Kodama, T; Kyoraku, Y; Matsumoto, N; Nakazato, M; Sano, A; Yanagi, S | 1 |
| Bemis, L; Bunn, PA; Cappuzzo, F; Chansky, K; Crino, L; Dziadziuszko, R; Franklin, WA; Gandara, DR; Gazdar, AF; Gumerlock, P; Hirsch, FR; McCoy, J; Varella-Garcia, M; West, H; Xavier, AC | 1 |
| Bernardi, RJ; Black, JD; Brattain, MG; Creaven, PJ; Fakih, MG; French, R; Hutson, A; Johnson, CS; Muindi, JR; Schwartz, J; Trump, DL | 1 |
| Duster, T | 1 |
| van de Vijver, MJ; van Zandwijk, N | 1 |
| Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ | 1 |
| Fukuoka, M; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Takada, M; Tamura, K; Terashima, M; Yoshida, T | 1 |
| Anderson, KS; Bell, DW; Ferrand, A; Haber, DA; Kim, Y; Mulloy, R; Settleman, J; Sordella, R | 1 |
| Aoe, M; Date, H; Ichihara, S; Ito, S; Kiura, K; Kobayashi, N; Sano, Y; Soh, J; Suehisa, H; Toyooka, S; Yamane, M | 1 |
| Serke, M | 1 |
| Bally, MB; Dragowska, WH; Edwards, L; Gelmon, K; Huxham, LA; Minchinton, AI; Ramsay, EC; Verreault, M; Warburton, C; Yapp, DT | 1 |
| Marais, R; Niculescu-Duvaz, D; Springer, C; Whittaker, S | 1 |
| Boggon, TJ; Eck, MJ; Greulich, H; Li, Y; Meyerson, M; Woo, MS; Yun, CH | 1 |
| Carlisle, DL; Gaither-Davis, A; Grandis, JR; Liu, X; Siegfried, JM; Swick, MC | 1 |
| Chen, YM; Chou, TY; Liu, JM; Perng, RP; Tsai, CM; Whang-Peng, J | 1 |
| Aoki, H; Iijima, H; Imai, H; Ishihara, S; Iwasaki, Y; Mori, M; Saito, R; Sunaga, N; Tomizawa, Y; Watanabe, S | 1 |
| Blaukat, A; Funk, JO; Irmer, D | 1 |
| Blatt, V; Brandes, AA; Cavallo, G; Crinò, L; Franceschi, E; Grosso, D; Lonardi, S; Magrini, E; Pession, A; Scopece, L; Tallini, G; Tosoni, A; Urbini, B | 1 |
| Bereczky, B; Nishimura, Y; Ono, M | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Lin, MF; Mimeault, M; Moore, E; Vankatraman, G | 1 |
| Amador, ML; Grunwald, V; Hidalgo, M; Iacobuzio-Donahue, C; Jimeno, A; Maitra, A; Rubio-Viqueira, B | 1 |
| Dutta, PR; Maity, A | 1 |
| Dobashi, K; Hisada, T; Iijima, H; Ishizuka, T; Kaira, K; Mori, M; Saito, R; Shimizu, K; Suga, T; Sunaga, N; Tanaka, S; Tomizawa, Y; Yanagitani, N | 1 |
| Díaz-Montero, CM; Estecio, M; Issa, JP; Mao, L; Montero, AJ; Shen, L; Youssef, EM | 1 |
| Clark, JW; Enzinger, PC; Fuchs, CS; Kawasaki, T; Kulke, MH; Loda, M; Meyerhardt, JA; Ogino, S; Ryan, DP; Wolpin, BM | 1 |
| Akie, K; Asahina, H; Dosaka-Akita, H; Harada, M; Ishida, T; Isobe, H; Kinoshita, I; Konishi, J; Munakata, M; Nishimura, M; Ogura, S; Sukoh, N; Yamazaki, K; Yokouchi, H | 1 |
| Asomaning, K; Christiani, DC; Gurubhagavatula, S; Heist, R; Liu, G; Lynch, TJ; Su, L; Wang, Z; Yeap, BY; Zhou, W | 1 |
| Costa, LJ; Drabkin, HA; Gemmill, RM | 1 |
| Adachi, S; Funada, Y; Kotani, Y; Mitsudomi, T; Negoro, S; Sakuma, T; Satouchi, M; Shimada, T; Takada, Y; Urata, Y; Watanabe, H; Yatabe, Y; Yoshimura, S | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shibata, K; Sone, T; Waseda, Y | 1 |
| Cho, BK; Choi, HJ; Kim, SY; Lee, JY; Park, HJ | 1 |
| Fujiwara, Y; Hisamoto, A; Hotta, K; Ichihara, E; Kiura, K; Kozuki, T; Ohashi, K; Osawa, M; Shibayama, T; Tabata, M; Tada, A; Takahashi, K; Takata, S; Takeyama, M; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Frederick, B; Gustafson, DL; Merz, AL; Raben, D | 1 |
| Jeon, NK; Kim, J; Lee, EJ; Whang, JH | 1 |
| Armando, E; Bertetto, O; Bonello, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Macrì, L; Sapino, A; Schena, M | 1 |
| Gadgeel, SM; Heath, EI; Heilbrun, LK; Ruckdeschel, JC; Venkatramanamoorthy, R; Wozniak, A | 1 |
| Aoe, M; Date, H; Kiura, K; Kosaka, T; Mitsudomi, T; Ogino, A; Ouchida, M; Shigematsu, H; Soh, J; Takata, M; Toyooka, S; Uchida, A | 1 |
| Argiris, A; Gooding, W; Hensing, T; Kolesar, J; Masters, G; Patel, S; Pins, M; Raji, A; Sturgis, C; Yeldandi, A | 1 |
| Fujimura, M; Ichikawa, Y; Ishiura, Y; Kasahara, K; Kashii, T; Kimura, H; Kita, T; Kobayashi, M; Kunitoh, H; Mizuguchi, M; Nakao, S; Nakatsumi, Y; Nishio, K; Shiarasaki, H; Shibata, K; Sone, T; Tamura, T; Waseda, Y; Watanabe, K; Yoshimoto, A | 1 |
| Evans, WK; Feld, R; Mackay, JA; Shepherd, FA; Sridhar, SS | 1 |
| Nokihara, H; Sekine, I; Takada, M; Tamura, T; Yamamoto, S | 1 |
| Deneulin, A; Fandi, A; Feld, R; Laurie, SA; Pujol, JL; Rebattu, P; Viens, P | 1 |
| Chang, GC; Chen, KC; Chiu, CH; Hsu, JY; Lin, CP; Perng, RP; Shih, JY; Tsai, CM; Yang, CH; Yang, PC; Yang, TY; Yu, CJ | 1 |
| Chen, YM; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J | 1 |
| Endoh, H; Kosaka, T; Kuwano, H; Mitsudomi, T; Yatabe, Y | 1 |
| Grandis, JR; Keohavong, P; Romkes, M; Siegfried, JM; Stabile, LP; Traynor, AM; Zhang, W | 1 |
| Kishi, K; Nakata, K; Yoshimura, K | 1 |
| Furuyashiki, G; Goya, T; Koshiishi, Y; Matsushima, S; Nogami, H; Ohnishi, H; Ohtsuka, K; Ooide, A; Watanabe, T | 1 |
| Botwood, N; Chang, A; Ganzon, D; Parikh, P; Perng, RP; Tan, EH; Thatcher, N; Thongprasert, S; Tsao, CJ; Watkins, C; Yang, CH | 1 |
| Han, JY; Hong, EK; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Nam, BH; Yu, SY | 1 |
| Davies, A; Fukuoka, M; Garfield, DH; Giaccone, G; Jassem, J; Kris, MG; Quoix, EA; Sandler, AB; Scagliotti, GV; Van Meerbeeck, JP; West, H | 1 |
| Hida, T; Horio, Y; Kosaka, T; Matsuo, K; Mitsudomi, T; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Bunn, PA; Dziadziuszko, R; Hirsch, FR; Jassem, J; Limon, J; Rzyman, W; Siemiatkowska, A; Varella-Garcia, M | 1 |
| Furukawa, M; Goya, S; Greene, MI; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Nagatomo, I; Osaki, T; Tachibana, I; Takahashi, R; Takeda, Y; Yamadori, T; Yoneda, T; Yoshida, M; Yoshimura, M | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Hwang, PG; Im, SA; Jeon, YK; Keam, B; Kim, DW; Kim, TY; Lee, KH; Lee, SH; Oh, DY | 1 |
| Chen, Z; Gonzalez, KD; Gu, D; Hill, KA; Li, K; Saldivar, JS; Scaringe, WA; Sommer, SS | 1 |
| Chen, XQ; Rong, TH; Wei, WD; Wen, ZS; Wu, HY | 1 |
| Yoneda, S | 1 |
| Sugio, K; Uramoto, H; Yasumoto, K | 1 |
| Li, YL; Li, Z; Wang, ZM; Wei, Z; Wu, C; Zhang, TX | 1 |
| Inuzuka, K; Kasahara, K; Kawashima, A; Kita, T; Yoshimoto, A | 1 |
| Chun, PY; Davis, MA; Feng, FY; Lawrence, TS; Li, X; Lopez, CA; Normolle, DP; Nyati, MK; Varambally, S | 1 |
| Huang, YJ; Huang, YS; Liao, RQ; Lin, JY; Wang, Z; Wu, YL; Xu, CR; Yang, JJ; Zhou, Q | 1 |
| Chen, YM; Chiu, CH; Liou, JL; Perng, RP; Shih, YN; Tsai, CM | 1 |
| Kohno, H; Maehara, Y; Mori, D; Shoji, F; Yamasaki, F; Yano, T; Yoshino, I | 1 |
| Fischer, JR; Geiger, D; Haffner, UJ; Lahm, H | 1 |
| Bergot, E; Richard, N; Zalcman, G | 1 |
| Amadori, D; Brigliadori, G; Fabbri, F; Granato, AM; Rosetti, M; Silvestrini, R; Tesei, A; Ulivi, P; Vannini, I; Zoli, W | 1 |
| Cantley, LC; Cappuzzo, F; Christensen, J; Engelman, JA; Gale, CM; Holmes, AJ; Hyland, C; Jänne, PA; Johnson, BE; Kosaka, T; Lee, C; Lindeman, N; Mitsudomi, T; Mok, T; Park, JO; Rogers, AM; Song, Y; Zejnullahu, K; Zhao, X | 1 |
| Arpino, G; Bharwani, L; De Placido, S; Gutierrez, C; Massarweh, S; Osborne, CK; Rimawi, M; Schiff, R; Weiss, H | 1 |
| Adjei, AA; Croghan, G; Hanson, LJ; Jett, JR; Lathia, C; Mandrekar, SJ; Marks, R; Molina, JR; Reid, JR; Simantov, R; Xia, C | 1 |
| Ciardiello, F; Hong, WK; Kim, ES; Kim, WY; Lee, HY; Morgillo, F | 1 |
| Basu, S; Bonomi, P; Buckingham, LE; Coon, JS; Gale, M; Jacobson, KK; Jewell, SS; Kaiser, KA; Mauer, AM; Morrison, LE; Muzzafar, T; Polowy, C; Villaflor, VM | 1 |
| Jiang, B; Li, LY; Lin, JY; Liu, W; Mok, T; Mu, XL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhang, L; Zhang, XT; Zhong, WZ; Zhou, CC; Zhou, Q | 1 |
| Gotoh, T; Hosoi, H; Iehara, T; Izumi, M; Kikuchi, K; Kuwahara, Y; Otabe, O; Sugimoto, T; Tamura, S; Tsuchiya, K | 1 |
| Bergman, E; Cantarini, MV; Dickinson, P; Farmer, MR; Forsell, P; Knutson, L; Lennernäs, H; Persson, EM; Smith, R; Swaisland, H | 1 |
| Aoe, K; Aoe, M; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Ichimura, K; Kiura, K; Kobayashi, N; Soh, J; Suehisa, H; Toyooka, S | 1 |
| Albitar, L; Carter, MB; Davies, S; Leslie, KK | 1 |
| Aakre, ME; Arteaga, CL; Bonine-Summers, AR; Brown, KA; Cheng, N; Moses, HL; Pietenpol, JA | 1 |
| Hanibuchi, M; Sone, S; Tomimoto, H; Yano, S | 1 |
| Arao, T; Kimura, H; Nishio, K; Sakai, K; Shimoyama, T; Tamura, T | 1 |
| Bekele, BN; Herbst, RS; Liu, DD; Massarelli, E; Ozburn, NC; Tang, X; Varella-Garcia, M; Wistuba, II; Xavier, AC | 1 |
| Chen, Z; Choe, MS; Klass, CM; Shin, DM; Zhang, X | 1 |
| Arao, T; Fukuoka, K; Kimura, H; Komatsu, T; Nishio, K; Saijo, N; Sasaki, H; Takeda, M; Tamura, T; Yamada, Y; Yanagihara, K; Yokote, H | 1 |
| Hayashi, A; Nakatani, K; Nishioka, J; Nobori, T; Noma, K; Takao, M; Wada, H; Yasuda, K | 1 |
| Hitomi, T; Kawanaka, M; Koyama, M; Matsuzaki, Y; Sakai, T; Yogosawa, S | 1 |
| Koldenhof, JJ; Sigurdsson, V; Tjin-A-ton, ML; van Montfrans, C; Voest, EE; Witteveen, PO | 1 |
| Foley, J; Gilmore, JL; Gonterman, RM; Koltz, PF; Konger, RL; Laughner, R; Lewis, DA; Lorch, G; Nadella, KS; Rosol, TJ; Toribio, RE | 1 |
| De Tursi, M; Grassadonia, A; Iacobelli, S; Innominato, PF; Irtelli, L; Iurisci, I; Lévi, F; Rich, T; Tinari, N | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Ciardiello, F; Crino, L; Finocchiaro, G; Holmes, AJ; Jänne, PA; Ligorio, C; Magrini, E; Paioli, D; Patelli, M; Rossi, E; Toschi, L; Trisolini, R; Varella-Garcia, M | 1 |
| Bunn, PA; Chan, D; Coldren, CD; Frederick, BA; Helfrich, BA; Raben, D; Zheng, D | 1 |
| Date, H; Kiura, K; Takata, M; Toyooka, S; Uchida, A | 1 |
| Bashar, AH; Funai, K; Kazui, T; Mori, H; Sugimura, H; Suzuki, K; Takamochi, K | 1 |
| Han, WD; Hao, HJ; Li, Q; Li, XH; Si, YL; Wu, ZQ; Zhao, YL | 1 |
| Brunet, J; Colomer, R; De Llorens, R; Ferrer-Soler, L; Menendez, JA; Vazquez-Martin, A | 1 |
| Liu, G; Shepherd, FA; Tsao, MS | 1 |
| Brahmer, J; Bunn, PA; Caprioli, R; Carbone, DP; Duncan, MW; Dziadziuszko, R; Gray, R; Gregorc, V; Grigorieva, J; Hirsch, FR; Hunsucker, SW; Kasahara, K; Ludovini, V; Massion, PP; Nishio, M; Roder, H; Schiller, J; Solomon, B; Spreafico, A; Taguchi, F; Tsypin, M | 1 |
| Chouaid, C; Fournel, P; Monnet, I; Perol, M; Robinet, G; Vergnenegre, A | 1 |
| Eguchi, K; Hisamoto, A; Kiura, K; Kozuki, T; Mandai, K; Nakata, M; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Allan, G; Campbell, MJ; Goldfine, ID; Hodges, L; Kerner, JA; Kushner, P; Maddux, BA; Shiry, L; Youngren, JF; Zavodovskaya, M | 1 |
| Cescon, TP; Dennison, SK; Geyer, CE; Jacobs, SA; Raymond, JM; Seeger, J; Swain, SM; Wilson, JW; Wolmark, N | 1 |
| Okamoto, H; Watanabe, K | 1 |
| Costa, DB | 1 |
| Ang, BK; Chen, Y; Choong, LY; Druker, BJ; Hew, CL; Li, B; Lim, S; Lim, YP; Lin, Q; Low, TY; Ray, RS; Sze, NS; Tan, YL; Toy, W; Wong, CH | 1 |
| Aftab, DT; Bentzien, F; Cancilla, B; Chen, J; Chu, F; De Costa, A; Engell, K; Gendreau, SB; Jackman, L; Jaeger, CT; Joly, AH; Keast, P; Laird, AD; Lutman, J; Martini, JF; Meyer, SM; Shi, Y; Ventura, R; Wang, J; Yakes, FM; Yu, P; Zhang, W | 1 |
| Baker, SD; He, P; Hidalgo, M; Li, J; Zhao, M | 1 |
| Han, Y; Li, YM; Liu, XQ; Song, ST; Xu, JM; Yang, WW; Zhang, Y | 1 |
| Bunn, PA | 1 |
| Chang, J; Cho, BC; Choi, HJ; Im, CK; Kim, H; Kim, JH; Kim, SK; Kim, YJ; Park, JP; Park, MS; Shin, SJ; Sohn, JH | 1 |
| Azzoli, CG; Gomez, JE; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Milton, DT; Pao, W; Pizzo, B; Riely, GJ; Rizvi, NA | 1 |
| Brahmer, J; Juergens, R | 1 |
| Bozec, A; Formento, P; Hofman, P; Lassalle, S; Lippens, C; Milano, G | 1 |
| Boselli, S; de Braud, F; Lorizzo, K; Magni, E; Martignetti, A; Massacesi, C; Santoro, L; Zampino, MG; Zaniboni, A; Zorzino, L | 1 |
| Borner, M; Knuth, A; Morant, R; Pedrazzini, A; Rochlitz, C; Roggero, E; Salzberg, M; Schönenberger, A; Thalmann, G | 1 |
| An, SJ; Gan, B; Guo, AL; Huang, Y; Li, R; Lin, JY; Mok, TS; Nie, Q; Wang, Z; Wu, YL; Zhang, GC | 1 |
| Hur, GY; In, KH; Jung, JY; Jung, KH; Kang, EH; Kang, KH; Kim, JH; Kim, SJ; Lee, EJ; Lee, KJ; Lee, SH; Lee, SY; Shim, JJ; Shin, C; Yoo, SH | 1 |
| Calhoun, R; Gandara, DR; Jablons, D; Wakelee, H | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S | 1 |
| Bolognesi, A; Dell'Oca, I; Ghio, D; Giovannini, M; Gregorc, V; Spreafico, A; Viganò, MG; Villa, E | 1 |
| Kubota, K | 1 |
| Ishikawa, N | 1 |
| Colquhoun, AJ; Kriajevska, M; Mchugh, LA; Mellon, JK; Tulchinsky, E | 1 |
| Costa, DB; Huberman, MS; Kobayashi, S; Tenen, DG | 1 |
| Bologna, M; Festuccia, C; Gravina, GL; Millimaggi, D; Muzi, P; Ricevuto, E; Speca, S; Vicentini, C | 1 |
| Guo, J; Sheng, G; Warner, BW | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Spinella, F; Tortora, G | 1 |
| Chang, JW; Cheung, YC; Chou, CL; Hsieh, JJ; Hsu, T; Huang, SF; Wang, HM | 1 |
| Furukawa, K; Ichinose, S; Imai, K; Inoue, T; Kato, H; Kubota, M; Maehara, S; Ohira, T; Ohtani, K; Oikawa, T; Okunaka, T; Suga, Y; Sugimoto, Y; Tsunoda, Y; Tsutsui, H; Usuda, J | 1 |
| Ishiguro, N; Maeda, T; Minami, H; Oyabu, M; Sato, T; Tamai, I | 1 |
| Barclay, L; Bebb, G; English, J; Fee, J; Ho, C; Horsman, D; Laskin, JJ; Marra, MA; Melosky, B; Murray, N; O'Connor, R; Pugh, TJ; Salski, C; Sutcliffe, M; Vielkind, J | 1 |
| Brahmer, JR; Hann, CL | 1 |
| Akimoto, S; Anyoji, H; Fujii, K; Fukuoka, M; Hada, S; Harbron, CG; Higenbottam, T; Hirano, T; Jiang, H; Kanazawa, M; Kato, H; Kawakami, T; Kawamura, T; Kudoh, S; Kunito, H; Kyono, Y; Marko-Varga, G; Nakata, K; Nishimura, T; Nishio, K; Nishiwaki, Y; Nyberg, F; Ogiwara, A; Peers, IS; South, MC; Tsuboi, M; Tu, HK | 1 |
| Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT | 1 |
| Dibbley, SK; Lonardo, F; Piechocki, MP; Yoo, GH | 2 |
| Choi, YH; Kim, GY; Kim, MO; Lee, JD; Lee, MK; Moon, DO | 1 |
| Hu, WG; Liu, T; Wang, CY; Xiong, JX | 1 |
| Agata, J; Asahina, H; Itoh, T; Nishimura, M; Shinagawa, N; Yamazaki, K | 1 |
| Christophylakis, C; Georgoulias, V; Ignatiadis, M; Kalbakis, K; Kotsakis, A; Polyzos, A; Potamianou, A; Stathopoulos, GP; Tselepatiotis, E; Vamvakas, L | 1 |
| Fernández-Guarino, M; Gónzalez-López, C; Olasolo, PJ; Pérez-García, B; Ryan, AM | 1 |
| Cognetti, F; Di Costanzo, F; Ferraresi, V; Gabriele, A; Gamucci, T; Gasperoni, S; Gelibter, AJ; Giannarelli, D; Nuzzo, C; Pollera, CF; Signorelli, C; Zeuli, M | 1 |
| Chen, YR; Cheng, HH; Fu, YN; Huang, SF; Tsai, SF; Yang, CH; Yeh, CL | 1 |
| Aasrum, M; Christoffersen, T; Dajani, OF; Guren, TK; Lilleby, P; Meisdalen, K; Sandnes, D; Thoresen, GH; Tveteraas, IH | 1 |
| Jones, DV; Klementich, FJ; Ravindranathan, M | 1 |
| Gyergyay, F | 1 |
| Brand, RE; Carneiro, BA; Fine, E; Khandekar, JD; Knop, RH; Locker, GY; Uhlig, W | 1 |
| Botwood, N; Carbone, D; Danson, S; Dunlop, D; O'Byrne, KJ; Ranson, M; Taguchi, F | 1 |
| Curigliano, G; De Braud, F; De Cobelli, O; De Pas, T; Matei, V; Noberasco, C; Nolè, F; Renne, G; Rocco, B; Scardino, E; Spitaleri, G; Teresa Sandri, M; Verweij, F; Zorzino, L | 1 |
| Basti, S; Jampol, LM; Zhang, G | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Milleron, B; Wislez, M | 1 |
| Clark, E; Detre, S; Dowsett, M; Llombart, A; Magill, P; Mayordomo, JI; Salter, J; Skene, A; Smith, IE; Walsh, G | 1 |
| Koike, A; Ohta, T | 1 |
| Tsukuda, M | 1 |
| Barrow, D; Ellis, IO; Gee, JM; Hiscox, SE; Hutcheson, IR; Knowlden, JM; Nicholson, RI; Robertson, JF | 1 |
| Thatcher, N | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okumura, M; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 1 |
| Fukui, T; Mitsudomi, T | 2 |
| Andreetta, C; Banna, G; Battelli, N; Berardi, R; Bisagni, G; Boni, C; Bottini, A; Conte, P; Cresti, N; Di Blasio, B; Ficarra, G; Frassoldati, A; Giovannelli, S; Guarneri, V; Jovic, G; Maiorana, A; Michelotti, A; Piacentini, F; Puglisi, F; Santoro, A | 1 |
| Chang, S; Cloughesy, T; Dancey, J; Fink, K; Junck, L; Kuhn, J; Prados, MD; Robins, HI; Wen, PY; Yung, WK | 1 |
| Hirano, S; Ishiai, M; Kitao, H; Kiura, K; Kozuki, T; Ogino, A; Takata, M; Takigawa, N; Tanimoto, M; Uchida, A | 1 |
| Bailey, KE; Cai, Z; Chen, Z; Costantini, DL; Reilly, RM; Scollard, DA; Vallis, KA | 1 |
| Abe, S; Chiba, H; Hasegawa, T; Igarashi, Y; Inokuchi, J; Iseki, K; Ishii, A; Kabayama, K; Kaneko, M; Noguchi, M; Saitoh, M; Satoh, M; Shiratori, M; Suzuki, T; Tagami, S; Takahashi, H; Watanabe, A | 1 |
| Baker, SD; Cusatis, G; Ghio, D; Gregorc, V; Hidalgo, M; Ingersoll, RG; Ludovini, V; Marsh, S; Sparreboom, A; Spreafico, A; Steinberg, SM; Viganò, MG; Villa, E | 1 |
| Hao, HJ; Li, Q; Li, XH; Zhao, YL | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Song, ST; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Colantuoni, G; Del Gaizo, F; Ferrara, C; Galetta, D; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Rossi, A | 1 |
| Ahuja, A; Chan, AT; Hui, EP; Kam, M; King, A; Leung, SF; Lo, YM; Ma, B; Mo, F; Mok, T; To, KF; Zee, B | 1 |
| Date, H; Fujiwara, Y; Hotta, K; Kanehiro, A; Kato, K; Kiura, K; Soh, J; Tabata, M; Takigawa, N; Tanimoto, M; Tanimoto, Y; Toyooka, S | 1 |
| Akhurst, T; Kris, MG; Miller, VA; Milton, DT; Moore, E; Pao, W; Riely, GJ; Rizvi, NA; Schwartz, LH; Tyson, L; Zhao, B | 1 |
| Hare, KJ; Hartmann, B; Holst, JJ; Kissow, H; Poulsen, SS | 1 |
| DiPaola, RS; Fontana, J; Iacona, RB; Kabbinavar, FF; Rubin, M; Small, EJ; Tannir, N; Wilding, G | 1 |
| Arpin, D; Balme, B; Becuwe, C; Dalle, S; Thomas, L | 1 |
| Eichler, GS; Kane, D; Reimers, M; Weinstein, JN | 1 |
| Araya, T; Fujimura, M; Kasahara, K; Kimura, H; Koizumi, F; Miyamoto, K; Nakao, S; Nishio, K; Sone, T; Suminoe, M; Tamori, S | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Stewart, CF; Wolf, JK; Yu, J | 1 |
| Ji, M; Li, MD; Zheng, YG | 1 |
| Aparicio, S; Astanehe, A; Buys, TP; Dunn, SE; Habibi, G; Hu, K; Jiang, H; Klinge, U; Lam, W; Marra, M; Mertens, PR; Nielsen, TO; Park, E; Pugh, T; Shadeo, A; Stratford, AL | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Matsuno, Y; Nokihara, H; Ohe, Y; Sakamoto, H; Sekine, I; Takano, T; Tamura, T; Tateishi, U; Tsuta, K; Yamamoto, N; Yoshida, T | 1 |
| Andersson, M; Nielsen, DL | 1 |
| Abe, D; Amano, Y; Fujii, A; Kitano, Y; Nakamura, H; Ohya, J; Suzuki, T | 1 |
| Almaraz-Pro, C; Colás, B; Colomer, R; Cortés, MA; López-Ruiz, P; Martín-Orozco, RM; Rodríguez-Ubreva, FJ; Ropero, S | 1 |
| Anderson, M; Atherfold, P; Beddard, K; Ferry, DR; Harrison, R; Jankowski, J; Obszynska, J; Tomlinson, S | 1 |
| Daly, RJ; Lehrbach, GM; Musgrove, EA; Sutherland, RL; Timpson, P; Wilson, AS | 1 |
| Bailey, CJ; Cantarini, MV; Collins, B; Smith, RP | 1 |
| Bendell, JC; Clark, JW; Czito, BG; Duda, DG; Jain, RK; Willett, CG | 1 |
| Banerjee, S; Chellappan, S; Rastogi, S; Simon, GR | 1 |
| Gemma, A; Kataoka, K; Kokubo, Y; Kosaihira, S; Kudoh, S; Matsuda, K; Minegishi, Y; Miyanaga, A; Nara, M; Noro, R; Okano, T; Seike, M; Yoshimura, A | 1 |
| Endo, K; Hisada, T; Ishizuka, T; Kaira, K; Mori, M; Oriuchi, N; Sunaga, N; Tomizawa, Y; Yanagitani, N | 1 |
| Baker, CH; Bekele, N; Fidler, IJ; Herbst, RS; Langley, RR; O'Reilly, MS; Onn, A; Tang, XM; Tsan, RZ; Wu, W | 1 |
| Horn, F; Klappenberger, S; Lattrich, C; Ortmann, O; Pfeiler, G; Treeck, O | 1 |
| Biordi, L; Bologna, M; Festuccia, C; Gravina, GL; Martella, O; Muzi, P; Ronchi, P; Vicentini, C | 1 |
| Andersson, U; Behnam-Motlagh, P; Johansson, D; Johansson, M; Malmer, B | 1 |
| Ashley, S; Barbachano, Y; Norton, A; O'Brien, M; Popat, S | 1 |
| Bajorin, D; Halabi, S; Philips, GK; Sanford, BL; Small, EJ | 2 |
| Elenius, K; Erjala, K; Grénman, R; Kulmala, J; Sundvall, M; Zhang, N | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y | 1 |
| Endo, K; Fujii, Y; Iuchi, K; Kawaguchi, T; Kawahara, M; Kawano, O; Kitahara, N; Matsumura, A; Okuda, K; Sasaki, H; Takada, M; Tanaka, H; Yano, M; Yokoyama, T; Yukiue, H | 2 |
| Aguilera, J; Chang, C; Chen, JS; Lopez, JP; Ongkeko, WM; Pardo, FS; Wang-Rodriguez, J | 1 |
| Hanaoka, T; Hayano, T; Okada, M; Sone, S; Yamaguchi, S | 1 |
| Cadranel, J; Gounant, V; Khalil, A; Lavole, A; Milleron, B; Poulot, V; Wislez, M | 1 |
| Ahmed, F; Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Bajetto, A; Barbieri, F; Favoni, R; Ferrari, A; Florio, T; Gatti, M; Lunardi, G; Pattarozzi, A; Porcile, C; Ratto, A; Würth, R | 1 |
| Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Jordis, U; Knesl, P; Röseling, D | 1 |
| Campone, M; Coudert, B; Favier, L; Ferrant, E; Fumoleau, P; Mayer, F | 1 |
| Besse, B; Italiano, A; Planchard, D; Soria, JC | 1 |
| Chen, C; Damek, DM; Gaspar, LE; Kavanagh, BD; Lillehei, K; Schwer, AL; Stuhr, K | 1 |
| Aliu, S; Hann, B; Hom, YK; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ; Wong, CH | 1 |
| Baron, A; Campana, J; Chen, C; Dancey, J; Eckhardt, SG; Harrison, L; Hu, K; Kane, M; Quon, H; Raben, A; Raben, D; Said, S; Song, J | 1 |
| Boggon, TJ; Costa, DB; Halmos, B; Huberman, MS; Kobayashi, S; Kumar, A; Schumer, ST; Tenen, DG | 1 |
| Cragg, MS; Huang, DC; Kuroda, J; Puthalakath, H; Strasser, A | 1 |
| Ardizzoni, A; Bortesi, B; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; Chiaramondia, M; Dadati, P; Franciosi, V; Grossi, F; Kunkl, A; Lagrasta, C; Loprevite, M; Naldi, N; Nizzoli, R; Rindi, G; Spiritelli, E; Tiseo, M; Zennaro, D | 1 |
| Carrasco, AT; Chaigneau, L; Extra, JM; Fabbro, M; Floquet, A; Gladieff, L; Goncalves, A; Lhommé, C; Viens, P | 1 |
| Gemma, A; Kudoh, S; Matsuda, K; Minegishi, Y; Nara, M; Noro, R; Okano, T; Shibuya, M; Takemura, A; Yoshimura, A | 1 |
| Chen, GS; Lan, CC; Wu, CY | 1 |
| Castellano, A; De Ioris, MA; De Laurentis, C; Dominici, C; Donfrancesco, A; Garganese, MC; Ilari, I; Jenkner, A; Milano, GM | 1 |
| Clark, JR; Daniels, GH; Evans, T; Fidias, PH; Gurubhagavatula, S; Haddad, RI; Heist, RS; Lynch, TJ; Pennell, NA; Ross, DS; Temel, JS; Wirth, LJ | 1 |
| Chen, CS; Chen, Y; Choong, LY; Druker, BJ; Hande, MP; Lim, S; Lim, YP; Loh, MC; Man, X; Pan, M; Poonepalli, A; Salto-Tellez, M; Shah, N; Tan, PH; Toy, W; Wong, CY | 1 |
| Briasoulis, E; Georgoulias, V; Kalikaki, A; Koutsopoulos, A; Mavroudis, D; Murray, S; Pallis, AG; Souglakos, J; Stathopoulos, E; Tripaki, M; Voutsina, A | 1 |
| Hizawa, N; Ishikawa, H; Kurishima, K; Ohara, G; Satoh, H | 1 |
| Ng, K; Zhu, AX | 1 |
| Ambudkar, SV; Ashby, CR; Bates, SE; Chen, ZS; Fu, LW; Kim, IW; Peng, XX; Robey, RW; Shen, T; Shi, Z; Shukla, S; Si, QS | 1 |
| Bang, YJ; Han, SW; Kim, TY | 1 |
| Okagawa, T; Suyama, M; Uchida, T | 1 |
| Fujita, S; Hoshino, Y; Ichikawa, M; Masago, K; Mio, T; Mishima, M; Nakamura, H; Nakamura, T; Sakuma, K; Tabata, C; Ueda, S; Yodoi, J | 1 |
| Ardizzoni, A; Berardi, R; Beretta, GD; Cascinu, S; Catalano, V; Crocicchio, F; Labianca, R; Mari, E; Pucci, F; Salvagni, S; Scartozzi, M; Sobrero, A; Tagliaferri, P | 1 |
| Campiglio, M; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Mancino, M; Menard, S; Normanno, N | 1 |
| Kubo, K | 1 |
| Ge, FJ; Luo, WD; Wang, Y; Xu, JM; Yuan, SJ; Zhao, CH | 1 |
| Cao, WG; Chen, XH; Ji, YB; Jin, YN; Li, H; Li, JF; Liu, BY; Ma, T | 1 |
| Miyazaki, M; Nakagawa, K | 1 |
| Bell, DW; Brannigan, BW; Morabito, A; Moscato, M; Normanno, N; Zampa, G | 1 |
| Albergaria, A; Coombes, RC; Francis, RE; Krol, J; Lam, EW; Polychronis, A; Sunters, A | 1 |
| Althaus, IW; Bradner, JE; Engelman, JA; Gale, CM; Gandhi, L; Gonzales, AJ; Heymach, JV; Jänne, PA; Lifshits, E; Meyerson, M; Naumov, GN; Nelson, JM; Shapiro, GI; Shimamura, T; Vincent, PW; Wong, KK; Zejnullahu, K; Zhao, F | 1 |
| Balak, M; Bean, J; Brennan, C; Broderick, S; Chang, WC; Chitale, D; Gazdar, A; Gerald, W; Huang, SF; Ladanyi, M; Miller, V; Motoi, N; Pao, W; Pass, H; Riely, G; Rusch, V; Shih, JY; Szoke, J; Viale, A; Wang, L; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Betticher, DC; Bihl, M; Bubendorf, L; D'Addario, G; Jost, L; Lerch, S; Mach, N; Mayer, M; Pless, M; Rauch, D; Ribi, K; Stahel, R; Stupp, R; Tapia, C; Widmer, L | 1 |
| Imagawa-Ishiguro, Y; Kato, Y; Sano, D; Taguchi, T; Tsukuda, M | 1 |
| Chen, L; He, Y; Huang, H; Liao, H; Wei, W | 1 |
| Blume, JE; Miller, CC | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Koizumi, K; Maeda, J; Oda, K; Okami, J; Orita, N; Taniguchi, K | 1 |
| Comb, MJ; Guo, A; Gygi, SP; Innocenti, G; Kornhauser, J; Lee, KA; MacNeill, J; Mitchell, J; Nardone, J; Polakiewicz, RD; Possemato, A; Rikova, K; Rush, J; Stokes, MP; Villén, J; Wang, Y; Wetzel, R | 1 |
| Arai, Y; Kojima, A | 1 |
| Hanagiri, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K | 1 |
| Carroll, KJ; Ellis, S; Pemberton, K | 1 |
| Azzariti, A; Gatti, G; Nicolin, A; Paradiso, A; Porcelli, L | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Jeon, YK; Kim, DW; Kim, HP; Kim, TY; Lee, SH; Oh, DY | 1 |
| Kano, Y | 1 |
| Hida, T; Mitsudomi, T; Sugiura, H; Sugiura, T; Yamada, K | 1 |
| Goya, S; Kawase, I; Kijima, T; Kumagai, T; Matsuoka, H; Minami, S; Osaki, T; Suzuki, M; Tachibana, I; Takeda, Y; Ueda, K; Yokota, S; Yoshida, M | 1 |
| Alligood, K; Cable, L; Carter, HL; Gallagher, KT; Gilmer, TM; Rusnak, D; Shewchuk, L; Spehar, G; Truesdale, AT; Woldu, E; Wood, ER | 1 |
| Ando, M; Gemma, A; Hagiwara, K; Iwanami, H; Kataoka, K; Kobayashi, K; Kosaihira, S; Kudoh, S; Minegishi, Y; Miyanaga, A; Miyazawa, H; Nara, M; Noro, R; Okano, T; Tanaka, T; Tsuboi, E; Yoshimura, A | 1 |
| Becker, JC; Schrama, D; Ugurel, S | 1 |
| Alonso, V; Bovio, H; Colomer, R; Cortés-Funes, H; Escudero, P; García-Carbonero, R; Grávalos, C; Jimeno, A; Juez, I; Sevilla, I; Vega-Villegas, ME | 1 |
| Chen, L; Zhang, PL | 1 |
| Au, GK; Chua, DT; Nicholls, J; Sham, JS; Wei, WI; Wong, MP | 1 |
| Bunn, PA; Dziadziuszko, R; Franklin, WA; Hirsch, FR; Holloway, B; Mann, H; Parums, DV; Speake, G; Thatcher, N; Watkins, C | 1 |
| Miller, VA | 1 |
| Ano, T; Miyazaki, K; Nakazawa, K; Ohtsuka, M; Satoh, H | 1 |
| Eck, MJ; Greulich, H; Mengwasser, KE; Meyerson, M; Toms, AV; Wong, KK; Woo, MS; Yun, CH | 1 |
| Lindsley, CW; Thomas, AL | 1 |
| Costa, DB; Kobayashi, S | 2 |
| Bodenstein, C; Czernin, J; Dubinett, SM; Ferl, GZ; Fueger, B; Hsu, YT; Kim, KJ; Phelps, ME; Seimbille, Y; Su, H; Weber, WA | 1 |
| Addeo, A; Barone, C; Birocco, N; Buffoni, L; Bussolati, G; Ciuffreda, L; Daniele, L; Dongiovanni, D; Dongiovanni, V; Fissore, C; Gaspari, F; Grillo, R; Macrì, L; Sapino, A; Schena, M | 1 |
| Fang, Z; Li, B; Xia, TB; Xiu, QY; Zang, YS | 1 |
| Creighton, CJ; Huang, S; Massarweh, S; Osborne, CK; Qin, L; Rimawi, M; Schiff, R; Tsimelzon, A; Weiss, H | 1 |
| Erickson, LA; Hobday, T; Jin, L; Leontovich, AA; Lloyd, RV; Ruebel, KH; Stilling, GA; Tanizaki, Y; Zhang, H; Zhang, S | 1 |
| Antonaci, S; Azzariti, A; Giannelli, G; Paradiso, A; Porcelli, L; Sgarra, C | 1 |
| Bridgewater, J; Glynne-Jones, R; Harrison, M; Propper, D; Stebbing, J | 1 |
| Almasi, A; Conte, P; Dominici, M; Eckhardt, S; Jori, B; Kanya, M; Keri, G; Kopper, L; Moldvay, J; Papay, J; Petak, I; Pinter, F; Sapi, Z; Schwab, R; Szabo, E; Szondy, K; Tamasi, A; Varkondi, E | 1 |
| Sun, Y; Wang, B; Wang, Y; Xu, NZ; Zhang, XR; Zhu, HX | 1 |
| Akamine, S; Akizuki, S; Hijiya, N; Kadota, J; Kawahara, K; Matsuura, K; Miyawaki, M; Moriyama, M; Tsuji, K; Tsukamoto, Y; Uchida, T | 1 |
| Hagiwara, K; Hirama, T; Ikebuchi, K; Kanazawa, M; Kobayashi, K; Koyama, N; Matsuoka, M; Miyazawa, H; Murayama, Y; Nagai, Y; Nagata, M; Nukiwa, T; Sutani, A; Takenoshita, S; Tanaka, T; Udagawa, K; Zhang, J | 1 |
| Aoe, K; Date, H; Fujiwara, Y; Hotta, K; Ichihara, S; Kiura, K; Kosaka, T; Matsuo, K; Mitsudomi, T; Ohe, Y; Otani, H; Soh, J; Takano, T; Toyooka, S; Yatabe, Y | 1 |
| Alfieri, RR; Bonelli, M; Bordi, F; Carmi, C; Cavazzoni, A; Frazzi, R; Fumarola, C; Galetti, M; Lodola, A; Mor, M; Petronini, PG; Zuliani, V | 1 |
| Gallo, JM; Guo, P; Wang, S; Wang, X; Zhou, Q | 1 |
| Brooks, C; Hobbs, ML; Liu, J; Meyn, RE; Munshi, A; Tanaka, T | 1 |
| Chu, CY; Hsiao, CH; Sheen, YS | 1 |
| Ebi, N; Fukuoka, J; Fukuoka, M; Hirashima, T; Ichinose, Y; Kashii, T; Katakami, N; Kudoh, S; Negoro, S; Nishimura, T; Okamoto, I; Satoh, T; Sawa, T; Shibata, K; Shimizu, E; Tamura, K | 1 |
| Giordano, S; Petrelli, A | 1 |
| Aoki, H; Ikegame, Y; Inagaki, A; Iwama, T; Kunisada, T; Nakashima, S; Oka, N; Soeda, A; Yoshimura, S | 1 |
| Al Moustafa, AE | 1 |
| Antonia, SJ; Begum, M; Bepler, G; Chiappori, A; Extermann, M; Haura, EB; Ismail-Khan, R; Kapoor, R; Schell, MJ; Simon, GR; Williams, CC | 1 |
| Claasen, J; Sos, ML; Staratschek-Jox, A; Thomas, RK; Wolf, J; Zander, T | 1 |
| Chang, JW; Chen, YH; Chen, YR; Chen, YT; Chiu, YT; Fang, YF; Hsi, BL; Hsieh, JJ; Hsieh, MH; Hsieh, MS; Hsu, HY; Huang, SF; Liu, HP; Tsai, HY; Tsai, SF | 1 |
| Bemis, LT; Birks, DK; Bunn, PA; Franklin, WA; Haney, J; Helfrich, BA; Hirsch, FR; Kato, H; Nakajima, E; Robinson, WA; Sugita, M; Varella-Garcia, M; Weiss, GJ | 1 |
| Duan, R; Grandis, JR; Johnson, DE; Jones, JE; Miranda, MB; Redner, RL; Thomas, SM | 1 |
| Costa, DB; Kobayashi, S; Schumer, ST; Tenen, DG | 1 |
| Halle, JS; Hayes, DN; Lee, CB; Moore, DT; Morris, DE; Rivera, MP; Rosenman, JG; Socinski, MA; Stinchcombe, TE | 1 |
| Belani, CP; Evans, T; Forster, J; Lu, H; Naret, C; Ramalingam, S; Sulecki, M; Teegarden, P; Weber, MR | 1 |
| Fong, T; Govindan, R; Morgensztern, D | 1 |
| Bianco, R; Ciardiello, F; Damiano, V; Daniele, G; Garofalo, S; Gelardi, T; Marciano, R; Rosa, R; Tortora, G | 1 |
| de Gruijl, TD; Giaccone, G; Hoekman, K; Kuenen, BC; Scheper, RJ; Stam, AG; van Cruijsen, H; van den Eertwegh, AJ | 1 |
| Chang, AY | 1 |
| Higashiyama, M; Kato, K; Kodama, K; Okami, J; Taniguchi, K | 1 |
| Biffi, R; Chiappa, A; de Braud, F; Dell'Orto, P; Fazio, N; Magni, E; Monfardini, L; Santoro, L; Sonzogni, A; Zampino, MG; Zorzino, L | 1 |
| Fujisaki, R; Gu, Z; Horii, A; Inomata, K; Inoue, A; Kondo, T; Nukiwa, T; Sakurada, A; Sato, M; Yamanaka, S | 1 |
| Armour, A; Fukuoka, M; Higenbottam, T; Ichinose, Y; Itoh, Y; Jiang, H; Kato, H; Kudoh, S; Nakagawa, K; Nakata, K; Nishiwaki, Y; Nyberg, F; Suga, M; Tsuboi, M; Watkins, C; Yokota, S | 1 |
| Burgin, S; Heidary, N; Naik, H | 1 |
| Heymann, WR | 1 |
| Asahina, H; Konishi, J; Nishimura, M; Suzuki, M; Yamazaki, K | 1 |
| Fukuoka, M; Hatashita, E; Iwasa, T; Nakagawa, K; Okabe, T; Okamoto, I; Satoh, T; Tamura, K; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Bang, YJ; Han, SW; Im, SA; Kim, HP; Kim, SH; Kim, TY; Oh, DY | 1 |
| Arlt, D; Korf, U; Laible, M; Löbke, C; Poustka, A; Rappl, C; Ruschhaupt, M; Sahin, O; Sültmann, H; Wiemann, S | 1 |
| Goto, H; Hanibuchi, M; Ikuta, K; Kakiuchi, S; Nakataki, E; Nishioka, Y; Ogino, H; Ryan, A; Sone, S; Yamada, T; Yano, S | 1 |
| Batra, SK; Depreux, P; Hauke, R; Henichart, JP; Lin, MF; Mehta, PP; Mimeault, M | 1 |
| Caldara, A; Graiff, C; Mandarà, M; Pedersini, R; Sava, T; Vattemi, E | 1 |
| Bode, AM; Christov, K; Ericson, ME; Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE; Szabo, E | 1 |
| Hong, JH; Ko, JC; Lin, YW; Wang, LH | 1 |
| Fojo, T | 1 |
| Arteaga, CL; Johnson, DH; Keedy, VL | 1 |
| Albain, KS; Chansky, K; Crowley, JJ; Gandara, DR; Gaspar, LE; Jett, J; Kelly, K; Lau, DH; Ung, YC | 1 |
| Nishio, M; Okano, Y | 1 |
| Agarwala, A; Breen, T; Bruetman, D; Einhorn, LH; Fisher, W; Hanna, N; Juliar, B; McClean, J; Taber, D; Titzer, M; Yu, M | 1 |
| Advani, S; Aggarwal, S; Babu, G; Bhattacharyya, GS; Chacko, RT; Chang, AY; Digumarti, R; Doval, DC; Hargreaves, L; Jagannathan, R; Nag, S; Parikh, P; Ranade, A; Thatcher, N | 1 |
| Chin, TM; Chuah, KL; Lim, SW; Nga, ME; Seah, SB; Soo, RA; Soong, R; Wong, AS | 1 |
| Ardizzoni, A; Ciardiello, F; De Marinis, F; De Petris, L; Di Maio, M; Gridelli, C; Hanna, N; Heymach, JV; Perrone, F; Rosell, R; Shepherd, FA; Thatcher, N; Vansteenkiste, J | 1 |
| Shih, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Dorfman, JD; Fuchs, BC; Fujii, T; Goodwin, JM; Lanuti, M; Tanabe, KK; Zhu, AX | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; Heymach, JV; Kim, WY; Lee, HY; Morelli, MP; Morgillo, F; Pepe, S; Rodolico, G; Tortora, G | 1 |
| Byun, BH; Cheon, GJ; Choe, DH; Kang, HJ; Kim, CH; Koh, JS; Lee, JC; Lim, SM; Na, II; Ryoo, BY; Yang, SH | 1 |
| Conaway, M; Gioeli, D; Theodorescu, D; Weber, MJ; Wu, Z | 1 |
| Devanz, P; Gaspar, N; Geoerger, B; Grill, J; Lacroix, L; Lecluse, Y; Morizet, J; Opolon, P; Valent, A; Vassal, G | 1 |
| De Grève, J; Decoster, L; Schallier, D; Teugels, E; Van Meerbeek, J; Vermeij, J | 1 |
| Kimpe, M; Nuyts, S; Prenen, H | 1 |
| Bartolini, S; Cancellieri, A; Cappuzzo, F; Castaldini, L; Crino, L; Finocchiaro, G; Magrini, E; Metro, G; Tallini, G; Toschi, L; Trisolini, R | 1 |
| Barba, MC; Barbaro, B; Boz, G; De Paoli, A; Doglietto, GB; Frattegiani, A; Gambacorta, MA; Innocente, R; Lupattelli, M; Mantini, G; Ratto, C; Rossi, C; Valentini, V; Vecchio, FM | 1 |
| Perng, RP; Su, HT; Tsai, CM | 1 |
| An, SJ; Guo, AL; Li, R; Mok, TS; Wu, YL; Zhang, GC; Zhang, XC; Zhang, YF; Zhong, WZ; Zhu, JQ | 1 |
| Iwasaki, T; Kimura, H; Kitada, S; Maekura, R; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Chang, GD; Chen, CS; Hung, JH; Kashida, Y; Kulp, SK; Sargeant, AM; Wang, D; Wang, YC; Yamaguchi, M; Yang, CC | 1 |
| Brannigan, BW; Godin-Heymann, N; Haber, DA; Lamb, J; Maheswaran, S; McDermott, U; Settleman, J; Ulkus, L | 1 |
| Aluri, L; Bissonnette, M; Cerda, S; Chumsangsri, A; Cohen, EE; Delgado, J; Dougherty, U; Fichera, A; Hart, J; Jagadeeswaran, S; Joseph, L; Little, N; Mustafi, R; Sehdev, A; Tretiakova, M; Yuan, W | 1 |
| Guo, AL; Wang, Z; Wu, YL; Xu, CR; Zhang, GC; Zhou, Q | 1 |
| Amato, RJ; Hernandez-McClain, J; Jac, J | 1 |
| Chan, KA; Chang, CH; Chen, KY; Kurth, T; Orav, EJ; Yang, PC; Young-Xu, Y | 1 |
| Bull Phelps, SL; Lea, JS; Miller, DS; Peyton, MJ; Schorge, JO; Shigematsu, H; Xiang, LL | 1 |
| Davidson, C; Hardie, WD; Ikegami, M; Korfhagen, TR; Le Cras, TD; Leikauf, GD; Prestridge, A; Whitsett, JA | 1 |
| Hamburger, AW | 1 |
| Piechocki, MP | 1 |
| Amin, DN; Bielenberg, DR; Heymach, JV; Klagsbrun, M; Lifshits, E | 1 |
| Fukuhara, T; Inoue, A; Kanamori, M; Morikawa, N; Nakashima, I; Nukiwa, T; Saijo, Y; Sakakibara, T | 1 |
| Blay, JY; Bui, BN; Hogendoorn, P; Le Cesne, A; Marreaud, S; Ray-Coquard, I; Schoffski, P; van Glabbeke, M; Verweij, J; Whelan, JS | 1 |
| Cadranel, J; de Prost, N; Lavolé, A; Taillade, L; Wislez, M | 1 |
| Boerner, JL; Ethier, SP; Hunter, LA; Mueller, KL | 1 |
| Dicker, A; Heymach, J; Korchin, B; Lazar, A; Lev, D; Pollock, RE; Ren, W; Wei, C; Zhu, QS | 1 |
| Adjei, AA; Cassivi, SD; Molina, JR; Schild, SE; Yang, P | 1 |
| Engelman, JA; Evans, TL; Goldberg, JS; Grunberg, SM; Haber, DA; Han, M; Iafrate, AJ; Jänne, PA; Johnson, BE; Joshi, VA; Kuhlmann, GL; Lynch, TJ; Martins, RG; McCollum, D; Muzikansky, A; Sequist, LV; Settleman, J; Spigel, D; Spira, A | 1 |
| Bertalanffy, A; Dieckmann, K; Dietrich, W; Gelpi, E; Hainfellner, JA; Marosi, C; Prayer, D; Preusser, M; Rottenfusser, A; Widhalm, G | 1 |
| Ceresoli, GL; Comoglio, P; Destro, A; Floor, K; Garassino, I; Giaccone, G; Giovannetti, E; Rodriguez, JA; Roncalli, M; Ruiz, MG; Santoro, A; Varella-Garcia, M; Zucali, PA | 1 |
| Liau, LM; Salgaller, ML | 1 |
| Abe, S; Azuma, A; Kudoh, S; Li, Y; Matsuda, K; Usuki, J; Wang, C; Yu, C | 1 |
| Aguilera, J; Chang, CY; Lopez, JP; Ongkeko, WM; Pardo, FS; Sneh, G; Wang-Rodriguez, J; Yu, MA | 1 |
| Black, JD; Iyer, RV; Javle, MM; Levea, CM; Maddipatla, S; Nwogu, CE; Pande, AU; Rani, A; Yang, GY | 1 |
| Li, AW; Xu, JF; Zhou, CC | 1 |
| Li, LY; Wang, HZ; Wang, MZ; Wang, SL; Wu, C; Zhang, L; Zhang, XT; Zhong, W | 1 |
| Fujiwara, Y; Hotta, K; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Akita, H; Kinoshita, I | 1 |
| Bereczky, B; Itoh, K; Nishimura, Y; Yoshioka, K | 1 |
| Bokemeyer, C; Hartmann, JT; Höhler, T; Holtmann, M; Kröning, H; Pintoffl, JP | 1 |
| Hirakawa, K; Inoue, H; Mimori, K; Mori, M; Nagahara, H; Ohira, M; Sawada, T; Zhang, X | 1 |
| Saijo, N | 3 |
| Sherman, SI | 2 |
| Accardi, R; Azzariti, A; Conti, D; LaCalamita, R; Paradiso, A; Pilato, B; Porcelli, L; Sebastian, S; Simone, GM; Tommasi, S; Tommasino, M | 1 |
| Colantuoni, G; Del Gaizo, F; Falanga, M; Ferrara, C; Gridelli, C; Guerriero, C; Maione, P; Nicolella, D; Palazzolo, G; Rossi, A | 1 |
| Bean, J; Chang, YC; Chen, KY; Cheng, AL; Hu, FC; Huang, CJ; Huang, CL; Lin, ZZ; Pao, W; Shih, JY; Shun, CT; Tsai, MC; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Riely, GJ | 2 |
| Dunsford, J | 1 |
| Belli, C; Giovannini, M; Gregorc, V; Villa, E | 1 |
| Khuri, FR; Roman, J | 1 |
| Azuma, A; Hagiwara, K; Kudoh, S | 1 |
| Christodoulou, C; Dahabreh, J; Mavri, A; Murray, S; Nikolakopoulou, A; Petraki, K; Skarlos, D | 1 |
| Dahse, R; Kosmehl, H | 1 |
| Fishkin, PA; Gross, HM; Jatoi, A; Johnson, DB; Kahanic, SP; Loprinzi, CL; Novotny, PJ; Rowland, K; Schaefer, PL; Sloan, JA; Tschetter, LK | 1 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, YW; Ling, ST; Wang, LH | 1 |
| Ledford, H | 1 |
| Herder, GJ; Lind, JS; Smit, EF | 1 |
| Fujiwara, Y; Hirano, S; Kiura, K; Kondo, E; Ohashi, K; Osawa, M; Rai, K; Takata, K; Takata, M; Tanimoto, M; Yoshino, T | 1 |
| Barrett, GM; Cemeus, C; Dimitroulakos, J; Lorimer, IA; Zhao, TT | 1 |
| Arteaga, CL; Engelman, JA; Faber, AC; Guix, M; Olivares, MG; Qu, S; Rinehart, C; Seidel, B; Song, Y; Wang, SE; Yee, D | 1 |
| Greene, MI; Wang, Q | 1 |
| Breza, N; Keri, G; Orfi, L; Petak, I; Pinter, F; Robert, K; Schwab, R; Varkondi, E | 1 |
| Fujisaki, K; Hirakata, H; Iida, M; Inoshima, I; Katafuchi, R; Maeda, H; Masutani, K; Takayama, K; Toyonaga, J; Tsuruya, K | 1 |
| Crinò, L; Reck, M | 1 |
| Chang, YC; Chiu, YH; Gow, CH; Hsu, YC; Shih, JY; Wei, PF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Endoh, H; Ishibashi, Y; Kimura, H; Kosaka, T; Kuwano, H; Mitsudomi, T; Onozato, R; Tanaka, S; Yajima, T; Yamaki, E; Yoshida, T | 1 |
| Becker, M; Börgermann, C; Rose, A; Rübben, H; Vom Dorp, F | 1 |
| Fukai, M; Fushitani, K; Kimura, H; Mori, M; Naka, N; Nakagawa, M; Nakazawa, Y; Namba, Y; Niinaka, M; Okada, T; Yano, Y; Yokota, S | 1 |
| Adamo, V; Caponigro, F; Franchin, G; Mari, E; Milano, A; Morrica, B; Pepe, S; Romano, C; Solla, R | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Na, II; Rho, JK; Ryoo, BY; Yang, SH | 1 |
| Bernhard, JC; Ferrière, JM; Ravaud, A; Robert, G; Wallerand, H | 1 |
| Ishikawa, H; Kikuchi, N; Ohara, G; Satoh, H; Sekizawa, K | 1 |
| Adès, L; Boehrer, S; de Botton, S; Fenaux, P; Galluzzi, L; Gardin, C; Kroemer, G; Tailler, M; Tajeddine, N | 1 |
| Aoe, K; Bessho, A; Fujiwara, Y; Gemba, K; Hotta, K; Kamei, H; Kiura, K; Kuyama, S; Matsuo, K; Moritaka, T; Segawa, Y; Shibayama, T; Sugimoto, K; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Yonei, T | 1 |
| Hamada, H; Hamaguchi, N; Higaki, J; Ito, R; Kadowaki, T; Miyoshi, S | 1 |
| Feng, YL; Guan, AY; Wang, BD; Wen, FQ; Xu, ZB | 1 |
| Gemma, A; Noro, R | 1 |
| Fujita, K; Ishiguro, Y; Kimura, M; Kondo, N; Matsuda, H; Sakakibara, A; Sano, D; Taguchi, T; Toth, G; Tsukuda, M | 1 |
| Aleskog, A; Danielsson, K; Eriksson, A; Grundmark, B; Henriksson, R; Höglund, M; Larsson, R; Lindhagen, E; Nygren, P; Wickström, M | 1 |
| Adam, L; Bar-Eli, M; Black, PC; Brown, GA; Dinney, CP; Fisher, MB; Gallagher, D; Inamoto, T; Kassouf, W; Luongo, T; McConkey, DJ | 1 |
| Kim, SW; Lee, DH; Lee, JS; Suh, C; Yi, EJ; Yoon, DH | 1 |
| Ackman, JB; Iafrate, AJ; Sequist, LV; Settleman, JE | 1 |
| Chang, JW; Chen, CM; Cheung, YC; Hsieh, JJ; Hsu, T; Huang, SF; Lin, G | 1 |
| Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; Daniele, G; Gelardi, T; Lahn, M; Pepe, S; Tortora, G | 1 |
| Carnaghi, C; Comandone, A; Granetti, C; Lorusso, V; Mari, E; Oliva, C; Pressiani, T; Rimassa, L; Ronzoni, M; Santoro, A; Siena, S; Zuradelli, M | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Manoloukos, M; Murray, S | 1 |
| Chella, A; Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Han, HS; Han, JY; Hwang, SW; Lim, KY | 1 |
| Chang, YL; Gow, CH; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Donangelo, I; Gutman, S; Melmed, S; Ren, SG; Siegel, E; Vlotides, G | 1 |
| Agulnik, M; Wang, LX | 1 |
| Castellani, G; Ceccarelli, C; Coppola, D; Francesconi, M; Guidotti, L; Lauriola, M; Martini, D; Mattei, G; Montroni, I; Pezzetti, F; Rosati, G; Ruggeri, A; Santini, D; Solmi, R; Strippoli, P; Taffurelli, M; Ugolini, G; Voltattorni, M; Zanotti, S | 1 |
| Agulnik, M; Brockstein, B; Lacouture, M | 1 |
| Bourhis, J; Castadot, P; Chargari, C; Deutsch, E; Ghalibafian, M; Haie-Meder, C; Magné, N; Soria, JC | 1 |
| Bianco, R; Del Vecchio, S; Fonti, R; Iommelli, F; Lettieri, A; Papaccioli, A; Pirozzi, G; Salvatore, M; Sommella, J; Tortora, G; Zannetti, A | 1 |
| Dacic, S; Dubey, S; Eickhoff, JC; Hoang, T; Kolesar, JM; Marcotte, SM; Schiller, JH; Siegfried, JM; Stabile, LP; Traynor, AM | 1 |
| Battaglia, M; Boccardo, F; Conti, G; Cruciani, G; Lapini, A; Manganelli, A; Ricci, S; Rubagotti, A | 1 |
| Antonacopoulou, A; Floratou, K; Giannopoulou, E; Kalofonos, HP; Papavassiliou, AG | 1 |
| Kjellén, E; Lindén, O; Stenberg, L | 1 |
| Brown, J; Gaikwad, A; Ramondetta, LM; Smith, JA; Wolf, JK | 1 |
| Arao, T; Fujita, Y; Fujiwara, Y; Hanafusa, T; Maegawa, M; Matsumoto, K; Nishio, K; Shimizu, C; Tanaka, K; Yokote, H | 1 |
| Fukuhara, T; Inoue, A; Kanehira, M; Kikuchi, T; Kuroki, Y; Maemondo, M; Nukiwa, T; Saijo, Y; Suzuki, T; Xin, H | 1 |
| Bongarzone, I; Cassinelli, G; Cremona, M; Cuccuru, G; Gorla, L; Lanzi, C; Miccichè, F; Mondellini, P; Pierotti, MA | 1 |
| Li, JR; Li, LY; Wang, MZ; Wang, SL; Zhang, L; Zhang, XT; Zhong, W | 2 |
| Chin, TM; Seto, KY; Soo, RA; Wong, AS | 1 |
| Neckers, L; Pashtan, I; Tsutsumi, S; Wang, S; Xu, W | 1 |
| Cambar, J; De Giorgi, F; Ichas, F; L'Azou, B; Passagne, I; Pédeboscq, S; Pometan, JP | 1 |
| Chandrasekara Reddy, G; Chandregowda, V; Kush, AK | 1 |
| Stewart, DJ | 1 |
| Bhutani, M; Mao, L; Pathak, AK | 1 |
| Dahlberg, SE; Gray, RJ; Johnson, BE | 1 |
| Eguchi, K; Fukuoka, M; Harada, M; Ichinose, Y; Imamura, F; Inoue, A; Itoh, Y; Jiang, H; Maruyama, R; Masuda, N; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Shinkai, T; Takeda, K; Tamura, T; Tomii, K; Tsuboi, M; Yamamoto, N | 1 |
| Armour, AA; Cappuzzo, F; Crinò, L; Cullen, M; Duffield, EL; Ford, HE; Ghiorghiu, S; Hirsch, FR; Pesek, M; Reck, M; Speake, G; Thompson, JC; Varella-Garcia, M; Zatloukal, P | 1 |
| Socinski, MA; Stinchcombe, TE | 1 |
| Hayakawa, K; Jiang, SX; Katagiri, M; Masuda, N; Okayasu, I; Piao, CJ; Saegusa, M; Umezawa, A; Yamamoto, M; Yamashita, K; Yoshida, T | 1 |
| Fandi, A; Giaccone, G; Herbst, RS; Iacona, RB; Janas, M; Johnson, DH; Ochs, JS | 1 |
| Bissonnette, M; Koetsier, JL; Kunte, DP; Roy, HK; Wali, RK | 1 |
| Creighton, CJ; Hilsenbeck, SG; Huang, S; Malorni, L; Massarweh, S; Osborne, CK; Schiff, R; Shou, J; Tsimelzon, A | 1 |
| Back, JB; Heng, HH; Jacob, JB; Jones, RF; Piechocki, MP; Wei, WZ; Whittington, PJ | 1 |
| Fukui, T; Furuta, K; Kunitoh, H; Nokihara, H; Ohe, Y; Sekine, I; Takano, T; Tamura, T; Tsuta, K; Yamamoto, N; Yamamoto, S | 1 |
| Bafaloukos, D; Bobos, M; Christodoulou, C; Economopoulos, T; Fountzilas, G; Kalogera-Fountzila, A; Kalogeras, KT; Karayannopoulou, G; Kosmidis, P; Koutras, AK; Linardou, H; Murray, S; Samantas, E; Xiros, N | 1 |
| Tamura, K | 1 |
| Ferlini, C; Mozzetti, S; Riccardi, A; Riccardi, R; Servidei, T | 1 |
| Loeffler-Ragg, J; Schwentner, I; Sprinzl, GM; Zwierzina, H | 1 |
| Eguchi, K; Ishizaka, A; Kawada, I; Kawamura, M; Kobayashi, K; Nakachi, I; Naoki, K; Soejima, K; Watanabe, H; Yasuda, H | 1 |
| Alfieri, RR; Ardizzoni, A; Boni, L; Bortesi, B; Bozzetti, C; Camisa, R; Capelletti, M; Cavazzoni, A; De Palma, G; Franciosi, V; Galetti, M; Goldoni, M; Loprevite, M; Mozzoni, P; Petronini, PG; Rindi, G; Tiseo, M | 1 |
| Akamine, SJ; Ebi, N; Kuraki, T; Nakanishi, Y; Okamoto, I; Semba, H; Takayama, K; Tokunaga, SJ; Wataya, H; Yamamoto, H | 1 |
| Ali-Osman, F; Cao, X; Lo, HW; Zhu, H | 2 |
| Arteaga, CL; Davidson, NE; Moulder, SL; O'Neill, A; Pins, M; Sledge, GW; Sparano, JA | 1 |
| Fu, L; Li, J; Li, L; Liu, H; Luo, X; Mei, C; Xiong, X | 1 |
| Ikegami, Y; Ito, A; Kohno, S; Nakamura, Y; Nakano, H; Oka, M; Sano, K; Satake, K; Sawada, S; Soda, H; Yoshida, H; Yoshikawa, M | 1 |
| Alloisio, M; Cappuzzo, F; Destro, A; Finocchiaro, G; Incarbone, M; Jänne, PA; Ligorio, C; Roncalli, M; Rossi, E; Santoro, A; Skokan, M; Terracciano, L; Toschi, L; Varella-Garcia, M; Zucali, PA | 1 |
| Abidoye, O; Salgia, R; Sattler, M | 1 |
| Black, J; Iyer, R; Javle, M; LeVea, C; Nava, H; Nwogu, C; Pande, A; Wilding, G; Yang, G | 1 |
| Ishihara, S; Minato, K; Mogi, A; Naito, Y; Saito, R; Shitara, Y; Suga, T; Takise, A; Tsuchiya, S; Yamabe, K | 1 |
| Hotta, K; Kiura, K; Shirahige, A; Tabata, M; Takata, S; Takigawa, N; Tanimoto, M; Watanabe, H | 1 |
| Fennell, DA; Johnston, PG; Kelly, DM; Kyula, J; Longley, DB; Stokesberry, S; Van Schaeybroeck, S | 1 |
| Dilworth, JT; Hancock, CN; Mathieu, P; Mattingly, RR; Reiners, JJ; Tainsky, MA; Wojtkowiak, JW | 1 |
| Abbott, A | 1 |
| Chang, GC; Chen, JC; Hsu, SL; Tsai, CH; Tsai, JR; Wu, CC; Wu, WJ; Yu, CT | 1 |
| Endo, T; Funayama, Y; Furukawa, K; Hashimoto, T; Hayashibara, K; Ichimura, H; Inagaki, M; Ishikawa, H; Ishikawa, S; Kaburagi, T; Kagohashi, K; Kamiyama, K; Kishi, K; Kurishima, K; Matsumura, T; Nawa, T; Satoh, H; Shinohara, Y; Sumi, M | 1 |
| Dastane, AM; Gupta, R; Marchevsky, AM; McKenna, R | 1 |
| Homes, AJ; Jackman, DM; Jänne, PA; Johnson, BE; Lindeman, N; Rogers, AM; Yonesaka, K; Zejnullahu, K; Zhao, F | 1 |
| Cho, BC; Costa, DB; Halmos, B; Huberman, MS; Jackman, DM; Jänne, PA; Kim, JH; Kobayashi, S; Nguyen, KS; Pao, W; Riely, GJ; Sequist, LV; Tenen, DG; Yeap, BY | 1 |
| Cho, CD; Fisher, GA; Halsey, J; Kuo, T; Ramsey, M; Rouse, RV; Schwartz, E; Sikic, BI | 1 |
| Hanagiri, T; Ichiki, Y; Mizukami, M; Onitsuka, T; Oyama, T; Sugaya, M; Sugio, K; Takenoyama, M; Uramoto, H; Yasuda, M; Yasumoto, K | 1 |
| Chen, KY; Cheng, AL; Hu, FC; Huang, CL; Lin, ZZ; Shih, JY; Yang, CH; Yang, PC; Yeh, KH; Yu, CJ | 1 |
| Fukuyama, S; Ichinose, Y; Ikeda, J; Maruyama, R; Nishimura, M; Okamoto, T; Osoegawa, A; Seto, T; Tagawa, T; Wataya, H; Yamanaka, T; Yamazaki, K | 1 |
| Owonikoko, TK; Ramalingam, S | 1 |
| Cheng, CM; Ciou, SC; Hong, JH; Jheng, MY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Im, KC; Kim, SW; Lee, DH; Lee, JS; Moon, DH; Oh, SJ; Ryu, JS; Sohn, HJ; Suh, C; Yang, YJ | 1 |
| Balak, M; Bean, J; Ladanyi, M; Marks, JL; Miller, VA; Pao, W; Riely, GJ | 1 |
| Hanibuchi, M; Kakiuchi, S; Li, Q; Matsumoto, K; Mitsudomi, T; Nakamura, T; Nishioka, Y; Ogino, H; Sakurama, H; Sone, S; Uehara, H; Wang, W; Yano, S; Yatabe, Y | 1 |
| Chen, C; Gaspar, LE; Kavanagh, BD; Kleinschmidt-De Masters, BK; McCammon, R; Schwer, AL; Stuhr, K | 1 |
| Donovan, JC; Ghazarian, DM; Shaw, JC | 1 |
| Abrey, LE; Kreisl, TN; Lassman, AB; Lis, E; Mischel, PS; Rosen, N; Scher, HI; Shaffer, D; Teruya-Feldstein, J | 1 |
| Brunet, J; Del Barco, S; López-Bonet, E; Martín-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Azzariti, A; Duan, HQ; Galetta, D; Gao, EM; Han, Y; Liu, XQ; Paradiso, A; Toschi, L; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Ahn, BM; Choi, DR; Choi, JS; Jung, JY; Kim, HJ; Kim, HS; Kim, HY; Kim, JH; Kwon, JH; Lee, KM; Park, S; Shin, YC; Song, HH; Zang, DY | 1 |
| Cullen, M; Thatcher, N | 1 |
| Armour, AA; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Li, LY; Liao, ML; Lippman, SM; Lowe, ES; Mok, T; Osterlind, K; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Sun, Y; Watkins, CL; Wu, YL | 1 |
| Cusano, G; Ferlini, C; Giangaspero, F; Meco, D; Riccardi, A; Riccardi, R; Servidei, T; Zannoni, GF | 1 |
| Harichand-Herdt, S; Ramalingam, SS | 2 |
| Bang, YJ; Han, SW; Heo, DS; Im, SA; Kim, CS; Kim, DW; Kim, HJ; Kim, TY; Kim, YJ; Lee, SH; Oh, DY; Yi, HG | 1 |
| Chang, YL; Hsu, YC; Shih, JY; Tsai, MF; Wu, JY; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Cooley-Zgela, T; Gius, D; Morris, JC; Sharp, H; Singh, AK; Van Waes, C | 1 |
| Baron, A; Basche, M; Dancey, J; Eckhardt, SG; Gore, L; Gustafson, DL; Holden, SN; Lam, ET; O'Bryant, CL; Serkova, N | 1 |
| Chu, DT; Sun, Y; Wang, B; Wang, HJ; Wang, Y; Zhang, XR | 1 |
| Jiang, H | 1 |
| Deng, Q; Ma, S; Xu, Y; Yu, X | 1 |
| Hirama, M; Ishiwata, T; Miura, K; Miyaji, A; Seyama, K; Shukuya, T; Takahashi, K; Yae, T | 1 |
| Hida, T; Horio, Y; Ogawa, S; Park, JC; Park, JY; Shimizu, J; Yoshida, K | 1 |
| Bang, YJ; Chung, DH; Han, SW; Heo, DS; Im, SA; Kim, DW; Kim, TY; Kim, YW; Lee, JS; Lee, SH; Oh, DY; Sim, SH | 1 |
| Corman, J; Isacson, C; Kozlowski, P; Picozzi, V; Porter, C; Vaughan, M; Vuky, J | 1 |
| Bajetto, A; Barbieri, F; Capra, MC; Corte, G; Daga, A; Favoni, RE; Florio, T; Gatti, M; Griffero, F; Lo Casto, M; Marubbi, D; Melotti, A; Pattarozzi, A; Porcile, C; Spaziante, R; Zona, G | 1 |
| Carloni, F; Lazzari Agli, L; Santelmo, C; Sartori, S; Tamburini, E; Tassinari, D; Tombesi, P | 1 |
| Blanco, R; Delgado, MD; Donertas, D; Dotto, P; Eilers, M; Ferrandiz, N; Leon, J; Martin-Perez, J; Weber, A | 1 |
| Clynes, M; Corkery, B; Crown, J; O'Donovan, N | 1 |
| Bunn, PA; Dziadziuszko, R; Hedman, K; Hirsch, FR; Varella-Garcia, M; Witta, SE; Yoshida, K | 1 |
| Katayama, H; Kishino, D; Kiura, K; Kuyama, S; Ohashi, K; Okada, T; Sato, K; Takigawa, N; Tanimoto, M | 1 |
| Aoyagi, D; Kanda, S; Kobayashi, N; Koizumi, T; Kubo, K; Nakayama, J; Ushiki, A; Yamamoto, H; Yasuo, M | 1 |
| Choi, Y; Kim, JE; Kim, SW; Lee, DH; Lee, JS; Suh, C; Yoon, DH | 1 |
| Ciou, SC; Hong, JH; Jhan, JY; Ko, JC; Lin, ST; Lin, YW; Wang, LH | 1 |
| Deng, QF; Su, B; Zhao, YM; Zhou, CC | 1 |
| Bissonette, R; Brown, PH; Hill, J; Hilsenbeck, SG; Kittrell, F; Medina, D; Zhang, Y | 1 |
| Abba, MC; Aldaz, CM; Bissonnette, RP; Brown, PH; Gaddis, S; Hill, J; Hu, Y; Kittrell, FS; Levy, CC; Medina, D | 1 |
| Ahn, JS; Ahn, MJ; Choi, MK; Hong, JY; Jae Park, M; Lee, J; Lee, SJ; Oh, SJ; Park, K; Park, MJ; Yi, JH | 1 |
| Aritakula, A; Ramasamy, A | 1 |
| Calabrò, E; De Marinis, F; Fabbri, A; Marchianò, A; Novello, S; Orsenigo, M; Pastorino, U; Sozzi, G; Tamborini, E | 1 |
| Kometani, T; Maehara, Y; Miura, N; Ohba, T; Okazaki, H; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Beau-Faller, M; Gaub, MP; Guerin, E; Jeung, MY; Legrain, M; Mennecier, B; Molard, A; Neuville, A; Oudet, P; Quoix, E; Ruppert, AM; Voegeli, AC | 1 |
| Adamo, B; Adamo, V; Caristi, N; Chiofalo, G; Denaro, N; Franchina, T; Gambadauro, P; Giordano, A; Russo, A; Scimone, A | 1 |
| O'Neill, ID | 1 |
| Date, H; Fujiwara, Y; Hosokawa, S; Hotta, K; Kiura, K; Soh, J; Takigawa, N; Tanimoto, M; Tokumo, M; Toyooka, S; Yoshino, T | 1 |
| Fukuoka, M; Hatashita, E; Jänne, PA; Nakagawa, K; Nishio, K; Okabe, T; Okamoto, I; Tsukioka, S; Uchida, J; Yamada, Y; Yoshida, T | 1 |
| Armstrong, EA; Benavente, S; Chi, A; Harari, PM; Hsu, KT; Huang, S; Wheeler, DL | 1 |
| Lin, SS; Tsai, TH; Yang, HH | 1 |
| Barbachano, Y; Box, C; Chambers, P; Eccles, SA; Harrington, KJ; Nutting, CM; Rhŷs-Evans, P; Rogers, SJ; Workman, P | 1 |
| Chu, D; Lin, D; Ma, F; Shi, Y; Sun, T; Sun, Y; Tan, W; Wu, C; Xu, B; Yang, M; Yu, D | 1 |
| Cappuzzo, F; Drabkin, H; Gajapathy, S; Gemmill, R; Rossi, E; Valente, M; Varella-Garcia, M | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Gajjar, A; Wright, KD | 1 |
| Aggarwal, AN; Singh, N | 1 |
| Bergot, E; Zalcman, G | 1 |
| Dai, J; Guo, D; Ji, C; Ma, D; Qu, X; Ye, J; Zang, S | 1 |
| Bemis, LT; Flaig, TW; Li, Y; McCoach, C; Raben, D; Su, LJ; Varella-Garcia, M | 1 |
| Chang, JW; Hsieh, JJ; Hsu, T; Li, YY; Shen, YC; Wang, CH; Yeh, KY | 1 |
| Andersen, P; Poulsen, HS; Stockhausen, MT; Villingshøj, M | 1 |
| Gandhi, J; Gazdar, AF; Girard, L; Lam, WL; Lockwood, WW; Minna, JD; Peyton, M; Shigematsu, H; Soh, J; Varella-Garcia, M; Xie, Y; Yamamoto, H; Zhang, J; Zhang, W | 1 |
| Ahn, JS; Ahn, MJ; Jun, HJ; Kim, HS; Kim, S; Lee, J; Lee, S; Park, K; Park, YH; Yi, SY | 1 |
| Bunn, PA; Franklin, WA; Hirsch, FR; Kosaka, T; Mitsudomi, T; Nakajima, E; Skokan, M; Varella-Garcia, M; Xavier, AC; Yatabe, Y; Zeng, C | 1 |
| Brell, JM; Dranko, S; Evans, T; Kiefer, GJ; Lenzner, D; Matin, K; Ramanathan, RK; Rath, L; Schlesselman, JJ; Schmotzer, A; Volkin, RL | 1 |
| Ginsberg, MS; Heelan, R; Hussain, S; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rusch, VW; Zakowski, MF | 1 |
| Ikeda, K; Itoh, S; Matsumoto, F; Ohba, S | 1 |
| Falcone, A; Tibaldi, C; Vasile, E | 1 |
| Bender, A; Cleaver, S; Cornella-Taracido, I; Davies, JW; Glick, M; Harrington, E; Jenkins, JL; Marshall, S; Mikhailov, D; Scheiber, J; Tallarico, JA | 1 |
| Bayer-Zubek, V; Cordon-Cardo, C; Costa, J; Donovan, MJ; Greco, FA; Hainsworth, JD; Kotsianti, A; Parums, DV; Teverovskiy, M; Verbel, D | 1 |
| Coombes, RC; Francis, RE; Guest, SK; Krol, J; Kwok, JM; Lam, EW; McGovern, UB; Myatt, SS; Peck, B; Polychronis, A; Wang, J | 1 |
| Casalini, P; Croce, CM; Di Leva, G; Iorio, MV; Ménard, S; Merlo, A; Piovan, C; Tagliabue, E; Triulzi, T | 1 |
| Calhau, C; Giovannetti, E; Jansen, G; Kathmann, I; Lemos, C; Peters, GJ | 1 |
| Hirai, Y; Kawago, M; Kiyoi, M; Naito, K; Ohta, F; Okamura, Y; Oura, S; Shimizu, Y; Tamaki, T; Yoshimasu, T | 1 |
| Eguchi, K; Fukuoka, M; Ichinose, Y; Imamura, F; Itoh, Y; Nakagawa, K; Negoro, S; Nishiwaki, Y; Saijo, N; Sekine, I; Shinkai, T; Takeda, K; Tamura, T; Tsuboi, M; Yamamoto, N | 1 |
| Burris, HA; Greco, FA; Hainsworth, JD; Kuzur, M; Lunin, S; Markus, TM; Shipley, D; Spigel, DR | 1 |
| Ali, S; Gadgeel, SM; Philip, PA; Sarkar, FH; Wozniak, A | 1 |
| Armour, AA; Ataman, OU; Biesma, B; Duffield, E; Ferry, D; Goss, G; Hirsch, FR; Laurie, SA; Thompson, J; Varella-Garcia, M; Wierzbicki, R; Zarenda, M | 1 |
| Armour, A; Cohen, EE; Garin, AM; Ghiorghiu, S; Hargreaves, L; Hirsch, FR; Khorprasert, C; Licitra, L; Rischin, D; Soulieres, D; Speake, G; Stewart, JS; Swaisland, A; Van Herpen, CM; Varella-Garcia, M; Vodvarka, P; Vokes, EE | 1 |
| Burstein, HJ; Gelman, RS; Harris, LN; Mayer, EL; Partridge, AH; Schumer, ST; Winer, EP | 1 |
| Dreyer, C; Faivre, S; Raymond, E | 1 |
| Chen, XG; Feng, ZQ; Li, J; Li, Y | 1 |
| Chen, H; Chen, Y; Eckhardt, SG; Kane, M; Leong, S; Mack, P; McCarter, MD; Olsen, CC; Raben, D; Schefter, TE; Stiegmann, G | 1 |
| Allen, CT; Calvo, KR; Chen, Z; Dabir, B; Friedman, J; Morris, JC; Mundinger, GS; Pernas, FG; Saigal, K; Van Waes, C; Winters, ME; Xu, X; Yan, B | 1 |
| Curigliano, G; de Braud, F; De Cobelli, O; Sbanotto, A; Scardino, E; Spitaleri, G | 1 |
| Lu, MQ; Wang, J; Wei, Q; Wen, CH; Xu, XH; Zhou, ZT | 1 |
| Fukumura, T; Hatori, A; Irie, T; Kanno, I; Kawamura, K; Konno, F; Kumata, K; Suzuki, K; Yamasaki, T; Yui, J; Zhang, MR | 1 |
| Bodkin, D; Capó, A; Eberhardt, WE; Germonpré, P; Govindan, R; Kennedy, SJ; Natale, RB; Ranson, M; Rizvi, NA; Sleckman, BG; Stockman, PK | 1 |
| Li, L; Li, XQ; Liu, H; Liu, XJ; Zhen, YS | 1 |
| Lin, CC; Yang, CH | 1 |
| Distel, RJ; Jänne, PA; Kuang, Y; Makrigiorgos, M; Rogers, A; Thiede, S; Vetrand, K; Wang, L; Yeap, BY | 1 |
| Boyer, MJ; Davis, ID; Gurney, H; Kotasek, D; Pezaro, C; Rosenthal, MA; Solomon, B; Toner, GC; Underhill, C | 1 |
| Altman, RB; Brunak, S; Hansen, NT | 1 |
| Asano, T; Hayakawa, M; Horiguchi, A; Ito, K; Kuroda, K; Sumitomo, M | 1 |
| Reck, M | 2 |
| Cohen, EE; Cooper, JB | 1 |
| Chang, SE; Choe, H; Choi, J; Hong, JP; Lee, SW; Song, JY | 1 |
| Fujii, Y; Kawano, O; Okuda, K; Sasaki, H; Yano, M; Yukiue, H | 1 |
| Chen, HJ; Chen, ZH; Guo, AL; Mok, TS; Su, J; Wu, YL; Zhang, XC | 1 |
| Aliu, SO; Hann, BC; Hylton, NM; Li, KL; Moasser, MM; Wang, D; Wilmes, LJ | 1 |
| Kunitoh, H; Saijo, N; Takeuchi, M | 1 |
| Christy, R; Engler, KL; Fakih, MG; Johnson, CS; Muindi, JR; Trump, DL | 1 |
| Chen, ZG; Choe, MS; Hurwitz, SJ; Klass, CM; Shin, DM; Tighiouart, M; Zhang, X | 1 |
| Katayama, K; Mitsuhashi, J; Noguchi, K; Shibata, K; Sugimoto, Y | 1 |
| Egawa, S; Katayose, Y; Mizuma, M; Motoi, F; Oda, A; Ohtuska, H; Oikawa, M; Onogawa, T; Rikiyama, T; Sasaki, T; Shirasou, S; Unno, M; Yabuuchi, S; Yamamoto, K; Yoshida, H | 1 |
| Geoerger, B; Gerstenmeyer, A; Lagodny, J; Niemeyer, CM; Odenthal, E; Rössler, J; Vassal, G | 1 |
| Engelman, JA; Lynch, TJ; Sequist, LV | 1 |
| An, TT; Bai, H; Duan, CJ; Guo, ZQ; Liu, HN; Liu, YX; Mao, L; Wang, HS; Wang, J; Wang, X; Wang, YY; Wu, NM; Yang, L; Zhao, J | 1 |
| Filipits, M; Minar, W; Pirker, R | 1 |
| Chadjichristos, C; Chatziantoniou, C; Dussaule, JC; Flamant, M; François, H; Guerrot, D; Helle, F; Jouzel, C; Placier, S | 1 |
| Chen, ZG; Ferris, RL; Grandis, JR; Ming, L; Sun, Q; Thomas, SM; Wang, Y; Yu, J; Zhang, L | 1 |
| Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Capelletti, M; Cavazzoni, A; Fumarola, C; Galetti, M; Generali, D; Goldoni, M; La Monica, S; Mutti, A; Petronini, PG; Tagliaferri, S; Tiseo, M | 1 |
| Arnold, LL; Chen, B; Cohen, SM; Le, XC; Pennington, KL; Suzuki, S | 1 |
| Ren, XB; Sun, J; Wang, CL; Wang, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ | 1 |
| Abdiu, A; Djerf, EA; Hallbeck, AL; Thunell, LK; Trinks, C; Walz, TM | 1 |
| de Boüard, S; Guillamo, JS; Leuraud, P; Marie, Y; Marteau, L; Parienti, JJ; Peschanski, M; Poupon, MF; Raymond, E; Valable, S | 1 |
| Akslen, LA; Briggs, A; Byers, LA; Cascone, T; Engelman, J; Folkman, J; Halmos, B; Heymach, JV; Jänne, P; Johnson, BE; Kobayashi, S; Lifshits, E; Naumov, GN; Nilsson, MB; Straume, O; Tang, XM; Tenen, D; Wu, HK; Xu, L; Yeap, B | 1 |
| Chang, BW; Saif, MW | 1 |
| Arteaga, CL; Boimel, PJ; Coniglio, SJ; Hynes, NE; Kedrin, D; Segall, JE; Wyckoff, J | 1 |
| Fujimoto, T; Ito, T; Kanda, S; Mori, S | 1 |
| Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Ardizzoni, A; Boni, L; Bozzetti, C; Camisa, R; Campanini, N; Capelletti, M; De Palma, G; Franciosi, V; Lagrasta, C; Marchioni, A; Rindi, G; Rossi, G; Sartori, G; Spiritelli, E; Tiseo, M | 1 |
| Agelaki, S; Georgoulias, V; Kallergi, G; Markomanolaki, H; Mavroudis, D; Spiliotaki, M; Stournaras, C | 1 |
| Chang, CP; Chao, HS; Chen, YM; Chiu, CH; Chu, LS; Tsai, CM | 1 |
| Han, JY; Kang, KW; Kim, HT; Kim, HY; Kim, SK; Lee, DH; Lee, HY; Lee, JS; Lee, SY; Park, SH | 1 |
| Cheng, LC; Chua, DT; Chung, LP; Ho, JC; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Azzariti, A; Berardi, F; Colabufo, NA; D'Incalci, M; Paradiso, A; Perrone, R; Porcelli, L; Quatrale, AE; Simone, GM; Xu, JM; Zucchetti, M | 1 |
| Cantarini, MV; Connolly, SM; Dickinson, PA; Farmer, MR; O'Mahony, B; Smith, RP; Swaisland, HC; Wilson, CG | 1 |
| Clynes, M; Collins, DM; Crown, J; Devery, A; O'Connor, R; O'Donovan, N; O'Driscoll, L; O'Sullivan, F | 1 |
| Chen, RS; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lee, WT; Lin, ST; Lin, YW; Su, YJ | 1 |
| Gallo, JM; Wang, S; Zhou, Q | 1 |
| Li, D; Shen, QJ; Wang, F; Xing, WH; Xu, J; Zhang, LN; Zhang, XH; Zhuo, RJ; Zou, ZQ | 1 |
| Ansari, J; Hussain, SA; Palmer, DH; Rea, DW | 1 |
| Adachii, M; Ando, K; Hirose, T; Hosaka, T; Inoue, F; Ishida, H; Kadofuku, T; Kanome, T; Kusumoto, S; Ohmori, T; Ohnishi, T; Okuda, K; Saijo, N; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, JW; Kim, TY; Lee, JH; Oh, DY; Park, J; Yoon, YK | 1 |
| He, C; Liu, M; Ouyang, M; Xu, J; Zhang, J; Zhong, N; Zhou, C | 1 |
| Asahina, H; Fukuoka, M; Hagiwara, K; Hida, T; Hirashima, T; Inoue, A; Kobayashi, K; Mitsudomi, T; Morita, S; Nukiwa, T; Okamoto, I; Sugio, K; Sunaga, N; Yamazaki, K; Yanagitani, N; Yasumoto, K; Yoshida, K | 1 |
| Chen, KY; Ho, CC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Guan, ZZ; Huang, H; Wang, ZQ; Xu, F; Xu, GC; Zhang, L; Zhang, Y; Zhao, HY | 1 |
| Ayabe, E; Endo, M; Igawa, S; Kaira, K; Kaira, R; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shimoyama, R; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Cho, EK; Ha, SY; Hong, J; Kim, YS; Lee, H; Lee, JH; Lee, JI; Park, J; Park, SH; Shin, DB; Sim, H | 1 |
| Choo, SP; Leong, SS; Li, HH; Lim, WT; Tan, EH; Tan, SH; Tham, CK; Toh, CK | 1 |
| Basser, R; Chan, A; Fong, A; Forbes, JF; Francis, PA; Gebski, V; Green, MD; Harvey, V; Karapetis, C; Snyder, R | 1 |
| Abrey, LE; Aldape, K; Chang, SM; Cloughesy, TF; Dancey, J; Deangelis, LM; Fine, HA; Gilbert, MR; Lamborn, KR; Lassman, AB; Lieberman, F; Mehta, M; Norden, AD; Prados, MD; Raizer, JJ; Robins, HI; Wen, PY; Yung, WK | 1 |
| Chikaishi, Y; Inoue, M; Nose, N; So, T; Sugio, K; Yasumoto, K | 1 |
| Carcaboso, AM; Elmeliegy, MA; Hubbard, KE; Panetta, JC; Shen, J; Stewart, CF; Tagen, M; Waters, CM; Wynn, HG | 1 |
| Baudrin, L; Cadranel, J; Milleron, B; Morere, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Souquet, PJ | 1 |
| Choe, du H; Kim, CH; Koh, JS; Lee, JC; Na, II; Ryoo, BY; Yang, SH | 1 |
| Antoine, M; Baudrin, L; Cadranel, J; Isaac-Sibille, S; Lebitasy, MP; Longchampt, E; Neuville, A; Poulot, V; Pradere, M; Wislez, M | 1 |
| Goudarzi, A; Heravi, M; Jean-Claude, BJ; Muanza, TM; Rachid, Z; Radzioch, D; Schlisser, A | 1 |
| Dorans, K | 1 |
| Cohen, EE; Halpern, AB; Kasza, K; Kocherginsky, M; Vokes, EE; Williams, R | 1 |
| Hanagiri, T; Nose, N; Onitsuka, T; Sugio, K; Takenoyama, M; Uramoto, H; Yasumoto, K | 1 |
| Dziadziusko, R; Fennell, D; Gridelli, C; Lacombe, D; Pallis, AG; Serfass, L; van Meerbeeck, JP; Welch, J | 1 |
| Elenius, K; Grenman, R; Iivanainen, E; Kulmala, J; Lauttia, S; Salven, P; Tvorogov, D; Zhang, N | 1 |
| Endo, M; Igawa, S; Kaira, K; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tamiya, A; Tsuya, A; Yamamoto, N | 1 |
| Hisamoto, A; Kashihara, H; Kiura, K; Kubo, T; Nishida, A; Ochi, N; Takigawa, N; Tanimoto, M; Umemura, S | 1 |
| Greer, J; Lynch, TJ; Pirl, WF; Sequist, L; Solis, J; Temel, JS | 1 |
| Chen, P; Chen, ZG; Du, Y; Fu, H; Khuri, FR; Li, L; Li, Z; Shin, DM; Sun, SY | 1 |
| Fleisher, M; Hu, G; Kang, Y; Lu, X; Massagué, J; Reiss, M; Van Poznak, C; Wang, Q | 1 |
| Ji, Y; Lu, YJ; Ma, SL; Tang, JJ; Wu, YM; Zhang, YP | 1 |
| Balius, TE; Rizzo, RC | 1 |
| Costa, DB; Kobayashi, S; Nguyen, KS | 1 |
| Aono, N; Isa, S; Kawaguchi, T; Koh, Y; Kubo, A; Kurata, T; Nakao, K; Tachibana, K; Takada, M; Tsujino, K | 1 |
| Jiang, W; Wu, JX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Fujita, S; Harada, Y; Hata, A; Imai, Y; Ishihara, K; Katakami, N; Nishimura, T; Seo, R; Takeshim, Y; Tomii, K | 1 |
| Friedrich, MJ | 2 |
| Babu, RJ; Chadha, G; Jean Lin, YJ; Parsons, DL; Phillip Lee, YH; Rangari, VK; Ravis, WR; Sathigari, S; Wright, N | 1 |
| Chen, F; Han, X; Lin, H; Sun, Y; Yong, W; Zheng, M; Zhou, X; Zhu, Y | 1 |
| Aizawa, H; Azuma, K; Basaki, Y; Hattori, S; Kage, M; Kashihara, M; Kawahara, A; Kuwano, M; Nakano, K; Ono, M; Shirouzu, K; Takamori, S; Terazaki, Y; Yanagawa, T | 1 |
| Date, H; Hotta, K; Jida, M; Kiura, K; Kubo, T; Matsuo, K; Mitsudomi, T; Miyoshi, S; Ohe, Y; Oto, T; Sano, Y; Takano, T; Toyooka, S; Tsukuda, K; Yamamoto, H; Yamane, M; Yatabe, Y | 1 |
| Goto, Y; Hojo, M; Kobayashi, N; Kudo, K; Takeda, Y | 1 |
| Anderton, J; Davies, BR; Mark Hickinson, D; Marshall, G; Rukazenkov, Y; Speake, G; Swaisland, A; Wilkinson, RW | 1 |
| Fujita, Y; Fukai, S; Kawabata, T; Kawahra, M; Saito, R; Shibata, S; Shibayama, T; Shirai, M; Tamura, A; Tomizawa, Y | 1 |
| Admane, S; Chirieac, LR; Costa, DB; Digumarthy, SR; Heist, RS; Iafrate, AJ; Kobayashi, S; Kwak, EL; Lynch, TJ; Mark, EJ; McDermott, U; Mino-Kenudson, M; Rodig, SJ; Settleman, J; Shaw, AT; Solomon, B; Stubbs, H; Yeap, BY | 1 |
| Chin, TM; Wong, AS; Zee, YK | 1 |
| Kim, YM; Park, SY; Pyo, H | 2 |
| Cheng, LC; Chua, DT; Chung, LP; Leung, EL; Sihoe, AD; Tam, IY; Tin, VP; Wong, MP | 1 |
| Cioffredi, LA; Giaccone, G; Jackman, DM; Jänne, PA; Johnson, BE; Miller, VA; Riely, GJ; Ruiz, MG; Sequist, LV; Yeap, BY | 1 |
| Hata, R; Imagawa-Ishiguro, Y; Ito, S; Kato, Y; Komori, R; Kubota, E; Maehata, Y; Ozawa, S; Ozono, S; Shiiki, N; Taguchi, T; Tsukinoki, K; Tsukuda, M | 1 |
| Gazdar, AF | 3 |
| Cappuzzo, F; Hirsch, FR; Varella-Garcia, M | 1 |
| Ho, JC; Ip, MS; Lam, B; Lam, WK; Lo, AI; Wong, MK | 1 |
| Crews, KR; Daw, NC; Furman, WL; Gajjar, AJ; Houghton, PJ; McCarville, MB; McGregor, LM; Navid, F; Panetta, JC; Rodriguez-Galindo, C; Santana, VM; Spunt, SL; Stewart, CF; Wu, J | 1 |
| Hirano, S; Ichihara, E; Kiura, K; Kubo, T; Ohashi, K; Osawa, M; Takata, M; Takeda, H; Takigawa, N; Tanimoto, M; Yoshino, T | 1 |
| Tsai, CC; Wang, HC; Wang, PH | 1 |
| Armour, AA; Chewaskulyong, B; Chu, DT; Duffield, EL; Fukuoka, M; Han, B; Ichinose, Y; Jiang, H; Margono, B; Mok, TS; Nishiwaki, Y; Ohe, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Watkins, CL; Wu, YL; Yang, CH; Yang, JJ | 1 |
| Murakami, H; Ohashi, Y; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Hirano, S; Kobayashi, N; Kudo, K; Morii, S; Morita, A; Sano, K; Sugiyama, H; Takeda, Y; Uruga, K | 1 |
| Fukui, T; Hatooka, S; Hida, T; Ito, S; Katayama, T; Mitsudomi, T; Onozato, R; Shimizu, J; Suda, K; Sueda, T; Yatabe, Y | 1 |
| Becquemont, L; Bergmann, JF; Chhun, S; Mouly, S; Peretti, I; Rizzo-Padoin, N; Simoneau, G; Swaisland, A; Verstuyft, C; Wortelboer, R | 1 |
| Gold, KA; Kim, ES; William, WN | 1 |
| Garfield, DH; West, HL | 1 |
| Arai, S; Fukui, T; Hataishi, R; Iwasaki, M; Katagiri, M; Katono, K; Kobayashi, H; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Onoda, S; Otani, S; Ryuge, S; Takakura, A; Wada, M; Yamamoto, M; Yanaihara, T; Yanase, N; Yokoba, M | 1 |
| Baron, A; Bladt, F; Blivet-Van Eggelpoël, MJ; Desbois-Mouthon, C; Fartoux, L; Housset, C; Rosmorduc, O; Venot, C | 1 |
| Ikeda, S; Suzuki, K; Takabe, K | 1 |
| Lazzari-Agli, L; Sartori, S; Tassinari, D; Tombesi, P | 1 |
| Wang, CL; Wang, J; Wang, P; Yuan, ZY; Zhao, LJ; Zhuang, HQ | 1 |
| Jeibmann, A; Klämbt, C; Paulus, W; Witte, HT | 1 |
| Alì, G; Baldini, E; Boldrini, L; Camacci, T; Comin, CE; Fontanini, G; Gisfredi, S; Lucchi, M; Maddau, C; Melfi, F; Mussi, A; Servadio, A; Tibaldi, C; Ursino, S | 1 |
| Gelderblom, H; Guchelaar, HJ; van Erp, NP | 1 |
| Agrawal, A; Cheung, KL; Gee, J; Gutteridge, E; Nicholson, R; Robertson, J | 1 |
| Beijnen, JH; Rooswinkel, RW; Schinkel, AH; Sparidans, RW; van Herwaarden, AE; van Waterschoot, RA | 1 |
| Bang, YJ; Han, SW; Hur, HS; Im, SA; Kim, HP; Kim, TY; Oh, DY; Yoon, YK | 1 |
| Kim, YH; Mio, T; Mishima, M | 1 |
| Chan, AT; Chen, H; Cheng, SH; Lo, KW; Lui, VW; Ma, BB; Ng, MH; Poon, FF; Tao, Q; To, KF; Wong, E; Wong, SC | 1 |
| Han, JY; Jung, JI; Kim, JY; Park, IH | 1 |
| Auclair, PL; Battelli, C; Carrier, K; Emery, IF; Hayes, DM | 1 |
| Stang, JL; Tran, LM; Zhong, H | 1 |
| Hida, T; Horio, Y; Matsuo, K; Mitsudomi, T; Ogawa, S; Park, J; Park, JY; Shimizu, J; Yatabe, Y; Yoshida, K | 1 |
| Ando, K; Hatori, A; Kawamura, K; Koike, S; Kumata, K; Suzuki, K; Takai, N; Toyohara, J; Yamasaki, T; Yanamoto, K; Yui, J; Zhang, MR | 1 |
| Boggon, TJ; Cappuzzo, F; Clifford, B; Eisenberg, R; Franklin, WA; Fu, P; Halmos, B; Hamdan, A; Hirsch, FR; Jin, C; Leidner, RS; Skokan, M; Varella-Garcia, M | 1 |
| Kondo, T; Murakami, S; Oshita, F; Saito, H; Yamada, K | 1 |
| Hughes, B | 1 |
| Buttitta, F; Cappuzzo, F; Carlone, D; Ceribelli, A; Cognetti, F; Del Grammastro, M; Felicioni, L; Finocchiaro, G; Gelibter, AJ; Iacobelli, S; Irtelli, L; Malatesta, S; Marchetti, A; Mezzetti, A; Milella, M; Nuzzo, C; Perrucci, B; Sciarrotta, M | 1 |
| Teng, KY; Xu, RH | 1 |
| Downing, JR | 1 |
| Berchuck, JE; Carr, SA; Carroll, M; Clauser, K; Davis, TN; DeAngelo, DJ; Galinsky, I; Golub, TR; Hahn, CK; Hahn, WC; Kakoza, RM; Kung, AL; Root, DE; Ross, KN; Ross, L; Schinzel, AC; Silver, SJ; Stegmaier, K; Stone, RM | 1 |
| Cameron, MD; Kamenecka, TM; Li, X | 1 |
| Choi, YJ; Kim, CH; Lee, JC; Lee, JK; Lee, SS; Na, II; Rho, JK; Ryoo, BY; Yang, SH; Yoo, YD | 1 |
| Goto, D; Hizawa, N; Kohno, M; Ohara, G; Satoh, H; Sumida, T | 1 |
| Castellano, A; Cialfi, S; De Ioris, MA; De Laurentis, C; De Pasquale, MD; Dominici, C; Donfrancesco, A; Ilari, I; Jenkner, A; McDowell, HP | 1 |
| Angelo, LS; Gong, J; Kohanim, S; Kurzrock, R; Yang, DJ | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Niang, C; Sancey, L | 1 |
| Busser, B; Coll, JL; Favrot, MC; Hurbin, A; Josserand, V; Khochbin, S; Niang, C; Sancey, L | 1 |
| Ishikawa, T; Nakagawa, H | 1 |
| Chen, F; Lu, Y; Luo, R; Luo, X; Zhang, J | 1 |
| Kayano, Y; Li, Q; Matsumoto, I; Matsumoto, K; Nishioka, Y; Oda, M; Sone, S; Wang, W; Watanabe, G; Yamada, T; Yano, S | 1 |
| Ichinose, Y; Maruyama, R; Seto, T; Wataya, H | 1 |
| House, L; Liu, Y; Ramírez, J; Ratain, MJ | 1 |
| Bronson, RT; Chen, Z; Engelman, JA; Faber, AC; García-Echeverría, C; Li, D; Liang, MC; Lifshits, E; Maira, SM; Song, Y; Wong, KK; Yeap, BY | 1 |
| Banat, GA; Cornitescu, T; Dahal, BK; Dumitrascu, R; Ghofrani, HA; Grimminger, F; Kosanovic, D; Pullamsetti, SS; Schermuly, RT; Seeger, W; Tretyn, A; Voswinckel, R; Weissmann, N | 1 |
| Sanford, M; Scott, LJ | 1 |
| Chahbouni, A; den Burger, JC; Sinjewel, A; Vos, RM; Wilhelm, AJ | 1 |
| Castaldo, V; Ferrara, ML; Gridelli, C; Maione, P; Mazzeo, N; Palazzolo, G; Rossi, A | 1 |
| Allen, CT; Chen, Z; Citrin, D; Colevas, AD; Dancey, J; Gius, D; Harold, NA; Morris, JC; Muir, C; Nottingham, L; Rudy, S; Singh, AK; Van Waes, C | 1 |
| Iizasa, T; Itakura, M; Kimura, H; Nakajima, T; Nishimura, H; Shingyoji, M | 1 |
| Boerner, S; Chung, CT; Joshua, AM; Lara-Guerra, H; Leighl, NB; Liu, G; Ludkovski, O; Ma, C; Paul, N; Sakurada, A; Salvarrey, MA; Shepherd, FA; Squire, J; Tsao, MS; Waddell, TK | 1 |
| Chen, JH; Chen, KY; Shih, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Kanda, S; Miyata, Y; Naba, A | 1 |
| Mekada, E; Miyamoto, S; Mizushima, H; Wang, X | 1 |
| Kappers, I; Klomp, HM | 1 |
| Anisimov, VV; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Moiseyenko, VM; Semionov, II; Yargnian, SM | 1 |
| Cha, MY; Kim, JW; Kim, MS; Kim, YH; Lee, CG; Lee, GS; Lee, KO; Park, SB; Song, JY | 1 |
| Atkins, JN; Crawford, ED; Goodwin, JW; Kakhil, SR; Lange, MK; Mansukhani, M; Petrylak, DP; Tangen, CM; Twardowski, PW; Van Veldhuizen, PJ | 1 |
| Yano, S | 2 |
| Bai La, BL; Endo, J; Funaguchi, N; Ito, F; Minatoguchi, S; Mori, H; Nakano, M; Ohno, Y; Yanase, K | 1 |
| Lee, CH | 1 |
| Choi, YH; Heo, MS; Kim, GY; Kim, MO; Lee, JD; Moon, DO | 1 |
| Dempoya, J; Hayashi, A; Mikuniya, M; Morimoto, T; Nakamura, K; Okudera, K; Okumura, K; Takanashi, S | 1 |
| Choi, SJ; Choi, YJ; Jeon, BS; Kim, CH; Kim, HR; Lee, JC; Lee, SS; Park, SC; Rho, JK | 1 |
| Ito, F; Takeuchi, K | 1 |
| Wong, ST | 1 |
| Carter, CA; Giaccone, G; Kelly, RJ | 1 |
| D'Alessio, A; De Luca, A; Gallo, M; Lamura, L; Maiello, MR; Napolitano, M; Normanno, N; Rachiglio, AM | 1 |
| Engelman, JA; Jackman, D; Jänne, PA; Johnson, BE; Kris, MG; Lynch, T; Miller, VA; Pao, W; Riely, GJ | 1 |
| Benlloch, S; Molina, MA; Rosell, R; Taron, M; Viteri, S | 1 |
| Alessandro Fanti, P; Balestri, R; Dika, E; Misciali, C; Patrizi, A; Vaccari, S | 1 |
| Abdallah, N; Altiok, S; Berman, D; Forastiere, A; Gibson, MK; Jagannath, S; Mezzadra, H; Rudek, MA; Tsottles, N | 1 |
| Büttner, R; Heukamp, LC | 1 |
| Collan, J; Hemminki, A; Isola, J; Joensuu, G; Joensuu, T; Kouri, M; Kupelian, PA; Nokisalmi, P; Pesonen, S; Reddy, C; Ruutu, M | 1 |
| Gao, W; Shen, H; Shu, YQ; Sun, J; Yuan, Y | 1 |
| Inoue, F; Momosaki, N; Morizono, G; Takenaka, T; Tanaka, T; Tomisaki, S | 1 |
| Iwakawa, J; Kawamata, Y; Kumamoto, T; Suetsugu, T; Tanoue, A | 1 |
| Mintz, A; Nguyen, V | 1 |
| Adelstein, DJ; Ives, DI; Mason, DP; Murthy, SC; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Videtic, GM | 1 |
| Ballatori, E; Fatigoni, S; Roila, F | 1 |
| Asami, K; Fukuoka, M; Hirashima, T; Katakami, N; Kudoh, S; Mitsudomi, T; Morita, S; Nakagawa, K; Negoro, S; Okamoto, I; Saito, H; Satouchi, M; Seto, T; Shibata, K; Shimizu, E; Tada, H; Takada, M; Toyooka, S; Tsurutani, J; Yatabe, Y; Yoshioka, H | 1 |
| Baba, N; Fujio, K; Kimura, S; Kohno, M; Kosugi, M; Ozaki, K; Sakamoto, T; Tanimura, S | 1 |
| Eck, MJ; Yun, CH | 1 |
| Kris, MG; Ladanyi, M; Pao, W; Rizvi, NA; Rusch, VW; Solomon, SB; Thornton, RH; Zakowski, MF | 1 |
| Gutteridge, E; Robertson, JF | 1 |
| Aractingi, S; Nassar, D; Soutou, B | 1 |
| Ayala, D; Blackstock, AW; Capellari, J; Center, B; Hinson, WH; Lovato, J; Miller, AA; Oaks, T; Petty, WJ | 1 |
| Fukui, T; Hataishi, R; Igawa, S; Jiang, SX; Katagiri, M; Kubota, M; Masuda, N; Mitsufuji, H; Nishii, Y; Otani, S | 1 |
| Abe, K; Akasaka, K; Imai, Y; Imura, J; Kaburagi, T; Nagao, K; Ohmori, K; Sagara, H; Ueda, Y; Yasuda, S | 1 |
| Duan, HQ; Han, Y; Liu, XQ; Xu, JM; Zhang, JS; Zhang, Y | 1 |
| Armour, AA; Bischoff, H; Douillard, JY; Gervais, R; Hirsh, V; Kim, ES; Liao, ML; Mok, T; Reck, M; Sellers, MV; Shepherd, FA; Socinski, MA; Speake, G; Watkins, CL | 1 |
| Ando, M; Fukuoka, M; Hida, T; Ichinose, Y; Iwamoto, Y; Kashii, T; Katakami, N; Kudoh, S; Kurata, T; Matsui, K; Nakagawa, K; Okamoto, I; Sasaki, J; Sato, T; Satouchi, M; Sawa, T; Seto, T; Takayama, K; Takeda, K; Yamamoto, N | 1 |
| Huang, MS; Hung, HC; Hung, JY; Lai, CL; Lai, YF; Lin, MC; Shieh, JM; Yang, CT | 1 |
| Amano, O; Chu, Q; Kanda, Y; Kunii, S; Sakagami, H; Wang, Q | 1 |
| Amir, E; Seruga, B; Tannock, I | 1 |
| Takano, T | 1 |
| Giaccone, G; Hoekman, K; Jürgensmeier, JM; Meijerink, MR; Puchalski, TA; Punt, CJ; Robertson, J; Saunders, O; van Cruijsen, H; van Herpen, CM; Voest, EE; Witteveen, PO | 1 |
| Chang, J; Cho, BC; Choi, HJ; Kim, JH; Kim, SK; Lee, YJ; Moon, JW; Park, IK | 1 |
| Beika, Y; Enomoto, T; Fujii, T; Kishi, K; Kurosaki, A; Miyamoto, A; Morokawa, N; Takaya, H; Uruga, H; Yoshimura, K | 1 |
| Argiris, A; Burtness, BA; Caprioli, RM; Carbone, DP; Chung, CH; Cohen, EE; Forastiere, AA; Gilbert, J; Grigorieva, J; Murphy, B; Roder, H; Roder, J; Seeley, EH; Tsypin, M | 1 |
| Neal, JW | 1 |
| Chang, SC; Kuo, LC; Lin, PC; Wang, KF; Yuan, MK | 1 |
| Bajetto, A; Barbieri, F; Corte, G; Favoni, RE; Florio, T; Gatti, M; Gaudino, G; Lo Casto, M; Mutti, L; Paleari, L; Pattarozzi, A; Porcile, C | 1 |
| Baldi, E; Forti, G; Gelmini, S; Maggi, M; Marchiani, S; Nesi, G; Orlando, C; Paglierani, M; Tamburrino, L | 1 |
| Araki, T; Baba, M; Hayashizaki, Y; Kaira, K; Kakegawa, S; Kawai, Y; Lezhava, A; Mitani, Y; Miyamae, Y; Shimizu, K; Sugano, M; Takeyoshi, I; Yamamoto, K | 1 |
| Chen, L; Ma, X; Sun, C; Zhong, M | 1 |
| Aoe, K; Bessho, A; Fujiwara, K; Harita, S; Hotta, K; Kamei, H; Kato, K; Kawai, H; Kiura, K; Kuyama, S; Maeda, T; Moritaka, T; Segawa, Y; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H; Umemura, S; Yonei, T; Yoshioka, H | 1 |
| Dirschka, T; Hauschild, A; Kroth, J; Wollenberg, A | 1 |
| Chen, YM; Chou, KT; Fan, WC; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Wu, CH | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Sung, JH; Yun, T | 1 |
| Ayabe, E; Endo, M; Horie, Y; Kaira, K; Kondo, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Bougnoux, P; Carrasco, AT; Fumoleau, P; Joly, F; Kerbrat, P; Lhommé, C; Pautier, P; Petit, T; Ringeisen, F; Rixe, O | 1 |
| Hudish, TM; Karoor, V; Keith, RL; Le, M; Miller, YE; Mozer, AB | 1 |
| Neal, JW; Sequist, LV | 2 |
| Brown, A; Capelletti, M; Christensen, JG; Engelman, JA; Ercan, D; Jänne, PA; Kwiatkowski, DJ; Lee, C; Lifshits, E; Rogers, A; Xiao, Y; Yonesaka, K; Zejnullahu, K | 1 |
| Baldi, A; Canino, C; Cardillo, I; Galati, R; Sacchi, A; Stoppoloni, D; Verdina, A | 1 |
| Hao, YY; Iwamori, M; Li, FF; Lin, B; Liu, DW; Liu, JJ; Qi, Y; Zhang, SL; Zhu, LC | 1 |
| Baum, MS; Chen, I; Ginsberg, MS; Harmon, CS; Hudes, GR; Kim, ST; Motzer, RJ; Redman, BG | 1 |
| Ahn, JS; Ahn, MJ; Kang, JH; Kim, JH; Kim, SW; Lee, DH; Lee, JS; Park, K; Shin, SW; Suh, C | 1 |
| Anderton, J; Barlaam, B; Beck, S; Callis, R; Davenport, S; Grosios, K; Hickinson, DM; Klinowska, T; Marshall, G; Mills, E; Ogilvie, D; Smith, P; Speake, G; Trigwell, C; Vincent, J; Wilkinson, RW | 1 |
| Ali-Osman, F; Cao, X; Keir, S; Lo, HW; Zhu, H | 1 |
| Fujimoto, H; Hashimoto, K; Ishizuka, H; Kameyama, Y; Oyama, T; Suito, T; Yasuda, H | 1 |
| Caicun, Z; Jian, G; Jie, Z; Liang, T; Ling, Z; Qinfang, D; Songwen, Z | 1 |
| Bozec, A; Etienne-Grimaldi, MC; Fischel, JL; Formento, P; Milano, G | 1 |
| Burgers, JA; Cortesi, F; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Peters, GJ; Santoro, A; Smit, EF; Tibaldi, C; Zucali, PA | 1 |
| Agus, DB; Favero, K; Hodge, A; Jain, A; Mink, S; Penuel, E; Schmidt, J; Tindell, C | 1 |
| Duncan, R; Ferguson, EL; Richardson, SC | 1 |
| Hilbe, W; Pircher, A; Ploner, F; Popper, H | 1 |
| Liao, XB; Liu, JQ; Sun, XL; Wang, YX; Yan, DF; Yan, SX; Yang, JS | 1 |
| Grubbs, CJ; Juliana, MM; Lubet, RA; Steele, VE | 1 |
| Batra, SK; Depreux, P; Henichart, JP; Johansson, SL; Mimeault, M | 1 |
| Glynne-Jones, R; Harrison, M; Mawdsley, S | 1 |
| Ishida, T; Iwasaku, M; Kunimasa, K; Nishiyama, A; Ubukata, S; Yoshioka, H | 1 |
| Arao, T; Fujita, Y; Fukuoka, M; Ito, H; Nakagawa, K; Nishio, K; Okamoto, I; Takeda, M | 1 |
| Arakawa, M; Hasegawa, T; Honda, N; Nakamura, K; Rosser, CJ; Saito, H; Tobiume, M; Yamada, Y | 1 |
| Ke, QH; Su, XY; Xu, XM; Yang, JY; Yuan, GJ | 1 |
| Cadranel, J; De Fraipont, F; Faller, MB; Fraboulet, G; Lantuejoul, S; Legendre, A; Milleron, B; Moro-Sibilot, D; Oliveiro, G; Perol, M; Pluquet, E; Quoix, E; Souquet, PJ; Zalcman, G | 1 |
| Fujimoto, N; Fujiwara, Y; Kiura, K; Tabata, M; Takigawa, N; Tanimoto, M; Toyooka, S; Ueoka, H; Umemura, S | 1 |
| Aikou, T; Akiba, S; Baba, M; Castillo, A; Eizuru, Y; Higashi, M; Itoh, T; Khan, N; Koriyama, C; Matsumoto, H; Natsugoe, S; Shuyama, KY; Yanagi, M | 1 |
| Chen, L; Shi, YX; Wang, F; Zhang, L; Zhang, Y; Zhao, H | 1 |
| Bovio, H; de Sande González, L; García-Foncillas, J; García-Girón, C; García-López, JL; Lacave, AJ; Peláez, I; Reboredo, M; Valladares, M; Viéitez, JM | 1 |
| Dvorák, J; Hyspler, R; Kalábová, H; Kasparová, M; Krcmová, L; Melichar, B; Solichová, D; Urbánek, L | 1 |
| Bachawal, SV; Sylvester, PW; Wali, VB | 2 |
| Gao, ZQ; Gu, AQ; Han, BH; Shi, CL; Wang, HM; Xiong, LW | 1 |
| Burenkova, O; Crosby, K; Engelman, JA; Faber, AC; Fulgham, A; Li, D; Liang, MC; Nie, L; Nielsen, UB; Onsum, M; Pace, E; Schoeberl, B; Song, Y; Walton, Z; Wong, KK | 1 |
| Anderson, E; Arena, FP; Bacus, S; Cora, EM; Cristofanilli, M; Curcio, E; Kroener, JF; Magill, PJ; Mangalik, A; Rabinowitz, I; Royce, M; Valero, V; Watkins, C | 1 |
| Frieling, T; Graeven, U; Hegewisch-Becker, S; Lehnert, L; Reinacher-Schick, A; Schmiegel, W; Trarbach, T; Vanhoefer, U | 1 |
| Li, YX; Sun, Q; Wang, H; Wang, SN | 1 |
| Baek, JH; Cha, SJ; Kim, H; Min, YJ; Noh, EK; Park, JH; Park, MJ; Won, JH | 1 |
| Byrne, AT; Crown, J; Gallagher, WM; McGee, S; O'Connor, AE; O'Donovan, N | 1 |
| Funato, T; Takeda, M | 1 |
| Aizawa, H; Akiba, J; Azuma, K; Basaki, Y; Hattori, S; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kono, S; Kuwano, M; Nakashima, K; Ono, M; Takamori, S; Yanagawa, T | 1 |
| Hang, J; Li, Z; Su, B; Su, C; Zhang, L; Zhao, Y; Zhou, C; Zhou, S | 1 |
| Gotoh, N; Higuchi, T; Imoto, S; Kojima, K; Miyano, S; Nagasaki, M; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yoshida, R | 1 |
| Cheng, Y; Hait, WN; Li, H; Niu, T; Ren, X; Yang, J | 1 |
| Hasegawa, S; Hashimoto, M; Kondo, N; Matsumoto, S; Okumura, Y; Takuwa, T; Tanaka, F; Torii, I; Yoneda, K | 1 |
| Hansen, O; Schytte, T | 1 |
| Chen, W; Chen, WC; Hsia, TC; Lai, HC; Shih, CM; Tseng, GC | 1 |
| Harris, TJ; McCormick, F | 1 |
| Chua, BT; Lim, SJ; Poh, WJ; Tham, SC; Ullrich, A | 1 |
| Barchuk, AS; Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Protsenko, SA; Semenov, II; Togo, AV | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; La Monica, S; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M | 1 |
| Amadori, D; Brigliadori, G; Carloni, S; Fabbri, F; Silvestrini, R; Ulivi, P; Zoli, W | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Berna, MJ; Chan, D; Giaccone, G; Jensen, RT; Mantey, S; Moody, TW; Ridnour, L; Sancho, V; Wink, DA | 1 |
| Barlési, F; Baudrin, L; Bréchot, JM; Debieuvre, D; Gounant, V; Lebeau, B; Milleron, B; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Vaylet, F; Westeel, V; Zalcman, G | 1 |
| Doi, S; Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Nakano, H; Nakatomi, K; Soda, H; Takasu, M; Takatani, H; Tomonaga, N; Tsukamoto, K; Yamaguchi, H | 1 |
| Chen, J; Liu, H; Xu, Y; Zhou, Q | 1 |
| Atkinson, T; Berlin, ST; Bunnell, CA; Campos, SM; Chen, WY; Harris, L; Hirsch, MS; Krasner, CN; Lee, J; Matulonis, U; Parker, LM | 1 |
| Chan, R; Jacks, T; Jasper, PJ; Lane, K; Lauffenburger, DA; Lazzara, MJ; Neel, BG; Sorger, PK; Yaffe, MB | 1 |
| Cai, CJ; Deng, QH; He, JX; Huang, J; Li, HL; Wang, DY; Wang, W; Wen, DP; Xie, SM; Zhang, L; Zhong, NS | 1 |
| Agarwal, S; Elmquist, WF; Gallardo, JL; Ohlfest, JR; Sane, R | 1 |
| Dive, C; Harrison, LR; Mironov, A; Moreira-Leite, FF; Roberts, RA | 1 |
| Blackhall, F; Campbell, L; Thatcher, N | 1 |
| Heo, DS; Kang, JH; Kim, DW; Kim, HK; Kim, SY; Lee, JS; Lee, MA; Lee, SH; Shin, SW | 1 |
| Hsu, WH; Hung, JJ; Jeng, WJ; Liu, JS; Wu, YC | 1 |
| Acheson, KL; Beran, GJ; Bunn, PA; Cassidy, AM; French, T; Graham, A; Hickinson, DM; Hirsch, FR; Holloway, BR; Marshall, GB; McCormack, RM; McWalter, G; Mills, EA; South, MC; Speake, G; Varella-Garcia, M | 1 |
| Cho, BC; Choi, SY; Kim, EM; Kim, HK; Kim, JH; Kim, JS; Kim, SM; Solca, F; Yun, CO | 1 |
| Fukuoka, M; Itoh, Y; Jiang, H; Negoro, S; Nishiwaki, Y; Saijo, N; Yamamoto, N | 1 |
| Bollinger, N; Joslin, EJ; Lauffenburger, DA; Opresko, LK; Shankaran, H; Wiley, HS | 1 |
| Guo, Y; Jiang, W; Li, S; Liao, H; Shi, YX; Xue, C; Zhang, L; Zhang, Y; Zhao, HY; Zhao, YY | 1 |
| Calabrese, C; Carcaboso, AM; Elmeliegy, MA; Juel, SJ; Shen, J; Stewart, CF; Tracey, L; Waters, CM; Zhang, ZM | 1 |
| Ji, M; Li, M; Lian, J; Qu, Y; Tang, W; Wu, X; Xu, L; Zheng, Y | 1 |
| Jean-Claude, BJ; Rachid, Z; Watt, HL | 1 |
| Amornphimoltham, P; Chiorini, JA; Gutkind, JS; Schmidt, M; Weller, ML; Wilson, PA | 1 |
| Miller, VA; Oxnard, GR | 1 |
| Ramalingam, SS; Stinchcombe, TE | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Cheng, H; Dong, S; Guo, AL; Lin, QX; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Blair, EA; Brockstein, B; Cohen, EE; Dekker, A; Dignam, JJ; Grushko, TA; Haraf, DJ; Kunnavakkam, R; Lester, EP; Lingen, MW; Olopade, OI; Salama, JK; Stenson, KM; Vokes, EE; Williams, R; Witt, ME | 1 |
| Barchuk, AS; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Procenko, SA; Semionov, II; Togo, AV | 1 |
| Ballman, KV; Behrens, RJ; Buckner, JC; Dakhill, SR; Flynn, PJ; Giannini, C; Jaeckle, KA; James, CD; Krauss, JC; Schaefer, PL; Scheithauer, BW; Uhm, JH; Wu, W | 1 |
| Bodio, K; Costa, DB; Huberman, MS; Kobayashi, S; Kris, MG; Lau, MW; Pao, W; Riely, GJ; Tenen, DG; Warner, JL; Yeap, BY; Yeo, WL | 1 |
| Fujita, S; Ichikawa, M; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M | 1 |
| Choi, YJ; Kim, CH; Kim, HR; Kim, HT; Kim, YM; Koh, JS; Kook, EH; Lee, JC; Rho, JK | 1 |
| Batra, S; Batra, U; Dhiman, A; Doval, DC; Suresh, P; Talwar, V | 1 |
| Fukuoka, M; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Takezawa, K; Tanizaki, J; Yamaguchi, H | 1 |
| Bartolotti, M; Bordi, P; Gelsomino, F; Tiseo, M | 1 |
| Guo, P; Kris, MG; Ladanyi, M; Moskowitz, CS; Oxnard, GR; Pao, W; Rizvi, NA; Rusch, VM; Schwartz, LH; Zhao, B | 1 |
| Higashi, Y; Kanekura, T; Kawai, K; Uchimiya, H | 1 |
| Dunn, EF; Harari, PM; Wheeler, DL | 1 |
| Ahn, JS; Ahn, MJ; Choi, YL; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW | 1 |
| Wörmann, B | 1 |
| Markaverich, BM; Rodriguez, M; Shoulars, K; Vijjeswarapu, M | 1 |
| Fujikura, Y; Hizawa, N; Homma, S; Kurishima, K; Morishima, Y; Ota, K; Otsuka, S | 1 |
| Ji, H | 1 |
| Ahn, JS; Ahn, MJ; Kim, JH; Kim, ST; Lee, J; Park, K; Park, YH; Sun, JM; Won, YW; Yun, J | 1 |
| Ge, XQ; Huang, JJ; Shen, H; Yuan, Y; Zhong, X | 1 |
| Dong, Y; Li, A; Michel, LS; Wang, J; Weber, JD | 1 |
| Hosoda, W; Kitamura, A; Mitsudomi, T; Sasaki, E; Yatabe, Y | 1 |
| Ando, M; Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Miyazawa, H; Morita, S; Nukiwa, T; Ogura, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Tanaka, T; Yoshimori, K; Yoshizawa, H | 1 |
| Belsanova, B; Benesova, L; Minarik, M; Pesek, M; Sekerka, P | 1 |
| Döme, B; Ostoros, G; Strausz, J; Tímár, J | 1 |
| Brückl, WM; Ficker, JH; Wiest, GH | 1 |
| Fukuoka, M; Makimura, C; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Chang, CY; Chang, SC; Chen, CY; Yu, CJ | 1 |
| Lin, CC; Shao, YY; Yang, CH | 1 |
| Muro, Y; Shimoyama, Y; Sugiura, K; Tomita, Y; Yamaki, M | 1 |
| Giaccone, G; Lopez-Chavez, A | 1 |
| Ahn, JS; Ahn, MJ; Ahn, YC; Kim, JA; Lee, J; Lee, S; Park, HC; Park, K; Park, YH; Sun, JM | 1 |
| Du, H; He, L; Sun, M; Wang, S; Zhang, Y | 1 |
| Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Martinelli, E; Morgillo, F; Orditura, M; Troiani, T | 1 |
| Allen, JW; Daw, NC; Furman, WL; Geyer, JR; McGregor, LM; McKibbin, T; Stewart, CF; Tagen, M; Zhao, W | 1 |
| Dondi, D; Festuccia, C; Gravina, GL; Locatelli, A; Motta, M; Piccolella, M; Tombolini, V | 1 |
| Chang, JG; Feng, YH; Lee, JC; Lu, PJ; Shiau, AL; Shieh, GS; Tsao, CJ; Wu, CL; Yeh, KT | 1 |
| Chang, SH; Hsu, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Luger, P; Lüth, A; Mebs, S | 1 |
| Ding, YM; Ju, LX; Li, W; Meng, SY; Su, B; Tang, L; Yan, LH; Yang, XJ; Zhao, YM; Zhou, CC | 1 |
| Bokemeyer, C; Laack, E; Sauter, G | 1 |
| Aebersold, DM; Bernier, J; Bucher, SE; Ciernik, IF; Glanzmann, C; Lippuner, T; Lombrieser, N; Lütolf, UM; Ries, G; Rothschild, S; Zouhair, A | 1 |
| Inoue, A | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Fukuda, M; Hayashi, T; Kohno, S; Nagashima, S; Nakamura, Y; Oka, M; Sano, K; Soda, H; Takatani, H; Tsukamoto, K | 1 |
| Cufí, S; Del Barco, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Vazquez-Martin, A | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishihara, K; Kaji, R; Katakami, N; Nishimura, T; Takahashi, Y; Tomii, K | 1 |
| Byers, L; Cai, D; Gao, B; Gazdar, AF; Girard, L; Heymach, J; Kim, YH; Kodadek, T; Mills, G; Minna, JD; Nanjundan, M; Peyton, M; Pollack, JR; Raso, MG; Shames, DS; Sullivan, JP; Wistuba, I; Xie, Y | 1 |
| Chen, L; Li, C; Liu, X; Tian, Q; Wang, P; Xu, Y; Yang, Z; Zhao, W | 1 |
| Lv, P; Zhou, T | 1 |
| Akiyama, H; Hishida, T; Horinouchi, H; Kondo, H; Mitsudomi, T; Nagai, K; Nagayasu, T; Tsuboi, M; Yokoi, K | 1 |
| Chen, J; Liu, H; Wang, Y | 1 |
| Hanagiri, T; Iwata, T; Onitsuka, T; Oyama, T; Shimokawa, H; Uramoto, H | 1 |
| Fujita, J; Furuta, J; Hizawa, N; Kikuchi, N; Miyazaki, K; Morishima, Y; Nozato, K; Ogawa, R; Sakamoto, T | 1 |
| Bogart, J; Dipetrillo, T; Garst, J; Graziano, S; Green, MR; Gu, L; Jänne, PA; Ready, N; Vokes, EE; Wang, X | 1 |
| Huang, C; Jiang, K; Wu, B; Xu, Z; Zhang, J; Zhuang, W | 1 |
| Katayama, T; Kosaka, T; Matsuo, K; Mitsudomi, T; Sueda, T; Yatabe, Y | 1 |
| Banerjee, A; Blaney, SM; Boyett, JM; Broniscer, A; Douglas, JG; Geyer, JR; Gilbertson, RJ; Gururangan, S; Kieran, MW; Kocak, M; Kun, LE; Packer, RJ; Phillips, P; Stewart, CF | 1 |
| Chan, N; Lim, SW; Soo, RA; Teo, C; Wong, AS; Wong, E | 1 |
| Altorki, N; Camiolo, M; Fenoglio, S; Gao, DC; Johns, C; Kenner, L; Lindsted, T; Mittal, V; Schlederer, M; Sordella, R; Stiles, B; Yao, Z | 1 |
| Arao, T; Fukuoka, M; Hatashita, E; Jänne, PA; Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, W; Tanaka, K; Yamada, Y; Yamaguchi, H | 1 |
| Lam, KC; Mok, TS | 2 |
| Ahn, HK; Ahn, JS; Ahn, MJ; Chang, MH; Choi, YL; Jung, CK; Lee, J; Park, K; Park, YH | 1 |
| Matsuzaki, T; Miyauchi, J; Morishita, T; Naitou, A; Ogawa, R; Terashima, T | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Nishiyama, A; Tomii, K; Yoshioka, H | 1 |
| Chopra, A; Ku, GY; Lopes, Gde L | 1 |
| Chen, LA; Liang, ZX; Sun, JP; Tian, Q; Wang, P; Xu, SF; Yang, Z | 1 |
| Chung, KP; Shih, JY; Yu, CJ | 1 |
| Bafaloukos, D; Dahabreh, IJ; Kosmidis, P; Linardou, H; Murray, S | 1 |
| Fukuoka, M; Nakagawa, K; Nakamatsu, K; Nishimura, Y; Okamoto, H; Okamoto, I; Takahashi, T; Watanabe, K; Yamamoto, N | 1 |
| Cho, EK; Hong, J; Jung, SH; Kyung, SY; Lee, JH; Lee, JI; Lee, SP; Park, J; Park, JW; Park, SH; Shin, DB; Sym, SJ | 1 |
| Chang, YC; Chang, YL; Hsu, YC; Shih, JY; Wu, JY; Wu, SG; Yang, CH; Yang, PC | 1 |
| Alam, N; Dudek, AZ; Gustafson, KS; Kapoor, A; Ladanyi, M; Truskinovsky, AM; Zakowski, MF | 1 |
| Iqbal, SA; Myerson, JS; O'Brien, ME; Popat, S | 1 |
| Andreuccetti, M; Borghi, F; Caparello, C; Caponi, S; D'Incecco, A; Falcone, A; Ginocchi, L; Lucchesi, M; Tibaldi, C; Vasile, E | 1 |
| Geng, YT; Li, XD; Shen, H; Shu, YQ; Sun, J; Wu, CP; Yin, YM | 1 |
| Addison, CL; Dimitroulakos, J; Trinh, D; Zhao, TT | 1 |
| Geng, YT; Hu, XL; Li, W; Shao, YF; Shu, YQ; Wang, ZX; Yin, YM | 1 |
| Chang, CH; Chang, KC; Chu, CY; Kuo, TC; Lu, PH | 1 |
| Ferris, RL; Ferrone, S; Grandis, JR; Sharafinski, ME | 1 |
| Dennison, G; Foulstone, EJ; Frankow, A; Holly, JM; Jarrett, C; McIntosh, J; Perks, CM; Winters, ZE | 1 |
| Ambrosio, R; Barbato, V; Bareschino, MA; Falanga, M; Gridelli, C; Maione, P; Rossi, A; Sacco, PC; Schettino, C | 1 |
| Cheng, G; Li, L; Wu, XN; Zhang, P; Zhang, ZJ | 1 |
| Arcila, ME; Azzoli, CG; Heelan, RT; Kris, MG; Krug, LM; Miller, VA; Pao, W; Pietanza, MC; Price, KA; Riely, GJ; Rizvi, NA | 1 |
| Becker, A; Chiappori, A; Haura, EB; Sommers, E; Song, L | 1 |
| Fukuhara, A; Hatachi, Y; Kim, YH; Kubo, T; Masago, K; Mio, T; Mishima, M; Sakamori, Y; Togashi, K; Togashi, Y | 1 |
| Der, CJ; Roberts, PJ; Socinski, MA; Stinchcombe, TE | 1 |
| Guo, Y; Jiang, X; Li, Z; Wang, G; Xi, Z; Yan, B; Yao, Y | 1 |
| Aburatani, H; Fukayama, M; Ishikawa, S; Matsubara, D; Niki, T; Sachiko, O | 1 |
| Hamada, N; Harada, C; Kawaguchi, T; Kuwano, K; Maeyama, T; Nakanishi, Y; Ogata-Suetsugu, S; Souzaki, R; Taguchi, T; Tajiri, T; Yamada, M | 1 |
| Hojjati, M; Nguyen, S | 1 |
| Murashige, N; Oshima, Y; Tanimoto, T | 1 |
| Bertran, E; Caja, L; Campbell, J; Fabregat, I; Fausto, N | 1 |
| Hosomi, Y; Iguchi, M; Miyamoto, S; Ohkuma, Y; Okamura, T; Shibuya, M; Shimokawa, T; Takagi, Y | 1 |
| Chang, YH; Lim, KH | 1 |
| Armour, AA; Watkins, CL | 1 |
| Chun, KS; Langenbach, R; Lao, HC | 1 |
| Basaki, Y; Izumi, H; Kage, M; Kawahara, A; Kohno, K; Kuwano, M; Nakashima, K; Ono, M; Uramoto, H; Yamamoto, C; Yasumoto, K | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, CP; Chen, CT; Chen, YR; Chu, CY; Coumar, MS; Fang, MY; Hsieh, HP; Hsieh, SH; Hsu, H; Hsu, JT; Liao, CC; Lien, TW; Lin, WH; Rafi, S; Shiao, HY; Wang, SY; Wu, CH; Yeh, KC; Yeh, TK | 1 |
| Brunner, C; Hubalek, M; Marth, C; Matthä, K | 1 |
| Benlloch, S; Cardenal, F; Molina, MA; Moran, T; Porta, R; Rosell, R; Taron, M; Viteri, S | 1 |
| Jones, SJ; Milenkova, T | 1 |
| Britt, GJ; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Rabin, MS; Yeap, BY | 1 |
| Chang, TH; Huang, CP; Lan, CC; Lin, SB; Shih, JY; Su, KY; Tsai, MF; Wu, CP; Wu, SG; Yang, CH; Yang, PC; Yu, SL; Yu, YL | 1 |
| Bagust, A; Boland, A; Brown, T; Dickson, R; Dundar, Y; Hockenhull, J; Oyee, J; Proudlove, C; Ramani, VS | 1 |
| Boyett, JM; Geyer, R; Haas-Kogan, D; Kieran, MW; Kun, L; Ng, S; Pollack, IF; Poussaint, TY; Prabhu, SP; Vajapeyam, S | 1 |
| Ju, L; Li, W; Yan, L; Zhou, C | 1 |
| Duchnowska, R | 1 |
| Chen, X; Dai, L; Fang, J; Han, J; Han, S; Hu, W; Liu, X; Nie, J; Tian, G | 1 |
| Abbruzzese, JL; Logsdon, CD | 1 |
| Crawford, H; Ely, M; Janakiram, NB; Li, Q; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE | 1 |
| Ahn, JS; Ahn, MJ; Chung, MJ; Hwang, HS; Kim, TS; Lee, HY; Lee, JW; Lee, KS; Park, K; Yi, CA | 1 |
| Ellerbrok, H; Koban, R; Langhammer, S; Yue, C | 1 |
| Ho, CC; Kuo, YW; Shih, JY; Wu, SG | 1 |
| Bannykh, S; Cooper, O; Fukuoka, H; Melmed, S; Mizutani, J; Ren, SG; Tong, Y | 1 |
| Chen, YM; Chou, KT; Fan, WC; Hsia, TC; Huang, MS; Huang, SF; Lai, CL; Lee, YC; Perng, RP; Tien, YJ; Tsai, CM; Wu, CH; Yu, CJ | 1 |
| Haramoto, M; Horibe, T; Kawakami, K; Kohno, M; Matsuzaki, K; Nakajima, O; Ohara, K; Yano, Y | 1 |
| Guan, ZZ; Guo, GF; Wan, DS; Wu, PH; Xia, JC; Xia, LP; Zeng, YX; Zhang, B | 1 |
| Abbott, DW; Asara, JM; Tigno-Aranjuez, JT | 1 |
| Bischoff, H; Kindermann, M; Reinmuth, N; Steins, MB; Thomas, M | 1 |
| Bellini, P; Favoni, RE; Harvey, BJ; Manente, AG; Moro, L; Mutti, L; Pinton, G; Thomas, W | 1 |
| Al-Khater, AM; Rasul, KI | 1 |
| Asamura, H; Furuta, K; Kohno, T; Kozu, Y; Sekine, I; Suzuki, K; Tamura, T; Tsuda, H; Tsuta, K; Watanabe, S; Yokota, J; Yoshida, A | 1 |
| Miller, GP | 1 |
| Banerjee, R; Belinsky, G; Huang, Y; Jean-Claude, BJ; McNamee, JP; Qiu, Q | 1 |
| Baak, JP; Guo, H; Liu, JX; Madebo, T; Xu, L | 1 |
| Fenning, CS; Fenton, A; Johnston, PG; Kyula, JN; Longley, DB; Sasazuki, T; Shirasawa, S; Van Schaeybroeck, S | 1 |
| Hui, RC; Ko, JH; Shih, YC; Yang, CH | 1 |
| Azzoli, CG; D'Angelo, SP; Janjigian, YY; Kris, MG; Ladanyi, M; Pao, W; Park, BJ; Shen, R; Zakowski, MF; Zheng, J | 1 |
| Doebele, RC; Heasley, LE; Heasley, LR; Helfrich, BA; Hercule, P; Hinz, TK; Marek, L; Marshall, ME; Ware, KE | 1 |
| Gelderblom, H; Guchelaar, HJ; Pander, J | 1 |
| Kuwata, K; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Okamoto, W; Takezawa, K; Tanaka, K; Yamaguchi, H | 1 |
| Lee, P | 1 |
| Cortot, AB | 1 |
| Choi, YJ; Chung, JH; Kim, CH; Kim, HR; Lee, CT; Lee, JC; Lee, JS; Rho, JK; Xu, X; Yoon, HI | 1 |
| Lin, CC; Yang, JC | 1 |
| Cai, L; Huang, WJ; Li, L; Li, WF; Yuan, WF | 1 |
| Heigener, DF; Reck, M | 1 |
| Kickler, TS; Lynch, DR; Rade, JJ | 1 |
| Imai, H; Ishizuka, T; Kaira, K; Kanai, Y; Mori, M; Nagamori, S; Nakajima, T; Oriuchi, N; Promchan, K; Shimizu, K; Sunaga, N; Tominaga, H; Yamamoto, N; Yanagitani, N | 1 |
| Katsifis, A; Lin, HQ; Meriaty, H | 2 |
| Chu, Z; Huang, L; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Baba, J; Ichikawa, K; Kagamu, H; Kondo, R; Koshio, J; Miyabayashi, T; Narita, I; Ota, T; Tanaka, H; Tanaka, J; Watanabe, S; Yoshizawa, H | 1 |
| Erdem, L; Giovannetti, E; Leon, LG; Olcay, E; Peters, GJ | 1 |
| Dobashi, Y; Kanai, Y; Koyama, S; Tetsuka, K | 1 |
| Berardi, F; Colabufo, NA; Contino, M; Leopoldo, M; Niso, M; Perrone, R | 1 |
| Angelo, A; Azzariti, A; Colucci, G; Porcelli, L; Quatrale, AE; Silvestris, N | 1 |
| Azzariti, A; Colucci, G; Fratto, ME; Galluzzo, S; Maiello, E; Santini, D; Silvestris, N; Tommasi, S; Tonini, G; Vincenzi, B; Zoccoli, A | 1 |
| Grazioso Russi, E; Numico, G; Silvestris, N | 1 |
| Longo, M; Merlo, V; Novello, S; Scagliotti, GV | 1 |
| Chen, B; Liu, S; Wang, D; Wang, Y; Wu, J; Zhao, W | 1 |
| Baselga, J; Chandarlapaty, S; Grbovic-Huezo, O; Majumder, PK; Rodrik-Outmezguine, V; Rosen, N; Sawai, A; Scaltriti, M; Serra, V | 1 |
| Chang, GC; Hsu, SL; Lai, JM; Wu, CC; Yu, CT | 1 |
| Cappuzzo, F; Cortinovis, D; De Marinis, F; Di Maio, M; Gridelli, C; Mok, T | 2 |
| Doussau, A; Le Tourneau, C; Ollivier, L; Paoletti, X; Postel-Vinay, S; Servois, V | 1 |
| Boss, DS; Britten, CD; Camidge, DR; Eckhardt, SG; Engelman, JA; Garon, EB; Guo, F; Jänne, PA; Letrent, S; Liang, J; Millham, R; Schellens, JH; Taylor, I; Wong, S | 1 |
| Donev, IS; Li, Q; Matsumoto, K; Nishioka, Y; Sone, S; Takeuchi, S; Wang, W; Yamada, T; Yamori, T; Yano, S | 1 |
| Anagnostou, VK; Dirix, LY; Gutierrez, C; Mackey, JR; Magill, P; Migliaccio, I; Neven, P; Osborne, CK; Rimm, DL; Robert, J; Schiff, R; Sellers, M; Underhill, C | 1 |
| Honda, T; Kameda, Y; Kondo, T; Miyagi, Y; Murakami, S; Noda, K; Obata, M; Oshita, F; Saito, H; Sakuma, Y; Yamada, K; Yokose, T | 1 |
| Fan, Y; Huang, ZY; Luo, LH; Yu, HF | 1 |
| Coveney, PV; Wan, S | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Ingvar, C; Jakobsen, EH; Jörgensen, L; Kimper-Karl, ML; Kroman, N; Saetersdal, A; Tuxen, MK | 1 |
| Bueno, R; Corson, JM; Fletcher, JA; Flynn, DL; Hubert, C; Ou, WB; Sugarbaker, DJ | 1 |
| Chang, CC; Chang, HJ; Chi, KH; Hsieh, YS; Hsu, PS; Jiang, JS; Kao, SJ; Tsang, YW; Yeh, YW | 1 |
| Duyster, J; Kancha, RK; Peschel, C | 1 |
| An, SJ; Chen, ZH; Cheng, H; Dong, S; Wu, YL; Zhang, XC; Zhang, YF | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Stewart, DJ; Tsai, CM | 1 |
| Huang, Y; Jean-Claude, BJ; Rachid, Z | 1 |
| Ito, K; Kawano, D; Maehara, Y; Morodomi, Y; Shoji, F; Yano, T | 1 |
| Han, JH; Han, JY; Kim, HT; Lee, GK; Lee, JS; Lee, YJ; Park, JH; Yoon, KA; Yoon, SJ; Yun, T | 1 |
| Beck, JF; Kurtze, I; Sonnemann, J | 1 |
| Endo, M; Kaira, K; Kaira, R; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, K; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Asami, K; Atagi, S; Kawaguchi, T; Kawahara, M; Okishio, K | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 2 |
| Amir, E; Bradbury, PA; Douillard, JY; Horgan, AM; Kim, ES; Leighl, NB; Ng, R; Shepherd, FA | 1 |
| Fujitaka, K; Hamada, A; Haruta, Y; Hattori, N; Ishikawa, N; Iwamoto, H; Kanehara, M; Kohno, N; Masuda, T; Murai, H; Ohshimo, S | 1 |
| Chung, YH; Kim, KH; Kim, KM; Lee, D; Lee, HC; Lee, SG; Lee, YJ; Lee, YS; Lim, YS; Park, YK; Shim, JH; Suh, DJ | 1 |
| Camidge, DR; Cappuzzo, F; Varella-Garcia, M | 1 |
| Banerjee, A; Boyett, JM; Broniscer, A; Douglas, JG; Geyer, JR; Kocak, M; Kun, LE; Pollack, IF; Poussaint, TY; Stewart, CF | 1 |
| Boyett, JM; Cha, S; Geyer, R; Haas-Kogan, D; Kocak, M; Kun, LE; Packer, RI; Patay, Z; Pollack, IF; Poussaint, TY; Robertson, RL; Vajapeyam, S; Vezina, G; Zimmerman, R | 1 |
| Ferreira, CG; Herchenhorn, D | 1 |
| Farndon, PA; Kobayashi, S; Li-Wan-Po, A; Mitsudomi, T; Potter, VA | 1 |
| Andersson, K; Björkelund, H; Gedda, L | 1 |
| Gazdar, AF; Girard, L; Imai, H; Kaira, K; Larsen, JE; Minna, JD; Mori, M; Peyton, M; Sato, M; Shames, DS; Soh, J; Sunaga, N; Xie, Y; Yanagitani, N | 1 |
| Durbin, JE; Koromilas, AE; Muller, WJ; Raven, JF; Tremblay, ML; Wang, S; Williams, V | 1 |
| Abraham, J; Davis, C | 1 |
| Hanagiri, T; Kuwano, M; Ono, M; Shimokawa, H; Uramoto, H | 1 |
| Babu, VC; Harini, VV; Kumar, BS; Nargund, A; Patil Okaly, GV; Rao, R; Rao, S; Sahoo, R; Venkataswamy, E | 1 |
| Assaraf, YG; D'Incecco, A; Danesi, R; Falcone, A; Giaccone, G; Giovannetti, E; Guchelaar, HJ; Lemos, C; Peters, GJ; Santoro, A; Scheffer, GL; Tibaldi, C; van der Straaten, T; Zucali, PA | 1 |
| Nagashima, T; Naka, T; Nakakuki, T; Naruo, Y; Okada-Hatakeyama, M; Saeki, Y; Tanaka, H; Tsai, SF; Ushikoshi-Nakayama, R | 1 |
| Gao, L; Liu, X; Ni, L | 1 |
| Behrens, RJ; Cannon, MW; Friedman, EL; Gross, GG; Hillman, SL; Jatoi, A; Mc Kean, H; Rowland, KM; Sborov, MD; Stella, PJ | 1 |
| Chang, DS; Di, YP; Li, HQ; Li, P; Liu, LY; Wang, J; Wang, JD; Wang, X; Wang, YJ; Wu, WZ; Xia, TY | 1 |
| Buhren, BA; Gerber, PA; Homey, B; Kukova, G | 1 |
| Chen, X; Guo, R; Shu, Y; Sun, J; Wang, T; Zhang, Z | 1 |
| Kitamura, Y; Sakakura, N; Suyama, M; Uchida, T | 1 |
| Morio, A; Ninomiya, H; Sunada, K | 1 |
| Bode, AM; Grubbs, CJ; Juliana, MM; Lu, Y; Lubet, RA; Steele, VE; Townsend, R; Verney, ZM; You, M | 1 |
| Breinig, M; Chiosis, G; Dienemann, H; Giaccone, G; Goeppert, B; Harjung, A; Hartmann, A; Kern, MA; Malz, M; Mayer, P; Neumann, O; Penzel, R; Rieker, RJ; Schirmacher, P | 1 |
| Bergot, E; Creveuil, C; Lechapt, E; Levallet, G; Zalcman, G | 1 |
| De Marinis, F; Karapanagiotou, EM; Oikonomopoulos, G; Saif, MW; Syrigos, KN | 1 |
| Cataldo, VD; Gibbons, DL; Pérez-Soler, R; Quintás-Cardama, A | 1 |
| Castel, M; Despas, F; Mazières, J; Pathak, A | 1 |
| Chen, J; Chu, BB; Deng, J; Fang, HM; Fang, WJ; Mou, HB; Qian, J; Teng, LS; Wu, DP; Xu, N; Zhang, XC | 1 |
| Hirano, S; Ishii, S; Kobayashi, N; Kudo, K; Naka, G; Sugiyama, H; Takeda, Y | 1 |
| Chiu, HC; Chou, DL; Hsu, JT; Huang, CT; Lien, TW; Lin, WH; Yen, KJ | 1 |
| Fan, Z; Li, X; Liang, K; Lu, Y; Luwor, RB | 1 |
| Han, JY; Hyung, LS; Kim, HT; Lee, JS; Lee, SH; Moon, YJ; Yoo, NJ; Yun, T | 1 |
| Chen, YM; Chou, KT; Chou, TY; Fan, WC; Lee, YC; Liu, SH; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, CH | 1 |
| Antoine, M; Cadranel, J; Gounant, V; Lavolé, A; Wislez, M | 1 |
| Chang, GC; Chen, KC; Hsu, KH; Lee, HM; Tsai, CR; Yang, TY | 1 |
| Akhavanfard, S; Bergethon, K; Christensen, JG; Cosper, AK; Dias-Santagata, D; Digumarthy, S; Engelman, JA; Fidias, P; Gettinger, S; Heist, RS; Iafrate, AJ; Lanuti, M; Lynch, TJ; Mark, EJ; Mino-Kenudson, M; Sequist, LV; Shaw, AT; Temel, J; Turke, AB; Vernovsky, K; Wain, JC; Waltman, BA | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Frankel, P; Gandara, DR; Lara, PN; Longmate, J; Margolin, KA; Pan, CX; Quinn, DI; Shek, D; Twardowski, P | 1 |
| Murphy, M; Stordal, B | 1 |
| de Marinis, F; Di Maio, M; Gridelli, C; Ricciardi, S; Rossi, A | 1 |
| Döme, B; Fehniger, TE; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, A | 1 |
| Choi, BG; Han, JY; Kim, JY; Lee, SH; Yoo, NJ | 1 |
| Nishizawa, S; Saito, T; Soejima, Y; Takahashi, M; Yamamoto, J | 1 |
| Abe, H; Aikawa, E; Akiba, J; Azuma, K; Kage, M; Kawahara, A; Nakashima, K; Sumi, A; Taira, T; Takamori, S; Yamaguchi, T | 1 |
| Asano, K; Bozec, A; Gresh, L; Ikeda, E; Kamiya, K; Kobayashi, K; Matsuo, K; Takada, Y; Toyama, Y; Wagner, EF; Watanabe, M | 1 |
| Argyle, DJ; Bergkvist, GT; Muirhead, R; Pang, LY; Yool, DA | 1 |
| Fukuoka, J; Isa, S; Kawaguchi, T; Kitaichi, M; Koh, Y; Kubo, A; Kusunoki, Y; Nakagawa, K; Okamoto, I; Takada, M | 1 |
| Bady, P; Delorenzi, M; Diserens, AC; Frei, K; Hamou, MF; Hegi, ME; Heppner, FL; Hofer, S; Kamoshima, Y; Koch, A; Kouwenhoven, MC; Lambiv, WL; Mariani, L; Matter, MS; Merlo, A; Yonekawa, Y | 1 |
| Asahina, H; Dosaka-Akita, H; Fujita, Y; Harada, M; Inoue, A; Ishida, T; Isobe, H; Kinoshita, I; Maemondo, M; Nishimura, M; Nukiwa, T; Oizumi, S; Saijo, Y; Sukoh, N | 1 |
| Cabodi, S; Camacho-Leal, MP; Defilippi, P; Morello, V; Papotti, M; Repetto, D; Sigismund, S; Turco, E; Volante, M | 1 |
| Chen, Y; Ding, Z; Li, J; Liang, H; Pan, F; Peng, Q; Ran, L; Yang, L; Zhao, X | 1 |
| Dhalluin, X; Scherpereel, A | 1 |
| Chang, WC; Chen, AJ; Chen, CH; Chen, YJ; Chiu, PC; Hsu, SC; Huang, WC; Huang, WP; Hung, MC; Li, LY; Tsai, CH; Tsai, SL; Wang, YN; Wei, YL | 1 |
| Cantarini, M; Carmichael, J; Harris, AL; Holt, A; Horak, J; Macpherson, M; Swaisland, A; Swaisland, H; Twelves, C; Verrill, M; White, J | 1 |
| Guo, J; Ma, B; Wang, Y; Zhang, Y; Zhou, H | 1 |
| Tuder, RM; Winn, RA | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, H; Kim, MJ; Kim, SH; Kim, SJ; Park, SJ | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chen, KY; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Menden, MP; Millard, BL; Muhlich, JL; Niepel, M; Sorger, PK | 1 |
| Balslev, E; Bernsdorf, M; Ejlertsen, B; Grabau, D; Harder, E; Jakobsen, EH; Kroman, N; Lykkesfeldt, AE; von der Maase, H | 1 |
| Han, E; Naoghare, PK; Song, JM; Tak, YK | 1 |
| Kimura, H; Nakagawara, A; Nakajima, T; Yasufuku, K; Yoshino, I | 1 |
| Fujita, S; Hata, A; Hayashi, H; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Kunimasa, K; Morita, S; Nanjo, S; Nishiyama, A; Otsuka, K; Tomii, K; Yoshioka, H | 1 |
| Chang, YC; Shih, JY; Wu, JY; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Anadkat, MJ; Balagula, Y; Lacouture, ME; Wu, PA | 1 |
| Abbate, I; Bongarzone, I; Cremona, M; De Bortoli, M; Galetta, D; Garrisi, VM; Mangia, A; Paradiso, A; Pastorino, U; Quaranta, M; Vaghi, E | 1 |
| Kolosov, VP; Li, Q; Perelman, JM; Yu, H; Zhou, X | 1 |
| Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES | 1 |
| Antoine, M; Cadranel, J; Lacave, R; Poulot, V; Ruppert, AM; Wislez, M | 1 |
| Chang, HC; Chao, TY; Chung, YH; Lie, CH; Lin, MC; Wang, CC; Wang, JL | 1 |
| Di Gion, P; Doroshyenko, O; Fuhr, U; Scheffler, M; Wolf, J | 1 |
| Crinò, L; Metro, G | 1 |
| Dyckhoff, G; Gottschling, S; Herpel, E; Kuhnt, T; Pelz, T; Penzel, R; Schnabel, PA; Thomas, M | 1 |
| Fujita, Y; Hiroshima, K; Niijima, M; Nishio, K; Saitoh, M; Takiguchi, Y; Tatsumi, K | 1 |
| Azzoli, CG; Bains, M; Chaft, JE; Downey, R; Flores, R; Heelan, RT; Kris, MG; Krug, LM; Ladanyi, M; Miller, VA; Pao, W; Park, B; Rizvi, NA; Rusch, V; Shen, R; Singh, B; Zakowski, M | 1 |
| de Lima Lopes, G; Haaland, BA; Ku, GY | 1 |
| Ji, M; Li, M; Liu, Y; Sun, M; Zheng, Y | 1 |
| Wang, L; Xiao, F; Zhang, W; Zheng, J | 1 |
| Cui, CX; Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, HY; Wang, Y; Zhang, XR; Zhao, LD | 1 |
| Horai, T; Horiike, A; Kudo, K; Nishio, M; Ohyanagi, F; Yanagitani, N | 1 |
| Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Kuhara, H; Minami, T; Nagatomo, I; Osa, A; Tachibana, I; Takahashi, R; Takeda, Y; Tetsumoto, S | 1 |
| Fujii, M; Maehara, Y; Mitsudomi, T; Murakami, H; Osada, H; Sekido, Y; Suda, K; Tomizawa, K; Yatabe, Y | 1 |
| Antoine, M; Brambilla, E; Busser, B; Cadranel, J; Coll, JL; de Fraipont, F; Dufort, S; Hurbin, A; Moro-Sibilot, D; Rabbe, N; Tenaud, C; Wislez, M | 1 |
| Gruber-Mösenbacher, U; Hilbe, W; Hulla, W; Mohn-Staudner, A; Pirker, R; Ploner, F; Popper, H; Studnicka, M; Wrba, F | 1 |
| Bhattacharyya, A; Kundu, S; Sengupta, S | 1 |
| Hopper, C; Jerjes, W; Mahil, J; Sudhoff, H; Upile, T | 1 |
| Ji, Y; Lu, YJ; Ma, SL; Wang, CR; Wu, YM; Zhao, YF | 1 |
| Gooding, WE; Grandis, JR; Gubish, CT; Siegfried, JM; Stabile, LP; Xu, H | 1 |
| Azzoli, CG; Ginsberg, MS; Johnson, ML; Kris, MG; Miller, VA; Pao, W; Riely, GJ; Rizvi, NA; Sima, CS | 1 |
| Garrido, P; Longo, F; Olmedo, ME; Riquelme, A; Rodríguez, M | 1 |
| Haro, A; Ito, K; Kawano, D; Maehara, Y; Miura, N; Morodomi, Y; Shoji, F; Takenaka, T; Yano, T; Yoshino, I | 1 |
| Katzumata, A; Kawauchi, M; Kuramoto, S; Matsumoto, Y; Ono, Y; Toyoshima, A; Toyota, Y | 1 |
| Ma, S; Xu, Y; Zhang, Y | 1 |
| Heneberg, P | 1 |
| Li, Y; Liu, B; Qin, X; You, J; Zhou, Q | 1 |
| Horinouchi, H; Izumi, Y; Kamiya, K; Kawamura, M; Kohno, M; Nomori, H; Shimada, N; Watanabe, M | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, YJ; Yoon, KA; Yun, T | 1 |
| Chen, Y; Feng, L; Ge, W; Han, W; Jin, H; Li, J; Lin, X; Pan, H; Sun, J; Wang, X; Wang, Y | 1 |
| Berglund, C; Chernoguz, A; Crawford, K; Cripe, TP; Donovan, E; Frischer, JS; Vandersall, A | 1 |
| Bryce, J; Carillio, G; Costanzo, R; Daniele, G; De Feo, G; Di Maio, M; Giordano, P; Montanino, A; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC; Rocco, G; Sandomenico, C | 1 |
| Boerner, JL; Bohin, N; Ge, Y; Irwin, ME; Mueller, KL | 1 |
| Bruzzese, F; Budillon, A; Caraglia, M; Carbone, C; Di Gennaro, E; Leone, A; Piro, G; Rocco, M | 1 |
| Shepherd, FA | 1 |
| Armour, AA; Chao, TY; Chu, DT; Duffield, EL; Fukuoka, M; Jiang, H; Leong, SS; Mok, TS; Nakagawa, K; Rukazenkov, Y; Saijo, N; Speake, G; Sriuranpong, V; Sunpaweravong, P; Thongprasert, S; To, KF; Wu, YL; Yang, JC | 1 |
| Dallas, J; Jantz, MA; Kaye, FJ | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Nukiwa, T; Oizumi, S; Saijo, Y; Satoh, H; Yoshizawa, H | 1 |
| Chen, YY; Kiura, K; Noujima, D; Ochi, N; Takigawa, N; Tanimoto, M; Tanimoto, Y; Zhang, D | 1 |
| Ahn, JS; Ahn, MJ; Jung, SH; Kim, ST; Kim, SW; Lee, J; Park, K; Park, YH; Sohn, I; Sun, JM; Uhm, JE | 1 |
| Curtit, E; Mansi, L; Viel, E; Vignot, S | 1 |
| Kosaka, T; Kuwano, H; Mogi, A; Yamaki, E | 1 |
| He, BF; Huang, BY; Luo, RC; Sun, AM; Wang, WJ; Zheng, XK | 1 |
| Altavilla, G; Benecchi, S; Magri, I; Pettineo, G; Rosell, R; Salazar, MF; Santarpia, M | 1 |
| Chan, SY; Chin, TM; Goh, BC; Ho, PC; Lim, MY; Nye, PL; Thuya, WL; Wang, LZ; Wong, A | 1 |
| Asano, H; Harada, M; Kagawa, S; Kanazawa, S; Katsui, K; Maki, Y; Masuda, H; Miyoshi, S; Muraoka, T; Naito, M; Naomoto, Y; Takemoto, M; Toyooka, S; Tsukuda, K | 1 |
| Hashimoto, K; Komune, S; Nakano, T; Nakashima, T; Oda, Y; Oyama, M; Shiratsuchi, H; Tamiya, S; Yamamoto, H | 1 |
| Iwamoto, Y; Katakami, N; Kobayashi, M; Matsui, K; Moriyama, A; Nakagawa, K; Sueoka-Aragane, N; Takada, M; Takeda, K; Yoshioka, H | 1 |
| He, W; Jiang, G; Liu, M; Song, N; Zhang, P | 1 |
| Chang, YL; Jan, IS; Luo, SC; Shih, JY; Su, KY; Tsai, TH; Wu, SG; Yang, PC; Yu, CJ; Yu, SL | 1 |
| Han, JY; Kim, HT; Lee, GK; Lee, JS; Lim, KY; Park, SY; Won, YW; Yoon, KA; Yun, T | 1 |
| Baryawno, N; Ekström, TJ; Johnsen, JI; Larsson, C; Marino, AM; Sofiadis, A; Vukojević, V | 1 |
| Ameshima, S; Asami, K; Atagi, S; Hirai, K; Kawahara, M; Koizumi, T; Morikawa, A; Morozumi, N; Tsukadaira, A | 1 |
| Chang, KY; Chang, WC; Chen, YJ; Chou, CK; Chou, TC; Hsu, SC; Huang, WC; Hung, MC; Lee, JJ; Lin, HY; Su, WC; Tsai, CH; Wei, YL; Wistuba, II; Yen, CJ; Yuan, P | 1 |
| Amato, KR; Arcila, M; Chmielecki, J; de Stanchina, E; Foo, J; Ginsberg, MS; Hutchinson, K; Inoue, A; Kris, MG; Ladanyi, M; Michor, F; Miller, VA; Ohashi, K; Oxnard, GR; Pao, W; Socci, ND; Somwar, R; Sos, ML; Thomas, RK; Viale, A; Wang, L | 1 |
| Blanchet, B; Dauphin, A; Dusser, D; Faivre, L; Goldwasser, F; Gomo, C; Mir, O; Ropert, S; Schoemann-Thomas, A; Taieb, F; Vidal, M | 1 |
| Bar-Eli, M; Bassett, RL; Bedikian, AY; Bronstein, Y; Dobroff, A; Hwu, P; Hwu, WJ; Kim, KB; Papadopoulos, NE; Patel, SP; Prieto, VG; Vardeleon, AG; Zigler, M | 1 |
| Belkhiri, A; El-Rifai, W; Zhu, S | 1 |
| Chang, CY; Chen, CJ; Shen, CC; Su, HL | 1 |
| Berrino, L; Cascone, T; Ciardiello, F; D'Aiuto, E; De Palma, R; Heymach, JV; Martinelli, E; Morgillo, F; Saintigny, P; Troiani, T; Tuccillo, C | 1 |
| Han, SY; Li, PP; Zhao, MB; Zhuang, GB | 1 |
| Armini, A; Bianchi, L; Bini, L; Bruzzese, F; Budillon, A; Di Gennaro, E; Gagliardi, A; Gimigliano, A; Leone, A; Pucci, B; Puglia, M; Rocco, M | 1 |
| Ando, M; Dote, H; Jida, M; Kawasaki, K; Kiura, K; Kobayashi, N; Kubo, T; Miyoshi, S; Ogino, A; Otani, H; Soh, J; Toyooka, S; Ueno, T; Yamamoto, H | 1 |
| Ang, MK; Baskaran, N; Goh, C; Hui, KM; Hwang, J; Khoo, ML; Lim, A; Lim, TH; Lim, WT; Ng, QS; Soo, KC; Tan, DS; Tan, EH; Tan, PH; Tan, SH; Tan, T; Teng, YH | 1 |
| Douillard, JY; Lokiec, F | 1 |
| Moro-Sibilot, D | 1 |
| Besse, B; Zalcman, G | 1 |
| Barlesi, F | 1 |
| Giroux Leprieur, E; Planchard, D | 1 |
| Fujita, S; Kim, YH; Masago, K; Mio, T; Mishima, M; Okuda, C; Sakamori, Y; Togashi, Y | 1 |
| Barratt, BJ; Fukuoka, M; Hada, S; Jawaid, A; Kamatani, N; Kato, H; Kudoh, S; March, R; Mushiroda, T; Nakamura, Y; Nakata, K; Nyberg, F; Ohe, Y; Takahashi, A; Umemura, T | 1 |
| An, SJ; Chen, HJ; Chen, ZH; Huang, YS; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Yin, XL; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Beyer, A; Cai, WY; Elledge, R; Fuqua, S; Hilsenbeck, S; Huang, J; Massarweh, S; Rimawi, M; Sexton, K; Tham, YL; Tsimelzon, A; Weiss, H | 1 |
| de Lima Lopes, G; Do, YK; Finkelstein, EA; Mok, T; Segel, JE; Tan, DS | 1 |
| Billups, CA; Davidoff, AM; Furman, WL; Hawkins, D; Houghton, PJ; Kovach, S; McCarville, MB; McGregor, LM; McPherson, V; Onciu, M; Santana, VM; Stewart, CF; Wu, J | 1 |
| Akimoto, S; Clausen, IG; Dobashi, T; Fukuoka, M; Harbron, CG; Higenbottam, T; Kato, H; Kawakami, T; Kihara, M; Komatsu, Y; Kudoh, S; Kyono, Y; Marko-Varga, G; Nagasaka, K; Nakata, K; Nishimura, T; Nyberg, F; Ogiwara, A; Ohe, Y; Otsuji, M; Peers, IS; South, MC; Takami, S; Tu, HK; Wada, K | 1 |
| Gaafar, RM; Hasan, B; Papamichael, D; Scagliotti, GV; Surmont, VF; Torri, V; Van Klaveren, RJ; van Meerbeeck, JP; Welch, JJ | 1 |
| Fujita, S; Fukuhara, A; Hatachi, Y; Irisa, K; Kim, YH; Masago, K; Mio, T; Mishima, M; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Clarke, AR; Maughan, TS; Shaw, PH | 1 |
| Chen, C; D'Cruz, AK; Fijuth, J; Gregoire, V; Hamoir, M; Julka, PK; Kane, M; Kawecki, A; Korzeniowski, S; Kumar, RR; Machiels, JP; Prasad, S; Raben, D; Radosevic-Jelic, L; Sellers, MV; Tchakov, I; Wang, HM | 1 |
| Cunningham, D; Yim, KL | 1 |
| Pandiella, A; Sánchez-Martín, M | 1 |
| Arcila, ME; Azzoli, CG; Janjigian, YY; Kass, SL; Kris, MG; Ladanyi, M; Miller, VA; Oxnard, GR; Pao, W; Riely, GJ; Sima, CS | 1 |
| Bellevicine, C; Malapelle, U; Palombini, L; Troncone, G; Zeppa, P | 1 |
| Chen, X; Geng, Y; Hu, X; Li, W; Shu, Y; Wang, R; Yin, Y | 1 |
| Barberis, M; Catania, C; de Braud, F; De Pas, T; Delmonte, A; Fumagalli, C; Giovannini, M; Manzotti, M; Spaggiari, L; Spitaleri, G; Toffalorio, F | 1 |
| Kawano, Y; Kawasaki, M; Kitasato, Y; Mizuta, Y; Sakoda, Y; Takata, S | 1 |
| Chaft, JE; Kris, MG; Miller, VA; Oxnard, GR; Riely, GJ; Sima, CS | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Hsieh, WY; Lee, JY; Lee, YM; Yang, PC; Yu, SL | 1 |
| Lin, D; Ma, F; Shi, Y; Sun, T; Xu, B | 1 |
| Adelstein, DJ; Ives, DI; Rice, TW; Rodriguez, CP; Rybicki, LA | 1 |
| Aoki, T; Hanagiri, T; Korogi, Y; Mukae, H; Uramoto, H; Yamashita, Y; Yoshii, C | 1 |
| Gong, Y; Pao, W | 1 |
| Fiegl, M; Hack, R; Hilbe, W; Jamnig, H; Pall, G; Pircher, A; Sterlacci, W; Ulsperger, E; Zelger, B | 1 |
| Douillard, JY; Jiang, GL; Kim, ES; Li, LY; Liao, ML; Milenkova, T; Sun, Y; Wu, YL | 1 |
| Hao, XZ; Hu, XS; Li, B; Li, JL; Shi, YK; Wang, B; Wang, L; Wang, Y; Zhang, XR; Zhu, HX | 1 |
| Li, L; Liu, JL; Su, H; Xu, CA; Zou, HW | 1 |
| Conzelmann, H; Kleiman, LB; Lauffenburger, DA; Maiwald, T; Sorger, PK | 1 |
| Beier, F; Dupuis, HL; Enomoto-Iwamoto, M; Koyama, E; Lan, S; Qin, L; Siclari, VA; Zhang, X; Zhu, J | 1 |
| Asahina, H; Horinouchi, H; Kubota, K; Nokihara, H; Sekine, I; Tamura, T; Yamamoto, N | 1 |
| Azuma, K; Hattori, S; Kage, M; Kawahara, A; Kinoshita, T; Kuwano, M; Nakagawa, K; Nakashima, K; Okamoto, I; Ono, M; Taira, T; Takamori, S; Takeda, M | 1 |
| Ji, M; Li, M; Lian, J; Tang, W; Wu, X; Xu, L; Zheng, Y | 1 |
| Cavenee, WK; Furnari, F; Gonias, SL; Hu, J; Jo, M; VandenBerg, SR | 1 |
| Duffield, E; Fukuoka, M; Goto, K; Ichinose, Y; Itoh, Y; Jiang, H; McCormack, R; Mok, T; Negoro, S; Nishio, K; Ohe, Y; Saijo, N; Yamamoto, N | 1 |
| Chen, PC; Huang, YY; Juang, JL | 1 |
| Cappuzzo, F; D'Incecco, A | 1 |
| Horai, T; Horiike, A; Kasahara, K; Kudo, K; Miyauchi, E; Nishio, M; Ohyanagi, F | 1 |
| Ait-Tihyaty, M; Jean-Claude, BJ; Mihalcioiu, C; Rachid, Z | 1 |
| Chua, KT; Lai, NL; Lee, CH; Liam, CK; Lim, BK; Pang, YK | 1 |
| Abe, T; Hayashi, S; Hirai, M; Hosomi, T; Iwanaga, K; Kimura, S; Komiya, K; Nakamura, T; Sato, A; Sueoka, E; Sueoka-Aragane, N; Ureshino, N | 1 |
| Atherton, PJ; Burger, KN; Jatoi, A; Loprinzi, CL; Miller, RC; Neben Wittich, MA; Sloan, JA | 1 |
| Guo, J; Liu, Y; Wang, Y; Wang, Z; Yang, J | 1 |
| Chen, SC; Chiou, SJ; Chuang, LY; Guh, JY; Hwang, CC; Ko, YM; Lin, TD | 1 |
| Carloni, F; Castellani, C; Drudi, F; Lazzari-Agli, L; Sartori, S; Scarpi, E; Tassinari, D; Tombesi, P | 1 |
| Andersson, K; Barta, P; Björkelund, H; Gedda, L; Malmqvist, M | 1 |
| Chen, ZW; Lu, S; Song, ZB; Yu, YF | 1 |
| Soyibo, AK; Whittle, DO | 1 |
| He, F; Huang, L; Wang, F; Yang, L | 1 |
| Bae, JH; Chung, JS; Kang, CD; Kim, MJ; Kim, SH; Kim, SJ; Oh, SO | 1 |
| Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B | 1 |
| Guo, ZZ; Huang, JJ; Huang, Y; Lin, TY; Tian, Y; Xu, F; Zhang, LL | 1 |
| Bodzin, AS; Doria, C; Gu, T; Hurtt, R; Wei, Z | 1 |
| Kani, K; Mallick, P; Sordella, R | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Liu, YC; Tang, GJ; Wei, YF; Yu, CJ; Yuan, MK | 1 |
| Baker, JH; Bally, MB; Dragowska, WH; Franssen, Y; Gelmon, KA; Kapanen, AI; Kierkels, GJ; Masin, D; Minchinton, AI; Qadir, MA; Weppler, SA; Wong, LY | 1 |
| Liebmann, C; Weisheit, S | 1 |
| Arao, T; Horiike, A; Ikeda, N; Kasahara, K; Kimura, H; Koizumi, F; Matsumoto, K; Nishio, K; Nishio, M; Ohira, T; Saijo, N; Sakai, A; Sakai, K; Sone, T; Yamanaka, T | 1 |
| Bachi, A; Bergamaschi, L; Bulotta, A; Cattaneo, A; Floriani, I; Garavaglia, D; Ghio, D; Gregorc, V; Grigorieva, J; Lazzari, C; Roder, H; Sorlini, C; Spreafico, A; Tsypin, M; Viganò, MG | 1 |
| Bignon, YJ; Cayre, A; El Guerrab, A; Nemlin, CC; Penault-Llorca, F; Rossignol, F; Vigier, F; Zegrour, R | 1 |
| Custers, E; DeGroot, J; Läppchen, T; Lub, J; Sio, CF; Steinbach, OC; Vlaming, ML | 1 |
| Grubbs, CJ; James, M; Liu, P; Lu, Y; Lubet, RA; Van den Bergh, F; Wen, W; You, M; Zellmer, V | 1 |
| Imyanitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Moiseyenko, FV; Moiseyenko, VM; Radzhabova, SA; Suspitsin, EN | 1 |
| Acquaviva, J; Boskovitz, A; Bronson, RT; Charest, A; Donovan, M; Housman, DE; Jun, HJ; Lessard, J; Pfannl, R; Raval, A; Ruiz, R; Whittaker, CA; Woolfenden, S; Zhu, H | 1 |
| Asuncion, BR; Gaire, F; Gustavson, M; Hirsch, FR; Ikeda, N; Kato, Y; Mascaux, C; Matsubayashi, J; Nagao, T; Ohira, T; Ranger-Moore, J; Tran, C; Wynes, MW; Yoshida, K; Zhao, JM | 1 |
| Hasegawa, T; Hirakawa, K; Matsuzaki, T; Qiu, H; Yashiro, M; Zhang, X | 1 |
| Belden, CJ; Fadul, CE; Harris, BT; Israel, MA; Pastel, DA; Paulsen, K; Ran, C; Roberts, DW; Valdes, PA | 1 |
| Cheng, H; Dicker, AP; Force, T; Kari, G; Koch, WJ; Rodeck, U | 1 |
| Agus, DB; Gross, ME; Leichman, L; Lowe, ES; Swaisland, A | 1 |
| Chen, W; Qiao, J | 1 |
| Armour, A; Chen, YM; Chu, DT; Duffield, E; Fukuoka, M; Kuo, HP; Lam, KC; Liao, M; Magill, P; Negoro, S; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC | 1 |
| Cho, J; Chowhan, NM; Funke, R; Gadgeel, SM; Lara, PN; Lynch, TJ; Miller, VA; Mitchell, B; Pennell, NA; Pietanza, MC; Vrindavanam, N; Wakelee, HA; Yanagihara, RH | 1 |
| Eguchi, S; Fujigaki, Y; Hishida, A; Suzuki, H; Yamamoto, T | 1 |
| Li, B; Sheng, ZX; Wang, F; Wang, LD | 1 |
| Goya, S; Hatazawa, J; Hirata, H; Inoue, A; Kawase, I; Kida, H; Kijima, T; Kumagai, T; Kumanogoh, A; Nagatomo, I; Okumura, M; Shimosegawa, E; Tachibana, I; Takahashi, R; Takeda, Y; Yoshida, M | 1 |
| Adelstein, DJ; Ives, DI; Michal, SA; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG | 1 |
| Ito, A; Katsuma, A; Naito, Y; Nojima, H; Ohno, S; Sakurai, MA; Shimizu, H; Tabara, H; Yabuta, N | 1 |
| Braoudaki, M; Hatziagapiou, K; Karpusas, M; Tzortzatou-Stathopoulou, F | 1 |
| Li, H; Schmid-Bindert, G; Su, B; Wang, D; Yang, X; Zhao, Y; Zhou, C | 1 |
| Chung, C; Frankel, P; Gu, L; Hurria, A; Kane, SE; Koczywas, M; Lau, SK; Leong, L; Luu, T; Martel, CL; McNamara, M; Morgan, R; Ruel, C; Russell, CA; Somlo, G | 1 |
| Barberis, M; Catania, C; De Pas, TM; Giovannini, M; Labianca, R; Manzotti, M; Spaggiari, L; Toffalorio, F; Trifirò, G | 1 |
| A'Hern, R; Anderson, H; Bliss, J; Dowsett, M; Dunbier, A; Evans, A; Ghazoui, Z; Iskender, A; Johnson, L; Pinhel, I; Robertson, J; Robison, L; Salter, J; Skene, T; Smith, I; Wilcox, M | 1 |
| Chang, JW; Chen, YR; Chen, YT; Chiu, YT; Hsieh, JJ; Huang, SF; Liu, HP; Wu, HD; Yu, TF | 1 |
| Higashiyama, M; Kimura, T; Kiura, K; Kondoh, K; Kudoh, S; Minami, Y; Mitsudomi, T; Noguchi, M; Nokihara, H; Oda, M; Ohe, Y; Saito, H; Tachibana, K; Takeuchi, S; Tanaka, H; Uramoto, H; Yamada, T; Yano, S; Yasumoto, K; Yatabe, Y; Yokota, J; Yoshida, J | 1 |
| Cheng, Y; Huber-Keener, KJ; Keihack, H; Liao, J; Liu, X; Ren, X; Rubin, E; Yan, L; Yang, JM; Zhang, L; Zhang, Y; Zhou, L | 1 |
| Tolcher, AW | 1 |
| Murakami, H; Naito, T; Nakamura, Y; Nishio, K; Nokihara, H; Sarashina, A; Seki, Y; Shahidi, M; Takahashi, T; Tamura, T; Yamamoto, N | 1 |
| Fujita, A; Gotoh, N; Imoto, S; Miyano, S; Nagasaki, M; Shimamura, T; Tamada, Y; Yamaguchi, R; Yamauchi, M | 1 |
| Brugarolas, A; Evgenyeva, E; Fernández, FJ; Forteza, J; González-Manzano, R; Martínez-Navarro, EM; Rebollo, J; Sureda, M; Valenzuela, B | 1 |
| Anchisi, S; Bernhard, J; Bodis, S; Caspar, CB; Cathomas, R; D'Addario, G; Fischer, N; Klingbiel, D; Kotrubczik, NM; Mayer, M; Pesce, GA; Peters, S; Pilop, C; Pless, M; Ribi, K; Schlaeppi, M; Stupp, R; von Moos, R; Weber, DC; Zouhair, A | 1 |
| Basu, S; Batus, M; Bonomi, PD; Buckingham, L; Coon, J; Fidler, MJ; Jacobson, KK; Jewell, SS; Morrison, LE; Walters, K | 1 |
| Azuma, A; Hoshino, T; Mizushima, T; Namba, T; Tanaka, K | 1 |
| Beijnen, JH; Lankheet, NA; Malingré, MM; Schaefer-Prokop, CM; Staaks, GH; ter Heine, R; van den Bosch, RT; van den Brand, JJ; van der Westerlaken, MM | 1 |
| Chen, Y; Deng, J; Zhuang, L | 1 |
| Wondisford, FE | 1 |
| Ben-Shlomo, A; Bruyette, D; Cooper, O; Fukuoka, H; Mamelak, A; Melmed, S; Ren, SG | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Cavazzoni, A; De Palma, G; Fumarola, C; Galetti, M; Galvani, E; La Monica, S; Mari, E; Mor, M; Mozzoni, P; Mutti, A; Petronini, PG; Tiseo, M; Tramonti, S | 1 |
| Chung, CT; Hwang, DM; Lara-Guerra, H; Leighl, NB; Pintilie, M; Schwock, J; Tsao, MS; Waddell, TK | 1 |
| Ding, L; He, W; Hu, Y; Shen, X; Tan, F; Wang, D; Wang, Y; Xie, G; Zhang, X | 1 |
| Daub, H; Schreiber, TB; Weber, C | 1 |
| Fang, W; Gu, XY; Jiang, Z | 1 |
| Cappuzzo, F; Jänne, PA; Mok, TS; Soria, JC | 1 |
| Lamorte, G; Meco, D; Pallini, R; Patriarca, V; Riccardi, R; Servidei, T; Trivieri, N; Vellone, VG; Zannoni, GF | 1 |
| Chang, YL; Chen, YH; Kuo, YW; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Düwel, P; Gehl, HB; Görner, M; Hirnle, P; Müller, F; Riesenberg, H | 1 |
| Chan, WK; Cheng, PN; Cheng, T; Ma, AT; Ma, ES | 1 |
| Coffey, RJ; Liebler, DC; Manning, HC; Myers, MV | 1 |
| Collan, J; Hemminki, A; Joensuu, G; Joensuu, T; Nupponen, N; Pesonen, S; Ruutu, M | 1 |
| Bar, J; Onn, A | 1 |
| Alder, H; Cascione, L; Condorelli, G; Croce, CM; Di Leva, G; Engelman, JA; Garofalo, M; Jeon, YJ; Lovat, F; Nephew, KP; Ngankeu, A; Nuovo, G; Ono, M; Rho, JK; Romano, G; Sun, J; Volinia, S | 1 |
| Boeck, S; Heinemann, V; Kächele, V; Parmar, S; Paul, T; Rüdiger, S; Schumann, C; Seeringer, A; Seufferlein, T; Stingl, JC | 1 |
| Cheng, H; De Luo, B; Liu, ZG; Ren, Y; Zhang, YF; Zhu, H | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Nagai, H; Nishiyama, A; Yoshioka, H | 1 |
| He, CS; Hu, ZH; Liu, JL; Tian, Y; Xie, M; Xu, F; Zhang, L; Zhao, LP | 1 |
| Kim, HP; Kim, TY; Lee, JW; Lee, MS | 1 |
| Adelstein, DJ; Ives, DI; Lorenz, RR; Rodriguez, CP; Rybicki, LA; Saxton, JP; Scharpf, J; Wood, BG | 1 |
| Dwivedi, A; Saxena, R | 1 |
| Funada, Y; Hatakeyama, Y; Hori, S; Kasai, D; Kobayashi, K; Kondoh, T; Kotani, Y; Nagano, T; Nishimura, H; Nishimura, Y | 1 |
| Arcila, ME; Capelletti, M; Eck, MJ; Ginsberg, MS; He, M; Jänne, PA; Kris, MG; Ladanyi, M; Miller, VA; Nafa, K; Oxnard, GR; Yun, CH; Zhao, B | 1 |
| Jongstra, J; Siu, A; Virtanen, C | 1 |
| Chen, X; Feng, S; Ji, P; Li, LL; Luo, SD; Ma, S; Pan, YL; Wang, ZR; Wei, YQ; Yang, SY; Zhong, L; Zhou, JP | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Nambara, D; Omi, K | 1 |
| Endo, M; Harada, H; Inomata, M; Kenmotsu, H; Murakami, H; Naito, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Chang, CY; Chang, TY; Chao, YS; Chen, CH; Chen, YR; Chu, CY; Fang, MY; Hsieh, HP; Hsu, JT; Huang, YW; Lien, TW; Lin, WH; Song, JS; Wu, SH; Yen, KJ | 1 |
| Lee, SH | 1 |
| Hao, X; Li, J; Shi, Y; Wang, Y; Zhang, X | 1 |
| Barni, S; Borgonovo, K; Cabiddu, M; Petrelli, F | 1 |
| Chen, LQ; Gao, Q; Wang, KN; Wang, WP | 1 |
| Agulnik, M | 1 |
| Daw, HA; Peerzada, MM; Spiro, TP | 1 |
| Berger, W; Grasl-Kraupp, B; Grunt, T; Grusch, M; Holzmann, K; Koppensteiner, H; Krupitza, G; Lackner, A; Losert, A; Lötsch, D; Marian, B; Peter-Vörösmarty, B; Schmid, K; Schulte-Hermann, R; Steiner, E | 1 |
| Chambers, MS; El-Naggar, AK; Feng, L; Glisson, BS; Lewis, CM; Lustig, RA; Rosenthal, DI; Tang, X; Wan, F; Weber, RS; Wistuba, II | 1 |
| Jin, YB; Ko, YG; Lee, JS; Lee, M; Lee, YJ; Lee, YS; Park, JJ; Yi, JY | 1 |
| Albanell, J; Bellmunt, J; Bellosillo, B; Bosch, F; Crespo, M; Dalmases, A; Gallen, M; Himmelbauer, H; Iglesias, M; Marsters, S; Minoche, A; Montagut, C; Pairet, S; Rovira, A; Salido, M; Serrano, S; Seshagiri, S; Settleman, J; Somasekar, S; Tsai, SP | 1 |
| Bardelli, A; Beijersbergen, RL; Bernards, R; Di Nicolantonio, F; Huang, S; Prahallad, A; Salazar, R; Sun, C; Zecchin, D | 1 |
| Amberger-Murphy, V; Clarke, C; Clynes, M; Doolan, P; Farrell, M; Howley, R; Kinsella, P; Madden, SF | 1 |
| Kaira, K; Yamamoto, N | 1 |
| Kondo, T; Murakami, S; Noda, K; Oshita, F; Saito, H; Yamada, K | 1 |
| Wu, YL; Zhou, Q | 1 |
| Adachi, K; Burioka, N; Chikumi, H; Igishi, T; Kanamori, Y; Miyake, N; Nanba, E; Shimizu, E; Takata, M; Yamasaki, A | 1 |
| Kurachi, H; Ohmichi, M; Ohta, T; Shibuya, T; Takahashi, K; Takahashi, T; Tsutsumi, S | 1 |
| Fujii, M; Hasegawa, Y; Ijichi, K; Kondo, E; Maseki, S; Murakami, S; Nakanishi, H; Ogawa, T; Tanaka, H | 1 |
| McIvor, RA; Popat, N; Raghavan, N | 1 |
| Koizumi, H; Li, Q; Matsumoto, K; Mukaida, N; Nakagawa, T; Nakamura, T; Nishioka, Y; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Cao, Z; Chen, X; Feng, S; Ji, P; Liu, J; Luo, S; Pan, Y; Wang, BL; Wang, L; Wang, X; Wang, Z; Wei, YQ; Xu, Y; Yang, HY; Yang, J; Yang, SY; Yu, Y; Zhang, S; Zheng, R; Zhong, L | 1 |
| Han, R; He, JK; Qin, ZH; Reid, PF; Wang, JH; Wu, JC; Xie, Y | 1 |
| Chung, KF; Huang, CD; Huang, TT; Kuo, HP; Lee, KY; Lin, HC; Lin, SM; Lo, YL; Wang, CH | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H | 1 |
| Chen, W; Hu, CP; Liu, JK; Lu, RL; Xiong, Z; Zhou, H; Zhou, ML | 1 |
| Ban, HJ; Kim, KS; Kim, YC; Oh, IJ | 1 |
| Li, Y; Song, L | 1 |
| Chang, S; Ding, J; Ding, K; Geng, M; Liu, Y; Lu, X; Luo, J; Pei, D; Ren, X; Tu, Z; Xu, S; Xu, T; Xu, Y; Zhang, L; Zhang, Z | 1 |
| Huang, B; Huang, YS; Wu, YL | 1 |
| Argyle, DJ; Bergkvist, GT; Cervantes-Arias, A; Muirhead, R; Pang, LY; Yool, DA | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Nagase, H; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Chen, L; Fujimoto, T; Handa, N; Kawa, S; Kobayashi, T; Kukimoto-Niino, M; Liu, ZJ; Parker, L; Sano, S; Sato, M; Semba, K; Shirouzu, M; Tanaka, T; Terada, T; Terazawa, Y; Wakiyama, M; Wang, BC; Yamamoto, T; Yokoyama, S; Yoshikawa, S | 1 |
| Barletta, G; Boldrini, L; Brianti, A; Cosso, M; Dal Bello, MG; Defferrari, C; Fontanini, G; Genova, C; Grossi, F; Murolo, C; Pronzato, P; Rijavec, E; Truini, M | 1 |
| Pick, A; Wiese, M | 1 |
| Atagi, S; Fukuoka, M; Ichinose, Y; Ishikura, S; Niho, S; Ohe, Y; Okamoto, H; Saijo, N; Shibata, T; Takeda, K; Tamura, T; Yokoyama, A | 1 |
| Kim, JJ | 1 |
| Fujita, A; Gotoh, N; Imoto, S; Kojima, K; Miyano, S; Yamaguchi, R; Yamauchi, M | 1 |
| Permsuwan, U; Thongprasert, S; Tinmanee, S | 1 |
| Ahn, JS; Ahn, MJ; Han, JH; Han, JY; Jo, SJ; Kim, HT; Kim, HY; Kim, SW; Lee, DH; Lee, JS; Lee, JW; Park, K; Suh, C; Yoon, SJ; Yun, T | 1 |
| Abhold, EL; Altuna, X; Blair, KJ; Brumund, KT; Haas, M; Kiang, A; Kuo, SZ; Lopez, JP; Ongkeko, WM; Patel, A; Rahimy, E; Wang-Rodriguez, J; Weisman, RA; Yu, MA | 1 |
| Fan, Q; Li, P; Ma, Z; Qi, G; Wang, H; Wang, Q; Yan, X; Zhang, G; Zhu, H | 1 |
| Agatsuma, T; Ameshima, S; Hayasaka, M; Ikegami, K; Kanda, S; Kobayashi, T; Koizumi, T; Kubo, K; Matsuo, A; Morikawa, M; Shiina, T; Suzuki, T; Takasuna, K; Yoshikawa, S | 1 |
| Choi, YH; Han, HS; Kim, ST; Lee, JY; Lee, KH; Lee, OJ; Lim, SN; Shim, YK | 1 |
| Agus, DB; Erde, J; Faca, VM; Fang, Q; Gross, ME; Hanash, S; Hughes, LD; Jain, A; Kani, K; Katz, JE; Luethy, R; Mallick, P; McIntosh, MW; Pitteri, SJ; Plevritis, SK; Schmidt, J; Shahbaba, B; Zhang, Q; Zhang, W | 1 |
| Aoudjehane, L; Barbu, V; Blivet-Van Eggelpoël, MJ; Chettouh, H; Desbois-Mouthon, C; Fartoux, L; Housset, C; Priam, S; Rey, C; Rosmorduc, O | 1 |
| Badve, SS; Carlson, RW; Gomez, HL; O'Neill, A; Sledge, GW; Vidaurre, T | 1 |
| Liu, G; Wang, W; Zhang, X; Zhu, X | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Teugels, E; Umelo, IA | 1 |
| Knecht, R; Kurzweg, T; Laban, S; Möckelmann, N | 1 |
| de Marinis, F; del Signore, E; Fulvi, A; Gori, B; Ricciardi, S | 1 |
| Yang, G; Yao, Y; Zhao, Q; Zhou, J | 1 |
| Bai, CX; Garfield, D; Ge, HY; Song, YL; Wang, X; Wang, XY; Xu, N; Yang, P; Zhang, X | 1 |
| Fujita, S; Hata, A; Imai, Y; Kaji, R; Katakami, N; Kida, Y; Tanaka, K | 1 |
| Aono, Y; Hanibuchi, M; Kakiuchi, S; Kishi, J; Miyake, K; Nishioka, Y; Sone, S; Suzuka, C; Tani, K; Tezuka, T; Toyoda, Y; Yuasa, S | 1 |
| Cadranel, J; Chao, TY; Chen, YM; Cong, XJ; Crino, L; Heo, DS; Hirsh, V; Kim, SW; Lorence, RM; Miller, VA; Park, K; Shahidi, M; Su, WC; Sun, Y; Tan, EH; Wang, M; Yang, JC; Zhou, C | 1 |
| Kawada, A; Nakagawa, K; Oiso, N; Okamoto, I; Takeda, M; Tsurutani, J | 1 |
| Chen, DR; Pawar, AA; Venkataraman, C | 1 |
| Bagnato, A; Cianfrocca, R; Di Castro, V; Rosanò, L; Spinella, F; Tocci, P | 1 |
| Bischoff, HG; Eberhardt, WE; Fischer, JR; Gottschling, S; Heigener, DF; Herpel, E; Klein, P; Köhne, CH; Kortsik, C; Kuhnt, T; Meister, M; Moldenhauer, I; Muley, T; Penzel, R; Schnabel, PA; Thomas, M | 1 |
| Fujiwara, K; Hamada, N; Horita, N; Hotta, K; Kamei, H; Kiura, K; Segawa, Y; Takata, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Umemura, S; Yamane, H; Yoshioka, H | 1 |
| Fu, H; Hu, YD; Liu, XJ; Long, C; Xiao, Y; Zhang, XL | 1 |
| Schmid-Bindert, G; Wang, YH; Wang, YS; Xia, HP; Zhou, CC; Zhou, SW | 1 |
| Furukawa, M; Kiura, K; Kubo, T; Maki, Y; Mitsudomi, T; Miyoshi, S; Muraoka, T; Shien, K; Soh, J; Suda, K; Tanaka, N; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| Cheng, Y; Han, B; Hayashi, N; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhang, X; Zhou, C | 1 |
| Reckamp, KL | 1 |
| Agulnik, M; Blair, EA; Cohen, EE; Dekker, A; Grushko, TA; Olopade, OI; Perez, CA; Raez, LE; Seiwert, TY; Song, H; Stenson, K; Vokes, EE | 1 |
| Ando, M; Hasegawa, Y; Horio, M; Horio, Y; Kondo, M; Saito, H; Tamura, M; Yamamoto, M | 1 |
| Gao, Q; Kang, KB; Ty, A; Wong, MC; Wong, YL; Zhu, C | 1 |
| Chang, YC; Chang, YL; Hu, FC; Lee, YC; Shih, JY; Wu, JY; Wu, SG; Yang, PC; Yu, CJ | 1 |
| Ahn, MJ; Blair, JM; Chen, YM; Kang, JH; Liang, J; Linn, C; Orlando, M; Peng, G; Xiu, Q; Yang, JC | 1 |
| He, XM; Li, Y; Zhang, LY | 1 |
| Burger, JA; Saintigny, P | 1 |
| Harada, K; Kawamura, T; Miyajima, S; Shibagaki, S; Shimada, S; Yamaguchi, M | 1 |
| Antalffy, G; Hegedüs, C; Kéri, G; Német, K; Orfi, L; Ozvegy-Laczka, C; Sarkadi, B; Settleman, J; Szakács, G; Truta-Feles, K; Váradi, A; Várady, G | 1 |
| Cao, Y; Chai, Y; Chen, X; Lv, D; Zhang, J; Zhu, Z | 1 |
| Gao, W; Guo, R; Shen, H; Shu, Y; Sun, J; Xu, R | 1 |
| Ariansen, S; Berg, T; Bremnes, R; Brustugun, OT; Dai, HY; Dønnem, T; Fjellbirkeland, L; Grønberg, BH; Helgeland, L; Helland, Å; Jebsen, P; Kleinberg, L; Mangseth, K; Scott, H; Wahl, SG | 1 |
| Chan, AT; Cheng, SH; Cheung, CS; Ho, K; Hui, EP; Lau, CP; Lui, VW; Ma, BB; Ng, MH; Ng, PK; Tsao, SW; Tsui, SK | 1 |
| Ayoola, A; Barochia, A; Belani, CP; Belani, K | 1 |
| Fung, AS; Jonkman, J; Tannock, IF | 1 |
| Arkhipov, A; Dror, RO; Eastwood, MP; Jumper, J; Kim, ET; Kuriyan, J; Shan, Y; Shaw, DE; Zhang, X | 1 |
| Balu-Iyer, SV; Iyer, V; O'Connor, R; Straubinger, RM; Trummer, BJ | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Kato, T; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yokomizo, Y; Yoshizawa, H | 1 |
| Boehm, JS; Butaney, M; Cheung, HW; Du, J; Engelman, JA; Golub, TR; Hahn, WC; He, F; Jänne, PA; Luo, B; Meyerson, M; Root, DE; Sequist, LV; Wang, X; Weir, BA | 1 |
| Gong, P; Jiang, N; Li, T; Liu, D; Wang, B; Zhai, X; Zhang, T | 1 |
| Buechner, SA; Erne, P; Joshi, MB; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Basu, S; Batus, M; Bonomi, P; Buckingham, L; Coon, J; Fidler, MJ; McCormack, S; Walters, K | 1 |
| Bertran-Alamillo, J; Costa, C; Giménez-Capitán, A; Mayo, C; Molina-Vila, MÁ; Rosell, R | 1 |
| Chang, CY; Chang, SC; Chang, SJ; Chen, CY; Kuo, LC; Lai, YC; Liu, YC; Yu, CJ; Yuan, MK | 1 |
| Ai, Z; Teng, Y; Tong, J; Wang, J; Xu, Y | 1 |
| Gao, H; Guo, W; Li, J; Liu, X; Qin, H; Qu, L; Tang, C; Wang, H; Wang, W; Wei, X | 1 |
| Guo, Z; Li, J | 1 |
| Eastman, BM; Gonias, SL; Jo, M; Takimoto, S; Webb, DL | 1 |
| Ambudkar, SV; Chen, XG; Chen, ZS; Fu, LW; He, JH; Liang, YJ; Liu, KJ; Sim, HM; Singh, S; Sodani, K; Su, XD; Talele, TT; Wang, F; Wu, HY; Xie, JD | 1 |
| Chen, LK; Dinglin, XX; Liang, Y; Liao, H; Liu, JL; Xu, F; Zeng, YD; Zhang, L | 1 |
| Harada, H; Mitsuya, K; Mizokami, Y; Nakamura, Y; Nakasu, Y; Nishimura, T; Ono, A; Takahashi, T; Toda, Y; Yamamoto, N | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Li, Z; Luo, B; Settleman, JE | 1 |
| Chang, KT; Chen, JT; Chen, YM; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Ahn, JS; Ahn, MJ; Hwang, IG; Jo, SJ; Kim, BS; Kim, HK; Kim, SW; Kim, YH; Lee, DH; Lee, JW; Lee, K; Lee, KH; Min, YJ; Park, K; Song, HS; Sun, JM; Yun, HJ | 1 |
| Adelstein, DJ; Ives, DI; Phillips, BE; Plesec, T; Rice, TW; Rodriguez, CP; Rybicki, LA; Saxton, JP; Tubbs, RR; Videtic, GM | 1 |
| Kim, HT; Kim, KP; Kim, SW; Lee, DH; Lee, JS; Park, SJ; Suh, C | 1 |
| Fukuda, A; Sonoda, T; Takenaka, T; Yamagata, M | 1 |
| Chen, Y; Gao, Z; Zhuang, L | 1 |
| Chen, J; Chen, L; Guan, Z; Han, B; Jiang, G; Li, L; Li, W; Liao, M; Liu, X; Luo, R; Tao, M; Wang, M; Wu, Y; Xu, J; Xu, N; Yu, S; Zhao, X; Zhong, W | 1 |
| Carrión-Salip, D; De Llorens, R; Massaguer, A; Menendez, JA; Oliveras, G; Pandiella, A; Panosa, C; Puig, T | 1 |
| Boerner, JL; Bollig-Fischer, A; Giordano, CR; Krentz, KA; Mueller, KL; Terlecky, LJ; Terlecky, SR | 1 |
| Hashimoto, K; Hayashi, Y; Horinouchi, H; Izumi, Y; Kohno, M; Nomori, H; Ohtsuka, T | 1 |
| Chen, Z; Gong, P; Han, J; Jiang, N; Liang, C; Sun, C; Zhai, X | 1 |
| Assiddiq, BF; Chan, SP; Chong, PK; Lim, YP; Tan, KY; Toy, W | 1 |
| Jett, JR; Pao, W; Yatabe, Y | 1 |
| Brown, MP; Cheetham, G; Scott, HS; Sharma, A; Tan, TH | 1 |
| Fujimura, M; Kasahara, K; Kimura, H; Nakao, S; Ohmori, T; Sakai, A; Sone, T | 1 |
| Hsu, CP; Hsu, PY; Lin, JJ; Wu, YL | 1 |
| Britt, GJ; Butaney, M; Costa, DB; Heon, S; Jackman, DM; Johnson, BE; Joshi, VA; Lindeman, NI; Rabin, MS; Yeap, BY | 1 |
| Bepler, G; Chen, W; Ghosh, D; Norkin, M; Raghunathan, TE; Sargent, DJ | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Gao, D; Helfrich, BA; Kim, J; Porter, CC; Scarborough, HA; Tan, AC; Zhang, Z | 1 |
| Cai, L; Cao, M; Gemma, A; Kitamura, K; Minegishi, Y; Mizutani, H; Noro, R; Seike, M; Soeno, C; Yoshimura, A | 1 |
| Hu, X; Huang, Y; Lee, RJ; Li, H; Xiang, G; Yung, B; Zhou, X | 1 |
| Ahn, JS; Ahn, MJ; Cho, SH; Choi, YL; Han, JH; Hwang, DW; Ji, JH; Lee, JY; Park, K; Park, LC; Park, S; Sun, JM | 1 |
| Gu, H; Li, X; Liu, S; Wang, D | 1 |
| Baudrin, L; Cadranel, J; Coëtmeur, D; Duruisseaux, M; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Mourlanette, P; Quoix, E; Soria, JC; Westeel, V; Wislez, M | 1 |
| Anand, S; Bachi, A; Floriani, I; Gregorc, V; Lazzari, C; Milan, E; Sorlini, C; Torri, V | 1 |
| Han, JY; Kim, HT; Kim, SH; Lee, JS; Lee, Y; Yun, T | 1 |
| Furcht, CM; Lazzara, MJ; Muñoz Rojas, AR; Nihalani, D | 1 |
| Behrman, SW; Chitkara, D; Danquah, M; Kumar, N; Kumar, V; Mahato, RI; Singh, S | 1 |
| Cao, WF; Cao, XC; Feng, WH; Li, Y; Song, YQ; Zhang, B; Zhang, F; Zhang, L; Zhao, HM | 1 |
| Cai, DY; Hong, TT; Hua, D; Wu, XH; Zhang, RX | 1 |
| Boerner, JL; Kuperwasser, C; List, K; Madden, JM; Mueller, KL; Zoratti, GL | 1 |
| Donev, IS; Kita, K; Li, Q; Matsumoto, K; Nakagawa, T; Nakamura, T; Nishioka, Y; Shimizu, E; Sone, S; Takeuchi, S; Uenaka, T; Wang, W; Yamada, T; Yano, S | 1 |
| Chaumais, MC; De Man, FS; Dorfmüller, P; Eddahibi, S; Fadel, E; François, C; Girerd, B; Guignabert, C; Huertas, A; Humbert, M; Lecerf, F; Montani, D; Perros, F; Tu, L | 1 |
| Huang, JA; Min, DL; Shen, Z; Tang, LN; Yang, Y; Yue, L; Zhou, XH | 1 |
| Fukudo, M; Ikemi, Y; Katsura, T; Kim, YH; Masago, K; Masuda, S; Mishima, M; Mizuno, T; Nagai, H; Sakamori, Y; Togashi, Y | 1 |
| Botteman, MF; Carter, JA; Ganguli, A; Gao, X; Ray, S; Wiegand, P | 1 |
| Dutkowski, C; Farrow, L; Fiegl, H; Gee, JM; McClelland, RA; McCloy, RA; Musgrove, EA; Nicholson, RI; Stone, A; Sutherland, RL; Valdés-Mora, F | 1 |
| Abe, H; Arao, T; Azuma, K; Hayashi, K; Kage, M; Kanda, R; Kawahara, A; Kubo, T; Kuwano, M; Murakami, Y; Nishio, K; Ono, M; Rosell, R; Sonoda, K; Tabara, K; Tahira, T; Yoshinaga, A | 1 |
| Bill, A; Famulok, M; Hannam, JS; Heukamp, LC; König, K; Schmitz, A | 1 |
| Gui, T; Shen, K | 1 |
| Abdul Razak, M; Chan, LC; Ong, CK; Tan, WC | 1 |
| Chen, Y; Han, B; Jia, J; Jiang, Y; Ma, X; Tan, C; Wei, X; Zhang, J; Zhu, F | 1 |
| Horn, L; Lovly, CM | 1 |
| Chen, M; Hu, P; Li, L; Nie, L; Wang, M; Xiao, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| An, K; Ishii, Y; Nishimura, Y; Yamada, H | 1 |
| Koma, Y; Matsuoka, H; Suzuki, Y; Yoshimatsu, H | 1 |
| Bensadoun, RJ; Bertucci, F; Cayre, A; Dassonville, O; De Raucourt, D; Etienne-Grimaldi, MC; Finetti, P; Geoffrois, L; Giraud, P; Grall, D; Milano, G; Morinière, S; Penault-Llorca, F; Racadot, S; Sudaka, A; Thariat, J; Van Obberghen-Schilling, E | 1 |
| Itoh, K; Nakabeppu, Y; Nishimura, Y; Takiguchi, S; Yoshioka, K | 1 |
| Hashimoto, M; Koizumi, F; Minakata, K; Moriyama, H; Murakami, A; Nara, T; Nishio, K; Nurwidya, F; Seyama, K; Tajima, K; Takahashi, F; Takahashi, K; Yae, S | 1 |
| Coveney, PV; Wan, S; Wright, DW | 1 |
| Gallo, JM; Lv, H; Sharma, J | 2 |
| Clement, PM; Cools, J; Gutkind, JS; Hoeben, A; Martin, D | 1 |
| Chang, J; Cho, BC; Hong, S; Jung, M; Kang, YA; Kim, DJ; Kim, JH; Kim, SH; Kim, SK; Rha, SY | 1 |
| Shi, YK | 1 |
| Gao, W; Huang, P; Liu, L; Liu, P; Shao, X; Shu, Y; Wang, R; Yin, Y; Zhang, Z | 1 |
| An, TT; Bai, H; Duan, JC; Wang, J; Wang, SH; Wang, YY; Wang, ZJ; Wu, MN; Yang, L; Zhao, J; Zhuo, ML | 1 |
| Bissell, MJ; Furuta, S; Kenny, PA; Lee, SY; Lenburg, ME; Meier, R; Xu, R | 1 |
| Ievleva, AG; Imianitov, EN; Ivantsov, AO; Levchenko, EV; Matsko, DE; Mitiushkina, NV; Moiseenko, FV; Moiseenko, VM; Novik, AV; Protsenko, SA; Rudakova, AV; Semënov, II; Togo, AV | 1 |
| Galvani, E; Giovannetti, E; Peters, GJ | 1 |
| Gemma, A; Gemmah, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kobayashi, K; Kudoh, S; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Tanaka, T | 1 |
| Chua, KT; Lee, CH; Liam, CK; Lim, BK; Pang, YK; Ruthranesan, M | 1 |
| Chu, DT; Duffield, E; Fukuoka, M; Han, B; Jiang, H; Liao, M; Liu, X; Mok, T; Wu, YL; Zhang, L; Zhou, C | 1 |
| Chen, HM; Kuo, R; Lai, MS; Lin, ZZ; Shao, YY; Shau, WY; Yang, JC | 1 |
| Ishikawa, D; Mouri, H; Nanjo, S; Ohtsubo, K; Takeuchi, S; Yamada, T; Yamashita, K; Yano, S; Yasumoto, K | 1 |
| Ding, N; Tang, L; Wang, S; Wu, Y; Xiao, G; Xiao, Z | 1 |
| Benešová, L; Bortlíček, Z; Brůha, F; Fiala, O; Fínek, J; Krejčí, J; Minárik, M; Pešek, M | 1 |
| Fujii, N; Fujimoto, N; Kato, T; Nagao, T; Nakanishi, G; Tanaka, T; Toda, N | 1 |
| Block, M; Emons, G; Fister, S; Gründker, C; Günthert, AR; Hemmerlein, B; Kubin, J; Mueller, MD; Wilkens, L | 1 |
| Amagaya, S; Chang, CM; Chang, PY; Chen, MY; Jao, HY; Kuo, SC; Lee, CY; Lu, CC; Tu, MG; Yang, JS | 1 |
| Dai, X; Du, Y; Feng, Y; Li, X; Liu, J; Wang, H; Xia, L; Zhang, J | 1 |
| Badurak, P; Janowicz-Żebrowska, A; Jaśkiewicz, P; Knetki-Wróblewska, M; Kowalski, DM; Krzakowski, M; Płużański, A; Zajda, K | 1 |
| Bai, YX; Bian, WX; Han, Y; Liu, L; Yuan, HH | 1 |
| Chen, ZH; Cheng, H; Dong, S; Wu, YL; Xie, Z; Zhang, XC; Zhang, YF; Zhu, JQ | 1 |
| Chisholm, JW; Igal, RA; Nashed, M | 1 |
| Choowongkomon, K; Gleeson, MP; Songtawee, N | 1 |
| Butaney, M; Capelletti, M; Ercan, D; Garraway, LA; Goetz, EM; Gray, NS; Ivanova, EV; Jänne, PA; Lazzara, MJ; Letai, A; Maertens, O; Monast, CS; Montero, J; Pratilas, CA; Repellin, C; Rogers, A; Rosen, N; Shimamura, T; Sholl, L; Tadi, M; Wong, KK; Xu, C; Yanagita, M | 1 |
| Aasrum, M; Christoffersen, T; Dajani, O; Guren, T; Müller, KM; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Hirano, H; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Okinaga, S; Saijo, Y; Sugawara, S; Yoshimori, K; Yoshizawa, H | 1 |
| Erdem, L; Giovannetti, E; Honeywell, R; Leon, LG; Peters, GJ | 1 |
| Biaoxue, R; Shuanying, Y; Wei, L; Wei, Z; Zongjuan, M | 1 |
| Chen, Z; Li, Z; Liao, M; Lu, S; Niu, X; Shen, L; Shen, S; Yu, Y | 1 |
| Byun, SY; Choi, JW; Hong, JS; Huh, CH; Kwon, SH; Na, JI; Park, KC; Youn, SW | 1 |
| Ahn, JH; Kim, EJ; Kim, SW; Kim, SY; Lee, HJ; Lee, SJ; Moon, DH; Oh, SJ; Ryu, JS | 1 |
| Dziadziuszko, R; Jassem, J | 1 |
| Lu, C; Mi, LZ; Schürpf, T; Springer, TA; Walz, T | 1 |
| Chen, M; Li, L; Wang, M; Xia, Y; Zhang, L; Zhao, J; Zhong, W | 1 |
| Bobos, M; Christodoulou, C; Fountzilas, G; Karavasilis, V; Kosmidis, P; Murray, S; Papadopoulos, S; Razis, E | 1 |
| Hasegawa, S; Kondo, N; Tanaka, F; Uramoto, H; Yamada, T; Yano, S | 1 |
| Maemondo, M | 1 |
| Katsura, Y; Ko, R; Koyama, R; Minakata, K; Murakami, A; Muraki, K; Namba, Y; Ohashi, R; Sakuraba, S; Shukuya, T; Takahashi, F; Takahashi, K; Yagishita, S | 1 |
| Cho, BC; Lee, JH; Park, JH; Shin, JU | 1 |
| Chen, J; Dassarath, M; Gu, R; Wang, Q; Wu, G; Yang, K; Yin, Z | 1 |
| Berry, DA; Gong, J; Janku, F; Kurzrock, R; Parsons, HA; Stewart, DJ | 1 |
| Jan, IS; Liao, WY; Shih, JY; Tsai, MF; Wu, SG; Yang, CH; Yang, PC; Yu, CJ | 1 |
| Chiang, HC; Du, S; Liang, B; Ma, W; Wang, L; Wu, W; Xie, Z; Yao, X; Zhong, Y | 1 |
| Chohnabayashi, N; Inoue, A; Mochizuki, S; Murakami, K; Nishimura, N; Nukiwa, T | 1 |
| Chang, PM; Chen, CC; Chen, KY; Chiou, JF; Ho, CC; Hsiao, M; Huang, CY; Kuo, YL; Lai, JM; Lee, PY; Liu, YW; Lu, PJ; Wang, LS; Wu, AT; Wu, CH; Yang, CN; Yang, PC; Yang, SC; Yeh, CT; Yen, CC | 1 |
| Beer, DG; Gotoh, N; Hatanaka, Y; Higuchi, T; Imoto, S; Kohno, T; Miyano, S; Nagasaki, M; Nakata, A; Nomura, M; Saito, A; Shimamura, T; Ueno, K; Yamaguchi, R; Yamauchi, M; Yokota, J; Yoshida, R | 1 |
| Dayekh, K; Dimitroulakos, J; Gorn-Hondermann, I; Ma, L; Niknejad, N | 1 |
| Hashisako, M; Ikegame, S; Kajiki, A; Kumazoe, H; Nagata, N; Wakamatsu, K | 1 |
| Iwanaga, K; Kimura, S; Mori, D; Nakamura, T; Sueoka-Aragane, N | 1 |
| Dang, NH; Hayashi, Y; Hosono, O; Ichihara, H; Inoue, Y; Iwata, S; Kamiya, K; Katayose, T; Kawasaki, H; Kichikawa, Y; Kondo, S; Morimoto, C; Sakamoto, M; Souta-Kuribara, A; Tanaka, H; Yamada, T; Yamazaki, H | 1 |
| Johansson, AC; La Fleur, L; Roberg, K | 1 |
| Gallia, GL; Joshi, AD; Loilome, W; Riggins, GJ; Siu, IM; Tyler, B | 1 |
| Biffoni, M; Canzonieri, V; Colarossi, C; D'Andrea, V; De Antoni, E; De Maria, R; Di Matteo, P; Eramo, A; Fecchi, K; Memeo, L; Salvati, V; Sette, G; Signore, M | 1 |
| Castillo-Pichardo, L; Dharmawardhane, SF | 1 |
| Bossi, P; Cortelazzi, B; Licitra, L; Locati, LD; Maurichi, A; Perrone, F; Pilotti, S; Resteghini, C | 1 |
| Hirano, S; Hojo, M; Iikura, M; Ishii, S; Izumi, S; Kobayashi, N; Kudo, K; Naka, G; Sano, K; Sugiyama, H; Takeda, Y | 1 |
| Jiao, W; Luo, Y; Shen, Y; Sui, A; Tang, D; Wang, M; Wang, Y; Wang, Z; Yang, R | 1 |
| Bevilacqua, S; Botti, G; Caraco, C; Caronna, A; Costanzo, R; De Lutio, E; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rocco, G; Sandomenico, C | 1 |
| Bivona, TG; Blakely, CM | 1 |
| Chen, HJ; Dong, S; Huang, YS; Jiang, BY; Liao, RQ; Nie, Q; Su, J; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Mitsuoka, S; Nagata, M; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Bouteloup, C; De Botton, S; Fenaux, P; Galluzzi, L; Kroemer, G; Lainey, E; Leroy, C; Scoazec, M; Sébert, M; Thépot, S | 1 |
| Harada, K; Nakanuma, Y; Sato, Y | 1 |
| Abe, K; Ebina, M; Endo, C; Inoue, A; Kobayashi, M; Kondo, T; Kumamoto, H; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nukiwa, T; Sasano, H; Sato, I; Suzuki, T; Yamada-Okabe, H | 1 |
| Bortlíček, Z; Coupková, H; Grygárková, Y; Havel, L; Hejduk, K; Hrnčiarik, M; Kolek, V; Košatová, K; Koubková, L; Pešek, M; Roubec, J; Salajka, F; Sixtová, D; Skřičková, J; Spelda, S; Tomíšková, M; Zatloukal, P; Zemanová, M | 1 |
| Chang, YJ; Huang, MH; Lee, JH; Lin, AM; Lin, YL; Tsai, HH; Yang, JC | 1 |
| Beckler, AD; Carlson, HT; Francom, CR; Jameson, MJ; Khalil, AA; Mendez, RE; Stuart, MM; Taniguchi, LE; Thomas, CY; VanKoevering, KK | 1 |
| Liu, BN; Meng, ZW; Pan, ZH; Wu, X; Xu, K; Yan, HQ; Zhou, QH; Zhu, Y | 1 |
| Chen, MS; Chi, CW; Hsu, CC; Huang, YC; Kuo, CD; Lee, HC; Lee, LM; Lee, YC; Liao, JF; Lin, AM; Yang, CH; Yin, PH | 1 |
| Fang, X; Hu, Y; Li, M; Ma, S; Shen, H; Tan, C; Yuan, Y | 1 |
| Alesini, D; Cortesi, E; Passaro, A; Pochesci, A | 1 |
| Hosoya, T; Imai, S; Kuzumaki, N; Morita, H; Nagasawa, A; Narita, M; Okada, Y; Okano, H; Okano, HJ; Suzuki, A; Suzuki, T; Yamamizu, K; Yamashita, JK | 1 |
| Albitar, L; Brachova, P; Dai, D; Ianzini, F; Kosmacek, EA; Laidler, LL; Leslie, KK; Liu, D; Mackey, MA; Meng, X; Wang, X; Xiong, Z; Yang, S; Zhang, Y; Zhu, D | 1 |
| Basti, S; Borkar, DS; Lacouture, ME | 1 |
| Ahye, N; Azzoli, CG; Chaft, JE; D'Angelo, SP; Dycoco, J; Janjigian, YY; Kris, MG; Ladanyi, M; Riely, GJ; Rusch, V; Shen, R; Sima, CS; Zakowski, MF; Zheng, J | 1 |
| Aburatani, H; Endo, S; Fukayama, M; Ishikawa, S; Kanai, Y; Kataoka, H; Matsubara, D; Murakami, Y; Niki, T; Oguni, S; Ohara, S; Sakatani, T; Tamura, T; Yoshimoto, T | 1 |
| Ebara, T; Nakano, T; Sato, Y; Sunaga, N; Takahashi, T | 1 |
| Gemma, A; Saito, Y | 1 |
| Han, XH; Ma, L; Shi, YK; Wang, JF; Wang, S | 1 |
| Chiu, NT; Chung, WP; Ho, CL; Song, HL; Su, WC | 1 |
| Baxter, RC; Lin, MZ; Martin, JL; Marzec, KA | 1 |
| Guirgis, HM | 1 |
| Brachman, DG; Bredel, M; Chakravarti, A; Choucair, A; Christiansen, J; Curran, WJ; Dicker, AP; Dolled-Filhart, M; Gustavson, M; Lautenschlaeger, T; Mehta, M; Mischel, P; Molinaro, A; Robins, HI; Schultz, CJ; Wang, M | 1 |
| Guo, LX; Jiao, J; Li, GQ; Liu, Y; Yao, ZJ; Zhang, B; Zhou, B; Zhou, GB | 1 |
| Chang, AY; Wang, M | 1 |
| Aldinucci, D; Borghese, C; Cattaruzza, L; Celegato, M; Colombatti, A; De Luca, A; Mazzucato, M; Normanno, N; Pivetta, E | 1 |
| Cohen, EE; Grushko, T; Liu, J; Liu, W; Olopade, OI; Pierce, C; Seiwert, TY; Shen, C; Wei, TF; Young, NR | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Suzumura, T; Tanaka, H; Umekawa, K; Yoshimura, N | 1 |
| Daga, H; Hirashima, T; Hirata, K; Kawaguchi, T; Kimura, T; Kobayashi, M; Kudoh, S; Mitsuoka, S; Okishio, K; Takeda, K; Yoshimura, N | 1 |
| Hou, B; Jiang, WR; Kong, QT; Li, B; Li, J; Liu, ZB; Shen, TZ; Wang, Y; Wang, Z; Wu, XH; Zhu, XX | 1 |
| Hirami, Y; Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yasuda, K; Yukawa, T | 1 |
| Albeck, JG; Brugge, JS; Mills, GB | 1 |
| Horiguchi, N; Kakizaki, S; Mori, M; Nakajima, Y; Sato, K; Sunaga, N; Takagi, H | 1 |
| Jeon, WI; Lee, SY; Ryu, PD | 1 |
| Fujii, H; Jimmy So, A; Kono, K; Mimura, K; Shabbir, A; Yong, WP | 1 |
| Hirashima, T; Kawase, I; Kitai, K; Morishita, N; Okamoto, N; Otsuka, T; Shiroyama, T; Suzuki, H; Tamiya, M; Yamadori, T | 1 |
| Fujita, S; Hata, A; Imai, Y; Ishida, T; Iwasaku, M; Kaji, R; Katakami, N; Korogi, Y; Kunimasa, K; Nishiyama, A; Notohara, K; Tachikawa, R; Tomii, K; Yoshioka, H | 1 |
| Bartolotti, M; Brandes, AA; Franceschi, E | 1 |
| Bayliss, G; He, S; Liu, N; Zhuang, S | 1 |
| Chang, H; Cho, BC; Cho, J; Ha, SJ; Hong, YK; Jeong, JH; Kim, HR; Kim, JH; Kim, SH; Kim, SM; Shim, HS; Sung, JH; Tania, C | 1 |
| Asami, K; Atagi, S; Hirashima, T; Kawaguchi, T; Kawahara, M; Okishio, K; Okuma, T; Omachi, N; Takeuchi, N | 1 |
| Abe, H; Azuma, K; Hattori, S; Hoshino, T; Kage, M; Kawahara, A; Yamada, K; Yamashita, F; Yoshida, T; Zaizen, Y | 1 |
| Li, H; Li, X; Schmid-Bindert, G; Wang, D; Wang, Y; Zhou, C; Zhou, S | 1 |
| Cai, Y; Chen, G; Jia, J; Liu, B; Liu, H; Liu, JY; Zhang, JL; Zhang, W; Zhao, YF; Zhong, HY | 1 |
| Brodsky, O; Feng, J; Ferre, R; Gajiwala, KS; Kath, JC; Ryan, K; Stewart, A; Weinrich, S | 1 |
| Essapen, S; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Beijnen, JH; Harmsen, S; Maas-Bakker, RF; Meijerman, I; Schellens, JH | 1 |
| Higami, Y; Kato, M; Kobayashi, T; Koshimo, Y; Marumo, S; Takeda, M; Teranishi, T | 1 |
| Hao, XZ; Li, JL; Shi, YK; Wang, B; Wang, Y; Wang, ZP; Zhang, XR | 1 |
| Cai, DY; Hua, D; Wu, XH; Zhang, RX | 1 |
| Casanovas, O; Castillo-Ávila, W; Condom, E; Garcia Del Muro, X; Germà, JR; Graupera, M; Hernández-Losa, J; Juliachs, M; Pandiella, A; Piulats, JM; Teixidó, C; Vidal, A; Villanueva, A; Viñals, F | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Corominas-Faja, B; Cufí, S; Martin-Castillo, B; Menendez, JA; Oliveras-Ferraros, C; Urruticoechea, A; Vazquez-Martin, A | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Lee, SH; Park, JH | 1 |
| Chen, Y; Du, XJ; Yang, M; Yu, S; Yuan, X; Zhang, L | 1 |
| Agatsuma, T; Hachiya, T; Hirai, K; Ichiyama, T; Koizumi, T; Koyama, S; Morozumi, N; Shiina, T; Tateishi, K | 1 |
| Matsuo, K; Takada, Y | 1 |
| An, C; Xuan, X; Zhou, C | 2 |
| Ji, L; Pei, Y | 1 |
| Cadranel, J; Cong, XJ; Fairclough, D; Finnern, HW; Hirsh, V; Lorence, RM; Miller, VA; Palmer, M; Yang, JC | 1 |
| Alba, E; Álvarez, M; de Luque, V; González-Hermoso, C; Jerez, JM; Medina, JA; Pajares, B; Rueda, A; Toledo, MD; Trigo, JM | 1 |
| Azuma, K; Daga, H; Hayashi, H; Kiyota, H; Miyazaki, M; Murakami, H; Naito, T; Nakagawa, K; Okada, H; Okamoto, I; Takeda, K; Takeda, M; Tanaka, K; Terashima, M; Yamamoto, N | 1 |
| Chang, SS; Chen, CT; Du, Y; Herbst, R; Hsu, JL; Hsu, MC; Hung, MC; Ko, HW; Wang, YN; Yamaguchi, H | 1 |
| Brooks, MB | 1 |
| Alfieri, R; Ardizzoni, A; Carmi, C; Cavazzoni, A; Dekker, H; Galvani, E; Giovannetti, E; Leon, LG; Mor, M; Peters, GJ; Petronini, PG; Saccani, F | 1 |
| Cai, J; Li, T; Wang, X; Wu, B; Xu, Y; Ye, M; Zhu, J | 1 |
| Fujita, H; Kashihara, M; Kuwano, M; Nakagawa, K; Ogi, S; Ohdo, S; Okamoto, I; Ono, M; Sonoda, K; Tanaka, Y; Yamamoto, C | 1 |
| Crawford, M; Fabbri, M; Friedman, A; Garofalo, M; Kang, HW; Nana-Sinkam, SP; Nuovo, G | 1 |
| Buechner, SA; Erne, P; Iezzi, G; Kyriakakis, E; Pfaff, D; Philippova, M; Resink, TJ; Schoenenberger, AW; Spagnoli, GC | 1 |
| Augustin, A; Avila, DW; Duchateau-Nguyen, G; Essioux, L; Golling, S; Hermann, JC; Klughammer, B; Lamerz, J; Langen, H; Meistermann, H; Scheiblich, S; Tzouros, M | 1 |
| Besse, B; Chaubet-Houdu, M | 1 |
| Ebi, H; Hasegawa, Y; Ishikawa, D; Nakagawa, T; Nanjo, S; Sano, T; Sato, M; Sekido, Y; Takeuchi, S; Yamada, T; Yano, S | 1 |
| Pallis, AG; Syrigos, KN | 1 |
| Kaur, J; Tikoo, K | 2 |
| Fujii, A; Furuyama, K; Giaccone, G; Harada, T; Ijichi, K; Iwama, E; Li, H; Nakanishi, Y; Okamura, K; Ota, K; Shiraishi, Y; Takayama, K; Wang, S | 1 |
| Dering, J; Desai, AJ; Dubinett, SM; Finn, RS; Garon, EB; Hosmer, W; Kamranpour, N; Márquez-Garbán, DC; Pietras, RJ; Pitts, S; Slamon, DJ; von Euw, EM | 1 |
| Fujiwara, M; Furuse, J; Goto, H; Goya, T; Hiraoka, S; Ishii, H; Saraya, T; Takizawa, H; Tamura, M; Yano, K; Yokoyama, T | 1 |
| Aldousari, S; Chevalier, S; Kassouf, W; Mansure, JJ; Nassim, R; Rocha, J; Szymanski, K | 1 |
| Fujiwara, Y; Horinouchi, H; Kanda, S; Kubota, K; Nakamichi, S; Nokihara, H; Tamura, T; Yamamoto, N | 1 |
| Contini, A; Erne, P; Ferri, N; Frachet, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ | 1 |
| Gwak, HS; Han, JY; Joo, J; Kim, HT; Kim, S; Lee, JS; Lee, SH; Shin, SH; Yoo, H | 1 |
| Gaffney, DC; Simpson, F; Soyer, HP | 1 |
| He, K; Yu, J; Zhang, L; Zheng, X | 1 |
| Huber, RM; Reck, M; Thomas, M | 1 |
| Couraud, S | 1 |
| Baron, AT; Darcy, KM; Fischer, E; Godwin, AK; Hanjani, P; Leslie, KK; Maihle, NJ; Mannel, RS; Schilder, RJ; Sill, MW; Singh, M; Tewari, KS; Wilken, JA | 1 |
| Cao, HX; Feng, JF; Li, XY; Ma, R; Wu, JQ; Wu, JZ; Zhong, YJ | 1 |
| Honda, Y; Ichihara, E; Kiura, K; Kubo, T; Kudo, K; Minami, D; Murakami, T; Ninomiya, T; Ochi, N; Takigawa, N; Tanimoto, M | 1 |
| Argiris, A; Burtness, B; Forastiere, AA; Ghebremichael, M; Gilbert, J; Kolesar, JM; Lee, JW; Sachidanandam, K | 1 |
| Deng, XB; Jin, ZR; Li, XQ; Liu, QZ; Liu, Y; Ma, L; Miao, XB; Sun, DX; Testa, JR; Wu, Y; Xiao, GH; Yao, KT; Zhang, G | 1 |
| Inoue, H; Ishikawa, T; Kajimoto, Y; Kuroiwa, T; Miyatake, S; Sun, W | 1 |
| Gandhi, AK; Jagadesan, P; Julka, PK; Kumar, S; Rath, GK; Sharma, DN | 1 |
| Arcila, ME; Kris, MG; Ladanyi, M; Miller, VA; Pao, W; Rekhtman, N; Riely, GJ; Sima, CS; Yu, HA; Zakowski, MF | 1 |
| Arriola, E; Martínez-Avilés, L; Mompradé, E | 1 |
| Araya, T; Demura, Y; Kasahara, K; Matsuoka, H; Nishi, K; Nishitsuji, M | 2 |
| Clément-Duchêne, C; Lamaze, R; Martinez, L | 1 |
| Chang, CY; Chang, SC; Liu, YC; Wang, KF; Yang, YH; Yuan, MK | 1 |
| Adachi, E; Matsugo, S; Matsumoto, K; Michikoshi, H; Nakamura, T; Sakai, K; Suzuki, Y | 1 |
| Akashi, M; Chin, TM; Doan, NB; Koeffler, HP; Mori, S; Said, JW; Sudo, M | 1 |
| Irifune, K; Ito, R; Miyawaki, S; Sayama, K; Tohyama, M | 1 |
| Acharyya, S; Chakraborty, A; Dasgupta, P; Gangopadhyay, S; Sau, S | 1 |
| Chang, CC; Chao, JI; Liu, HF; Tsai, CM; Wang, SP; Yu, SY | 1 |
| Chen, Y; Huang, Y; Mei, Q; Xia, S; Yu, S | 1 |
| Chen, G; De Grève, J; Kronenberger, P; Noor, A; Teugels, E; Umelo, IA | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Nakayama, S; Naoki, K; Ohgino, K; Sato, T; Satomi, R; Soejima, K; Terai, H; Yasuda, H; Yoda, S | 1 |
| Chu, DT; Fukuoka, M; Mok, TS; Rukazenkov, Y; Saijo, N; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ | 1 |
| Alcantara, LM; Ayong, LS; Franco, CH; Franzoi, KD; Freitas-Junior, LH; Kim, J; Lee, S; Moraes, CB | 1 |
| Asano, H; Gazdar, AF; Hashida, S; Ichihara, E; Jida, M; Kiura, K; Lam, WL; Maki, Y; Miyoshi, S; Shien, K; Soh, J; Takigawa, N; Thu, KL; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Chan, KS; Lim, KH; Lim, WT; Lynette, O; Montoya, J; Ng, QS; Sakktee Krisna, S; Takano, A; Tan, DS; Tan, EH | 1 |
| Bontognali, S; Brutsche, MH; Buess, M; Fischer, C; Pless, M; Rochlitz, C | 1 |
| Beasley, MB; Cagle, PT; Chitale, DA; Dacic, S; Giaccone, G; Jenkins, RB; Kwiatkowski, DJ; Ladanyi, M; Lindeman, NI; Saldivar, JS; Squire, J; Thunnissen, E | 1 |
| Chhatwani, L; Jacobs, CD; Lopez-Anaya, A; Padda, SK; Wakelee, HA; Zhou, L | 1 |
| Chen, X; Guo, R; Liu, Y; Qian, Y; Røe, OD; Shu, Y; Yin, Y; Zhu, L | 1 |
| Frasca, F; Gianì, F; Lotta, S; Messina, RL; Nicolosi, ML; Regalbuto, C; Vella, V; Vigneri, P; Vigneri, R | 1 |
| Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, JI; Kim, JY; Kim, S; Kim, TM; Koh, Y; Lee, JK; Lee, S; Lee, SH; Min, HS; Park, C; Shin, JY | 1 |
| Furukawa, T; Hamasaki, S; Itakura, S; Miyata, M; Suenaga, M; Tabata, S; Yamamoto, M | 1 |
| Goishi, K; Higashiyama, S; Ise, N; Kurokawa, M; Omi, K | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Nakai, T; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Ettinger, DS; Kris, MG | 1 |
| Cassidy, J; Hochster, H | 1 |
| Han, S; He, QH; Li, P; Liu, KY; Liu, XJ; Liu, XX; Liu, YN; Ma, SH; Qin, JZ; Shen, L; Wu, WH; Wu, WT; Yin, F; Zhang, JM; Zhang, XY | 1 |
| Al-Lazikani, B; Box, C; Box, GM; Brandon, Ade H; Eccles, SA; Gowan, S; Harrington, KJ; Mendiola, M; Rogers, SJ; Valenti, M; Wilkins, A | 1 |
| Akamatsu, H; Inoue, A; Kobayashi, K; Mitsudomi, T; Mori, K; Nakagawa, K; Nakanishi, Y; Nukiwa, T; Yamamoto, N | 1 |
| Chao, T; Chen, Y; Chu, Q; Gui, Q; Han, N; Peng, P; Xia, S; Yu, S; Zhuang, L; Zou, M | 1 |
| Fujimoto, D; Fujita, S; Hata, A; Kaji, R; Katakami, N; Kawamura, T; Matsumoto, T; Monden, K; Nagata, K; Nakagawa, A; Otoshi, T; Otsuka, K; Tachikawa, R; Takeshita, J; Tamai, K; Tanaka, K; Tomii, K | 1 |
| Ishiguro, H; Ishiguro, Y; Miyamoto, H | 1 |
| Bae, S; Jeong, JH; Kang, S; Kim, CH; Kim, EJ; Lim, YB | 1 |
| Au, JS; Brown, C; Chu, da T; Gebski, V; Gralla, RJ; Hirsh, V; Ho, JC; Inoue, A; Lee, CK; Lee, SM; Osorio Sanchez, JA; Tan, EH; Thongprasert, S; Tsai, CM; Vu, VV; Yang, JC; Zaatar, A | 1 |
| Bae, I; Hong, W; Kang, HJ; Kim, HJ; Seong, YS; Wang, A; Yi, YW; Zhao, W | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Chen, FH; Chiang, CS; Fu, SY; Hong, JH; Wang, CC; Yang, YC | 1 |
| Avila Martínez, RJ; Hernández Voth, A; Villena Garrido, V | 1 |
| Brenner, R; Hirsch, FR; Ikeda, N; Ilouze, M; Kato, Y; Mascaux, C; Ohira, T; Peled, N; Qian, J; Wynes, MW; Yoshida, K | 1 |
| Hou, YH; Pan, JB; Zhang, GJ | 1 |
| Eda, T; Iwakura, Y; Mizuno, M; Nagata, K; Namba, H; Nawa, H; Okubo, T; Shibuya, M; Sotoyama, H; Wang, R | 1 |
| Brewer, M; Janakiram, NB; Mohammed, A; Rao, CV; Steele, VE; Vedala, K | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Imamura, F; Kijima, T; Komuta, K; Kumanogoh, A; Minami, S; Mori, M; Namba, Y; Nonen, S; Otani, Y; Tachibana, I; Takimoto, T; Tsuruta, N; Uchida, J; Yokota, S | 1 |
| Gu, WG; He, ZR; Huang, Y; Luo, HT; Peng, RJ; Wang, SS; Yuan, ZY | 1 |
| Barzotti, E; Crinò, L; Drudi, F; Mangianti, M; Papi, M; Poggi, B; Ravaioli, A; Salvi, M; Santelmo, C | 1 |
| Ciardiello, F; D'Aiuto, E; De Palma, R; De Vita, F; Della Corte, CM; Martinelli, E; Morgillo, F; Orditura, M; Sasso, FC; Troiani, T; Vitagliano, D | 1 |
| Fang, X; Gu, P; Huang, B; Liang, A; Liu, F; Ren, S; Wu, Y; Yi, X; Zeng, Y; Zhang, Z; Zhao, Y; Zhou, C | 1 |
| Chen, J; Li, JY; Shi, JY; Su, B; Tang, L; Yang, XJ; Zhang, J; Zhao, YM | 1 |
| Lazarus, DR; Ost, DE | 1 |
| Chen, PC; Chu, CY; Shih, YH | 1 |
| Fujita, Y; Horiike, A; Irwin, DL; Kaburaki, K; Kudo, K; Nishio, K; Nishio, M; Ohyanagi, F; Saito, R; Sakai, K; Sakatani, T; Tanimoto, A; Yanagitani, N | 1 |
| Carrillo, V; Dubisz, E; Gulzar, H; Mahajan, SS; Morgan, D; Yelskaya, Z | 1 |
| Emsley, P; Turnbull, AP | 1 |
| Ashworth, A; Campbell, J; Herrera-Abreu, MT; Knowles, MA; Pearson, A; Shnyder, SD; Turner, NC | 1 |
| Bode, AM; Byun, S; Dong, Z; Farrand, L; Jeong, CH; Kim, JY; Lee, HJ; Lee, J; Lee, MH; Lee, SY; Lim, S; Reddy, K; Won Lee, K | 1 |
| He, P; Li, G | 1 |
| Arpin, D; Bringuier, PP; Couraud, S; Locatelli-Sanchez, M; Riou, R; Souquet, PJ | 1 |
| Canoll, P; Dionne, KR; Foreman, NK; Klaassen, M; Kleinschmidt-Demasters, BK; Massarwa, R; Niswander, L; Parker, JJ; Waziri, A | 1 |
| Fukuoka, J; Ichihara, E; Iioka, H; Kiura, K; Kondo, E; Kuwahara, K; Ohtani, N; Saito, K; Takigawa, N; Tomita, Y; Ueda, R | 1 |
| Bollu, LR; Gao, G; Huang, WC; Hung, MC; Ren, J; Su, F; Weihua, Z; Xu, L | 1 |
| Gao, H; Guo, W; Liu, X | 1 |
| Lin, B; Shao, L; Song, Z; Zhang, Y | 1 |
| Costanzo, R; De Lutio, E; Franco, R; Montanino, A; Morabito, A; Normanno, N; Pasquale, R; Rachiglio, AM; Rocco, G; Sandomenico, C | 1 |
| Idowu, MO | 1 |
| Bellevicine, C; Carlomagno, C; De Luca, C; de Rosa, N; De Stefano, A; Iaccarino, A; Illiano, A; Malapelle, U; Micheli, P; Pepe, F; Piantedosi, FV; Rocco, D; Russo, S; Salatiello, M; Troncone, G; Vitiello, F | 1 |
| Chen, MJ; Li, LY; Wang, MZ; Zhang, L; Zhao, J; Zhong, W | 1 |
| Aoudjehane, L; Clapéron, A; Conti, F; Desbois-Mouthon, C; Firrincieli, D; Fouassier, L; Ho-Bouldoires, TH; Housset, C; Merabtene, F; Mergey, M; Prignon, A; Scatton, O; Wendum, D | 1 |
| Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J | 1 |
| Cardarella, S; Hatabu, H; Jackman, DM; Jänne, PA; Johnson, BE; Nishino, M; Rabin, MS; Ramaiya, NH | 1 |
| Cheng, F; Chu, DT; Du, CX; Li, WG; Liu, ZD; Mi, YL; Peng, Y; Tang, KK; Wang, Y; Xi, XM; Yang, HY; Zhang, XR; Zhao, LM; Zheng, YQ | 1 |
| Ding, K; Han, C; Huang, Z; Ji, H; Lai, Y; Peng, S; Wan, L; Zhang, Y; Zheng, C | 1 |
| Adamo, V; David, A; Franchina, T; Gangemi, S; Kennez, I; Minciullo, PL; Profita, M; Zanghì, M | 1 |
| Han, ZG; Shan, L; Wang, Q; Zhang, Y | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, E; Lee, SH | 1 |
| Castellanos-Rizaldos, E; Guha, M; Makrigiorgos, GM | 1 |
| Hayakawa, H; Honda, Y; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kudo, K; Minami, D; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M | 1 |
| Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A | 1 |
| He, AN; Qi, WX; Shen, Z; Tang, LN; Yao, Y | 1 |
| Atagi, S; Ebisawa, R; Goto, K; Hida, T; Horai, T; Ichinose, Y; Inoue, A; Katakami, N; Kiura, K; Koboyashi, K; Nishio, K; Seki, Y; Shahidi, M; Takeda, K; Yamamoto, N | 1 |
| Han, JY; Kim, HT; Kim, HY; Lee, GK; Lee, JS; Lee, Y; Yun, T | 1 |
| Gavine, P; Huang, XS; Ji, Q; Li, M; Su, X; Wu, YL; Xie, L; Yang, XN; Zhan, P; Zhang, J; Zhang, L; Zhang, XC; Zheng, L; Zhong, WZ; Zhou, M; Zhu, G | 1 |
| Abadi, AH; Abou El Ella, DA; Engel, M; Hamed, MM; Hartmann, RW; Keeton, AB; Piazza, GA | 1 |
| Amaro, A; Angelini, G; Esposito, AI; Lanza, F; Mirisola, V; Mosci, C; Musso, A; Nasciuti, F; Perri, P; Pfeffer, U; Poggi, A; Puzone, R; Salvi, S; Tosetti, F; Truini, M | 1 |
| Fung, AS; Tannock, IF; Ye, QJ; Yu, M | 1 |
| Gallez, B; Grégoire, V; Jordan, BF; Karroum, O; Kengen, J | 1 |
| An, J; Gao, H; Guo, W; Li, J; Li, X; Liu, X; Qin, H; Qu, L; Tang, C; Wang, W | 1 |
| Aloj, SM; Chiaviello, A; Palumbo, G; Postiglione, I | 1 |
| Bernier-Chastagner, V; Chastagner, P; Chateau, A; Guérin, E; Merlin, JL; Mriouah, J; Pinel, S; Plénat, F; Taillandier, L; Vandamme, M | 1 |
| He, C; Li, Y; Liu, M; Xu, J; Xu, Y; Zheng, L | 1 |
| Ellis, PM; Leighl, NB; Sehdev, S; Verma, S; Younus, J | 1 |
| Aurisicchio, L; Ciliberto, G; Coluccia, P; D'Andrilli, A; De Vitis, C; Fattore, L; Giovagnoli, MR; Luberto, L; Malpicci, D; Mancini, R; Marra, E; Normanno, N; Noto, A; Roscilli, G; Ruco, L | 1 |
| Chandrashekara, KA; Reddy, CG; Udupi, A | 1 |
| Che, J; Shen, XJ; Sun, KK; Wu, XY; Yang, D; Zhao, H; Zhong, N | 1 |
| Hirata, K; Kimura, T; Kira, Y; Kudoh, S; Matsuura, K; Mitsuoka, S; Nagata, M; Oka, T; Suzumura, T; Umekawa, K; Yoshimura, N | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH | 1 |
| Chen, B; Li, B; Xiao, F; Xie, B; Zhang, W; Zheng, J; Zhou, J | 1 |
| Barrajón-Catalán, E; Bonavia, R; Bosch-Barrera, J; Corominas-Faja, B; Cufí, S; Cuyàs, E; Joven, J; Martin-Castillo, B; Menendez, JA; Micol, V; Oliveras-Ferraros, C; Segura-Carretero, A; Vazquez-Martin, A; Visa, J | 1 |
| He, CS; Wei, SH; Xie, M; Zhang, L | 1 |
| Kato, H; Oizumi, H; Sadahiro, M; Watarai, H | 1 |
| Aristei, C; Calzuola, M; Cecchini, D; Contavalli, P; Falzetti, F; Marini, V; Palumbo, I; Piattoni, S; Valentini, V; Vecchio, FM | 1 |
| Stinchcombe, TE; Weiss, JM | 1 |
| Akamizu, T; Hattori, Y; Iwakura, H; Kawano, K; Maitani, Y | 1 |
| Bedi, A; Chang, X; Chatterjee, A; Goodman, SN; Harari, PM; Hidalgo, M; Izumchenko, E; Kim, MS; Ling, S; Monitto, CL; Sidransky, D; Solis, LM; Wistuba, II | 1 |
| Gao, X; Guo, F; He, S; Li, D; Lin, Z; Ma, X; Sun, J; Wan, Y; Wang, Y; Ye, T; Yin, T | 1 |
| Chen, W; Dai, H; Xia, C; Xu, L | 1 |
| Camidge, DR | 1 |
| Bai, C; Chen, J; Cheng, Y; Dai, H; Ding, L; Feng, J; Hu, C; Jiao, S; Jin, Y; Li, Q; Liang, L; Liu, W; Liu, X; Luo, R; Qin, S; Shi, Y; Song, Y; Sun, Y; Tan, F; Wang, D; Wang, J; Wang, Y; Wei, Z; Wu, YL; Xu, N; Zhang, H; Zhang, L; Zhang, S; Zhang, W; Zhang, Y; Zhou, C; Zhou, J | 1 |
| Jeong, YJ; Kim, CH; Kim, DJ; Kim, JC; Lee, KB; Oh, SM; Park, JH | 1 |
| Baradia, D; Misra, A; Patil, S; Vhora, I; Yewale, C | 1 |
| Cheng, PS; Lai, FJ | 1 |
| Jiao, S; Liu, T; Xie, X; Yang, J; Zhang, G | 1 |
| Chen, JJ; Chen, X; Ma, SN; Zhao, J; Zhou, JY | 1 |
| Lacouture, ME; Rodeck, U | 1 |
| Garber, C; Keith, C; Kohn, E; Lam, G; Mascia, F; Steinberg, SM; Yuspa, SH | 1 |
| Dong, X; Lin, Z; Wang, F; Zhao, F; Zhao, W | 1 |
| Goto, K; Ishii, G; Matsumoto, S; Nagai, K; Niho, S; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Butts, C; Choy, H; Ding, K; Edelman, MJ; Gandara, D; Goss, GD; Hensing, TA; Jett, J; Kernstine, K; Khuri, F; Lilenbaum, R; Lorimer, I; Masters, GA; Noble, J; O'Callaghan, C; Pisters, K; Rowland, K; Schiller, J; Shepherd, FA; Tsao, MS | 1 |
| Fujii, T; Matsumura, S; Okamoto, T; Shinyama, M; Tanaka, H | 1 |
| Gao, HJ; Liu, H; Qin, HF; Qu, LL; Wang, SS | 1 |
| Fu, Y; He, Q; Lin, G; Lou, J; Ma, J; Wu, Y; Yang, B; Zheng, L; Zhu, H | 1 |
| Chen, Y; Wang, M; Zhao, J; Zhong, W | 1 |
| Imamura, F; Kijima, T; Komuta, K; Kumagai, T; Kumanogoh, A; Minami, S; Mori, M; Morita, S; Nakazawa, Y; Namba, Y; Nishino, K; Okuyama, T; Tachibana, I; Takahashi, R; Uchida, J; Yamamoto, S; Yano, Y | 1 |
| Hasegawa, Y; Hatano, K; Iizasa, T; Itakura, M; Iuchi, T; Kageyama, H; Kawasaki, K; Nagano, O; Sakaida, T; Shingyoji, M; Yokoi, S | 1 |
| Atkey, N; Bolton, LM; Cree, IA; Dyson, M; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Chiu, HC; Chiu, HY | 1 |
| Hayakawa, H; Ichihara, E; Kiura, K; Matsumoto, K; Ninomiya, T; Ohashi, K; Sakai, K; Takata, S; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Diao, P; Wang, LY; Wei, Y; Xie, H; Yao, WX; Zeng, C; Zhao, X; Zhou, H; Zhou, J | 1 |
| Bronte, G; Castiglia, M; Cicero, G; Fiorentino, E; Giovannetti, E; Passiglia, F; Pauwels, P; Rizzo, S; Rolfo, C; Russo, A; Van Meerbeeck, J; Vullo, FL | 1 |
| Shen, W; Turchi, JJ; Xu, J; Zeng, LF; Zhang, ZY | 1 |
| Köhler, J; Schuler, M | 1 |
| Bai, F; Ding, K; Ku, X; Li, H; Liu, X; Tu, Z; Xu, Y; Zhang, L; Zhao, Z; Zhou, W | 1 |
| Chang, KT; Chen, JT; Chiu, CH; Hsiao, SY; Lai, CL; Tsai, CM | 1 |
| Chen, YM; Lee, YC; Perng, RP; Shih, JF; Tsai, CM; Whang-Peng, J; Wu, WS | 1 |
| Cho, SY; Choi, J; Hwang, JJ; Jang, SJ; Kim, CS; Lee, G; Lee, JH; Lee, SW; Lim, C; Seo, J; Song, JY | 1 |
| Bi, H; Chen, J; Hou, J; Liu, B; Liu, D; Liu, J; Shi, H; Wen, X; Yuan, J; Yue, L; Zhang, C; Zhang, X | 1 |
| Autry, AM | 1 |
| Dimitriadis, E; Gao, Y; Greenall, SA; Horne, AW; Johns, TG; Kaitu'u-Lino, T; Menkhorst, E; Nilsson, UW; Saglam, B; Tong, S; Whitehead, C; Wilmann, T | 1 |
| Critchley, HOD; Duncan, WC; Horne, AW; Johns, TG; Nilsson, UW; Skubisz, MM; Tong, S; Wallace, EM | 1 |
| Bahra, M; Ehemann, V; Endris, V; Goeppert, B; Kamphues, C; Klauschen, F; Lorenz, K; Muckenhuber, A; Neuhaus, P; Sinn, B; Stenzinger, A; Warth, A; Weichert, W | 1 |
| Bhosle, J; Hartley, JA; Hochhauser, D; Kiakos, K; Makris, A; Porter, AC; Wu, J | 1 |
| Day, RO; Kerridge, IH; Lewis, JR; Lipworth, WL | 1 |
| Anandappa, G; Turner, NC | 1 |
| Ashinuma, H; Chiba, T; Iwama, A; Kitamura, A; Kitazono, S; Kurosu, K; Saito-Kitazono, M; Sakaida, E; Sakao, S; Sekine, I; Tada, Y; Takiguchi, Y; Tanabe, N; Tatsumi, K; Yokosuka, O | 1 |
| Baskaran, S; Forsberg Nilsson, K; Gerlee, P; Häggblad, M; Hansson, C; Karlsson-Lindahl, L; Kling, T; Lundgren, B; Martens, U; Monsefi, N; Nelander, S; Olsson, M; Schmidt, L; Uhrbom, L; Westermark, B | 1 |
| Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X | 1 |
| Chen, S; Hao, X; Li, J; Lin, L; Shi, Y; Wang, B; Zhang, X | 1 |
| Ding, JF; Zhong, DF | 1 |
| Döme, B; Fehniger, TE; Jansson, B; Laurell, T; Marko-Varga, G; Rezeli, M; Végvári, Á; Welinder, C | 1 |
| Li, YQ; Sun, H; Xue, D | 1 |
| Abrams, JS; Conley, BA; Freidlin, B; Korn, EL; McShane, LM; Polley, MY | 1 |
| Chen, CY; Chen, HJ; Chiu, HC; Huang, YC; Huang, YJ; Jian, YJ; Jian, YT; Ko, JC; Lin, YW; Syu, JJ; Tseng, SC; Wo, TY | 1 |
| Cohen, PR; Jalalat, SZ | 1 |
| Bally, MB; Donohue, E; Dragowska, WH; Gelmon, KA; Gorski, SM; Kapanen, AI; Qadir, MA; Rawji, JS; Roberge, M; Wang, JC; Warburton, C; Weppler, SA; Wong, LY | 1 |
| Lin, J; Pan, W; Shi, H; Wu, H; Yu, H; Zhu, J | 1 |
| Han, SY; Li, PP; Zhao, HY; Zhou, F; Zhou, N | 1 |
| Alfieri, RR; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; Galvani, E; Gatti, R; Giovannetti, E; La Monica, S; Petronini, PG; Saccani, F; Sirangelo, R; Tiseo, M | 1 |
| Cass, CE; Damaraju, VL; Kuzma, M; Mowles, D; Ryan, AJ; Sawyer, MB; Scriver, T | 1 |
| Mehta, A; Tripathy, D | 1 |
| Beau-Faller, M; Bièche, I; Blons, H; Bringuier, PP; Cadranel, J; Cayre, A; de Cremoux, P; de Fraipont, F; Denis, MG; Domerg, C; Escande, F; Gajda, D; Legrain, M; Lizard, S; Morin, F; Mosser, J; Nanni-Metellus, I; Olschwang, S; Piard, F; Pignon, JP; Pretet, JL; Richard, N; Rouquette, I; Saulnier, P; Solassol, J; Voegeli, AC; Zalcman, G | 1 |
| Dosaka-Akita, H; Hirata, K; Kuge, Y; Shiga, T; Takei, T; Takeuchi, S; Tamaki, N; Zhao, S; Zhao, Y | 1 |
| Bosdet, I; Ho, C; Ionescu, D; Karsan, A; Laskin, JJ; Mariano, C; Melosky, B; Murray, N; Sun, S; Zhai, Y | 1 |
| Li, X; Shen, Y; Tang, D; Wang, M; Wang, Y; Yao, R; Yao, Y; Zhang, H | 1 |
| Beijnen, JH; Durmus, S; Schellens, JH; Schinkel, AH; Sparidans, RW | 1 |
| Chen, CH; Chen, JY; Chen, WS; Chen, YJ; Chien, PH; Hsia, TC; Huang, WC; Liu, SH; Shih, CY; Tu, CY; Wei, YL; Yeh, MH; Yu, MC; Yu, YL | 1 |
| Hishima, T; Hosomi, Y; Kato, K; Nagamata, M; Okamura, T; Okuma, Y; Sekihara, K; Yamada, Y | 1 |
| Koyama, N; Uchida, Y | 1 |
| Azuma, K; Hoshino, T; Itoh, K; Kasama-Kawaguchi, Y; Kim, J; Matsueda, S; Muta, E; Nishio, K; Sasada, T; Sugawara, S; Yamada, T; Yamashita, T; Yamashita, Y; Zhang, GL | 1 |
| Herr, MJ; Jameson, JF; Jennings, LK; Mabry, SE | 1 |
| Fang, X; Gu, P; Luo, BF; Ren, SX; Wu, YJ; Yi, XH; Zeng, Y; Zhao, YM; Zhou, CC; Zhu, XY | 1 |
| Song, Z; Zhang, Y | 1 |
| Gemma, A; Kitamura, K; Kubota, K; Matsuda, K; Minegishi, Y; Miyanaga, A; Mizutani, H; Noro, R; Okano, T; Seike, M | 1 |
| Ciuleanu, T; Cobo, M; Douillard, JY; McCormack, R; Milenkova, T; Ostoros, G; Webster, A | 1 |
| Han, JY; Kim, H; Kim, HT; Lee, GK; Lee, YJ; Yun, T | 1 |
| Chen, Q; Li, Q; Liu, J; Qian, X; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, R; Xu, T; Zheng, J | 1 |
| Chang, Q; Chen, B; Chen, F; Kowluru, A; Li, L; Lu, Y; Qiu, P; Sun, J; Thakur, C; Wu, K | 1 |
| Lee, VH; Lee, VW; Schwander, B | 1 |
| Gu, YF; Mo, ML; Song, P; Su, D; Zhang, F; Zhang, H; Zhang, SC | 1 |
| Brame, LS; Cao, A; Fang, YT; Fung, KM; Humphreys, MR; Kropp, BP; Lin, HK; Shih, PT; Wu, W; Yang, Q | 1 |
| Ito, S; Itoh, K; Nishimura, Y; Takiguchi, S | 2 |
| Gu, QH; Hu, CP; Li, YY; Lu, RL; Wu, L; Yang, HP | 1 |
| Ambudkar, SV; Bakhsheshian, J; Chang, KE; Gottesman, MM; Hall, MD; Shukla, S; Simpson, RM; Wei, BR | 1 |
| Saya, H; Yoshida, GJ | 1 |
| Jang, SH; Jang, TW; Kim, HJ; Kim, HR; Kim, KS; Kim, SY; Kim, YC; Lee, GH; Lee, JC; Lee, JE; Lee, KY; Lee, MK; Lee, SY; Oh, IJ; Ryu, JS; Shin, KC; Son, JW | 1 |
| Deng, HB; Gong, YB; Kang, XH; Wang, LF; Wang, ZQ; Wu, J; Xu, ZY; Zhao, XZ | 1 |
| Chen, M; Chen, X; Fan, L; Fei, K; Gao, G; Garfield, D; He, Y; Kuang, P; Li, B; Li, X; Ren, S; Schmit-Bindert, G; Su, C; Wang, Y; Zhou, C; Zhou, S | 1 |
| Liu, Z; Shi, L; Tang, J; Tong, L | 1 |
| Baxter, RC; de Silva, HC; Lin, MZ; Martin, JL; Scott, CD | 1 |
| Liang, YC; Liu, Q; Liu, T; Shi, LL; Wu, G; Wu, HG; Xue, HJ | 1 |
| Fu, S; Jiang, L; Lin, YB; Long, H; Shao, JY; Su, XD; Wang, F; Wang, JF; Zhang, SL; Zhang, YG; Zhao, ZR | 1 |
| Choi, CM; Choi, YJ; Kim, HR; Kim, SY; Lee, JC; Park, GM; Rho, JK; So, GS | 1 |
| Arcila, ME; Chaft, JE; Cohen, DW; Costa, DB; Eck, MJ; Hanna, M; Huberman, MS; Ishioka, K; Kobayashi, SS; Lathan, CS; Lucena-Araujo, AR; Meyerson, M; Moran, T; Nakayama, S; Oxnard, GR; Park, E; Riely, GJ; Sequist, LV; Sng, NJ; Soo, RA; Yamaguchi, N; Yasuda, H; Yeo, WL; Yun, CH | 1 |
| Chan, V; Fukuoka, M; Kurnianda, J; McCormack, R; McWalter, G; Mok, TS; Nakagawa, K; Saijo, N; Wu, YL; Yang, JC | 1 |
| Choi, CM; Chun, SM; Jang, SJ; Ji, W; Kim, SW; Kim, WS; Lee, DH; Lee, JC; Lee, JS; Park, YS; Rho, JK | 1 |
| Brambilla, E; Busser, B; Cadranel, J; Coll, JL; Hurbin, A; Jeannot, V; Robin, B; Wislez, M | 1 |
| Kwon, MJ; Lee, KB; Lee, MY; Lee, SH; Lee, YM; Nguyen, MP; Park, GH | 1 |
| Borczuk, AC; Siegelin, MD | 1 |
| Homicsko, K; Hottinger, AF; Stupp, R | 1 |
| Dandekar, G; Dandekar, T; Fecher, D; Göttlich, C; Nietzer, SL; Stratmann, AT; Walles, H; Walles, T; Wangorsch, G | 1 |
| Bria, E; Garassino, M; Massari, F; Pelosi, G; Peretti, U; Pilotto, S; Tortora, G | 1 |
| Chen, CH; Chen, LC; Chen, YJ; Chien, PH; Chien, YF; Hsieh, YL; Hsu, SC; Huang, WC; Hung, CM; Lin, YM; Tu, CY | 1 |
| Bobilev, D; Peleg, R; Priel, E | 1 |
| Bai, Q; Chen, X; Du, Y; Hou, J; Nan, J; Wang, Q; Wang, Y; Yang, J; Zhang, J; Zhang, X; Zhu, N | 1 |
| An, J; Gao, H; Li, J; Li, X; Liu, X; Liu, Y; Qin, H; Qu, L; Tang, C; Wang, W; Yang, S | 1 |
| Baresic, T; Basso, SM; Del Conte, A; Lumachi, F; Minatel, E; Schinella, D | 1 |
| Antoine, M; Cadranel, J; Duruisseaux, M; Lacave, R; Lavole, A; Leprieur, EG; Rabbe, N; Rozensztajn, N; Ruppert, AM; Vieira, T; Wislez, M | 1 |
| Fiegl, M; Hilbe, W; Manzl, C; Pircher, A; Pirker, R; Popper, H | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Narita, C; Niioka, T; Sato, K | 1 |
| Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Ishii, Y; Isobe, H; Kobayashi, K; Maemondo, M; Minegishi, Y; Sugawara, S; Watanabe, S; Yoshizawa, H | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 2 |
| Hida, T; Horio, Y; Kondo, C; Park, J; Shimizu, J; Yoshida, K | 1 |
| Harada, D; Hotta, K; Ichihara, E; Kiura, K; Ochi, N; Tabata, M; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Ju, L; Zhou, C | 1 |
| Fukihara, J; Hasegawa, Y; Kataoka, K; Kimura, T; Kondoh, Y; Matsuda, T; Taniguchi, H; Watanabe, N; Yokoyama, T | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Nakagawa, H; Nakamura, Y; Sano, K; Suzuki, T; Yoshida, H | 1 |
| Hasegawa, T; Higashino, H; Kataoka, M; Masaoka, Y; Matsui, R; Sakuma, S; Yamamoto, M; Yamashita, S | 1 |
| Dong, X; He, C; Jiang, H; Jiang, X; Ma, L; Pan, S; Qiao, H; Sun, X; Tan, G; Wei, Z; Zhai, B; Zhao, D | 1 |
| Hashimoto, M; Iwakami, S; Kato, M; Kobayashi, I; Koizumi, F; Minakata, K; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Shimada, N; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Akashi, A; Funaki, S; Kadota, Y; Nakagiri, T; Okumura, M; Shiono, H; Takeuchi, Y | 1 |
| Agelaki, S; Georgoulias, V; Kallergi, G; Kalykaki, A; Mavroudis, D; Xyrafas, A | 1 |
| Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P | 1 |
| Azuma, K; Hattori, S; Hoshino, T; Itoh, K; Kawahara, A; Komatsu, N; Matsueda, S; Sasada, T | 1 |
| Bogatyreva, L; Braun, JA; Faller, G; Fichter, CD; Geddert, H; Gudernatsch, V; Hauschke, D; Klimstra, D; Lassmann, S; Schöpflin, A; Tang, L; Timme, S; Werner, M | 1 |
| Hu, J; Niu, M; Wu, S; Xiaoe, Z; Xu, H; Yang, Y; Zhang, J; Zhang, Y | 1 |
| Ando, M; Asami, K; Atagi, S; Ishii, M; Kanazu, M; Kawaguchi, T; Kubo, A; Kusunoki, Y; Maruyama, K; Matsuda, Y; Minomo, S; Ogawa, Y; Takada, M; Uehira, K | 1 |
| Chen, M; Huang, H; Wang, C; Xie, J; Yang, A; Yin, Q; Zhang, B | 1 |
| Amrein, PC; Berchuck, J; Deangelo, DJ; Galinsky, I; Golub, T; Neuberg, D; Sirulnik, LA; Stegmaier, K; Stone, RM; Wadleigh, M | 1 |
| Song, T; Wu, SX; Yu, W | 1 |
| Dinglin, X; Fang, W; Hou, X; Hu, Z; Huang, P; Huang, Y; Liang, W; Ma, Y; Qin, T; Tian, Y; Wu, X; Xue, C; Yan, Y; Yang, Y; Zhang, J; Zhang, L; Zhao, H; Zhao, Y; Zhou, T | 1 |
| Fu, X; Giuliano, M; Klinowska, T; Morrison, G; Nanda, S; Osborne, CK; Rimawi, MF; Schiff, R; Shea, M; Wang, T | 1 |
| Funakoshi, Y; Maeda, H; Takeuchi, Y | 1 |
| Ge, H; Guan, L; Liu, X; Sun, M; Sun, X; Xiao, Q; Zhang, H; Zhang, Y | 1 |
| Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O | 1 |
| Barinow-Wojewódzki, A; Krawczyk, P; Kucharczyk, T; Milanowski, J; Milecki, P; Powrózek, T; Ramlau, R; Sura, S; Szumiło, J; Szyszka-Barth, K; Walczyna, B; Wojas-Krawczyk, K | 1 |
| Deng, Y; Fan, X; Fu, X; Gao, Y; Li, W; Ping, W | 2 |
| Hirata, M; Kagawa, S; Kanai, Y; Kawai, K; Naka, S; Nishii, R; Ohmomo, Y; Yoshimoto, M | 1 |
| Fang, Q; Li, N; Ou, W; Sun, HB; Wang, BX; Wang, SY; Ye, X; Zhang, L; Zhang, SL | 1 |
| Blumenschein, GR; El-Naggar, AK; Glisson, BS; Gonzalez-Angulo, AM; Jakob, JA; Kies, MS; Kupferman, ME; Lee, JJ; Liu, DD | 1 |
| Chen, G; Li, J; Lu, Q; Peng, L; Tan, C; Wan, X; Wang, Y; Yi, L; Zeng, X | 1 |
| Liu, J; Sun, W; Zhou, YM | 1 |
| Bokobza, SM; Devery, AM; Jiang, Y; Ryan, AJ; Weber, AM | 2 |
| Ding, K; Han, C; Huang, Z; Ji, H; Lai, Y; Peng, S; Wan, L; Zhang, Y | 1 |
| Katanasaka, Y; Kitamura, Y; Kodera, Y; Koizumi, F; Tamura, T; Yunokawa, M | 1 |
| Chi, HS; Cho, YU; Jang, S; Kim, SW; Kim, YJ; Park, CJ; Park, SH | 1 |
| Fukuoka, M; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Acharjee, A; Basu, S; Honrao, P; Rastogi, H; Ravindran, S; Surve, P | 1 |
| Bae, MK; Cho, BC; Kang, DR; Kim, EY; Kim, HR; Kim, JH; Kim, MH; Lee, CY; Lee, JS | 1 |
| Liu, D; Yang, Y; Zhao, S | 1 |
| Hwang, KE; Jeong, ET; Kim, BR; Kim, HR; Kim, YS; Kwon, SJ; Park, DS; Yoon, KH | 1 |
| Hao, X; Ji, L; Li, X; Lin, Y; Lü, S; Luo, Q; Wang, F; Wang, X; Yang, L; Zheng, W | 1 |
| Kato, M; Kobayashi, I; Murakami, A; Nurwidya, F; Shimada, N; Shukuya, T; Tajima, K; Takahashi, F; Takahashi, K | 1 |
| Jia, B; Liu, H; Liu, Z; Ma, T; Shi, J; Sun, X; Wang, F; Zhao, H | 1 |
| Chen, H; Han, R; He, Y; Jiang, J; Li, K; Li, L; Lin, C; Liu, H; Sun, F; Wang, Y; Xiao, H; Yang, Z | 1 |
| Altimari, A; Di Tullio, P; Fiorentino, M; Giunchi, F; Gruppioni, E; Martorana, G; Pinto, C | 1 |
| Jo, U; Kim, YH; Park, JK; Park, KH; Sung, JS; Whang, YM; Won, NH | 1 |
| Fan, XX; He, JX; Leung, EL; Li, N; Liu, L; Wu, JL; Zhou, YL | 1 |
| Lin, CC; Tsai, CM; Wang, SY | 1 |
| Pan, YY; Wu, M; Yuan, Y; Zhang, Y | 2 |
| Chen, X; Fan, L; Fei, K; Gao, G; He, Y; Li, A; Li, J; Li, S; Li, W; Li, X; Ren, S; Schmid-Bindert, G; Shi, J; Zhao, C; Zhou, C | 1 |
| Iwase, T; Kishimoto, Y; Mori, H; Yano, T | 1 |
| Ebina, M; Iida, S; Ise, K; Iwabuchi, E; Kondo, T; Maemondo, M; Miki, Y; Mori, K; Narumi, S; Nihira, K; Ono, K; Saito, M; Sasano, H; Sato, I; Yamada-Okabe, H | 1 |
| Adejumo, O; Allak, A; Hubbard, MA; Jameson, MJ; Khalil, AA; Maxwell, AK; Mendez, RE; Schoeff, SS; VanKoevering, KK | 1 |
| Horai, T; Horiike, A; Kudo, K; Murakami, H; Naito, T; Nishio, M; Ohyanagi, F; Ono, A; Tanaka, H; Yamamoto, N; Yanagitani, N | 1 |
| Chang, YW; Chen, HA; Chen, JC; Chiu, CF; Su, JL; Su, YH; Tseng, CF; Yu, YH | 1 |
| Qi, WX; Shen, Z; Sun, YJ; Yao, Y | 1 |
| Fang, Q; Jiang, Y; Yuan, Q | 1 |
| Choi, JW; Jeong, Y; Jung, SH; Kim, HW; Kim, J; Park, KH; Wairagu, PM; Yeh, BI; Yong, SJ | 1 |
| Ahn, JS; Ahn, MJ; Lee, JY; Lim, SH; Park, K; Sun, JM | 1 |
| Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Karaseva, NA; Kulikova, YE; Lozhkina, AM; Mitiushkina, NV; Orlov, SV; Tiurin, VI; Togo, AV; Volodina, LN | 1 |
| Han, JY; Hwang, JA; Kim, HT; Kim, JH; Kim, SH; Lee, GK; Lee, JS; Lee, Y; Lee, YS; Nam, BH; Yun, T; Zhang, W | 1 |
| Ding, D; Huang, H; Jia, X; Song, J; Sun, E; Yan, H; Zhang, Z; Zhong, R | 1 |
| Fujiwara, K; Hosokawa, A; Ichiba, Y; Kajiume, S; Kiba, T; Kimoto, S; Nakano, K; Nakashima, T; Ogawa, Y; Okada, Y; Taniguchi, H | 1 |
| Berezo, JÁ; de la Cruz, V; Sanz Rubiales, A; Torres, MÁ | 1 |
| Hayakawa, Y; Kaneto, N; Kato, S; Saiki, I; Sakurai, H; Yokoyama, S | 1 |
| Chang, J; Feng, Y; Luo, Z; Peng, W; Qiao, J; Sun, S; Wang, H; Wang, J; Wu, X; Yu, H; Zhang, J | 1 |
| Hong, W; Lin, B; Mao, W; Zhang, B; Zhang, Y | 1 |
| Dziadziuszko, R; Peters, S; Zimmermann, S | 1 |
| Harada, D; Honda, Y; Ichihara, E; Kiura, K; Murakami, T; Ninomiya, T; Ochi, N; Ohashi, K; Takigawa, N; Tanimoto, M; Yasugi, M | 1 |
| Gao, M; Ge, CH; Ge, ZQ; Li, CY; Wang, XH; Yang, XM; Yu, M; Zhan, YQ; Zhang, JH | 1 |
| Chung, JH; Jheon, S; Jin, Y; Kim, H; Kim, JE; Kim, K; Lee, CT; Sun, PL; Yoo, SB | 1 |
| Wu, YL; Yan, HH; Yang, JJ; Zhang, XC; Zhao, N | 1 |
| de Castro, G; Haaland, B; Lopes, G; Tan, PS | 1 |
| Chun, KS; Hong, YS; Jang, WJ; Jeong, CH | 1 |
| Kassem, MG; Korashy, HM; Rahman, AF | 1 |
| Chiara, MD; de Santa-María, IS; Merlo, A; Secades, P; Suarez, C | 1 |
| Kuang, K; Yang, K; Yang, X | 1 |
| Duncan, WC; Horne, AW; Johns, TG; Neil, P; Skubisz, MM; Tong, S; Wallace, EM | 1 |
| Farias-Hesson, E; Finigan, JH; Heasley, LE; Kang, J; Kern, JA; Kim, J; Leach, SM; Mason, RJ; Mishra, R; Ramamoorthy, P; Singleton, KR; Tan, AC; Vasu, VT; Yoo, M | 1 |
| Chen, L; Li, Q; Liu, XD; Wu, B; Xu, HF; Zhan, YH; Zhang, HH | 1 |
| Arriola, E; Luque, A; Martínez-Avilés, L; Vollmer, I | 1 |
| Eroles, P; Lluch, A; Perez-Fidalgo, JA | 1 |
| Asada, H; Imoto, K; Ommori, R; Park, K | 1 |
| Cai, H; Chen, X; Miao, L; Wang, Y; Xia, H; Zhuang, Z | 1 |
| Ballon-Landa, E; Galen, B; Kalinowski, A; Knoff, D; Koff, JL; Lanier, LL; Min-Oo, G; Nadel, JA; Ueki, I | 1 |
| Hao, X; Hu, X; Li, J; Liu, Y; Shi, Y; Sun, Y; Wang, H; Wang, Y; Wang, Z; Zhang, X | 1 |
| Costa, DB; Gandhi, L; Gerber, DE | 1 |
| Meng, X; Sun, X; Yu, J; Zhang, J | 1 |
| Eisenstein, M | 2 |
| Chen, PJ; Huang, GB; Li, B; Lou, YF; Luo, XY; Yu, XR; Zheng, DQ; Zou, ZZ | 1 |
| Chang, CY; Chen, CJ; Chen, WY; Huang, HY; Kuan, YH; Li, JR; Ou, YC; Pan, PH; Wu, CC | 1 |
| Ding, HR; Han, SY; Li, PP; Teng, F; Zhao, W | 1 |
| Han, Y; Jiang, T; Li, Q; Shang, Y; Wang, P; Yong, X; Yu, W; Zhang, P | 1 |
| Alfieri, RR; Ampollini, L; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Frati, C; Fumarola, C; Galetti, M; La Monica, S; Lagrasta, C; Petronini, PG; Quaini, F; Saccani, F; Tiseo, M | 1 |
| Carter, RL; Grisanti, LA; Repas, AA; Talarico, JA; Tilley, DG; Yu, JE | 1 |
| Beaty, BT; Condeelis, JS; Cox, D; Eddy, RJ; Sharma, VP | 1 |
| Bianco, C; Giaccone, G; Lee, LC; Luo, J; Mitsudomi, T; Mok, T; Moon, YW; Okamoto, I; Park, KS; Pham, T; Raffeld, M; Rosell, R; Salomon, DS; Subramaniam, D; Wang, Y; Xi, L; Yatabe, Y | 1 |
| Fujimura, S; Fukaya, K; Katsumata, H; Minowa, M; Tabata, T | 1 |
| Gillissen, A; Nieber, K; Oelkrug, C; Schubert, A; Simasi, J | 2 |
| Ardizzoni, A; Artioli, F; Bersanelli, M; Lucchi, L; Tiseo, M | 1 |
| Hu, G; Liu, D; Long, G; Sun, W; Wang, J | 1 |
| Li, QX; Lu, X; Wu, HL; Yang, M; Yu, SY; Yuan, XL; Zhang, L | 1 |
| Li, H; Ma, D; Qu, Y; Wu, X; Yang, Y; Yin, Y | 1 |
| Choi, DY; Freeman, MR; Jung, JH; Kim, J; Kim, KP; Lee, JC; Lee, KY; Rho, JK; You, S | 1 |
| Ford, HE | 1 |
| Abbas, H; Blazeby, JM; Chatterjee, A; Dahle-Smith, A; Davoudianfar, M; Dutton, SJ; Falk, S; Ferry, DR; Fyfe, DW; Gamble, T; Garcia-Alonso, A; Harrison, M; Hubner, RA; Jankowski, J; Julier, P; Kerr, R; Mansoor, W; Peachey, L; Pearson, SR; Petty, RD; Thompson, J | 1 |
| Buonato, JM; Furcht, CM; Lazzara, MJ; Mathew, LK; Muñoz Rojas, AR; Simon, MC; Skuli, N | 1 |
| Ahn, MJ; Altug, S; Barraclough, H; Kang, JH; Kim, DW; Lin, CC; Mok, T; Orlando, M; Park, K; Srimuninnimit, V; Tsai, CM; Yang, JC | 1 |
| de Marinis, F; Del Signore, E; Di Maio, M; Gori, B; Passaro, A | 1 |
| He, G; Hu, M; Li, J; Xu, Q; Ye, W; Zhang, Y; Zhong, G | 1 |
| Banerji, U; Bhosle, J; de Bono, JS; O'Brien, ME; Popat, S; Puglisi, M; Stewart, A; Thavasu, P | 1 |
| Aieta, M; Gregorc, V; Lazzari, C; Lerose, R; Tartarone, A | 1 |
| Bolton, LM; Cree, IA; Glaysher, S; Johnson, P; Torrance, C | 1 |
| Casey, PJ; Go, ML; Guo, D; Lau, HY; Ramanujulu, PM; Wang, M; Wirawan, M; Yang, T | 1 |
| Hagiyama, M; Inoue, T; Ito, A; Naito, Y; Nojima, H; Okamoto, A; Okuzaki, D; Ozaki, Y; Sakurai, MA; Sasakura, T; Tabara, H; Yabuta, N | 1 |
| Bode, AM; Chen, H; Dong, Z; Jeong, CH; Jung, SK; Kim, JE; Lee, HJ; Lee, KW; Lee, MH; Lee, SY; Lim, DY; Lim, TG | 1 |
| Dowsett, M; Gao, Q; Garcia-Murillas, I; López-Knowles, E; Martin, LA; Segal, CV; Smith, I; Turner, NC | 1 |
| Bao, Z; Chen, X; Liu, ZF; Zhang, P; Zhao, J; Zhou, JY | 1 |
| Deluca, KA; Jaskoll, T; Melnick, M | 1 |
| Deng, Q; He, J; Liu, X; Xu, X; Yang, H; Yang, X; Zhang, Y; Zhao, M | 1 |
| Schnellmann, RG; Smith, JA; Stallons, LJ | 1 |
| Escudero-Vilaplana, V; Gonzalez-Haba, E; Ribed, A; Sanjurjo, M | 1 |
| Chung, DH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH; Sim, SH | 1 |
| Li, M; Lv, L; Lv, S; Lv, W; Song, B; Wang, J; Wei, H; Zhao, B | 1 |
| Balázs, G; Kovalszky, I; Losonczy, G; Moldvay, J; Pápay, J; Puskás, R | 1 |
| Benaich, N; Huang, Y; Kwok, HF; Murphy, G; Tape, C | 1 |
| Fujita, M; Hara, M; Ito, Y; Kanemitsu, Y; Kondo, E; Nakanishi, H; Nakata, S; Tanaka, H; Yatabe, Y | 1 |
| Asakuma, M; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Masuda, N; Otani, S; Sasaki, J | 1 |
| Cao, R; Li, ZS; Shao, JH; Tang, YT; Xiao, N; Zhao, XH; Zou, JM | 1 |
| Chen, Q; Jiang, B; Li, Q; Liu, J; Pei, D; Qian, Y; Shen, H; Shi, Z; Shu, Y; Wang, L; Wang, R; Xu, T; Zheng, J; Zhu, F | 1 |
| Dohrmann, T; Drenckhan, A; Dupree, A; Grob, T; Gros, SJ; Izbicki, JR; Mann, O | 1 |
| Ando, M; Hasegawa, Y; Kimura, T; Kojima, E; Nomura, F; Ogasawara, T; Saito, H; Shindoh, J; Sugino, Y; Suzuki, R; Takahashi, K; Yamamoto, M; Yoshida, N | 1 |
| Ali, SK; Chakraborty, C; Doss, GP; NagaSundaram, N; Rajith, B; Zhu, H | 1 |
| Chen, HW; Chen, WJ; Ho, CC; Ho, CL; Hsieh, WY; Lee, JY; Li, LH; Li, PR; Wang, CC; Wu, P; Yang, SM; Yen, MY | 1 |
| Hayashi, H; Nakagawa, K; Nishio, K; Togashi, Y | 1 |
| Bae, MK; Hong, YS; Jang, WJ; Jeong, CH; Jeong, JW; Joo, SH; Jung, SK; Kang, JS; Kundu, JK; Park, GH | 1 |
| Ciuleanu, T; Cobo, M; Cole, R; Dearden, S; Douillard, JY; McCormack, R; McWalter, G; Milenkova, T; Ostoros, G; Walker, J; Webster, A | 1 |
| Bode, AM; Chen, H; Dong, Z; Li, H; Li, W; Lim, DY; Liu, K; Ma, WY; Oi, N; Peng, C; Reddy, K; Sheng, Y; Yao, K; Zhu, F | 1 |
| Bose, S; Chen, J; Cui, X; Cui, Y; Giuliano, AE; Han, B; Jin, Y; Karlan, BY; Orsulic, S; Wiedemeyer, R; Zhang, X | 1 |
| Boerner, JL; Bollig-Fischer, A; Madden, JM; Mattingly, RR; Mueller, KL; Stemmer, P | 1 |
| Jiao, SC; Peng, L; Song, ZG | 1 |
| Ahn, HK; Cho, EK; Hong, J; Kim, YS; Lee, HY; Lee, JH; Park, I; Park, J; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Hata, A; Imai, Y; Katakami, N; Masago, K; Yatabe, Y | 1 |
| Asakuma, M; Harada, S; Hiyoshi, Y; Igawa, S; Ishihara, M; Kasajima, M; Katono, K; Kimura, M; Kusuhara, S; Masuda, N; Niwa, H; Otani, S; Sasaki, J | 1 |
| Han, J; Jeon, M; Jung, T; Kil, WH; Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Geng, Z; Han, X; Hu, L; Li, Z; Qin, X; Wang, Z; Xiao, X; Zeng, C | 1 |
| Bi, F; Chen, L; Chen, Q; Ge, X; Leng, W; Pang, X; Tang, Q; Wu, YP; Xia, H; Yuan, D; Zhang, Y | 1 |
| Kim, EO; Kim, J; Kim, JH; Kim, SH; Lee, D; Lee, H; Lee, J; Yun, M | 1 |
| Luo, J; Shen, L; Zheng, D | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Chai, S; Ke, CQ; Lin, G; Tang, C; To, KK; Wang, YZ; Yao, S; Ye, Y; Yin, C | 1 |
| Cai, W; Cheng, K; Li, T; Shao, T; Zhao, B; Zheng, Y | 1 |
| Bai, C; Chen, S; Ning, X; Sun, Z; Wang, Y; Yang, XD; Ying, H | 1 |
| Cho, KH; Choo, J; Ganbold, EO; Joo, SW; Kim, D; Lam, AT; Lee, K; Lee, SY; Singh, DK; Yoon, J | 1 |
| Fang, W; Hong, S; Hu, Z; Kang, S; Liang, W; Qin, T; Sheng, J; Wu, X; Yan, Y; Zhang, L; Zhang, Y | 1 |
| Burke, NS; Dassanayake, S; Mealey, KL | 1 |
| Ahn, SH; Jeong, EH; Kim, CH; Kim, HR; Kim, SY; Lee, TG | 1 |
| Fischer, JR; Grohé, C; Gütz, S; Kimmich, M; Laack, E; Märten, A; Schneider, CP; Schuler, M; Thomas, M | 1 |
| Horne, AW; Skubisz, MM; Tong, S | 1 |
| Beckett, AJ; Clague, MJ; Coulson, JM; Prior, IA; Tang, WYY; Urbé, S | 1 |
| Groen, HJ; Grünberg, K; Heideman, DA; Kuiper, JL; Smit, EF; Würdinger, T | 1 |
| Ahn, HJ; Nam, HW; Yang, Z | 1 |
| Brennan, RC; Furman, W; Mao, S; McGregor, LM; Santana, V; Stewart, CF; Turner, DC; Wu, J | 1 |
| Banerji, V; Dielschneider, RF; Gibson, SB; Johnston, JB; Li, H; Marshall, AJ; Noh, E; Xiao, W; Yoon, JY | 1 |
| Chen, HJ; Chen, JH; Chen, ZH; Cheng, Y; Feng, WN; Liu, YP; Song, Y; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Zhang, L; Zhang, XC; Zhao, MF; Zhong, WZ; Zhou, Q | 1 |
| Costa, DB; Jorge, SE; Kobayashi, SS | 1 |
| Asbagh, LA; Baietti, MF; Budinska, E; De Vriendt, V; Hoe, N; Imjeti, NS; Jacobs, B; Sablina, A; Singh, S; Steklov, M; Tejpar, S; Vazquez, I; Vecchione, L; Zimmermann, P | 1 |
| Chao, JI; Chen, C; Hsieh, YH; Sulake, RS; Wang, SP; Yin, KH | 1 |
| Chen, M; Gao, B; Qin, X; Wang, J; Wang, Y; Zhang, Z | 1 |
| Hong, SS; Jang, WJ; Jeong, CH; Jeong, GS; Park, B | 1 |
| Chen, S; Hao, Y; Li, B; Li, L; Liu, C; Ning, F; Wang, F; Yu, Z | 1 |
| Fu, S; Guo, XM; Qi, WX; Zhang, Q | 1 |
| Hohenforst-Schmidt, W; Huang, H; Kakolyris, S; Kioumis, I; Lampaki, S; Li, Q; Organtzis, J; Papaiwannou, A; Petridis, D; Pitsiou, G; Porpodis, K; Syrigos, K; Tsiouda, T; Turner, JF; Zarogoulidis, K; Zarogoulidis, P | 1 |
| Cui, A; Hou, J; Hua, H; Jiang, Y; Luo, T; Song, P | 1 |
| Chu, NM; Feng, AC; Hsu, LH; Kao, SH; Liu, KJ; Tsai, MF; Wu, CR | 1 |
| Bi, F; Ge, X; Huang, M; Wang, Y; Zheng, L | 1 |
| Bai, F; Han, R; Jiang, F; Liu, Y; Pang, W; Shen, H; Tian, X; Wang, J; Xing, L; Yan, X; Zhang, X | 1 |
| Akamatsu, H; Endo, M; Hisamatsu, Y; Imai, H; Kenmotsu, H; Ko, R; Mori, K; Murakami, H; Naito, T; Nakashima, K; Ohde, Y; Omori, S; Ono, A; Oyakawa, T; Shukuya, T; Taira, T; Takahashi, K; Takahashi, T; Wakuda, K | 1 |
| Ali, SA; Burotto, M; O'Sullivan Coyne, G | 1 |
| Cavenee, WK; Furnari, FB; Gonias, SL; Hu, J; Muller, KA; VandenBerg, SR | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Ikemura, S; Ishioka, K; Kanai, Y; Naoki, K; Ohgino, K; Sato, T; Soejima, K; Terai, H; Yasuda, H | 1 |
| Cui, W; Feng, B; Li, H; Liu, L; Liu, M; Shi, Y; Su, C; Su, R; Zhao, L | 1 |
| Chen, XQ; Lin, GN; Liu, DY; Liu, PP; Peng, JW; Xiao, JJ | 1 |
| Gao, HM; Gao, Z; Jia, YF; Tan, W; Tian, YL; Wang, YS; Zhang, MX; Zhang, N; Zhang, RX; Zhao, JQ | 1 |
| Perek, N; Prevot, N; Puech, C | 1 |
| Bubendorf, L; Erne, P; Frachet, A; Frismantiene, A; Kyriakakis, E; Maslova, K; Pfaff, D; Philippova, M; Resink, TJ; Ruiz, C; Vlajnic, T | 1 |
| Dastgheib, S; Kannan, N; Katiyar, S; Kochut, K; McSkimming, DI; Narayanan, A; Talevich, E; Taylor, SS | 1 |
| Goto, K; Hashimoto, H; Iida, S; Ishii, G; Matsumoto, S; Nagai, K; Neri, S; Niho, S; Niimi, A; Ochiai, A; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Hu, C; Li, W; Ma, JA; Ren, J; Wei, Y; Zhou, D; Zhou, Y; Zou, F; Zou, W | 1 |
| Gan, B; Huang, Y; Liao, R; Lou, N; Wu, Y; Xu, C; Yan, H; Yang, J; Yang, X; Yang, Y; Zhou, Q | 1 |
| Li, ZX; Qiu, XS; Qu, LY; Wang, EH; Wen, H; Xu, K; Zhong, HS | 1 |
| Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK | 1 |
| Choi, DY; Jung, JH; Kim, J; Kim, KP; Lee, JW; Lee, KY; Lee, MY; You, S | 1 |
| Du, YJ; Hu, YM; Li, J; Qian, H; Shi, WL; Wu, Y; Zhu, LR | 1 |
| Chen, LK; Dinglin, XX; Hou, X; Huang, JJ; Ma, SX; Qin, T; Wang, Z; Zeng, YD | 1 |
| Enoki, H; Katahira, K; Teraoka, A; Tsuchiya, Y; Yoshikawa, T | 1 |
| Jenks, S | 1 |
| Cavenee, WK; Chen, CC; Furnari, FB; Gomez, GG; Gonias, SL; Hu, J; Mischel, PS; Pizzo, D; Taylor, T; Thorne, AH; VandenBerg, SR; Villa, GR; Wykosky, J | 1 |
| Gao, Z; Gu, Y; Guo, L; Guo, W; Hong, S; Shen, Y; Sun, Y; Wu, X; Xu, Q | 1 |
| Guo, R; Huang, X; Shu, Y; Wu, H; Xiang, C; Yin, Y; Yu, Q; Yu, S; Zhang, B | 1 |
| Takeuchi, S; Yano, S | 1 |
| Deng, H; Long, SQ; Pan, ZQ; Wu, WY; Yang, XB | 1 |
| Cheng, W; Hu, Y; Peng, P; Qiu, N; Sheng, R; Yuan, Y | 1 |
| Eibl-Lindner, K; Kampik, A; Klingenstein, A; Kook, D; Mayer, WJ; Siedlecki, J; Wertheimer, C; Wolf, A | 1 |
| Frank, M; Golpon, H; Lange, A; Prenzler, A; von der Schulenburg, JM; Welte, T | 1 |
| Apte, RN; Kogan-Zviagin, I; Peleg, R; Priel, E; Romzova, M | 1 |
| Chen, B; Li, B; Xie, B; Zeng, Y; Zhang, W; Zheng, J; Zhou, J | 1 |
| He, Z; Li, J; Li, X; Lin, B; Tang, X; Zhou, K | 1 |
| Li, M; Lv, S; Lv, WP; Song, B; Tian, LM; Wang, J; Wei, H; Zhao, BX | 1 |
| Carter, RL; Gold, JI; Grisanti, LA; Koch, WJ; Repas, AA; Talarico, JA; Tilley, DG | 1 |
| Choung, S; Jeong, JW; Joung, KH; Kim, HJ; Kim, JM; Kim, KS; Ku, BJ; Lee, JC; Lee, JH; Park, BK; Rhee, SD | 1 |
| Choi, CM; Choi, YJ; Chun, YJ; Kim, CH; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS; Song, JS | 1 |
| Duan, J; Fan, J; Fan, S; Li, X; Pan, Y; Wang, Y; Xiaokaiti, Y; Yang, H; Yuan, L | 1 |
| Sheng, Z; Zhang, Y | 1 |
| Liu, Q; Liu, Z; Song, H; Wang, L; Wang, X; Yu, Q; Yu, Z | 1 |
| Cai, Z; Yang, X; Zhang, L; Zhao, B | 1 |
| Díaz, L; Esparza-López, J; García-Becerra, R; García-Quiroz, J; González-González, ME; Ibarra-Sánchez, MJ; Larrea, F; Martínez-Reza, I; Prado-Garcia, H; Segovia-Mendoza, M | 1 |
| Aokage, K; Hishida, T; Nagai, K; Tsuboi, M; Yoshida, J | 1 |
| Boeck, S; Bruns, CJ; Camaj, P; Gamba, S; Giessen, C; Haertl, C; Heinemann, V; Laubender, RP; Modest, DP; Stintzing, S; Wang, Y; Zhao, Y | 1 |
| Ahn, MJ; Campbell, AK; Cho, BC; Gernhardt, D; Giri, N; Heo, DS; Kim, DW; Lee, SY; Letrent, SP; O'Connell, J; Park, K; Taylor, I; Zhang, H | 1 |
| Koeffler, HP; Leong, G; Madan, V; Mori, S; Sudo, M; Yang, H | 1 |
| Bellizzi, A; Cardone, RA; Forciniti, S; Greco, MR; Paradiso, A; Reshkin, SJ; Rubino, R; Zeeberg, K | 1 |
| Nakamoto, Y; Nakatsura, T; Ofuji, K; Saito, K; Shimomura, M; Tada, Y; Yoshikawa, T; Yoshimura, M | 1 |
| Hua, X; Jin, J; Katona, BW; Liu, Y; Ma, A | 1 |
| Cheng, Y; Fan, Y; Han, B; Huang, C; Liu, X; Liu, Y; Lu, S; Ma, S; Song, X; Wang, J; Wang, M; Yang, S; Zhang, L; Zhang, S; Zhao, H; Zhou, C | 1 |
| Han, JY; Hwang, KH; Kim, HT; Kim, JY; Lee, GK; Lee, SH; Lee, YJ; Yun, T | 1 |
| Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Sato, K | 1 |
| Chou, YH; Hsieh, MS; Hua, SF; Jhuang, JY | 1 |
| Jonstrup, SP; Lindahl, KH; Loeschke, S; Olsen, KE; Sørensen, FB | 1 |
| He, C; He, J; Wei, S; Xie, M | 1 |
| Jensen, RT; Moody, TW; Nakamura, T; Nuche-Berenguer, B | 1 |
| Igishi, T; Izumi, H; Kodani, M; Kurai, J; Makino, H; Matsumoto, S; Nakazaki, H; Nirodi, CS; Nishii-Ito, S; Sakamoto, T; Shimizu, E; Takata, M; Takeda, K; Tanaka, N; Touge, H; Ueda, Y; Yanai, M | 1 |
| Anderson, KS; Apetri, M; Kim, Y; Luo, B; Settleman, JE | 1 |
| Chang, H; Chang, WC; Ho, CL; Hsu, HH; Hsu, YC; Huang, TW; Ko, KH; Tung, HJ; Wu, YC | 1 |
| Chen, Y; Deng, M; Liu, D; Wang, J; Zhang, L | 1 |
| Chu, JH; Cui, SX; Qu, XJ; Song, ZY; Zhang, YS | 1 |
| Chang, YL; Chao, SW; Chen, CC; Huang, WJ; Lin, YC; Shih, JY | 1 |
| Anderson, RA; Sun, Y; Tan, X; Thapa, N | 1 |
| Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Kobayashi, K; Maemondo, M; Minegishi, Y; Morikawa, N; Nukiwa, T; Oizumi, S; Okinaga, S; Sugawara, S | 1 |
| Ang, KK; Chang, SS; Chang, WC; Chen, CH; Cheng, CC; Hsu, MC; Hung, MC; Lan, L; Lavin, M; Lee, HJ; Liao, HW; Lin, SY; Nakajima, S; Peng, G; Wang, YN; Wei, L | 1 |
| Fang, H; Lin, RY; Sun, MX; Tian, Y; Wang, Q; Wang, XY; Yu, JL; Zhao, YL | 1 |
| Asano, H; Furukawa, M; Hashida, S; Kanazawa, S; Maki, Y; Miyoshi, S; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Yamamoto, H | 1 |
| Liao, BC; Lin, CC; Yang, JC | 1 |
| Atagi, S; Hirashima, T; Kurata, K; Minomo, S; Nakatani, T; Okamoto, N; Okishio, K; Omachi, N; Saijo, N; Shiroyama, T; Suzuki, H; Takeuchi, N; Tamiya, A; Tamiya, M; Tsuji, T | 1 |
| Hara, A; Iwama, T; Kunisada, T; Park, DM; Soeda, A; Yoshimura, S | 1 |
| Guan, X; Liu, Q; Wang, L; Wang, X; Xie, L; Yu, Z | 1 |
| Reguart, N; Remon, J | 1 |
| Andratschke, N; Hildebrandt, G; Kuhnt, T; Lewitzki, V | 1 |
| Chen, J; Han, H; Hu, H; Liu, C; Lu, H; Yang, Y; Yin, H; Zhang, P; Zhou, W; Zhu, L | 1 |
| Chang, CH; Ho, CC; Lee, CH; Wang, JY; Yu, CJ | 1 |
| Dhillon, S | 1 |
| Izumi, H; Kuwano, M; Maeda, M; Murakami, Y; Ono, M; Watari, K | 1 |
| Ikegami, Y; Inoue, Y; Ishikawa, T; Kajimoto, Y; Kuroiwa, T | 1 |
| Dong, W; Fang, S; Li, C; Li, M; Liu, J; Song, B; Tang, B; Wang, Z; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Han, YF; Lin, X; Wu, LQ; Zhang, QY; Zhang, T | 1 |
| Beijersbergen, RL; Bernards, R; Grernrum, W; Hölzel, M; Huang, S; Knijnenburg, TA; Nijkamp, W; Papadakis, AI; Sun, C; Wessels, LF; Xue, Y | 1 |
| Jean-Claude, BJ; Larroque-Lombard, AL; Peyrard, L; Rachid, Z; Rao, S; Thauvin, C; Williams, C | 1 |
| Chang, PY; Chen, CY; Jian, YJ; Jian, YT; Lin, YW; Syu, JJ; Tung, CL; Wang, TJ | 1 |
| Chang, FK; Chih-Hsin Yang, J; Chiu, CH; Chuang, CY; Ho, CL; Hsia, TC; Hsiao, SH; Huang, MS; Lai, CL; Lai, RS; Lee, KY; Lin, CB; Lin, YC; Perng, RP; Shih, JY; Su, WC; Tsai, CM; Wang, CC; Wu, MF; Yang, CT; Yu-Wung Yeh, D | 1 |
| Fujita, Y; Gemma, A; Hagiwara, K; Harada, M; Harada, T; Inoue, A; Isobe, H; Ito, K; Kinoshita, I; Kobayashi, K; Kurihara, M; Maemondo, M; Minato, K; Morita, S; Nishitsuji, M; Nukiwa, T; Oizumi, S; Sugawara, S; Yoshizawa, H | 1 |
| Balkwill, FR; Bowtell, DD; Everitt, G; Gopinathan, G; Grose, R; Hochhauser, D; Hollingsworth, RE; Kulbe, H; Milagre, CS; Thompson, RG; Zhong, H | 1 |
| Bao, WM; Chen, H; Chen, JH; Fu, CW; Geng, DY; He, WQ; Hu, RG; Huang, CX; Huang, S; Ji, J; Li, SQ; Li, YM; Li, ZQ; Liu, YC; Ma, ZY; Mao, Y; Pan, L; Peng, H; Qiao, ND; Qin, XL; Qiu, HJ; Shen, JW; Shen, M; Shi, YY; Shi, ZF; Shou, XF; Song, ZJ; Tang, QS; Tang, WJ; Wang, QZ; Wang, T; Wang, Y; Wang, YF; Wen, ZJ; Xie, R; Ye, HY; Ye, Z; Zhang, QL; Zhang, Y; Zhang, YC; Zhang, ZY; Zhao, Y; Zheng, J; Zhou, DZ; Zhou, J; Zhou, LF | 1 |
| Coughlan, KA; Okon, IS; Wang, Q; Zhang, M; Zou, MH | 1 |
| Fujii, A; Furuyama, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Okamoto, I; Okamoto, T; Ota, K; Takayama, K | 1 |
| Bhattacharya, R; Bovonratwet, P; Liu, L; Mathew, MP; Saeui, CT; Tan, E; Yarema, KJ | 1 |
| Chang, SM; Chen, LH; Chen, TS; Chiu, KL; Liu, CM; Ma, WL; Ni, YL; Sher, YP; Yang, SY; Yu, SL | 1 |
| Aoe, K; Bessho, A; Chikamori, K; Fujii, M; Harada, D; Hisamoto-Sato, A; Hosokawa, S; Hotta, K; Ichihara, E; Kishino, D; Kiura, K; Kozuki, T; Kubo, T; Kuyama, S; Nogami, N; Oze, I; Tabata, M; Takigawa, N; Tanimoto, M; Ueoka, H | 1 |
| Barlesi, F; Braun, D; Debieuvre, D; Des Guetz, G; Fraboulet, G; Landre, T; Milleron, B; Molinier, O; Monnet, I; Morère, JF; Morin, F; Moro-Sibilot, D; Souquet, PJ; Urban, T; Uzzan, B; Vaylet, F; Westeel, V | 1 |
| Berghmans, T; Grigoriu, B; Meert, AP | 1 |
| Benesova, L; Bortlicek, Z; Fiala, O; Finek, J; Minarik, M; Pesek, M; Topolcan, O | 1 |
| Chuttani, K; Dhawan, D; Ghai, A; Kumar, P; Mishra, AK; Mittal, BR; Singh, B | 1 |
| de Velasco, MA; Fujita, Y; Fumita, S; Hayashi, H; Nakagawa, K; Nishio, K; Okamoto, K; Sakai, K; Terashima, M; Togashi, Y; Tomida, S | 1 |
| Chen, X; Huang, H; Ma, S; Wang, B; Wu, K; Zhang, S; Zheng, X | 1 |
| Fujita, Y; Fukuhara, T; Gemma, A; Hagiwara, K; Harada, M; Inoue, A; Isobe, H; Kinoshita, I; Kobayashi, K; Maemondo, M; Morita, S; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Cai, X; Chen, S; Deng, H; Fang, Y; Hu, M; Li, J; Li, Z; Vaughn, A; Wan, W; Wu, S; Xiao, J; Xu, L; Yang, X | 1 |
| Akamatsu, H; Endo, M; Kenmotsu, H; Murakami, H; Naito, T; Nakajima, T; Nakamura, Y; Ono, A; Shukuya, T; Takahashi, T; Tsuya, A; Yamamoto, N | 1 |
| Chang, WA; Chong, IW; Chou, SH; Huang, MS; Hung, JY; Kuo, TY; Lee, JY; Liu, TC; Shen, CH; Tsai, MJ; Wu, KL; Yang, CJ; Yen, CJ | 1 |
| Ghatak, A; Gupta, S; Husain, N; Jamal, N; Khan, H; Kushwaha, VS; Negi, MP | 1 |
| Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA | 1 |
| Bae, SY; Hong, JY; Lee, HJ; Lee, SK; Park, HJ | 2 |
| Chiba, K; Ejiri, Y; Hashimoto, M; Hosoda, M; Kobayashi, K; Mimura, H; Xu, L | 1 |
| Beom, SH; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, JO; Lee, SH; Park, JH; Sim, SH | 1 |
| Ahn, HK; Cho, EK; Hong, J; Jeong, SH; Kang, SM; Kim, YS; Kyung, SY; Lee, JH; Park, I; Park, J; Park, JW; Shin, DB; Sym, SJ; Woo, HS | 1 |
| Jensen, RT; Moody, TW; Moreno, P; Nuche-Berenguer, B | 1 |
| Baek, IJ; Bivona, TG; Choi, CM; Choi, SH; Choi, YJ; Kim, SY; Kim, WS; Lee, JC; Rho, JK; So, KS | 1 |
| Demehri, FR; Dempsey, PJ; Feng, Y; Freeman, JJ; Teitelbaum, DH | 1 |
| Cioffredi, LA; Jackman, DM; Jacobs, L; Johnson, BE; Kesari, S; Lucca, J; Lynch, TJ; Marcoux, PJ; Morse, LK; Plotkin, SR; Rabin, MS; Sharmeen, F | 1 |
| Cui, G; Cui, M; Guo, H; Li, W; Li, Y; Liang, Y; Zhao, S | 1 |
| Chen, LK; Dinglin, XX; Liang, JZ; Liao, H; Ma, SX; Qin, T; Wei, WD; Xu, F; Zeng, YD; Zhang, L | 1 |
| Bao, W; Cheng, SB; Chin, YE; Liu, N; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Yan, H; Yang, T; Zhuang, S | 1 |
| Bierbach, U; Day, CS; Gueble, MJ; Kucera, GL; Pickard, AJ; Qiao, X; Yang, M | 1 |
| Burotto, M; Fojo, T; Manasanch, EE; Wilkerson, J | 1 |
| Abdel-Rahman, O; Elhalawani, H | 1 |
| Chang, YT; Huang, HJ; Hwang, MH; Lin, AM; Tang, MC; Wu, MY; Yang, JC | 1 |
| Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H | 1 |
| Han, S; Pu, R; Shi, LW; Zhao, YL | 1 |
| Liang, J; Su, N; Xie, Y | 1 |
| Bill, A; Bonenfant, D; Duvvuri, U; Gaither, LA; Gutierrez, A; Kemp, C; Kulkarni, S; Voshol, H | 1 |
| Chinda, J; Fujino, T; Hasebe, N; Kabara, M; Kuroshima, T; Maruyama, K; Nakagawa, N; Ogawa, Y; Ohsaki, Y; Yamamoto, Y | 1 |
| Choi, SJ; Gu, HR; Han, CJ; Jeong, JH; Kim, J; Kim, YC; Kim, YJ; Lee, JC; No, SH; Noh, GY; Park, SC; Yang, KY | 1 |
| Chen, J; Jiang, M; Liu, TT; Shi, JH; Wang, Q | 1 |
| Bidart, JM; Broutin, S; Gil, S; Goffinet, F; Jovelet, C; Mir, O; Paci, A; Seck, A; Simasotchi, C | 1 |
| Seo, YH | 1 |
| Chung, C | 1 |
| Che, XF; Hiramoto, M; Ito, K; Miyazawa, K; Moriya, S; Sugita, S; Yamashiro, Y; Yokoyama, T | 1 |
| Cai, JZ; Deng, H; He, WF; Li, QP; Liao, GY; Long, SQ; Pan, ZQ; Wu, WY; Xiao, SJ; Yang, XB; Zhou, YS | 1 |
| Han, X; Liu, M; Lv, G; Ma, L; Shi, Y; Wang, S; Zeng, C | 1 |
| Gemma, A; Hagiwara, K; Inoue, A; Isobe, H; Kobayashi, K; Maemondo, M; Miyauchi, E; Nukiwa, T; Oizumi, S; Saijo, Y; Sugawara, S; Yoshizawa, H | 1 |
| Chudacek, Z; Pesek, M; Svaton, M; Vosmiková, H | 1 |
| Kempf, E; Le Chevalier, T; Planchard, D; Soria, JC | 1 |
| Gemma, A; Kitamura, K; Kosaihira, S; Kubota, K; Matsuda, K; Matsumoto, M; Minegishi, Y; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T; Yoshimura, A; Zou, F | 1 |
| Huang, Y; Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Gao, K; Li, XY; Liang, Y; Wu, N; Zhang, LF; Zhou, LN | 1 |
| Chang, H; Chen, G; Chen, Y; Ding, J; Huang, R; Ji, D; Song, B; Yuan, L | 1 |
| Ahn, JS; Ahn, MJ; Chang, WJ; Choi, MK; Choi, YL; Do, IG; Hong, JY; Jung, HA; Kim, MJ; Kim, SM; Park, K; Sun, JM | 1 |
| Amato, E; Bria, E; Brunelli, M; Chilosi, M; Corbo, V; Fassan, M; Giglioli, E; Kinspergher, S; Milella, M; Novello, S; Peretti, U; Pilotto, S; Righi, L; Santo, A; Scarpa, A; Sperduti, I; Tortora, G; Vavalà, T | 1 |
| Li, W; Liu, Y; Xing, Y | 1 |
| Chen, X; Dong, S; Li, P; Li, W; Qu, X; Shao, M; Yang, S; Zhang, L; Zhong, X | 1 |
| Buettner, R; Dellinger, TH; Han, ES; Horne, D; Hsieh, MY; Jove, R; Liu, L; Tian, Y; Wen, W; Wu, J; Yim, JH | 1 |
| Chang, JC; Colon-Otero, G; Dave, B; Patel, TA; Perez, EA; Rodriguez, AA | 1 |
| Julka, PK; Mallick, S; Singh, A; Venkatesulu, BP | 1 |
| Hu, C; Li, M; Wang, Q | 1 |
| Chu, L; Kan, P; Li, X; Wang, Q; Wang, Z; Xin, X; Yang, P; Zhu, Y | 1 |
| Bonetti, A; Giuliani, J; Martelli, S; Remo, A | 1 |
| Aoyama, A; Chen, F; Date, H; Menju, T; Omasa, M; Sato, M; Sato, T; Sonobe, M; Yamada, T; Yokoyama, Y | 1 |
| Bae, EJ; Bae, I; Kwak, SJ; Seong, YS; Yi, YW; You, K | 1 |
| Bevilacqua, S; D'Alessio, A; De Luca, A; Gallo, M; Maiello, MR; Normanno, N | 1 |
| Busto, ME; Koch, H; Kramer, K; Kuster, B; Médard, G | 1 |
| Al-Ejeh, F; Bessette, DC; Chenevix-Trench, G; Cocciardi, S; Grimmond, SM; Khanna, KK; Lakhani, SR; McCart-Reed, A; Quinn, MC; Saunus, JM; Seidens, T; Shi, W; Simpson, PT; Tilch, E; Waddell, N; Wiegmans, AP | 1 |
| Chen, NY; Chen, YJ; Hsu, TL; Liu, YC; Tsai, CF; Wang, YT; Wong, CH; Yang, PC; Yen, HY | 1 |
| Aljohani, H; Bahassi, el M; Koncar, RF; Lee, SH; Park, BS; Zarzour, A | 1 |
| Fan, LL; Gao, S; Li, WC; Li, XQ; Liu, JT; Sun, GP; Wang, F; Wang, H; Wei, W; Yu, HQ | 1 |
| Chariot, A; Shostak, K | 1 |
| Chang, YH; Hong, SE; Hong, SI; Hong, YJ; Jin, HO; Kim, B; Kim, CS; Kim, JH; Kim, JY; Lee, JK; Park, IC; Park, JA | 1 |
| An, G; Han, SY; Li, PP; Sun, H; Zhao, W; Zhou, F; Zhou, N | 1 |
| Hisada, T; Imai, H; Ishihara, S; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Yamada, M; Yoshino, R | 1 |
| Lee, VH; Ma, L; Wang, DD; Wong, MP; Yan, H | 1 |
| Jia, Y; Sun, T; Xiao, D | 1 |
| Ahn, JS; Ahn, MJ; Jung, HA; Kim, H; Kim, M; Kim, S; Ku, BM; Lee, JY; Lee, MY; Lim, SH; Park, K; Sun, JM | 1 |
| Fang, L; Li, F; Lin, N; Song, Y; Weng, X; Xu, Y | 1 |
| Cho, S; Kang, YK; Kim, BY; Kwon, T; Lee, JC; Park, YH; Rho, JK; Shin, HJ; Yoon, DY; Yu, DY | 1 |
| Chasapi, V; Soura, E; Stratigos, AJ | 1 |
| Hotta, K; Ichihara, E; Iwasaku, M; Kato, Y; Kiura, K; Kudo, K; Kunimasa, K; Oze, I; Takigawa, N; Tanimoto, M; Tsubouchi, K; Yoshioka, H | 1 |
| Ai, YQ; He, WJ; Li, RQ; Li, WH; Li, YF; Wang, Y; Xia, YX; Zhang, J; Zhao, PZ | 1 |
| Chicchinelli, N; De Luca, A; Fenizia, F; Forgione, L; Franco, R; Iannaccone, A; Lambiase, M; Morabito, A; Normanno, N; Pasquale, R; Piccirillo, MC; Rocco, G; Rossi, A; Sacco, A | 1 |
| Huang, Z; Liu, P; Qian, J; Shu, Y; Wu, Y; Zhou, X; Zhu, W | 1 |
| Chang, SN; Hsu, KH; Lin, CH; Pan, HC; Sheehan, J; Sheu, ML; Tsou, HK | 1 |
| Chen, L; Chen, X; Luo, S; Xie, X | 1 |
| Fan, F; Liu, Z; Lu, Y; Shen, C; Wang, A; Wu, H | 1 |
| Miller, K; Morant, R; Stenzl, A; Wirth, M; Zuna, I | 1 |
| Carpentier, O; Jégu, J; Prim, N; Purohit, A; Quoix, E; Selvaggi, L; Velten, M | 1 |
| Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Kramchaninov, MM; Moiseenko, FV; Moiseenko, VM | 1 |
| Alama, A; Barletta, G; Biello, F; Boccardo, S; Bottoni, G; Coco, S; Dal Bello, MG; Genova, C; Grossi, F; Rijavec, E; Sambuceti, G; Truini, A; Vanni, I | 1 |
| Asano, H; Hatakeyama, S; Jida, M; Kawahara, E; Kiura, K; Kubo, T; Miyoshi, S; Naomoto, Y; Otani, H; Sakaguchi, M; Soh, J; Takaoka, M; Toyooka, S; Tsukuda, K; Ueno, T; Yamamoto, H | 1 |
| An, T; Bai, H; Ding, X; Duan, J; Li, Z; Liu, Z; Shen, Z; Sun, Y; Wang, J; Wang, S; Wang, Y; Wang, Z; Wu, M; Zhao, J; Zhong, J; Zhuo, M | 1 |
| Chen, HL; Hsiao, FY; Lu, HM; Shen, LJ; Wei, CP | 1 |
| Vignot, S; Zalcman, G | 1 |
| Denny, EC; Kane, SE | 1 |
| Aderhold, C; Erben, P; Faber, A; Hoermann, K; Hofheinz, RD; Schultz, JD; Umbreit, C; Weiss, C; Wenzel, A | 1 |
| Hata, A; Hattori, Y; Imamura, F; Kaji, R; Kaneda, T; Katakami, N; Mori, M; Morita, S; Negoro, S; Nishino, K; Otsuka, T; Tachihara, M; Uchida, J; Urata, Y; Yano, Y; Yokota, S | 1 |
| Geng, D; Sun, D; Zhang, L; Zhang, W | 1 |
| Liu, W; Qin, ZP; Xing, RC; Yao, RC; Zheng, J; Zheng, WH | 1 |
| Bagust, A; Beale, S; Boland, A; Dickson, R; Dundar, Y; Dwan, K; Greenhalgh, J; Hockenhull, J; Marshall, E; Mullard, A; Proudlove, C; Richardson, M | 1 |
| Fang, WF; Hong, SD; Huang, Y; Ma, YX; Sheng, J; Tian, Y; Xue, C; Yang, YP; Zhang, L; Zhao, YY | 1 |
| Chang, Y; Gao, Y; He, Z; Li, S; Liu, K; Ma, J; Ma, W; Ma, Z; Tang, H; Wang, Q; Wei, B; Zhang, Z | 1 |
| Eisele, DW; McCormick, F; Phuchareon, J; Tetsu, O | 1 |
| Ahn, MJ; Atagi, S; Jiang, H; Kim, SW; Lee, DH; Liu, Y; Lu, Y; Mok, TS; Nakagawa, K; Ponce, S; Shi, X; Soria, JC; Wang, J; Webster, A; Wu, YL; Yang, JC; Yang, JJ; Yoh, K; Zhou, JY | 1 |
| Chang, VH; Chen, CC; Jiang, X; Lin, HY; Liu, YR; Wang, J; Yang, SH; Yen, Y; Zhang, K | 1 |
| Kim, S; Lee, J; Lee, JE; Nam, SJ; Oh, SJ | 1 |
| Cao, W; Chen, H; Huang, L; Liu, Y; Mei, L; Ming, P; Wang, T; Zhang, B; Zhang, H; Zhang, R; Zhu, X | 1 |
| Bi, Z; Jiang, Y; Li, D; Liu, Y | 1 |
| Chen, Q; Ding, L; Hong, X; Liang, Y; Quan, Q; Wu, H; Zhou, N | 1 |
| Anand, A; Carver, B; Heller, G; Larson, SM; Morris, MJ; Rathkopf, DE; Rosen, N; Scher, HI; Shaffer, DR; Slovin, SF | 1 |
| Alp, E; Elmazoglu, Z; Menevse, S; Yar Saglam, AS | 1 |
| Chu, W; Gao, L; Liu, J; Lv, B; Tan, G; Wang, R; Zhang, Y; Zhao, X; Zhen, Q | 1 |
| Cheong, JG; Choi, J; Jung, JW; Kang, M; Kim, HJ; Kim, TY; Lee, GH; Lee, HY; Lee, JW; Nam, SH; Ryu, J | 1 |
| Ando, T; Hirose, Y; Ishikawa, T; Kameyama, H; Kobayashi, T; Kosugi, S; Koyama, Y; Maruyama, T; Minagawa, M; Nagahashi, M; Ohtsubo, A; Okabe, Y; Sakata, J; Shimada, Y; Takizawa, K; Wakai, T; Watanabe, S | 1 |
| Chung, DH; Chung, JK; Heo, DS; Jeon, YK; Kang, KW; Keam, B; Kim, DW; Kim, TM; Lee, SH; Lee, SJ; Paeng, JC | 1 |
| Blagg, J; Boxall, K; Burke, R; Cheung, KM; Faisal, A; Gurden, MD; Hoelder, S; Linardopoulos, S; Mak, G; McAndrew, C; Naud, S; Schmitt, J; Van Montfort, RL; Westwood, IM; Wood, A; Workman, P | 1 |
| Chen, J; Li, L; Luo, M; Pan, L; Qin, G; Qin, S; Yang, J; Zhang, Q | 1 |
| Kempf, E; Lacroix, L; Soria, JC | 1 |
| Adachi, K; Okamoto, S | 1 |
| Chavan, H; Dong, B; Guan, X; Krishnamurthy, P; Li, F; Liu, X; Lu, Y; Wang, J; Zhang, Y | 1 |
| Azzoli, CG | 1 |
| Cao, X; Dong, W; Feng, W; Hong, S; Jia, J; Li, N; Lin, D; Peng, J; Wang, S; Xue, C; Zhang, H; Zhang, L; Zhang, W | 1 |
| Chen, L; Guo, Y; Hu, Z; Huang, M; Huang, Y; Li, H; Li, J; Ma, Y; Wang, X; Xin, S; Zhang, J; Zhang, L; Zhao, Y | 1 |
| Cai, L; Hu, J; Liu, C; Liu, W; Meng, QW; Ning, JF; Zhao, YB | 1 |
| Ando-Makihara, R; Hayashi, Y; Makino, Y; Motonaga, M; Ohe, Y; Takano, M; Yamamoto, N | 1 |
| Cruz, FM; Del Giglio, A; Normando, SR | 1 |
| Asai, K; Hirata, K; Kawaguchi, T; Kimura, T; Kudoh, S; Matusura, K; Mitsuoka, S; Nakai, T; Oka, T; Suzumira, T; Tochino, Y; Yoshimoto, N; Yoshimura, N | 1 |
| Li, E; Li, J; Qiao, H; Ren, K; Shi, H; Zhao, D | 1 |
| Hisada, T; Imai, H; Ishihara, S; Ishizuka, T; Kaira, K; Kuwako, T; Masuda, T; Minato, K; Miura, Y; Mogi, A; Saito, R; Seki, K; Shimizu, K; Sunaga, N; Takise, A; Tomizawa, Y; Utsugi, M; Yamada, M; Yoshino, R | 1 |
| Cao, Q; Fu, SY; Li, Y; Wang, FY; Wang, LH; Wang, NN; Wang, YT; Wu, CF; Yang, JY | 1 |
| Chiba, K; Kurokawa, T; Matsushima, Y; Nakanishi, Y; Narita, Y; Shiroiwa, T; Urushihara, H | 1 |
| DeGroot, J; Jansen, HT; Kivits, S; Läppchen, T; Sio, CF; Steinbach, OC; van de Steeg, E; van der Hoorn, JW; van Driel, A; Vlaming, ML | 1 |
| Boone, E; Breyne, J; De Laere, E; Dedeurwaerdere, F; Demedts, I; Oyaert, M; Vandorpe, J | 1 |
| Fujita, A; Gotoh, N; Higashiyama, M; Higuchi, T; Imoto, S; Kimura, T; Kondoh, K; Miyano, S; Nakata, A; Nishihara, H; Nokihara, H; Nomura, M; Shimamura, T; Tamada, Y; Tojo, A; Yamaguchi, R; Yamauchi, M; Yano, S; Yoshida, R | 1 |
| Nishio, K; Togashi, Y | 1 |
| Uhara, H | 1 |
| Ashinuma, H; Sekine, I | 1 |
| Al-Shahrour, F; Becker, JH; Capelletti, M; Carretero, J; Jänne, PA; Kikuchi, E; Kuang, Y; Patel, TB; Paweletz, CP; Pulido, I; Shapiro, GI; Shimamura, T; Soucheray, M; Wong, KK; Xu, C | 1 |
| Doddapaneni, R; Godugu, C; Mercer, R; Patel, AR; Singh, M; Singh, R | 1 |
| Hwang, SG; Kim, EM; Park, JK; Um, HD | 1 |
| Imai, S; Koyama, S; Matsubara, K; Nakagawa, S; Nakagawa, T; Omura, T; Yano, I; Yonezawa, A | 1 |
| Bora-Singhal, N; Chellappan, S; Nguyen, J; Perumal, D | 1 |
| Chan, CH; Chan, HL; Chen, JT; Chou, HC; Chung, TW; Lin, CC; Lin, MW; Lyu, KW; Wen, YF; Wu, SB | 1 |
| Adamo, V; Ferraro, G; Franchina, T; Giordano, A; Picone, A; Ricciardi, GR; Russo, A; Toscano, G; Zanghì, M | 1 |
| Fang, L; Li, F; Lin, N; Ma, S; Song, Y; Sun, X; Xu, Y; Zhang, Y | 1 |
| Chang, GC; Chen, HW; Chen, JJ; Chen, MH; Lai, YH; Lin, SY; Wong, YH; Yang, CH; Yu, SL | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Nomura, S; Ohe, Y; Ohmatsu, H; Sugiyama, E; Tsuboi, M; Umemura, S; Yoh, K | 1 |
| Igawa, S; Ishihara, M; Katagiri, M; Masuda, N; Otani, S; Sasaki, J; Takakura, A | 1 |
| Anaya, P; Arrieta, O; Morales-Oyarvide, V; Polanco, AC; Ramírez-Tirado, LA | 1 |
| Fu, F; Geng, J; Sun, D; Wang, H; Xie, X; Yu, G; Zhang, L | 1 |
| Abdulkhalek, S; Bandyopadhyay, SK; Chattopadhyay, S; Fensterl, V; Poddar, D; Sen, GC; Veleeparambil, M | 1 |
| Cosmai, L; Gallieni, M; Porta, C | 1 |
| Cao, M; Chen, H; Chu, Q; Han, R; He, Y; Sun, J; Wang, D; Wang, Y; Yao, W | 1 |
| Cho, BC; Choi, JM; Choi, YR; Jang, JY; Kim, HR; Lee, HW | 1 |
| Fujita, S; Hata, A; Kaji, R; Katakami, N; Masago, K; Okuda, C; Otsuka, K; Takeshita, J | 1 |
| Ettinger, DS; Forde, PM | 1 |
| Gilligan, D; Pacey, S; Tan, CS | 1 |
| Essapen, S; Fan, Z; Khelwatty, SA; Modjtahedi, H; Seddon, AM | 1 |
| Liu, X; Shi, Y; Xu, J; Yang, S; Zhang, X | 1 |
| Aasrum, M; Brusevold, IJ; Christoffersen, T; Sandnes, D; Tveteraas, IH; Ødegård, J | 1 |
| Bessho, A; Hotta, K; Ichinose, Y; Katsui, K; Kishimoto, J; Kiura, K; Nogami, N; Saeki, S; Sasaki, J; Shioyama, Y; Takayama, K; Takigawa, N; Tanimoto, M | 1 |
| Gu, J; Hu, J; Mao, W; Sun, W; Sun, X; Wu, W; Xu, Y; Yu, X; Zhang, G; Zheng, Y | 1 |
| Chang, J; Shi, Y; Su, C; Yang, G; Zhao, L | 1 |
| Bruzzese, F; Budillon, A; Ciardiello, C; Ciliberto, G; Di Gennaro, E; Leone, A; Mancini, R; Roca, MS; Terranova-Barberio, M; Vitagliano, C | 1 |
| Badiger, MV; Gonnade, RG; Patwadkar, MV; Sahu, SK; Thorat, SH | 1 |
| Dikomey, E; Gal, A; Grob, TJ; Kriegs, M; Lamszus, K; Petersen, C; Rieckmann, T; Riedel, M; Rothkamm, K; Schulte, A; Struve, N | 1 |
| Biddick, L; Brewer, M; Devarkonda, V; Janakiram, NB; Lightfoot, S; Madka, V; Mohammed, A; Rao, CV; Steele, VE | 1 |
| Kiessling, R; Lundqvist, A; Maeda, A; Nakata, M; Nakayama, E; Oka, M; Okita, R; Saisho, S; Seliger, B; Shimizu, K; Wolf, D; Yamaguchi, Y; Yasuda, K; Yukawa, T | 1 |
| Ding, X; Li, Y; Mao, W; Meng, X; Tang, H; Wang, X; Xie, S; Yang, H | 1 |
| Chaplain, MAJ; Hill, L; Kapelyukh, Y; Wolf, R | 1 |
| Cappuzzo, F; D'Incecco, A; Minuti, G | 1 |
| Barber, TA; Engelman, JA; Fleisher, M; Fox, DB; Giri, U; Haber, DA; Heymach, JV; Jänne, PA; Johnson, BE; Kapur, R; Koch, WH; Maher, R; Maheswaran, S; Muzikansky, A; Riely, GJ; Sequist, LV; Stott, SL; Sullivan, JP; Sundaresan, TK; Toner, M; Tran, HT; Walsh, JR; Webb, A; Wei, W; Yu, HA | 1 |
| Cheng, NS; Li, FY; Ma, WJ; Mao, H; Shrestha, A; Yang, Q; Zhang, W; Zhou, Y | 1 |
| Han, BW; Hou, BX; Li, YW; Luo, XY; Ma, ZK; Nie, PP; Shi, XP; Zou, ZZ | 1 |
| Amoresano, A; Camorani, S; Carpentieri, A; Cerchia, L; Chiariello, M; Colecchia, D; Crescenzi, E; Fedele, M | 1 |
| Bradbury, MS; Brennan, C; Burns, A; Ma, K; Mellinghoff, I; Sequeira, S; Wiesner, U; Yoo, B; Zhang, L | 1 |
| Gong, P; Li, H; Li, J; Li, N; Ma, X; Su, F | 1 |
| Fukusumi, M; Hamamoto, Y; Honma, C; Ibe, T; Kameyama, N; Kamimura, M; Mouri, A; Takeoka, S | 1 |
| Cao, HX; Feng, JF; Hu, Y; Liu, SW; Wu, Y; Yu, DD; Yu, SR | 1 |
| Cui, F; He, X; Wang, M; Wang, W; Wu, D; Wu, J | 1 |
| Cameron, MG; Kersten, C; Laird, B; Mjåland, S | 1 |
| Du, J; Hu, H; Li, C; Li, H; Li, Y; Wang, L; Yang, H; Zhang, Z | 1 |
| Chen, Y; Ding, J; Geng, M; Huang, M; Shen, A; Shen, YY; Sun, J; Wang, L; Wang, X; Yang, X | 1 |
| Liu, G; Liu, H; Ma, T; Zhang, X | 1 |
| Chang, CY; Chen, CJ; Chen, WY; Kuan, YH; Li, JR; Ou, YC; Wang, WY; Wu, CC | 1 |
| Ahn, JH; Choi, CM; Choi, YJ; Kim, SW; Lee, DH; Lee, JS; Lee, SJ | 1 |
| Chen, H; Han, R; He, Y; Huang, W; Li, K; Li, L; Lin, C; Lu, C; Sun, F; Wang, Y; Zhang, K | 1 |
| Alharbi, KK; Chakravarthy, S; Goud, I; Khan, IA; Lakshmi M, AM; Matam, K; Prasad, SV; Ravi, V; Shaik, NA; Sridhar, K; Syed, R; Tabassum, SN; Vijayanand, PR | 1 |
| Bode, AM; Chang, X; Chen, H; Dong, Z; Jiang, Y; Liu, K; Reddy, K; Ryu, J; Shi, C; Yao, K; Zhang, C; Zhang, Y; Zhao, S | 1 |
| Dickson, JM; Flanagan, JU; McKeage, MJ; Patterson, AV; Silva, S; Smaill, JB; Squire, CJ; Yosaatmadja, Y | 1 |
| Hayashi, H; Hirose, C; Iihara, H; Itoh, Y; Kita, Y; Kitaichi, K; Minatoguchi, S; Ohno, Y; Sugiyama, T; Todoroki, K; Yamada, M; Yanase, K | 1 |
| Berger, W; Kubista, B; Lötsch, D; Mayr, L; Micksche, M; Pirker, C; Sevelda, F; van Schoonhoven, S; Windhager, R | 1 |
| Fan, XX; Jiang, ZH; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Tin, VP; Wong, MP; Yao, XJ; Yau, LF; Zhou, YL | 1 |
| Alfieri, RR; Andreoli, R; Ardizzoni, A; Bonelli, M; Caffarra, C; Cavazzoni, A; Cretella, D; Fumarola, C; Galetti, M; La Monica, S; Mutti, A; Petronini, PG; Saccani, F; Tiseo, M | 1 |
| Ding, J; Fan, XX; He, JX; Huang, J; Huang, M; Jiang, ZB; Kam, RK; Leung, EL; Liu, L; Michelangeli, F; Mujtaba, T; Wong, VK; Xiao, DK; Xu, SW; Xue, WW; Yao, XJ; Zhou, YL | 1 |
| Chen, X; He, L; Li, M; Li, Q; Li, T; Xu, X; Zhang, D | 1 |
| Hsiue, TR; Hwang, JS; Lai, WW; Lin, CK; Su, WC; Wang, JD; Yang, SC | 1 |
| Gao, Q; Ji, J; Li, BB; Tong, XH; Wu, XX; Zhang, XY | 1 |
| Cho, KM; Heo, DS; Keam, B; Kim, DW; Kim, TM; Lee, SH | 1 |
| Jiang, M; Liu, TT; Shen, GF; Shi, JH; Wang, Q | 1 |
| Abdel-Rahman, O; Ahmed, H; ElHalawani, H | 1 |
| An, G; Bi, Y; Deng, J; Murry, DJ | 1 |
| Clark, SW; Ma, Y; Mobley, BC; Sarkaria, JN; Tang, N; Thompson, RC; Wang, J | 1 |
| Cherpelis, B; Rudnick, EW; Thareja, S | 1 |
| Protsenko, SA; Rudakova, AV | 1 |
| Kim, H; Kim, HS; Kwon, JW; Shin, S; Sohn, HS | 1 |
| Bradshaw, TD; Collins, H; Kuruppu, AI; Thomas, NR; Turyanska, L; Zhang, L | 1 |
| Aebersold-Keller, F; Aebi, S; Baumann, C; Betticher, D; Buser, K; Büttner, R; Calderoni, A; Casty, A; Diebold, J; DʼAddario, G; Gautschi, O; Heukamp, LC; Irlé, C; Jehle-Schwertfeger, S; König, K; Mamot, C; Morant, R; Pellicioli, E; Stadelmann, C; Trojan, A | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Yoshida, T | 1 |
| Cai, XH; Feng, CJ; Huang, CY; Liu, XK; Lu, Y; Wang, L; Wang, Y; Wang, YS; Xu, Y; Yao, WX; Yu, P; Zhou, J; Zhu, WJ | 1 |
| Chan, KK; Furness, S; Glenny, AM; Wakeford, H; Weldon, JC; Worthington, HV | 1 |
| Cai, L; Hu, J; Li, C; Liu, W; Lu, H; Meng, Q; Ning, J | 1 |
| Dong, M; He, X; Li, J; Wang, J; Wang, Y; Wang, Z; Wu, Y | 1 |
| Chen, H; Gao, X; He, W; Li, B; Mei, C; Xu, R; Zhu, Y | 1 |
| Inoue, A; Kobayashi, K; Nukiwa, T; Watanabe, S | 1 |
| Bertrán-Alamillo, J; Bosch-Barrera, J; Bria, E; Carcereny, E; Chaib, I; Codony-Servat, C; Codony-Servat, J; Crisetti, E; de Marinis, F; Drozdowskyj, A; Felip, E; Felipe Cardona, A; García-Campelo, R; Gervais, R; Giménez-Capitán, A; González-Cao, M; Karachaliou, N; López-Vivanco, G; Luis Ramírez, J; Majem, M; Massuti, B; Miguel Sánchez, J; Molina-Vila, MA; Morales-Espinosa, D; Morán, T; Pilotto, S; Rosell, R; Sánchez Hernández, JJ; Santarpia, M; Sperduti, I; Teixidó, C; Vergnenegre, A; Verlicchi, A; Viteri, S | 1 |
| Barone, C; Basso, M; Cassano, A; Cerchiaro, E; D'Argento, E; Dadduzio, V; Martini, M; Rossi, S; Strippoli, A | 1 |
| Chen, YW; Cheng, KH; Hsiao, PJ; Hung, WC; Kuo, KK; Su, HT; Weng, CC; Wu, DC | 1 |
| Bennouna, J; Chand, VK; Chen, YM; Chouaid, C; De Marinis, F; Feng, JF; Grossi, F; Kim, DW; Kim, JH; Liu, X; Lu, S; Park, K; Planchard, D; Schuler, M; Strausz, J; Vinnyk, Y; Wang, B; Wiewrodt, R; Yang, JC; Zhou, C | 1 |
| Feng, B; Liu, M; Shi, Y; Su, C; Yang, G; Yu, X; Zhao, L | 1 |
| Chen, KL; Cho, YT; Chu, CY; Lin, CC; Sheen, YS; Tsai, HE; Yang, CW | 1 |
| Bae, SY; Hong, JY; Jung, C; Kang, JI; Lee, HJ; Lee, SK; Park, HJ | 1 |
| Ahn, JS; Ahn, MJ; Bae, YH; Jung, KS; Kim, HS; Koh, J; Ku, BM; Lee, JY; Lee, SH; Lim, SH; Park, K; Song, HN; Sun, JM; Yoo, KH | 1 |
| Liu, N; Mao, H; Qiu, A; Shi, Y; Wang, L; Xiong, C; Xu, L; Zang, X; Zhuang, S | 1 |
| Kong, J; Liu, D; Luan, T; Wang, HF; Zhang, Y | 1 |
| Chung, DH; Han, JJ; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, SH | 1 |
| Mitsudomi, T; Mizuuchi, H; Murakami, I; Nishio, K; Sakai, K; Sato, K; Suda, K; Tomizawa, K | 1 |
| Byrn, S; Chen, X; Fang, K; Lubach, JW; Nie, H; Smith, D; Song, Y; Su, Z; Yang, X; Zemlyanov, D | 1 |
| Iwakami, S; Katsura, Y; Kido, K; Ko, R; Namba, Y; Sasaki, S; Shukuya, T; Takahashi, K; Tominaga, S; Yoshioka, Y | 1 |
| Che, XF; Handa, H; Hiramoto, M; Itoi, T; Kazama, H; Kokuba, H; Miyazawa, K; Moriya, S; Mukai, S; Ōmura, S; Sakamoto, S; Sugawara, A; Sunazuka, T; Yokoyama, T | 1 |
| Deng, Y; Feng, W; Liang, J; Wu, J; Xian, H; Yang, S; Zhang, H | 1 |
| Gao, B; Li, GH; Shao, GG; Yang, B; Yang, ZG | 1 |
| Basaran, G; Bogaerts, J; Cameron, D; Cufer, T; Debled, M; Dirix, L; Piccart, M; Thery, JC; Tjan-Heijnen, VC; Tryfonidis, K; Van den Weyngaert, D | 1 |
| Chonan, M; Narita, N; Tominaga, T | 1 |
| Ahn, MJ; Kim, SW; Lin, CC; Mok, T; Orlando, M; Park, K; Puri, T; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Ashida, A; Koizumi, T; Ogawa, E; Okuyama, R; Uhara, H | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Niu, M; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Chen, M; He, Q; Luo, P; Peng, X; Shao, J; Xu, L; Xu, Z; Yang, B; Zhu, H; Zhu, Y | 1 |
| Hasegawa, T; Hirai, S; Kojima, T; Niki, T; Nishikiori, H; Sakuma, Y; Takahashi, H; Watanabe, A; Yamada, G; Yamaguchi, M | 1 |
| Kang, HH; Kim, IK; Lee, HI; Lee, HY; Lee, SH; Mo, JY; Moon, HS; Yeo, CD | 1 |
| Arora, H; Biswas, S; Gandhi, G; Naseem, A; Perwez, A; Qureshi, R; Rizvi, MA; Wajid, S | 1 |
| Chen, Z; Wu, JH; Zhang, X; Zhao, J | 1 |
| Dahlberg, SE; Digumarthy, SR; Fulton, LE; Hatabu, H; Johnson, BE; Nishino, M; Sequist, LV | 1 |
| Chiba, M; Gemma, A; Kubota, K; Matsumoto, M; Miyanaga, A; Nishijima, N; Noro, R; Seike, M; Soeno, C; Sugano, T | 1 |
| Li, Y; Liu, D; Qu, S; Song, J; Song, L; Tang, H; Wu, Y | 1 |
| Chang, BC; Hong, GR; Shim, CY; Shim, HS; Song, S | 1 |
| Han, SY; He, XR; Jiang, ST; Li, PP; Xu, GB; Zhao, C; Zheng, N | 1 |
| Bao, H; Li, H; Wang, Q; Zhang, H; Zhuang, Y | 1 |
| Atobe, O; Fujimori, A; Hachiya, T; Ikuyama, Y; Imai, A; Shiba, H; Sonehara, K | 1 |
| Boye, M; Kang, JH; Kim, JS; Orlando, M; Puri, T; Rajan, N; Srimuninnimit, V; Tsai, CM; Wang, X; Yang, JC | 1 |
| Dong, QZ; Han, Y; Jiang, GY; Liu, Y; Wang, EH; Wang, L; Wang, S | 1 |
| Kinomura, A; Misumi, K; Miyata, Y; Okada, M; Sun, J; Tashiro, S | 1 |
| Hagen, T; Hong, SY; Luo, Y; Yu, FX | 1 |
| Archibald, HL; Bardelli, A; Bhang, HE; Costa, C; Crystal, AS; Damon, LJ; Engelman, JA; Faber, AC; Getz, G; Gomez-Caraballo, M; Hata, AN; Hu, H; Iafrate, AJ; Ji, F; Kalsy, A; Keating, CL; Krishnamurthy Radhakrishna, V; Lee, D; Lockerman, E; Maruvka, YE; Mulvey, HE; Niederst, MJ; Piotrowska, Z; Raoof, S; Ruddy, DA; Sadreyev, RI; Sequist, LV; Siddiqui, FM; Siravegna, G; Stegmeier, F | 1 |
| Ge, Y; Han, X; Huang, S; Jin, Y; Li, Y; Liu, K; Ma, X; Song, Z; Wang, C; Yu, H; Zhen, Y; Zhou, Y | 1 |
| Ni, J; Zhang, L | 1 |
| Chiba, M; Kobayashi, Y; Mitsudomi, T; Mizuuchi, H; Murakami, I; Nishio, K; Sakai, K; Sato, K; Sekido, Y; Sesumi, Y; Shimoji, M; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Du, LW; Feng, JG; Jiang, H; Li, JH; Ma, SL; Song, SC; Zhao, PJ; Zhou, GH; Zhu, XH | 1 |
| Chou, SH; Han, DX; Hu, P; Ruan, RS; Tzeng, CM; Zheng, LM | 1 |
| Kubo, T; Morimoto, K; Sato, Y; Seyama, T; Yanagihara, K | 1 |
| Gottesman, MM; Hall, MD; Kumar, JS; Madigan, JP; Simpson, RM; Wei, BR | 1 |
| Bagadi, M; Binda, MM; Chaltin, P; Daniels, VW; Dehairs, J; Khan, NA; Marchand, A; Munck, S; Rueda-Rincon, N; Swinnen, JV; Talebi, A; Thimiri Govinda Raj, DB; Vanderhoydonc, F; Willemarck, N | 1 |
| Fahmy, O; Fend, F; Feyerabend, S; Gakis, G; Scharpf, M; Schubert, T; Schwentner, C; Stenzl, A | 1 |
| Choe, J; Han, M; Jeoung, D; Kim, H; Kim, Y; Kim, YM; Lee, H; Lee, YS; Park, D | 1 |
| Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W | 1 |
| Jang, JY; Jeon, YK; Keam, B; Kim, CW; Kim, TM; Kim, YG; Nam, SJ | 1 |
| Chan, LW; Cho, WC; Meng, F; Sin, TK; Siu, PM; Wang, F; Wong, SC; Yung, BY | 1 |
| Syed, YY | 1 |
| Fujita, K; Hirose, T; Ishida, H; Kusumoto, S; Murata, Y; Nakashima, M; Ohmori, T; Oki, Y; Okuda, K; Sasaki, Y; Shirai, T; Sugiyama, T; Yamaoka, T | 1 |
| Crowe, PJ; Garrett, K; Goldstein, D; Wang, X; Yang, JL; Yang, M; Zeps, N | 1 |
| Bogdanowicz, BS; Hartranft, ME; Hoch, MA | 1 |
| Chen, L; Li, Q; Peng, S; Wang, R; Wang, W; Yang, H | 1 |
| Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM | 1 |
| An, SJ; Bai, XY; Chen, ZH; Gou, LY; Su, J; Wu, YL; Xie, Z; Yang, SQ; Zhang, XC | 1 |
| Goto, K; Matsumoto, S; Niho, S; Ohe, Y; Ohmatsu, H; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Hong, D; Liang, X; Zhang, G; Zhang, X | 1 |
| Boerner, J; Joiakim, A; Mathieu, PA; Reiners, JJ; Shelp, C | 1 |
| Broutin, S; Gil, S; Jovelet, C; Mir, O; Paci, A | 1 |
| Arimoto, T; Honda, Y; Kadomatsu, K; Kadowaki, S; Kinoshita, D; Kishida, S; Kubota, I; Miyamoto, T; Narumi, T; Netsu, S; Nishiyama, S; Shishido, T; Takahashi, H; Takahashi, T; Takeishi, Y; Watanabe, T | 1 |
| Fukuoka, M; Imamura, F; Inoue, A; Morita, S; Muto, S; Nakagawa, K; Okamoto, I; Seto, T; Yamamoto, N; Yoshida, K | 1 |
| Blumenthal, GM; He, K; Kazandjian, D; Keegan, P; Pazdur, R; Yuan, W | 1 |
| Hanawa, T; Hyuga, M; Hyuga, S; Itoh, K; Nishimura, Y; Takiguchi, S | 1 |
| Ebata, T; Ishiwata, T; Iwama, A; Iwasawa, S; Koide, S; Kurimoto, R; Sekine, I; Tada, Y; Takiguchi, Y; Tatsumi, K | 1 |
| Ahn, JS; Ahn, MJ; Lee, HY; Lee, JH; Lee, KS; Park, K; Sun, JM | 1 |
| Du, H; Guo, L; He, L; Huang, H; Jiang, J; Li, M; Li, Y; Luan, M; Ma, C; Qin, S; Ruan, Y; Shen, L; Zhang, X | 1 |
| Adamo, V; Alù, M; Bazan, V; Blasi, L; Bronte, G; Celesia, C; De Tursi, M; Franchina, T; Gambale, E; Laudani, A; Natoli, C; Passiglia, F; Picone, A; Rizzo, S; Russo, A; Savio, G; Sortino, G | 1 |
| Watanabe, A | 1 |
| Hashimoto, M; Hidayat, M; Kobayashi, I; Moriyama, H; Moriyama, M; Murakami, A; Nara, T; Nurwidya, F; Sasaki, S; Shimada, N; Suina, K; Tajima, K; Takahashi, F; Takahashi, K; Yagishita, S; Yoshioka, Y | 1 |
| Chen, C; Lian, ZZ; Sun, YF | 1 |
| Chen, X; Fan, XX; He, JX; Huang, J; Leung, EL; Liu, L; Xiao, DK; Xu, JH; Yao, XJ; Zhang, YZ; Zheng, SY; Zhou, YL | 1 |
| Alfieri, R; Ardizzoni, A; Barocelli, E; Bonelli, M; Cavazzoni, A; Cretella, D; Falco, A; Fumarola, C; Galetti, M; Gervasi, A; La Monica, S; Lagrasta, CA; Madeddu, D; Naldi, N; Petronini, PG; Quaini, F; Tiseo, M; Vivo, V | 1 |
| Huo, LM; Sun, HT; Tian, JH; Xu, JG; Yang, G; Yang, KH; Zhang, P; Zheng, MH | 1 |
| Houk, KN; McDonald, JJ; Park, J; Petter, RC | 1 |
| Ma, A; Shi, J; Wang, D; Yang, J; Zhai, Q; Zhang, C; Zhang, H; Zhang, X | 1 |
| Heo, DS; Keam, B; Kim, DW; Kim, TM; Kim, YW; Lee, SH; Park, S; Suh, B | 1 |
| Daga, H; Fujimoto, D; Goto, I; Ikeda, N; Imamura, F; Iwamoto, Y; Kaji, R; Kanehara, M; Katakami, N; Morita, S; Murakami, H; Nakagawa, K; Nakanishi, Y; Negoro, S; Nogami, N; Oguri, T; Saka, H; Satouchi, M; Seto, T; Sugawara, S; Urata, Y; Yoshioka, H | 1 |
| Cheng, L; Fan, LL; Gao, J; Li, XQ; Liu, JT; Liu, Y; Sun, GP; Wang, F; Wang, H; Wei, W; Yu, HQ | 1 |
| Carbonnaux, M; Couraud, S; Meert, AP; Peters, M; Scherpereel, A; Souquet, PJ | 1 |
| Bowen, JM; Gibson, RJ; Van Sebille, YZ; Wardill, HR | 1 |
| Sakiyama, S; Takizawa, H; Tangoku, A; Toba, H | 1 |
| Chiba, R; Maeyama, K; Moriguchi, S; Morikawa, N; Nakamura, Y; Nitanai, H; Ogasawara, M; Ohta, M; Saito, H; Sugai, T; Takaoka, Y; Tanita, T; Yamauchi, K | 1 |
| Luo, Z; Nitin, N; Samadzadeh, KM | 1 |
| Dandekar, G; Dandekar, T; Göttlich, C; Kunz, M; Müller, LC; Nietzer, SL; Schmitt, F; Walles, H; Walles, T | 1 |
| Cai, F; Cao, W; Duan, C; Fan, C; He, Z; Huang, Q; Liu, Y; Wang, J; Wang, X; Xiao, X; Zhang, L | 1 |
| Arvis, CD; Boyer, M; Hirsh, V; Kim, DW; Kim, M; Kim, SW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, KH; Lu, S; Massey, D; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shahidi, M; Shi, Y; Tan, EH; Tsai, CM; Yang, JC; Zazulina, V; Zhang, L | 1 |
| Ahmad, SF; Al-Alallah, IA; Alhaider, AA; Anazi, FE; Ansari, MA; Assiri, MA; Attafi, IM; Belali, OM; Korashy, HM | 1 |
| Chen, L; Huang, M; Li, J; Ma, Y; Wang, X; Xin, S; Yang, Y; Zhang, L; Zhang, Y; Zhao, H; Zhao, Y; Zhu, C; Zhu, X; Zhuang, W | 1 |
| Chang, YW; Chen, FC; Cheng, CC; Chiu, CF; Hsu, MK; Kuo, KT; Kuo, TC; Lee, KY; Liu, CY; Ma, JT; Shen, YS; Su, JL; Yu, YH | 1 |
| Du, J; Kang, Y; Lin, Y; Luo, Q; Wang, F; Wang, Y; Wang, Z; Wu, K; Zhang, Y; Zhao, Y; Zheng, W | 1 |
| Abreu, S; Bernardes, N; Carvalho, FA; Fernandes, F; Fialho, AM; Santos, NC | 1 |
| Mitsudomi, T; Mizuuchi, H; Nishio, K; Sakai, K; Sato, K; Shimizu, S; Suda, K; Takemoto, T; Tomizawa, K | 1 |
| Amary, F; Barnard, M; Brüderlein, S; Cottone, L; Drewry, DH; Flanagan, AM; Guppy, N; Jorgensen, M; Leite, AP; Leithner, A; Möller, P; Pillay, N; Scheipl, S; Smith, JA; Strauss, SJ; Tirabosco, R; Turlais, F; Ye, H; Zuercher, WJ | 1 |
| Chen, JN; Chen, SY; Lin, PS; Liu, HC; Wei, CW; Yiang, GT | 1 |
| Feng, C; Guo, F; Huang, C; Li, X; Liu, X; Qin, Q; Wang, Y | 1 |
| Ahn, JS; Ahn, MJ; Cho, BC; Cho, EK; Jeong, HC; Kim, EK; Kim, HR; Kim, JH; Lee, JH; Lim, SM; Min, YJ; Park, K | 1 |
| Buiting, HM; de Kanter, W; Linn, SC; Smorenburg, CH | 1 |
| Chamberlain, MC; Le Rhun, E; Taillibert, S | 1 |
| Fei, Z; Jiang, H; Li, J; Xu, J; Zhu, X | 1 |
| An, C; Chu, H; Gu, C; Lu, R; Shi, H; Xiao, F; Yi, X; Zhang, H; Zhang, J; Zhu, F | 1 |
| Li, L; Shao, Z; Wang, Z; Xie, H; Yang, F; Zhou, N | 1 |
| Büch, J; Gress, A; Kalinina, OV; Keller, A; Ramensky, V | 1 |
| Ikegami, D; Kuzumaki, N; Narita, M | 1 |
| Huang, HY; Ji, H; Wang, Y; Yang, L; Zhang, Z | 1 |
| Cao, XJ; Garcia, BA; Kharbanda, A; Runkle, KB; Stypulkowski, E; Wang, W; Witze, ES | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Niioka, T; Okuda, Y; Sato, K; Takeda, M | 1 |
| Li, JL; Liu, JL; Liu, ZL; Sun, YN; Tang, ZS; WANG, CL; Wang, Z; Zhang, N | 1 |
| Chang, N; Duan, Q; Liu, W; Pang, C; Zhang, J | 1 |
| Chakravarti, B; Chattopadhyay, N; Datta, D; Dogra, S; Gurjar, A; Kumar, H; Kushwaha, S; Rao, G; Sanyal, S; Singh, AK; Tripathi, AK; Trivedi, AK; Vishwakarma, AL; Yadav, M; Yadav, PN | 1 |
| Barone, C; Cassano, A; D'Argento, E; Dadduzio, V; Di Noia, V; Rossi, S; Schinzari, G | 1 |
| Hsiue, EH; Lee, JH; Lin, CC; Yang, JC | 2 |
| Gong, J; Hu, P; Sun, S; Tang, F; Wang, Y; Wang, Z; Xie, C | 1 |
| Bates, V; Boland, A; Dundar, Y; Dwan, K; Green, JA; Greenhalgh, J; Jain, P; Vecchio, F | 1 |
| Brown, N; Clifton-Hadley, L; Dungey, F; Hopkins, K; Jeffries, S; Khan, I; Krell, D; McBain, C; Mulholland, P; Nash, S; Phillips, M; Sanghera, P; Saran, F; Smith, P; Wanek, K | 1 |
| Choi, YS; Kong, SH; Seong, JY; Suh, HS | 1 |
| David, JM; Dominguez, C; Fernando, RI; Hamilton, DH; McCampbell, KK; Palena, C | 1 |
| Han, W; Jiang, L; Jing, J; Jing, Z; Pan, H; Shou, J; Sui, X; Xie, J; Yao, J; You, L | 1 |
| Arai, J; Matsumoto, K; Miyazaki, T; Mochinaga, K; Nagasaki, T; Nagayasu, T; Nanashima, A; Tominaga, T; Tsuchiya, T; Tsukamoto, K; Yamasaki, N | 1 |
| Choi, YR; Kim, KY; Lee, Y; Shin, DH | 1 |
| Lai, FC; Li, X; Lin, JB; Lin, JW; Lin, M; Liu, B; Luo, RG; Qiu, ML; Tu, YR | 1 |
| Cai, XW; Chang, JH; Fu, XL; Huang, QL; Liu, Q; Liu, ZB; Lu, YN; Pan, SY; Wang, JL; Wu, XH; Zhao, XM | 1 |
| Jia, L; Li, S; Li, W; Li, Y; Wang, S; Wang, T; Xu, S; Yang, Z; Zhang, S | 1 |
| Fujita, M; Hirano, R; Hirota, T; Kubo, A; Matsumoto, T; Nabeshima, K; Uchino, J; Watanabe, K; Yamaguchi, E; Yokoi, T | 1 |
| Chin, TM; Lee, JZ; Leow, YN; Lim, B; Lim, EH; Lim, EK; Lim, PX; Lim, WT; Lunny, DP; Malusay, SR; Nga, ME; Pang, YH; Shyh-Chang, N; Soo, RA; Sun, LL; Tai, BC; Tam, WL; Tan, BJ; Tan, DS; Tan, EH; Yang, H; Zhang, WC | 1 |
| Darko, KO; Huang, Y; Peng, CY; Peng, M; Su, Q; Tao, T; Tao, X; Xu, W; Yang, X | 1 |
| Fukuda, M; Ikeda, T; Ikegami, Y; Izumikawa, K; Mizoguchi, K; Motoshima, K; Mukae, H; Nakamura, Y; Nakatomi, K; Ogawara, D; Sano, K; Sato, S; Senju, H; Sugasaki, N; Takemoto, S; Yamaguchi, H | 1 |
| He, KW; Huo, ZJ; Liu, ZY; Ma, QH; Song, XG; Wang, XW; Wang, XZ; Yu, ZY; Zhuo, PY | 1 |
| Chang, HH; Coumar, MS; Hsieh, HP; Kuo, CC; Shiao, HY; Singh, VK | 1 |
| Chen, TC; Huang, HS; Lee, H; Wu, DW | 1 |
| Li, H; Li, S; Sun, P; Wu, D; Xu, K; Yan, J; Yang, H | 1 |
| Han, SY; Li, PP; Zhao, C | 1 |
| Dong, L; Guo, L; Li, L; Li, W; Li, Z; Lin, D; Ling, Y; Qiu, T; Yang, L; Yang, X; Ying, J | 1 |
| Choi, JW; Hua, TN; Jeong, Y; Kim, HW; Kim, KW; Kim, MK; Phan, AN; Rho, JK; Vo, VT | 1 |
| Doi, T; Enatsu, S; Kojima, T; Nakamura, T; Ohmatsu, H; Takahashi, H; Turner, K; Uenaka, K; Wacheck, V; Yoh, K; Zenke, Y | 1 |
| Chavez, J; De La Chapa, JJ; Dybdal-Hargreaves, NF; Gonzales, CB; Horning, AM; Kirma, NB; Parra, J; Saikumar, P; Singha, PK | 1 |
| Álvarez-Fernández, C; Esteban-González, E | 1 |
| Hai, P; Wang, YY; Xia, B; Zhang, CY; Zhao, R; Zhe, H; Zhou, S | 1 |
| Ding, Q; Li, H; Li, J; Wang, S; Wang, Y; Xia, J; Ye, P; Zhang, Y | 1 |
| Chang, WC; Chu, YY; Hour, TC; Li, CF; Wang, JM; Wang, WJ; Wang, YH; Yen, CJ | 1 |
| Ballard, P; Box, M; Cantarini, M; Cross, D; Grist, M; Hickey, M; Jänne, PA; Johnström, P; Jordan, A; Kim, DW; Malmquist, J; Pickup, K; Thress, KS; Varnäs, K; Yang, JC; Yang, Z; Yates, JW | 1 |
| Cajal, R; Calle, C; Clopes, A; Cordero, LA; Crespo, R; Gasol, M; Germà, JR; Gilabert, A; Mora, R; Segú, L; Simon, S | 1 |
| Huang, G; Jia, W; Li, J; Liu, J; Liu, L; Miao, P; Song, S; Sun, X; Yan, H; Yang, H; Zhao, L; Zhao, X; Zhou, X | 1 |
| Chang, GC; Close, S; Garrus, JE; Geater, SL; Han, M; Komarnitsky, P; Mok, TS; Park, K; Payumo, F; Su, WC; Tan, EH; Yang, JC | 1 |
| Fan, Z; Li, X; Lu, H; Lu, Y; Qiu, S | 1 |
| Close, AJ; Jones, RN; Kemmitt, P; Ocasio, CA; Roe, SM; Spencer, J | 1 |
| Creighton, CJ; Deng, B; Gibbons, DL; Guo, L; Lu, Q; Molina, JR; Sun, Z; Yang, P; Yang, Y; Yi, ES; Zhang, T | 1 |
| Al-Daccak, R; Antonicelli, F; Bastid, J; Bensussan, A; Cure, H; Fabre, J; Fuselier, C; Garbar, C; Giustiniani, J; Merrouche, Y | 1 |
| Fukuhara, T; Maemondo, M; Morita, M; Nukiwa, T; Suzuki, A; Tanaka, N; Terasaki, H; Tsukita, Y; Watanabe, K | 1 |
| Chen, Y; Dendy, M; Gruvberger-Saal, SK; Hibshoosh, H; Horlings, HM; Isola, J; Jumppanen, M; Lau, YK; Maurer, M; Memeo, L; Parsons, R; Rosen, N; Saal, LH; She, QB; Su, T; van de Vijver, MJ | 1 |
| Li, Y; Liu, W; Luo, E; Tian, L; Wang, Y; Wen, L; Wen, M; Wen, N; Yang, H; Yun, Y; Zhang, W; Zhao, L; Zhu, X | 1 |
| He, X; Hong, S; Huang, Y; Ma, Y; Sheng, J; Yang, Y; Zhang, J; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H; Zhou, T | 1 |
| Maeda, A; Nakata, M; Okita, R; Saisho, S; Shimizu, K; Yukawa, T | 1 |
| Coghi, PS; Fan, XX; Law, BY; Leung, CH; Leung, EL; Liu, L; Ma, DL; Mok, SW; Wong, VK; Xu, SW; Zeng, W | 1 |
| Chen, Y; Mu, L; Tang, X; Wang, T; Yuan, Y; Zhao, Y | 1 |
| Buck, A; Bundschuh, R; Dandekar, G; Fecher, D; Hofmann, E; Lückerath, K; Nietzer, S; Steinke, M; Walles, H; Walles, T | 1 |
| Cheng, Y; Enatsu, S; He, J; Kang, JH; Kim, JH; Murakami, H; Nakagawa, K; Orlando, M; Puri, T; Wang, X; Yang, JC; Yang, PC | 1 |
| Cataisson, C; Krymskaya, L; Mascia, F; McKinnon, KM; Schloemann, DT; Wolcott, KM; Yuspa, SH | 1 |
| Dietel, M; Eberhardt, W; Griesinger, F; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Fan, S; Wang, W; Zang, H | 1 |
| Chen, X; Du, Y; Han, J; Sun, H; Sun, M; Wang, F; Zhao, J; Zong, Z | 1 |
| Chapman, S; Kannan, R; Leevy, M; Srikar, R; Suresh, D; Taylor, K; Upendran, A; Zambre, A | 1 |
| Conner, GE; Fregien, NL; Valencia-Gattas, M | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Goto, K; Kirita, K; Matsumoto, S; Niho, S; Ohmatsu, H; Sugiyama, E; Umemura, S; Yoh, K; Zenke, Y | 1 |
| Bidoli, P; Buosi, R; Burgio, MA; Cappuzzo, F; Cerea, G; Chiari, R; Cortinovis, D; De Marinis, F; Del Conte, A; Ferrari, S; Finocchiaro, G; Foltran, L; Giannetta, L; Mazzoni, F; Migliorino, MR; Montanino, A; Morabito, A; Normanno, N; Tiseo, M | 1 |
| Allison, JP; Cha, JH; Chan, LC; Chang, SS; Ding, Q; Hortobagyi, GN; Hsu, JL; Hsu, JM; Hung, MC; Khoo, KH; Kim, T; Kuo, CW; Lee, CC; Lee, HH; Li, CW; Lim, SO; Sahin, AA; Wang, Y; Wu, HJ; Wu, Y; Xia, W; Yamaguchi, H; Yao, J; Yu, D | 1 |
| Chang, CL; Chang, YW; Chen, SY; Chen, TH; Lin, SB | 1 |
| Kowalski, DM; Krzakowski, M; Piórek, A; Szmit, S; Zaborowska-Szmit, M | 1 |
| Chang, TY; Chen, PS; Hsu, HP; Huang, MT; Kuo, KT; Lai, HH; Li, JN; Lyu, YJ; Su, CM; Su, JL | 1 |
| Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Minami, D; Ninomiya, K; Ninomiya, T; Oda, N; Ohashi, K; Sato, A; Tabata, M; Takigawa, N; Tanimoto, M; Yoshioka, H | 1 |
| Du, Z; Tang, X; Yang, M; Zhou, Y; Zhuang, J | 1 |
| Dietel, M; Eberhardt, WE; Radke, S; Schirmacher, P; Schuette, W; Thomas, M; Waller, C; Zirrgiebel, U | 1 |
| Arata, S; Hirose, T; Ishida, H; Kishino, Y; Kusumoto, S; Murata, Y; Ohba, M; Ohmori, T; Ohnishi, T; Sasaki, Y; Shirai, T; Yamaoka, T | 1 |
| Chen, DQ; Ding, J; Geng, MY; Liu, HC; Shen, AJ; Shen, JK; Sun, JY; Wang, X; Wang, YQ; Xiong, B; Zhang, MM; Zheng, M | 1 |
| Chen, HJ; Chen, ZH; Su, J; Tu, HY; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Chen, L; Cheng, H; Guo, X; Meng, Y; Sheng, X; Tai, G; Zhang, F; Zhou, Y | 1 |
| Eigenmann, MJ; Frances, N; Hoffmann, G; Lavé, T; Walz, AC | 1 |
| Beijnen, JH; Rood, JJM; Rosing, H; Schellens, JHM; Sparidans, RW | 1 |
| Chen, H; Deng, J; Guo, G; Liu, Y; Peng, X; Tong, A; Wang, Y; Xu, J; You, C; Zhou, L | 1 |
| Aerts, HJ; Grossmann, P; Oxnard, GR; Rizvi, N; Schwartz, LH; Tan, Y; Zhao, B | 1 |
| Fukuoka, M; Hohjoh, H; Takahashi, M; Yoshioka, K | 1 |
| Bunn, PA; Casás-Selves, M; Chan, DC; DeGregori, J; Grosskurth, SE; Helfrich, BA; Kim, J; Scarborough, HA; Schuller, AG; Tan, AC; Zaberezhnyy, V; Zhang, Z | 1 |
| Böhning, E; Calvisi, DF; Cigliano, A; Dombrowski, F; Evert, M; Günther, J; Merz, J; Peters, K; Pilo, MG; Ribback, S; Sailer, V; Steinmüller, F; Utpatel, K | 1 |
| Chang, YH; Chien, KH; Hsu, CR; Tai, MC | 1 |
| Nakamura, H; Nishimura, T | 1 |
| Andäng, M; Baskaran, S; Claesson-Welsh, L; Elfineh, L; Forsberg-Nilsson, K; Green, LC; Häggblad, M; Johansson, P; Krona, C; Lönnstedt, I; Lundgren, B; Martens, U; Matuszewski, D; Nelander, S; Padhan, N; Schmidt, L; Sintorn, IM; Uhrbom, L; Wee, S; Westermark, B | 1 |
| Feng, X; Jiang, J; Wu, Y; Yang, Y; Zhou, W | 1 |
| Aleksakhina, SN; Chubenko, VA; Imyanitov, EN; Ivantsov, AO; Iyevleva, AG; Kozyreva, KS; Kramchaninov, MM; Mitiushkina, NV; Moiseyenko, FV; Moiseyenko, VM; Preobrazhenskaya, EV; Shelekhova, KV; Venina, AR; Volkov, NM; Zhuravlev, AS | 1 |
| Cai, H; Miao, L; Qian, D; Tian, Y; Wang, Y; Yang, J; Yang, Z; Zhang, Z | 1 |
| Kawahara, K; Maeda, T; Watanabe, S; Yamada, D | 1 |
| Dong, SY; Ji, J; Li, BB; Tao, L; Tong, XH; Wu, DD; Wu, JF; Yu, ML | 1 |
| Kataoka, K; Okamura, Y; Osaka, E; Shimizu, T; Tokuhashi, Y; Yoshida, Y | 1 |
| Du, Y; Liu, H; Ma, T; Pan, Y; Shen, Y; Zhu, Y | 1 |
| Chen, Z; Jiang, B; Su, J; Wu, YL; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhou, Q | 1 |
| Hosomi, Y; Kashima, J; Miwa, M; Okuma, Y | 2 |
| Adam, J; Artignan, X; Bardet, E; Lacas, B; Lacroix, L; Le Péchoux, C; Levy, A; Pignon, JP; Verrelle, P | 1 |
| Bi, M; Chen, W; Ding, F; Tang, C; Tang, DJ; Wang, J; Yu, H | 1 |
| Chen, M; Gu, Y; Sun, Y; Wang, M; Xu, Y; Yang, Z; Ye, X; Zhao, J; Zhong, W; Zhu, G | 1 |
| Jeong, JH; Kwon, TK; Oh, YJ; Seo, YH | 1 |
| Holtrich, U; Karn, T; Kedan, A; Kothari, C; Lev, S; Mills, GB; Müller, AK; Nguyen, LK; Panayotopoulou, E; Selitrennik, M; Shin, S; Verma, N | 1 |
| Beck, S; Frejno, M; Klaeger, S; Koch, H; Kuster, B; Ruprecht, B; Wilhelm, M | 1 |
| Wu, YL; Xu, CR; Yang, JJ; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Han, B; Jin, B; Lou, Y; Wang, H; Wu, D; Xu, J; Yang, H; Zhang, X; Zhang, Y; Zhong, H | 1 |
| Li, B; Lin, D; Wan, Y; Yao, Z | 1 |
| Chai, Y; Yu, T; Zhu, Z | 1 |
| Ahn, MJ; Cho, BC; Jang, JS; Jung, I; Kim, DW; Kim, HR; Kim, JH; Kim, SW; Lee, DH; Lee, KH; Sun, JM | 1 |
| Chen, J; Li, Y; Liu, H; Liu, M; Wang, Y; Xu, S; Zhang, H | 1 |
| Cheng, YD; Chung, JG; Hsia, TC; Hsiao, YT; Huang, AC; Kuo, CL; Lin, TS; Ma, YS; Peng, SF; Yang, MD | 1 |
| Chang, HY; Chang, YL; Chao, MW; Cheng, CC; Cheng, HC; Hsu, CC; Hsu, JT; Lin, SI; Liu, SJ; Liu, TW; Pan, SL; Tsai, HJ; Tseng, CP; Wang, HY | 1 |
| Fujimoto, J; Goshima, N; Higa, A; Hiyama, G; Hoshi, H; Inageda, K; Ishikawa, K; Kawamura, Y; Semba, K; Takagi, M; Takahashi, N; Togashi, T; Wakamatsu, A; Watanabe, S | 1 |
| Chow, LW; Fan, XX; Jiang, ZB; Leung, EL; Li, X; Liu, L; Loo, WT; Yao, XJ | 1 |
| Antunes, A; Massa, A; Varela, P | 1 |
| Chen, G; Gao, Y; Huang, C; Lu, Z; Shi, L; Song, Z; Wang, B; Wang, Y; Xu, D; Zhang, H; Zhang, W; Zhang, Y; Zhuang, N | 1 |
| Chang, H; Kim, HS; Kim, JW; Lee, JS; Moon, SU; Sung, JH | 1 |
| Asmat, A; Kumarakulasinghe, NB; Loy, EY; Pang, B; Soo, RA; Soon, YY; Syn, N; Zheng, H | 1 |
| Ang, MK; Chowbay, B; Jain, A; Kanesvaran, R; Lim, WT; Ng, QS; Sutiman, N; Tan, EH; Tan, SW; Tan, WL; Toh, CK | 1 |
| Pakkala, S; Ramalingam, SS | 1 |
| Hong, ST; Lin, AM; Lin, KH; Lo, YL; Wang, HT; Yang, JC | 1 |
| Cao, XN; Deng, Y; Hu, FY; Hu, JB; Lai, SY; Ma, J; Xu, QZ | 1 |
| Chen, M; Guo, Y; Huang, J; Jiang, H; Li, M; Xie, Y; Yue, S; Zhang, F; Zhou, G | 1 |
| Kannan, N; Katiyar, S; Ruan, Z | 1 |
| Emons, G; Girgert, R; Gründker, C | 1 |
| Chen, W; Hennink, WE; Kok, RJ; Palazzo, A | 1 |
| An, N; Cai, J; Li, Q; Li, Z; Niu, H; Zhang, Y; Zhao, Q | 1 |
| Hann, SS; Li, L; Wang, S; Wu, W; Zheng, F | 1 |
| Cai, W; Cao, TH; Chen, C; Li, Y; Lu, HL; Ning, ZQ; Shen, H; Shu, YQ; Wang, L; Zhu, J | 1 |
| Jung, YS; Kim, YJ; Kwak, JH; Pyo, JS | 1 |
| Back, D; Clotet, B; Miranda, C; Moltó, J; Owen, A; Rajoli, R; Siccardi, M; Valle, M | 1 |
| Chen, Z; Deng, W; Ke, E; Niu, F; Su, J; Wu, Y; Xu, C; Yan, H; Yang, J; Zhang, Q; Zhang, X; Zhao, N; Zhou, Q | 1 |
| Song, Z; Wang, W; Zhang, Y | 1 |
| Abe, T; Hirata, A; Ito, H; Mano, N; Sato, T; Yamaguchi, H | 1 |
| Bray, V; Ding, PN; Gebski, V; Gralla, RJ; Lee, CK; Links, M; Lord, SJ; Yang, JC | 1 |
| Bertolini, F; Bettelli, S; Longo, L; Manfredini, S; Mengoli, MC; Rossi, G | 1 |
| Hanaoka, J; Hayashi, H; Iihara, H; Itoh, Y; Kawaguchi, Y; Mizusaki, N; Sugiyama, T | 1 |
| Bashir, ES; Chan, CY; Kwan, AK; Mun Keong, K | 1 |
| Ding, L; Fu, J; Lu, S; Tan, F; Wu, B; Ye, M | 1 |
| Han, L; He, J; Huang, Z; Li, W; Ma, P; Nie, F; Zhang, M | 1 |
| Bai, JP; Chen, X; Li, Y; Liu, LR; Liu, YH; Qu, X; Qu, YC; Zhang, FL; Zhang, HB; Zheng, GJ; Zhu, YJ; Zhu, YZ | 1 |
| Chen, HY; He, Y; Kang, J; Li, KL; Li, L; Wang, YB; Zhang, P | 1 |
| Chen, L; Gonzalez, FJ; Gu, J; Hu, CL; Hu, L; Li, L; Li, S; Lin, XM; Liu, JF; Tang, J; Wang, HY; Wang, RY; Wu, MC; Yan, XZ; Zhang, BH; Zhou, WP; Zhu, YJ | 1 |
| Cui, Y; He, Y; Liu, M; Ma, H; Qiu, P; Tang, Y; Wang, S; Xu, H; Xu, L; Zeng, X; Zhang, L; Zhang, M | 1 |
| Jänne, PA; Saxon, JA; Sholl, LM | 1 |
| Jiang, H; Li, J; Liu, X; Xu, H; Zheng, R | 1 |
| Bai, XY; Chen, HJ; Jiang, BY; Su, J; Tu, HY; Wang, BC; Wang, Z; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zhong, WZ; Zhou, Q | 1 |
| Erbacher, I; Gotham, D; Harada, R; Hill, A; Meldrum, J; Redd, C | 1 |
| Hagiwara, K; Iwai, Y; Kawamura, R; Koyama, N; Koyama, S; Miwa, C; Nagai, Y; Watanabe, Y | 1 |
| Bae, E; Ikeda, N; Kato, M; Kuroda, M; Makino, Y; Mamura, M; Miyazawa, K; Ohira, T; Yoon, JH | 1 |
| Fukui, T; Ichinoe, M; Igawa, S; Katagiri, M; Kubota, M; Masuda, N; Murakumo, Y; Nakahara, Y; Nakashima, H; Otani, S; Ryuge, S; Sasaki, J; Sato, Y; Satoh, Y | 1 |
| Bachoo, RM; Cho, SK; Hatanpaa, KJ; Humphries, CG; Kim, RS; Kittler, R; Klingler, S; Kollipara, RK; Maher, EA; Mashimo, T; Mickey, B; Nannepaga, S; Piccirillo, S; Raisanen, J; Regmi, N; Singh, DK; Sirasanagandla, S; Sun, Y; Vemireddy, V; Wang, S; Yang, XL; Zheng, H | 1 |
| Assi, T; El Rassy, E; Ghosn, M; Kattan, J; Moussa, T | 1 |
| Kuai, ZY; Li, W; Liu, LW; Meng, YQ; Zhao, YW | 1 |
| Di Maio, M; La Salvia, A; Rossi, A | 1 |
| Jensen, RT; Mantey, SA; Moody, TW; Moreno, P; Ramos-Alvarez, I; Ridnour, L; Wink, D | 1 |
| Acquaviva, G; Brand, T; Brandes, AA; Cavallo, G; de Biase, D; Degli Esposti, R; Di Battista, M; Genestreti, G; Pession, A; Tallini, G; Visani, M | 1 |
| Chang, CH; Lee, CH; Wang, JY | 1 |
| Masson, E; Tang, W; Tomkinson, H | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wang, Z; Wu, J; Wu, Y; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Chen, W; Clauser, J; Hennink, WE; Jockenhoevel, S; Kelly, N; Kok, RJ; McGrath, DJ; McHugh, PE; Steinseifer, U; Thiebes, AL; van Steenbergen, MJ | 1 |
| Benveniste, EN; Dees, KJ; Gibson, SA; Hjelmeland, AB; McFarland, BC; Meares, GP; Nozell, SE; Rajbhandari, R; Rowse, AL | 1 |
| Li, P; Ma, Z; Wang, H; Yan, X; Zhang, G; Zhang, M | 1 |
| Ellison, K; Hirsch, FR; Kim, J; Mitsudomi, T; Murakami, I; Rivard, CJ; Suda, K; Yu, H | 1 |
| Chewaskulyong, B; Fukuoka, M; Haddad, V; Han, B; Ichinose, Y; Margono, B; Mok, TS; Ohe, Y; Rukazenkov, Y; Saijo, N; Sunpaweravong, P; Thongprasert, S; Wu, YL; Yang, JC; Yang, JJ; Young, H | 1 |
| Pi, C; Xu, CR; Zhang, YC; Zhou, Q | 1 |
| Song, Y; Yuan, DM | 1 |
| Choi, SY; Kim, HR; Lee, SY; Ryu, PD | 1 |
| Aiuchi, T; Arakawa, K; Hamada, Y; Igarashi, K; Ikegami, D; Iwasawa, C; Kuzumaki, N; Nagasawa, A; Narita, M; Ochiya, T; Shimura, E; Suda, Y; Takeshima, H; Ushijima, T; Yoshioka, Y | 1 |
| Li, Y; Lu, H; Pan, J; Shi, Y; Xie, Z; Xu, Y; Zhang, M | 1 |
| Ajithkumar, T; Geropantas, K; Glenn, A; Kouroupis, M; Maskell, D | 1 |
| Chen, L; Li, B; Liu, J; Wang, W; Zhang, Y; Zhao, L | 1 |
| Fraser, A | 1 |
| Peng, H; Xia, L; Xiaoli, Z; Zhiqiang, L | 1 |
| Fujii, S; Kashiwabara, K; Semba, H; Tsumura, S | 1 |
| Chen, Y; Fuller-Pace, FV; Gong, D; Huang, L; Huang, Z; Li, K; Li, Y; Lin, P; Mo, C; Wei, Y; Zhang, J | 1 |
| Chen, H; Dong, D; Dong, L; Fu, M; Hong, R; Liu, X; Lu, N; Ma, L; Ou, Y; Song, Y; Xiao, W; Xue, L; Zhan, Q; Zhang, W; Zhao, Z | 1 |
| Hu, Y; Jin, X; Shi, L; Su, Y; Zhang, C; Zhu, X | 1 |
| Akashi, K; Harada, T; Ijichi, K; Iwama, E; Nakanishi, Y; Obara, T; Ogata, H; Okamoto, I; Yoshimoto, G | 1 |
| Ahmadinia, L; Alimoghaddam, K; Amanpour, S; Barghi, F; Dardaei, L; Dehpour, AR; Emami, AH; Eyvani, H; Ghaffari, SH; Ghavamzadeh, A; Ghazi-Khansari, M; Gortany, NK; Mirshahvaladi, S; Moghaddaskho, F; Momeny, M; Sabourinejad, Z; Tavangar, SM; Yousefi, H; Zarrinrad, G | 1 |
| Chen, YJ; Choong, WK; Hong, TM; Hsu, YL; Kuo, TC; Liao, YC; Pan, SH; Sung, TY; Tsai, CF; Wang, YT; Wu, HY; Yang, PC; Yen, HY | 1 |
| Feng, Q; Fu, X; Hackshaw, A; Mao, C; Tang, J; Yang, Z; Zhang, Y | 1 |
| Arimura-Omori, M; Hamada, N; Harada, E; Ikeda-Harada, C; Mikumo, H; Nakanishi, Y; Ogata-Suetsugu, S; Suzuki, K; Yanagihara, T; Yokoyama, T | 1 |
| Biswas, L; Keechilat, P; Melge, AR; Mohan, CG; Panicker, PS | 1 |
| Berghmans, T; Besse, B; De Maio, E; Dziadziuszko, R; Hasan, B; Menis, J; Novello, S; Peric, A; Reck, M; Remon, J; Wasag, B | 1 |
| Kaneda, H; Koyama, A; Matsuoka, H; Nakagawa, K; Nishio, K; Sakai, K | 1 |
| Cao, H; Fan, F; Feng, J; Hu, Y; Liu, S; Ma, R; Ni, J; Qin, X; Sha, H; Wu, J; Xu, X; Yan, D; Yu, S; Zang, J; Zhou, L | 1 |
| Chen, JK; Dong, G; Dong, Z; Liu, Y; Yao, Q; Zhang, H; Zhang, M; Zhang, W; Zhou, X | 1 |
| Breunig, JJ; Chan, SL; Chen, Y; Ching, J; Ding, LW; Doan, N; Dutra-Clarke, M; Hazawa, M; Jiang, YY; Koeffler, HP; Kovalik, JP; Lin, DC; Madan, V; Mayakonda, A; Müschen, M; Said, JW; Savinoff, SE; Tyner, JW; Watkins, A; Xu, L; Yang, H; Yong, WH | 1 |
| Al Mamun Bhuyan, A; Cao, H; Lang, F; Wagner, T | 1 |
| Agarwal, SM; Gupta, M; Pal, D; Saini, R | 1 |
| Li, J; Ma, J; Wang, Y; Wang, Z; Wu, X | 1 |
| Ansari, A; Noolvi, M; Patel, HM; Pawara, R; Surana, S | 1 |
| Davies, L; Fukuoka, M; Gebski, V; Gralla, RJ; Inoue, A; Lee, CK; Lord, S; Marschner, I; Mitsudomi, T; Mok, T; Nakagawa, K; Rosell, R; Thongprasert, S; Tu, YK; Wu, YL; Yang, JC; Zhou, C | 1 |
| He, H; He, X; Lan, BH; Li, MX; Li, RQ; Liu, GD; Ruan, ZH; Wang, G; Wu, Y; Xiao, HL; Yang, ZZ; Zhang, ZM; Zhu, B; Zhu, YX | 1 |
| Asano, M; Hasegawa, Y; Ito, H; Kobayashi, H; Miura, H; Miura, M; Niioka, T; Okuda, Y; Sano, M; Sato, K; Sudo, K; Takeda, M; Watanabe, H | 1 |
| Huang, S; Jiang, Y; Li, Y; Liu, K; Ma, X; Meng, Q; Shu, X; Song, Z; Sun, H; Wang, C; Yu, H | 1 |
| Bai, Y; Chen, H; Chen, ZH; Chuai, S; Gan, B; Gao, H; Gou, LY; Han-Zhang, H; Jiang, BY; Li, A; Liu, SY; Su, J; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xie, Z; Xu, CR; Yang, JJ; Yang, XN; Yang, Z; Zhang, Q; Zhang, XC; Zhang, Z; Zhong, WZ; Zhou, Q | 1 |
| Chen, CM; Cheng, CY; Lin, KY; Lu, CY; Wu, YH | 1 |
| Shi, Y; Su, C; Zhao, L; Zheng, Y | 2 |
| Belli, V; Ciaramella, V; Ciardiello, F; Della Corte, CM; Malapelle, U; Martinelli, E; Morgillo, F; Pepe, F; Troiani, T; Troncone, G; Vigliar, E | 1 |
| Cho, YJ; Chung, JH; Eo, EY; Jung, MH; Kim, CH; Kim, S; Lee, CT; Lee, JH; Lee, SH; Lee, YJ; Park, JS; Park, MY; Yoon, HI | 1 |
| Boyer, M; Dodd, N; Fan, J; Hirsh, V; Kim, DW; Kölbeck, K; Laskin, J; Laurie, SA; Lee, DH; Lee, KH; Lu, S; Märten, A; Mok, T; O'Byrne, K; Park, K; Paz-Ares, L; Shi, Y; Tan, EH; Yang, JC; Zhang, L | 1 |
| Bai, H; Hong, C; Mei, TH; Wang, J | 1 |
| Dai, PC; Lai, GX; Lin, XH; Liu, DL; Wang, Q; Ye, J; Zhang, HW; Zhang, L | 1 |
| Dokuni, R; Kiriu, T; Kobayashi, K; Kunimasa, K; Nagano, T; Nishimura, Y; Satouchi, M; Shimono, Y; Tachihara, M; Tamura, D; Tokunaga, S; Yamamoto, M | 1 |
| Jean-Claude, B; Thibault, B | 1 |
| Amin, Z; Jayalie, VF; Rajabto, W | 1 |
| Boeck, S; Heinemann, V; Hichert, V; Kächele, V; Paul, T; Rüdiger, S; Scholl, C; Schumann, C; Seufferlein, T; Steffens, M; Stingl, J | 1 |
| Cai, J; Fang, P; Ge, H; He, J; Hu, G; Tang, P; Zheng, X | 1 |
| Chen, G; Huang, X; Huang, Y; Kang, S; Miao, S; Wu, M; Zhang, L; Zhang, Y; Zhang, Z; Zhao, H | 1 |
| Cui, S; Jiang, L | 1 |
| Liu, S; Liu, X; Pan, X; Qin, A; Ren, H; Yang, B; Yu, G; Zhang, K | 1 |
| Acunzo, M; Coppola, V; Croce, CM; Fadda, P; Fassan, M; Fattore, L; Kladney, R; Laganà, A; Nigita, G; Rizzotto, L; Romano, G; Veneziano, D; Zanesi, N | 1 |
| Chong, IW; Chou, SH; Hsu, JS; Huang, MS; Hung, JY; Lee, JY; Liu, TC; Tsai, MJ; Wu, KL; Yang, CJ | 1 |
| Burgio, F; Faia-Torres, AB; Fontana, AO; Marchi, F; Paganetti, P; Pieles, U; Piffaretti, D; Pinton, S; Reinert, M | 1 |
| Chen, JS; Chen, KY; Chih-Hsin Yang, J; Ho, CC; Liao, WY; Lin, CC; Lin, ZZ; Shih, JY; Yao, ZH; Yu, CJ | 1 |
| Ben-Shlomo, A; Cooper, O | 1 |
| He, K; Liu, C; Liu, Z; Ma, Q; Ndege, I; Wang, X; Yu, Q; Yu, Z | 1 |
| Chic, N; Mayo-de-Las-Casas, C; Reguart, N | 1 |
| Johnson, JR; Krogan, NJ; Lien, KA; Sogi, KM; Stanley, SA | 1 |
| Chatterjee, A; Chau, I; Chong, IY; Clark, C; Dahle-Smith, A; Dutton, SJ; Elyan, S; Falk, SJ; Ferry, DR; Fyfe, DW; Garcia-Alonso, A; Harrison, M; Mansoor, W; Massie, D; Miedzybrodzka, Z; Murray, GI; Osborne, A; Petty, RD; Roberts, C; Stevenson, DAJ; Thompson, J; Wadsley, J | 1 |
| Chen, YW; Chiou, SP; Chou, TL; Ho, MY; Li, LT; Liang, YJ; Lin, CY; Lin, YJ; Wang, CY; Wang, IA; Wang, YH; Yu, J | 1 |
| Chen, KL; Cheng, YP; Cho, YT; Chu, CY; Liau, JY; Sheen, YS; Yang, CW | 1 |
| Li, Y; Liu, D; Quan, Y; Wu, B; Wu, Y; Zhang, D; Zhang, X | 1 |
| Aderhold, C; Birk, R; Hock, C; Hörmann, K; Kramer, B; Kuhlin, B; Lammert, A; Schultz, JD | 1 |
| Chu, T; Dong, Y; Gu, A; Han, B; Jin, B; Lou, Y; Niu, Y; Pei, J; Shi, C; Wang, H; Xu, J; Zhang, W; Zhang, X; Zhang, Y; Zhong, H; Zhu, L | 1 |
| Höllhumer, R; Jacob, K; Moloney, G | 1 |
| Chen, H; Hu, J; Li, D; Li, J; Shi, M; Wang, X; Zhang, H; Zhang, L; Zhang, R | 1 |
| Asano, M; Ito, H; Kobayashi, H; Miura, M; Okuda, Y; Sato, K; Takeda, M; Yokota, H | 1 |
| Liu, F; Liu, Y; Luo, H; Wu, Y; Zhao, Y | 1 |
| Hida, T; Horio, Y; Inaba, Y; Kuroda, H; Oya, Y; Sakao, Y; Shimizu, J; Yatabe, Y; Yoshida, T | 1 |
| Dong, Z; Gao, H; Hu, H; Li, X; Liu, B; Liu, X; Liu, Y; Shi, W; Sun, Y; Tang, C; Xu, H; Zhu, G | 1 |
| Döring, E; Engel, J; Günther, M; Juchum, M; Keul, M; Lategahn, J; Laufer, S; Rauh, D; Tumbrink, HL | 1 |
| Chen, Z; He, Q; Huang, G; Tong, Y; Wang, J | 1 |
| Burbridge, MF; Cattan, V; Chargari, C; Clémenson, C; Deutsch, E; Ferté, C; Jacquet-Bescond, A; Liu, W; Mondini, M | 1 |
| Bosch-Barrera, J; Costa, EC; Insa, A; Isla, D; Kraemer, S; Lee, C; Majem, M; Moran, T; Palmero, R; Provencio, M; Puig, M; Reguart, N; Rosell, R; Schnell, D | 1 |
| Abbas, A; Basak, S; Bhattacharya, P; Deep Punetha, V; Dey, S; Gopal Sahoo, N; Mondal, S; Saha, A | 1 |
| Chang, CH; Chang, LY; Ko, JC; Lee, CH; Lee, MC; Wang, JY; Yu, CJ | 1 |
| Dai, ZR; Ge, GB; Hao, DC; Jin, Q; Li, N; Liu, Y; Piao, HL; Wang, DD; Yang, L; Zhang, Y | 1 |
| Fan, XX; Fu, J; He, JX; Huang, J; Jiang, ZB; Kam, RK; Leung, EL; Liu, L; Liu, ZQ; Lu, LL; Luo, LX; Wei, CL; Wu, JL; Xiao, DK; Xie, Y; Yao, XJ; Yuan, ZW; Zheng, YF; Zhou, YL | 1 |
| Fukagawa, S; Ishikawa, T; Katsuda, T; Manabe, S; Miyahara, D; Miyamoto, S; Miyata, K; Nam, SO; Odawara, T; Yasunaga, S; Yotsumoto, F | 1 |
| Chen, HJ; Chen, WC; Hsia, TC; Li, CH; Liao, WC; Shen, YC; Tseng, GC; Tu, CY | 1 |
| Chen, CJ; Chen, MC; Huang, MS; Lee, AF; Liu, YP; Yang, CJ | 1 |
| Cho, SY; Choi, W; Chung, C; Jung, SS; Kang, D; Kim, HB; Kim, JO; Lee, BS; Lee, DH; Lee, JE; Lim, DS; Moon, JY; Park, DI; Park, HS; Park, YH; Yeo, MK; Yoo, G | 1 |
| Bai, P; Chen, L; Li, W; Luo, H; Peng, A; Tang, M; Wan, L; Wang, F; Wen, J; Wu, W; Yang, J; Yang, L; Yang, S; Ye, H; Zheng, L | 1 |
| Fu, J; Hong, T; Huang, J; Ji, Q; Jin, S; Li, L; Li, Y; Liang, Y; Liu, Y; Lyu, Z; Song, Q; Wang, T; Xu, X; Ye, Q; You, W; Zhao, W | 1 |
| Copello, GJ; De Fino, FT; Evelson, PA; Filia, MF; Marchini, T; Minoia, JM; Peroni, RN; Roma, MI; Rubio, MC | 1 |
| Corrao, G; Facchinetti, F; Ganzinelli, M; Garassino, MC; Lo Russo, G; Minari, R; Proto, C; Tiseo, M | 1 |
| Danilov, AV; Hamilton, BJ; Jones, JD; Rigby, WFC; Skopelja-Gardner, S | 1 |
| Chen, KC; Chen, PC; Cheng, CH; Huang, YH; Lan, CH; Lee, WY; Lin, CW; Wu, HC; Wu, WS | 1 |
| Cao, Y; Jiang, AY; Jiang, XF; Jin, H; Wang, H; Wu, Y | 1 |
| Fan, Y; Gong, L; Huang, Z; Xu, Y | 1 |
| Beretta, GD; Caprioli, A; Ceresoli, GL; Codignola, C; Fraccon, AP; Meriggi, F; Ogliosi, C; Prochilo, T; Scartozzi, M; Zaniboni, A | 1 |
| Cui, Y; Flamini, V; Jiang, WG | 1 |
| Chung, SJ; Kim, MS; Lee, JH; Maeng, HJ; Noh, CK | 1 |
| Bennouna, J; Chouaid, C; de Pouvourville, G; Do, P; LeLay, K; Luciani, L; Moro-Sibilot, D; Perol, M; Vergnenègre, A | 1 |
| Fei, Z; Jiang, H; Wang, H | 1 |
| Amadori, D; Bongiovanni, A; De Vita, A; Ghetti, M; Ibrahim, T; La Manna, F; Liverani, C; Mercatali, L; Miserocchi, G; Recine, F; Spadazzi, C | 1 |
| Chen, X; Chen, Z; Kong, R; Li, Y; Lu, D; Niu, K; Sun, J; Wang, Y; Xia, L | 1 |
| Baxter, RC; Boyle, FM; de Silva, HC; Julovi, SM; Lin, MZ; Martin, JL | 1 |
| Cao, B; Li, F; Liang, L; Wang, J; Zhu, T | 1 |
| Jameson, MJ; Khalil, A | 1 |
| Arata, S; Ohba, M; Ohmori, T; Yamaoka, T | 1 |
| Benveniste, MF; de Groot, PM; Papadimitrakopoulou, VA; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC | 1 |
| Arulananda, S; Do, H; Dobrovic, A; John, T; Mitchell, P; Musafer, A | 1 |
| Chen, H; Chen, J; Cui, L; Li, M; Liu, X; Ren, Y; Sun, Y; Wang, L; Wang, X; Wu, C; Yang, J; Zhang, J; Zhou, W | 1 |
| Groen, HJM; Heideman, DAM; Hiltermann, TJN; Kok, K; Kuiper, JL; Saber, A; Schuuring, E; Smit, EF; Terpstra, MM; Thunnissen, E; Timens, W; van den Berg, A; van der Wekken, AJ; Wei, J | 1 |
| Hu, J; Huang, J; Huang, X; Leng, D; Sun, J; Yang, S; Yao, Q | 1 |
| Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K | 1 |
| Hu, X; Tam, KY; Yang, Z; Zhang, S; Zhang, W | 1 |
| Fujii, I; Hagiwara, M; Katayama, M; Kobayashi, SS; Nakase, I; Sugiyama, A; Takatani-Nakase, T; Takenaka, T | 1 |
| Hamaguchi, R; Hasegawa, M; Okamoto, T; Sato, M; Wada, H | 1 |
| Bertrand, D; Chia, S; Chong, FT; DasGupta, R; Gopalakrishna Iyer, N; Hentze, H; Hui Choo, S; Hwang, JSG; Koh, JLY; Kwang, XL; Leong, HS; Lezhava, A; Lim, KH; Low, JL; Periyasamy, G; Sharma, A; Skanthakumar, T; Su, Y; Tan, DSW; Tan, HK; Tan, IBH; Tan, P; Thangavelu, MT; Toh, SY; Zhang, X | 1 |
| Chen, CY; Lee, H; Lin, PL; Wang, L; Wu, DW; Wu, TC | 1 |
| Baek, YM; Hwang, YE; Jang, D; Kim, DE; Park, H | 1 |
| Kharbanda, A; Runkle, K; Wang, W; Witze, ES | 1 |
| Li, J; Tang, C; Zhou, B | 1 |
| Ang, MK; Chang, MM; Chong, FT; Chowbay, B; Chua, BT; DasGupta, R; Iyer, NG; Kwang, XL; Lau, DP; Leong, HS; Lim, TKH; Lim, WT; Sampath, P; Skanderup, AJ; Sundaram, GM; Tan, DSW; Tan, EH; Tan, GS; Toh, SY; Zhang, X | 1 |
| Jiang, Y; Lin, Q; Liu, G; Pang, J; Wei, D; Zhao, Z | 1 |
| Gao, W; Liu, Z | 1 |
| Abdel-Aziz, AA; Al-Gendy, MA; El-Azab, AS; Ghabbour, HA | 1 |
| Ando, M; Fujiwara, T; Hasegawa, Y; Inoue, A; Katakami, N; Nagase, K; Shimizu, S; Takahashi, T; Takeuchi, S; Yano, S; Yoshimura, K | 1 |
| Cheng, Y; Corral, J; Lee, KH; Linke, R; Migliorino, MR; Mok, TS; Nadanaciva, S; Nakagawa, K; Niho, S; Pluzanski, A; Rosell, R; Sandin, R; Sbar, EI; Tsuji, F; Wang, T; White, JL; Wu, YL; Zhou, X | 1 |
| Chen, LX; Chen, Y; Fu, SZ; Liu, J; Ni, XL; Wu, JB; Wu, M; Xu, S; Yang, B; Yang, LL; Zhang, H | 1 |
| Feng, L; Ferrarotto, R; Ginsberg, L; Glisson, B; Kies, M; Kim, ES; Lippman, S; William, WN | 1 |
| Balaji, S; Dayakar, G; Guda, R; Kasula, M; Korra, R; Kumar, G; Myadaraveni, P; Palabindela, R; Yellu, NR | 1 |
| Ding, L; He, QJ; Liang, GK; Tariq, M; Yang, B; Zhang, JQ | 1 |
| Alvarez-Mon, M; Duran, A; Fuenmayor, E; Mosquera, J; Valero, N | 1 |
| Jafari, M; Kim, J; Lee, JY; Ruiz-Torres, SJ; Sriram, V; Waltz, SE; Zhou, Z | 1 |
| Cao, H; Ding, L; Dong, S; Du, Y; Fan, F; Feng, J; Li, H; Liu, S; Lou, R; Ma, R; Ni, J; Wang, Z; Wu, J; Zhao, X; Zhou, LL | 1 |
| Epistolio, S; Forcella, M; Frattini, M; Freguia, S; Fusi, P; Monti, E; Oldani, M | 1 |
| Chang, S; Choi, BW; Han, K; Hong, YJ; Hur, J; Kim, YJ; Lee, HJ | 1 |
| Asselah, J; Badescu, D; Basik, M; Bertos, NR; Blanchet-Cohen, A; Guiot, MC; Kleinman, CL; Liu, L; Meterissian, S; Munoz-Ramos, V; Omeroglu, A; Park, M; Petrecca, K; Ragoussis, J; Revil, T; Saleh, SMI; Savage, P; Wang, YC; Zuo, D | 1 |
| Alam, MM; Hassan, AHE; Kim, DH; Kim, NY; Kwon, YH; Lee, HJ; Lee, SY; Lee, YS; Min, KH | 1 |
| Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L | 1 |
| Gotoda, H; Hotta, K; Ichihara, E; Ichimura, K; Kato, Y; Kiura, K; Kubo, T; Maeda, Y; Makimoto, G; Ninomiya, K; Ohashi, K; Tamura, T; Tanaka, T | 1 |
| Ahn, HJ; Bhatt, L; Kim, YH; Lee, WK; Nam, HW; Yang, Z | 1 |
| Camidge, DR; Chand, VK; Fan, J; Freiwald, M; Gettinger, S; Groen, HJM; Horn, L; Janjigian, YY; Miller, VA; Pao, W; Smit, EF; Wang, B | 1 |
| Hashimoto, N; Honma, T; Sato, T | 1 |
| Hayashi, T; Kohsaka, S; Mano, H; Nagano, M; Shimada, N; Suehara, Y; Suzuki, K; Takahashi, F; Takahashi, K; Takamochi, K; Ueno, T | 1 |
| Cheng, Y; Chewaskulyong, B; Cho, BC; Cho, EK; Dechaphunkul, A; Gray, JE; Hodge, R; Imamura, F; Kurata, T; Lee, KH; Lee, SM; Marotti, M; Nogami, N; Ohe, Y; Okamoto, I; Planchard, D; Ramalingam, SS; Reungwetwattana, T; Rukazenkov, Y; Soria, JC; Su, WC; Vansteenkiste, J; Voon, PJ; Zhou, C | 1 |
| Kodama, K; Maniwa, T; Takeda, M; Yamamoto, Y | 1 |
| Bai, XY; Chen, HJ; Chen, ZH; Dong, ZY; Jiang, BY; Ke, EE; Luo, DL; Mei, P; Su, J; Sun, YL; Tu, HY; Wang, BC; Wang, Z; Wu, SP; Wu, YL; Xu, CR; Yan, HH; Yang, JJ; Yang, XN; Zhang, XC; Zheng, MY; Zhong, WZ; Zhou, Q | 1 |
| Gao, XX; Han, B; Jiang, ZM; Li, C; Wang, P; Wang, XH; Yang, RF; Yu, B; Zhang, L; Zhang, RQ; Zhang, Y | 1 |
| Nanbu, K; Nanbu, T; Ohkoshi, E; Sakagami, H; Shimada, J; Umemura, N | 1 |
| Wu, X | 1 |
| Akizuki, R; Endo, S; Ikari, A; Maruhashi, R; Matsunaga, T; Sakai, H; Sato, T; Yamaguchi, M; Yamazaki, Y | 1 |
| Kastelijn, EA; Peters, BJM; Roepman, P; Schramel, FMNH; Sluga, R; VAN DEN Borne, BEEM | 1 |
| Wang, N; Zhang, T | 1 |
| D'Alessandro-Gabazza, CN; Fujimoto, H; Fujiwara, A; Gabazza, EC; Hataji, O; Ito, K; Kobayashi, T; Nakahara, H; Nishihama, K; Taguchi, O; Yasuma, T; Yoshida, M | 1 |
| Jeong, SW; Joo, SH; Kim, MG; Kim, TH; Ma, E; Shin, BS; Shin, S; Weon, KY; Yoo, SD; Youn, YS | 1 |
| Bowman, RV; Fong, KM; Sim, EH; Wood-Baker, R; Yang, IA | 1 |
| Girard, N | 1 |
| Kwak, SJ; Seong, YS; Yi, YW; You, KS | 1 |
| Chen, J; Guo, R; Wang, X; Yao, J | 1 |
| Hu, Z; Li, R; Ma, Y; Peng, H; Wei, Z; Yue, C; Zhang, W; Zhou, M | 1 |
| Kang, Y; Ma, W; Yang, L; Yang, T; Zhu, M | 1 |
| Bommu, UD; Konidala, KK; Pamanji, R; Yeguvapalli, S | 1 |
| Chiba, M; Gemma, A; Ishikawa, A; Kobayashi, K; Kubota, K; Kunugi, S; Noro, R; Seike, M; Zou, F | 1 |
| Cappuzzo, F; Cseh, A; Forman, ND; Hilbe, W; Hochmair, M; Jazieh, AR; Lam, KC; Linden, S; Lorence, RM; Schuler, M; Soo, R; Stehle, G; Tsai, CM | 1 |
| Loong, HHF; To, KKW; Wu, WKK | 1 |
| Amador, M; Andrade Santiago, JM; Aparisi, F; Arriola, E; Artal, A; Barneto, I; Diz, P; García Gómez, R; Gutierrez, V; Isla, D; Majem, M; Martínez Aguillo, M; Paredes, A; Peralta Muñoz, S; Ponce, S; Provencio, M; Sánchez-Torres, JM; Valdivia, J; Vicente Baz, D | 1 |
| Hu, Q; Xie, B; Xu, Z; Zhang, W; Zhang, X; Zheng, J; Zhou, J | 1 |
| Bai, R; Bode, AM; Dong, Z; Fan, S; Liu, K; Lu, B; Yang, R; Yeung, YT; Yin, S; Zhang, C | 1 |
| Dietel, M; Eberhardt, WEE; Muehlenhoff, L; Schirmacher, P; Schuette, W; Thomas, M; Zirrgiebel, U | 1 |
| Anderson, JC; Bellis, SL; Britain, CM; Holdbrooks, AT; Willey, CD | 1 |
| Brownfoot, F; Campbell, L; Ellett, L; Hannan, NJ; Hastie, R; Horne, AW; Kaitu'u-Lino, TJ; Lim, E; Sluka, P; Tong, S | 1 |
| Furukawa, R; Matsumoto, Y; Ohara, S; Taniguchi, Y; Usui, K | 1 |
| Karpov, I; Kovalenko, S; Kozlov, V; Shamanin, V | 1 |
| Hino, H; Hiramoto, M; Hirasawa, K; Kazama, H; Kikuchi, H; Kokuba, H; Miyahara, K; Miyazawa, K; Moriya, S; Saito, Y; Takano, N; Tsukahara, K | 1 |
| Lokhande, KB; Murthy, PS; Nagar, S; Reddy, PS; Reddy, VD; Swamy, KV | 1 |
| Lee, VHF; Yan, H; Zou, B | 1 |
| Lu, H; Xie, Z; Xu, Y | 1 |
| He, R; Liu, Y; Luo, H; Luo, J; Pi, G; Quan, J; Su, X; Wang, G; Xiao, H; Ye, Y; Zhang, Q; Zhao, L | 1 |
| Hao, L; Hu, H; Jiang, Q; Li, X; Wang, G; Yan, B; Yao, J; Zhu, Y | 1 |
| Dziadziuszko, R; Palczewski, P; Płatek, AE; Szymański, FM; Łęgosz, P | 1 |
| Bode, A; Grubbs, CJ; Juliana, MM; Lubet, RA; Moeinpour, F; Steele, VE | 1 |
| Borics, A; Dömötör, O; Enyedy, ÉA; Keppler, BK; Kowol, CR; Pelivan, K | 1 |
| Hou, W; Wan, X; Zhang, L; Zhu, Y | 1 |
| Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W | 1 |
| Cao, J; Chen, Y; Cui, Y; Jiang, N; Jiang, W; Ke, Z; Lei, Y; Sun, Y; Wang, H; Wang, Y; Xu, D; Zhang, Y | 1 |
| Chen, CY; Chen, HY; Cheng, ZY; Chou, YC; Chueh, FS; Chung, JG; Hsia, TC; Hsiao, YT; Huang, YP; Jiang, YW; Peng, SF | 1 |
| Arimoto, T; Chihara, Y; Date, K; Imabayashi, T; Iwasaki, Y; Kaneko, Y; Morimoto, Y; Seko, Y; Takayama, K; Takemura, Y; Tanimura, K; Ueda, M | 1 |
| Feng, W; Ji, Y; Jin, L; Li, C; Liu, S; Wang, C; Xie, Q | 1 |
| Chen, H; Chen, X; Li, X; Liu, J; Liu, S; Mao, G; Wang, S; Wu, H; Ye, Y | 1 |
| Imamura, Y; Matsuda, S; Sano, K; Umeda, Y; Yoshida, H; Yoshimura, H | 1 |
| Peng, J; Wei, Y; Xu, J; Yu, D; Zhang, W | 1 |
| Chang, E; Gambhir, SS; Hori, SS; Hughes, NP; Kani, K; Kjær, A; Lee, S; Mallick, P; Natarajan, A; Nielsen, CH; Wang, SX; Xu, L | 1 |
| Fukui, T; Harada, S; Igawa, S; Kasajima, M; Katagiri, M; Kubota, M; Kusuhara, S; Mitsufuji, H; Naoki, K; Nishinarita, N; Okuma, Y; Ozawa, T; Sasaki, J; Sugita, K; Yokoba, M | 1 |
| Li, L; Liu, W; Meng, L; Wang, Y; Wang, Z; Yan, H; Zhang, H | 1 |
| Chai, Y; Wu, Y; Yao, Y; Zhu, Z | 1 |
| Chen, JY; Jiang, Z; Long, F; Ren, YG; Tang, JC; Zhao, J | 1 |
| Ghaedi, K; Mojtabavi Naeini, M; Tavassoli, M | 1 |
| Homma, S; Isobe, K; Iyoda, A; Kaburaki, K; Kakimoto, A; Kobayashi, H; Makino, T; Mikami, T; Nakano, Y; Otsuka, H; Sakamoto, S; Sano, G; Sugino, K; Takai, Y; Tochigi, N; Yoshizawa, T | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Zhou, J | 1 |
| Goto, Y; Hasegawa, Y; Hosomi, Y; Inoue, A; Isobe, H; Kaburagi, T; Kato, T; Kim, YH; Kunitoh, H; Minato, K; Mori, Y; Nishio, M; Ohashi, Y; Sakai, H; Tanai, C; Tomizawa, Y; Yamada, K; Yoh, K | 1 |
| An, C; Chen, P; Chen, Y; Lei, X; Ouyang, H; Pan, Z; Qin, T; Sun, H; Wu, H; Wu, Y; Yu, D; Yuan, C; Zhang, S; Zhang, X; Zou, W | 1 |
| Li, F; Liang, L; Wang, J; Yue, Y; Zhu, T; Zhu, X | 1 |
| Fujita, S; Fukushima, S; Imamichi, F; Irie, K; Katakami, N; Masago, K; Okada, Y; Yatabe, Y | 1 |
| Qi, Y; Qian, S; Wu, X; Xing, K; Zhang, L; Zhang, P | 1 |
| Bin, L; Guo-Qiang, LI; Liang, S; Yu-Hua, Z | 1 |
| Bhattacharya, S; Colin Duncan, W; Doust, A; Horne, AW; Johns, TG; Krzys, N; Mollison, J; Neil, P; Robinson, M; Skubisz, MM; Tong, S; Wallace, E | 1 |
| Gu, J; Jin, Y; Liang, X; Liu, T; Ma, H; Ma, X; Tao, J; Yang, T | 1 |
| Cunha, SI; Jia, M; Souchelnytskyi, S | 1 |
| Bai, C; Chang, M; Hu, J; Kwak, KJ; Lee, LJ; Li, J; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhou, J | 1 |
| Ahmed, M; Carrascosa, LG; Mainwaring, P; Trau, M; Wuethrich, A | 1 |
| Chen, J; Kang, C; Li, Y; Liu, H; Liu, M; Ren, D; Wang, R; Zhang, H | 1 |
| Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H | 1 |
| Hagiwara, K; Kondoh, Y; Lasky, JA; Saito, S | 1 |
| Aro, A; Choong, YS; McGaw, LJ; Mmonwa, MM; Mphahlele, MJ | 1 |
| Hameed, I; Lin, JZ; Ren, ZY; Xu, Z; Yu, Y; Zhu, JG | 1 |
| Hu, C; Hu, J; Jin, Z; Ke, J; Lu, Q; Sun, R; Wan, DC; Wang, X; Zhan, X | 1 |
| Bi, F; Bi, NX; Gong, QY; Liu, BS; Liu, Q; Nie, YZ; Tang, QL; Xia, HW; Zhou, JT; Zhou, S | 1 |
| Bai, C; Chang, M; Fang, T; Hong, Q; Li, J; Zhang, G; Zhou, J | 1 |
| Akhtar, M; Akhtar, MS; Hassan, MQ; Najmi, AK; Paudel, YN; Shah, S | 1 |
| Hanada, S; Kishi, K; Miyamoto, A; Mochizuki, S; Moriguchi, S; Morokawa, N; Murase, K; Ogawa, K; Takahashi, Y; Takaya, H; Uruga, H | 1 |
| Choo, J; Chung, HY; Heo, G; Im, E; Jung, JH; Jung, Y; Kim, DH; Kim, MJ; Kim, SJ; Kim, W; Lee, Y; Moon, HR; Noh, TH; Son, S | 1 |
| Hagiwara, K | 1 |
| Chen, HY; Chou, YC; Chung, JG; Hsia, TC; Hsiao, YT; Huang, YP; Jiang, YW; Peng, SF; Yang, JL | 1 |
| Li, J; Li, Y; Pan, W; Yang, M; Zhang, L; Zhang, N; Zhu, H | 1 |
| Chihara, Y; Hasegawa, I; Hiranuma, O; Hiraoka, N; Kaneko, Y; Kubota, Y; Shiotsu, S; Takayama, K; Takeda, T; Takumi, C; Tamiya, N; Tanimura, K; Uchino, J; Yamada, T; Yoshimura, A | 1 |
| Gu, P; Hu, F; Hu, P; Li, C; Nie, W; Shen, Y; Wang, H; Wang, S; Xu, J; Zhang, B; Zhang, X; Zhang, Y | 1 |
| Li, XF; Liu, GF; Miao, YY; Yu, SN; Zhang, SH | 1 |
| Chen, SM; Chen, X; Han, SW; Long, SQ; Wu, WY; Yang, XB | 1 |
| Kawai, S; Kitazono, M; Murata, K; Ohashi, K; Takahashi, Y; Takamori, M; Wada, A; Yamamoto, M | 1 |
| Bai, C; Chang, M; Fang, T; Hu, J; Li, J; Liu, J; Qu, G; Song, Y; Wu, Z; Yang, D; Zeng, H; Zhang, G; Zhou, J | 1 |
| Hu, Y; Peng, L; Wang, C; Xu, S; Zhang, B; Zhang, H; Zheng, P; Zhu, W | 1 |
| Brenner, JC; Carey, TE; Harris, M; Herbst, G; Jiang, H; Kulkarni, A; Leonard, E; Matovina, C; Michmerhuizen, NL; Zhai, J | 1 |
| Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y | 1 |
| Cao, Z; Ding, X; Lin, G; Liu, D; Su, B; Wang, N; Wu, C; Xu, W; Zhou, X | 1 |
| Adelson, DL; Aung, TN; Chen, Z; Cui, J; Lin, L; Liu, X; Qu, Z; Sun, L; Wang, J; Zhang, J | 1 |
| Pan-Pan, L; Qing, L; Yang, F; Ye, H; Yue-Yun, C; Zhen-Yu, D | 1 |
| Cheng, Y; Enatsu, S; He, J; Hozak, RR; Kang, JH; Kim, JH; Murakami, H; Nakagawa, K; Nguyen, TS; Orlando, M; Puri, T; Yang, JC; Yang, PC; Zhang, WL | 1 |
| Chae, JI; Cho, SS; Choi, JS; Kim, E; Kwak, AW; Lee, MH; Lee, SM; Oh, HN; Seo, JH; Seo, KS; Shim, JH; Yoon, G | 1 |
| Chen, J; Li, X; Liu, H; Liu, M; Zhang, H | 1 |
| Cao, B; Mao, X; Qiao, C; Wang, Q; Wang, X; Xu, X; Xu, Y; Zeng, K; Zeng, Y; Zhang, J; Zhang, Z | 1 |
| Bach, DH; Hu, R; Kim, D; Lee, SK; Luu, TT; Park, HJ | 1 |
| Liu, L; Liu, S; Wang, Y; Yuan, Y | 1 |
| Bohra, GK; Kumar, D; Meena, DS; Midha, N | 1 |
| Cai, J; Jiang, X; Li, X; Sun, L; Tu, L; Wei, M; Wu, Z | 1 |
| Arrieta, O; Bosch-Barrera, J; Caro, RB; Dómine, M; Drozdowskyj, A; Garcia-Campelo, R; Granados, ALO; Guirado, M; Insa, A; Karachaliou, N; Lianes, P; Majem, M; Massuti, B; Molina-Vila, MA; Reguart, N; Rodriguez-Abreu, D; Rosell, R; Sala, MÁ; Vázquez-Estevez, S; Verdú, A; Vicente, D | 1 |
| Chen, X; Guo, Z; Hou, X; Li, J; Li, M; Liu, L; Sun, M; Wang, Q; Xi, N; Xie, C; Xie, N | 1 |
| Dou, Z; Fang, G; Han, X; Huo, R; Li, X; Liu, W; Shang, Y; Shi, X; Wang, K; Yuan, S; Zang, A; Zhang, J; Zhang, L; Zhang, Y | 1 |
| Bates, V; Boland, A; Chaplin, M; Dundar, Y; Green, JA; Greenhalgh, J; Vecchio, F | 1 |
| Cheng, G; Li, L; Nie, X; Wu, XN; Zhang, P | 1 |
| Singh Badhan, RK; Yu, H | 1 |
| Cui, J; Du, X; Fan, Y; Fang, Y; Fu, X; Gu, K; Gu, W; Hou, Z; Hu, C; Jiang, O; Liu, J; Miao, L; Min, X; Wang, Q; Wu, G; Yao, W; Yu, G; Yu, Q; Yuan, X; Zhang, L; Zhang, Z; Zhao, H; Zheng, R; Zhou, X; Zhu, X | 1 |
| Akamatsu, H; Daga, H; Harada, H; Hasegawa, Y; Hayashi, H; Kato, T; Kim, YH; Murakami, H; Nakagawa, K; Nishimura, Y; Shimizu, J; Tokunaga, S; Yamamoto, N | 1 |
| Chan, YC; Chang, CJ; Chao, JI; Chen, C; Chen, CH; Hsu, YP; Liang, MC; Liu, KK; Pan, PY; Wang, RH; Wang, SP; Wong, KK; Wu, YH; Yang, CM; Yang, JM | 1 |
| Asano, K; Hayama, N; Ito, Y; Niimi, K; Obayashi, S; Oguma, T; Tanaka, J; Tomomatsu, K; Urata, M | 1 |
| Du, X; Liu, W; Wang, Z; Xiong, X; Yang, L; Yang, P; Zhang, Y; Zhou, C | 1 |
| Imoto, S; Miyano, S; Park, H; Yamaguchi, R | 1 |
| Chen, S; Deng, Q; Fang, Q; Huang, X; Li, X; Lin, Z; Liu, X; Miao, Y; Wang, J; Yang, L; Yu, XY | 1 |
| Feng, X; Jiang, H; Meng, J; Meng, W; Wang, K; Zhang, F; Zhao, F | 1 |
| Chung, SW; Coyle, L; de Kok, TM; Ferreira, S; Fisher, C; Herpers, B; Jennen, DGJ; Jo, H; Kleinjans, JCS; Rodrigues, D | 1 |
| Akangunduz, B; Akdeniz, N; Aksoy, A; Akyol, M; Alan, Ö; Arak, H; Atci, MM; Balli, S; Bayram, E; Bekmez, ET; Bilgin, B; Bilici, A; Cavdar, E; Celik, E; Demirci, NS; Demirkazik, A; Ellez, Hİ; Erdem, D; Erdoğan, AP; Goker, E; Gursoy, P; Hedem, E; Katgi, N; Kilickap, S; Kut, E; Menekse, S; Nart, D; Oyan, B; Ozturk, A; Pilanci, KN; Sakalar, T; Sakin, A; Selçukbiricik, F; Tatli, AM; Telli, TA; Topcu, A; Turhal, S; Turkoz, FP; Yapar, B; Yildirim, HÇ; Yumuk, PF | 1 |
| Chang, JS; Hsieh, KP; Huang, YB; Lee, CH; Shen, MC; Tsai, MJ; Yang, YH | 1 |
| Ali, SM; Chen, G; Chen, J; Chen, S; Chen, Y; Cui, J; Dong, X; Duan, J; Fang, J; Feng, J; Guo, R; Hu, C; Hu, J; Hu, Y; Ji, Y; Jian, H; Jiang, L; Jie, W; Jie, Z; Li, B; Li, C; Li, J; Li, W; Lin, Z; Liu, C; Lu, J; Lu, S; Lu, Y; Lv, D; Ma, L; Ma, R; Miller, VA; Shi, J; Sun, C; Sun, M; Sun, Y; Tong, W; Wang, Q; Wang, Z; Wei, H; Wu, Q; Wu, X; Xiong, J; Xu, X; Xu, Z; Yang, H; Yang, N; Yao, Y; Ye, X; Yu, X; Yu, Z; Zhang, G; Zhang, H; Zhang, L; Zhang, Z; Zhou, J; Zhou, X | 1 |
| Cao, L; Chen, G; Cheng, Y; Cui, J; Feng, J; Gu, C; Hao, Y; Jiang, Y; Li, Y; Liu, C; Liu, F; Liu, J; Liu, Y; Shi, Y; Wang, X; Wu, L; Yang, N; Zang, A; Zhang, S; Zhang, X; Zhao, H; Zhu, S | 2 |
| Cai, Y; Cao, HQ; Fang, L; He, ML; Jiang, YY; Li, YP; Qian, XD; Wang, DG; Wang, GR; Wang, J; Zhao, ZT | 1 |
| Guo, J; Li, M; Xie, Y | 1 |
| Dai, X; Feng, C; Guo, D; Huang, L; Jiang, S; Liu, Y; Ma, S; Qahar, M; Wang, L | 1 |
| Cha, HJ; Choi, SK; Jang, SJ; Kim, M; Kwon, Y; Lee, H; Lee, YS; Na, Y | 1 |
| Ho, JCM; Ip, MSM; Kwok, WC; Lam, DCL; Tam, TCC | 1 |
| Espinoza, JL; Fujii, A; Fujimoto, K; Fujiwara, R; Hanamoto, H; Iwata, Y; Kumode, T; Matsumura, I; Morita, Y; Rai, S; Serizawa, K; Tanaka, H; Taniguchi, Y | 1 |
| Dong, W; Gong, Y; Hu, S; Li, M; Wang, C; Xie, C; Zhao, K | 1 |
| Fujii, R; Hayashi, K; Honda, T; Ishida, T; Kawamura, M; Matsutani, N; Ochiai, R; Saichi, N; Seki, N; Shimizu, T; Shinchi, H; Ueda, K; Yamamoto, H | 1 |
| Hong, J; Kang, S; Kim, JH; Ko, SG; Kwon, YY; Moon, JH | 1 |
| Chen, D; Li, J; Mao, C; Xia, S; Ye, F; Yu, W; Yuan, X; Zhang, M | 1 |
| Cai, Y; Chen, T; Chen, W; Cui, D; Guo, H; Wang, L; Wang, X; Xie, D; Xie, S; Zhang, X | 1 |
| Cheng, Y; Song, R; Zheng, T | 1 |
| Aggarwal, G; Ahsan, A; Ahsan, W; Javed, S; Kumar, P; Mangla, B; Musyuni, P | 1 |
| Daga, H; Fujisaka, Y; Hattori, Y; Ikeda, N; Iwamoto, Y; Katakami, N; Kozuki, T; Morita, S; Nakagawa, K; Nishino, K; Oguri, T; Okamoto, T; Oki, M; Sato, Y; Sugawara, S; Takahashi, T; Urata, Y; Yamamoto, N; Yokoyama, T | 1 |
| Rosengren, RJ; Taurin, S | 1 |
| Li, M; Lu, S; Zhang, Y; Zhao, B | 1 |
| Harada, H; Katagiri, H; Miyagi, M; Mori, K; Murakami, H; Murata, H; Takahashi, M; Takahashi, T; Wasa, J | 1 |
| Jia, YY; Lv, WH; Nie, F; Wu, H; Zhu, YY | 1 |
| Bai, M; Li, C; Li, M; Li, Y; Liu, H; Lu, S; Ma, S; Su, P; Yin, X; Zhang, C | 1 |
| Chen, CH; Hour, MJ; Hsieh, HH; Kuo, YH; Wu, TY | 1 |
| Igai, H; Kamiyoshihara, M; Numajiri, K; Ohsawa, F | 1 |
| Lai, XY; Shi, YM; Zhou, MM | 1 |
| Cui, Y; Dai, J; Guo, R; Qu, T; Yin, D; Zhang, C; Zhang, E | 1 |
| Gu, S; Song, P; Wang, W; Wu, K; Zhou, J | 1 |
| Chen, Y; Dai, J; Guo, R; Jin, S; Li, J; Zhang, C; Zhang, Z | 1 |
| Chen, H; Cui, J; Fan, L; Fu, Y; Han, K; Hu, H; Yin, S; Zhao, C; Zhao, S | 1 |
| Chang, X; Chen, Y; Ding, L; He, Y; Lei, C; Ma, C; Tang, Q; Xiao, Z; Yu, Y; Zhang, H; Zhu, Y | 1 |
| Chen, MC; Li, YH; Liao, WL; Lin, H; Yang, TY | 1 |
| Cui, Y; Kang, X; Liang, J; Liu, M; Zhang, H; Zhang, Q | 1 |
| Chen, J; Chen, Q; Chen, Y; Jiang, C; Jiao, D; Liu, X; Liu, Y; Tang, X | 1 |
| Ahn, MJ; Arslan, C; Bondarenko, I; Cho, BC; Cicin, I; Danchaivijitr, P; Fong, CH; Kang, JH; Kilickap, S; Kim, JH; Lee, H; Lee, KH; Lee, SS; Lee, YG; Lim, CS; Lim, YN; Orlov, S; Pang, YK; Park, SN; Soo, RA; Yang, JC; Zimina, A | 1 |
| Ding, T; Guo, N; Jiang, L; Ma, J; Shao, L; Song, D; Wang, J; Yan, L; Zhai, W; Zhang, W; Zhao, F | 1 |
605 review(s) available for quinazolines and gefitinib
| Article | Year |
|---|---|
Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents.
Topics: Administration, Oral; Antibodies, Monoclonal; Antineoplastic Agents; Disease Progression; ErbB Receptors; Gefitinib; Humans; Ligands; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2000 |
ZD1839 ('Iressa') as an anticancer agent.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Mice; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2000 |
On receptor inhibitors and chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Caenorhabditis elegans Proteins; Cetuximab; ErbB Receptors; Gefitinib; Helminth Proteins; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2 | 2000 |
[Zd 1839 "Iressa"].
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Half-Life; Humans; Mice; Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2000 |
[Tumor angiogenesis and tumor angiogenesis inhibitors].
Topics: Angiogenesis Inhibitors; Angiostatins; Animals; Antigens, CD; Antineoplastic Agents; Cadherins; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Neoplasms; Oxindoles; Peptide Fragments; Plasminogen; Propionates; Pyrroles; Quinazolines; Vascular Cell Adhesion Molecule-1 | 2001 |
[Tyrosine kinase inhibitors--solid cancers].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Enzyme Inhibitors; Gefitinib; Humans; Neoplasm Metastasis; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2001 |
The EGF receptor family as targets for cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2000 |
Growth factors and their receptors: new targets for prostate cancer therapy.
Topics: Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotides, Antisense; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Trastuzumab | 2001 |
A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines; Xenograft Model Antitumor Assays | 2001 |
Tyrosine kinase inhibitors-ZD1839 (Iressa).
Topics: Animals; Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Division; Clinical Trials as Topic; Disease Progression; Dogs; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Neoplasms; Quinazolines; Rats | 2001 |
Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2001 |
Pharmacodynamic studies with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Ligands; Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2001 |
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2001 |
Inhibitors of HER2/neu (erbB-2) signal transduction.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2001 |
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Chemoprevention; Clinical Trials as Topic; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Quinazolines; Signal Transduction; Transplantation, Heterologous; Up-Regulation | 2002 |
[Non surgical new treatment modalities for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy | 2002 |
[Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Prospects for combining hormonal and nonhormonal growth factor inhibition.
Topics: Antineoplastic Agents; Breast Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Quinazolines; Tamoxifen | 2001 |
[Progress in diagnosis and treatment of lung cancer].
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Endothelial Growth Factors; Enzyme Inhibitors; Gefitinib; Genetic Therapy; Humans; Hydroxamic Acids; Lung Neoplasms; Lymphokines; Mass Screening; Metalloendopeptidases; Quinazolines; Receptor Protein-Tyrosine Kinases; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
ZD1839: targeting the epidermal growth factor receptor in cancer therapy.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Device Approval; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Signal Transduction | 2002 |
Targeting epidermal growth factor receptor in lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2002 |
New drugs in gynecologic cancer.
Topics: Aminopyridines; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cisplatin; Female; Gefitinib; Genital Neoplasms, Female; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Organoplatinum Compounds; Paclitaxel; Protein-Tyrosine Kinases; Pyrazines; Quinazolines; Trastuzumab | 2001 |
[ZD1839].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
[New treatment strategy for stage III non-small-cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Small Cell; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Docetaxel; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Neoplasm Staging; Paclitaxel; Quinazolines; Radiotherapy; Taxoids; Treatment Outcome; Vinblastine | 2002 |
[Latest therapeutic strategy for stage IV non-small cell lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Hyperthermia, Induced; Immunotherapy; Lung Neoplasms; Neoplasm Staging; Quinazolines; Radiotherapy; Stents | 2002 |
[Future trends in anticancer chemotherapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Drug Design; Drug Therapy; Drugs, Investigational; Endothelial Growth Factors; Forecasting; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Recombinant Proteins; Trastuzumab; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
ZD1839 (IRESSA): a selective EGFR-TK inhibitor.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2002 |
Molecular mechanisms in signal transduction: new targets for the therapy of gynecologic malignancies.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Immunotoxins; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2002 |
Epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
HER (erbB) tyrosine kinase inhibitors in the treatment of breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2002 |
[New therapeutic targets and strategies in lung cancer].
Topics: Alkyl and Aryl Transferases; Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Benzodiazepines; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Endothelial Growth Factors; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Metalloendopeptidases; Multicenter Studies as Topic; Piperazines; Polyisoprenyl Phosphates; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Quinolones; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Sesquiterpenes; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Why the epidermal growth factor receptor? The rationale for cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2002 |
ZD1839 (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2002 |
ZD1839 (Iressa): for more than just non-small cell lung cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Colorectal Neoplasms; Combined Modality Therapy; Controlled Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Neoplasms; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Treatment Outcome | 2002 |
ZD1839 (Iressa): what's in it for the patient?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Patients; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Research Design; Treatment Outcome | 2002 |
Epidermal growth factor receptor dependence in human tumors: more than just expression?
Topics: Antinematodal Agents; Dimerization; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Ligands; Mutation; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Signal Transduction | 2002 |
The role of EGFR-directed therapy in the treatment of breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mammary Neoplasms, Experimental; Quinazolines | 2002 |
Gefitinib.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Quinazolines; Signal Transduction; Treatment Outcome; Tumor Cells, Cultured | 2002 |
HER-targeted tyrosine-kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2 | 2002 |
Epidermal growth factor receptor-targeted therapy in colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
Cancer genome targets: RAF-ing up tumor cells to overcome oncogene addiction.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Gefitinib; Genetic Therapy; Genome, Human; Humans; Imatinib Mesylate; Neoplasms; Oncogenes; Piperazines; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2002 |
Epithelial growth factor receptor interacting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Cisplatin; Clinical Trials as Topic; Combined Modality Therapy; Drug Design; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunization, Passive; Irinotecan; MAP Kinase Signaling System; Mice; Mice, Nude; Neoplasm Proteins; Neoplasms; Quinazolines; Recombinant Fusion Proteins; Xenograft Model Antitumor Assays | 2002 |
Overview of clinical trials with epidermal growth factor receptor inhibitors in advanced non-small cell lung cancer.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Oncology Nursing; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
[Molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Delivery Systems; Endothelial Growth Factors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Lymphokines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2003 |
Recurrent small cell lung cancer: update.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Clinical Trials as Topic; Gefitinib; Humans; Immunotoxins; Lung Neoplasms; Neoplasm Recurrence, Local; Oligonucleotides, Antisense; Prognosis; Quinazolines; Thionucleotides | 2003 |
The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Topics: Antineoplastic Agents; Cell Transformation, Neoplastic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Studies with ZD1839 in preclinical models.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Phase I studies of ZD1839 in patients with common solid tumors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Morpholines; Ovarian Neoplasms; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
New directions for ZD1839 in the treatment of solid tumors.
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Interference with EGFR signaling: paradigm for improving radiation response in cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2002 |
[Molecular targetting therapy for non-small-cell lung neoplasms with EGF-R inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Small Cell; Cetuximab; Clinical Trials as Topic; Depression, Chemical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines | 2003 |
Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
Development of ZD1839 in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Drug Screening Assays, Antitumor; Epidermal Growth Factor; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2003 |
[Epidermal growth factor receptors (EGFR): a new target for anticancer therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biopsy; Cell Transformation, Neoplastic; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Analysis; Treatment Outcome | 2003 |
Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Survival Rate | 2003 |
Targeting epidermal growth factor receptor--are we missing the mark?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure | 2003 |
Understanding the mechanisms of action of EGFR inhibitors in NSCLC: what we know and what we do not know.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Research Design; Treatment Outcome | 2003 |
Gefitinib (Iressa) trials in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
The benefits of achieving stable disease in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survivors | 2003 |
Gefitinib (Iressa, ZD 1839) for non-small cell lung cancer (NSCLC): recents results and further strategies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Random Allocation; Treatment Outcome | 2003 |
[Non-small cell lung cancer: 1) Molecular-target therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
[Non-small cell lung cancer: 2) Epidermal growth factor receptor inhibitor and severe adverse phenomena].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines | 2003 |
[Iressa (gefitinib)].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
New targeted therapies in gastrointestinal cancers.
Topics: Adult; Aged; Antibodies, Monoclonal; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Immunotherapy; Male; Middle Aged; Neoplasm Staging; Panitumumab; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Survival Analysis; Treatment Outcome | 2003 |
The biology of antihormone failure in breast cancer.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Gefitinib therapy for advanced non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
[Angiogenesis and metastasis in colorectal cancer].
Topics: Angiopoietin-1; Angiopoietin-2; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Hydroxamic Acids; Metalloendopeptidases; Neoplasm Metastasis; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2003 |
Epidermal growth factor receptor inhibitors, gefitinib and erlotinib (Tarceva , OSI-774), in the treatment of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2003 |
Growth factor receptor tyrosine kinase inhibitors; clinical development and potential for prostate cancer therapy.
Topics: Epidermal Growth Factor; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Growth Factor | 2003 |
EGFR tyrosine kinase inhibitor "gefitinib (Iressa)" for cancer therapy.
Topics: Animals; Antineoplastic Agents; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, fos; Humans; Ki-67 Antigen; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
The impact of gefitinib on epidermal growth factor receptor signaling pathways in cancer.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2003 |
Biologically targeted treatment of non-small-cell lung cancer: focus on epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Ligands; Lung Neoplasms; Male; Middle Aged; Neoplasm Invasiveness; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Pharmacokinetic evaluation of gefitinib when administered with chemotherapy.
Topics: Administration, Oral; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Drug Interactions; Gefitinib; Humans; Paclitaxel; Quinazolines | 2003 |
Molecular targeted agents in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase C; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Primary and secondary prevention of non-small-cell lung cancer: the SPORE Trials of Lung Cancer Prevention.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Clinical Trials as Topic; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Precancerous Conditions; Protein-Tyrosine Kinases; Quinazolines; Quinolones | 2003 |
[Current screening for molecular target therapy of cancer].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; Drug Delivery Systems; Drug Screening Assays, Antitumor; Gefitinib; Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactones; Mice; Neoplasms; Phthalazines; Piperazines; Piperidines; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sunitinib | 2003 |
Small-molecule epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Differentiation; Cell Movement; Cell Survival; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; History, Modern 1601-; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Tolerability of gefitinib in patients receiving treatment in everyday clinical practice.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Quinazolines; Treatment Outcome | 2003 |
Quality-of-life benefits and evidence of antitumour activity for patients with brain metastases treated with gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quality of Life; Quinazolines | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2003 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Topics: Animals; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome | 2003 |
Can rash associated with HER1/EGFR inhibition be used as a marker of treatment outcome?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Dose-Response Relationship, Drug; Endpoint Determination; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Ovarian Neoplasms; Quinazolines; Severity of Illness Index; Survival Analysis; Treatment Outcome | 2003 |
[Development of novel molecular targeted drug, "Iressa", for the treatment of malignant diseases--its basic and clinical studies].
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Male; Neoplasms; Quinazolines; Rats | 2003 |
Inhibition of HER1 signaling pathway enhances antitumor effect of endocrine therapy in breast cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Gene Expression Regulation; Genes, erbB-1; Humans; Quinazolines; Signal Transduction | 2004 |
Gefitinib (Iressa): a novel treatment for non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
HER1/EGFR targeting: refining the strategy.
Topics: Antineoplastic Agents; Drug Delivery Systems; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction | 2004 |
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Receptor, ErbB-3; Trastuzumab | 2003 |
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines | 2003 |
[Inhibitors of epidermal growth factor receptor and colorectal cancer].
Topics: Antineoplastic Agents; Colorectal Neoplasms; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[Therapeutic implications of epidermal growth factor receptor in lung cancer].
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Rationale and clinical basis for combining gefitinib (IRESSA, ZD1839) with radiation therapy for solid tumors.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasm Proteins; Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents | 2004 |
Emerging role of epidermal growth factor receptor inhibition in therapy for advanced malignancy: focus on NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cisplatin; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Quinazolines | 2004 |
Epidermal growth factor receptor inhibitors in clinical development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Protein-Tyrosine Kinases; Quinazolines | 2004 |
A review of small-molecule epidermal growth factor receptor-specific tyrosine kinase inhibitors in development for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib: phase II and III results in advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: application in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Changes in therapy for solid tumors: potential for overcoming drug resistance in vivo with molecular targeting agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Molecular Biology; Neoplasms; Paracrine Communication; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2004 |
Challenges in the development of anti-epidermal growth factor receptor therapies in breast cancer.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2004 |
[Molecular pathogenesis of lung cancers and the preservative therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Cycle Proteins; Cisplatin; Enzyme Inhibitors; Etoposide; Gefitinib; Gene Targeting; Genes, bcl-2; Genes, p53; Genetic Therapy; Humans; Lung Neoplasms; Mass Screening; Mutation; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2004 |
Rationale and clinical validation of epidermal growth factor receptor as a target in the treatment of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines | 2004 |
Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biological Availability; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Infusions, Intravenous; Neoplasms; Quinazolines | 2004 |
Gefitinib, a novel, orally administered agent for the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Doxorubicin; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Methotrexate; Muscle Neoplasms; Neoadjuvant Therapy; Oncogene Proteins v-erbB; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Urinary Bladder Neoplasms; Vinblastine | 2004 |
[Tumor biotherapy based on epidermal growth factor receptor as a target].
Topics: Antibodies, Monoclonal; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Vaccines, DNA | 2004 |
Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines | 2004 |
Epidermal growth factor receptor inhibitors for the treatment of colorectal cancer: a promise fulfilled?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Potential role for epidermal growth factor receptor inhibitors in combined-modality therapy for non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2004 |
Review of epidermal growth factor receptor biology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Morpholines; Neoplasm Proteins; Panitumumab; Quinazolines; Radiation Tolerance; Receptor, ErbB-2 | 2004 |
Epidermal growth factor receptor-targeted therapy with ZD1839: symptom improvement in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Gefitinib: a new antineoplastic for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Estrogen receptor pathways in lung cancer.
Topics: Age Factors; Animals; Antineoplastic Agents; Epidermal Growth Factor; Estrogen Receptor alpha; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Receptors, Estrogen; Risk Factors; Sex Distribution; Sex Factors; Signal Transduction; Smoking; Survival Rate; United States | 2004 |
Gefitinib (iressa) in oncogene-addictive cancers and therapy for common cancers.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Genes, abl; Humans; Neoplasms; Quinazolines | 2004 |
Pharmacological background of EGFR targeting.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2004 |
Effects of ZD1839 (Iressa, gefitinib) treatment on symptoms and quality of life in patients with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Severity of Illness Index; Sickness Impact Profile; Survival Analysis | 2004 |
Management of acneiform rashes related to gefitinib therapy.
Topics: Clinical Trials, Phase II as Topic; Combined Modality Therapy; Dermatologic Agents; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mouth Neoplasms; Prognosis; Quinazolines; Skin Care | 2004 |
Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Prognosis; Quinazolines; Signal Transduction | 2004 |
The role of gefitinib in lung cancer treatment.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Models, Animal; Disease Progression; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2004 |
New oncology strategy: molecular targeting of cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Boronic Acids; Bortezomib; Cetuximab; Cysteine Endopeptidases; ErbB Receptors; Gefitinib; Genetics, Medical; Humans; Medical Oncology; Molecular Biology; Multienzyme Complexes; Neoplasms; Neovascularization, Pathologic; Nurse's Role; Oncology Nursing; Protease Inhibitors; Proteasome Endopeptidase Complex; Pyrazines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2004 |
Targeting the epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Mutations in the EGFR: the importance of genotyping.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
[New advance of the molecular targeting agents in advanced non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Development of the novel biologically targeted anticancer agent gefitinib: determining the optimum dose for clinical efficacy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Keratinocytes; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Tissue Distribution; Treatment Outcome | 2004 |
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[The mechanisms of the resistance to molecular targeting agents].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Drug Delivery Systems; Drug Resistance, Neoplasm; Gefitinib; Humans; Imatinib Mesylate; In Vitro Techniques; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
[Gefitinib in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
[Resistance to target-based therapy and its circumvention].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Rituximab; Trastuzumab | 2004 |
[Preclinical and clinical results with the epidermal growth factor receptor inhibitor Gefitinib (ZD1839, Iressa)].
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials as Topic; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Protein-Tyrosine Kinases; Quinazolines; Transplantation, Heterologous | 2004 |
Interstitial lung disease associated with drug therapy.
Topics: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Respiratory Distress Syndrome; Risk Factors | 2004 |
New directions in oncology nursing care: focus on gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Patient Education as Topic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: review of 15 clinical cases.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib: a review of its use in the management of advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biological Availability; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Half-Life; Humans; Intestinal Absorption; Lung Neoplasms; Metabolic Clearance Rate; Middle Aged; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2004 |
Targeted therapies for cancer 2004.
Topics: Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Bevacizumab; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gemtuzumab; Humans; Neoplasms; Pharmacogenetics; Quinazolines; Rituximab; Trastuzumab | 2004 |
Brain metastasis responding to gefitinib alone.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gingival Neoplasms; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2004 |
Overview of the tolerability of gefitinib (IRESSA) monotherapy : clinical experience in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Product Surveillance, Postmarketing; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib--a novel targeted approach to treating cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Gefitinib (Iressa, ZD1839): a novel targeted approach for the treatment of solid tumors.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines | 2004 |
[Does molecular targeted therapy change the treatment for lung cancer?].
Topics: Antineoplastic Agents; Cell Cycle; Gefitinib; Genes, erbB-1; Genetic Therapy; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Suppressor Protein p53; Vaccines, Synthetic | 2004 |
Gefitinib: current status in the treatment of non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Therapy, Combination; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Quinazolines | 2004 |
Gefitinib therapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2005 |
A molecular chink in the lung cancer armour.
Topics: ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Pharmacogenetics; Quinazolines; Treatment Outcome | 2004 |
Epidermal growth factor receptor inhibition strategies in oncology.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Neuro-oncology: the growing role of chemotherapy in glioma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Brain Neoplasms; Chemotherapy, Adjuvant; Dacarbazine; Drug Resistance, Neoplasm; Gefitinib; Glioblastoma; Glioma; Humans; Meta-Analysis as Topic; Nitrosourea Compounds; Oligodendroglioma; Paraneoplastic Syndromes; Protein Kinase Inhibitors; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Temozolomide | 2005 |
[Tumor response to gefitinib (IRESSA) in pulmonary adenocarcinoma: toward a molecular basis for therapeutic targetting].
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-raf; Quinazolines | 2004 |
Molecular changes in gliomas.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Central Nervous System Neoplasms; Epidermal Growth Factor; Gefitinib; Glioma; Humans; Neovascularization, Pathologic; Quinazolines | 2004 |
Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
[Second-line treatment for advanced non-small-cell lung cancers].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Drug Administration Schedule; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Vinblastine; Vinorelbine | 2005 |
Reversing resistance to targeted therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Drug Delivery Systems; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Male; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Risk Assessment; Sensitivity and Specificity; Trastuzumab | 2004 |
Endocrine treatment options for advanced breast cancer--the role of fulvestrant.
Topics: Anastrozole; Androstadienes; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Nitriles; Postmenopause; Quinazolines; Tamoxifen; Treatment Outcome; Triazoles | 2005 |
Clinical development of gefitinib in non-small-cell lung cancer and the Iressa Survival Evaluation in Lung Cancer trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2005 |
The epidermal growth factor receptor as a target for colorectal cancer therapy.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction | 2005 |
Gefitinib ("Iressa"): a new therapy for advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[Molecular diagnosis of solid tumors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gastrointestinal Neoplasms; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Trastuzumab | 2005 |
[Gefitinib as targeted treatment for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2005 |
[Molecular target therapy for malignant tumors].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Hematologic Neoplasms; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Neoplasms; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Rituximab; Signal Transduction; Trastuzumab; Tretinoin | 2005 |
Spotlight on gefitinib in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
Computer-assisted image analysis of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2005 |
Small molecules with EGFR-TK inhibitor activity.
Topics: Aminoquinolines; Aniline Compounds; Animals; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Mutation; Neoplasms; Organic Chemicals; Quinazolines; Signal Transduction | 2005 |
Epidermal growth factor receptor as a target for chemotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2005 |
Epidermal growth factor receptor inhibitors in the treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Trying to compose the puzzle with all the pieces: epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Metaphor; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Targeted therapies: last focus on EGF receptor inhibitors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Clinical Trials, Phase II as Topic; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2; Receptors, Estradiol; Taxoids; Trastuzumab | 2004 |
Therapy of breast cancer with molecular targeting agents.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclooxygenase 2; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Paclitaxel; Prenylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Vinblastine; Vinorelbine | 2005 |
ZD6474--clinical experience to date.
Topics: Administration, Oral; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Piperidines; Quinazolines; Vascular Endothelial Growth Factor A | 2005 |
[Tyrosine kinase inhibitors in tumor therapy--part 2. Current position and perspectives].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, abl; Humans; Imatinib Mesylate; Neoplasms; Patient Selection; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Trastuzumab; Vascular Endothelial Growth Factor A | 2005 |
Role of epidermal growth factor receptor mutations in predicting sensitivity or resistance to targeted agents in non-small-cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Quinazolines; Sex Factors; Threonine | 2005 |
Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Recent developments related to the EGFR as a target for cancer chemotherapy.
Topics: Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Medical treatment of non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Translational research on lung cancer--EGFR gene mutation].
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion; Smoking; Transcription, Genetic | 2005 |
[New anti-cancer agents--from cytotoxic systemic chemotherapy to target-based agents].
Topics: Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Deoxycytidine; Drug Combinations; Erlotinib Hydrochloride; Furans; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Oxonic Acid; Pemetrexed; Pyrazines; Pyridines; Quinazolines; Tegafur; Vinblastine; Vinorelbine | 2005 |
Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Factors predicting response to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines | 2005 |
HER1/EGFR tyrosine kinase inhibitors for the treatment of glioblastoma multiforme.
Topics: Animals; Brain Neoplasms; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2005 |
The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2005 |
Recent advances and future perspectives in the management of lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Forecasting; Gefitinib; Humans; Interleukin-2; Lung Neoplasms; Lung Transplantation; Mass Screening; Neoadjuvant Therapy; Neoplasm Staging; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Sentinel Lymph Node Biopsy; Smoking | 2005 |
Overview of tyrosine kinase inhibitors in clinical breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Development of strategies for the use of anti-growth factor treatments.
Topics: Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
Targeted therapies for non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Mutation; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor inhibition in solid tumours.
Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Perspectives on salvage therapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Second-line chemotherapy and beyond for non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Deoxycytidine; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; Female; Forecasting; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Pemetrexed; Pneumonectomy; Quinazolines; Salvage Therapy; Survival Rate; Taxoids; Time Factors | 2004 |
Novel agents for the treatment of advanced kidney cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Clinical Trials as Topic; Epothilones; Gefitinib; Humans; Indoles; Kidney Neoplasms; Lenalidomide; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide | 2004 |
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2005 |
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Taxoids | 2005 |
Activity of gefitinib in central nervous system metastases in patients with non-small-cell lung cancer: two case reports and a review of the literature.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Radiography | 2005 |
[Molecular targeted therapy for malignant brain tumors].
Topics: Antineoplastic Agents; Benzamides; Brain Neoplasms; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imatinib Mesylate; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Piperidines; Protein Kinases; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2005 |
[Development of individualized therapy of non-small cell lung cancer targeted at the EGF receptor].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2005 |
Adjuvant chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib: current and future status in cancer therapy.
Topics: Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation; ErbB Receptors; Gefitinib; Humans; Neoplasms; Quinazolines; Signal Transduction | 2003 |
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Epidermal growth factor receptor (EGFR) inhibitors in cancer therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Quinazolines | 2005 |
[Molecular targeted therapy--non-small-cell lung cancer and gefitinib].
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2005 |
[Genetic alterations and chemoresistance].
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Benzamides; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Piperazines; Polymorphism, Genetic; Pyrimidines; Quinazolines; Thymidylate Synthase; Xeroderma Pigmentosum Group D Protein | 2005 |
Survival impact of epidermal growth factor receptor overexpression in patients with non-small cell lung cancer: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Survival Analysis | 2006 |
[Antineoplastic agents targeting tyrosine kinases].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gastrointestinal Stromal Tumors; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Trastuzumab | 2005 |
Cancer diagnostics: decision criteria for marker utilization in the clinic.
Topics: Algorithms; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow Examination; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Immunohistochemistry; Lung Neoplasms; Lymphatic Metastasis; Neoplasm, Residual; Neoplasms; Neoplastic Cells, Circulating; Patient Selection; Practice Guidelines as Topic; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Technology Assessment, Biomedical; Trastuzumab | 2005 |
Advances in molecular diagnostics and therapeutics in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Clinical Trials as Topic; Diagnosis, Differential; DNA Methylation; DNA, Mitochondrial; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microsatellite Repeats; Prognosis; Quinazolines; RNA, Messenger | 2006 |
Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Targeted therapy for the treatment of advanced non-small cell lung cancer: a review of the epidermal growth factor receptor antagonists.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genetic Therapy; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
EGFR inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Quinazolines; Treatment Failure | 2005 |
[EGFR/HER1 inhibition: an example of new targeted therapies in non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines; Survival Rate | 2005 |
Targeting of EGFR tyrosine kinase by ZD1839 ("Iressa") in androgen-responsive prostate cancer in vitro.
Topics: Androgens; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Topics: Brain Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Protein Kinase Inhibitors; Quinazolines | 2006 |
Clinical experience with gefitinib: an update.
Topics: Clinical Trials as Topic; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Chemotherapy for lung cancer patients].
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Docetaxel; Erlotinib Hydrochloride; Etoposide; Evidence-Based Medicine; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2006 |
[Palliative chemotherapy of head and neck cancer: present status and future development].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Deoxycytidine; Disease Progression; ErbB Receptors; Forecasting; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Patient Selection; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Taxoids; Time Factors; Treatment Outcome; Vinblastine; Vinorelbine | 2006 |
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
Targeting the epidermal growth factor receptor. Trials in head and neck and lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Mice; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
A review of the benefit-risk profile of gefitinib in Asian patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asia; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2006 |
Gefitinib: an adverse effects profile.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Dose-Response Relationship, Drug; Drug Interactions; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
Clinical experience with anti-EGFR therapy.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Safety; Survival Rate; Treatment Outcome | 2006 |
Common side effects of anti-EGFR therapy: acneform rash.
Topics: Acneiform Eruptions; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Nurse's Role; Oncology Nursing; Patient Education as Topic; Quinazolines; Severity of Illness Index | 2006 |
[Present status of and new trends in therapy for lung cancer].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2006 |
[Molecular targets in colon cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Camptothecin; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Colonic Neoplasms; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Irinotecan; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolones; Receptors, Platelet-Derived Growth Factor; Receptors, Somatomedin; Signal Transduction; Sirolimus; Sunitinib | 2006 |
Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Imatinib Mesylate; Piperazines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Stomach Neoplasms; Trastuzumab | 2006 |
Nondermatologic adverse events associated with anti-EGFR therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Diseases, Interstitial; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Where next for gefitinib in patients with lung cancer?
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2006 |
[Problems in the current target therapy of malignancies].
Topics: Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antibodies, Neoplasm; Antineoplastic Agents; Azathioprine; Benzamides; Bevacizumab; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Phthalazines; Piperazines; Pyridines; Pyrimidines; Quinazolines; Quinolones; Rituximab; Sesquiterpenes; Sesquiterpenes, Guaiane; Trastuzumab | 2005 |
Tyrphostins and other tyrosine kinase inhibitors.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Graft Occlusion, Vascular; Humans; Imatinib Mesylate; Janus Kinase 2; Janus Kinase 3; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Tyrphostins | 2006 |
Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Treatment Outcome | 2006 |
Predicting the outcome of chemotherapy for lung cancer.
Topics: 14-3-3 Proteins; Antineoplastic Agents; Cell Transformation, Neoplastic; Clinical Trials as Topic; DNA Repair Enzymes; DNA-Binding Proteins; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Mutation; Nuclear Proteins; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Smoking; Thioredoxins; Treatment Outcome; Y-Box-Binding Protein 1 | 2006 |
Epidermal growth factor receptor inhibition and non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Denmark; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Structure, Tertiary; Quinazolines; Signal Transduction | 2006 |
Advanced non-small-cell lung cancer: new data, therapy choices, and challenging decisions.
Topics: Antineoplastic Agents; Biological Products; Biomedical Research; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Protein Kinase Inhibitors; Quinazolines | 2006 |
[New substances in the therapy of head and neck cancer].
Topics: Administration, Oral; Aminoquinolines; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Basal Cell; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Controlled Clinical Trials as Topic; Double-Blind Method; Erlotinib Hydrochloride; Fibroblast Growth Factor 7; Gefitinib; Head and Neck Neoplasms; Humans; Imiquimod; Infusions, Intravenous; Iodine Radioisotopes; Lung Neoplasms; Lymphatic Metastasis; Lymphoma, Non-Hodgkin; Ointments; Protein Kinase Inhibitors; Quinazolines; Radioimmunotherapy; Randomized Controlled Trials as Topic; Skin Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2006 |
Targeted induction of apoptosis for cancer therapy: current progress and prospects.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Apoptosis; Galectins; Gefitinib; Humans; Models, Biological; Neoplasms; Quinazolines; Rituximab; Signal Transduction | 2006 |
Biological agents versus chemotherapy in the treatment of colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Phthalazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor A | 2006 |
[Mutations in the epidermal growth factor receptor: structure and biological function in human tumors].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Neoplasms; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases | 2006 |
[Current status and problems of anticancer drug-induced lung injuries].
Topics: Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Neoplasms; Product Surveillance, Postmarketing; Quinazolines; Risk Factors | 2006 |
[Diffuse lung diseases and biological markers in serum].
Topics: Antibodies, Monoclonal; Antigens, Neoplasm; Biomarkers; Collagen Diseases; Gefitinib; Humans; Lung Diseases, Interstitial; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Radiation Pneumonitis; Reagent Kits, Diagnostic; Respiratory Distress Syndrome; Sensitivity and Specificity | 2006 |
[Drug induced lung injuries in Japanese population].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Asian People; Bleomycin; Gefitinib; Genetic Predisposition to Disease; Humans; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Pulmonary Alveoli; Quinazolines; Racial Groups | 2006 |
Targeted therapies in non-small cell lung cancer: proven concepts and unfulfilled promises.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neovascularization, Pathologic; Protease Inhibitors; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Targeted therapies in gynecologic cancers.
Topics: Angiogenesis Inhibitors; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Transfer Techniques; Genital Neoplasms, Female; Humans; Neovascularization, Pathologic; Oligonucleotides, Antisense; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; Thalidomide; Thionucleotides; Trastuzumab | 2006 |
Methodological aspects of current problems in target-based anticancer drug development.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Drug Design; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Research Design; Trastuzumab | 2006 |
Biological and clinical implications of EGFR mutations in lung cancer.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Vitro Techniques; Lung Neoplasms; Male; Models, Molecular; Mutation; Oncogenes; Quinazolines | 2005 |
Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Smoking | 2005 |
[Drug-induced lung diseases].
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antibiotics, Antineoplastic; Antirheumatic Agents; Contrast Media; Drugs, Chinese Herbal; Gefitinib; Granulocyte Colony-Stimulating Factor; Humans; Interferons; Iodine Radioisotopes; Lung Diseases, Interstitial; Minocycline; Paclitaxel; Quinazolines | 2006 |
Epidermal growth factor receptor targeting in cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Clinical breakthroughs in EGFR inhibition: applying the science to your clinical practice.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Communication; Cetuximab; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Forecasting; Gefitinib; Humans; Neoplasms; Nurse's Role; Nursing Assessment; Oncology Nursing; Patient Care Planning; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2006 |
The role of the epidermal growth factor receptor in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Prognosis; Quinazolines; Receptor, ErbB-2 | 2006 |
Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines | 2006 |
Novel concepts in hepatocellular carcinoma: from molecular research to clinical practice.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Hepatocellular; Cell Differentiation; Cell Transformation, Neoplastic; ErbB Receptors; Gefitinib; Humans; Liver Cirrhosis; Neoplasm Invasiveness; Prognosis; Quinazolines | 2006 |
Targeted therapy in advanced non-small cell lung cancer (NSCLC): where do we stand?
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Epidermal growth factor receptor mutations and susceptibility to targeted therapy in lung cancer.
Topics: Antineoplastic Agents; DNA, Neoplasm; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Clinical aspects of epidermal growth factor receptor inhibitors: benefit and risk.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2006 |
[Anti-EGFR therapy: towards a "à la carte" targeting of hepatocellular carcinoma].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Clinical Trials, Phase II as Topic; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Ligands; Liver Neoplasms; Multicenter Studies as Topic; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction; Transforming Growth Factor alpha | 2006 |
Defining clinically relevant molecular subsets of lung cancer.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Protein kinases as drug targets in cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Benzenesulfonates; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Neoplasms; Niacinamide; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sirolimus; Sorafenib; Trastuzumab | 2006 |
[Is it possible to treat bronchial carcinoma without chemotherapy?].
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meta-Analysis as Topic; Neoadjuvant Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Risk Factors; Sex Factors; Smoking | 2006 |
Somatic mutations of the epidermal growth factor receptor and non-small-cell lung cancer.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Transformation, Neoplastic; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; DNA, Neoplasm; Double-Blind Method; Drug Delivery Systems; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Genes, erbB-1; Genes, p53; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Mutagenesis, Insertional; Mutation; Mutation, Missense; Protein Structure, Tertiary; Quinazolines; Randomized Controlled Trials as Topic; Sequence Deletion; Smoking | 2007 |
Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Duplication; Genes, ras; Humans; Models, Biological; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Signal Transduction | 2006 |
Targeting EGF-receptor-signalling in squamous cell carcinomas of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2007 |
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lapatinib; Neovascularization, Pathologic; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
Topics: Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Growth factor receptor interplay and resistance in cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Binding; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction | 2006 |
Inductive mechanisms limiting response to anti-epidermal growth factor receptor therapy.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Carcinoma; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin Receptor Substrate Proteins; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoproteins; Quinazolines; Signal Transduction | 2006 |
The place of targeted therapies in the management of non-small cell bronchial carcinoma. Target therapies in lung cancer management.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2006 |
[Drug-induced lung injury].
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Prognosis; Quinazolines; Thoracoscopy | 2007 |
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Treatment Outcome | 2007 |
Medicalisation of race.
Topics: Age Distribution; Aged; Antineoplastic Agents; Black or African American; Clinical Trials as Topic; Drug Approval; Drug Combinations; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Lung Neoplasms; Middle Aged; Patents as Topic; Quinazolines; United States; United States Food and Drug Administration | 2007 |
EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2007 |
Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Topics: Antineoplastic Agents; Cell Movement; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morphogenesis; Neoplasm Invasiveness; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2007 |
Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2006 |
[Prediction of effectiveness of EGFR tyrosine kinase inhibitors for the patients with by EGFR mutations].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Smoking | 2007 |
[New biological treatments for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biopsy; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Mutation; Patient Selection; Polymerase Chain Reaction; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Analysis; Treatment Outcome; Vascular Endothelial Growth Factor A | 2007 |
Epidermal growth factor receptor mutations and their correlation with gefitinib therapy in patients with non-small cell lung cancer: a meta-analysis based on updated individual patient data from six medical centers in mainland China.
Topics: Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; China; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Analysis | 2007 |
Epidermal growth factor receptor inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Nucleus; Cytoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Models, Biological; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
Targeting the epidermal growth factor receptor in non-small-cell lung cancer: who, which, when, and how?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2007 |
[What is drug-epidemiology?].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Quinazolines | 2007 |
[Major drug-induced lung diseases: adverse effects of newly developed molecular targeted drugs].
Topics: Antineoplastic Agents; Gefitinib; Gene Targeting; Humans; Lung Diseases, Interstitial; Quinazolines | 2007 |
Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials, Phase II as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2007 |
"Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?".
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Medical Oncology; Mutation; Quinazolines; ras Proteins; Smoking | 2007 |
[Therapeutic management of extensive bronchiolo-alveolar adenocarcinoma: chemotherapy or inhibitors of epidermal growth factor receptor tyrosine kinase?].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Predictive markers in breast cancer treatment--focusing on a recent topic "basal-like breast cancer"].
Topics: Anthracyclines; Antibiotics, Antineoplastic; Antigens, Neoplasm; Antineoplastic Agents; BRCA1 Protein; Breast Neoplasms; DNA Topoisomerases, Type II; DNA-Binding Proteins; Estrogen Receptor alpha; Female; Forecasting; Gefitinib; Gene Expression Profiling; Humans; Mutation; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Tubulin | 2007 |
[Head and neck: molecular-targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Head and Neck Neoplasms; Humans; Paclitaxel; Quinazolines | 2007 |
The place of targeted therapy in the patient management of non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Gefitinib and epidermal growth factor receptor gene mutation].
Topics: Adenocarcinoma; Antineoplastic Agents; Enzyme Inhibitors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Respiratory Distress Syndrome; Smoking | 2007 |
[Molecular targeted therapies for metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Trastuzumab | 2007 |
Targeted therapy in rectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Camptothecin; Cetuximab; Drug Delivery Systems; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Quinazolines; Rectal Neoplasms; Vascular Endothelial Growth Factor A | 2007 |
[Targeting ErbB receptors in breast cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2007 |
[Targeting epidermal growth factor receptor in non-small cell lung cancer: current advances and perspectives].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2007 |
Targeting the epidermal growth factor receptor in metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Mutation; Neoplasm Metastasis; Panitumumab; Quinazolines | 2008 |
Chasing targets for EGFR tyrosine kinase inhibitors in non-small-cell lung cancer: Asian perspectives.
Topics: Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Drug-induced pulmonary edema].
Topics: Amiodarone; Anti-Arrhythmia Agents; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Diagnosis, Differential; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Glucocorticoids; Humans; Immunosuppressive Agents; Norepinephrine; Pulmonary Edema; Quinazolines; Respiration, Artificial; Risk Factors | 2007 |
[Adverse drug reactions induced by molecular target therapy].
Topics: Anaphylaxis; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzamides; Cetuximab; Communicable Diseases; ErbB Receptors; Etanercept; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Immunoglobulin G; Infliximab; Lung Diseases; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Tumor Necrosis Factor; Skin Diseases; Tumor Necrosis Factor-alpha | 2007 |
Strategies to optimize the use of targeted agents for tumor therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cell Transformation, Neoplastic; Clinical Trials as Topic; Drug Delivery Systems; Drug Evaluation, Preclinical; Drug Synergism; Gefitinib; Gene Silencing; Humans; Neoplasms; Prognosis; Quinazolines | 2008 |
EGFR mutations and EGFR tyrosine kinase inhibition in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Benzenesulfonates; Bevacizumab; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Lapatinib; Neoplasms; Neovascularization, Pathologic; Niacinamide; Phenylurea Compounds; Piperazines; Piperidines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib; Trastuzumab | 2008 |
EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors; Treatment Outcome | 2008 |
The role of gefitinib in the management of Asian patients with non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2008 |
Mutations in the epidermal growth factor receptor gene and effects of EGFR-tyrosine kinase inhibitors on lung cancers.
Topics: Adenocarcinoma; Case-Control Studies; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Diseases, Interstitial; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Chemotherapeutic agents and the skin: An update.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites; Antineoplastic Agents; Benzamides; Benzenesulfonates; Cetuximab; Drug Eruptions; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Hair Diseases; Humans; Imatinib Mesylate; Indoles; Mucous Membrane; Nail Diseases; Niacinamide; Phenylurea Compounds; Piperazines; Platinum Compounds; Proteasome Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Skin; Skin Diseases; Sorafenib; Sunitinib; Taxoids | 2008 |
Systemic therapies for recurrent and/or metastatic salivary gland cancers.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Benzamides; Boronic Acids; Bortezomib; Cetuximab; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Trastuzumab | 2008 |
Commentary: Novel therapies for cancer: why dirty might be better.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Microtubules; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Purinergic P2 | 2008 |
[Efficacy of gefitinib in treatment of lung cancer patients with bone metastasis].
Topics: Alkaline Phosphatase; Antineoplastic Agents; Biomarkers; Bone Neoplasms; Bone Resorption; Collagen Type I; Female; Fractures, Spontaneous; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Osteogenesis; Peptide Fragments; Peptides; Procollagen; Quinazolines | 2008 |
[Targeted therapies in the treatment of non-small cell lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Salivary gland carcinomas: molecular abnormalities as potential therapeutic targets.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzamides; Boronic Acids; Bortezomib; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrazines; Pyrimidines; Quinazolines; Salivary Gland Neoplasms; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Epidermal growth factor receptor (EGFR) targeted therapies in non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Quinazolines; Trastuzumab; Treatment Outcome | 2006 |
The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: a meta-analysis.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Quinazolines | 2008 |
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies.
Topics: Adaptor Proteins, Signal Transducing; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Estrogen Antagonists; Female; Gefitinib; Humans; Membrane Glycoproteins; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; RNA-Binding Proteins; Tamoxifen; Ubiquitin-Protein Ligases | 2008 |
Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Diet; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Lymph Node Excision; Neoplasm Staging; Pharmacogenetics; Quinazolines; Radiotherapy Dosage; Risk Factors; Smoking; Survival Analysis; Survivors; Tobacco Smoke Pollution; Treatment Outcome | 2008 |
Current status of clinical trials for glioblastoma.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Benzamides; Biocompatible Materials; Brain Neoplasms; Cancer Vaccines; Clinical Trials as Topic; Combined Modality Therapy; Dacarbazine; Decanoic Acids; ErbB Receptors; Erlotinib Hydrochloride; Farnesyltranstransferase; Gefitinib; Glioblastoma; Humans; Imatinib Mesylate; Immunotoxins; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Piperazines; Polyesters; Protein Kinase Inhibitors; Proteins; Pyrimidines; Quinazolines; Sirolimus; Temozolomide; TOR Serine-Threonine Kinases; Transcription Factors | 2006 |
Epidermal growth factor receptor-directed therapy in esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Barrett Esophagus; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Humans; Incidence; Lung Neoplasms; Quinazolines; Survival Analysis | 2007 |
[Non-small-cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Advances in the treatment of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Early clinical studies of novel therapies for thyroid cancers.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma; Clinical Trials as Topic; Drug Delivery Systems; Gefitinib; Humans; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Sorafenib; Thyroid Neoplasms | 2008 |
New insights in drug development for the non-small cell lung cancer therapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
The use of first-generation tyrosine kinase inhibitors in patients with NSCLC and somatic EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR tyrosine kinase inhibitors for the treatment of NSCLC in East Asia: present and future.
Topics: Antineoplastic Agents; Asia, Eastern; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
Challenges of detecting EGFR T790M in gefitinib/erlotinib-resistant tumours.
Topics: Alleles; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines | 2008 |
Nursing management of epidermal growth factor receptor inhibitor-induced toxicities.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diarrhea; Drug Eruptions; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Nursing Assessment; Oncology Nursing; Panitumumab; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2008 |
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Quinolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
[New therapies for the treatment of advanced non-small cell lung cancer: inhibitors of the epidermal growth factor receptor and angiogenesis].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neovascularization, Pathologic; Quinazolines | 2008 |
Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Medical Oncology; Quinazolines; Treatment Outcome; Vascular Endothelial Growth Factor A | 2009 |
[Case of bilateral pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple pulmonary metastases].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Pneumothorax; Quinazolines | 2008 |
[Targeted therapy for locally advanced and/or metastatic bladder cancer].
Topics: Angiogenesis Inhibitors; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Immunosuppressive Agents; Mutation; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction; Sirolimus; Targeted Gene Repair; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
The role of inhibitors of the epidermal growth factor in management of head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
The efficacy and toxicity of EGFR in the settings of radiotherapy: Focus on published clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2008 |
[Targeted therapies for lung cancer].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Gene Targeting; Humans; Lung Neoplasms; Patient Selection; Protein-Tyrosine Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
EGFR inhibition as a therapy for head and neck squamous cell carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Head and Neck Neoplasms; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2008 |
EGFR-targeted therapeutics: focus on SCCHN and NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2008 |
The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current "best evidence" with meta-analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biomarkers, Tumor; Double-Blind Method; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Quinazolines; Randomized Controlled Trials as Topic; Signal Transduction | 2009 |
Targeted therapy for the treatment of non-small cell lung cancer: focus on inhibition of epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2008 |
Overview of gefitinib in non-small cell lung cancer: an Asian perspective.
Topics: Antineoplastic Agents; Asia, Eastern; Asian People; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Second line treatments in advanced platinum-resistant non small cell lung cancer. A critical review of literature.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Treatment Outcome | 2009 |
Gefitinib in lung cancer therapy: clinical results, predictive markers of response and future perspectives.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2009 |
[Targeted therapies and their indications in solid neoplasias].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Indoles; Kidney Neoplasms; Liver Neoplasms; Neoplasms; Niacinamide; Phenylurea Compounds; Pyridines; Pyrroles; Quinazolines; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Sirolimus; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors in elderly or poor performance status patients with advanced non-small cell lung cancer.
Topics: Age Factors; Aging; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2009 |
Gefitinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Proteins; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Research Design; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2009 |
Mechanisms of resistance to EGFR inhibitors in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Signal Transduction; Treatment Outcome | 2009 |
Reasons for response differences seen in the V15-32, INTEREST and IPASS trials.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; Disease-Free Survival; Docetaxel; ErbB Receptors; Europe; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multicenter Studies as Topic; Neoplasm Metastasis; Neoplasm Staging; North America; Paclitaxel; Platinum Compounds; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Recurrence; South America; Survival Analysis; Taxoids; Tumor Burden | 2009 |
Integrating epidermal growth factor receptor-targeted therapies into platinum-based chemotherapy regimens for newly diagnosed non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Platinum Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2008 |
Combining epidermal growth factor receptor inhibitors and radiation therapy in pancreatic cancer: small step or giant leap?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Combined survival analysis of prospective clinical trials of gefitinib for non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2010 |
Targeted therapies in the treatment of advanced/metastatic NSCLC.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Erlotinib Hydrochloride; Gefitinib; Humans; Indoles; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2009 |
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Quinazolinones | 2009 |
Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Survival Rate | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Quinazolines; Randomized Controlled Trials as Topic | 2009 |
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptors, Growth Factor; Sequence Deletion; Treatment Outcome | 2009 |
Predictive value of EGFR and HER2 overexpression in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2009 |
Clinical pharmacokinetics of tyrosine kinase inhibitors.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Benzenesulfonates; Biological Availability; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Indoles; Intestinal Absorption; Lapatinib; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Tissue Distribution | 2009 |
EGFR inhibition in NSCLC: the emerging role of cetuximab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Docetaxel; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Taxoids | 2004 |
[Progress in chemotherapy for advanced gastric cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; Docetaxel; Doxorubicin; Drug Combinations; Fluorouracil; Gefitinib; Humans; Irinotecan; Methotrexate; Neoadjuvant Therapy; Neoplasm Staging; Organoplatinum Compounds; Oxaliplatin; Oxonic Acid; Paclitaxel; Quinazolines; Stomach Neoplasms; Survival Rate; Taxoids; Tegafur; Trastuzumab | 2009 |
Human ABC transporter ABCG2 in cancer chemotherapy and pharmacogenomics.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cyclin-Dependent Kinases; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Pharmacogenetics; Polymorphism, Single Nucleotide; Quantitative Structure-Activity Relationship; Quinazolines | 2009 |
Gefitinib: a review of its use in the treatment of locally advanced/metastatic non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2009 |
Treatment of advanced non-small-cell lung cancer in the elderly.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cardiovascular Diseases; Cisplatin; Clinical Trials as Topic; Comorbidity; Contraindications; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Vascular Endothelial Growth Factor A | 2009 |
[Molecular-targeted therapy in the developing stage. 1) VEGFR-TKI and EGFR-TKI].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; ErbB Receptors; Gefitinib; Humans; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2009 |
EGF receptor in relation to tumor development: molecular basis of responsiveness of cancer cells to EGFR-targeting tyrosine kinase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Bcl-2-Like Protein 11; bcl-Associated Death Protein; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
Emerging treatment combinations: integrating therapy into clinical practice.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Delivery Systems; Drugs, Investigational; ErbB Receptors; Everolimus; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Intracellular Signaling Peptides and Proteins; Models, Biological; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2009 |
Small-molecule inhibitors of the human epidermal receptor family.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Models, Biological; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Tyrosine kinase inhibitors and the thyroid.
Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Indoles; Niacinamide; Oligonucleotides; Pharmaceutical Preparations; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins B-raf; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thyroid Gland; Thyroid Neoplasms | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced nonsmall-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Gender-associated differences in lung cancer: clinical characteristics and treatment outcomes in women.
Topics: Adenocarcinoma; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sex Factors; Smoking; Survival Analysis; Vascular Endothelial Growth Factor A | 2009 |
[Molecular diagnostics in lung carcinoma for therapy stratification].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Diagnostic Techniques; Neoplasm Staging; Prognosis; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship | 2010 |
Successful treatment of gefitinib-induced acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Acute Disease; Adenocarcinoma; Adrenal Cortex Hormones; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Review Literature as Topic; Treatment Outcome | 2011 |
[Cutaneous side effects of EGFR inhibitors--appearance and management].
Topics: Acneiform Eruptions; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair Diseases; Humans; Ichthyosis; Mucositis; Neoplasms; Panitumumab; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2010 |
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Early Detection of Cancer; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; United States; White People | 2010 |
Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hemorrhage; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Medical Oncology; Middle Aged; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2010 |
Cetuximab and chemoradiation for rectal cancer--is the water getting muddy?
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Irinotecan; Neoadjuvant Therapy; Organoplatinum Compounds; Oxaliplatin; Panitumumab; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Rectal Neoplasms; Treatment Failure | 2010 |
[Current update and testing procedures for genetic diagnosis in malignant neoplasm: additional information on pathological tests].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Biomarkers, Tumor; Cetuximab; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, ras; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quality Control; Quinazolines | 2010 |
The molecular pathology of cancer.
Topics: Adenocarcinoma; Base Sequence; Breast Neoplasms; Female; Gefitinib; Genes, ras; Genome-Wide Association Study; Humans; Male; Mutation; Neoplasms; Nervous System Neoplasms; Pathology, Molecular; Quinazolines; Signal Transduction | 2010 |
First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Acquired resistance of lung adenocarcinoma to EGFR-tyrosine kinase inhibitors gefitinib and erlotinib.
Topics: Adenocarcinoma; Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Gefitinib for the treatment of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2010 |
Use of erlotinib or gefitinib as initial therapy in advanced NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Understanding resistance to EGFR inhibitors-impact on future treatment strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2010 |
A major step towards individualized therapy of lung cancer with gefitinib: the IPASS trial and beyond.
Topics: Asia; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
[Oncology 2010].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Chemotherapy, Adjuvant; Colorectal Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2010 |
Mechanistic insights into acquired drug resistance in epidermal growth factor receptor mutation-targeted lung cancer therapy.
Topics: Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Predictive Value of Tests; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[Current status of erlotinib and gefitinib in palliative therapy for NSCLC--does the EGF-R mutation state have any significance?].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Long-Term Care; Lung Neoplasms; Palliative Care; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Lessons learnt from gefitinib and erlotinib: Key insights into small-molecule EGFR-targeted kinase inhibitors in non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Discovery; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2010 |
[Molecular factors related to gefitinib efficacy in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
[The predictive value of EGFR status in non-small cell lung cancer patients treated with EGFR-TKIs].
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Targeted therapy: an evolving world of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genetic Markers; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; White People | 2011 |
Second-line treatment for non-small-cell lung cancer: one size does not fit all.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Prognosis; Quinazolines; Taxoids | 2010 |
Epidermal growth factor receptor targeted therapy of squamous cell carcinoma of the head and neck.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Quinazolines | 2010 |
Factors driving the choice of the best second-line treatment of advanced NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Docetaxel; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Taxoids; Thymidylate Synthase | 2011 |
Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cetuximab; Cisplatin; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Signal Transduction; Survival Analysis; Translocation, Genetic | 2010 |
Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy.
Topics: Aged; Antineoplastic Agents; Diphosphonates; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Octreotide; Osteoarthropathy, Secondary Hypertrophic; Pain; Quinazolines; Rheumatology; Treatment Outcome; Vagotomy | 2011 |
The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Precision Medicine; Quinazolines | 2010 |
Resistance to HER2-targeted therapy: mechanisms of trastuzumab resistance and possible strategies to overcome unresponsiveness to treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Division; Drug Delivery Systems; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Phosphatidylinositol 3-Kinase; Prognosis; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2010 |
Gefitinib for the first-line treatment of locally advanced or metastatic non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
[Consolidation therapy in advanced non-small cell lung cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Lung Neoplasms; Medical Oncology; Neoplasm Staging; Prognosis; Quinazolines; Risk Assessment | 2010 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines | 2010 |
Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.
Topics: ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Neoplasm Proteins; Pharmacogenetics; Piperazines; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2010 |
[EGFR inhibitors in non-small cell lung cancer: more than yesterday (but less than tomorrow)].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Controlled Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Targeted Therapy; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Mutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2011 |
Influence of polymorphisms on EGFR targeted therapy in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Exanthema; Gefitinib; Humans; Lung Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2011 |
Kinase-driven pathways of EGFR in lung carcinomas: perspectives on targeting therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases | 2011 |
EGFR tyrosine kinase inhibitors and multidrug resistance: perspectives.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence.
Topics: Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2011 |
Targeting EGFR in bilio-pancreatic and liver carcinoma.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Benzenesulfonates; Biliary Tract Neoplasms; Carcinoma; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Pancreatic Neoplasms; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib | 2011 |
Advances in EGFR-directed therapy in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Head and Neck Neoplasms; Humans; Lung Diseases, Interstitial; Panitumumab; Protein Kinase Inhibitors; Quinazolines; Radiodermatitis | 2011 |
EGFR pathway in advanced non-small cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2011 |
The safety and efficacy of EGFR TKIs monotherapy versus single-agent chemotherapy using third-generation cytotoxics as the first-line treatment for patients with advanced non-small cell lung cancer and poor performance status.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Quality of Life; Quinazolines | 2011 |
Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Quinazolines | 2011 |
[Dose finding methods for targeted agents: new perspectives].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2010 |
The Pharmacogenetic Rescue of Side-Lined Anticancer Drugs to the Front-Line: Gefitinib as a Case Example.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines; Retrospective Studies; Risk Assessment; Technology Transfer | 2011 |
[Gefitinib-induced acute lung injury: a case report and review of the literature].
Topics: Acute Lung Injury; Aged; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Tomography, X-Ray Computed | 2011 |
[Prognostic and predictive biomarkers in non-small cell lung cancers. From conditioned registrations to routine molecular mapping of lung cancers: Methodological issues].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Quinazolines; Salvage Therapy | 2011 |
Treatment of non-small-cell lung cancer with erlotinib or gefitinib.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Practice Guidelines as Topic; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2011 |
[Adverse effects of new biological therapies for non-small-cell bronchial cancer].
Topics: Angiogenesis Inhibitors; Biological Products; Carcinoma, Non-Small-Cell Lung; Cooperative Behavior; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Interdisciplinary Communication; Lung Neoplasms; Neoplasm Staging; Patient Care Team; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Bronchiolar-alveolar carcinoma: From concept to innovative therapeutic strategies].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pneumonectomy; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cisplatin; Clinical Trials as Topic; Drug Administration Schedule; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Gene Expression; Humans; Lung Neoplasms; Mutation; Ovarian Neoplasms; Platinum; Protein Kinase Inhibitors; Quinazolines; Recurrence; Survival Rate; Treatment Outcome | 2011 |
Chemotherapy and radiotherapy for mesothelioma.
Topics: Antineoplastic Agents; Asbestos; Combined Modality Therapy; Gefitinib; Genetic Therapy; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Mesothelioma; Pleural Neoplasms; Quinazolines; Ribonucleases; Thalidomide | 2011 |
[Gefitinib for non-small cell lung cancer: a meta analysis].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quality Control; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2011 |
Prophylaxis and treatment of dermatologic adverse events from epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2011 |
Novel molecular targeted therapies for refractory thyroid cancer.
Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Benzoquinones; Bibenzyls; Boronic Acids; Bortezomib; Depsipeptides; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Imatinib Mesylate; Imidazoles; Indazoles; Indoles; Lactams, Macrocyclic; Lenalidomide; Niacinamide; Oligonucleotides; Phenylurea Compounds; Piperazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrazines; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Sunitinib; Thalidomide; Thyroid Neoplasms; Valproic Acid; Vorinostat | 2012 |
[A simple view on lung cancer biology: The EGFR pathway].
Topics: Adenocarcinoma; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2011 |
KRAS-mutation positive, metastatic tonsil carcinoma with cancer stem-like cell features and long-term response to gefitinib: a case report and review of the literature.
Topics: Antineoplastic Agents; Biopsy; Carcinoma, Squamous Cell; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Mutation; Neoplasm Invasiveness; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Time Factors; Tomography, X-Ray Computed; Tonsillar Neoplasms; Treatment Outcome | 2011 |
Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: meta-analysis of phase III trials.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Therapy; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Smoking; Survival Analysis | 2011 |
EGFR inhibitors with concurrent thoracic radiation therapy for locally advanced non-small cell lung cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Combined Modality Therapy; Disease Progression; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines; Radiation Tolerance | 2011 |
[Indication of EGFR kinase inhibitors should be refined].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2011 |
Gefitinib in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
[EGFR/HER1: a target life].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Boronic Acids; Bortezomib; Cetuximab; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Panitumumab; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazines; Quinazolines; ras Proteins | 2012 |
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor | 2011 |
Tyrosine kinase inhibitors for non-small-cell lung cancer: finding patients who will be responsive.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Patient Selection; Precision Medicine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Problems involved in the clinical trials for non-small cell lung carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Maintenance Chemotherapy; Mutation; Patient Selection; Pemetrexed; Platinum; Quinazolines | 2012 |
Targeted drug therapies and cancer.
Topics: Antineoplastic Agents; Benzamides; Benzenesulfonates; Drug Delivery Systems; Erlotinib Hydrochloride; Gastrointestinal Neoplasms; Gefitinib; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Piperazines; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sorafenib; Sunitinib; Vascular Endothelial Growth Factor A | 2011 |
Cytology-based gene mutation tests to predict response to anti-epidermal growth factor receptor therapy: a review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Neoplasm Metastasis; Panitumumab; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2011 |
Gefitinib for non-small-cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2011 |
Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Docetaxel; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Randomized Controlled Trials as Topic; Taxoids; Topotecan | 2012 |
Genetics of glioblastoma: a window into its imaging and histopathologic variability.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Proliferation; Cell Survival; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Magnetic Resonance Imaging; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines | 2011 |
[Resistant mechanism and treatment strategy of tyrosine kinase inhibitors].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Gefitinib compared with systemic chemotherapy as first-line treatment for chemotherapy-naive patients with advanced non-small cell lung cancer: a meta-analysis of randomised controlled trials.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2012 |
The evolution of phase I trials in cancer medicine: a critical review of the last decade.
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Gefitinib; Humans; Maximum Tolerated Dose; Molecular Targeted Therapy; Neoplasms; Phthalazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyridines; Quinazolines | 2011 |
Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Myocardial Infarction; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGFR-mutated oncogene-addicted non-small cell lung cancer: current trends and future prospects.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2012 |
Long-term outcome after multidisciplinary approach for leptomeningeal carcinomatosis in a non-small cell lung cancer patient with poor performance status.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Treatment Outcome; Ventriculoperitoneal Shunt | 2011 |
Role of chemotherapy on brain metastasis.
Topics: Brain Neoplasms; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2012 |
Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Arterial Occlusive Diseases; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Neoplasms; Panitumumab; Quinazolines; Randomized Controlled Trials as Topic; Risk; Venous Thromboembolism | 2012 |
New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Topics: Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Neoplasm Metastasis; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2012 |
Pulmonary toxicities of tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Benzamides; ErbB Receptors; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; Lung Diseases, Interstitial; Neoplasms; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2011 |
Clinical trials and biomarker research on lung cancer in China.
Topics: Biomarkers, Tumor; China; Clinical Trials as Topic; Cytochrome P-450 CYP1A1; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Translational Research, Biomedical | 2012 |
[Research progress on resistance mechanisms of epidermal growth factor receptor
tyrosine kinase inhibitors in non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2012 |
Recent advances in treatment of advanced urothelial carcinoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cancer Vaccines; Carcinoma, Transitional Cell; Cetuximab; Cisplatin; Doxorubicin; Female; Gefitinib; Humans; Immunotherapy; Male; Methotrexate; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quality Improvement; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder Neoplasms; Vinblastine | 2012 |
Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year's literature.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzodioxoles; Carcinoma, Squamous Cell; Cetuximab; Combined Modality Therapy; Dasatinib; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Indoles; Neoplasm Recurrence, Local; Palliative Care; Pyrimidines; Pyrroles; Quinazolines; Quinazolinones; Salvage Therapy; Squamous Cell Carcinoma of Head and Neck; Sunitinib; Thiazoles | 2012 |
Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Recent advances in non-small cell lung cancer biology and clinical management.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Quinazolines; Vascular Endothelial Growth Factor A | 2012 |
Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2012 |
Pharmacogenetics of EGFR in lung cancer: perspectives and clinical applications.
Topics: Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines | 2012 |
The impact of second-line agents on patients' health-related quality of life in the treatment for non-small cell lung cancer: a systematic review.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Practice Guidelines as Topic; Quality of Life; Quinazolines; Sickness Impact Profile; Taxoids; Time Factors; Treatment Outcome | 2013 |
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Cetuximab; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Molecular Targeted Therapy; Mutation; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Panitumumab; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
EGF receptor-targeted therapy in non-small-cell lung cancer: role of germline polymorphisms in outcome and toxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Erosive pustular dermatosis of the scalp-like eruption due to gefitinib: case report and review of the literature of alopecia associated with EGFR inhibitors.
Topics: Aged; Alopecia; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Scalp Dermatoses | 2012 |
Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Germ-Line Mutation; Humans; Indoles; Molecular Targeted Therapy; Neoplasm Proteins; Neoplasms; Niacinamide; Phenylurea Compounds; Polymorphism, Genetic; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Treatment Outcome | 2012 |
Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; MEDLINE; Mutation; Quinazolines | 2012 |
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Potential therapeutic significance of HER-family in esophageal squamous cell carcinoma.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Drug Delivery Systems; Erlotinib Hydrochloride; Esophageal Neoplasms; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Lapatinib; Quinazolines; Trastuzumab | 2012 |
EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Prognostic significance and targeting of HER family in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Panitumumab; Prognosis; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Vascular Endothelial Growth Factor A | 2013 |
[Brain metastases of non small cell lung cancers: systemic treatments].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
The epidermal growth factor receptor in squamous cell carcinoma: An emerging drug target.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Panitumumab; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2014 |
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines | 2013 |
Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2013 |
New oxaliplatin-based combinations in the treatment of colorectal cancer.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Boronic Acids; Bortezomib; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Mitomycin; Organoplatinum Compounds; Oxaliplatin; Pyrazines; Quinazolines; Thiophenes | 2003 |
Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase III trials (NEJ 002 and WJTOG 3405).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Platinum; Protein Kinase Inhibitors; Quinazolines; Smoking | 2013 |
Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids | 2013 |
How and when to use genetic markers for nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Oncogene Proteins, Fusion; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Incidence and risk of treatment-related mortality in cancer patients treated with EGFR-TKIs: a meta-analysis of 22 phase III randomized controlled trials.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Risk Factors | 2013 |
Second-Line Therapy for Advanced NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Mutation; Oncogene Proteins, Fusion; Pemetrexed; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids | 2013 |
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Proliferation; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Neoplasms; Panitumumab; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Chemotherapy with or without gefitinib in patients with advanced non-small-cell lung cancer: a meta-analysis of 6,844 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic | 2013 |
Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single Nucleotide; Quinazolines | 2013 |
Targeting receptor tyrosine kinases in HER2-negative breast cancer.
Topics: Anastrozole; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase II as Topic; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Molecular Targeted Therapy; Nitriles; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Treatment Outcome; Triazoles; Up-Regulation | 2013 |
[Clinical pharmacokinetics of small molecule tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; Crown Ethers; Cytochrome P-450 Enzyme System; Dasatinib; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; Glucuronosyltransferase; Humans; Imatinib Mesylate; Indoles; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib | 2013 |
A severe dermatologic adverse effect related with gefitinib: case report and review of the literature.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Edema; Erythema; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Co-targeting estrogen receptor and HER2 pathways in breast cancer.
Topics: Anastrozole; Androstadienes; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms; Estradiol; Everolimus; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; Letrozole; Molecular Targeted Therapy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Sirolimus; Tamoxifen; Trastuzumab; Triazoles | 2014 |
Risk of interstitial lung disease with gefitinib and erlotinib in advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Risk; Survival Analysis | 2014 |
Epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Models, Biological; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2014 |
Standards of care and novel approaches in the management of glioblastoma multiforme.
Topics: Adult; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Brain Neoplasms; Cancer Vaccines; Electric Stimulation Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunotherapy; Quinazolines; Snake Venoms; Standard of Care; Vaccines, Subunit | 2014 |
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI?
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment | 2014 |
Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Bayes Theorem; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Data Collection; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Markov Chains; Mutation; Probability; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2014 |
Risk of interstitial lung disease associated with EGFR-TKIs in advanced non-small-cell lung cancer: a meta-analysis of 24 phase III clinical trials.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2015 |
Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Incidence; Lung Neoplasms; Molecular Targeted Therapy; Prognosis; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2014 |
Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
Gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemistry, Pharmaceutical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Solubility | 2014 |
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma | 2014 |
The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2014 |
Emerging EGFR antagonists for breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cetuximab; Drug Discovery; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Panitumumab; Protein Kinase Inhibitors; Quinazolines | 2014 |
Management and future directions in non-small cell lung cancer with known activating mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Mutation Rate; Neoplasms, Squamous Cell; Oncogenes; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2014 |
Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of central nerve system metastases from non-small cell lung cancer.
Topics: Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Predictive value of a serum-based proteomic test in non-small-cell lung cancer patients treated with epidermal growth factor receptor tyrosine kinase inhibitors: a meta-analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Proteomics; Quinazolines | 2014 |
Which tyrosine kinase inhibitor should be recommended as initial treatment for non-small cell lung cancer patients with EGFR mutations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence.
Topics: Asian People; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Protein Kinase Inhibitors; Quinazolines | 2014 |
Diagnostic value of circulating free DNA for the detection of EGFR mutation status in NSCLC: a systematic review and meta-analysis.
Topics: Antineoplastic Agents; Area Under Curve; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve | 2014 |
Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after first-line EGFR-TKIs for advanced non-small cell lung cancer: a meta-analysis.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Proportional Hazards Models; Quinazolines | 2014 |
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2014 |
Anti-epidermal-growth-factor-receptor agents and complete responses in the treatment of advanced non-small-cell lung cancer: a meta-analysis of 17 phase III randomized controlled trials.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials, Phase III as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Class act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma | 2014 |
A systematic review of the cost-effectiveness of targeted therapies for metastatic non-small cell lung cancer (NSCLC).
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2014 |
EGFR-TKIs combined with chemotherapy versus EGFR-TKIs single agent as first-line treatment for molecularly selected patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
EGFR Transactivation by Peptide G Protein-Coupled Receptors in Cancer.
Topics: Antineoplastic Agents; Bombesin; Cell Proliferation; Cholecystokinin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neurotensin; Protein Kinase Inhibitors; Quinazolines; Receptors, G-Protein-Coupled | 2016 |
First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Mutation; Quality of Life; Quinazolines; Retrospective Studies | 2015 |
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Common EGFR-mutated subgroups (Del19/L858R) in advanced non-small-cell lung cancer: chasing better outcomes with tyrosine kinase inhibitors.
Topics: Afatinib; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Signal Transduction; Survival Rate | 2015 |
Gefitinib: a review of its use in adults with advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Critical role of ABCG2 in ALA-photodynamic diagnosis and therapy of human brain tumor.
Topics: Aminolevulinic Acid; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Brain Neoplasms; Gefitinib; Humans; Mice; Neoplasm Proteins; NF-E2-Related Factor 2; Oxidative Stress; Photochemotherapy; Porphyrins; Protein Kinase Inhibitors; Protoporphyrins; Quinazolines; Transcription, Genetic; Treatment Outcome | 2015 |
Management of EGFR mutated nonsmall cell lung carcinoma patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2015 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Gefitinib and erlotinib in metastatic non-small cell lung cancer: a meta-analysis of toxicity and efficacy of randomized clinical trials.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Publication Bias; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Risk | 2015 |
The comparisons of the efficacy and toxicity between gefitinib and docetaxel for patients with advanced nonsmall-cell lung cancer: a meta-analysis from randomized controlled clinical trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Treatment Outcome | 2014 |
Tyrosine kinase inhibitors for epidermal growth factor receptor gene mutation-positive non-small cell lung cancers: an update for recent advances in therapeutics.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Dual HER2 blockade: preclinical and clinical data.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lapatinib; Molecular Targeted Therapy; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2014 |
EGFR and NF-κB: partners in cancer.
Topics: Animals; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronoglucosaminidase; Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proteins; Quinazolines; Signal Transduction | 2015 |
Pharmacologic treatment options for advanced epithelial skin cancer.
Topics: Anilides; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Targeted Therapy; Pyridines; Quality of Life; Quinazolines; Skin Neoplasms; Treatment Outcome | 2015 |
EGFR mutations in lung cancer: from tissue testing to liquid biopsy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2015 |
Clinical efficacy of mTOR inhibitors in solid tumors: a systematic review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Clinical Trials as Topic; Docetaxel; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; Taxoids; TOR Serine-Threonine Kinases | 2015 |
Evaluation on efficacy and safety of tyrosine kinase inhibitors plus radiotherapy in NSCLC patients with brain metastases.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic | 2015 |
Pathological complete response to gefitinib in a 10-year-old boy with EGFR-negative pulmonary mucoepidermoid carcinoma: a case report and literature review.
Topics: Carcinoma, Mucoepidermoid; Child; DNA-Binding Proteins; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Transcription Factors; Treatment Outcome | 2017 |
[Radiotherapy concomitant with first-generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of brain metastases from non small cell lung cancer: a meta-analysis].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2015 |
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases | 2015 |
Cumulative meta-analysis of epidermal growth factor receptor-tyrosine kinase inhibitors as first-line therapy in metastatic non-small-cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2015 |
[Kinase inhibitors and their resistance].
Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib | 2015 |
[Molecular target therapies for skin cancers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cetuximab; CTLA-4 Antigen; Enzyme Inhibitors; Gefitinib; Humans; MAP Kinase Kinase Kinases; Melanoma; Molecular Targeted Therapy; Programmed Cell Death 1 Receptor; Proto-Oncogene Proteins B-raf; Quinazolines; Skin Neoplasms | 2015 |
A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Medical Oncology; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2015 |
Renal toxicity of anticancer agents targeting HER2 and EGFR.
Topics: Acute Kidney Injury; Ado-Trastuzumab Emtansine; Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Maytansine; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Renal Dialysis; Renal Insufficiency, Chronic; Trastuzumab | 2015 |
Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Treatment approaches for EGFR-inhibitor-resistant patients with non-small-cell lung cancer.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2015 |
Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2015 |
Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.
Topics: Afatinib; Alanine Transaminase; Antineoplastic Agents; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies.
Topics: Administration, Oral; Anilides; Antineoplastic Agents; Biphenyl Compounds; Capecitabine; Carcinoma, Basal Cell; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Hedgehog Proteins; Molecular Targeted Therapy; Phthalazines; Podophyllotoxin; Pyridines; Quinazolines; Receptor, IGF Type 1; Retinoids; Skin Neoplasms; Tumor Burden | 2016 |
Effect of smoking status on progression-free and overall survival in non-small cell lung cancer patients receiving erlotinib or gefitinib: a meta-analysis.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Smoking | 2015 |
Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Cisplatin; Docetaxel; ErbB Receptors; Gefitinib; Humans; Immunotherapy; Lapatinib; Molecular Targeted Therapy; Mouth Neoplasms; Oropharyngeal Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2015 |
Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma | 2016 |
Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Incidence; Lung Diseases; Lung Neoplasms; Models, Statistical; Odds Ratio; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment | 2016 |
[Tyrosine kinase inhibitors and pregnancy: A risk to the fetus?].
Topics: Abnormalities, Drug-Induced; Adult; Antineoplastic Agents; Dasatinib; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lapatinib; Maternal Age; Placenta; Pregnancy; Pregnancy Complications, Neoplastic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk | 2016 |
FDA Approval of Gefitinib for the Treatment of Patients with Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Research Design; Treatment Outcome; United States; United States Food and Drug Administration | 2016 |
[Companion Diagnostics for Solid Tumors].
Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab | 2015 |
Combining Whole-Brain Radiotherapy with Gefitinib/Erlotinib for Brain Metastases from Non-Small-Cell Lung Cancer: A Meta-Analysis.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines | 2016 |
[Living with incurable cancer].
Topics: Aged; Anxiety; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Depression; Emotions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Psychotherapy; Quality of Life; Quinazolines | 2016 |
Molecular Understanding of the Acquisition of Resistance to Anti-cancer Drugs Associated with the Exacerbation of Cancer.
Topics: Adenosine Triphosphate; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled | 2016 |
Safety of gefitinib in non-small cell lung cancer treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2016 |
Pharmacokinetics of Gefitinib: Roles of Drug Metabolizing Enzymes and Transporters.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cytochrome P-450 Enzyme System; Gefitinib; Humans; Quinazolines | 2017 |
[Current status of EGFR/ErbB inhibitors in non-small cell lung carcinoma].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-2; Genetic Markers; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2016 |
The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Molecular Targeted Therapy; Quinazolines; Receptor Protein-Tyrosine Kinases | 2017 |
Rapid onset of radiation maculopathy after whole-brain radiation therapy: A case report.
Topics: Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Dose-Response Relationship, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Macular Degeneration; Middle Aged; Quinazolines; Radiation Injuries; Visual Acuity | 2016 |
Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pleural Effusion, Malignant; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA | 2016 |
EGFR tyrosine kinase inhibitors versus chemotherapy as first-line therapy for non-small cell lung cancer patients with the L858R point mutation.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Platinum Compounds; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Amino Acid Substitution; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
EGFR-TKIs versus taxanes agents in therapy for nonsmall-cell lung cancer patients: A PRISMA-compliant systematic review with meta-analysis and meta-regression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Survival Analysis; Taxoids | 2016 |
Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2017 |
Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Quinazolines | 2017 |
Treatment of choice for patients with EGFR mutation-positive non-small cell lung carcinoma presenting with choroidal metastases: radiotherapy or TKIs?
Topics: Carcinoma, Non-Small-Cell Lung; Choroid Neoplasms; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Gefitinib; Humans; Lung Neoplasms; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Insight into Discovery of Next Generation Reversible TMLR Inhibitors Targeting EGFR Activating and Drug Resistant T790M Mutants.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Purines; Pyridones; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2017 |
Prognostic value of early response assessment using (18F)FDG-PET in patients with advanced non-small cell lung cancer treated with tyrosine-kinase inhibitors.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Reproducibility of Results; Treatment Outcome | 2017 |
Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Retreatment; Sequence Deletion | 2017 |
Recent Management of Patients with Advanced Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer: Role of Afatinib and Lesson Learned for Developing Countries.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Developing Countries; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Indonesia; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic | 2017 |
Therapeutic Efficacy Comparison of 5 Major EGFR-TKIs in Advanced EGFR-positive Non-Small-cell Lung Cancer: A Network Meta-analysis Based on Head-to-Head Trials.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Crown Ethers; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Network Meta-Analysis; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic; Survival Rate | 2017 |
Factors associated with efficacy of first-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2017 |
Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mice; Mice, Transgenic; Pituitary Neoplasms; Prolactinoma; Protein Kinase Inhibitors; Quinazolines; Translational Research, Biomedical | 2017 |
Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2017 |
Targeted Therapy and Imaging Findings.
Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; Diagnostic Imaging; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2017 |
Surgical resection of advanced non-small cell lung cancer after a response to EGFR-TKI: presentation of two cases and a literature review.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines | 2017 |
A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2017 |
Gefitinib for advanced non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure | 2018 |
Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when?
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2018 |
Gefitinib provides similar effectiveness and improved safety than erlotinib for advanced non-small cell lung cancer: A meta-analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Comparative Effectiveness Research; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2018 |
Ethnic differences in idiopathic pulmonary fibrosis: The Japanese perspective.
Topics: Asian People; Cause of Death; Disease Progression; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Idiopathic Pulmonary Fibrosis; Japan; Lung Neoplasms; Male; Pneumonectomy; Prevalence; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Survival Rate | 2018 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Network Meta-Analysis; Piperidines; Progression-Free Survival; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Randomized Controlled Trials as Topic | 2019 |
First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Topics: Afatinib; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bias; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Pemetrexed; Progression-Free Survival; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic | 2021 |
Clinical outcomes of gefitinib and erlotinib in patients with NSCLC harboring uncommon EGFR mutations: A pooled analysis of 438 patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Gefitinib: An Updated Review of its Role in the Cancer Management, its Nanotechnological Interventions, Recent Patents and Clinical Trials.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patents as Topic; Quinazolines | 2023 |
491 trial(s) available for quinazolines and gefitinib
| Article | Year |
|---|---|
Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Apoptosis; Biomarkers; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Keratinocytes; Male; MAP Kinase Signaling System; Middle Aged; Neoplasms; Quinazolines; Skin; Statistics, Nonparametric; Tumor Suppressor Proteins | 2002 |
Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction.
Topics: Adult; Aged; Aged, 80 and over; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; Chromones; Dose-Response Relationship, Radiation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Neoplasm Staging; Oropharyngeal Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Prognosis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; ras Proteins; Signal Transduction | 2002 |
ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2002 |
Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Gastrointestinal Diseases; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Skin Diseases | 2002 |
Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Neoplasms; Quinazolines; Skin; Treatment Outcome | 2002 |
Dose-comparative monotherapy trials of ZD1839 in previously treated non-small cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2003 |
Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Illinois; Immunohistochemistry; Intubation, Gastrointestinal; Male; Middle Aged; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis; Treatment Outcome | 2003 |
Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Pilot Projects; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; United States | 2003 |
ZD1839, a novel, oral epidermal growth factor receptor-tyrosine kinase inhibitor, as salvage treatment in patients with advanced non-small cell lung cancer. Experience from a single center participating in a compassionate use program.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2003 |
Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Japan; Male; Middle Aged; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
A pharmacodynamic study of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in metastatic colorectal cancer patients.
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Cell Cycle Proteins; Cell Division; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p27; Cytoskeletal Proteins; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Trans-Activators; Tumor Suppressor Proteins | 2003 |
Gefitinib in pretreated non-small-cell lung cancer (NSCLC): analysis of efficacy and correlation with HER2 and epidermal growth factor receptor expression in locally advanced or metastatic NSCLC.
Topics: Adult; Aged; Biomarkers, Tumor; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease Progression; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prospective Studies; Quinazolines; Receptor, ErbB-2; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2003 |
A Phase I/II Trial of trastuzumab and gefitinib in patients with Metastatic Breast Cancer that overexpresses HER2/neu (ErbB-2).
Topics: Administration, Oral; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Infusions, Intravenous; Neoplasm Metastasis; Quinazolines; Trastuzumab; Treatment Outcome | 2003 |
Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC).
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets.
Topics: Administration, Oral; Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Approval; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Probability; Quinazolines; Reference Values; Survival Analysis; Tablets; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography; Survival Analysis; Treatment Outcome | 2003 |
Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Treatment Outcome | 2003 |
Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Frail Elderly; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Phase II trial of gefitinib in recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Disease-Free Survival; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Adjuvant systemic therapies in early-stage non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemoprevention; Chemotherapy, Adjuvant; Drug Resistance; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Metastasis; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant; Selenium; Survival Analysis | 2003 |
Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC).
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases | 2004 |
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Quinazolines; Reference Values; Survival Analysis; Treatment Outcome | 2004 |
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Paclitaxel; Predictive Value of Tests; Prognosis; Quinazolines; Reference Values; Risk Assessment; Survival Analysis; Treatment Outcome | 2004 |
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Epidermal Growth Factor; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Survival Analysis | 2004 |
Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis | 2004 |
Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; Drug Interactions; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2004 |
[Subset analysis of data in the Japanese patients with NSCLC from IDEAL 1 study on gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2004 |
Acute lung injury as an adverse event of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2004 |
Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis | 2004 |
Severe myelotoxicity in a combination of gefitinib and vinorelbine.
Topics: Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pilot Projects; Quinazolines; Thrombocytopenia; Vinblastine; Vinorelbine | 2004 |
Gefitinib in patients with brain metastases from non-small-cell lung cancer: a prospective trial.
Topics: Adult; Aged; Antineoplastic Agents; Brain; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Radiography; Skin Diseases; Survival Analysis; Treatment Outcome | 2004 |
Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Neoplasm Staging; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Analysis; Treatment Outcome | 2004 |
Evaluation of safety and efficacy of gefitinib ('iressa', zd1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme.
Topics: Acne Vulgaris; Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Remission Induction; Stomatitis; Treatment Outcome | 2004 |
Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis | 2005 |
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors | 2004 |
A phase II trial of gefitinib (Iressa, ZD1839) in stage IV and recurrent renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Outcome | 2004 |
Relative bioavailability and safety profile of gefitinib administered as a tablet or as a dispersion preparation via drink or nasogastric tube: results of a randomized, open-label, three-period crossover study in healthy volunteers.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Area Under Curve; Beverages; Biological Availability; Cross-Over Studies; Epidermal Growth Factor; Gefitinib; Humans; Intubation, Gastrointestinal; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Tablets | 2004 |
Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group.
Topics: Adenocarcinoma; Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Diarrhea; Disease Progression; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2005 |
Ocular findings in patients with solid tumours treated with the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Phase I and II clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Monitoring; ErbB Receptors; Eye Diseases; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Vision Disorders | 2005 |
A multicentre phase II study on gefitinib in taxane- and anthracycline-pretreated metastatic breast cancer.
Topics: Adult; Aged; Anthracyclines; Antineoplastic Agents; Breast Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Survival Analysis; Taxoids; Treatment Outcome | 2005 |
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Double-Blind Method; Endpoint Determination; Female; Gefitinib; Health Status; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sensitivity and Specificity; Survival Analysis | 2005 |
Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Survival Analysis | 2005 |
Skin rash and good performance status predict improved survival with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Confidence Intervals; Dose-Response Relationship, Drug; Drug Administration Schedule; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pneumonectomy; Predictive Value of Tests; Probability; Prognosis; Prospective Studies; Quinazolines; Risk Assessment; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2005 |
Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Neoplasm Recurrence, Local; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Risk Factors; RNA; Sensitivity and Specificity; Sex Factors; Survival Analysis | 2005 |
A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Area Under Curve; Canada; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Male; Middle Aged; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2005 |
Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gefitinib; Humans; Male; Metabolic Clearance Rate; Organ Specificity; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Sex Factors; Species Specificity; Tissue Distribution | 2004 |
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Male; Mesothelioma; Middle Aged; Peritoneal Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Skin Diseases; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Clinical benefit in NSCLC: advanced-stage patients require symptom-improving palliation. Experiences from the 'Iressa' expanded access program.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Terminal Care; Treatment Outcome | 2005 |
Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Research Design; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Analysis | 2005 |
Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Testosterone | 2005 |
A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dehydration; Diarrhea; Drug Interactions; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Irinotecan; Leucovorin; Male; Middle Aged; Neutropenia; Quinazolines; Treatment Outcome | 2005 |
Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Double-Blind Method; England; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Treatment Outcome; Triazoles; Ultrasonography | 2005 |
Non-small-cell lung cancer patients unsuitable for first-line chemotherapy: a new category of patients for clinical studies?
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Neoplasms; Breast Neoplasms; Cell Cycle Proteins; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Salvage Therapy; Soft Tissue Neoplasms; Treatment Outcome; Tumor Suppressor Proteins | 2005 |
A pilot trial of gefitinib in combination with docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Quinazolines; Survival Analysis; Taxoids | 2005 |
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Female; Gefitinib; Humans; Middle Aged; Neoplasm Staging; Paclitaxel; Quinazolines; Treatment Outcome | 2005 |
Benefit in lung function improvement and side-effect profile of long-term responders: an analysis of 14 NSCLC patients treated for at least 9 months with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Dyspnea; Female; Follow-Up Studies; Gefitinib; Health Status; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Function Tests; Retrospective Studies; Sex Factors; Survival Analysis; Treatment Outcome | 2005 |
Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Patient Selection; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
A phase I study to determine the effect of tamoxifen on the pharmacokinetics of a single 250 mg oral dose of gefitinib (IRESSA) in healthy male volunteers.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Biological Availability; Drug Combinations; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Selective Estrogen Receptor Modulators; Tamoxifen | 2005 |
A phase II, open-label study of gefitinib (IRESSA) in patients with locally advanced, metastatic, or relapsed renal-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2006 |
Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Catalytic Domain; Cloning, Molecular; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Middle Aged; Mutation; Ovarian Neoplasms; Peritoneal Neoplasms; Polymerase Chain Reaction; Protein Structure, Tertiary; Quinazolines; Recurrence; Time Factors; Treatment Outcome | 2005 |
Phase I/II trial of gefitinib and oxaliplatin in patients with advanced colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Drug Eruptions; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Nausea; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate; Vomiting | 2005 |
[Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quinazolines; Survival Rate | 2005 |
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Survival Analysis | 2005 |
Gefitinib (ZD1839) combined with weekly epirubicin in patients with metastatic breast cancer: a phase I study with biological correlate.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Epirubicin; ErbB Receptors; Female; Gefitinib; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Quinazolines; Receptor, ErbB-2 | 2005 |
Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Injections, Intravenous; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study.
Topics: Administration, Oral; Adolescent; Adult; Age Factors; Antineoplastic Agents; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Response of ovarian carcinomas to gefitinib-carboplatin-paclitaxel combination is not associated with EGFR kinase domain somatic mutations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Paclitaxel; Quinazolines; Treatment Outcome | 2006 |
Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: results from a prospective feasibility study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Contraindications; Cystitis; Feasibility Studies; Female; Gastrointestinal Diseases; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pneumonia; Quinazolines; Vomiting | 2005 |
Molecular alterations in tumors and response to combination chemotherapy with gefitinib for advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Camptothecin; Cell Cycle Proteins; Colorectal Neoplasms; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Leucovorin; Male; Middle Aged; Mutation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; Treatment Outcome; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2005 |
Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Palliative Care; Pyrazoles; Quinazolines; Sulfonamides | 2005 |
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol.
Topics: Adolescent; Adult; Antineoplastic Agents; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Gefitinib; Humans; Itraconazole; Male; Metoprolol; Microsomes, Liver; Middle Aged; Neoplasms; Quinazolines; Rifampin | 2005 |
Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Psychomotor Performance; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Impact of gefitinib ('Iressa') treatment on the quality of life of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Constipation; Disease Progression; Dyspnea; Fatigue; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires; Survival Analysis; Treatment Outcome | 2005 |
A willingness-to-pay study of oral epidermal growth factor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cost of Illness; ErbB Receptors; Erlotinib Hydrochloride; Fees, Pharmaceutical; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA; Survival Rate | 2005 |
Gefitinib in the adjuvant setting: safety results from a phase III study in patients with completely resected non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Postoperative Complications; Postoperative Period; Quinazolines | 2005 |
ECOG E1100: a phase II trial of trastuzumab and gefitinib in patients with metastatic breast cancer that overexpress HER2/neu (erbB-2).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Protocols; Gefitinib; Humans; Neoplasm Metastasis; Patient Selection; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2003 |
Gefitinib affects functions of platelets and blood vessels via changes in prostanoids balance.
Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Blood Vessels; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platelet Aggregation; Prostaglandins; Quinazolines | 2005 |
Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Topics: Antineoplastic Agents; Blotting, Western; Brain Neoplasms; Clinical Trials as Topic; Cluster Analysis; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Gene Expression Regulation, Neoplastic; Genome; Glioma; Humans; Lung Neoplasms; Models, Biological; Mutation; Nucleic Acid Hybridization; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Time Factors | 2005 |
Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Drug Administration Schedule; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Salvage Therapy; Survival Rate; Transforming Growth Factor alpha; Vascular Endothelial Growth Factor A | 2005 |
Randomized phase II trial of the clinical and biological effects of two dose levels of gefitinib in patients with recurrent colorectal adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Colorectal Neoplasms; Disease Progression; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Survival Analysis | 2005 |
EKB-569, a new irreversible epidermal growth factor receptor tyrosine kinase inhibitor, with clinical activity in patients with non-small cell lung cancer with acquired resistance to gefitinib.
Topics: Administration, Oral; Aminoquinolines; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Organic Chemicals; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2006 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2006 |
Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors.
Topics: Adolescent; Antineoplastic Agents; Biomarkers; Child; Child, Preschool; ErbB Receptors; Female; Gefitinib; Humans; Infant; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Neoplasms; Quinazolines; Vascular Endothelial Growth Factor A | 2007 |
Gefitinib treatment is highly effective in non-small-cell lung cancer patients failing previous chemotherapy in Taiwan: a prospective phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Taiwan; Treatment Failure | 2005 |
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Pancreatic Neoplasms; Quinazolines; Radiotherapy, Adjuvant; Rectal Neoplasms | 2006 |
Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2006 |
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Glioma; Humans; Male; Middle Aged; Quinazolines; Recurrence; Sirolimus; Treatment Outcome | 2006 |
Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
Topics: Aged; Antimetabolites, Antineoplastic; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Survival Rate; Treatment Outcome | 2006 |
Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Palliative Care; Quinazolines; Survival Analysis | 2006 |
Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2006 |
Aspirin reduces adverse effects of gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; P-Selectin; Platelet Activation; Platelet Aggregation Inhibitors; Prospective Studies; Quinazolines; Thromboxane B2 | 2006 |
A phase II trial of gemcitabine plus UFUR combination chemotherapy in non-small-cell lung cancer patients failing previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Gemcitabine; Hematologic Diseases; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Survival Rate; Tegafur | 2006 |
Results from a pilot Phase I trial of gefitinib combined with docetaxel and estramustine in patients with hormone-refractory prostate cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Docetaxel; Estramustine; Gefitinib; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Taxoids | 2006 |
Predictive factors for outcome in a phase II study of gefitinib in second-line treatment of advanced esophageal cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Esophageal Neoplasms; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Dosage; Genes, ras; Humans; Male; Middle Aged; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2006 |
Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
A phase I/II trial of weekly docetaxel and gefitinib in elderly patients with stage IIIB/IV non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Rate; Taxoids | 2006 |
A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome | 2006 |
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Dose-Response Relationship, Drug; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2006 |
Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Quinazolines; Receptors, Estrogen; Taxoids; Treatment Outcome | 2006 |
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics.
Topics: Adolescent; Adult; Aged; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gefitinib; Genotype; Humans; Male; Midazolam; Middle Aged; Phenotype; Quinazolines | 2006 |
Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Adult; Aged; Aged, 80 and over; Alanine; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Glutamic Acid; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Positron-Emission Tomography; Prospective Studies; Quinazolines; Treatment Outcome | 2006 |
Efficacy of cetuximab after treatment with oral epidermal growth factor receptor tyrosine kinase inhibitor-based chemotherapy in metastatic colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
Gefitinib monotherapy in chemotherapy-naive patients with inoperable stage III/IV non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Detection of epidermal growth factor receptor mutations in serum as a predictor of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Predictive Value of Tests; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines; Taxoids | 2007 |
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Area Under Curve; Biomarkers, Tumor; Carcinoma; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Male; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Stomach Neoplasms | 2006 |
Phase I trial of gefitinib with concurrent radiotherapy and fixed 2-h gemcitabine infusion, in locally advanced pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Deoxycytidine; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Gemcitabine; Humans; Interleukin-8; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Radiotherapy Dosage; Vascular Endothelial Growth Factor A | 2006 |
Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2006 |
Phase I study of gefitinib plus FOLFIRI in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pruritus; Quinazolines; Treatment Outcome | 2006 |
Sequential administration of docetaxel followed by maintenance gefitinib, as salvage treatment in patients with advanced NSCLC: a multicenter phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Smoking; Survival Analysis; Taxoids | 2007 |
Gefitinib in the treatment of elderly patients with advanced non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2007 |
The use of perfusion CT for the evaluation of therapy combining AZD2171 with gefitinib in cancer patients.
Topics: Administration, Oral; Adult; Aged; Angiography; Antineoplastic Combined Chemotherapy Protocols; Contrast Media; Disease Progression; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Gefitinib; Humans; Image Processing, Computer-Assisted; Injections, Intravenous; Liver Neoplasms; Male; Mediastinal Neoplasms; Middle Aged; Pancreatic Neoplasms; Pelvic Neoplasms; Pleural Neoplasms; Prognosis; Quinazolines; Tomography, Spiral Computed | 2007 |
Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Predictive Value of Tests; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Analysis | 2006 |
[Gefitinib in the treatment of advanced non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Analysis | 2006 |
CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP3A; Environmental Exposure; ErbB Receptors; Gefitinib; Humans; Neoplasms; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2006 |
Gefitinib in combination with tamoxifen in patients with ovarian cancer refractory or resistant to platinum-taxane based therapy--a phase II trial of the AGO Ovarian Cancer Study Group (AGO-OVAR 2.6).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bridged-Ring Compounds; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Humans; Middle Aged; Organoplatinum Compounds; Ovarian Neoplasms; Patient Compliance; Quinazolines; Tamoxifen; Taxoids | 2007 |
Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Patient Selection; Quinazolines; Survival Analysis | 2006 |
Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin- refractory colorectal cancer: a phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fatigue; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Treatment Outcome | 2006 |
Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Metastasis; Quinazolines | 2007 |
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Camptothecin; Colorectal Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Absence of epidermal growth factor receptor gene mutations in patients with hormone refractory prostate cancer not responding to gefitinib.
Topics: Adenocarcinoma; Adolescent; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Male; Mutation; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines | 2007 |
A phase I pharmacokinetic and pharmacodynamic study of intravenous calcitriol in combination with oral gefitinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Calcitriol; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Injections, Intravenous; Male; Middle Aged; Neoplasms; Phosphorylation; Quinazolines | 2007 |
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome | 2007 |
Phase II randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Male; Middle Aged; Polymerase Chain Reaction; Quinazolines; Vinblastine; Vinorelbine | 2007 |
Gefitinib in patients with progressive high-grade gliomas: a multicentre phase II study by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oligodendroglioma; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; Drug Administration Schedule; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Severity of Illness Index; Treatment Outcome | 2007 |
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Homozygote; Humans; Introns; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients with platinum refractory non-small cell lung cancer (NSCLC).
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Confidence Intervals; Cyclooxygenase 2 Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Platinum; Probability; Pyrazoles; Quinazolines; Risk Assessment; Sulfonamides; Survival Analysis | 2007 |
EGFR mutation of tumor and serum in gefitinib-treated patients with chemotherapy-naive non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2006 |
Gefitinib (IRESSA) with vinorelbine or vinorelbine/cisplatin for chemotherapy-naive non-small cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Vinblastine; Vinorelbine | 2006 |
Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
The role of gefitinib treatment for Korean never-smokers with advanced or metastatic adenocarcinoma of the lung: a prospective study.
Topics: Adenocarcinoma; Administration, Oral; Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Korea; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Staging; Probability; Prognosis; Proportional Hazards Models; Prospective Studies; Quality of Life; Quinazolines; Risk Assessment; Single-Blind Method; Smoking; Survival Rate; Treatment Outcome | 2006 |
Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Patient Selection; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Efficacy of gefitinib on advanced non-small cell lung cancer of bilateral diffuse or unilateral giant mass type].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pruritus; Quality of Life; Quinazolines; Remission Induction | 2007 |
Gefitinib as palliative therapy for lung adenocarcinoma metastatic to the brain.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quality of Life; Quinazolines; Survival Analysis | 2007 |
[Gefitinib target treatment in non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2007 |
Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib | 2007 |
Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors.
Topics: Administration, Oral; Adult; Antineoplastic Agents; Chemical Precipitation; Crystallization; Gastric Emptying; Gefitinib; Half-Life; Humans; Intestinal Secretions; Intubation, Gastrointestinal; Jejunum; Male; Microscopy; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Reference Values; Solubility; Spectrum Analysis, Raman | 2007 |
Association of epidermal growth factor receptor mutations in lung cancer with chemosensitivity to gefitinib in isolated cancer cells from Japanese patients.
Topics: Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tumor Cells, Cultured | 2007 |
Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Smoking | 2007 |
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Disease Progression; Docetaxel; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Quinazolines; Taxoids; Treatment Outcome | 2007 |
[Safety and efficacy of gefitinib for treatment of advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease Progression; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Sex Factors; Treatment Outcome | 2007 |
Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2007 |
Phase 1 trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Sirolimus; Survival Rate; United States | 2007 |
First clinical experience of orally active epidermal growth factor receptor inhibitor combined with simplified FOLFOX6 as first-line treatment for metastatic colorectal cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Diarrhea; Disease Progression; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neutropenia; Organoplatinum Compounds; Oxaliplatin; Patient Dropouts; Quinazolines; Time Factors; Treatment Outcome | 2007 |
An open-label, noncomparative phase II trial to evaluate the efficacy and safety of docetaxel in combination with gefitinib in patients with hormone-refractory metastatic prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2007 |
The epidermal growth factor receptor intron1 (CA) n microsatellite polymorphism is a potential predictor of treatment outcome in patients with advanced lung cancer treated with Gefitinib.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Microsatellite Repeats; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2007 |
A multicenter phase II study of docetaxel in combination with gefitinib in gemcitabine-pretreated patients with advanced/metastatic pancreatic cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2006 |
A phase II trial of gefitinib in combination with capecitabine and oxaliplatin as first-line chemotherapy in patients with advanced colorectal cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Survival Rate | 2007 |
Phase I trial of fixed dose rate infusion gemcitabine with gefitinib in patients with pancreatic carcinoma.
Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Dose-Response Relationship, Drug; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quinazolines | 2007 |
Combination therapy with gefitinib and rofecoxib in patients with platinum-pretreated relapsed non small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Drug Administration Schedule; Female; Gefitinib; Humans; Lactones; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proteomics; Quinazolines; Sulfones; Survival Rate; Treatment Outcome | 2007 |
Gefitinib combined with endocrine manipulation in patients with hormone-refractory prostate cancer: quality of life and surrogate markers of activity.
Topics: Aged; Androgen Antagonists; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Disease Progression; Drug Resistance, Neoplasm; Endpoint Determination; Gefitinib; Genes, erbB-1; Genes, erbB-2; Humans; Immunohistochemistry; Male; Middle Aged; Pain Measurement; Prostatic Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires | 2007 |
A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.
Topics: Aged; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; ErbB Receptors; Estradiol; Female; Gefitinib; Humans; Ki-67 Antigen; Mastectomy; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Progesterone; Triazoles | 2007 |
Phase II, randomized trial of preoperative epirubicin-paclitaxel +/- gefitinib with biomarker evaluation in operable breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Epirubicin; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Ki-67 Antigen; Neoplasm Staging; Paclitaxel; Patient Compliance; Quinazolines; Vascular Endothelial Growth Factor Receptor-1 | 2008 |
Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Brain Edema; Brain Neoplasms; Dacarbazine; Dose-Response Relationship, Drug; Female; Gefitinib; Glioblastoma; Glioma; Humans; Karnofsky Performance Status; Male; Middle Aged; Quinazolines; Temozolomide | 2008 |
A phase II study of patients with metastatic or locoregionally recurrent nasopharyngeal carcinoma and evaluation of plasma Epstein-Barr virus DNA as a biomarker of efficacy.
Topics: Adult; Antineoplastic Agents; Biomarkers, Tumor; Disease Progression; DNA, Viral; ErbB Receptors; Female; Gefitinib; Herpesvirus 4, Human; Humans; Male; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Radiography; Survival | 2008 |
A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2007 |
A phase II study of gefitinib monotherapy in advanced esophageal adenocarcinoma: evidence of gene expression, cellular, and clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Male; Middle Aged; Models, Biological; Quinazolines; Treatment Outcome | 2007 |
The relative bioavailability of gefitinib administered by granular formulation.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dosage Forms; Drug Administration Schedule; Gefitinib; Humans; Male; Quinazolines | 2008 |
A phase II trial of cisplatin, fixed dose-rate gemcitabine and gefitinib for advanced urothelial tract carcinoma: results of the Cancer and Leukaemia Group B 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2008 |
Phase II study of nedaplatin and irinotecan followed by gefitinib for elderly patients with unresectable non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Organoplatinum Compounds; Quinazolines | 2008 |
A phase I dose-escalation study of fractionated stereotactic radiosurgery in combination with gefitinib in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Dose Fractionation, Radiation; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Mental Status Schedule; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Treatment Outcome | 2008 |
Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines | 2007 |
A phase II trial to evaluate gefitinib as second- or third-line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Uterine Cervical Neoplasms | 2008 |
A phase II study of gefitinib in patients with advanced thyroid cancer.
Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Medullary; Carcinoma, Papillary; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Quinazolines; Severity of Illness Index; Thyroglobulin; Thyroid Neoplasms; Treatment Outcome | 2008 |
Elevation of serum thioredoxin in patients with gefitinib-induced interstitial lung disease.
Topics: Aged; Antineoplastic Agents; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Male; Middle Aged; Oxidative Stress; Quinazolines; Thioredoxins | 2007 |
A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; Leucovorin; Male; Middle Aged; NF-kappa B; Organoplatinum Compounds; Quinazolines; Survival Rate | 2008 |
Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quality of Life; Quinazolines; Radiography; ras Proteins; Risk Assessment; Risk Factors; Smoking; Surveys and Questionnaires; Switzerland; Treatment Outcome | 2008 |
Phase I/II study of gefitinib and capecitabine in patients with colorectal cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines | 2008 |
Phase II study of gefitinib for the treatment of recurrent and metastatic nasopharyngeal carcinoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Nasopharyngeal Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2008 |
Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmall-cell lung cancer.
Topics: Antibodies, Monoclonal; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Placebos; Predictive Value of Tests; Quinazolines | 2008 |
Gefitinib (ZD1839): therapy in selected patients with non-small cell lung cancer (NSCLC)?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Treatment Outcome | 2008 |
A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Pyrimidines; Quinazolines | 2008 |
Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines | 2008 |
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.
Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Comorbidity; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Taxoids | 2008 |
Induction chemotherapy with carboplatin, irinotecan, and paclitaxel followed by high dose three-dimension conformal thoracic radiotherapy (74 Gy) with concurrent carboplatin, paclitaxel, and gefitinib in unresectable stage IIIA and stage IIIB non-small ce
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Contraindications; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Conformal; Retrospective Studies; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Dual inhibition of the epidermal growth factor receptor with cetuximab, an IgG1 monoclonal antibody, and gefitinib, a tyrosine kinase inhibitor, in patients with refractory non-small cell lung cancer (NSCLC): a phase I study.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Humans; Immunoglobulin G; Immunohistochemistry; Infusions, Intravenous; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Treatment Outcome | 2008 |
Defective differentiation of myeloid and plasmacytoid dendritic cells in advanced cancer patients is not normalized by tyrosine kinase inhibition of the vascular endothelial growth factor receptor.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Differentiation; Dendritic Cells; Female; Flow Cytometry; Gefitinib; Humans; Male; Middle Aged; Myeloid Cells; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
Epidermal growth factor receptor serum (sEGFR) level may predict response in patients with EGFR-positive advanced colorectal cancer treated with gefitinib?
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Proteins; Organoplatinum Compounds; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Docetaxel; Etoposide; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Taxoids | 2008 |
Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Celecoxib; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrazoles; Quinazolines; Sulfonamides; Survival Rate | 2008 |
Clinical experience with gefitinib in Indian patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; India; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Second-line treatment of advanced non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Practice Guidelines as Topic; Practice Patterns, Physicians'; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Retrospective Studies; Salvage Therapy; Survival Rate; Taxoids | 2008 |
Infusional 5-fluorouracil and ZD1839 (Gefitinib-Iressa) in combination with preoperative radiotherapy in patients with locally advanced rectal cancer: a phase I and II Trial (1839IL/0092).
Topics: Anal Canal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Diarrhea; Drug Tolerance; Female; Fluorouracil; Gastrointestinal Diseases; Gefitinib; Humans; Infusions, Intravenous; Male; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Rectal Neoplasms; Safety | 2008 |
Interferon-alpha in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Renal Cell; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Imatinib Mesylate; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Survival Rate | 2008 |
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimens.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Biomarkers, Tumor; Disease Progression; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Sarcoma, Synovial; Treatment Failure; Treatment Outcome | 2008 |
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Epithelial Growth Factor Receptor Inhibitors for treatment of recurrent or progressive high grade glioma: an exploratory study.
Topics: Adult; Aged; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Secondary Prevention | 2008 |
[Gefitinib in the treatment of refractory non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Quality of Life; Quinazolines; Remission Induction; Survival Rate | 2007 |
[Gefitinib in the treatment of advanced non-small cell lung cancer with brain metastasis].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Survival Rate | 2007 |
Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the Arbeits gemeinschaft Internistische Onkologie (AIO).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Maximum Allowable Concentration; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2008 |
Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Survival Analysis | 2008 |
Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Evaluation; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Placebos; Quality of Life; Quinazolines; Tetracycline | 2008 |
A phase I/II trial of gefitinib and radiotherapy in patients with locally advanced inoperable squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Quinazolines; Radiotherapy Dosage | 2008 |
Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2008 |
A phase II randomized multicenter trial of gefitinib plus FOLFIRI and FOLFIRI alone in patients with metastatic colorectal cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Quinazolines | 2008 |
Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Double-Blind Method; Gefitinib; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Prednisone; Prognosis; Prostatic Neoplasms; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
[Efficacy and safety of gefitinib in maintenance therapy for patients with advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Smoking; Survival Rate | 2008 |
Phase III study, V-15-32, of gefitinib versus docetaxel in previously treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Survival Analysis; Taxoids | 2008 |
Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Survival Analysis; Vinblastine; Vinorelbine | 2008 |
Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Marrow Diseases; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gemcitabine; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Genes, erbB-2; Genes, ras; Humans; Male; Middle Aged; Pancreatic Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Receptor, ErbB-2; Survival Analysis | 2008 |
A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Health Surveys; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Neoplasm Staging; Prognosis; Quality of Life; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoplasm Metastasis; Protein Binding; Quinazolines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2008 |
Pilot study of gefitinib, oxaliplatin, and radiotherapy for esophageal adenocarcinoma: tissue effect predicts clinical response.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Administration Schedule; Female; Fluorouracil; Gefitinib; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2008 |
Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prospective Studies; Quinazolines; Treatment Outcome | 2009 |
Radiographic and histopathologic observations after combined EGFR inhibition and hypofractionated stereotactic radiosurgery in patients with recurrent malignant gliomas.
Topics: Adult; Aged; Antineoplastic Agents; Astrocytoma; Brain Neoplasms; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Radiosurgery; Tumor Burden; Young Adult | 2009 |
A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Disease-Free Survival; ErbB Receptors; Everolimus; Female; Gefitinib; Glioblastoma; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Recurrence, Local; Pilot Projects; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Sirolimus | 2009 |
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Survival Analysis; Taxoids | 2008 |
High incidence of oral dysesthesias on a trial of gefitinib, Paclitaxel, and concurrent external beam radiation for locally advanced head and neck cancers.
Topics: Adult; Aged; Amines; Anticonvulsants; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Combined Modality Therapy; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Gefitinib; Head and Neck Neoplasms; Humans; Incidence; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Paresthesia; Prognosis; Quinazolines; Radiation Injuries; Radiotherapy; Stomatitis | 2008 |
A phase I study of gefitinib, capecitabine, and celecoxib in patients with advanced solid tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Celecoxib; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Pyrazoles; Quinazolines; Risk; Sulfonamides | 2008 |
Treatment of brain metastasis from non-small cell lung cancer with whole brain radiotherapy and Gefitinib in a Chinese population.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemotherapy, Adjuvant; Combined Modality Therapy; Docetaxel; Follow-Up Studies; Gefitinib; Humans; Immunoenzyme Techniques; Male; Maximum Tolerated Dose; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Prostatectomy; Prostatic Neoplasms; Quinazolines; Risk Factors; Taxoids; Treatment Outcome | 2009 |
A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Quinazolines; Urologic Neoplasms | 2009 |
Phase II study of docetaxel and gefitinib as second-line therapy in gemcitabine pretreated patients with advanced pancreatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Deoxycytidine; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Pancreatic Neoplasms; Quinazolines; Taxoids | 2009 |
Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Surveys and Questionnaires; Taxoids; Treatment Outcome | 2009 |
Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Remission Induction; Taxoids; Treatment Outcome | 2009 |
Randomized phase II study of gefitinib compared with placebo in chemotherapy-naive patients with advanced non-small-cell lung cancer and poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2009 |
Phase III study of gefitinib compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck [corrected].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infusions, Intravenous; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer.
Topics: Administration, Oral; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Maximum Tolerated Dose; Medication Adherence; Middle Aged; Quinazolines | 2009 |
Results of a phase I trial of 12 patients with locally advanced pancreatic carcinoma combining gefitinib, paclitaxel, and 3-dimensional conformal radiation: report of toxicity and evaluation of circulating K-ras as a potential biomarker of response to the
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Humans; Imaging, Three-Dimensional; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pancreatic Neoplasms; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy, Conformal; ras Proteins; Survival Rate | 2009 |
Health-related quality of life in patients with hormone refractory prostate cancer receiving gefitinib.
Topics: Activities of Daily Living; Adenocarcinoma; Administration, Oral; Aged; Analgesics; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Pain; Pain Measurement; Prostatic Neoplasms; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Time Factors; Treatment Failure | 2009 |
Erlotinib in advanced non-small-cell lung cancer after gefitinib failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure; Treatment Outcome | 2009 |
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cross-Over Studies; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Piperidines; Quinazolines | 2009 |
An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; Orchiectomy; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Risk Assessment; Single-Blind Method; Survival Analysis; Testosterone; Treatment Outcome | 2009 |
A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calcitriol; Dexamethasone; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Hypercalcemia; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines | 2009 |
Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA; DNA, Neoplasm; ErbB Receptors; Exons; Feasibility Studies; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Odds Ratio; Patient Selection; Predictive Value of Tests; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Risk Assessment; Time Factors; Treatment Outcome | 2009 |
Gefitinib treatment in hormone-resistant and hormone receptor-negative advanced breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Receptors, Estrogen; Receptors, Progesterone | 2009 |
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma.
Topics: Adult; Aged; Aged, 80 and over; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Magnetic Resonance Imaging; Male; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Tomography, X-Ray Computed | 2010 |
IFCT-0401 Trial: a phase II study of gefitinib administered as first-line treatment in advanced adenocarcinoma with bronchioloalveolar carcinoma subtype.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Disease Progression; DNA Mutational Analysis; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transcription Factors | 2010 |
Factors associated with clinical benefit from epidermal growth factor receptor inhibitors in recurrent and metastatic squamous cell carcinoma of the head and neck.
Topics: Age Factors; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Erlotinib as salvage treatment after failure to first-line gefitinib in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Treatment Failure | 2010 |
Tyrosine kinase inhibitor enhances the bioavailability of oral irinotecan in pediatric patients with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biological Availability; Camptothecin; Child; Child, Preschool; Drug Synergism; Female; Gefitinib; Humans; Infant; Infusions, Intravenous; Irinotecan; Male; Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Toxicity Tests; Young Adult | 2009 |
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib-phenytoin interaction is not correlated with the C-erythromycin breath test in healthy male volunteers.
Topics: Adolescent; Adult; Aged; ATP Binding Cassette Transporter, Subfamily B, Member 1; Breath Tests; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; Epidemiologic Methods; Gefitinib; Genotype; Humans; Male; Middle Aged; Phenytoin; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2009 |
The effects of gefitinib in tamoxifen-resistant and hormone-insensitive breast cancer: a phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Biomarkers, Tumor; Breast Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen | 2010 |
Response to gefitinib and erlotinib in Non-small cell lung cancer: a restrospective study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; STAT3 Transcription Factor | 2009 |
Phase II study of paclitaxel and irinotecan with intercalated gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Molecular and clinical responses in a pilot study of gefitinib with paclitaxel and radiation in locally advanced head-and-neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Proliferation; Combined Modality Therapy; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Infections; Lung Diseases, Interstitial; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Paclitaxel; Pilot Projects; Quinazolines; Radiotherapy Dosage; Remission Induction; Stomatitis | 2010 |
Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Preoperative Period; Protein Kinase Inhibitors; Quinazolines | 2009 |
Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Transitional Cell; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urologic Neoplasms; Urothelium | 2010 |
A phase I/II trial of gefitinib given concurrently with radiotherapy in patients with nonmetastatic prostate cancer.
Topics: Aged; Antineoplastic Agents; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Gefitinib; Humans; Interleukin-1alpha; Interleukin-6; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Proteins; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Radiotherapy Dosage; Tumor Necrosis Factor-alpha | 2010 |
A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chi-Square Distribution; Combined Modality Therapy; Dose Fractionation, Radiation; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Female; Fluorouracil; Gefitinib; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Retrospective Studies; Statistics, Nonparametric; Survival Rate; Tomography, Emission-Computed; Treatment Outcome; Ultrasonography | 2010 |
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Taxoids | 2010 |
A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiotherapy Dosage; Radiotherapy, Conformal; Survival Rate; Taxoids | 2010 |
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Mutation; Odds Ratio; Patient Selection; Predictive Value of Tests; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Risk Assessment; Survival Analysis; Taxoids; Time Factors; Treatment Outcome | 2010 |
Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (W
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Selection; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Risk Assessment; Time Factors; Treatment Outcome | 2010 |
Phase I evaluation of cediranib, a selective VEGFR signalling inhibitor, in combination with gefitinib in patients with advanced tumours.
Topics: Adult; Aged; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Diarrhea; Drug Therapy, Combination; ErbB Receptors; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Netherlands; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Young Adult | 2010 |
Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; Fallopian Tube Neoplasms; Female; Gefitinib; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Peritoneal Neoplasms; Quinazolines | 2010 |
Phase I/II trial of sunitinib plus gefitinib in patients with metastatic renal cell carcinoma.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Indoles; Kidney Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Pyrroles; Quinazolines; Sunitinib; Survival Analysis; Treatment Outcome | 2010 |
Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum Compounds; Quinazolines; Retreatment; Taxoids; Time Factors | 2010 |
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143).
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Colorectal Neoplasms; Demography; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Thiophenes; Treatment Outcome; Young Adult | 2011 |
[Clinical observation of gefitinib for the treatment of 125 cases with advanced non-small cell lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Diarrhea; Disease-Free Survival; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate | 2010 |
Phase II, randomized trial to compare anastrozole combined with gefitinib or placebo in postmenopausal women with hormone receptor-positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lymphatic Metastasis; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Prospective Studies; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Survival Rate; Tissue Distribution; Treatment Outcome; Triazoles | 2010 |
Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Chemotherapy, Adjuvant; Colorectal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Randomized phase II trial of gefitinib or gemcitabine or docetaxel chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 or 3 (IFCT-0301 study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Taxoids | 2010 |
Serum levels of surfactant protein D predict the anti-tumor activity of gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Treatment Outcome | 2011 |
Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Boston; Breast Neoplasms; Doxorubicin; Drug Resistance, Neoplasm; Female; Gefitinib; Genital Neoplasms, Female; Humans; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations.
Topics: Adenocarcinoma; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2011 |
Disease control as a predictor of survival with gefitinib and docetaxel in a phase III study (V-15-32) in advanced non-small cell lung cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2010 |
The relationship between drug exposure and clinical outcomes of non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2011 |
Epidermal growth factor receptor inhibitor gefitinib added to chemoradiotherapy in locally advanced head and neck cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines | 2010 |
Phase II evaluation of gefitinib in patients with newly diagnosed Grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group Study N0074.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Chemotherapy, Adjuvant; Dexamethasone; Diarrhea; Disease-Free Survival; Drug Administration Schedule; Enzyme Activators; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, erbB-1; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Quinazolines; Young Adult | 2011 |
A pilot study of volume measurement as a method of tumor response evaluation to aid biomarker development.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Pilot Projects; Prognosis; Quinazolines; Sensitivity and Specificity; Tomography, X-Ray Computed; Tumor Burden | 2010 |
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2010 |
Gefitinib in combination with irradiation with or without cisplatin in patients with inoperable stage III non-small cell lung cancer: a phase I trial.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiotherapy; ras Proteins; Survival Rate; Treatment Outcome | 2010 |
[Clinical investigation of efficacy of pemetrexed in 32 patients with pulmonary adenocarcinoma after failure to chemotherapy and gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
A phase I and biology study of gefitinib and radiation in children with newly diagnosed brain stem gliomas or supratentorial malignant gliomas.
Topics: Adolescent; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Male; Maximum Tolerated Dose; Quinazolines; Supratentorial Neoplasms; Young Adult | 2010 |
Pemetrexed versus gefitinib versus erlotinib in previously treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Phase II trial of gefitinib and everolimus in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Clinical Trials, Phase I as Topic; Cohort Studies; ErbB Receptors; Everolimus; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Salvage Therapy; Sirolimus; Survival Rate; Treatment Outcome | 2010 |
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Heptanoic Acids; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Treatment Outcome | 2011 |
Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Placebos; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Treatment Outcome | 2011 |
[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neutropenia; Pemetrexed; Platinum; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Salvage Therapy; Taxoids; Treatment Failure | 2010 |
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Cyclophosphamide; Double-Blind Method; Epirubicin; Female; Fever; Gefitinib; Humans; Leukopenia; Middle Aged; Neoadjuvant Therapy; Neutropenia; Quinazolines; Receptors, Estrogen; Research Design; Treatment Outcome; Tumor Burden | 2011 |
Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Heart Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Pleural Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
A phase II study of gefitinib and irradiation in children with newly diagnosed brainstem gliomas: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Adult; Antineoplastic Agents; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase I as Topic; Combined Modality Therapy; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Quinazolines; Radiotherapy Dosage; Survival Rate; Tissue Distribution; Treatment Outcome; Young Adult | 2011 |
Exploring therapeutic decisions in elderly patients with non-small cell lung cancer: results and conclusions from North Central Cancer Treatment Group Study N0222.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Patient Selection; Practice Patterns, Physicians'; Quinazolines; Surveys and Questionnaires; Survival Analysis; Time Factors; Treatment Outcome; United States | 2011 |
Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
A randomized phase II study of gefitinib plus simvastatin versus gefitinib alone in previously treated patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Simvastatin; Treatment Outcome | 2011 |
A phase II randomized trial of gefitinib alone or with tegafur/uracil treatment in patients with pulmonary adenocarcinoma who had failed previous chemotherapy.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Taiwan; Tegafur; Treatment Failure; Uracil | 2011 |
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Disease-Free Survival; Female; Gefitinib; Humans; Interferon-alpha; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Polyethylene Glycols; Quinazolines; Recombinant Proteins | 2011 |
Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Hepatocyte Growth Factor; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2011 |
Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Young Adult | 2011 |
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Value of post-operative reassessment of estrogen receptor α expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Lobular; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Neoadjuvant Therapy; Phenotype; Quinazolines; Receptor, ErbB-2 | 2011 |
The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2011 |
Molecular characteristics predict clinical outcomes: prospective trial correlating response to the EGFR tyrosine kinase inhibitor gefitinib with the presence of sensitizing mutations in the tyrosine binding domain of the EGFR gene.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome; Tyrosine | 2011 |
Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Neoplasm Proteins; Quinazolines; Receptor, IGF Type 1; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dasatinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Thiazoles; Treatment Outcome | 2011 |
Circulating cell-free DNA in plasma of never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell-Free System; DNA; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Smoking; Treatment Outcome | 2011 |
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Paclitaxel; Patient Selection; Precision Medicine; Predictive Value of Tests; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2011 |
Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines | 2012 |
Phase II study of gefitinib as a first-line therapy in elderly patients with pulmonary adenocarcinoma: West Japan Thoracic Oncology Group Study 0402.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Agents; Diarrhea; Disease-Free Survival; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Smoking; Treatment Outcome | 2011 |
Gefitinib as first-line treatment in elderly epidermal growth factor receptor-mutated patients with advanced lung adenocarcinoma: results of a Nagano Lung Cancer Research Group study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
A phase II study of gefitinib in patients with metastatic melanoma.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Choroid Neoplasms; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Melanoma; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Texas; Time Factors; Treatment Outcome; Young Adult | 2011 |
Gefitinib, cisplatin, and concurrent radiotherapy for locally advanced head and neck cancer: EGFR FISH, protein expression, and mutational status are not predictive biomarkers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Chemoradiotherapy; Cisplatin; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Male; Matrix Metalloproteinase 11; Middle Aged; Oligonucleotide Array Sequence Analysis; Quinazolines; Risk Factors; Smoking; Treatment Outcome | 2012 |
A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Breast Neoplasms, Male; Cell Cycle; Cyclin D1; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Ki-67 Antigen; Male; Mitogen-Activated Protein Kinases; Neoadjuvant Therapy; Nitriles; Oncogene Protein v-akt; Proto-Oncogene Proteins; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Triazoles | 2011 |
Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Cetuximab; Cost-Benefit Analysis; ErbB Receptors; Gefitinib; Genetic Testing; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Pemetrexed; Pharmacogenetics; Quality-Adjusted Life Years; Quinazolines; Singapore; Treatment Outcome | 2012 |
A single-arm pilot phase II study of gefitinib and irinotecan in children with newly diagnosed high-risk neuroblastoma.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Child; Child, Preschool; Female; Gefitinib; Homovanillic Acid; Humans; Immunohistochemistry; Infant; Infant, Newborn; Irinotecan; L-Lactate Dehydrogenase; Male; Neoplasm Proteins; Neuroblastoma; Pilot Projects; Quinazolines; Risk Factors; Treatment Outcome; Tumor Burden; Vanilmandelic Acid | 2012 |
A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Double-Blind Method; Early Termination of Clinical Trials; ErbB Receptors; Europe; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Clinical significance of epidermal growth factor receptor mutations and insulin-like growth factor 1 and its binding protein 3 in advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor I; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Double-Blind Method; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Quinazolines; Squamous Cell Carcinoma of Head and Neck | 2011 |
Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate; Time Factors; Treatment Outcome | 2011 |
A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Esophageal Neoplasms; Esophagogastric Junction; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Patient Compliance; Quinazolines; Survival Analysis; Treatment Outcome | 2012 |
Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer.
Topics: Acrylic Resins; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; False Negative Reactions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Polyvinyls; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Paclitaxel; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Outcome | 2011 |
XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Azabicyclo Compounds; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2012 |
A phase I/II prospective, single arm trial of gefitinib, trastuzumab, and docetaxel in patients with stage IV HER-2 positive metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Docetaxel; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Taxoids; Trastuzumab; Treatment Outcome | 2012 |
Phase I study of continuous afatinib (BIBW 2992) in patients with advanced non-small cell lung cancer after prior chemotherapy/erlotinib/gefitinib (LUX-Lung 4).
Topics: Adult; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Outcome, quality of life and cognitive function of patients with brain metastases from non-small cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Ca
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Brief Psychiatric Rating Scale; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cognition; Cranial Irradiation; Dacarbazine; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Outcome Assessment, Health Care; Quality of Life; Quinazolines; Survival Analysis; Temozolomide | 2012 |
Histopathological and immunohistochemical features associated with clinical response to neoadjuvant gefitinib therapy in early stage non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2012 |
Icotinib (BPI-2009H), a novel EGFR tyrosine kinase inhibitor, displays potent efficacy in preclinical studies.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Crown Ethers; Disease-Free Survival; Double-Blind Method; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2012 |
Cryoablation combined with molecular target therapy improves the curative effect in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cryosurgery; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Quinazolines; Treatment Outcome | 2011 |
A phase II trial of gefitinib in patients with rising PSA following radical prostatectomy or radiotherapy.
Topics: Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Administration Schedule; Gefitinib; Humans; Male; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Treatment Outcome | 2012 |
Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
A phase II study of gefitinib for aggressive cutaneous squamous cell carcinoma of the head and neck.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Induction Chemotherapy; Male; Middle Aged; Neoadjuvant Therapy; Quinazolines; Skin Neoplasms; Survival Analysis; Treatment Outcome | 2012 |
Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Sequence Deletion; Treatment Outcome | 2012 |
The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2012 |
Induction chemotherapy followed by gefitinib and concurrent thoracic radiotherapy for unresectable locally advanced adenocarcinoma of the lung: a multicenter feasibility study (JCOG 0402).
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Disease-Free Survival; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Patient Compliance; Pneumonia; Quinazolines; Treatment Outcome; Vinblastine; Vinorelbine | 2012 |
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Treatment Failure | 2012 |
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non-small-cell lung cancer who previously responded to gefitinib.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retreatment; Salvage Therapy; Survival Rate; Treatment Outcome | 2012 |
A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Middle Aged; Neoplasm Metastasis; Nitriles; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Survival Analysis; Treatment Outcome; Triazoles | 2012 |
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome; Young Adult | 2012 |
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Disease-Free Survival; Dose-Response Relationship, Drug; Gefitinib; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Neoplasm Metastasis; Neoplasm Recurrence, Local; Quinazolines; Skin | 2012 |
Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quinazolines; Treatment Outcome | 2012 |
Quality of life with gefitinib in patients with EGFR-mutated non-small cell lung cancer: quality of life analysis of North East Japan Study Group 002 Trial.
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Endpoint Determination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quality of Life; Quinazolines; Treatment Outcome | 2012 |
[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Stomatitis; Treatment Outcome | 2012 |
Gefitinib versus pemetrexed as second-line treatment in patients with nonsmall cell lung cancer previously treated with platinum-based chemotherapy (KCSG-LU08-01): an open-label, phase 3 trial.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Follow-Up Studies; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Organoplatinum Compounds; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cisplatin; Cohort Studies; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Female; Fluorouracil; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Receptor, ErbB-2; Retrospective Studies; Stomach Neoplasms; Survival Rate; Trastuzumab; Treatment Outcome | 2013 |
Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Sequence Deletion; Treatment Outcome | 2012 |
Chemotherapy effectiveness after first-line gefitinib treatment for advanced lepidic predominant adenocarcinoma (formerly advanced bronchioloalveolar carcinoma): exploratory analysis of the IFCT-0401 trial.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adenocarcinoma, Mucinous; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Prospective Studies; Quinazolines; Salvage Therapy; Survival Rate | 2012 |
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Algorithms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proteomics; Quinazolines; Serum Amyloid A Protein; Survival Rate | 2012 |
Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Early Detection of Cancer; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphocytes; Male; Middle Aged; Neutrophils; Prognosis; Prospective Studies; Quinazolines; Treatment Outcome; Young Adult | 2012 |
Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2012 |
Contrasted outcomes to gefitinib on tumoral IGF1R expression in head and neck cancer patients receiving postoperative chemoradiation (GORTEC trial 2004-02).
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Neoplasm Staging; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Treatment Outcome | 2012 |
First-line gefitinib in patients aged 75 or older with advanced non-small cell lung cancer harboring epidermal growth factor receptor mutations: NEJ 003 study.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2012 |
Phase III, randomized, open-label, first-line study in Asia of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer: evaluation of patients recruited from mainland China.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Quality of Life; Quinazolines | 2012 |
Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Quinazolines; Survival Analysis | 2013 |
RTOG 0211: a phase 1/2 study of radiation therapy with concurrent gefitinib for newly diagnosed glioblastoma patients.
Topics: Age Factors; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; Combined Modality Therapy; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Maximum Tolerated Dose; Middle Aged; Quinazolines; Radiotherapy Dosage | 2013 |
Prospective assessment of continuation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of pemetrexed.
Topics: Aged; Aged, 80 and over; Anemia; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatigue; Female; Gefitinib; Glutamates; Guanine; Humans; Infections; Kaplan-Meier Estimate; Leukopenia; Lung Neoplasms; Male; Middle Aged; Neutropenia; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2013 |
Gefitinib combined with stereotactic radiosurgery in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiosurgery; Treatment Outcome | 2014 |
A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC).
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Skin Diseases; Treatment Outcome | 2013 |
[Prospective study on surface-enhanced laser desorption/ionization protein fingerprinting for diagnosing gene polymorphism leading to drug resistance drift: sequential therapy with a platinum-based regimen and gefitinib for non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Polymorphism, Genetic; Prospective Studies; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Treatment Outcome | 2013 |
Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1).
Topics: Adenocarcinoma; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cough; Double-Blind Method; Dyspnea; Erlotinib Hydrochloride; Fatigue; Female; Follow-Up Studies; Gefitinib; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain; Prognosis; Quality of Life; Quinazolines; Salvage Therapy | 2013 |
Phase I and pharmacokinetic study of gefitinib and S-1 combination therapy for advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Oxonic Acid; Quinazolines; Tegafur | 2013 |
A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Disease-Free Survival; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Survival Rate | 2013 |
Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Diarrhea; Docetaxel; Drug Administration Schedule; ErbB Receptors; Fatigue; Female; Gefitinib; Genotype; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Leukopenia; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Treatment Outcome | 2013 |
Role of gefitinib in patients with recurrent or metastatic cervical carcinoma ineligible or refractory to systemic chemotherapy: first study from Asia.
Topics: Adult; Antineoplastic Agents; Disease-Free Survival; Female; Gefitinib; Humans; India; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines; Uterine Cervical Neoplasms | 2013 |
Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Paclitaxel; Quality of Life; Quinazolines | 2013 |
Analysis of the EGFR mutation status in head and neck squamous cell carcinoma before treatment with Gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; Male; Middle Aged; Pilot Projects; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2013 |
Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer: brief report.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bexarotene; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tetrahydronaphthalenes; Treatment Outcome | 2013 |
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Computational Biology; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Survival Analysis; Xenograft Model Antitumor Assays | 2013 |
LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2013 |
Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
[A randomized clinical study of Gefitinib and pemetrexed as second line therapy for advanced non-squamous non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Treatment Outcome | 2013 |
Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2013 |
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Chemokines; Disease Models, Animal; ErbB Receptors; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Inflammation Mediators; Macrophages; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Ovarian Neoplasms; Quinazolines; RNA, Messenger; Skin; Translational Research, Biomedical | 2013 |
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Placebos; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2013 |
Phase II trial of gefitinib alone without radiation therapy for Japanese patients with brain metastases from EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Asian People; Brain Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2013 |
Combination gefitinib and methotrexate compared with methotrexate alone to treat ectopic pregnancy.
Topics: Abortifacient Agents, Nonsteroidal; Adult; Antineoplastic Agents; Drug Therapy, Combination; Female; Gefitinib; Humans; Injections, Intramuscular; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2013 |
A population-based review of the feasibility of platinum-based combination chemotherapy after tyrosine kinase inhibition in EGFR mutation positive non-small cell lung cancer patients with advanced disease.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paclitaxel; Platinum Compounds; Population Groups; Quinazolines | 2014 |
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; White People; Young Adult | 2014 |
Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS).
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; Early Detection of Cancer; ErbB Receptors; Gefitinib; Histological Techniques; Humans; Lung Neoplasms; Mutation; Precision Medicine; Quinazolines; Treatment Outcome; Tumor Burden | 2014 |
Establishment of a human 3D lung cancer model based on a biological tissue matrix combined with a Boolean in silico model.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Neoplasm Invasiveness; Neoplasm Proteins; Quinazolines; Signal Transduction; Swine; Tumor Microenvironment | 2014 |
Effectiveness of gefitinib against non-small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2014 |
Elimination of EGFR-expressing circulating tumor cells in patients with metastatic breast cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Microscopy, Fluorescence; Middle Aged; Neoplasm Metastasis; Neoplastic Cells, Circulating; Quinazolines | 2014 |
Early pharmacodynamic assessment using ¹⁸F-fluorodeoxyglucose positron-emission tomography on molecular targeted therapy and cytotoxic chemotherapy for clinical outcome prediction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Paclitaxel; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2014 |
A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Treatment Failure | 2014 |
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: a randomized, phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Pneumonectomy; Prospective Studies; Quinazolines; Survival Rate | 2014 |
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
Phase II study of erlotinib for acquired resistance to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Treatment Outcome | 2014 |
[Prospective study of biotin treatment in patients with erythema due to gefitinib or erlotinib].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biotin; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2014 |
A phase II randomized trial evaluating gefitinib intercalated with pemetrexed/platinum chemotherapy or pemetrexed/platinum chemotherapy alone in unselected patients with advanced non-squamous non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Association between GNAS1 T393C polymorphism and therapeutic efficacy of tyrosine kinase inhibitor in pretreated advanced non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chromogranins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Prognosis; Quinazolines; Signal Transduction; Smad3 Protein; Transforming Growth Factor beta; Treatment Outcome | 2014 |
Gefitinib for oesophageal cancer progressing after chemotherapy (COG): a phase 3, multicentre, double-blind, placebo-controlled randomised trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Deglutition Disorders; Diarrhea; Disease Progression; Disease-Free Survival; Double-Blind Method; Drug Eruptions; Eating; Esophageal Neoplasms; Fatigue; Female; Gefitinib; Humans; Male; Middle Aged; Pain; Proportional Hazards Models; Quality of Life; Quinazolines; Retreatment | 2014 |
First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2014 |
Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition.
Topics: Aged; Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Humans; Ki-67 Antigen; Mechanistic Target of Rapamycin Complex 1; Multiprotein Complexes; Nitriles; Phosphatidylinositol 3-Kinases; Prognosis; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; TOR Serine-Threonine Kinases; Triazoles | 2014 |
First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Monitoring; Drug Screening Assays, Antitumor; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Neoplasm Staging; Quality of Life; Quinazolines | 2014 |
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Single-Blind Method; Treatment Outcome | 2014 |
Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Asia, Southeastern; Carcinoma, Non-Small-Cell Lung; Cooking; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Inhalation Exposure; Life Style; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires | 2014 |
Rationale and study design of the IRENE-trial (NVALT-16): a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment.
Topics: Antineoplastic Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Research Design; Survival Analysis; Withholding Treatment | 2015 |
Phase I dose escalation and pharmacokinetic study of oral gefitinib and irinotecan in children with refractory solid tumors.
Topics: Administration, Oral; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Biological Availability; Camptothecin; Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Interactions; Female; Gefitinib; Humans; Irinotecan; Male; Maximum Tolerated Dose; Neoplasms; Quinazolines; Treatment Outcome; Young Adult | 2014 |
Pemetrexed versus gefitinib as a second-line treatment in advanced nonsquamous nonsmall-cell lung cancer patients harboring wild-type EGFR (CTONG0806): a multicenter randomized trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Quinazolines | 2014 |
Comparison of Gefitinib versus VMP in the combination with radiotherapy for multiple brain metastases from non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Female; Gefitinib; Humans; Male; Melphalan; Middle Aged; Prednisolone; Quinazolines; Radiotherapy, Intensity-Modulated; Treatment Outcome; Vindesine | 2015 |
[Efficacies of gefitinib versus paclitaxel/carboplatin for patients with advanced pulmonary adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; Carboplatin; Disease-Free Survival; Gefitinib; Hospitals, General; Humans; Lung Neoplasms; Paclitaxel; Platinum; Quinazolines; Smoking | 2014 |
Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Quinazolinones; ras Proteins; Republic of Korea; Treatment Outcome | 2014 |
Final overall survival results from a phase III, randomized, placebo-controlled, parallel-group study of gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804).
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult | 2015 |
Phase I/II study of gefitinib (Iressa(®)) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Quinazolines; Survival Rate; Treatment Outcome; Vorinostat | 2015 |
Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Asian People; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prospective Studies; Quinazolines | 2015 |
Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dihydrouracil Dehydrogenase (NADP); Drug Combinations; ErbB Receptors; Female; Fluorouracil; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Retrospective Studies; Tegafur; Treatment Outcome; Vinblastine; Vinorelbine | 2015 |
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Combinations; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Oxonic Acid; Quinazolines; Tegafur; Treatment Outcome | 2015 |
Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Potential therapeutic benefit of combining gefitinib and tamoxifen for treating advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tamoxifen | 2015 |
Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Similar survival rates with first-line gefitinib, gemcitabine, or docetaxel in a randomized phase II trial in elderly patients with advanced non-small cell lung cancer and a poor performance status (IFCT-0301).
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Disease-Free Survival; Docetaxel; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate; Taxoids; Treatment Outcome | 2015 |
Gefitinib, Methotrexate and Methotrexate plus 5-Fluorouracil as palliative treatment in recurrent head and neck squamous cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Male; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Palliative Care; Quality of Life; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Treatment Outcome | 2015 |
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pemetrexed; Quinazolines | 2016 |
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Meningeal Neoplasms; Middle Aged; Quinazolines | 2015 |
[Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; Clinical Protocols; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; Double-Blind Method; Drugs, Chinese Herbal; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Research Design; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult | 2015 |
Efficacy of chemotherapy after first-line gefitinib therapy in EGFR mutation-positive advanced non-small cell lung cancer-data from a randomized Phase III study comparing gefitinib with carboplatin plus paclitaxel (NEJ002).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2015 |
A Phase II Study of the Central European Society of Anticancer-Drug Research (CESAR) Group: Results of an Open-Label Study of Gemcitabine plus Cisplatin with or without Concomitant or Sequential Gefitinib in Patients with Advanced or Metastatic Transition
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Transitional Cell; Cisplatin; Deoxycytidine; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms; Urothelium | 2016 |
[Experience with the use of gefitinib in patients with inoperable non-squamous cell lung cancer with activating EGFR mutations].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
QoL analyses from INFORM study, a phase III study of gefitinib versus placebo as maintenance therapy in advanced NSCLC.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Proportional Hazards Models; Quality of Life; Quinazolines; Treatment Outcome; Young Adult | 2015 |
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Asia; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Europe; Female; Gefitinib; Genetic Predisposition to Disease; Glutamates; Guanine; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Phenotype; Proportional Hazards Models; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Everolimus; Gefitinib; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quinazolines; Receptors, Androgen; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Randomized, Multicenter Study of Gefitinib Dose-escalation in Advanced Non-small-cell Lung Cancer Patients Achieved Stable Disease after One-month Gefitinib Treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2015 |
Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Female; Follow-Up Studies; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Metabolic Clearance Rate; Middle Aged; Neoplasm Staging; Neutropenia; Patient Dropouts; Quinazolines; Taxoids | 2015 |
Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines | 2015 |
Gefitinib Combined With Standard Chemoradiotherapy in EGFR-Mutant Locally Advanced Non-Small-Cell Lung Cancer: The LOGIK0902/OLCSG0905 Intergroup Study Protocol.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Cisplatin; Docetaxel; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Prospective Studies; Quinazolines; Survival Rate; Taxoids | 2016 |
Concurrent radiotherapy with gefitinib in elderly patients with esophageal squamous cell carcinoma: Preliminary results of a phase II study.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Chemoradiotherapy; China; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Esophagoscopy; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Male; Middle Aged; Mutation; Neoplastic Cells, Circulating; Protein Kinase Inhibitors; Quinazolines | 2016 |
Epidermal growth factor receptor-inhibition (EGFR-I) in the treatment of neuropathic pain.
Topics: Adult; Aged; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Neuralgia; Pain Measurement; Panitumumab; Prospective Studies; Quinazolines; Recurrence; Young Adult | 2015 |
Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenocarcino
Topics: Adult; Aged; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; DNA, Neoplasm; Drug Administration Schedule; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Prospective Studies; Quinazolines | 2015 |
Comparison of Gefitinib Versus Chemotherapy in Patients with Non-small Cell Lung Cancer with Exon 19 Deletion.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Topics: Afatinib; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2016 |
A Phase Ib/II Study of Afatinib in Combination with Nimotuzumab in Non-Small Cell Lung Cancer Patients with Acquired Resistance to Gefitinib or Erlotinib.
Topics: Adult; Afatinib; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Immunological; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents | 2016 |
A European Organisation for Research and Treatment of Cancer randomized, double-blind, placebo-controlled, multicentre phase II trial of anastrozole in combination with gefitinib or placebo in hormone receptor-positive advanced breast cancer (NCT00066378)
Topics: Adult; Aged; Aged, 80 and over; Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Early Termination of Clinical Trials; Female; Gefitinib; Humans; Middle Aged; Nitriles; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Treatment Outcome; Triazoles | 2016 |
First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Quinazolines | 2016 |
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Rand
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Female; Gefitinib; Humans; Induction Chemotherapy; Maintenance Chemotherapy; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Pemetrexed; Quality of Life; Quinazolines; Smoking; Survival Analysis; Treatment Outcome; Young Adult | 2016 |
Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Case-Control Studies; Contrast Media; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, Spiral Computed; Tumor Burden; Young Adult | 2016 |
Randomized Phase III Study Comparing Gefitinib With Erlotinib in Patients With Previously Treated Advanced Lung Adenocarcinoma: WJOG 5108L.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2016 |
Multi-Center Randomized Phase II Study Comparing Cediranib plus Gefitinib with Cediranib plus Placebo in Subjects with Recurrent/Progressive Glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Male; Middle Aged; Molecular Targeted Therapy; Placebos; Quality of Life; Quinazolines; Recurrence; Safety; Vascular Endothelial Growth Factor A | 2016 |
Sequential treatment strategy for malignant pleural effusion in non-small cell lung cancer with the activated epithelial grow factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Paclitaxel; Pleural Effusion, Malignant; Quinazolines | 2017 |
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Half-Life; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Rate | 2016 |
A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2016 |
A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2016 |
Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Pharmacogenomic Testing; Point Mutation; Prevalence; Quinazolines; Radiation Injuries; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Treatment Outcome | 2016 |
Efficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Prediction of biomarkers of therapeutic effects of patients with lung adenocarcinoma treated with gefitinib based on progression-free-survival by metabolomic fingerprinting.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Disease-Free Survival; Female; Gefitinib; Humans; Least-Squares Analysis; Lung Neoplasms; Male; Mass Spectrometry; Metabolomics; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Prevalence; Quinazolines; Risk Factors; Sex Distribution; Smoking; Survival Analysis; Treatment Outcome | 2016 |
Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Disease-Free Survival; DNA; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
Defining a Radiomic Response Phenotype: A Pilot Study using targeted therapy in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoadjuvant Therapy; Pilot Projects; Quinazolines; Tomography, X-Ray Computed | 2016 |
Survival Outcomes in EGFR Mutation-Positive Lung Cancer Patients Treated with Gefitinib until or beyond Progression.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prevalence; Quinazolines; Risk Factors; Russia; Treatment Outcome | 2016 |
Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: A single center, single arm, phase II clinical trial.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2016 |
Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2016 |
A phase II open-label multicenter study of gefitinib in combination with irradiation followed by chemotherapy in patients with inoperable stage III non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2017 |
A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01).
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Platinum; Quinazolines | 2017 |
A Multicenter Double-blind Phase II Study of Metformin With Gefitinib as First-line Therapy of Locally Advanced Non-Small-cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Double-Blind Method; Female; Gefitinib; Humans; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Quinazolines; Research Design; Survival Analysis; Young Adult | 2017 |
A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Effect of Sustained Elevated Gastric pH Levels on Gefitinib Exposure.
Topics: Area Under Curve; Biological Availability; Cross-Over Studies; Gefitinib; Healthy Volunteers; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Least-Squares Analysis; Male; Quinazolines; Random Allocation; Ranitidine; Stomach | 2017 |
Efficacy according to blind independent central review: Post-hoc analyses from the phase III, randomized, multicenter, IPASS study of first-line gefitinib versus carboplatin/paclitaxel in Asian patients with EGFR mutation-positive advanced NSCLC.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2017 |
The APPLE Trial: Feasibility and Activity of AZD9291 (Osimertinib) Treatment on Positive PLasma T790M in EGFR-mutant NSCLC Patients. EORTC 1613.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA, Neoplasm; Drug Substitution; ErbB Receptors; Feasibility Studies; Gefitinib; Humans; Liquid Biopsy; Lung Neoplasms; Mutation; Piperazines; Quinazolines; Research Design; Response Evaluation Criteria in Solid Tumors | 2017 |
Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2017 |
Analyzing epidermal growth factor receptor mutation status changes in advanced non-small-cell lung cancer at different sampling time-points of blood within one day.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Mutation Rate; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Circulating Tumor Cells Predict Prognosis Following Tyrosine Kinase Inhibitor Treatment in EGFR-Mutant Non-Small Cell Lung Cancer Patients.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Neoplastic Cells, Circulating; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Combination of chemotherapy and gefitinib as first-line treatment for patients with advanced lung adenocarcinoma and sensitive EGFR mutations: A randomized controlled trial.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Point Mutation; Quinazolines | 2017 |
Dacomitinib Beats Gefitinib for EGFR
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2017 |
A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib.
Topics: Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retreatment; Sirolimus; Treatment Outcome | 2017 |
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2017 |
Phase I study of combined therapy with vorinostat and gefitinib to treat BIM deletion polymorphism-associated resistance in EGFR-mutant lung cancer (VICTROY-J): a study protocol.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Hydroxamic Acids; Lung Neoplasms; Mutation; Quinazolines; Vorinostat | 2017 |
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Confidence Intervals; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Mutation; Prognosis; Quinazolines; Quinazolinones; Survival Analysis; Treatment Outcome | 2017 |
Gefitinib for patients with incurable cutaneous squamous cell carcinoma: A single-arm phase II clinical trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin Neoplasms | 2017 |
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Cohort Studies; Diarrhea; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2017 |
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2018 |
Bevacizumab and gefitinib enhanced whole-brain radiation therapy for brain metastases due to non-small-cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Cranial Irradiation; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Quinazolines; Reproducibility of Results; Retrospective Studies; Statistics, Nonparametric; Time Factors; Treatment Outcome | 2017 |
Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Economics, Pharmaceutical; ErbB Receptors; Exanthema; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Outcome Assessment, Health Care; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2018 |
Feasibility Study of Sequentially Alternating EGFR-TKIs and Chemotherapy for Patients with Non-small Cell Lung Cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Induction Chemotherapy; Lung Neoplasms; Maintenance Chemotherapy; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2018 |
Gefitinib and Methotrexate to Treat Ectopic Pregnancies with a Pre-Treatment Serum hCG 1000-10,000 IU/L: Phase II Open Label, Single Arm Multi-Centre Trial.
Topics: Administration, Intranasal; Administration, Oral; Adult; Chorionic Gonadotropin; Drug Therapy, Combination; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines; Treatment Outcome | 2018 |
A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2020 |
Clinical study of apatinib combined with EGFR-TKI in the treatment of chronic progression after EGFR-TKI treatment in non-small cell lung cancer (ChiCTR1800019185).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Prospective Studies; Pyridines; Quinazolines; Research Design; Young Adult | 2020 |
Combination of gefitinib and olaparib versus gefitinib alone in EGFR mutant non-small-cell lung cancer (NSCLC): A multicenter, randomized phase II study (GOAL).
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Goals; Humans; Lung Neoplasms; Mexico; Mutation; Phthalazines; Piperazines; Protein Kinase Inhibitors; Quinazolines; Spain | 2020 |
Drug interaction of ningetinib and gefitinib involving CYP1A1 and efflux transporters in non-small cell lung cancer patients.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Interactions; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines | 2021 |
Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706).
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyridines; Quality of Life; Quinazolines; Vascular Endothelial Growth Factor A | 2021 |
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
Topics: Acrylamides; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Small Cell Lung Carcinoma | 2022 |
Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Double-Blind Method; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Tyrosine | 2022 |
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
Topics: Adenocarcinoma of Lung; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Central Nervous System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
2946 other study(ies) available for quinazolines and gefitinib
| Article | Year |
|---|---|
Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase.
Topics: Aminopterin; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Carboplatin; Cell Division; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; Paclitaxel; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Taxoids; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Vulvar Neoplasms | 2000 |
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation.
Topics: Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Ductal, Breast; Cell Division; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Mice; Mice, Nude; Middle Aged; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Trastuzumab; Tumor Cells, Cultured | 2001 |
[New targets in the treatment of lung cancer. Role of EGF-R tyrosine kinase inhibitors].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2000 |
The epidermal growth factor receptor (EGFR): role in corneal wound healing and homeostasis.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Cell Division; Dose-Response Relationship, Drug; Epithelium, Corneal; ErbB Receptors; Female; Gefitinib; Homeostasis; Quinazolines; Rats; Rats, Wistar; Time Factors; Wound Healing | 2001 |
Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Disease Models, Animal; Drug Synergism; Endothelial Growth Factors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Growth Substances; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lymphokines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2001 |
Pharmacokinetics and tolerability of the orally active selective epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in healthy volunteers.
Topics: Adolescent; Adult; Area Under Curve; Double-Blind Method; Electrocardiography; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Half-Life; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome | 2001 |
Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182,780 (Faslodex).
Topics: Antineoplastic Agents; Breast Neoplasms; Cytological Techniques; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured | 2001 |
Clinical trials referral resource. Epidermal growth factor receptor inhibitors in clinical trials.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2001 |
Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; KB Cells; Quinazolines; Sensitivity and Specificity; Tumor Cells, Cultured | 2001 |
Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Lung Neoplasms; Mammary Neoplasms, Experimental; Phthalimides; Quinazolines; Rats; Signal Transduction; Tumor Cells, Cultured | 2001 |
Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Keratinocytes; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction; Skin; Transforming Growth Factor beta | 2001 |
ZD-1839 (AstraZeneca).
Topics: Anemia; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Diarrhea; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Tolerance; Drugs, Investigational; Economics, Pharmaceutical; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nausea; Pancreatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2001 |
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Cells, Cultured | 2001 |
ZD1839 (Iressa), a novel epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, potently inhibits the growth of EGFR-positive cancer cell lines with or without erbB2 overexpression.
Topics: Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2001 |
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Catalytic Domain; Cell Cycle; Cell Division; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Mas; Quinazolines; Receptor, ErbB-2; Signal Transduction; Substrate Specificity; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Oral administration of a novel taxane, an antisense oligonucleotide targeting protein kinase A, and the epidermal growth factor receptor inhibitor Iressa causes cooperative antitumor and antiangiogenic activity.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligodeoxyribonucleotides, Antisense; Ovarian Neoplasms; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2001 |
High levels of HER-2 expression alter the ability of epidermal growth factor receptor (EGFR) family tyrosine kinase inhibitors to inhibit EGFR phosphorylation in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Phosphorylation; Piperazines; Pyrimidines; Quinazolines; Receptor, ErbB-2; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Targeted Therapies in the Treatment of Breast Cancer. Proceedings of a meeting. Kailua-Kona, Hawaii, July 19-23, 2000.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Prenylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2001 |
Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Carcinoma in Situ; Carcinoma, Ductal, Breast; Cell Division; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Precancerous Conditions; Quinazolines; Xenograft Model Antitumor Assays | 2002 |
Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; K562 Cells; Kinetics; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms; Phosphorylation; Quinazolines; RNA, Neoplasm; Tetradecanoylphorbol Acetate; Tumor Cells, Cultured | 2002 |
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Survival; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2002 |
Combined anti-EGF receptor and anti-HER2 receptor therapy in breast cancer: a promising strategy ready for clinical testing.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2002 |
Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa").
Topics: Animals; Cell Division; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2002 |
Sequence-dependent effects of ZD1839 ('Iressa') in combination with cytotoxic treatment in human head and neck cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Fluorouracil; Gefitinib; Genes, p53; Head and Neck Neoplasms; Humans; Quinazolines; Receptors, Growth Factor; Receptors, Mitogen; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2002 |
ZD1839 (IRESSA), an EGFR-selective tyrosine kinase inhibitor, enhances taxane activity in bcl-2 overexpressing, multidrug-resistant MCF-7 ADR human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Division; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Taxoids; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2002 |
ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model.
Topics: Animals; Carcinoma; Cell Division; Chemotherapy, Adjuvant; Colorectal Neoplasms; Enzyme Inhibitors; Gefitinib; Humans; Mice; Quinazolines; Radiation-Sensitizing Agents; Transplantation, Heterologous | 2002 |
ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase.
Topics: Angiogenesis Inhibitors; Animals; Carcinoma, Squamous Cell; Cell Movement; Cells, Cultured; Cornea; Endothelial Growth Factors; Endothelium, Vascular; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-8; Lymphokines; Male; Mitogen-Activated Protein Kinase Kinases; Neovascularization, Physiologic; Quinazolines; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Vulvar Neoplasms | 2002 |
Targeting the epidermal growth factor receptor with tyrosine kinase inhibitors: small molecules, big hopes.
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2002 |
Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 ("Iressa").
Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2002 |
Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bradykinin; Bradykinin Receptor Antagonists; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Division; Cisplatin; Dimerization; Doxorubicin; Drug Synergism; Drug Therapy, Combination; Etoposide; Gefitinib; Humans; Infusion Pumps; Injections, Intralesional; Injections, Intraperitoneal; Injections, Subcutaneous; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligopeptides; Paclitaxel; Quinazolines; Time Factors; Tumor Cells, Cultured; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2002 |
Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Carrier Proteins; Cell Death; Cell Line; Cell Survival; Cells, Cultured; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Insulin-Like Growth Factor I; Mammary Glands, Animal; MAP Kinase Signaling System; Mice; Mice, Inbred ICR; Mice, Knockout; Phosphatidylinositol 3-Kinases; Pregnancy; Quinazolines; Receptors, Somatomedin; Signal Transduction; Transcriptional Activation | 2002 |
A sensitive assay for ZD1839 (Iressa) in human plasma by liquid-liquid extraction and high performance liquid chromatography with mass spectrometric detection: validation and use in Phase I clinical trials.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Drug Stability; Gefitinib; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results | 2002 |
Cancer medicine hits a target.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Delivery Systems; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Selective inhibition of the epidermal growth factor receptor impairs intestinal adaptation after small bowel resection.
Topics: Adaptation, Physiological; Animals; Apoptosis; Enterocytes; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Intestine, Small; Male; Mice; Mice, Inbred ICR; Quinazolines; Short Bowel Syndrome; Signal Transduction | 2002 |
Modulation of epidermal growth factor receptor in endocrine-resistant, estrogen-receptor-positive breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Drug Resistance, Neoplasm; Endocrine Glands; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Trastuzumab; Tumor Cells, Cultured | 2002 |
Selective inhibition of the epidermal growth factor receptor by ZD1839 decreases the growth and invasion of ovarian clear cell adenocarcinoma cells.
Topics: Adenocarcinoma, Clear Cell; Animals; Antineoplastic Agents; Cell Division; Cytokines; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Growth Substances; Humans; Immunoenzyme Techniques; In Vitro Techniques; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, SCID; Ovarian Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Transforming Growth Factor alpha; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2002 |
Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa).
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Endothelium, Vascular; ErbB Receptors; Female; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Gefitinib (Iressa) for advanced non-small cell lung cancer.
Topics: Biological Availability; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Diarrhea; Drug Interactions; ErbB Receptors; Gefitinib; Half-Life; Lung Neoplasms; Multicenter Studies as Topic; Quinazolines | 2002 |
Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2002 |
A serum factor after intestinal resection stimulates epidermal growth factor receptor signaling and proliferation in intestinal epithelial cells.
Topics: Adaptation, Physiological; Animals; Blood Proteins; Cell Division; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Intestinal Mucosa; Intestine, Small; Male; Phosphatidylinositol 3-Kinases; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction | 2002 |
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Division; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Phosphorylation; Pleural Neoplasms; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2002 |
Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Culture Media, Conditioned; Dose-Response Relationship, Drug; EGF Family of Proteins; Gefitinib; Glycoproteins; HeLa Cells; Humans; Intercellular Signaling Peptides and Proteins; Jurkat Cells; Kinetics; Lung Neoplasms; Phosphorylation; Precipitin Tests; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; Time Factors; Tumor Cells, Cultured; Tyrosine; Tyrphostins | 2002 |
Surprise phase III failure for ZD1839.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Survival Analysis; Treatment Outcome | 2002 |
Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Animals; Antineoplastic Agents; bcl-X Protein; Blotting, Western; Combined Modality Therapy; Disease Models, Animal; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms, Experimental; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation, Ionizing; Survival Rate; Tumor Cells, Cultured | 2002 |
ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Division; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Growth Inhibitors; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Cancer drugs. Smart weapons prove tough to design.
Topics: Advisory Committees; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Drug Industry; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Neoplasms; Patient Selection; Piperazines; Pyrimidines; Quinazolines; United States; United States Food and Drug Administration | 2002 |
The multifunctional, multi-institutional, and sometimes even global phase I study: a better life for phase I evaluations or just "living large"?
Topics: Antineoplastic Agents; Clinical Trials, Phase I as Topic; Endpoint Determination; Gefitinib; Humans; Interprofessional Relations; Multicenter Studies as Topic; Neoplasms; Physician's Role; Quinazolines; Research Design | 2002 |
Despite concerns, FDA panel backs EGFR inhibitor.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2002 |
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa).
Topics: 3T3 Cells; Administration, Oral; Animals; Antineoplastic Agents; Blotting, Western; Brain Neoplasms; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Time Factors; Tumor Cells, Cultured; Tyrosine | 2002 |
Synthetic lethality: killing cancer with cancer.
Topics: Animals; Antineoplastic Agents; Benzamides; Benzoquinones; Cell Cycle Proteins; DNA-Binding Proteins; E2F Transcription Factors; Gefitinib; Genes, Tumor Suppressor; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Indoles; Lactams, Macrocyclic; Mutation; Neoplasms; Phosphoric Monoester Hydrolases; Piperazines; PTEN Phosphohydrolase; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Signal Transduction; Sirolimus; Transcription Factors; Tumor Suppressor Proteins | 2002 |
Demand grows for early access to promising cancer drugs.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Approval; Drug Costs; Drugs, Investigational; Gefitinib; Health Services Accessibility; Humans; Lung Neoplasms; Neoplasms; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration | 2002 |
The simpleton's error in drug development.
Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Drug Design; Drugs, Investigational; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2002 |
What went wrong with Iressa?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy, Combination; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Quinazolines; Treatment Outcome | 2002 |
Studies with CWR22 xenografts in nude mice suggest that ZD1839 may have a role in the treatment of both androgen-dependent and androgen-independent human prostate cancer.
Topics: Anilides; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carboplatin; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Hormone-Dependent; Nitriles; Paclitaxel; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptors, Androgen; Testosterone; Tosyl Compounds; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
Highlights from: 27th congress of the European Society for Medical Oncology. Nice, France. October 18-22, 2002.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Capecitabine; Cetuximab; Colorectal Neoplasms; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2002 |
Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling.
Topics: Allantois; Angiogenesis Inducing Agents; Animals; Capillaries; Cells, Cultured; Chick Embryo; Chorion; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Growth Substances; Humans; Isoenzymes; Membrane Proteins; Morphogenesis; Mucins; Muscle Proteins; Neovascularization, Physiologic; Neuropeptides; Nitrobenzenes; Peptides; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Sulfonamides; Trefoil Factor-2; Trefoil Factor-3 | 2003 |
Severe acute interstitial pneumonia and gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
BAD: a good therapeutic target?
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Carrier Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured | 2003 |
On target. A new generation of drugs offers customized cures.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Drug Delivery Systems; Drug Design; Enzyme Inhibitors; Female; Gefitinib; Humans; Male; Neoplasms; Pharmacogenetics; Quinazolines; Receptors, Growth Factor; Trastuzumab; United States | 2003 |
EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Division; Drug Screening Assays, Antitumor; Endothelial Growth Factors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Phosphorylation; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy Dosage; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Breast Neoplasms; Cell Death; Cell Division; Colonic Neoplasms; Cyclic AMP-Dependent Protein Kinases; Endothelial Growth Factors; ErbB Receptors; Female; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Oligonucleotides; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Transfection; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors | 2003 |
27th ESMO Congress, Nice, 18-22 October 2002. Iressa disappoints in NSCLC.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Congresses as Topic; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines; Treatment Failure | 2003 |
Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Transforming Growth Factor alpha; Trastuzumab; Tumor Cells, Cultured | 2003 |
Necrolytic migratory erythema (glucagenoma)-like skin lesions induced by EGF-receptor inhibition.
Topics: Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Erythema; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Critical role of both p27KIP1 and p21CIP1/WAF1 in the antiproliferative effect of ZD1839 ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, in head and neck squamous carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Macromolecular Substances; Oligonucleotides, Antisense; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Transfection; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
Impact of ZD1839 on non-small cell lung cancer-related symptoms as measured by the functional assessment of cancer therapy-lung scale.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Status Indicators; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Surveys and Questionnaires; Treatment Outcome | 2003 |
A case study documenting the anticancer activity of ZD1839 (Iressa) in the brain.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Treatment Outcome | 2003 |
Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Middle Aged; Neoplasm Staging; Paclitaxel; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Taxoids; Treatment Outcome | 2003 |
Commentary on ZD1839 (Iressa) in non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
[14th EORTC-NCI-AAACR Symposium on New Molecular Targets and Cancer Therapeutics].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Gefitinib; Germany; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Dimerization; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Fluorescein-5-isothiocyanate; Gefitinib; Humans; Ligands; Models, Biological; Neuregulin-1; Phosphorylation; Precipitin Tests; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Time Factors | 2003 |
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Topics: Agar; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Sulfonamides | 2003 |
Paronychia induced by gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Aged; Aged, 80 and over; Biopsy, Needle; Enzyme Inhibitors; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
Apparent adverse drug reactions prompt concern about Iressa.
Topics: Adverse Drug Reaction Reporting Systems; Antineoplastic Agents; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Japan; Neoplasms; Protein-Tyrosine Kinases; Quinazolines; United States; United States Food and Drug Administration | 2003 |
Signal transduction modulators for cancer therapy: from promise to practice?
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Health Knowledge, Attitudes, Practice; Humans; Neoplasms; Quinazolines; Signal Transduction; United States; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
Suppression of epidermal growth factor receptor, mitogen-activated protein kinase, and Pak1 pathways and invasiveness of human cutaneous squamous cancer cells by the tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Differentiation; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Cells, Cultured; Cytoskeleton; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Keratinocytes; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Skin Neoplasms | 2003 |
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Male; Phosphorylation; Prostatic Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured; Tyrosine | 2003 |
Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibition.
Topics: Astatine; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioma; Humans; Metabolic Clearance Rate; Protein-Tyrosine Kinases; Quinazolines; Radioisotopes; Radiopharmaceuticals | 2003 |
FDA announces fast track approval of new drug for lung cancer.
Topics: Antineoplastic Agents; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2003 |
Gefitinib in recurrent non-small-cell lung cancer: an IDEAL trial?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate | 2003 |
Biologists take tentative steps towards bespoke cancer drugs.
Topics: Antineoplastic Agents; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Pharmacogenetics; Pneumonia; Polymorphism, Single Nucleotide; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Diffuse alveolar damage after ZD1839 therapy in a patient with non-small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Pulmonary Alveoli; Quinazolines | 2003 |
Inhibition of epidermal growth factor receptor signaling decreases p63 expression in head and neck squamous carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Northern; Blotting, Western; Carcinoma, Squamous Cell; Cell Division; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Membrane Proteins; Mouth Neoplasms; Phosphoproteins; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Signal Transduction; Trans-Activators; Transcription Factors; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2003 |
More haste, less speed.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Drug Approval; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Research Design; Treatment Failure; United States; United States Food and Drug Administration | 2003 |
Gene-expression profiles of human tumor xenografts in nude mice treated orally with the EGFR tyrosine kinase inhibitor ZD1839.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Complementary; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kinetics; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Protein-Tyrosine Kinases; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; Time Factors; Up-Regulation | 2003 |
Is there a role for the assessment of health-related quality of life in the clinical evaluation of novel cytostatic agents?: Commentary re: P. M. LoRusso, Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral
Topics: Administration, Oral; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Health Status; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2003 |
Helicobacter pylori VacA toxin up-regulates vascular endothelial growth factor expression in MKN 28 gastric cells through an epidermal growth factor receptor-, cyclooxygenase-2-dependent mechanism.
Topics: Bacterial Proteins; Cyclooxygenase 2; ErbB Receptors; Gefitinib; Helicobacter pylori; Humans; Isoenzymes; MAP Kinase Signaling System; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Quinazolines; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Up-Regulation; Vascular Endothelial Growth Factor A | 2003 |
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Patient Compliance; Quality of Life; Quinazolines | 2003 |
Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells: limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinase 1; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2003 |
Clinical efficacy and toxicity of gefitinib in patients with lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Pulmonary Fibrosis; Quinazolines; Radiography | 2003 |
Clinical efficacy and toxiciy of gefitinib in patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Ascites; Carcinoma, Non-Small-Cell Lung; Gefitinib; Hepatitis C, Chronic; Humans; Hypoalbuminemia; Liver Cirrhosis; Lung Diseases, Interstitial; Lung Neoplasms; Male; Quinazolines | 2003 |
ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Hepatocellular; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Liver Neoplasms; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Phosphorylation; Quinazolines; Signal Transduction | 2003 |
Iressa : first angiogenesis inhibitor approved for the treatment of advanced NSCLC.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2003 |
Accelerated approval scrutinized: confirmatory phase 4 studies on new drugs languish.
Topics: Antineoplastic Agents; Clinical Trials, Phase IV as Topic; Drug Approval; Gefitinib; Quinazolines; United States; United States Food and Drug Administration | 2003 |
A report of two bronchioloalveolar carcinoma cases which were rapidly improved by treatment with the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 ("Iressa").
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Middle Aged; Quinazolines; Radiography; Sputum | 2003 |
Gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
ZD 1839 in patients with brain metastases from non-small-cell lung cancer (NSCLC): report of four cases.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2003 |
Wound healing is not impaired by the epidermal growth factor receptor-tyrosine kinase inhibitor gefitinib.
Topics: Administration, Oral; Aged; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Epidermal Growth Factor; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Pneumonectomy; Postoperative Care; Quinazolines; Risk Assessment; Sampling Studies; Wound Healing | 2003 |
Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells.
Topics: Amphiregulin; Animals; Cells, Cultured; Colonic Neoplasms; Dogs; EGF Family of Proteins; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, src; Glycoproteins; Growth Substances; Humans; Intercellular Signaling Peptides and Proteins; Kidney; Mucins; Muscle Proteins; Mutation; Neoplasm Invasiveness; Neuropeptides; Peptides; Phosphatidylinositol 3-Kinases; Proteins; Quinazolines; Receptors, Thromboxane; Signal Transduction; Transforming Growth Factor alpha; Trefoil Factor-1; Trefoil Factor-2; Trefoil Factor-3; Tumor Suppressor Proteins | 2003 |
Acute lung injury as a possible adverse drug reaction related to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Respiratory Distress Syndrome | 2003 |
[From molecular biology to new treatment approaches to colorectal cancer: basic research, experimental trials and surgical implications].
Topics: Adenomatous Polyposis Coli; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Colorectal Neoplasms, Hereditary Nonpolyposis; ErbB Receptors; Follow-Up Studies; Gefitinib; Genes, APC; Genes, DCC; Genes, p53; Genes, ras; Humans; Indoles; Mutation; Prognosis; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Research; Time Factors | 2003 |
Molecular mechanisms underlying the interaction between ZD1839 ('Iressa') and cisplatin/5-fluorouracil.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cisplatin; DNA Repair; Drug Interactions; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2003 |
[Alveolar hemorrhage as a possible adverse drug reaction by gefitinib (ZD1839, Iressa)].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pulmonary Alveoli; Quinazolines; Respiratory Insufficiency | 2003 |
Characterization of sequence-dependent synergy between ZD1839 ("Iressa") and oxaliplatin.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; DNA Adducts; Drug Synergism; ErbB Receptors; gamma-Glutamyltransferase; Gefitinib; HT29 Cells; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Platinum; Quinazolines | 2003 |
Does hope match the hype for targeted drugs?
Topics: Antineoplastic Agents; Benzamides; Drug Design; Gefitinib; Humans; Imatinib Mesylate; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines | 2003 |
Successful treatment of multifocal bronchioloalveolar cell carcinoma with ZD1839 (Iressa) in two patients.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2003 |
Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGF.
Topics: Antineoplastic Agents; Astatine; Astrocytoma; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Epidermal Growth Factor; Gefitinib; Humans; Quinazolines; Radiopharmaceuticals; Treatment Outcome | 2003 |
Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis.
Topics: Animals; Bleomycin; Cell Division; Disease Models, Animal; ErbB Receptors; Gefitinib; Male; Mice; Mice, Inbred ICR; Phosphorylation; Pulmonary Fibrosis; Quinazolines | 2003 |
The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro.
Topics: Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Combinations; Drug Resistance; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Estradiol; Estrogen Antagonists; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tamoxifen | 2003 |
Selection bias, phase II trials, and the FDA accelerated approval process.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Quinazolines; Selection Bias; Treatment Outcome; United States; United States Food and Drug Administration | 2003 |
The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Adducts; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Organoplatinum Compounds; Oxaliplatin; Precipitin Tests; Quinazolines | 2003 |
Fatal pulmonary toxicity in a patient treated with gefitinib for non-small cell lung cancer after previous hemolytic-uremic syndrome due to gemcitabine.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Female; Gefitinib; Gemcitabine; Hemolytic-Uremic Syndrome; Humans; Lung; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2003 |
[Radiation recall pneumonitis induced by Gefitinib (Iressa): a case report].
Topics: Aged; Antineoplastic Agents; Carcinoma, Large Cell; Combined Modality Therapy; Enzyme Inhibitors; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Radiation Pneumonitis | 2003 |
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Combined Modality Therapy; Dose-Response Relationship, Radiation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Neoplasms; Quinazolines; Radiation-Sensitizing Agents; Receptor, ErbB-2; Time Factors | 2003 |
The sensitivity of lung cancer cell lines to the EGFR-selective tyrosine kinase inhibitor ZD1839 ('Iressa') is not related to the expression of EGFR or HER-2 or to K-ras gene status.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured | 2003 |
Enhancement of radiosensitivity in head and neck cancer cells by ZD1839 ('IRESSA'), a selective epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance | 2003 |
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
Topics: Breast Neoplasms; Chromones; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoric Monoester Hydrolases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection; Tumor Cells, Cultured | 2003 |
Development of multiple paronychia and periungual granulation in patients treated with gefitinib, an inhibitor of epidermal growth factor receptor.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Nail Diseases; Paronychia; Quinazolines; Risk Assessment; Severity of Illness Index | 2003 |
ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine.
Topics: Administration, Oral; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Survival; Deoxycytidine; DNA Primers; Floxuridine; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Models, Chemical; Polymerase Chain Reaction; Pyrimidines; Quinazolines; RNA; RNA, Messenger; Time Factors; Transcription, Genetic | 2003 |
Clinically meaningful response to the EGFR tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in non small cell lung cancer.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines | 2003 |
A novel approach in the treatment of neuroendocrine gastrointestinal tumours. Targeting the epidermal growth factor receptor by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoid Tumor; Carcinoma, Neuroendocrine; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Fluorescent Antibody Technique; Gastrointestinal Neoplasms; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulinoma; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2003 |
The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase.
Topics: Animals; Breast; Cell Division; Epithelial Cells; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor I; Mice; Mitogen-Activated Protein Kinases; Mitogens; NIH 3T3 Cells; Phosphorylation; Quinazolines | 2004 |
Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Combined Modality Therapy; Flow Cytometry; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; Reproducibility of Results; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ('Iressa') is independent of EGFR expression level.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Division; Cell Line, Tumor; Enzyme Activation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2 | 2004 |
Pulmonary toxicity due to chemotherapy how is the risk and benefit from ZD1839 treatment against non-small cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases; Lung Neoplasms; Quinazolines | 2003 |
Gefitinib ('Iressa'), an epidermal growth factor receptor tyrosine kinase inhibitor, mediates the inhibition of lymph node metastasis in oral cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Enzyme Inhibitors; ErbB Receptors; Fibronectins; Focal Adhesion Kinase 1; Focal Adhesion Protein-Tyrosine Kinases; Focal Adhesions; Gefitinib; Green Fluorescent Proteins; Integrins; Luminescent Proteins; Lymph Nodes; Lymphatic Metastasis; Mice; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tongue Neoplasms; Tumor Cells, Cultured | 2003 |
Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioma; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Trans-Activators; Tumor Suppressor Proteins | 2003 |
[Significance of gefitinib combined with immunotherapy in tumor-bearing mice].
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; ErbB Receptors; Gefitinib; Immunotherapy; Interleukin-12; Mice; Quinazolines | 2003 |
Combinations of targeted therapies take aim at multiple pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Boronic Acids; Bortezomib; Clinical Trials as Topic; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrazines; Pyrimidines; Quinazolines; Research Design | 2003 |
Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells.
Topics: Amphiregulin; Animals; Antigens, CD; Antigens, Neoplasm; Basigin; Breast Neoplasms; Cell Communication; Cell Line, Transformed; Coculture Techniques; DNA, Antisense; EGF Family of Proteins; Epithelial Cells; ErbB Receptors; Female; Fibroblasts; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Glycoproteins; Mice; Mice, Nude; Protein Serine-Threonine Kinases; Quinazolines; RNA, Messenger | 2003 |
The heat shock protein 90 inhibitor geldanamycin and the ErbB inhibitor ZD1839 promote rapid PP1 phosphatase-dependent inactivation of AKT in ErbB2 overexpressing breast cancer cells.
Topics: Animals; Antibiotics, Antineoplastic; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; COS Cells; Enzyme Activation; Enzyme Inhibitors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Phosphoprotein Phosphatases; Phosphorylation; Protein Phosphatase 1; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinones; Receptor, ErbB-2 | 2003 |
Time and dose-dependent radiosensitization of the glioblastoma multiforme U251 cells by the EGF receptor tyrosine kinase inhibitor ZD1839 ('Iressa').
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Division; Cerebellum; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Phosphorylation; Placenta; Quinazolines; Radiation-Sensitizing Agents; Radiation, Ionizing; Radiotherapy Dosage; Time Factors; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2003 |
[Targeted molecular therapy: the example of Iressa (ZD1839)].
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Division; Colorectal Neoplasms; DNA Topoisomerases, Type I; Drug Interactions; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topoisomerase I Inhibitors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2004 |
The 'Iressa' Clinical Experience Meeting. June 2003, Madrid, Spain. Proceedings and abstracts.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2003 |
Extensive experience of disease control with gefitinib and the role of prognostic markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Survival Analysis | 2003 |
Lessons from the ("Iressa" Expanded Access Programme: gefitinib in special non-small-cell lung cancer patient populations.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines | 2003 |
Gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, up-regulates p27KIP1 and induces G1 arrest in oral squamous cell carcinoma cell lines.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mouth Neoplasms; Quinazolines; S Phase; Tumor Suppressor Proteins; Up-Regulation | 2004 |
Getting to grips with gefitinib.
Topics: Antineoplastic Agents; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2003 |
Highlights from the 10th World Conference on Lung Cancer. Vancouver, British Columbia, Canada, August 10-14, 2003.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Deoxycytidine; Docetaxel; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Taxoids | 2003 |
Antitumor activity and tolerability of gefitinib in patients with non-small-cell lung cancer treated in an expanded access program.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2003 |
Activity of a specific inhibitor, gefitinib (Iressa, ZD1839), of epidermal growth factor receptor in refractory non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis | 2004 |
Effect of re-treatment with gefitinib ('Iressa', ZD1839) after acquisition of resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Disease Progression; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Neoplasm Metastasis; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Taxoids | 2004 |
Investigational drug access taken to task in lawsuit against FDA.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Conflict of Interest; Drug Approval; Drug Industry; Drug Prescriptions; Drugs, Investigational; Empathy; Gefitinib; Humans; Legislation, Drug; Patient Advocacy; Quinazolines; United States; United States Food and Drug Administration | 2003 |
Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line; Cell Line, Tumor; Enzyme Inhibitors; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Transgenic; Microfilament Proteins; Mitogen-Activated Protein Kinases; Muscle Proteins; Phosphorylation; Precancerous Conditions; Quinazolines; Receptors, Estrogen; Signal Transduction | 2003 |
Combinatorial efficacy achieved through two-point blockade within a signaling pathway-a chemical genetic approach.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Division; Cell Line, Tumor; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Glioma; Humans; Mice; Mice, Inbred BALB C; Naphthalenes; NIH 3T3 Cells; Oncogene Proteins v-erbB; Phosphoinositide-3 Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Signal Transduction; Transduction, Genetic; Xenograft Model Antitumor Assays | 2003 |
Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Epidermal Growth Factor; Estradiol; Estrogen Receptor Modulators; Female; Fulvestrant; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Receptors, Estrogen; Signal Transduction; Tumor Cells, Cultured | 2004 |
Modulation of tumor growth and tumor induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 in renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Cell Division; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Male; Middle Aged; Neovascularization, Pathologic; Quinazolines | 2004 |
Pharmacy practice issues with targeted therapy for lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Costs; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Insurance, Health, Reimbursement; Lung Neoplasms; Patient Compliance; Patient Education as Topic; Pharmaceutical Services; Quinazolines; United States | 2003 |
Epidermal growth factor receptor-targeted therapy and symptom improvement in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; United States | 2003 |
[A case of peritonitis carcinomatosa of pulmonary adenocarcinoma in which gefitinib was effective].
Topics: Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Ascitic Fluid; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Peritonitis; Quinazolines | 2004 |
New drugs 04, part 1.
Topics: Adalimumab; Alefacept; alpha-Galactosidase; Anisoles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antioxidants; Antiprotozoal Agents; Antirheumatic Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Drug Approval; Drug Therapy; Fabry Disease; Gefitinib; Humans; Iduronidase; Indoles; Isoenzymes; Lentigo; Lung Neoplasms; Migraine Disorders; Mucopolysaccharidosis I; Nitro Compounds; Patient Education as Topic; Propylamines; Psoriasis; Pyrrolidines; Quinazolines; Recombinant Fusion Proteins; Serotonin Receptor Agonists; Thiazoles; Tryptamines | 2004 |
Novel cancer therapies: targeting the molecules.
Topics: Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Farnesyltranstransferase; Gefitinib; Humans; Lymphoma, B-Cell; Medical Oncology; Neoplasms; Quinazolines; Rituximab | 2003 |
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses c-Src and Pak1 pathways and invasiveness of human cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Survival; CSK Tyrosine-Protein Kinase; Cytoskeleton; Disease Progression; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; p21-Activated Kinases; Phenotype; Phosphorylation; Precipitin Tests; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; src-Family Kinases; Transfection; Vinculin | 2004 |
ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Down-Regulation; Drug Synergism; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; Paclitaxel; Phosphorylation; Quinazolines; Time Factors | 2004 |
[Transient liver injury caused by gefitinib].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Response to gefitinib in pericardial effusion due to lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Pericardial Effusion; Protein-Tyrosine Kinases; Quinazolines | 2003 |
Lung cancer: looking ahead in 2004.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2004 |
United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.
Topics: Adolescent; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Administration Schedule; Drug Approval; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Middle Aged; Models, Chemical; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2004 |
Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Topics: Acneiform Eruptions; Adenocarcinoma; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Treatment Outcome | 2004 |
As targeted therapies evolve, challenges remain.
Topics: Animals; Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Piperazines; Pyrimidines; Quinazolines | 2004 |
[Advanced lung cancer of performance status 3 successfully treated by gefitinib--a case report].
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pain, Intractable; Quality of Life; Quinazolines | 2004 |
Induction of remission in a patient with metastatic breast cancer refractory to trastuzumab and chemotherapy following treatment with gefitinib ('Iressa', ZD1839).
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Female; Gefitinib; Humans; Lymph Nodes; Middle Aged; Quinazolines; Receptors, Growth Factor; Remission Induction; Skin Neoplasms; Trastuzumab | 2004 |
Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Smoking | 2004 |
Prevention of renal vascular and glomerular fibrosis by epidermal growth factor receptor inhibition.
Topics: Animals; Capillaries; Collagen; Collagen Type I; Creatinine; Endothelin-1; ErbB Receptors; Fibrosis; Gefitinib; Gene Expression Regulation; Genes, Reporter; Glomerulosclerosis, Focal Segmental; Hypertension; Ischemia; Kidney; Kidney Cortex; Kidney Diseases; Kidney Glomerulus; Male; MAP Kinase Signaling System; Mice; Mice, Transgenic; Necrosis; NG-Nitroarginine Methyl Ester; Nitric Oxide; Phosphorylation; Promoter Regions, Genetic; Protein Processing, Post-Translational; Proteinuria; Quinazolines; Rats; Rats, Sprague-Dawley | 2004 |
Cutaneous side effects in non-small cell lung cancer patients treated with Iressa (ZD1839), an inhibitor of epidermal growth factor.
Topics: Acneiform Eruptions; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Quinazolines; Retrospective Studies; Signal Transduction; Skin; Urticaria | 2004 |
Predictors of clinical response of non-small cell cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Treatment of HER-2/neu overexpressing breast cancer xenograft models with trastuzumab (Herceptin) and gefitinib (ZD1839): drug combination effects on tumor growth, HER-2/neu and epidermal growth factor receptor expression, and viable hypoxic cell fraction
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Membrane; Cell Survival; Coloring Agents; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Hypoxia; Mammary Neoplasms, Animal; Mice; Mice, SCID; Neoplasm Transplantation; Phosphorylation; Quinazolines; Receptor, ErbB-2; Subcellular Fractions; Tetrazolium Salts; Thiazoles; Time Factors; Trastuzumab | 2004 |
Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for proliferation.
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Cell Survival; Down-Regulation; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Ubiquitin-Protein Ligases | 2004 |
Gefitinib ('Iressa', ZD1839) inhibits the growth response of bladder tumour cell lines to epidermal growth factor and induces TIMP2.
Topics: Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Protease Inhibitors; Quinazolines; Tissue Inhibitor of Metalloproteinase-2; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2004 |
[Screening of antiangiogenic compound].
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cyclooxygenase 2; Drug Screening Assays, Antitumor; Gefitinib; Humans; Interleukin-1; Isoenzymes; Lung Neoplasms; Membrane Proteins; Mice; Prostaglandin-Endoperoxide Synthases; Quinazolines; Transforming Growth Factor alpha | 2004 |
[Structure-activity relationship analysis].
Topics: Antineoplastic Agents; Benzamides; Camptothecin; Docetaxel; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Imatinib Mesylate; Irinotecan; Macrolides; Oligopeptides; Paclitaxel; Piperazines; Pyrimidines; Quinazolines; Structure-Activity Relationship; Taxoids; Topotecan; Vinblastine | 2004 |
Targeting targeted therapy.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2004 |
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Heterozygote; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2004 |
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
Topics: Adenocarcinoma; Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Controlled Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Mutation, Missense; Phosphorylation; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Treatment Outcome; United States | 2004 |
Medicine. Why a new cancer drug works well, in some patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.
Topics: Animals; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Quinazolines | 2004 |
[The effect of IRESSA on H22 mouse hepatocellular carcinoma].
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cisplatin; Disease Models, Animal; Gefitinib; Liver Neoplasms; Mice; Quinazolines; Random Allocation; Treatment Outcome | 2004 |
Resistance to tyrosine kinase inhibition by mutant epidermal growth factor receptor variant III contributes to the neoplastic phenotype of glioblastoma multiforme.
Topics: Animals; Cell Division; Cell Line, Tumor; Cell Movement; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Swiss 3T3 Cells; Time Factors | 2004 |
Effect of type I growth factor receptor tyrosine kinase inhibitors on phosphorylation and transactivation activity of the androgen receptor in prostate cancer cells: Ligand-independent activation of the N-terminal domain of the androgen receptor.
Topics: Androgens; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Luciferases; Male; Mitogen-Activated Protein Kinases; Phosphorylation; Promoter Regions, Genetic; Prostatic Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Trans-Activators; Transcriptional Activation; Transfection; Tumor Cells, Cultured | 2004 |
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor ZD1839 on nasopharyngeal carcinoma cells].
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fluorouracil; G1 Phase; Gefitinib; Humans; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2004 |
Molecular markers to predict response to gefitinib: EGFR, ErbB-2, or more?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Confounding Factors, Epidemiologic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Protein kinase inhibitors: novel tools in cancer therapy.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Transformation, Neoplastic; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Quinazolines; Signal Transduction | 2004 |
New cancer therapeutics: target-specific in, cytotoxics out?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Drug Delivery Systems; Enzyme Inhibitors; Gefitinib; Humans; Indoles; Intracellular Signaling Peptides and Proteins; Neoplasms; Proteomics; Pyrroles; Quinazolines; Sunitinib | 2004 |
A deadly disease, a promising drug.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Gefitinib as first-line, compassionate use therapy in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Severe acute interstitial pnuemonia and gefitinib.
Topics: Acute Disease; Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Effect of gefitinib (ZD1839) on metastatic brain tumour.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Enzyme Inhibitors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Salvage Therapy; Treatment Outcome | 2004 |
The miracle of Iressa.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Look before you leap.
Topics: Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Neoplasms; Patient Selection; Quinazolines | 2004 |
Selecting the right patient for tumor therapy.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Quinazolines | 2004 |
EGFR inhibitors square off at ASCO.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Industry; Economic Competition; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Panitumumab; Quinazolines | 2004 |
An image worth a thousand lives?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Benzoquinones; Bibenzyls; Diagnostic Imaging; Down-Regulation; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 1-Ring; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Magnetic Resonance Imaging; Molecular Probe Techniques; Mutation; Neoplasms; Phthalazines; Physiological Phenomena; Positron-Emission Tomography; Protein Binding; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptors, Vascular Endothelial Growth Factor; Rifabutin; Stilbenes; Tissue Distribution; Trastuzumab | 2004 |
Cancer. A bull's eye for targeted lung cancer therapy.
Topics: Adenocarcinoma; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Controlled Clinical Trials as Topic; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Japan; Ligands; Lung Neoplasms; Mutation; Phosphorylation; Protein Structure, Tertiary; Quinazolines; Sequence Deletion; Smoking; Treatment Outcome; United States | 2004 |
Japanese chest physicians face hopes and enigmas of gefitinib, a molecular targeting drug for lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839).
Topics: Antineoplastic Agents; Apoptosis; Camptothecin; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Irinotecan; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
From bench to bedside and back again?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Orphan Drug Production; Quinazolines; Research Design | 2004 |
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ('Iressa', ZD1839) in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Membrane; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2004 |
Side effects of therapy: case 1. Nephrotic syndrome associated with gefitinib therapy.
Topics: Aged; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasms, Squamous Cell; Nephrotic Syndrome; Quinazolines | 2004 |
Tamoxifen: Dr. Jekyll and Mr. Hyde?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Breast Neoplasms; Carcinoma, Ductal, Breast; Chemotherapy, Adjuvant; Clinical Trials as Topic; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Gefitinib; Humans; Neoplasms, Hormone-Dependent; Phosphorylation; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Retrospective Studies; Selective Estrogen Receptor Modulators; Tamoxifen; Trastuzumab | 2004 |
Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
Topics: Animals; Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Estrogen Receptor Modulators; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transplantation, Heterologous; Up-Regulation | 2004 |
Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines | 2004 |
Epidermal growth factor receptor mutations: a new insight.
Topics: Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Mutations in the epidermal growth factor receptor tyrosine kinase may predict response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2004 |
Gefitinib in recurrent glioblastoma.
Topics: Antineoplastic Agents; Brain Neoplasms; Clinical Trials as Topic; Disease-Free Survival; Endpoint Determination; Epidermal Growth Factor; Gefitinib; Glioblastoma; Humans; Neoplasm Recurrence, Local; Protein-Tyrosine Kinases; Quinazolines; Reproducibility of Results | 2004 |
[Interstitial pneumonia due to gefitinib followed in detail by high-resolution CT in a patient with adenocarcinoma of the lung].
Topics: Adenocarcinoma; Aged; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2004 |
Cancer: understanding the target.
Topics: Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Quinazolines; Randomized Controlled Trials as Topic | 2004 |
The story of gefitinib, an EGFR kinase that works in lung cancer.
Topics: Antineoplastic Agents; Enzyme Inhibitors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Salvage Therapy; Sex Factors; Time Factors; Treatment Outcome | 2004 |
Direct inhibition of EGF receptor activation in vascular endothelial cells by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Cell Culture Techniques; Endothelial Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Neovascularization, Pathologic; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Risk Assessment; Statistics, Nonparametric; Survival Analysis; Treatment Outcome | 2004 |
Imatinib: paradigm or anomaly?
Topics: Antineoplastic Agents; Benzamides; Clinical Trials as Topic; Drug Design; Early Diagnosis; Gefitinib; Humans; Imatinib Mesylate; Mutation; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Receptors, Growth Factor; Signal Transduction | 2004 |
Gefitinib ('IRESSA', ZD1839) inhibits EGF-induced invasion in prostate cancer cells by suppressing PI3 K/AKT activation.
Topics: Antineoplastic Agents; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; In Situ Nick-End Labeling; Male; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
[Efficacy of gefitinib (Iressa) in the treatment of an inoperable bronchioloalveolar cell carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Early-stage lung cancer findings end a debate, put focus on next steps.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Canada; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemotherapy, Adjuvant; Cisplatin; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Quinazolines; Randomized Controlled Trials as Topic; Selection Bias; Survival Analysis; Treatment Outcome; United States; Vinblastine; Vinorelbine | 2004 |
[Gefitinib for advanced bronchioloalveolar carcinoma].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2004 |
Combined targeting of epidermal growth factor receptor and MDM2 by gefitinib and antisense MDM2 cooperatively inhibit hormone-independent prostate cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Nuclear Proteins; Oligonucleotides, Antisense; Phosphorylation; Prostatic Neoplasms; Protein Biosynthesis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2004 |
Evaluation of the therapeutic potential of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in preclinical models of bladder cancer.
Topics: Animals; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2004 |
Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours.
Topics: Acneiform Eruptions; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasms; Quinazolines | 2004 |
Targeted inhibition of the epidermal growth factor receptor-tyrosine kinase by ZD1839 ('Iressa') induces cell-cycle arrest and inhibits proliferation in prostate cancer cells.
Topics: Androgen Antagonists; Antineoplastic Agents; Cell Cycle Proteins; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Flutamide; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Tumor Suppressor Proteins | 2004 |
[Target molecules of molecular target therapy of cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Drug Delivery Systems; Gefitinib; Molecular Chaperones; Neoplasms; Quinazolines; Rituximab; Trastuzumab | 2004 |
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; Cell Line; Cell Line, Tumor; Cell Survival; DNA-Binding Proteins; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Milk Proteins; Mitogen-Activated Protein Kinases; Mutation; Mutation, Missense; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Sequence Deletion; Signal Transduction; STAT5 Transcription Factor; Trans-Activators; Transfection; Tyrosine | 2004 |
Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mitogen-Activated Protein Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Cell growth after withdrawal of gefitinib ("Iressa", ZD1839) in human lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Coloring Agents; Dose-Response Relationship, Drug; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Tetrazolium Salts; Thiazoles; Time Factors | 2004 |
Predicting sensitivity of non-small-cell lung cancer to gefitinib: is there a role for P-Akt?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Predictive Value of Tests; Prognosis; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2004 |
Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Organophosphorus Compounds; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2004 |
[Recurrence of non-small cell lung cancer after successful treatment with gefitinib--report of three cases].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Pharmacogenomics. Cancer sharpshooters rely on DNA tests for a better aim.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Mutation; Pharmacogenetics; Quinazolines | 2004 |
Exacerbation of psoriasis after treatment with an EGFR tyrosine kinase inhibitor.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Psoriasis; Quinazolines; Recurrence; Severity of Illness Index | 2004 |
'Fast-track' drug approvals hit speed bumps in Japan.
Topics: Drug Approval; Drug Evaluation; Gefitinib; Isoxazoles; Japan; Leflunomide; Public Policy; Quinazolines | 2004 |
Molecular mechanisms of ZD1839-induced G1-cell cycle arrest and apoptosis in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Caspases; CDC2-CDC28 Kinases; Cell Cycle Proteins; Cell Division; Cyclin-Dependent Kinase 2; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase 6; Cyclin-Dependent Kinases; Enzyme Activation; fas Receptor; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2004 |
Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
Topics: Angiogenesis Inhibitors; Apoptosis; Carcinoma, Squamous Cell; Celecoxib; Cell Cycle; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Synergism; Drug Therapy, Combination; Endothelium, Vascular; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Isoenzymes; Laryngeal Neoplasms; Lymphatic Metastasis; Membrane Proteins; Neovascularization, Pathologic; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured; Tumor Stem Cell Assay; Tyrphostins | 2004 |
Antitumor activity of gefitinib in malignant rhabdoid tumor cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Division; ErbB Receptors; Female; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; Immunoenzyme Techniques; In Vitro Techniques; Infant; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Quinazolines; Rhabdoid Tumor; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
Research unveils the 'who' and 'why' of gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines; Trastuzumab | 2004 |
Gefitinib reverses breast cancer resistance protein-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Estrone; Gefitinib; Humans; Irinotecan; Neoplasm Proteins; Quinazolines; Topotecan | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Quinazolines | 2004 |
EGFR mutations and sensitivity to gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Tamoxifen resistance in breast cancer cells is accompanied by an enhanced motile and invasive phenotype: inhibition by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Phenotype; Quinazolines; Tamoxifen | 2004 |
Synergistic antiproliferative and apoptotic effects induced by mixed epidermal growth factor receptor inhibitor ZD1839 and nitric oxide donor in human prostatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Caspases; Cell Division; Cell Line, Tumor; Ceramides; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Mitochondria; Nitric Oxide Donors; Nitroprusside; Prostatic Neoplasms; Quinazolines; Reactive Oxygen Species | 2005 |
[Clinical observation of ZD1839 in treating 32 cases of non-small-cell lung cancer].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2004 |
Effects of gefitinib on serum epidermal growth factor receptor and HER2 in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Time Factors; Treatment Outcome | 2004 |
Gefitinib (Iressa) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prospective Studies; Quinazolines | 2004 |
Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasms; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2 | 2004 |
Gefitinib as a first line of therapy in non-small cell lung cancer with brain metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2004 |
Retrospective analysis of the predictive factors associated with the response and survival benefit of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2004 |
Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; Chromones; Cisplatin; Comet Assay; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Etoposide; Gefitinib; Humans; Melphalan; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors | 2004 |
Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinases; Neoplasms, Experimental; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2004 |
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Gefitinib enhances the antitumor activity and oral bioavailability of irinotecan in mice.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Availability; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Irinotecan; Mice; Mice, Inbred ICR; Mice, SCID; Neoplasm Proteins; Osteosarcoma; Quinazolines; Xenograft Model Antitumor Assays | 2004 |
Small cell lung cancer cells express EGFR and tyrosine phosphorylation of EGFR is inhibited by gefitinib ("Iressa", ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Small Cell; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tumor Cells, Cultured; Tyrosine | 2004 |
Synergistic interaction between gefitinib (Iressa, ZD1839) and paclitaxel against human gastric carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Base Pair Mismatch; Carrier Proteins; Cell Division; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA Repair; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Fluorouracil; Formazans; G1 Phase; G2 Phase; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Models, Biological; MutL Protein Homolog 1; Neoplasm Proteins; Nuclear Proteins; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Quinazolines; Stomach Neoplasms; Tetrazolium Salts | 2004 |
Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
[Two cases of lung cancer in the third decade of life].
Topics: Adult; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed | 2004 |
Approved use of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Labeling; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States | 2004 |
Immunity in medicine.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Rate; Treatment Outcome | 2004 |
Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells.
Topics: Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Cyclooxygenase 2; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Membrane Proteins; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Quinazolines; Signal Transduction; Tyrphostins; Ubiquitin | 2004 |
Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Enzyme Inhibitors; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2005 |
Dominant papillary subtype is a significant predictor of the response to gefitinib in adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Phosphorylation; Quinazolines; Time Factors; Treatment Outcome | 2004 |
ERBB2 kinase mutations in lung-cancer tumours.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2004 |
Complexity in the treatment of pulmonary large cell neuroendocrine carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Large Cell; Chemotherapy, Adjuvant; Cisplatin; Etoposide; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroendocrine Tumors; Quinazolines; Radiotherapy, Adjuvant; Retrospective Studies; Treatment Failure; Treatment Outcome | 2005 |
Inhibition of mutant EGF receptors by gefitinib: targeting an Achilles' heel of lung cancer.
Topics: ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2004 |
Trichomegaly following treatment with gefitinib (ZD1839).
Topics: Antineoplastic Agents; Drug Eruptions; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Hair Diseases; Humans; Middle Aged; Quinazolines | 2004 |
Complications of therapy in cancer patients: Case 1. Paronychia and skin hyperpigmentation induced by gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Hyperpigmentation; Lung Neoplasms; Middle Aged; Paronychia; Protein-Tyrosine Kinases; Quinazolines | 2004 |
Additive interaction of gefitinib ('Iressa', ZD1839) and ionising radiation in human tumour cells in vitro.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; DNA Damage; Flow Cytometry; Gefitinib; HeLa Cells; Humans; Quinazolines; Radiation, Ionizing | 2004 |
Laminin-5 offsets the efficacy of gefitinib ('Iressa') in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Hepatocellular; Cell Adhesion Molecules; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Kalinin; Phosphorylation; Predictive Value of Tests; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Acute gefitinib-induced pneumonitis.
Topics: Acute Disease; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Pneumonia; Quinazolines; Respiratory Insufficiency | 2004 |
Combining targeted agents in lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2004 |
Practical management of patients with non-small-cell lung cancer treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Interactions; ErbB Receptors; Exanthema; Eye; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Patient Education as Topic; Quinazolines; Radiography | 2005 |
Prompt control of bronchorrhea in patients with bronchioloalveolar carcinoma treated with gefitinib (Iressa).
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum | 2005 |
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Colorectal Neoplasms; Deoxycytidine; Drug Screening Assays, Antitumor; Female; Gefitinib; Gemcitabine; Humans; Melanoma; Neoplasms; Neoplasms, Unknown Primary; Organoplatinum Compounds; Ovarian Neoplasms; Oxaliplatin; Quinazolines; Sarcoma; Skin Neoplasms; Stomach Neoplasms; Uveal Neoplasms | 2004 |
[Effect of epidermal growth factor receptor-selective tyrosine kinase inhibitor gefitinib on nasopharyngeal carcinoma xenografts].
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Cisplatin; Drug Synergism; ErbB Receptors; Female; Gefitinib; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Random Allocation | 2004 |
Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
Topics: Antineoplastic Agents; Blotting, Southern; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cyclin D1; DNA; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Prognosis; Protein Kinase Inhibitors; Quinazolines; S Phase; Time Factors | 2004 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Cell Cycle; Cell Division; Cell Line, Tumor; Dose-Response Relationship, Drug; Down-Regulation; Drug Administration Schedule; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptors, Somatomedin; RNA, Messenger | 2004 |
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Gefitinib; Lung Neoplasms; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Tyrosine; Xenograft Model Antitumor Assays | 2004 |
CYFRA 21-1 level predicts survival in non-small-cell lung cancer patients receiving gefitinib as third-line therapy.
Topics: Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratin-19; Keratins; Lung Neoplasms; Male; Prognosis; Quinazolines | 2005 |
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.
Topics: Base Sequence; Cell Line, Tumor; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Sequence Data; Neoplasms; Piperidines; Quinazolines; Transfection; Vascular Endothelial Growth Factor Receptor-2 | 2004 |
An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors.
Topics: Cell Line, Tumor; Colorectal Neoplasms; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Silencing; Genes, erbB-1; Genetic Predisposition to Disease; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Introns; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; RNA, Small Interfering; Skin | 2004 |
PLC and PI3K pathways are important in the inhibition of EGF-induced cell migration by gefitinib ('Iressa', ZD1839).
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Type C Phospholipases | 2004 |
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Topics: Adenosine Triphosphate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Calcium; Calcium Signaling; Carcinoma, Squamous Cell; Cetuximab; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Protein Kinase Inhibitors; Quinazolines; Receptors, Purinergic; Tumor Cells, Cultured | 2004 |
Differential radiosensitisation by ZD1839 (Iressa), a highly selective epidermal growth factor receptor tyrosine kinase inhibitor in two related bladder cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Division; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2005 |
Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; DNA, Complementary; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Growth Substances; Humans; Quinazolines; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2004 |
[French experience of gefitinib in non-small cell bronchial carcinoma].
Topics: Adult; Aged; Antineoplastic Agents; Bronchial Neoplasms; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Epidermal Growth Factor; Female; Gefitinib; Humans; Male; Middle Aged; Palliative Care; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sex Factors; Smoking | 2004 |
High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Adenosquamous; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Phosphorylation; Quinazolines; Sequence Homology, Nucleic Acid; Taiwan | 2004 |
Coexpression of matrix metalloproteinase-7 (MMP-7) and epidermal growth factor (EGF) receptor in colorectal cancer: an EGF receptor tyrosine kinase inhibitor is effective against MMP-7-expressing cancer cells.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Cell Nucleus; Colorectal Neoplasms; Cytoplasm; DNA-Binding Proteins; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Male; Matrix Metalloproteinase 7; Middle Aged; Phosphorylation; Protein Transport; Quinazolines; Smad4 Protein; Trans-Activators; Transfection; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Endothelial Cells; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oxygen; Piperidines; Quinazolines; Radiotherapy; Signal Transduction; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2004 |
Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Quinazolines; Thyroid Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2004 |
[New era in cancer therapy. Gefitinib: small molecule--strong action].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Clinical Trials, Phase IV as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Time Factors | 2004 |
[Successes in late solid tumors. New therapy offer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Colorectal Neoplasms; Combined Modality Therapy; ErbB Receptors; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Humans; Leucovorin; Organoplatinum Compounds; Palliative Care; Quinazolines; Salvage Therapy; Time Factors | 2004 |
Somatic mutations of EGFR in colorectal cancers and glioblastomas.
Topics: Brain Neoplasms; Colorectal Neoplasms; DNA, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, erbB-1; Glioblastoma; Point Mutation; Quinazolines | 2004 |
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Caspase 8; Caspases; Cell Line; Cell Line, Tumor; Cell Membrane; Cell Survival; Dose-Response Relationship, Drug; Down-Regulation; Enzyme Inhibitors; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoglobulin Variable Region; Jurkat Cells; Membrane Potentials; Models, Biological; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Signal Transduction; Single-Chain Antibodies; Time Factors | 2005 |
Signaling mechanisms that mediate invasion in prostate cancer cells.
Topics: Androgens; Cell Line, Tumor; Cell Proliferation; Collagen; Drug Combinations; Electrophoresis, Polyacrylamide Gel; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; Quinazolines; Receptors, Androgen; Signal Transduction; Transfection; Tyrosine | 2004 |
Increase in amphiregulin and epiregulin in prostate cancer xenograft after androgen deprivation-impact of specific HER1 inhibition.
Topics: Amphiregulin; Androgens; Animals; EGF Family of Proteins; Epidermal Growth Factor; Epiregulin; ErbB Receptors; Gefitinib; Gene Expression; Glycoproteins; Intercellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, SCID; Orchiectomy; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2005 |
Gefitinib therapy for life-threatening laryngeal papillomatosis.
Topics: Adolescent; Antiviral Agents; Bronchoscopy; ErbB Receptors; Gefitinib; Humans; Laryngeal Neoplasms; Male; Papilloma; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Recurrence; Treatment Outcome | 2005 |
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2005 |
Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Diethylnitrosamine; ErbB Receptors; Gefitinib; Liver Cirrhosis; Liver Neoplasms; Male; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Innovative therapy for patients with brain metastases: oral treatments.
Topics: Administration, Oral; Brain Neoplasms; Capecitabine; Combined Modality Therapy; Dacarbazine; Deoxycytidine; Fluorouracil; Gefitinib; Humans; Quinazolines; Temozolomide | 2004 |
[A case of postoperative recurrent lung cancer with chronic renal failure and respiratory failure successfully treated with gefitinib].
Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Postoperative Period; Quality of Life; Quinazolines; Respiratory Insufficiency | 2005 |
[Targeted drugs in radiation therapy].
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Mice; Mice, Nude; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Radiation-Sensitizing Agents; Randomized Controlled Trials as Topic; Trastuzumab; Tumor Cells, Cultured | 2004 |
Immunohistochemical detection of HER1/HER2 can be considered a predictive marker of gefitinib activity in non-small-cell lung cancer?
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-2 | 2005 |
Gefitinib and cisplatin-based chemotherapy in non-small-cell lung cancer: simply a bad combination?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials, Phase III as Topic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Quinazolines | 2005 |
Keeping pace with innovation.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Scientists hopeful as they uncover molecular clues to prostate cancer.
Topics: Androgen Receptor Antagonists; Androgens; Antineoplastic Agents; Biomarkers, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Tumor Suppressor; Humans; Male; Phosphoric Monoester Hydrolases; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Receptors, Androgen; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Up-Regulation | 2005 |
Purpuric drug eruption possibly due to gefinitib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Ecchymosis; Female; Gefitinib; Humans; Purpura; Quinazolines | 2005 |
Iressa's fall from grace points to need for better clinical trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate | 2005 |
Implications of the Iressa Survival Evaluation in Lung Cancer trial and the future of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis | 2005 |
Cellular targets of gefitinib.
Topics: Animals; Antineoplastic Agents; Chlorocebus aethiops; COS Cells; ErbB Receptors; Gefitinib; HeLa Cells; Humans; Protein Kinase Inhibitors; Proteomics; Quinazolines; Structure-Activity Relationship | 2005 |
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Decision Making; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2005 |
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro.
Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Dihydrotestosterone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; Quinazolines; Tosyl Compounds; Transplantation, Heterologous | 2005 |
Top 10 health stories of 2004.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Antidepressive Agents; Antineoplastic Agents; Biomedical Research; Cholesterol, LDL; Cloning, Organism; Coronary Disease; Delivery of Health Care; Dementia; Gefitinib; Humans; Influenza Vaccines; Insurance, Health; Lactones; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Registries; Sulfones; Walking | 2004 |
Gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2005 |
The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.
Topics: Adult; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Homology, Amino Acid; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Safety profile of gefitinib in advanced non-small cell lung cancer elderly patients with chronic renal failure: two clinical cases.
Topics: Administration, Oral; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Comorbidity; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Quinazolines; Treatment Outcome | 2005 |
Failing survival advantage in crucial trial, future of Iressa is in jeopardy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Drug Approval; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Survival Analysis; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Amphiregulin; Antineoplastic Agents; Camptothecin; Cell Line, Tumor; Drug Screening Assays, Antitumor; EGF Family of Proteins; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glycoproteins; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Phosphorylation; Quinazolines; Reactive Oxygen Species; Signal Transduction; Stomach Neoplasms; Transforming Growth Factor alpha; Tyrosine | 2005 |
Gefitinib ("Iressa", ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells.
Topics: Adenocarcinoma; Amphiregulin; Antineoplastic Agents; Camptothecin; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Interleukin-8; Irinotecan; Metalloproteases; Phosphorylation; Quinazolines; Reactive Oxygen Species; Stomach Neoplasms; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2005 |
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.
Topics: Aged; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Models, Structural; Molecular Structure; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; RNA, Neoplasm; Sequence Analysis, DNA; Sequence Analysis, RNA | 2005 |
Chasing mutations in the epidermal growth factor in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, abl; Humans; Lung Neoplasms; Mutation; Quinazolines | 2005 |
APL during gefitinib treatment for non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines | 2005 |
ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CHO Cells; Cricetinae; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3 | 2005 |
EGFR mutations in non-small cell lung carcinomas may predict response to gefitinib: extension of an emerging paradigm.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2005 |
[IRESSA in the treatment of advanced non-small-cell lung cancer patients who failed to respond previous chemotherapy].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction | 2004 |
Combined targeting of the estrogen receptor and the epidermal growth factor receptor in non-small cell lung cancer shows enhanced antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, SCID; Mitogen-Activated Protein Kinase 3; Quinazolines; Receptors, Estrogen; Xenograft Model Antitumor Assays | 2005 |
Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Topics: Adenosine Triphosphate; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Breast Neoplasms; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Cell Membrane; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Irinotecan; Lung Neoplasms; Mitoxantrone; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
Topics: Amphiregulin; Antineoplastic Agents; Apoptosis; Bone Marrow Cells; Cell Proliferation; EGF Family of Proteins; ErbB Receptors; Gefitinib; Gene Expression Profiling; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Multiple Myeloma; Oligonucleotide Array Sequence Analysis; Plasma Cells; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2005 |
Gefitinib ('Iressa', ZD1839) is active against brain metastases in a 77 year old patient.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured | 2005 |
Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).
Topics: Adenosine Triphosphate; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neoplasm Proteins; Phosphorylation; Quinazolines; Tumor Cells, Cultured | 2005 |
Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Oligonucleotides, Antisense; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Transcriptional Activation | 2005 |
Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Drug Administration Schedule; Drug Interactions; Female; Gefitinib; Mice; Mice, Nude; Paclitaxel; Quinazolines; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor double targeting by a tyrosine kinase inhibitor (Iressa) and a monoclonal antibody (Cetuximab). Impact on cell growth and molecular factors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cetuximab; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2005 |
Radiosensitivity of tumor cell lines after pretreatment with the EGFR tyrosine kinase inhibitor ZD1839 (Iressa).
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance | 2005 |
Iressa failure raises fears about accelerated approvals.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Approval; Gefitinib; Humans; Quinazolines; Treatment Outcome | 2005 |
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; GRB2 Adaptor Protein; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Son of Sevenless Protein, Drosophila | 2005 |
Antitumor effect of Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, combined with cytotoxic agent on murine hepatocellular carcinoma.
Topics: Animals; Antineoplastic Agents; Blood Cell Count; Body Weight; Carcinoma, Hepatocellular; Cisplatin; Cytotoxins; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Liver Neoplasms; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Organ Size; Quinazolines; Spleen; Thymus Gland | 2005 |
Pharmacokinetics of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat and dog.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Dogs; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gefitinib; Injections, Intravenous; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Rats; Rats, Wistar; Sex Factors; Species Specificity | 2004 |
A man whose scapula was spared a drug-associated rash.
Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peripheral Nervous System Neoplasms; Phrenic Nerve; Protein Kinase Inhibitors; Quinazolines; Scapula; Sebaceous Glands | 2005 |
Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mutation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Efficacy of the tyrosine kinase inhibitor gefitinib in a patient with metastatic small cell lung cancer.
Topics: Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Small Cell; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Modulation of survival signaling pathways and persistence of the genotoxic stress as a basis for the synergistic interaction between the atypical retinoid ST1926 and the epidermal growth factor receptor inhibitor ZD1839.
Topics: Adamantane; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 8; Caspases; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Cinnamates; DNA Damage; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Ovarian Neoplasms; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Signal Transduction; Vulvar Neoplasms | 2005 |
Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines.
Topics: Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Transplantation; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Thyroid Neoplasms; Transplantation, Heterologous | 2005 |
[Gefitinib therapy in non-small-cell lung cancer].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Finland; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Risk Assessment; Survival Analysis; Treatment Outcome | 2005 |
Cytochrome P450-dependent metabolism of gefitinib.
Topics: Cells, Cultured; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Gefitinib; Humans; Microsomes, Liver; Quinazolines | 2005 |
Predictors of the response to gefitinib in refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Quinazolines; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Targeting the mevalonate pathway inhibits the function of the epidermal growth factor receptor.
Topics: Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Binding Sites; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colonic Neoplasms; Drug Synergism; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mevalonic Acid; Mitogen-Activated Protein Kinases; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry.
Topics: Animals; Biliary Tract Neoplasms; Chromatography, High Pressure Liquid; Drug Stability; ErbB Receptors; Female; Gefitinib; Humans; Liver; Mass Spectrometry; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Skin | 2005 |
Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Fatal Outcome; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Pulmonary Fibrosis; Quinazolines | 2005 |
Gefitinib does not increase survival in lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; Gefitinib; Genotype; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
FDA Oncology Committee debates Iressa's status following negative trial results.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Approval; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2005 |
EGFR pharmacogenomics: the story continues to mutate and evolve.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic | 2005 |
Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Models, Chemical; Mutation; Neoplasm Transplantation; Neoplasms; Quinazolines; Rats; Rats, Nude; Scintillation Counting; Signal Transduction; Time Factors; Tissue Distribution | 2005 |
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Topics: Acetylation; Androgen Receptor Antagonists; Androgens; Cell Line, Tumor; Chromatin; Chromatin Immunoprecipitation; Dihydrotestosterone; ErbB Receptors; Gefitinib; Histones; Humans; Immunoglobulin Fragments; Lapatinib; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Response Elements; Transcription, Genetic | 2005 |
EGFR Mutation status in Japanese lung cancer patients: genotyping analysis using LightCycler.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Mutation, Missense; Polymerase Chain Reaction; Quinazolines | 2005 |
Selective inhibition of TNF-alpha-induced activation of mitogen-activated protein kinases and metastatic activities by gefitinib.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines; Tumor Necrosis Factor-alpha | 2005 |
The effect of ZD1839 (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor, in combination with cisplatin, on apoptosis in SCC-15 cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Tumor Suppressor Protein p53 | 2005 |
Pulmonary adenocarcinomas with mutant epidermal growth factor receptors.
Topics: Adenocarcinoma; Antineoplastic Agents; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Ligands; Lung Neoplasms; Mutation, Missense; Quinazolines; Sequence Deletion; Stromal Cells; Transforming Growth Factor alpha | 2005 |
High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Treatment Failure | 2005 |
Third-line chemotherapy for advanced non-small-cell lung cancer--is there enough evidence to support its use?
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2005 |
Interstitial pneumonia during gefitinib treatment of non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Treatment Outcome | 2005 |
Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Spain; Treatment Outcome | 2005 |
EGFR tyrosine kinase domain mutations in human gliomas.
Topics: Astrocytoma; Brain Neoplasms; Carcinoma; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Glioblastoma; Glioma; Humans; Lung Neoplasms; Mutation; Oligodendroglioma; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2005 |
[Treatment of non-small cell lung cancer with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines; Treatment Outcome | 2005 |
Will lung cancer targeting hit its mark?
Topics: Antineoplastic Agents; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
A curious link between epidermal growth factor receptor amplification and survival: effect of "allele dilution" on gefitinib sensitivity?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines | 2005 |
Reduction of PTEN protein and loss of epidermal growth factor receptor gene mutation in lung cancer with natural resistance to gefitinib (IRESSA).
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Molecular Sequence Data; Mutation; p38 Mitogen-Activated Protein Kinases; Phosphoric Monoester Hydrolases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Tumor Cells, Cultured; Tumor Suppressor Proteins | 2005 |
Changes in angiogenic growth factor levels after gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Angiogenesis Inducing Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Middle Aged; Quinazolines; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Vascular Endothelial Growth Factors | 2005 |
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
Topics: Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Chemotaxis; Collagen; Dose-Response Relationship, Drug; Drug Combinations; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Laminin; Male; MAP Kinase Signaling System; Microscopy, Fluorescence; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphatidylinositol 3-Kinases; Phosphatidylinositol Diacylglycerol-Lyase; Phosphoinositide Phospholipase C; Phosphoric Monoester Hydrolases; Phosphorylation; Prostatic Neoplasms; Proteoglycans; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Proteins; Urokinase-Type Plasminogen Activator | 2005 |
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Topics: Aminoquinolines; Aniline Compounds; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Organic Chemicals; Phosphorylation; Quinazolines; Quinolines; Receptor, ErbB-2; Sequence Analysis, DNA; Signal Transduction; Tumor Cells, Cultured | 2005 |
HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Dose-Response Relationship, Drug; ErbB Receptors; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Transfection; Tumor Suppressor Proteins | 2005 |
EGFR mutation and response of lung cancer to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Point Mutation; Quinazolines | 2005 |
[Non-small-cell lung cancer third-line therapy with gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Gefitinib (ZD1839, Iressa) in non-small-cell lung cancer: a review of clinical trials from a daily practice perspective.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Databases, Factual; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Quinazolines | 2005 |
Absence of epidermal growth factor receptor exon 18-21 mutation in hepatocellular carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Hepatocellular; Cell Transformation, Neoplastic; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Liver Neoplasms; Male; Middle Aged; Molecular Sequence Data; Point Mutation; Quinazolines; Sequence Analysis, DNA | 2005 |
EGFR mutations in malignant pleural effusion of non-small cell lung cancer: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Positron-Emission Tomography; Quinazolines; Treatment Outcome | 2005 |
Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Trastuzumab; Xenograft Model Antitumor Assays | 2005 |
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cetuximab; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Piperidines; Quinazolines; Taxoids | 2005 |
Gefitinib has the potential of activating cell immunity against malignant cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Immunity, Cellular; Lung Neoplasms; Quinazolines | 2005 |
Asian ethnicity and adenocarcinoma histology continues to predict response to gefitinib in patients treated for advanced non-small cell carcinoma of the lung in North America.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; North America; Predictive Value of Tests; Quinazolines; Retrospective Studies; White People | 2005 |
Serum carcinoembryonic antigen as a predictive marker for sensitivity to gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Retrospective Studies; Survival Analysis | 2005 |
Gefitinib is more effective in never-smokers with non-small-cell lung cancer: experience among Asian patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2005 |
Updated data from the Iressa survival in lung cancer trial.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Multicenter Studies as Topic; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Smoking | 2005 |
Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis.
Topics: Antineoplastic Agents; Bone Marrow Cells; Bone Neoplasms; Cell Differentiation; ErbB Receptors; Gefitinib; Humans; Osteoclasts; Quinazolines; Stromal Cells | 2005 |
Novel effects of gefitinib on mucin production in bronchioloalveolar carcinoma; two case reports.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; Dyspnea; Female; Gefitinib; Humans; Lung Neoplasms; Mucins; Quinazolines | 2005 |
Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells.
Topics: Adenosine Triphosphatases; Adenosine Triphosphate; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lung Neoplasms; Models, Statistical; Polymerase Chain Reaction; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Rhodamine 123; Tetrazolium Salts; Thiazoles | 2005 |
The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Phosphorylation; Prognosis; Quinazolines; Survival Rate; Treatment Outcome | 2005 |
Synergistic growth inhibition by Iressa and Rapamycin is modulated by VHL mutations in renal cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Mutation; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins; Ubiquitin-Protein Ligases; Von Hippel-Lindau Tumor Suppressor Protein | 2005 |
Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Treatment Outcome | 2005 |
The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Coculture Techniques; Drug Synergism; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; In Situ Nick-End Labeling; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Pyridines; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2005 |
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Failure | 2005 |
Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Ligands; Lung Neoplasms; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Receptors, Bombesin; Signal Transduction; Transforming Growth Factor alpha | 2005 |
Overcoming acquired resistance to Iressa/Tarceva with inhibitors of a different class.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalysis; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2005 |
Drug targeting: is race enough?
Topics: Asian People; Black or African American; Drug Combinations; Drug Industry; ErbB Receptors; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide Dinitrate; Pharmacogenetics; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Female; Gefitinib; Humans; Insulin-Like Growth Factor I; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Gefitinib induces myeloid differentiation of acute myeloid leukemia.
Topics: Biomarkers, Tumor; Cell Differentiation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tumor Cells, Cultured | 2005 |
Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Polymerase Chain Reaction; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies | 2005 |
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Death; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; PTEN Phosphohydrolase; Quinazolines; Sirolimus; Tumor Cells, Cultured | 2006 |
Antitumor effect of gefitinib ('Iressa') on esophageal squamous cell carcinoma cell lines in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Dose-Response Relationship, Drug; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Drug interaction between gefitinib and warfarin.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Interactions; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Thrombosis; Warfarin | 2005 |
Response to gefitinib in bronchioloalveolar carcinoma in the absence of EGFR mutation.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2005 |
Gefitinib inhibits MUC5AC synthesis in mucin-secreting non-small cell lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme-Linked Immunosorbent Assay; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Mucin 5AC; Mucins; Oncogene Protein v-akt; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured | 2005 |
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Topics: Adult; Aged; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2005 |
Somatic mutation of EGFR catalytic domain and treatment with gefitinib in colorectal cancer.
Topics: Antineoplastic Agents; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mutation; Quinazolines | 2005 |
EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Lack of mutations in EGFR in gastroenteropancreatic neuroendocrine tumors.
Topics: Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gastrointestinal Neoplasms; Gefitinib; Humans; Molecular Sequence Data; Mutation; Neuroendocrine Tumors; Pancreatic Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines | 2005 |
An overview of Eastern Cooperative Oncology Group stage III non-small cell lung cancer studies.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Quinazolines | 2005 |
ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Topics: Apoptosis Regulatory Proteins; Carcinoma, Squamous Cell; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Esophageal Neoplasms; G1 Phase; Gefitinib; Humans; Membrane Glycoproteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Tumor Necrosis Factor-alpha; Up-Regulation | 2005 |
Gefitinib is also active for carcinomatous meningitis in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningitis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Cord Neoplasms; Treatment Outcome | 2005 |
Somatic mutations in epidermal growth factor receptor underlying complete responsiveness to gefitinib in a Taiwanese female patient with metastatic adenocarcinoma of lung.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asian People; Cisplatin; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Polymerase Chain Reaction; Quinazolines | 2005 |
Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Treatment with gefitinib (ZD 1839) in a patient with advanced cutaneous squamous cell carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; Facial Neoplasms; Gefitinib; Humans; Male; Quinazolines; Skin Neoplasms | 2005 |
New studies look beyond EGFR mutations for clues to sensitivity to erlotinib.
Topics: Animals; Canada; Cell Cycle Proteins; Clinical Trials as Topic; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Multicenter Studies as Topic; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2005 |
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Gefitinib; Humans; Mass Spectrometry; Quinazolines; Reproducibility of Results; Sensitivity and Specificity | 2005 |
Myocarditis temporally related to the use of gefitinib (Iressa).
Topics: Acute Disease; Aged; Antineoplastic Agents; Drug Hypersensitivity; Fatal Outcome; Gefitinib; Humans; Male; Myocarditis; Myocytes, Cardiac; Necrosis; Quinazolines | 2005 |
Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Dosage; Gene Expression Profiling; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Common EGFR mutations conferring sensitivity to gefitinib in lung adenocarcinoma are not prevalent in human malignant mesothelioma.
Topics: Adenocarcinoma; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Mesothelioma; Point Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Gefitinib reverses chemotherapy resistance in gefitinib-insensitive multidrug resistant cancer cells expressing ATP-binding cassette family protein.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Topotecan | 2005 |
Chemopreventive and therapeutic efficacy of orally active tyrosine kinase inhibitors in a transgenic mouse model of gallbladder carcinoma.
Topics: Animals; Anticarcinogenic Agents; Antineoplastic Agents; Blotting, Western; Body Weight; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gallbladder; Gallbladder Neoplasms; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Signaling System; Mice; Mice, Transgenic; Microscopy, Fluorescence; Neoplasms, Experimental; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2; Tolonium Chloride | 2005 |
Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Benzoquinones; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Vitro Techniques; Inhibitory Concentration 50; Lactams, Macrocyclic; Piperazines; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Rifabutin; Sarcoma, Synovial; Trastuzumab | 2005 |
Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Pancreatic Neoplasms; Quinazolines | 2005 |
Epithelial membrane protein-1 is a biomarker of gefitinib resistance.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Models, Animal; Mutation; Neoplasm Proteins; Prostatic Neoplasms; Quinazolines; Receptors, Cell Surface; Xenograft Model Antitumor Assays | 2005 |
Gefitinib in patients with non-small cell lung cancer: symptomatic improvement within a few days.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2005 |
Cross-talk between cyclooxygenase-2 and epidermal growth factor receptor in non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Celecoxib; Clinical Trials as Topic; Cyclooxygenase 2; Dinoprostone; Disease Progression; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Taxoids; Treatment Outcome | 2005 |
An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Growth Processes; Cell Line, Tumor; DNA-Binding Proteins; Drug Interactions; ErbB Receptors; Gefitinib; Genes, erbB-1; Interleukin-3; Mice; Milk Proteins; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; STAT5 Transcription Factor; Trans-Activators | 2005 |
Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2005 |
Gefitinib versus cetuximab in lung cancer: round one.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2005 |
Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2005 |
BiDil raises questions about race as a marker.
Topics: Biomarkers; Black People; Clinical Trials as Topic; Dihydropyrimidine Dehydrogenase Deficiency; Dihydrouracil Dehydrogenase (NADP); Drug Approval; Drug Combinations; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Heart Failure; Humans; Hydralazine; Isosorbide; Middle Aged; Mutation; National Institutes of Health (U.S.); Polymorphism, Genetic; Quinazolines; Risk Factors; Socioeconomic Factors; Treatment Outcome; United States; Uracil; White People | 2005 |
Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Proliferation; DNA Damage; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction; Trans-Activators; Tumor Cells, Cultured; Veratrum Alkaloids | 2006 |
Gefitinib in colorectal cancer: if wishes were horses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Colorectal Neoplasms; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Gefitinib-responsive EGFR-positive colorectal cancers have different proteome profiles from non-responsive cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Division; Cell Line, Tumor; Colonic Neoplasms; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Protein Kinase Inhibitors; Proteome; Quinazolines; Receptor, ErbB-3 | 2005 |
Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genotype; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2005 |
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Asian People; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dinucleotide Repeats; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Odds Ratio; Protein-Tyrosine Kinases; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome; White People | 2005 |
Retreatment of lung adenocarcinoma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Pleural Effusion; Quinazolines; Recurrence; Retreatment; Time Factors | 2005 |
Gefitinib (Iressa) inhibits the CYP3A4-mediated formation of 7-ethyl-10-(4-amino-1-piperidino)carbonyloxycamptothecin but activates that of 7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]carbonyloxycamptothecin from irinotecan.
Topics: Camptothecin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Gefitinib; Humans; Irinotecan; Microsomes, Liver; Midazolam; Quinazolines | 2005 |
Antiangiogenic effect of ZD1839 against murine renal cell carcinoma (RENCA) in an orthotopic mouse model.
Topics: Animals; Biopsy, Needle; Blotting, Western; Carcinoma, Renal Cell; Cell Proliferation; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Kidney Neoplasms; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Quinazolines; Sensitivity and Specificity; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Interstitial lung disease associated with gefitinib.
Topics: Aged; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Chemokine CXCL10; Chemokines, CC; Chemokines, CXC; Female; Gefitinib; Glucocorticoids; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Quinazolines; Radiography; Respiratory Function Tests; Retrospective Studies | 2006 |
Interferon-alpha promotes the anti-proliferative effect of gefitinib (ZD 1839) on human colon cancer cell lines.
Topics: Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunologic Factors; Interferon-alpha; Quinazolines; Time Factors; Up-Regulation | 2005 |
Mutations of epidermal growth factor receptor of non-small cell lung cancer were associated with sensitivity to gefitinib in recurrence after surgery.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Sex Characteristics | 2005 |
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Pyrazoles; Quinazolines; Sulfonamides | 2005 |
Tumor growth inhibition by simultaneously blocking epidermal growth factor receptor and cyclooxygenase-2 in a xenograft model.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Disease Progression; DNA-Binding Proteins; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Hypopharyngeal Neoplasms; Immunoblotting; Immunoenzyme Techniques; Membrane Proteins; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Prostaglandin-Endoperoxide Synthases; Prostaglandins E; Pyrazoles; Quinazolines; RNA, Small Interfering; STAT3 Transcription Factor; Sulfonamides; Trans-Activators; Transplantation, Heterologous; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2005 |
Hair growth after gefitinib treatment.
Topics: Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Gefitinib; Hair; Humans; Hypertrichosis; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2005 |
Is the gefitinib plus trastuzumab combination feasible in breast cancer patients?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Patient Selection; Quinazolines; Reproducibility of Results; Trastuzumab; Treatment Outcome | 2005 |
Conflicting signals on US accelerated approvals.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cyclooxygenase Inhibitors; Drug Approval; Drug Industry; Drugs, Investigational; Gefitinib; Humans; Lung Neoplasms; Quinazolines; United States; United States Food and Drug Administration | 2005 |
Irreversible pan-ErbB tyrosine kinase inhibitor CI-1033 induces caspase-independent apoptosis in colorectal cancer DiFi cell line.
Topics: Amino Acid Chloromethyl Ketones; Apoptosis; Apoptosis Inducing Factor; Caco-2 Cells; Caspase 3; Caspases; Cathepsin D; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Gefitinib; Genes, Tumor Suppressor; Humans; Morpholines; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Serpins | 2005 |
Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2006 |
Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemokine CCL4; Cytokines; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Macrophage Inflammatory Proteins; Male; Middle Aged; Phenotype; Predictive Value of Tests; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Risk Factors; Skin | 2005 |
Continued gefitinib treatment after disease stabilisation prolongs survival of Japanese patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome | 2005 |
Simultaneous bilateral spontaneous pneumothorax observed during the administration of gefitinib for lung adenocarcinoma with multiple lung metastases.
Topics: Adenocarcinoma; Administration, Oral; Adult; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Pneumothorax; Quinazolines; Radiography | 2005 |
Preclinical evaluation of ZD1839 alone or in combination with oxaliplatin in a panel of human tumor cell lines -- implications for clinical use.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Lethal Dose 50; Neoplasms; Organoplatinum Compounds; Oxaliplatin; Quinazolines | 2005 |
Advances in radiosensitization.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Cetuximab; Chemotherapy, Adjuvant; Clinical Trials as Topic; Combined Modality Therapy; Drug Delivery Systems; Flucytosine; Fluorouracil; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Prodrugs; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Trastuzumab | 2004 |
[Anti-angiogenic therapy of a renal angiomyolipoma in a seriously disabled patient suffering from multiple sclerosis].
Topics: Administration, Oral; Angiogenesis Inhibitors; Angiomyolipoma; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Kidney Neoplasms; Middle Aged; Multiple Sclerosis; Neoplasms, Second Primary; Nephrectomy; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2005 |
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Glucose Tolerance Test; Gonanes; Humans; Hyperglycemia; Hypoglycemic Agents; Lung Neoplasms; Male; Metformin; Mice; Mice, SCID; Neutrophils; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Pioglitazone; Quinazolines; Thiazolidinediones; Transplantation, Heterologous; Tumor Cells, Cultured | 2005 |
Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Humans; Hypoxia; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Oxidation-Reduction; Oxygen; Positron-Emission Tomography; Quinazolines; Tissue Distribution | 2005 |
Acquired gefitinib-resistant mutation of EGFR in a chemonaive lung adenocarcinoma harboring gefitinib-sensitive mutation L858R.
Topics: Adenocarcinoma; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genetic Therapy; Humans; Mice; Mice, Nude; Mutation; Neoplasms, Experimental; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Shc Signaling Adaptor Proteins; Src Homology 2 Domain-Containing, Transforming Protein 1; STAT3 Transcription Factor; Transfection; Tumor Stem Cell Assay | 2005 |
Analogs of GnRH-I and GnRH-II inhibit epidermal growth factor-induced signal transduction and resensitize resistant human breast cancer cells to 4OH-tamoxifen.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Estrogen Antagonists; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Phosphorylation; Quinazolines; Signal Transduction; Tamoxifen; Triptorelin Pamoate | 2005 |
Differential response to gefitinib of cells expressing normal EGFR and the mutant EGFRvIII.
Topics: Cell Adhesion; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phenotype; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2005 |
Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2005 |
Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2006 |
Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Colonic Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity; Stomach Neoplasms | 2005 |
Clinicopathologic significance of the mutations of the epidermal growth factor receptor gene in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Methylation; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Exons; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Promoter Regions, Genetic; Protein Structure, Tertiary; Proto-Oncogene Proteins p21(ras); Quinazolines; Smoking; Tumor Suppressor Proteins | 2005 |
Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Growth Processes; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interleukin-3; Mice; Mutagenesis, Site-Directed; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transfection | 2005 |
A specific and sensitive assay for gefitinib using the enzyme-linked immunosorbent assay in human serum.
Topics: Animals; Blood; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Rabbits; Sensitivity and Specificity | 2005 |
Distinctive activation patterns in constitutively active and gefitinib-sensitive EGFR mutants.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chlorocebus aethiops; COS Cells; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Immunoprecipitation; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Tyrosine; Ubiquitin | 2006 |
[Cutaneous side effects of EGF-receptor inhibition and their management].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Diagnosis, Differential; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Statistics as Topic | 2006 |
Gefitinib is effective against juvenile pilocytic astrocytoma in vitro.
Topics: Astrocytoma; Cell Proliferation; Central Nervous System Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Profiling; Humans; Immunohistochemistry; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sensitivity and Specificity; Thymidine; Tumor Cells, Cultured | 2006 |
Preclinical study of a "tailor-made" combination of NK4-expressing gene therapy and gefitinib (ZD1839, Iressa) for disseminated peritoneal scirrhous gastric cancer.
Topics: Adenocarcinoma, Scirrhous; Administration, Oral; Adult; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytokines; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Genetic Therapy; Hepatocyte Growth Factor; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Peritoneum; Quinazolines; Stomach Neoplasms; Survival Analysis; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
The epidermal growth factor receptor tyrosine kinase inhibitor gefitinib sensitizes colon cancer cells to irinotecan.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Camptothecin; Cell Cycle; Cell Line, Tumor; Colonic Neoplasms; Cyclin E; DNA Topoisomerases, Type II; DNA-Binding Proteins; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Irinotecan; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2005 |
Drug discovery: playing dirty.
Topics: Animals; Benzamides; Cardiovascular Diseases; Clinical Trials as Topic; Clozapine; Depression; Drug Approval; Drug Design; Drug Evaluation, Preclinical; Drug Industry; Gefitinib; Humans; Imatinib Mesylate; Neoplasms; Piperazines; Pyrimidines; Quinazolines; Sensitivity and Specificity; Substrate Specificity; Therapeutics; United States; United States Food and Drug Administration | 2005 |
Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Safety; Survival Rate; Treatment Outcome | 2005 |
Gefitinib, a selective EGFR tyrosine kinase inhibitor, induces apoptosis through activation of Bax in human gallbladder adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gallbladder Neoplasms; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors | 2006 |
Increases of amphiregulin and transforming growth factor-alpha in serum as predictors of poor response to gefitinib among patients with advanced non-small cell lung cancers.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; EGF Family of Proteins; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Quinazolines; Transforming Growth Factor alpha | 2005 |
Single-dose clinical pharmacokinetic studies of gefitinib.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antineoplastic Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Dose-Response Relationship, Drug; Epidermal Growth Factor; Fasting; Female; Gefitinib; Humans; Injections, Intravenous; Linear Models; Male; Middle Aged; Quinazolines; Suspensions; Tablets | 2005 |
Improvements in quality of life and disease-related symptoms in patients with advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quality of Life; Quinazolines | 2005 |
Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2005 |
Erlotinib in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2005 |
Epidermal growth factor receptor inhibitors: a moving target?
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor activity determines response of colorectal cancer cells to gefitinib alone and in combination with chemotherapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Antagonism; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2005 |
Cooperative cell-growth inhibition by combination treatment with ZD1839 (Iressa) and trastuzumab (Herceptin) in non-small-cell lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Interactions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2005 |
Systemic tumor embolism mimicking gefitinib ('IRESSA')-induced interstitial lung disease in a patient with lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplastic Cells, Circulating; Quinazolines | 2005 |
Biomarkers of response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2004 |
Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor.
Topics: Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Neuroblastoma; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines | 2005 |
First-line systemic treatment with gefitinib in stage IV non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Quinazolines; Sequence Deletion; Treatment Outcome | 2005 |
New approaches in the management of lung cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Quinazolines | 2005 |
Glioblastoma multiforme and the epidermal growth factor receptor.
Topics: Amino Acid Sequence; Base Sequence; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Gene Expression; Glioblastoma; Humans; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2005 |
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Gene Deletion; Gene Expression; Genes, erbB-1; Genes, erbB-2; Glioblastoma; Humans; Male; Middle Aged; Mutation; Oligodendroglioma; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA; Signal Transduction | 2005 |
Gefitinib for previously untreated patients with non-small cell lung cancer (NSCLC)--a retrospective study of 12 patients treated in one institution.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies | 2005 |
Emerging trends in combinations of gefitinib and cytotoxic agents: new opportunities.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Therapy; Gefitinib; Humans; Lung Neoplasms; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines | 2005 |
Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Cells, Cultured; Drug Eruptions; ErbB Receptors; Facial Dermatoses; Fatal Outcome; Gefitinib; Humans; Male; Protein-Tyrosine Kinases; Quinazolines; Skin; Stevens-Johnson Syndrome | 2005 |
Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Growth Processes; Cell Line, Tumor; Cyclin D1; Drug Resistance, Neoplasm; Enzyme Activation; Enzyme Induction; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Urinary Bladder Neoplasms | 2005 |
HER3 genomic gain and sensitivity to gefitinib in advanced non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Prognosis; Quinazolines; Receptor, ErbB-3; Sex Factors; Survival Analysis | 2005 |
Skin rash and bronchoalveolar histology correlates with clinical benefit in patients treated with gefitinib as a therapy for previously treated advanced or metastatic non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Bronchoalveolar Lavage Fluid; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2006 |
Side effects related to cancer treatment: CASE 1. Hepatitis following treatment with gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2005 |
Acute myocardial infarction with lung cancer during treatment with gefitinib: the possibility of gefitinib-induced thrombosis.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Myocardial Infarction; Quinazolines; Thrombosis | 2005 |
Combining EGFR targeted therapy with chemotherapy in pancreatic cancer: is timing important?
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Pancreatic Neoplasms; Quinazolines | 2005 |
Response of some head and neck cancers to epidermal growth factor receptor tyrosine kinase inhibitors may be linked to mutation of ERBB2 rather than EGFR.
Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2005 |
Epidermal growth factor receptor inhibitors in lung cancer: smaller or larger molecules, selected or unselected populations?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines | 2005 |
Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Culture Techniques; Cetuximab; Dimerization; ErbB Receptors; Exanthema; Gefitinib; Humans; Keratinocytes; Ligands; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2006 |
Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Eruptions; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2005 |
EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2006 |
Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Clinical Trials as Topic; Drug Resistance, Neoplasm; Estradiol; Estrogens; Female; Fulvestrant; Gefitinib; Humans; Mice; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Prognosis; Quinazolines; Receptor Cross-Talk; Receptor, ErbB-2; Receptors, Estrogen; Tamoxifen; Trastuzumab; Tumor Cells, Cultured; Tumor Escape; Xenograft Model Antitumor Assays | 2005 |
Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Phosphorylation; Prognosis; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Array Analysis | 2005 |
Molecular aspects of gefitinib antiproliferative and pro-apoptotic effects in PTEN-positive and PTEN-negative prostate cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chromones; Drug Resistance, Neoplasm; ErbB Receptors; G1 Phase; Gefitinib; Humans; Male; Mitogen-Activated Protein Kinase Kinases; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2005 |
Zoledronic acid cooperates with a cyclooxygenase-2 inhibitor and gefitinib in inhibiting breast and prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Male; Mice; Mice, Nude; Prostatic Neoplasms; Proteins; Pyrazoles; Quinazolines; Signal Transduction; Sulfonamides; Xenograft Model Antitumor Assays; Zoledronic Acid | 2005 |
Targeted kinase inhibitors in lung cancer: from EGFR to patients.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2006 |
EGFR tyrosine kinase inhibitors in non-small cell lung cancer: report of a 3-year compassionate use experience with gefitinib in stage IIIB/IV outpatients.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
Re: Cetuximab therapy and symptomatic hypomagnesemia.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Magnesium; Magnesium Deficiency; Protein-Tyrosine Kinases; Quinazolines | 2005 |
Elevated Src activity promotes cellular invasion and motility in tamoxifen resistant breast cancer cells.
Topics: Antineoplastic Agents, Hormonal; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Focal Adhesion Kinase 1; Gefitinib; Humans; Microscopy, Fluorescence; Neoplasm Invasiveness; Paxillin; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; src-Family Kinases; Tamoxifen | 2006 |
The epidermal growth factor receptor gene sequence is highly conserved in primary gastric cancers.
Topics: Adult; Aged; Aged, 80 and over; Cell Line, Tumor; Female; Gefitinib; Genes, erbB-1; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Stomach Neoplasms | 2006 |
EGFR mutation in gefitinib-responsive small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2006 |
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Ligands; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Neoplasms, Glandular and Epithelial; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured; Tyrosine | 2005 |
Gefitinib-sensitizing mutation in esophageal carcinoma cell line Kyse450.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mutation, Missense; Protein Structure, Tertiary; Quinazolines | 2006 |
Enhancement of sensitivity to tumor necrosis factor alpha in non-small cell lung cancer cells with acquired resistance to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 8; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Necrosis Factor-alpha | 2005 |
[A case of lung adenocarcinoma of the lung with disappearance of brain metastasis by re-treatment with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain; Brain Neoplasms; Combined Modality Therapy; Cranial Irradiation; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Remission Induction; Retreatment; Tomography, X-Ray Computed | 2005 |
The role of EGFR-TK inhibition in non-small cell lung cancer.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germany; Humans; Lung Neoplasms; Male; Middle Aged; Palliative Care; Quinazolines; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminal Care; Treatment Outcome | 2005 |
Dimerization and the signal transduction pathway of a small in-frame deletion in the epidermal growth factor receptor.
Topics: Cell Line; Dimerization; ErbB Receptors; Gefitinib; Gene Expression Regulation; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Sequence Deletion; Signal Transduction | 2006 |
Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Endometrial Neoplasms; Epidermal Growth Factor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Phosphoproteins; Quinazolines; Signal Transduction | 2005 |
Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation.
Topics: Blotting, Western; Cell Division; Cells, Cultured; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Humans; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Vascular Endothelial Growth Factor A | 2005 |
PPAR-gamma agonist increase gefitinib's antitumor activity through PTEN expression.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Humans; Lung Neoplasms; PPAR gamma; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Statistics, Nonparametric; Thiazolidinediones; Tumor Cells, Cultured | 2006 |
Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2005 |
Gefitinib response of erlotinib-refractory lung cancer involving meninges--role of EGFR mutation.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Meningeal Neoplasms; Mutation; Quinazolines; Ribs; Treatment Failure | 2006 |
[Enhanced expression of EGFR, TGF-alpha, EGF in hyperplastic parathyroid glands in established stage of renal failure in rats].
Topics: Animals; Cell Proliferation; Disease Models, Animal; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Hyperplasia; Intracellular Signaling Peptides and Proteins; Male; Parathyroid Glands; Parathyroid Hormone; Phosphorus, Dietary; Quinazolines; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Time Factors; Transforming Growth Factor alpha | 2005 |
Epidermal growth factor receptor inhibitor (PD168393) potentiates cytotoxic effects of paclitaxel against androgen-independent prostate cancer cells.
Topics: Adenocarcinoma; Androgens; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Combinations; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Male; Paclitaxel; Prostatic Neoplasms; Quinazolines | 2006 |
Hitting the target: measuring EGFR response to tyrosine kinase inhibitors.
Topics: Colon; Colorectal Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunoblotting; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines | 2005 |
The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antineoplastic Agents; Apoptosis; bcl-Associated Death Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flavonoids; Gefitinib; Humans; Inhibitory Concentration 50; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transfection | 2006 |
Gefitinib-induced lung injury successfully treated with high-dose corticosteroids.
Topics: Acute Disease; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Middle Aged; Photomicrography; Quinazolines; Tomography, X-Ray Computed | 2006 |
Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase Inhibitors; Homeodomain Proteins; Humans; Lung Neoplasms; Predictive Value of Tests; Prognosis; Quinazolines; Transcription Factors; Transfection; Zinc Finger E-box-Binding Homeobox 1 | 2006 |
Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Deoxycytidine; Drug Administration Schedule; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Humans; Quinazolines; Tumor Cells, Cultured | 2006 |
Synergistic antitumor activity of epidermal growth factor receptor tyrosine kinase inhibitor gefitinib and IFN-alpha in head and neck cancer cells in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Interferon-alpha; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2006 |
Additive antitumor effects of gefitinib and imatinib on anaplastic thyroid cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Cell Line, Tumor; DNA Primers; Drug Synergism; Female; Gefitinib; Humans; Imatinib Mesylate; Mice; Piperazines; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Neoplasms | 2006 |
[Current status of the study of the mechanism of epidermal growth factor receptor targeting drug therapy and their related markers].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2005 |
[Current status and prospect of neoplasm targeted therapy].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Cetuximab; Drug Delivery Systems; Drug Design; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Immunologic Factors; Neoplasms; Palliative Care; Piperazines; Pyrimidines; Quinazolines; Signal Transduction | 2005 |
[Advances in the molecular target therapy in lung cancer].
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines | 2005 |
Activation of MEK/ERK and PI3K/Akt pathways by fibronectin requires integrin alphav-mediated ADAM activity in hepatocellular carcinoma: a novel functional target for gefitinib.
Topics: ADAM Proteins; Animals; Carcinoma, Hepatocellular; Drug Therapy, Combination; ErbB Receptors; Fibronectins; Gefitinib; Integrin alphaV; Liver Neoplasms; MAP Kinase Kinase Kinases; Mice; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Smoking; Survival Rate | 2006 |
Gefitinib for refractory advanced non-small-cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Response of glioblastomas to EGFR kinase inhibitors.
Topics: ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Deletion; Glioblastoma; Humans; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2006 |
Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; Deoxyribonuclease I; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Exons; Female; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Paraffin Embedding; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity | 2006 |
Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis.
Topics: Animals; Anticarcinogenic Agents; Butylhydroxybutylnitrosamine; Carcinogens; Carcinoma, Transitional Cell; Cyclooxygenase Inhibitors; Gefitinib; Male; Meloxicam; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Inbred F344; Thiazines; Thiazoles; Treatment Outcome; Urinary Bladder Neoplasms | 2006 |
Iressa induces cytostasis and augments Fas-mediated apoptosis in acinic cell adenocarcinoma overexpressing HER2/neu.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Acinar Cell; Caspases; Cell Cycle; Cell Proliferation; Dose-Response Relationship, Drug; fas Receptor; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Immunohistochemistry; Male; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Neoplasm Proteins; Phosphorylation; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Receptor, ErbB-2; Salivary Gland Neoplasms; Signal Transduction; Up-Regulation | 2006 |
[Acneiform eruption from epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2005 |
Discovery of EGFR selective 4,6-disubstituted pyrimidines from a combinatorial kinase-directed heterocycle library.
Topics: Combinatorial Chemistry Techniques; ErbB Receptors; Gefitinib; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Quinazolines; Structure-Activity Relationship | 2006 |
Epidermal growth factor receptor and hedgehog signaling pathways are active in esophageal cancer cells from rat reflux model.
Topics: Animals; Apoptosis; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Hedgehog Proteins; Male; MAP Kinase Signaling System; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Trans-Activators; Veratrum Alkaloids | 2006 |
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
Topics: Aged; Bronchi; Cell Adhesion; Cell Growth Processes; Cell Transformation, Neoplastic; Dual Specificity Phosphatase 6; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genes, p16; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase Kinases; Oncogenes; Phosphorylation; Protein Tyrosine Phosphatases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; STAT3 Transcription Factor; Telomerase; Transfection; Up-Regulation | 2006 |
C-fos assessment as a marker of anti-epidermal growth factor receptor effect.
Topics: Animals; Biomarkers, Tumor; Cell Growth Processes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, fos; Humans; Mice; Mice, Nude; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2006 |
Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
Topics: Animals; Blood Cells; Blood Proteins; Dogs; ErbB Receptors; Gefitinib; Humans; Mice; Protein Kinase Inhibitors; Quinazolines; Rats; Reproducibility of Results; Time Factors | 2006 |
Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2006 |
Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment.
Topics: Androstadienes; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Nucleus; Cisplatin; Cytosol; DNA; DNA-Activated Protein Kinase; ErbB Receptors; Etoposide; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; RNA, Small Interfering; Wortmannin | 2006 |
Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.
Topics: Adenocarcinoma; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Incidence; Lung Neoplasms; Male; Molecular Biology; Mutation; Protein Kinase Inhibitors; Quinazolines; ROC Curve; Smoking | 2006 |
Minimal contribution of desmethyl-gefitinib, the major human plasma metabolite of gefitinib, to epidermal growth factor receptor (EGFR)-mediated tumour growth inhibition.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; KB Cells; Lethal Dose 50; Metabolic Clearance Rate; Mice; Mice, Nude; Quinazolines; Tissue Distribution | 2006 |
Gefitinib, an epidermal growth factor receptor blockade agent, shows additional or synergistic effects on the radiosensitivity of esophageal cancer cells in vitro.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Mitosis; Quinazolines; Radiation Tolerance; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction | 2006 |
EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Quinazolines | 2006 |
BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer.
Topics: Adenosine Triphosphatases; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spectrometry, Fluorescence; Topoisomerase I Inhibitors; Topotecan | 2006 |
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents | 2006 |
Activated Src and Ras induce gefitinib resistance by activation of signaling pathways downstream of epidermal growth factor receptor in human gallbladder adenocarcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gallbladder; Gefitinib; Humans; Inhibitory Concentration 50; Lactams, Macrocyclic; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Rifabutin; Signal Transduction; Tyrosine | 2006 |
YM-359445, an orally bioavailable vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor, has highly potent antitumor activity against established tumors.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Biological Availability; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Male; Mice; Mice, Inbred ICR; Mice, Nude; Molecular Structure; Neoplasms; Neovascularization, Pathologic; Paclitaxel; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Quinazolines; Thiazoles; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2006 |
[Mutations in the epidermal growth factor receptor and targeted therapy of non-small-cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2005 |
What's the rush? The dissemination and adoption of preliminary research results.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Congresses as Topic; Diffusion of Innovation; Evidence-Based Medicine; Female; Gefitinib; Humans; Information Dissemination; Lung Neoplasms; Multicenter Studies as Topic; Neoplasms; Practice Patterns, Physicians'; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Taxoids; Treatment Outcome; United States | 2006 |
EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms.
Topics: Binding Sites; Carcinoma, Squamous Cell; Cell Line, Tumor; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Sp1 Transcription Factor; Vascular Endothelial Growth Factor A | 2006 |
EGFR regulates the side population in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Immunohistochemistry; In Vitro Techniques; Neoplasm Proteins; Quinazolines | 2006 |
Cell cycle- and apoptosis-regulatory protein-1 is involved in apoptosis signaling by epidermal growth factor receptor.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Caspase 9; Caspases; Cell Cycle Proteins; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Glycoproteins; Humans; p38 Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction | 2006 |
Gefitinib-induced interstitial lung disease showing improvement after cessation: disassociation of serum markers.
Topics: Adenocarcinoma; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers; Biopsy; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Mucin-1; Mucins; Pulmonary Surfactant-Associated Protein A; Pulmonary Surfactant-Associated Protein D; Quinazolines; Tomography, X-Ray Computed | 2006 |
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzoquinones; Caspase 3; Caspases; Cell Proliferation; Drug Combinations; Enzyme Activation; ErbB Receptors; Fibroblasts; G1 Phase; Gefitinib; Glioma; Humans; Lactams, Macrocyclic; Lung; Mitogen-Activated Protein Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Rifabutin; Signal Transduction; Tumor Stem Cell Assay | 2006 |
Analgesic effect of gefitinib in the treatment of non-small cell lung cancer.
Topics: Aged; Analgesics; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Osteoarthritis; Quinazolines | 2006 |
Long-term survival in three patients with metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Time Factors | 2006 |
High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cohort Studies; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Saudi Arabia; Tissue Array Analysis | 2006 |
Gefitinib and the modulation of the signaling pathways downstream of epidermal growth factor receptor in human liver cancer cells.
Topics: ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Tumor Cells, Cultured | 2006 |
Imaging of gefitinib-related interstitial lung disease: multi-institutional analysis by the West Japan Thoracic Oncology Group.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Diagnosis, Differential; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2006 |
Gefitinib accumulation in glioblastoma tissue.
Topics: Antineoplastic Agents; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mass Spectrometry; Quinazolines | 2006 |
Transforming growth factor alpha expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (Iressa) in human pancreatic cancer cell lines.
Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Male; Mice; Mice, Nude; Pancreatic Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2006 |
[Contribution to acneiform eruptions by epidermal growth factor receptor inhibitors].
Topics: Acneiform Eruptions; Adenocarcinoma; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Colonic Neoplasms; Disease Susceptibility; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Proteins; Quinazolines; Staphylococcal Skin Infections; Superinfection | 2006 |
EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Patient Selection; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptor, IGF Type 1; Survival Analysis | 2006 |
Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: different mechanisms of action for a novel therapeutic application?
Topics: Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2006 |
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Culture Media, Conditioned; ErbB Receptors; Gefitinib; Humans; Immunoprecipitation; Incidence; Male; Matrix Metalloproteinase 9; Mice; Mice, Nude; Prostatic Neoplasms; Quinazolines; Signal Transduction; Stromal Cells; Xenograft Model Antitumor Assays | 2006 |
Role of exon-16-deleted HER2 in breast carcinomas.
Topics: 3T3 Cells; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Cells, Cultured; Drug Tolerance; Emodin; Enzyme Inhibitors; ErbB Receptors; Exons; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kidney; Mice; Mice, Inbred BALB C; Mice, Nude; Polymerase Chain Reaction; Quinazolines; Receptor, ErbB-2; RNA Splicing; Trastuzumab | 2006 |
Development and therapeutic options for the treatment of raloxifene-stimulated breast cancer in athymic mice.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Quinazolines; Raloxifene Hydrochloride; RNA, Messenger; Structure-Activity Relationship; Transplantation, Heterologous; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
[Gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Administration Schedule; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2006 |
[A case of complete response in a primary lesion treated by gefitinib for two years after surgery of brain metastasis from lung cancer].
Topics: Adenocarcinoma, Papillary; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cerebellar Neoplasms; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2006 |
[Inhibitory effects of iressa on hepatocellular carcinoma Hep-3B and HepG2 cell xenografts in nude mice].
Topics: Animals; Antineoplastic Agents; Body Weight; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gefitinib; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Random Allocation; Xenograft Model Antitumor Assays | 2006 |
Lack of response to erlotinib after progression on gefitinib in patients with advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2006 |
In-frame deletion in the EGF receptor alters kinase inhibition by gefitinib.
Topics: Antineoplastic Agents; Cell Line; ErbB Receptors; Gefitinib; Humans; Kinetics; Mutation; Phosphorylation; Quinazolines; Sequence Deletion | 2006 |
Clustered incidence of acute promyelocytic leukemia during gefitinib treatment for non-small-cell lung cancer: experience at a single institution.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Humans; Incidence; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2006 |
The gefitinib-sensitizing mutant epidermal growth factor receptor enables transformation of a mouse fibroblast cell line.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Cell Transformation, Neoplastic; DNA; Enzyme Activation; ErbB Receptors; Fibroblasts; Gefitinib; Mice; Mitogen-Activated Protein Kinases; Mutation; Quinazolines; Transfection | 2006 |
Epidermal growth factor receptor targeted therapy with gefitinib in locally advanced and metastatic primary lung adenocarcinoma.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2006 |
Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Patient Selection; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Survival Analysis | 2006 |
Asian ethnicity as a predictor of response in patients with non-small-cell lung cancer treated with gefitinib on an expanded access program.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies; United States | 2006 |
Expect the unexpected.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Gefitinib; Heart Diseases; Humans; Multiple Organ Failure; Neoplasms; Pneumonia; Quinazolines | 2006 |
Mig6 is a negative regulator of EGF receptor-mediated skin morphogenesis and tumor formation.
Topics: Adaptor Proteins, Signal Transducing; Animals; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Keratinocytes; MAP Kinase Signaling System; Mice; Mice, Inbred C57BL; Mice, Knockout; Mitogen-Activated Protein Kinases; Morphogenesis; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2006 |
Gefitinib modulates the function of multiple ATP-binding cassette transporters in vivo.
Topics: Absorption; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Interactions; Female; Gefitinib; Humans; LLC-PK1 Cells; Mice; Mice, Inbred C57BL; Mice, SCID; Mouth Mucosa; Quinazolines; Swine; Topotecan | 2006 |
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Knockout; Mutation; Protein Isoforms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Quinolines; Tumor Suppressor Protein p14ARF | 2006 |
Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Inflammatory Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clindamycin; Drug Eruptions; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Sulfacetamide; Triamcinolone | 2006 |
Gefitinib inhibits the growth and invasion of urothelial carcinoma cell lines in which Akt and MAPK activation is dependent on constitutive epidermal growth factor receptor activation.
Topics: Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Urologic Neoplasms | 2006 |
Identification of genes linked to gefitinib treatment in prostate cancer cell lines with or without resistance to androgen: a clue to application of gefitinib to hormone-resistant prostate cancer.
Topics: Androgens; Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines | 2006 |
Canonical WNT signaling pathway and human AREG.
Topics: Amino Acid Sequence; Amphiregulin; Animals; Antineoplastic Agents; Base Sequence; Binding Sites; Computational Biology; Drug Resistance, Neoplasm; EGF Family of Proteins; Gefitinib; Gene Expression Profiling; Genomics; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Molecular Sequence Data; Neoplasms; Pan troglodytes; Phylogeny; Promoter Regions, Genetic; Quinazolines; Signal Transduction; TCF Transcription Factors; Wnt Proteins | 2006 |
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Xenograft Model Antitumor Assays | 2006 |
Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Neoplasms; Positron-Emission Tomography; Quinazolines | 2006 |
Impact of genetic diagnostics on drug development strategy.
Topics: Antineoplastic Agents; Dasatinib; Drug Design; Drug Resistance, Neoplasm; Gefitinib; Genetic Testing; Humans; Neoplasms; Pharmacogenetics; Pyrimidines; Quinazolines; Thiazoles | 2006 |
Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Protein Kinase Inhibitors; Quinazolines; Radiography, Thoracic; Tomography, X-Ray Computed; X-Ray Film | 2006 |
PTEN/Akt signaling through epidermal growth factor receptor is prerequisite for angiogenesis by hepatocellular carcinoma cells that is susceptible to inhibition by gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Growth Processes; Chemokine CXCL1; Chemokines, CXC; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Dosage; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; Mice; Mice, Inbred BALB C; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2006 |
Epidermal growth factor receptor messenger RNA expression, gene dosage, and gefitinib sensitivity in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Dosage; Gene Expression Profiling; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Quinazolines; RNA, Messenger; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib-sensitizing mutations in esophageal carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; DNA, Neoplasm; ErbB Receptors; Esophageal Diseases; Esophageal Neoplasms; Gefitinib; Humans; Mutation; Neoplasms, Squamous Cell; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2006 |
Is there a role for the irreversible epidermal growth factor receptor inhibitor EKB-569 in the treatment of cancer? A mutation-driven question.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasms; Organic Chemicals; Protein Kinase Inhibitors; Quinazolines | 2006 |
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Irinotecan; Lung Neoplasms; Mice; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Deletion; Survival Rate; Tumor Cells, Cultured | 2006 |
[From ASCO and WCLC 2005 to the clinical practice: targeted therapies].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Forecasting; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Patient Selection; Placebos; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Sex Factors; Smoking; Time Factors; Vascular Endothelial Growth Factor A | 2006 |
Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Risk Factors | 2006 |
Three-year survival in metastatic non-small cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors | 2006 |
Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cytotoxins; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Sorafenib; Vinblastine; Vinorelbine; Weight Loss; Xenograft Model Antitumor Assays | 2007 |
Double mutation and gene copy number of EGFR in gefitinib refractory non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Genotype; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Quinazolines | 2006 |
Chemotherapy-induced epidermal growth factor receptor activation determines response to combined gefitinib/chemotherapy treatment in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 3; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Gefitinib prevents bleomycin-induced lung fibrosis in mice.
Topics: Animals; Bleomycin; Cell Culture Techniques; Cell Proliferation; Disease Models, Animal; Dose-Response Relationship, Drug; Fibroblasts; Gefitinib; Humans; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Tyrphostins | 2006 |
Perspectives in central nervous system malignancies.
Topics: Antineoplastic Agents; Central Nervous System Neoplasms; Combined Modality Therapy; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Glioma; Humans; Indoles; Protein Kinase C; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Randomized Controlled Trials as Topic; Sirolimus; TOR Serine-Threonine Kinases | 2006 |
Gefitinib efficacy in relapsed small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Small Cell; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Treatment Outcome | 2006 |
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelium, Vascular; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms, Experimental; Neovascularization, Pathologic; Piperidines; Pleural Effusion, Malignant; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Gefitinib for epidermal growth factor receptor mutant lung cancers: searching for a weapon of mass destruction.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prospective Studies; Quinazolines | 2006 |
Synchronous multiple primary lung cancers with different response to gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Male; Neoplasms, Multiple Primary; Quinazolines; Tomography, X-Ray Computed | 2006 |
[Gefitinib treatment for carcinomatous meningitis in non-small cell lung cancer].
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Cisplatin; Combined Modality Therapy; Cranial Irradiation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Meningitis; Middle Aged; Neoplasm Proteins; Paclitaxel; Palliative Care; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Vinblastine; Vinorelbine | 2006 |
[Gefitinib-induced perforating dermatosis].
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; Combined Modality Therapy; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Skin Ulcer | 2006 |
Different responses to gefitinib in lung adenocarcinoma coexpressing mutant- and wild-type epidermal growth factor receptor genes.
Topics: Adenocarcinoma; Antineoplastic Agents; Drug Resistance, Neoplasm; Gefitinib; Genes, erbB-1; Humans; Laminectomy; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms | 2006 |
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; ErbB Receptors; Fluorine; Gefitinib; Humans; Inhibitory Concentration 50; Mice; Molecular Structure; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Structure-Activity Relationship; Thiazoles; Xenograft Model Antitumor Assays | 2006 |
Promising new treatment schedule for gefitinib responders after severe hepatotoxicity with daily administration.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Administration Schedule; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Middle Aged; Quinazolines | 2006 |
Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Docetaxel; Drug Administration Schedule; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Quinazolines; Taxoids; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2006 |
Epidermal growth factor receptor mutations and response to chemotherapy in patients with non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gemcitabine; Genes, erbB-1; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Paclitaxel; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies | 2006 |
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate; Treatment Outcome | 2006 |
Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Profiling; Head and Neck Neoplasms; Humans; Male; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Reverse Transcriptase Polymerase Chain Reaction; Sensitivity and Specificity; Sequence Analysis, DNA; Signal Transduction; Structure-Activity Relationship; Time Factors | 2006 |
Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells.
Topics: Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Diphosphonates; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Insulin-Like Growth Factor II; Phosphorylation; Protein Isoforms; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured | 2006 |
Successful re-treatment with gefitinib for carcinomatous meningitis as disease recurrence of non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Biopsy; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Mutation; Quinazolines; Recurrence | 2006 |
Gefitinib is of more benefit in chemotherapy-naive patients with good performance status and adenocarcinoma histology: retrospective analysis of 575 Korean patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Korea; Lung Neoplasms; Middle Aged; Multivariate Analysis; Odds Ratio; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2006 |
A rapid, sensitive assay to detect EGFR mutation in small biopsy specimens from lung cancer.
Topics: Biopsy; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Models, Biological; Point Mutation; Predictive Value of Tests; Quinazolines; Sensitivity and Specificity; Treatment Failure | 2006 |
Elevation of soluble interleukin-2 receptor in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; CD4 Antigens; Chemokine CCL5; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Neoplasm Staging; P-Selectin; Prognosis; Quinazolines; Receptors, Interleukin-2 | 2006 |
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Nude; Models, Biological; Morpholines; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering; Transforming Growth Factor alpha; Trastuzumab; Xenograft Model Antitumor Assays | 2006 |
Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Ligands; Mice; Mice, Inbred BALB C; Mice, Nude; Models, Biological; Paclitaxel; Piperidines; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Spiro Compounds; Xenograft Model Antitumor Assays | 2006 |
Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Inflammation; Lung Neoplasms; Quinazolines; Time Factors | 2006 |
[Diagnosis of and therapy for diffuse lung diseases (discussion)].
Topics: Alveolitis, Extrinsic Allergic; Biomarkers; Bronchiolitis; Gefitinib; Humans; Isoxazoles; Leflunomide; Lung Diseases, Interstitial; Quinazolines; Sarcoidosis, Pulmonary; Tomography, X-Ray Computed | 2006 |
Gefitinib: a cause of pyogenic granulomalike lesions of the nail.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nail Diseases; Quinazolines | 2006 |
[Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma].
Topics: Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Docetaxel; Gefitinib; Humans; Male; Mice; Middle Aged; Prognosis; Prostatic Neoplasms; Quality of Life; Quinazolines; Taxoids | 2006 |
[Molecular-targeted therapy for hormone-refractory prostate cancer].
Topics: Angiotensin Receptor Antagonists; Antineoplastic Agents; Atrasentan; Benzamides; Boronic Acids; Bortezomib; Calcitriol; Celecoxib; Cyclooxygenase 2 Inhibitors; Endothelin A Receptor Antagonists; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Male; Piperazines; Prostatic Neoplasms; Pyrazines; Pyrazoles; Pyrimidines; Pyrrolidines; Quinazolines; Sulfonamides; Thalidomide; Vitamin D | 2006 |
Carcinomatous meningitis from non-small-cell lung cancer responding to gefitinib.
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Quinazolines | 2006 |
Thai female non-smoker with recurrent lung adenocarcinoma who has dramatic and prolonged response to gefitinib for over one year.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Evaluation of the epidermal growth factor receptor gene mutation and copy number in non-small cell lung cancer with gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2006 |
Acetylsalicylic acid enhances antiproliferative effects of the EGFR inhibitor gefitinib in the absence of activating mutations in gastric cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Blotting, Western; Cell Survival; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Humans; Middle Aged; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Stomach Neoplasms; Tumor Cells, Cultured | 2006 |
K-ras mutations in lung cancer: the "mysterious mutation".
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2006 |
Complex mutation patterns of epidermal growth factor receptor gene associated with variable responses to gefitinib treatment in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA Primers; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Quinazolines | 2006 |
Baseline gene expression predicts sensitivity to gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Cluster Analysis; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Inhibitory Concentration 50; Lung Neoplasms; Multigene Family; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proteome; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Responses of human colorectal tumor cells to treatment with the anti-epidermal growth factor receptor monoclonal antibody ICR62 used alone and in combination with the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Cell Growth Processes; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2 | 2006 |
L858R EGFR mutation status correlated with clinico-pathological features of Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Genotype; Humans; Japan; Linear Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Statistics, Nonparametric; Survival Rate | 2006 |
Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration.
Topics: Animals; Antineoplastic Agents; Benzamides; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biopsy, Fine-Needle; Cholangiocarcinoma; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Signal Transduction | 2006 |
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Topics: Alleles; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mice; Mutation, Missense; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; RNA Interference; Transfection; Xenograft Model Antitumor Assays | 2006 |
Adverse reactions to gefitinib (Iressa): revealing sycosis- and pyoderma gangrenosum-like lesions.
Topics: Antineoplastic Agents; Folliculitis; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pyoderma Gangrenosum; Quinazolines | 2006 |
Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methionine; Mutation; Polymerase Chain Reaction; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Threonine | 2006 |
[Lung cancer with bone metastasis].
Topics: Analgesics; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Camptothecin; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Diphosphonates; Docetaxel; Drug Administration Schedule; Etoposide; Fractures, Bone; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Paclitaxel; Pain, Intractable; Prognosis; Quinazolines; Radiotherapy Dosage; Taxoids | 2006 |
Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Cycle; Combined Modality Therapy; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Quinazolines; Rabbits; Radiation Tolerance; Sulfonamides | 2006 |
Influence of whole-brain radiotherapy on remission of brain metastases.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cranial Irradiation; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Usefulness of EGFR mutation screening in pleural fluid to predict the clinical outcome of gefitinib treated patients with lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Predictive Value of Tests; Quinazolines; Treatment Outcome | 2006 |
Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
Topics: Animals; Antineoplastic Agents; Biliary Tract Neoplasms; Cell Division; Cell Line, Tumor; Cholangiocarcinoma; DNA, Complementary; DNA, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; In Situ Hybridization, Fluorescence; Mice; Mice, Nude; Purines; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Vascular Endothelial Growth Factor Receptor-2 | 2006 |
Impact of EGFR point mutations on the sensitivity to gefitinib: insights from comparative structural analyses and molecular dynamics simulations.
Topics: Adenosine Triphosphate; Binding Sites; Computational Biology; Computer Simulation; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Ligands; Models, Molecular; Point Mutation; Protein Structure, Secondary; Protein Structure, Tertiary; Proto-Oncogene Proteins c-abl; Quinazolines; Static Electricity | 2006 |
Significance of the papillary subtype in relation to durable response to gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2006 |
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chromatography, High Pressure Liquid; Colonic Neoplasms; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Piperidines; Quinazolines; Signal Transduction; Time Factors | 2006 |
Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Organophosphorus Compounds; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Xenograft Model Antitumor Assays | 2006 |
EGF-independent activation of cell-surface EGF receptors harboring mutations found in gefitinib-sensitive lung cancer.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Interleukin-3; Lung Neoplasms; Models, Molecular; Mutation; Phosphorylation; Protein Binding; Quinazolines | 2007 |
Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Characteristics; Smoking; Survival Analysis | 2006 |
Enhancement of radiosensitivity by dual inhibition of the HER family with ZD1839 ("Iressa") and trastuzumab ("Herceptin").
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; G2 Phase; Gefitinib; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase Kinase 2; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Receptor, ErbB-2; Trastuzumab | 2006 |
Clinical factors affecting acquired resistance to gefitinib in previously treated Japanese patients with advanced nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Risk Factors | 2006 |
Lymphangitis carcinomatosis as a potential predictor for a response to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Female; Forecasting; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Male; Quinazolines; Treatment Outcome | 2006 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2006 |
Smoking history and prior surgical resection predict sensitivity to gefitinib in advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Prognosis; Quinazolines; Retrospective Studies; Smoking; Survival Analysis; Treatment Outcome | 2006 |
Impact of IGF-1R/EGFR cross-talks on hepatoma cell sensitivity to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2006 |
Survival outcome and predictors of gefitinib antitumor activity in East Asian chemonaive patients with advanced nonsmall cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasms, Squamous Cell; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Smoking; Survival Analysis; Survival Rate; Treatment Outcome | 2006 |
Inhibition of intrahepatic bile duct dilation of the polycystic kidney rat with a novel tyrosine kinase inhibitor gefitinib.
Topics: Animals; Bile Ducts, Intrahepatic; Dilatation, Pathologic; Disease Models, Animal; ErbB Receptors; Gefitinib; Liver; Liver Diseases; Mitogen-Activated Protein Kinase 3; Mitogen-Activated Protein Kinase 7; Polycystic Kidney Diseases; Protein Kinase Inhibitors; Quinazolines; Rats | 2006 |
AZD3409 inhibits the growth of breast cancer cells with intrinsic resistance to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Epidermal Growth Factor; Female; Flow Cytometry; Gefitinib; Humans; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Gefitinib monotherapy in advanced nonsmall cell lung cancer: a large Western community implementation study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Belgium; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Gefitinib concentrations in human glioblastoma tissue.
Topics: Antineoplastic Agents; Biological Availability; Brain Neoplasms; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Quinazolines | 2007 |
Treatment of gefitinib-associated folliculitis.
Topics: Adult; Aged; Antineoplastic Agents; Folliculitis; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2006 |
Novel combination therapy against metastatic and androgen-independent prostate cancer by using gefitinib, tamoxifen and etoposide.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Proliferation; Cells, Cultured; Ceramides; Cytochromes c; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Etoposide; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Male; Membrane Potential, Mitochondrial; Neoplasms, Hormone-Dependent; Prostate; Prostatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tamoxifen | 2007 |
Cooperative effect of gefitinib and fumitremorgin c on cell growth and chemosensitivity in estrogen receptor alpha negative fulvestrant-resistant MCF-7 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitoxantrone; Neoplasm Proteins; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Quinazolines | 2006 |
Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Topics: Apoptosis; Beta Particles; Carcinoma, Non-Small-Cell Lung; DNA Repair; DNA Replication; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gamma Rays; Gefitinib; Genes, erbB-1; Genes, p53; Humans; Lung Neoplasms; Mutation; Neoplasm Proteins; Protein Structure, Tertiary; Quinazolines; Radiation Tolerance; Recombinant Fusion Proteins; Sequence Deletion; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2006 |
A case of acute promyelocytic leukemia during gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Female; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Middle Aged; Neoplasms, Second Primary; Quinazolines; Remission Induction; Tretinoin | 2006 |
Monitoring targeted therapy: is fluorodeoxylucose uptake a marker of early response?
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Quinazolines; Radionuclide Imaging | 2006 |
Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fluorodeoxyglucose F18; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, SCID; Neoplasm Staging; Positron-Emission Tomography; Quinazolines; Sensitivity and Specificity; Treatment Outcome; Tumor Cells, Cultured | 2006 |
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Point Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Homology, Amino Acid | 2006 |
Concurrent use of vinorelbine and gefitinib induces supra-additive effect in head and neck squamous cell carcinoma cell lines.
Topics: Analysis of Variance; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Carcinoma, Squamous Cell; Cell Division; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; In Vitro Techniques; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured; Vinblastine; Vinorelbine | 2007 |
[Prolonged survival of gefitinib treatment in patients with advanced and previously treated non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Survival Rate | 2006 |
Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Topics: Acute Disease; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Tumor inhibitory effect of gefitinib (ZD1839, Iressa) and taxane combination therapy in EGFR-overexpressing breast cancer cell lines (MCF7/ADR, MDA-MB-231).
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Breast Neoplasms; Bridged-Ring Compounds; Cell Proliferation; Doxorubicin; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase; Gefitinib; Humans; Immunoprecipitation; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Survival Rate; Taxoids; Transplantation, Heterologous; Tumor Cells, Cultured | 2007 |
[Two lung adenocarcinoma patients with multiple brain metastasis treated with Gefitinib and surviving more than 2 years].
Topics: Adenocarcinoma, Papillary; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiotherapy Dosage; Survivors | 2006 |
Non-responsiveness to gefitinib in a patient with lung adenocarcinoma having rare EGFR mutations S768I and V769L.
Topics: Adenocarcinoma; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Isoleucine; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Serine; Valine | 2006 |
Novel heteroduplex method using small cytology specimens with a remarkably high success rate for analysing EGFR gene mutations with a significant correlation to gefitinib efficacy in non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Nucleic Acid Heteroduplexes; Quinazolines; Treatment Outcome | 2006 |
Molecular on/off switch.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2006 |
Cross-over response to erlotinib of brain metastatic disease from bronchial adenocarcinoma after gefitinib failure, and an unusual rash.
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Bronchial Neoplasms; Drug Hypersensitivity; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Skin Diseases, Vesiculobullous | 2006 |
Gefitinib is an additional prognostic factor in metastatic lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Drug Resistance; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2006 |
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.
Topics: Carcinoma; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Thyroid Neoplasms; Vascular Endothelial Growth Factor A | 2006 |
EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2007 |
EGFR mutation status in tumour-derived DNA from pleural effusion fluid is a practical basis for predicting the response to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Feasibility Studies; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Sensitivity and Specificity; Treatment Outcome | 2006 |
Effect of gefitinib on brain metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2006 |
[Treatment of acneiform rash by epidermal growth factor inhibitors with oral tetracyclines].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antineoplastic Agents; Doxycycline; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2006 |
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.
Topics: Adenocarcinoma; Amino Acid Sequence; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Dosage; Humans; In Situ Hybridization; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Liver Neoplasms; Male; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptor, ErbB-2; Stomach Neoplasms | 2006 |
Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; ErbB Receptors; Etoposide; Gefitinib; Humans; Quinazolines; Treatment Outcome; Urinary Bladder Neoplasms | 2007 |
The epidermal growth factor family has a dual role in deciding the fate of cancer cells.
Topics: Biomarkers; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ligands; Multigene Family; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Urinary Bladder Neoplasms | 2006 |
Should every lung cancer patient be tested for EGFR mutation?
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Patient Selection; Pharmacogenetics; Quinazolines | 2006 |
Detection of epidermal growth factor receptor variations by partially denaturing HPLC.
Topics: Antineoplastic Agents; Biopsy; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2007 |
Combinatorial treatment of non-small-cell lung cancers with gefitinib and Ad.mda-7 enhances apoptosis-induction and reverses resistance to a single therapy.
Topics: Adenoviridae; Adenoviridae Infections; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; eIF-2 Kinase; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Therapy; Genetic Vectors; Humans; Interleukins; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Insulin-induced proliferation of bladder cancer cells is mediated through activation of the epidermal growth factor system.
Topics: Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Ligands; Quinazolines; RNA, Messenger; Signal Transduction; Tumor Cells, Cultured; Tyrphostins; Up-Regulation; Urinary Bladder Neoplasms | 2006 |
Epidermal growth factor receptor gene copy number in esophageal cancer and outcome prediction to gefitinib: does intratumoral heterogeneity matter?
Topics: Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Treatment Outcome | 2006 |
[Meningeal carcinomatosis in patients with lung cancer].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cerebrospinal Fluid; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quality of Life; Quinazolines; Retrospective Studies; Survival Rate | 2006 |
Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Predictive Value of Tests; Quinazolines; Signal Transduction; Structure-Activity Relationship; Transplantation, Heterologous | 2006 |
Topotecan central nervous system penetration is altered by a tyrosine kinase inhibitor.
Topics: Administration, Oral; Algorithms; Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood Proteins; Blood-Brain Barrier; Brain; Central Nervous System; Dose-Response Relationship, Drug; Extracellular Fluid; Female; Gefitinib; Immunohistochemistry; Injections, Intravenous; Mice; Mice, Inbred C57BL; Microdialysis; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Time Factors; Topotecan | 2006 |
Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin D; Cyclin-Dependent Kinases; Cyclins; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flavonoids; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutant Proteins; Mutation, Missense; Oligonucleotide Array Sequence Analysis; Piperidines; Quinazolines; Signal Transduction; Transcription, Genetic; Transfection | 2006 |
Pharmacogenetics of ABCG2 and adverse reactions to gefitinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Diarrhea; ErbB Receptors; Gefitinib; Genetic Variation; Humans; Neoplasm Proteins; Neoplasms; Polymorphism, Genetic; Quinazolines; Skin | 2006 |
Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; In Situ Hybridization, Fluorescence; Ligands; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2006 |
[Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2006 |
Liver toxicity after treatment with gefitinib and anastrozole: drug-drug interactions through cytochrome p450?
Topics: Anastrozole; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Gefitinib; Humans; Isoenzymes; Lymphatic Metastasis; Middle Aged; Nitriles; Quinazolines; Triazoles | 2006 |
[Efficacy of gefitinib on advanced non-small cell lung cancer in expanded access program (EAP)].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Survival Rate; Young Adult | 2006 |
Resistance to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines | 2006 |
Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Mutation; Quinazolines; Signal Transduction | 2006 |
Effect of an epidermal growth factor receptor inhibitor in mouse models of lung cancer.
Topics: Animals; Antineoplastic Agents; Chemoprevention; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, ras; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Quinazolines | 2006 |
The impact of epidermal growth factor receptor gene status on gefitinib-treated Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Polymorphism, Genetic; Promoter Regions, Genetic; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Treatment Outcome | 2006 |
Effectiveness of cetuximab/gefitinib in the therapy of a sacral chordoma.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cetuximab; Chordoma; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Sacrum; Spinal Neoplasms; Treatment Outcome | 2006 |
Gefitinib induces premature senescence in non-small cell lung cancer cells with or without EGFR gene mutation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p16; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2007 |
Gefitinib and chemotherapy combination studies in five novel human non small cell lung cancer xenografts. Evidence linking EGFR signaling to gefitinib antitumor response.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; MAP Kinase Kinase 4; Maximum Tolerated Dose; Mice; Mice, Nude; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Survival Rate; Transplantation, Heterologous; Vinblastine; Vinorelbine | 2007 |
Derivatives of Iressa, a specific epidermal growth factor receptor inhibitor, are powerful apoptosis inducers in PC3 prostatic cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Male; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Amrubicin, a novel 9-aminoanthracycline, enhances the antitumor activity of chemotherapeutic agents against human cancer cells in vitro and in vivo.
Topics: Animals; Anthracyclines; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Synergism; Female; Gefitinib; Gemcitabine; Humans; In Vitro Techniques; Irinotecan; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Stomach Neoplasms; Tegafur; Trastuzumab; Uracil; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2007 |
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Barrett Esophagus; Chromatography, High Pressure Liquid; Codon; ErbB Receptors; Esophageal Neoplasms; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein-Tyrosine Kinases; Quinazolines | 2007 |
[Two cases of meningeal carcinomatosis during gefitinib therapy for non-small cell lung cancer].
Topics: Adenocarcinoma; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Quinazolines | 2006 |
Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis.
Topics: Adenoma; Animals; Azoxymethane; beta Catenin; Carcinogens; Cell Transformation, Neoplastic; Colonic Neoplasms; Cyclin D1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, ras; Male; Mice; Mice, Inbred A; Mutation; Quinazolines; Signal Transduction; Up-Regulation | 2007 |
[Experimental study of effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with irinotecan].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; DNA Topoisomerases, Type I; Drug Synergism; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Inhibitory Concentration 50; Irinotecan; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2006 |
Molecular correlates of gefitinib responsiveness in human bladder cancer cells.
Topics: Animals; Antineoplastic Agents; Biomarkers; Cell Line, Tumor; DNA, Neoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; G1 Phase; Gefitinib; Humans; Mesoderm; Mice; Quinazolines; S Phase; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2007 |
[Associations of tyrosine kinase inhibitors with chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Bronchial Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Inhibition of the epidermal growth factor receptor enhances castration-induced prostate involution and reduces testosterone-stimulated prostate growth in adult rats.
Topics: Animals; Apoptosis; Cell Proliferation; Drug Antagonism; Drug Therapy, Combination; ErbB Receptors; Fluorescent Antibody Technique, Indirect; Gefitinib; Gene Expression; Male; Neovascularization, Physiologic; Orchiectomy; Prostate; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Testosterone | 2007 |
Activation of downstream epidermal growth factor receptor (EGFR) signaling provides gefitinib-resistance in cells carrying EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transfection | 2007 |
p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; fas Receptor; Gefitinib; Humans; Lung Neoplasms; Oligonucleotides, Antisense; Quinazolines; Transfection; Tumor Suppressor Protein p53 | 2007 |
[Mutational analysis of EGFR and K-RAS in Chinese patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines | 2007 |
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2007 |
Upregulation of retinoic acid receptor-beta by the epidermal growth factor-receptor inhibitor PD153035 is not mediated by blockade of ErbB pathways.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; CpG Islands; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ovarian Neoplasms; Quinazolines; Receptors, Retinoic Acid; RNA Processing, Post-Transcriptional; Transcription, Genetic; Tyrphostins; Up-Regulation | 2007 |
Proteomic signature corresponding to the response to gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Algorithms; Drug Resistance, Neoplasm; Electrophoresis, Gel, Two-Dimensional; ErbB Receptors; Fatty Acid Binding Protein 3; Fatty Acid-Binding Proteins; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2007 |
Identification of endosomal epidermal growth factor receptor signaling targets by functional organelle proteomics.
Topics: Cell Culture Techniques; Electrophoresis, Gel, Two-Dimensional; Endosomes; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Proteins; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
[International clinical trials for a medical oncologist in Japan].
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Industry; Gefitinib; Humans; International Cooperation; Japan; Medical Oncology; Neoplasms; Quinazolines; Workforce | 2007 |
Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspase Inhibitors; Caspases; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; TNF-Related Apoptosis-Inducing Ligand; Urinary Bladder Neoplasms; X-Linked Inhibitor of Apoptosis Protein | 2007 |
hEGR1 is induced by EGF, inhibited by gefitinib in bladder cell lines and related to EGF receptor levels in bladder tumours.
Topics: Antineoplastic Agents; Blotting, Northern; Blotting, Western; Cell Line, Tumor; Early Growth Response Protein 1; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Urinary Bladder Neoplasms | 2007 |
New insights into oncogene addiction found.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Benzamides; Cyclin D1; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, bcl-1; Humans; Imatinib Mesylate; Mutation; Neoplasms; Oncogenes; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction; Trastuzumab | 2007 |
Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
[A case of lung adenocarcinoma keeping complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Radiosurgery; Remission Induction; Smoking | 2007 |
Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Genes, ras; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Quinazolines; Treatment Outcome | 2007 |
Clairvoyance or reliable prediction of the future?
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Patient Selection; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome | 2007 |
Lung cancer: not just for smokers. People who never smoked may have a different form of the disease that responds better to a new generation of targeted medications.
Topics: Antineoplastic Agents; Benzamides; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Genetic Predisposition to Disease; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Pyrimidines; Quinazolines; Tobacco Smoke Pollution | 2007 |
Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Tumor Cells, Cultured | 2007 |
Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib.
Topics: Animals; Antineoplastic Agents; Baculoviridae; Catalysis; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutant Proteins; Phosphotransferases; Quinazolines; Spodoptera; Substrate Specificity | 2007 |
EGFR mutation status in pleural fluid predicts tumor responsiveness and resistance to gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Mutation; Pleural Effusion, Malignant; Polymerase Chain Reaction; Prognosis; Quinazolines; Tomography, X-Ray Computed | 2007 |
[Lung cancer: targeted therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Models, Biological; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Hypoxia; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice; Protein Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
The EGF receptor Hokey-Cokey.
Topics: Antineoplastic Agents; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity.
Topics: Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutation; Protein Conformation; Protein Structure, Tertiary; Purines; Quinazolines; Staurosporine | 2007 |
Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.
Topics: Antibodies; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gastrin-Releasing Peptide; Gastrointestinal Agents; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Bombesin; Signal Transduction; src-Family Kinases; Transfection | 2007 |
[A case of pulmonary hypertrophic osteoarthropathy associated with primary lung cancer in a young adult successfully treated with gefitinib].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Bone and Bones; Female; Gefitinib; Genes, erbB-1; Humans; Lung Diseases; Lung Neoplasms; Mutation; Osteoarthropathy, Secondary Hypertrophic; Quinazolines; Radionuclide Imaging; Tomography, X-Ray Computed | 2007 |
The EGFR inhibitor gefitinib suppresses ligand-stimulated endocytosis of EGFR via the early/late endocytic pathway in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cathepsin D; Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lysosomal Membrane Proteins; Lysosomes; Microscopy, Fluorescence; Protein Transport; Qa-SNARE Proteins; Quinazolines; Receptors, Scavenger; Signal Transduction; Transferrin | 2007 |
Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Movement; Cell Proliferation; Cytochromes c; Docetaxel; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Immunohistochemistry; Male; Membrane Potential, Mitochondrial; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured; Veratrum Alkaloids | 2007 |
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biliary Tract Neoplasms; Biomarkers, Tumor; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Mitogen-Activated Protein Kinases; Oligonucleotide Array Sequence Analysis; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer.
Topics: Antineoplastic Agents; Azacitidine; Breast Neoplasms; Cell Line; Cell Line, Tumor; Decitabine; Dinucleoside Phosphates; DNA Methylation; DNA Primers; Epigenesis, Genetic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Organ Specificity; Quinazolines; Restriction Mapping; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Colorectal Neoplasms; CpG Islands; DNA Methylation; Female; Fluorouracil; Gefitinib; Humans; Irinotecan; Leucovorin; Male; Massachusetts; Microsatellite Instability; Middle Aged; Quinazolines; Survival Rate | 2007 |
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.
Topics: Administration, Oral; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Combined Modality Therapy; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Upstream signaling inhibition enhances rapamycin effect on growth of kidney cancer cells.
Topics: Antibiotics, Antineoplastic; Benzamides; Blotting, Western; Calcium-Calmodulin-Dependent Protein Kinases; Carcinoma, Renal Cell; Cell Cycle; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Kidney Neoplasms; Mitogen-Activated Protein Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Tumor Cells, Cultured | 2007 |
Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking | 2007 |
Comparative analysis of epidermal growth factor receptor mutations and gene amplification as predictors of gefitinib efficacy in Japanese patients with nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Amplification; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies | 2007 |
An unusual terminal hair growth on the nose tip associated with gefitinib therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Nose; Quinazolines | 2007 |
Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Camptothecin; Carcinoma, Small Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gefitinib; Humans; Imatinib Mesylate; Irinotecan; Lung Neoplasms; Neoplasm Proteins; Piperazines; Pyrimidines; Quinazolines | 2007 |
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2008 |
The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa) suppresses proliferation and invasion of human oral squamous carcinoma cells via p53 independent and MMP, uPAR dependent mechanism.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Matrix Metalloproteinases; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptors, Cell Surface; Receptors, Urokinase Plasminogen Activator; Tongue Neoplasms; Tumor Suppressor Protein p53 | 2007 |
Predicting gefitinib responsiveness in lung cancer by fluorescence in situ hybridization/chromogenic in situ hybridization analysis of EGFR and HER2 in biopsy and cytology specimens.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biopsy; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Receptor, ErbB-2 | 2007 |
The effect of gefitinib on B-RAF mutant non-small cell lung cancer and transfectants.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins B-raf; Quinazolines; Receptor, ErbB-2; Sensitivity and Specificity; Transfection; Tumor Cells, Cultured | 2007 |
Combined analysis of molecular and clinical predictors of gefitinib activity in advanced non-small cell lung cancer: epidermal growth factor receptor mutations do not tell the whole story.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Knowledge of efficacy of treatments in lung cancer is not enough, their clinical effectiveness should also be known.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Meta-Analysis as Topic; Quinazolines; Research Design | 2006 |
Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Multivariate Analysis; Neoplasm Staging; Probability; Proportional Hazards Models; Quinazolines; Retrospective Studies; Risk Assessment; Survival Analysis; Taiwan; Treatment Outcome | 2006 |
Salvage therapy for Chinese non-small cell lung cancer patients who failed previous chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Gemcitabine; Humans; Ifosfamide; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Probability; Prognosis; Quinazolines; Retrospective Studies; Risk Factors; Salvage Therapy; Statistics, Nonparametric; Survival Analysis; Taiwan; Taxoids; Treatment Outcome | 2006 |
PTEN and PIK3CA expression is associated with prolonged survival after gefitinib treatment in EGFR-mutated lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Survival Rate | 2006 |
Mutation and polymorphism in the EGFR-TK domain associated with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Smoking | 2006 |
Efficacy of gefitinib in a patient with lung cancer associated with idiopathic pulmonary fibrosis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2006 |
Clinico-pathological and biological significance of tyrosine kinase domain gene mutations and overexpression of epidermal growth factor receptor for lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2006 |
Increasing osteoblastic lesions as a manifestation of a major response to gefitinib.
Topics: Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2006 |
Systemic therapy of bronchioloalveolar carcinoma: results of the first IASLC/ASCO consensus conference on bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Infusions, Intravenous; Lung Neoplasms; Male; Neoplasm Staging; Paclitaxel; Prognosis; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2006 |
Unusual chemosensitivity of advanced bronchioalveolar carcinoma after gefitinib response and progression: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |
Gefitinib-sensitive EGFR lacking residues 746-750 exhibits hypophosphorylation at tyrosine residue 1045, hypoubiquitination, and impaired endocytosis.
Topics: Animals; Binding Sites; Chlorocebus aethiops; COS Cells; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ligands; Mice; Mutation; Phosphorylation; Phosphotyrosine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Sequence Deletion; Tyrosine; Ubiquitin | 2007 |
Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Genetic; Quinazolines | 2007 |
Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking-associated signature.
Topics: Adult; Aged; Base Sequence; Cluster Analysis; Databases, Genetic; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutagenesis, Insertional; Neoplasms; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines; Sequence Deletion; Smoking | 2007 |
[Outpatient chemotherapy for lung cancer].
Topics: Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Administration Schedule; Etoposide; Gefitinib; Gemcitabine; Humans; Informed Consent; Irinotecan; Lung Neoplasms; Neutropenia; Paclitaxel; Quality of Life; Quinazolines; Taxoids; Vinblastine; Vinorelbine | 2007 |
Remarkable effect of gefitinib retreatment in a patient with nonsmall cell lung cancer who had a complete response to initial gefitinib.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2007 |
Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Combined Modality Therapy; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Rats; Transplantation, Heterologous | 2007 |
Serum tumor markers as predictors for survival in advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; CA-19-9 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Predictive Value of Tests; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
The characteristics and failure pattern of gefitinib responders with postoperative recurrence of pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Care; Quinazolines; Treatment Failure | 2008 |
[Successful individualized and targeted therapy of an NSCLC patient with Gefitinib based on a predictive assessment of the EGF-receptor mutation status].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Sequence Deletion | 2007 |
Iressa strengthens the cytotoxic effect of docetaxel in NSCLC models that harbor specific molecular characteristics.
Topics: Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids; Time Factors | 2007 |
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Amplification; Humans; Indoles; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor; Signal Transduction; Sulfones | 2007 |
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Trastuzumab | 2007 |
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Microtubule-Associated Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Somatomedins; Survivin; Up-Regulation | 2007 |
The prognostic value of chromosome 7 polysomy in non-small cell lung cancer patients treated with gefitinib.
Topics: Aged; Aneuploidy; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Chromosomes, Human, Pair 7; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Logistic Models; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Induction of apoptosis by an inhibitor of EGFR in neuroblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Neuroblastoma; Phosphorylation; Quinazolines | 2007 |
Impact of HER2 and EGFR gene status on gefitinib-treated patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Humans; In Situ Hybridization, Fluorescence; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2007 |
Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer.
Topics: Antineoplastic Agents; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Gefitinib; Genes, Tumor Suppressor; Humans; PTEN Phosphohydrolase; Quinazolines; Retinoblastoma Protein; Transfection; Tumor Suppressor Protein p53 | 2007 |
Epidermal growth factor receptor plays a significant role in hepatocyte growth factor mediated biological responses in mammary epithelial cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2007 |
[Differences in the therapeutic strategies for lung cancer between Europe/United States and Japan].
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Chemotherapy, Adjuvant; Cisplatin; Europe; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tegafur; United States; Uracil | 2007 |
Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cetuximab; Complement System Proteins; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Mutation; Quinazolines; Transfection | 2007 |
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2007 |
Enhancement of docetaxel-induced cytotoxicity by blocking epidermal growth factor receptor and cyclooxygenase-2 pathways in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Docetaxel; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Microtubules; Mitosis; Pyrazoles; Quinazolines; Sulfonamides; Taxoids | 2007 |
AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dimerization; Gefitinib; Humans; Mice; Mice, Inbred Strains; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; RNA, Small Interfering; Stomach Neoplasms; Up-Regulation; Xenograft Model Antitumor Assays | 2007 |
ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p15; Extracellular Signal-Regulated MAP Kinases; Flavonoids; G1 Phase; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Models, Biological; Phosphorylation; Quinazolines; Signal Transduction | 2007 |
[Skin eruptions as an adverse reaction to epidermal growth-factor receptor inhibitors].
Topics: Acneiform Eruptions; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma; Cetuximab; Drug Eruptions; ErbB Receptors; Gefitinib; Humans; Kidney Neoplasms; Male; Melanoma; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2007 |
Inhibition of epidermal growth factor receptor signalling reduces hypercalcaemia induced by human lung squamous-cell carcinoma in athymic mice.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; EGF Family of Proteins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Hypercalcemia; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Parathyroid Hormone-Related Protein; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Signal Transduction; Xenograft Model Antitumor Assays | 2007 |
Relief of symptoms after gefitinib is associated with improvement of rest/activity rhythm in advanced lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Circadian Rhythm; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2007 |
Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Division; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial Cells; Female; Gefitinib; Head and Neck Neoplasms; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Oligonucleotide Array Sequence Analysis; Quinazolines | 2007 |
The epidermal growth factor receptor D761Y mutation and effect of tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Surgical resection after gefitinib treatment in patients with lung adenocarcinoma harboring epidermal growth factor receptor gene mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm, Residual; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Epidermal growth factor receptor mutation in non-small cell lung cancer and breast cancer].
Topics: Adult; Age Distribution; Aged; Base Sequence; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Quinazolines; Racial Groups; Sex Distribution | 2007 |
Serum proteomic classifier for predicting response to epidermal growth factor receptor inhibitor therapy: have we built a better mousetrap?
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
Mass spectrometry to classify non-small-cell lung cancer patients for clinical outcome after treatment with epidermal growth factor receptor tyrosine kinase inhibitors: a multicohort cross-institutional study.
Topics: Adult; Aged; Aged, 80 and over; Algorithms; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Survival Rate; Treatment Outcome | 2007 |
Economic impact of gefitinib for refractory non-small-cell lung cancer: a Markov model-based analysis.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Costs and Cost Analysis; Drug Costs; Female; Gefitinib; Humans; Lung Neoplasms; Male; Markov Chains; Middle Aged; Quinazolines; Survival Analysis | 2007 |
Mutation of the epidermal growth factor receptor gene in the development of adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adenomatosis, Pulmonary; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Mutation; Neoplasms, Multiple Primary; Quinazolines; Retrospective Studies | 2007 |
Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Apoptosis; Breast Neoplasms; Cell Division; Cell Line, Tumor; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Masoprocol; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Selective Estrogen Receptor Modulators; Tamoxifen | 2008 |
[Medical treatment for stage III non-small-cell lung cancer (NSCLC)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Drug Administration Schedule; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Lymphatic Metastasis; Mitomycin; Neoplasm Staging; Paclitaxel; Pneumonectomy; Quinazolines; Radiotherapy Dosage; Radiotherapy, Adjuvant; Survival Rate | 2007 |
To re-treat or not with gefitinib/erlotinib: This is the question for tyrosine kinase inhibitor-responsive lung cancers that progress.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Phosphoproteomics identified Endofin, DCBLD2, and KIAA0582 as novel tyrosine phosphorylation targets of EGF signaling and Iressa in human cancer cells.
Topics: Amino Acid Sequence; Cell Line, Tumor; Epidermal Growth Factor; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Microtubule-Associated Proteins; Molecular Sequence Data; Neoplasms; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Serine Endopeptidases; Signal Transduction; Tandem Mass Spectrometry | 2007 |
Inhibition of the T790M gatekeeper mutant of the epidermal growth factor receptor by EXEL-7647.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azabicyclo Compounds; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mice, SCID; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2007 |
Differential metabolism of gefitinib and erlotinib by human cytochrome P450 enzymes.
Topics: Anesthetics, Intravenous; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Erlotinib Hydrochloride; Gefitinib; Humans; Microsomes, Liver; Midazolam; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins | 2007 |
Can acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors be overcome by different small-molecule tyrosine kinase inhibitors?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2007 |
Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Combined Modality Therapy; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Transplantation, Heterologous; Xenograft Model Antitumor Assays | 2007 |
Potential use of an anticancer drug gefinitib, an EGFR inhibitor, on allergic airway inflammation.
Topics: Animals; Antineoplastic Agents; Bronchoalveolar Lavage Fluid; Cytokines; Enzyme Activation; Eosinophils; ErbB Receptors; Gefitinib; Goblet Cells; Inflammation; Male; Mice; Mice, Inbred BALB C; Ovalbumin; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Respiratory Hypersensitivity; Respiratory Mucosa | 2007 |
Adjuvant chemotherapy of stage I non-small cell lung cancer in North America.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Quinazolines | 2007 |
Clinical significance of epidermal growth factor receptor gene mutations on treatment outcome after first-line cytotoxic chemotherapy in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2007 |
Endothelial growth factor receptor inhibition after radiotherapy.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radiation Injuries; Receptors, Vascular Endothelial Growth Factor; Skin | 2007 |
Combination treatment with ionising radiation and gefitinib ('Iressa', ZD1839), an epidermal growth factor receptor (EGFR) inhibitor, significantly inhibits bladder cancer cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Radiotherapy, Adjuvant; Treatment Outcome; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2007 |
Uncoupling of the epidermal growth factor receptor from downstream signal transduction molecules guides the acquired resistance to gefitinib in prostate cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Male; Nerve Growth Factor; Phosphorylation; Prostatic Neoplasms; Quinazolines; Receptor, ErbB-2; Receptor, Nerve Growth Factor; Receptor, trkA; Receptor, trkB; Signal Transduction; Time Factors | 2007 |
Epidermal growth factor receptor signaling modulates apoptosis via p38alpha MAPK-dependent activation of Bax in intestinal epithelial cells.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Cell Line; Dose-Response Relationship, Drug; Enterocytes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Ileum; Imidazoles; Mitochondria; Mitogen-Activated Protein Kinase 14; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Pyridines; Quinazolines; Rats; RNA Interference; RNA, Small Interfering; Signal Transduction; Time Factors; Tyrphostins | 2007 |
Combined targeting of endothelin A receptor and epidermal growth factor receptor in ovarian cancer shows enhanced antitumor activity.
Topics: Animals; Antineoplastic Agents; Cadherins; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Matrix Metalloproteinase 2; Mice; Mice, Nude; Neoplasm Invasiveness; Ovarian Neoplasms; Pyrrolidines; Quinazolines; Receptor, Endothelin A | 2007 |
Erlotinib response of EGFR-mutant gefitinib-resistant non-small-cell lung cancer.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Tomography, X-Ray Computed | 2007 |
Breast cancer resistance protein (BCRP) affected acquired resistance to gefitinib in a "never-smoked" female patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autopsy; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Fatal Outcome; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Proteins; Quinazolines; Radiography, Thoracic; Smoking; Tomography, X-Ray Computed | 2007 |
Decreased biosynthesis of lung surfactant constituent phosphatidylcholine due to inhibition of choline transporter by gefitinib in lung alveolar cells.
Topics: Animals; Antigens, CD; Cell Line, Tumor; Cells, Cultured; Choline; Gefitinib; Humans; Organic Cation Transport Proteins; Phosphatidylcholines; Pulmonary Alveoli; Pulmonary Surfactants; Quinazolines; Rats; Rats, Wistar | 2008 |
Correlations of EGFR mutations and increases in EGFR and HER2 copy number to gefitinib response in a retrospective analysis of lung cancer patients.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-2; Humans; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Polymorphism, Single Nucleotide; Protein Structure, Tertiary; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2007 |
Personalized medicine and proteomics: lessons from non-small cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Neoplasm Proteins; Proteomics; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2007 |
[Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Breast cancer expressing the activated HER2/neu is sensitive to gefitinib in vitro and in vivo and acquires resistance through a novel point mutation in the HER2/neu.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Mice; Mice, Inbred BALB C; Point Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3 | 2007 |
Molecular mechanisms of ZD1839 (Iressa)-induced apoptosis in human leukemic U937 cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase Inhibitors; Chromones; Dose-Response Relationship, Drug; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; MAP Kinase Signaling System; Morpholines; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-bcl-2; Quinazolines; U937 Cells; X-Linked Inhibitor of Apoptosis Protein | 2007 |
Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Pancreatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids | 2007 |
Gefitinib administration in a patient with lung cancer undergoing hemodialysis.
Topics: Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Quinazolines; Renal Dialysis | 2007 |
Necrotizing vasculitis due to gefitinib (Iressa).
Topics: Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Skin; Vasculitis | 2007 |
EGFR mutants found in non-small cell lung cancer show different levels of sensitivity to suppression of Src: implications in targeting therapy.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Immunoprecipitation; Lung Neoplasms; Phosphorylation; Point Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Quinazolines; Sequence Deletion; Tyrosine | 2008 |
Prostaglandin E2 upregulates EGF-stimulated signaling in mitogenic pathways involving Akt and ERK in hepatocytes.
Topics: Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cells, Cultured; Culture Media, Serum-Free; Cyclin D; Cyclins; Dinoprostone; DNA; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation; Hepatocytes; Liver Neoplasms; Male; Pertussis Toxin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Rats, Wistar; Signal Transduction; Tyrphostins | 2008 |
Potential interaction of chemotherapy and gefitinib in the induction of hematologic neoplasia.
Topics: Adenocarcinoma; Aged; Anemia, Refractory; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Combined Modality Therapy; Deoxycytidine; Drug Interactions; ErbB Receptors; Gefitinib; Gemcitabine; Hematopoiesis; Humans; Leukemia, Promyelocytic, Acute; Lung Neoplasms; Male; Neoplasm Proteins; Neoplasms, Second Primary; Protein Kinase Inhibitors; Quinazolines | 2007 |
[Role of targeted therapy in the treatment of squamous cell head and neck cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cetuximab; Chemotherapy, Adjuvant; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Protein-Tyrosine Kinases; Quinazolines; Radiotherapy, Adjuvant | 2007 |
Acquired trichomegaly and symptomatic external ocular changes in patients receiving epidermal growth factor receptor inhibitors: case reports and a review of literature.
Topics: Acneiform Eruptions; Adenocarcinoma, Bronchiolo-Alveolar; Aged, 80 and over; Antineoplastic Agents; Blepharitis; Carcinoma, Small Cell; ErbB Receptors; Erlotinib Hydrochloride; Eyelashes; Female; Gefitinib; Humans; Hypertrichosis; Lung Neoplasms; Middle Aged; Quinazolines; Retrospective Studies | 2007 |
Heregulin beta1 drives gefitinib-resistant growth and invasion in tamoxifen-resistant MCF-7 breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neuregulin-1; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tamoxifen; Trastuzumab | 2007 |
EGFR exon 20 insertion mutation in Japanese lung cancer.
Topics: Aged; Asian People; Base Sequence; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Neoplasm Recurrence, Local; Quinazolines; Tomography Scanners, X-Ray Computed | 2007 |
Emergence of epidermal growth factor receptor T790M mutation during chronic exposure to gefitinib in a non small cell lung cancer cell line.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3 | 2007 |
Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.
Topics: Antineoplastic Agents; Cell Compartmentation; Cell Line, Tumor; Cell Nucleus; Electrons; Epidermal Growth Factor; ErbB Receptors; Fluorescein-5-isothiocyanate; Fluorescent Dyes; Gefitinib; Humans; Indium Radioisotopes; Pentetic Acid; Phosphorylation; Protein Transport; Quinazolines; Radiopharmaceuticals; Signal Transduction | 2007 |
GM3 synthase gene is a novel biomarker for histological classification and drug sensitivity against epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Animals; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; G(M3) Ganglioside; Gefitinib; Humans; Immunoblotting; Immunoprecipitation; Lung Neoplasms; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Sialyltransferases; Tumor Cells, Cultured | 2007 |
Germline polymorphisms in EGFR and survival in patients with lung cancer receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Survival Rate | 2008 |
[EGFR gene mutation status among lung cancer patients in China].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Gene Frequency; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Sex Factors; Smoking; Treatment Outcome | 2007 |
[EGFR mutation predicts response and prognosis in iressa-treated advanced-stage non-small cell lung cancer].
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Point Mutation; Prognosis; Quinazolines; Sequence Deletion | 2007 |
Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2007 |
Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Prognosis; Quinazolines; Retrospective Studies | 2008 |
Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Tomography, X-Ray Computed | 2007 |
The intestinotrophic peptide, glp-2, counteracts intestinal atrophy in mice induced by the epidermal growth factor receptor inhibitor, gefitinib.
Topics: Animals; Antineoplastic Agents; Atrophy; Body Weight; ErbB Receptors; Female; Gefitinib; Glucagon-Like Peptide 2; Intestines; Mice; Mice, Inbred C57BL; Organ Size; Quinazolines | 2007 |
Exfoliative eruption secondary to gefitinib (ZD1839).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
The LeFE algorithm: embracing the complexity of gene expression in the interpretation of microarray data.
Topics: Algorithms; Breast Neoplasms; Cell Line, Tumor; Cluster Analysis; Computational Biology; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Oligonucleotide Array Sequence Analysis; Pattern Recognition, Automated; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Smoking | 2007 |
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA).
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2007 |
In vitro evaluation of the effects of gefitinib on the modulation of cytotoxic activity of selected anticancer agents in a panel of human ovarian cancer cell lines.
Topics: Antineoplastic Agents; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Interactions; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Indicators and Reagents; Ovarian Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA; RNA, Neoplasm; Signal Transduction; Solutions | 2008 |
Synthesis of gefitinib from methyl 3-hydroxy-4-methoxy-benzoate.
Topics: Antineoplastic Agents; Gefitinib; Hydroxybenzoates; Quinazolines | 2007 |
Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luciferases; Nucleic Acid Hybridization; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tissue Array Analysis; Y-Box-Binding Protein 1 | 2007 |
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Arginine; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Leucine; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Survival Analysis; Treatment Outcome | 2007 |
Pharmacological characterization of MP-412 (AV-412), a dual epidermal growth factor receptor and ErbB2 tyrosine kinase inhibitor.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Membrane; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Piperazines; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Recombinant Proteins | 2007 |
EGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/Akt.
Topics: Adenocarcinoma; Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Differentiation; Cell Line, Tumor; Culture Media, Serum-Free; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2007 |
Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: implication for Gefitinib ('Iressa') response and resistance.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Insulin Receptor Substrate Proteins; Lung Neoplasms; Male; Neoplasms; Prostatic Neoplasms; Quinazolines; Receptor Cross-Talk; Receptors, Somatomedin; Signal Transduction | 2008 |
Aberrant expression of cortactin in head and neck squamous cell carcinoma cells is associated with enhanced cell proliferation and resistance to the epidermal growth factor receptor inhibitor gefitinib.
Topics: Anoikis; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Adhesion; Cell Growth Processes; Chromosomes, Human, Pair 11; Cortactin; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Head and Neck Neoplasms; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2007 |
Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Apoptosis; Biological Transport; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cisplatin; Drug Synergism; Gefitinib; Glucose; Glucose Transporter Type 1; Humans; Neoplasms; Paclitaxel; Quinazolines | 2007 |
PTEN inactivation in lung cancer cells and the effect of its recovery on treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lung Neoplasms; Polymerase Chain Reaction; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sequence Analysis, DNA | 2007 |
Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, Emission-Computed | 2008 |
Expression of epidermal growth factor (EGF)/transforming growth factor-alpha by human lung cancer cells determines their response to EGF receptor tyrosine kinase inhibition in the lungs of mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Phosphorylation; Purines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor alpha; Xenograft Model Antitumor Assays | 2007 |
Apoptotic effects of signal transduction inhibitors on human tumor cells with different PTEN expression.
Topics: Antineoplastic Agents; Apoptosis; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Estrogen Antagonists; Flavonoids; Gefitinib; Humans; Mitogen-Activated Protein Kinases; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tamoxifen | 2007 |
Gefitinib and bicalutamide show synergistic effects in primary cultures of prostate cancer derived from androgen-dependent naive patients.
Topics: Androgens; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; Gefitinib; Humans; Male; Nitriles; Prostatic Neoplasms; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Tosyl Compounds | 2007 |
Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; DNA Fragmentation; Drug Administration Schedule; Endothelium, Vascular; ErbB Receptors; Gefitinib; Glioma; Humans; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Receptor, ErbB-2 | 2007 |
Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Retrospective Studies; Survival Rate; Taxoids; Treatment Outcome | 2008 |
Concomitant chemoirradiation with vinorelbine and gefitinib induces additive effect in head and neck squamous cell carcinoma cell lines in vitro.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Receptor, ErbB-3; Vinblastine; Vinorelbine | 2007 |
Responses of cancer cells with wild-type or tyrosine kinase domain-mutated epidermal growth factor receptor (EGFR) to EGFR-targeted therapy are linked to downregulation of hypoxia-inducible factor-1alpha.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Kinetics; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases | 2007 |
Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Smoking | 2008 |
Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Blotting, Western; Carcinoma; Cell Line, Tumor; Cell Proliferation; Culture Media; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Nick-End Labeling; Neoplasm Proteins; Quinazolines; RNA, Neoplasm; Thyroid Neoplasms | 2007 |
[An octogenarian case of postoperative recurrent lung cancer responding to treatments with radiation plus gefitinib].
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines | 2007 |
Subsequent brain metastasis responses to epidermal growth factor receptor tyrosine kinase inhibitors in a patient with non-small-cell lung cancer.
Topics: Adult; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2007 |
Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Division; Cell Survival; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Prostaglandins E; Pyrazoles; Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2007 |
17beta-estradiol promotes breast cancer cell proliferation-inducing stromal cell-derived factor-1-mediated epidermal growth factor receptor transactivation: reversal by gefitinib pretreatment.
Topics: Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Chemokine CXCL12; ErbB Receptors; Estradiol; Gefitinib; Humans; Quinazolines; Transcriptional Activation | 2008 |
Improved synthesis of substituted 6,7-dihydroxy-4-quinazolineamines: tandutinib, erlotinib and gefitinib.
Topics: Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Magnetic Resonance Spectroscopy; Piperazines; Protein Kinase Inhibitors; Quinazolines | 2006 |
Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Capillary Permeability; Contrast Media; Gadolinium DTPA; Gefitinib; Magnetic Resonance Imaging; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2007 |
BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines | 2007 |
Gefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimetics.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Nitrophenols; Piperazines; Proto-Oncogene Proteins; Quinazolines; Sulfonamides | 2007 |
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; MAP Kinase Signaling System; Mouth Mucosa; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; Time Factors | 2007 |
Gemcitabine resistance in a highly metastatic subpopulation of a pulmonary adenocarcinoma cell line resistant to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; bcl-X Protein; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Resistance, Neoplasm; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasm Metastasis; Quinazolines; RNA, Small Interfering; Transfection | 2007 |
Erosive pustular dermatosis of the scalp after gefitinib and radiotherapy for brain metastases secondary to lung cancer.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Combined Modality Therapy; Female; Gefitinib; Humans; Quinazolines; Radiotherapy; Scalp Dermatoses | 2008 |
Prolonged response to oral gefitinib, cyclophosphamide, and topotecan in heavily pretreated relapsed stage 4 neuroblastoma: a case report.
Topics: Administration, Oral; Adrenal Gland Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Child, Preschool; Cyclophosphamide; Female; Gefitinib; Humans; Neuroblastoma; Quinazolines; Radionuclide Imaging; Recurrence; Topotecan; Treatment Outcome | 2007 |
Progressive loss of epidermal growth factor receptor in a subpopulation of breast cancers: implications in target-directed therapeutics.
Topics: Animals; Asian People; Breast Neoplasms; Cell Line, Tumor; Disease Progression; Drug Delivery Systems; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Mice; Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphotyrosine; Proteomics; Quinazolines; Reproducibility of Results | 2007 |
'Classical' but not 'other' mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Frequency; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2007 |
KL-6 and poor prognosis in NSCLC patients treated with gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Mucin-1; Quinazolines | 2008 |
Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Estradiol; Gefitinib; Humans; Methotrexate; Mitoxantrone; Neoplasm Proteins; Neoplasms; Paclitaxel; Protein Binding; Quinazolines | 2007 |
[A case of postoperative recurrent lung cancer with long survival due to gefitinib efficacy].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Recurrence, Local; Quinazolines; Survivors | 2007 |
Breast cancer cells with acquired resistance to the EGFR tyrosine kinase inhibitor gefitinib show persistent activation of MAPK signaling.
Topics: Blotting, Western; Breast Neoplasms; Cell Adhesion; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Immunoprecipitation; Mitogen-Activated Protein Kinase 1; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured | 2008 |
[Gefitinib in the treatment of male patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease Progression; ErbB Receptors; Exanthema; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2007 |
Gefitinib prevents cancer progression in mice expressing the activated rat HER2/neu.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Acinar Cell; Carcinoma, Lobular; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Mice; Mice, Inbred BALB C; Mice, Transgenic; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Receptor, ErbB-2; Signal Transduction; Up-Regulation | 2008 |
[Cytotoxic effect of epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in combination with oxaliplatin on lung cancer cell line A549].
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Organoplatinum Compounds; Oxaliplatin; Protein Kinase Inhibitors; Quinazolines; Tumor Burden | 2007 |
[Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Particle Accelerators; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Stomach Neoplasms | 2007 |
[In these days molecule target drug in advanced non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Delivery Systems; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2007 |
Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Time Factors | 2008 |
The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; G1 Phase; Gefitinib; Gene Silencing; Humans; Immunohistochemistry; Quinazolines; Resting Phase, Cell Cycle; RNA, Small Interfering | 2007 |
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Division; Cell Line, Tumor; Cloning, Molecular; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Oncogene Proteins v-erbB; Quinazolines; Quinazolinones | 2007 |
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Chromosomes, Human, Pair 7; Cohort Studies; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines | 2007 |
Involvement of EGFR in the response of squamous cell carcinoma of the head and neck cell lines to gefitinib.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Molecular Sequence Data; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2008 |
Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bisbenzimidazole; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Sulfonamides | 2008 |
Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Topics: Aged; Antineoplastic Agents; Drug Eruptions; Gefitinib; Humans; Livedo Reticularis; Male; Prostatic Neoplasms; Purpura; Quinazolines; Skin | 2007 |
Prognostic factors for gefitinib-treated postoperative recurrence in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Postoperative Period; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2007 |
Signaling networks assembled by oncogenic EGFR and c-Met.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Models, Biological; Neoplasm Metastasis; Phosphotyrosine; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2008 |
[A case of lung cancer with alkaline phosphatase flare phenomenon during gefitinib therapy].
Topics: Adenocarcinoma; Aged; Alkaline Phosphatase; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2007 |
[Molecular targeted therapy and tailor-made therapy for lung cancer].
Topics: Antineoplastic Agents; Drug Delivery Systems; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2008 |
Analysis of duration of response in oncology trials.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Cytotoxins; Data Interpretation, Statistical; Gefitinib; Humans; Models, Theoretical; Neoplasms; Prognosis; Quinazolines; Time Factors; Treatment Outcome | 2008 |
Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Vascular Endothelial Growth Factor A | 2008 |
Mucoepidermoid carcinoma of lung: potential target of EGFR-directed treatment.
Topics: Adult; Antineoplastic Agents; Carcinoma, Mucoepidermoid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Predictors of survival in patients with bone metastasis of lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Time Factors; Treatment Outcome | 2008 |
Short-term gefitinib treatment brought about a long-term regression of bronchioloalveolar carcinoma without EGFR gene alterations: a case report.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Remission Induction | 2007 |
Impact of common epidermal growth factor receptor and HER2 variants on receptor activity and inhibition by lapatinib.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Models, Molecular; Mutant Proteins; Phosphorylation; Polymorphism, Single Nucleotide; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Tumor Cells, Cultured | 2008 |
E-cadherin expression and epidermal growth factor receptor mutation status predict outcome in non-small cell lung cancer patients treated with gefitinib.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2008 |
[Analysis of therapeutic efficacy in 49 patients with advanced non-small cell cancer treated with gefitinib].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate; Vomiting | 2007 |
Late fatal recurrence in gefitinib-treated NSCLC patients.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diagnosis, Differential; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Tomography, X-Ray Computed | 2007 |
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP.
Topics: Adenosine Triphosphate; Animals; Crystallography, X-Ray; Drug Resistance; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Insecta; Kinetics; Mutation; Protein Conformation; Quinazolines | 2008 |
Molecule of the month. Overcoming resistance.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Design; Drug Resistance; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2008 |
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; Sequence Deletion | 2008 |
Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.
Topics: Animals; Cell Line, Tumor; Chlorocebus aethiops; ErbB Receptors; Fluorine Radioisotopes; Gefitinib; Metabolic Clearance Rate; Mice; Molecular Probe Techniques; Neoplasms; Organ Specificity; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2008 |
Case report: dramatic recovery of lung adenocarcinoma-associated dermatomyositis with targeted lung cancer therapy alone.
Topics: Adenocarcinoma; Antineoplastic Agents; Dermatomyositis; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Treatment Outcome | 2008 |
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
Topics: Animals; Breast Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptor, ErbB-2; Receptor, IGF Type 1; Receptors, Estrogen; Signal Transduction; Tamoxifen; Transcription, Genetic; Xenograft Model Antitumor Assays | 2008 |
Characterization of the functional and growth properties of cell lines established from ileal and rectal carcinoid tumors.
Topics: Adenoviridae; Antigens, Polyomavirus Transforming; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoid Tumor; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genetic Vectors; Humans; Ileal Neoplasms; Immunohistochemistry; Octreotide; Oligonucleotide Array Sequence Analysis; Quinazolines; Receptors, Calcitriol; Receptors, Somatostatin; Rectal Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factors | 2007 |
EGFR and VEGFR as potential target for biological therapies in HCC cells.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor | 2008 |
Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Molecular Sequence Data; Mutation; Quinazolines; Treatment Outcome | 2008 |
[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2007 |
Phosphorylation status of epidermal growth factor receptor is closely associated with responsiveness to gefitinib in pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Polymerase Chain Reaction; Quinazolines | 2008 |
Peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp-based detection test for gefitinib-refractory T790M epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Oligonucleotides; Peptide Nucleic Acids; Point Mutation; Polymerase Chain Reaction; Quinazolines; Sensitivity and Specificity | 2008 |
Epidermal growth factor receptor mutation, but not sex and smoking, is independently associated with favorable prognosis of gefitinib-treated patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Prognosis; Quinazolines; Sex Factors; Smoking; Treatment Outcome | 2008 |
Dual mechanisms of action of the 5-benzylidene-hydantoin UPR1024 on lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzylidene Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; DNA Damage; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydantoins; Lung Neoplasms; Models, Biological; Phosphorylation; Quinazolines; Tumor Suppressor Protein p53 | 2008 |
Preclinical pharmacokinetic/pharmacodynamic models of gefitinib and the design of equivalent dosing regimens in EGFR wild-type and mutant tumor models.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Models, Biological; Mutation; Pharmacogenetics; Quinazolines; Xenograft Model Antitumor Assays | 2008 |
Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Comet Assay; DNA Repair; Electrophoresis, Gel, Pulsed-Field; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Quinazolines; Radiation Tolerance; Radiotherapy | 2008 |
Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Erythema; Female; Gefitinib; Humans; Leg; Lung Neoplasms; Male; Purpura; Quinazolines | 2008 |
Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells.
Topics: AC133 Antigen; Antigens, CD; Brain Neoplasms; Enzyme Inhibitors; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Models, Biological; Peptides; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Stem Cells; Tumor Cells, Cultured; Tyrphostins | 2008 |
Human cervical carcinomas and EGF-R tyrosine kinase inhibitors.
Topics: Carcinoma, Squamous Cell; Clinical Trials, Phase II as Topic; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Uterine Cervical Neoplasms | 2008 |
Expression of signaling mediators downstream of EGF-receptor predict sensitivity to small molecule inhibitors directed against the EGF-receptor pathway.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Farnesyltranstransferase; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Morpholines; Phosphatidylinositols; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins; Sirolimus | 2008 |
Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genes, ras; Humans; In Situ Hybridization; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2008 |
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Survival Analysis | 2008 |
Gefitinib potentiates myeloid cell differentiation by ATRA.
Topics: Antineoplastic Agents; Bone Marrow Cells; Cell Differentiation; Drug Synergism; Gefitinib; HL-60 Cells; Humans; Leukemia, Myeloid, Acute; Quinazolines; Tretinoin | 2008 |
Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.
Topics: Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Inhibition of mTOR pathway by everolimus cooperates with EGFR inhibitors in human tumours sensitive and resistant to anti-EGFR drugs.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Everolimus; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Neoplasm Transplantation; Neoplasms; Neovascularization, Physiologic; Protein Kinases; Quinazolines; Sirolimus; TOR Serine-Threonine Kinases; Transplantation, Heterologous | 2008 |
Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Quinazolines | 2008 |
siRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma; DNA Mutational Analysis; DNA, Neoplasm; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Gene Targeting; Genes, ras; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Receptor, ErbB-2; RNA, Small Interfering | 2008 |
Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Gefitinib; Humans; Incidence; Japan; Kaplan-Meier Estimate; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2008 |
Epidermal growth factor receptor inhibitors and hair.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hair; Humans; Neoplasms; Quinazolines | 2008 |
Recurrent gefitinib-induced interstitial lung disease.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Tomography, X-Ray Computed | 2008 |
Synergistic antitumor effect of S-1 and the epidermal growth factor receptor inhibitor gefitinib in non-small cell lung cancer cell lines: role of gefitinib-induced down-regulation of thymidylate synthase.
Topics: Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Probes; Down-Regulation; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Thymidylate Synthase | 2008 |
Combined lapatinib and cetuximab enhance cytotoxicity against gefitinib-resistant lung cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Chlorocebus aethiops; COS Cells; Dimerization; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Lapatinib; Lung Neoplasms; Mutation; Quinazolines | 2008 |
Contact spotting of protein microarrays coupled with spike-in of normalizer protein permits time-resolved analysis of ERBB receptor signaling.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glutathione Transferase; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Protein Array Analysis; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-4; Recombinant Fusion Proteins; Reference Standards; Signal Transduction; Trastuzumab; Tumor Cells, Cultured | 2008 |
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Base Sequence; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Rearrangement; Humans; Male; Mesothelioma; Mice; Mice, SCID; Molecular Sequence Data; Neoplasm Transplantation; Neovascularization, Pathologic; Piperidines; Pleural Neoplasms; Proto-Oncogene Proteins c-ret; Quinazolines; Transplantation, Heterologous; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Improvement of cytotoxic effects induced by mitoxantrone on hormone-refractory metastatic prostate cancer cells by co-targeting epidermal growth factor receptor and hedgehog signaling cascades.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Hedgehog Proteins; Humans; Hydrogen Peroxide; Male; Membrane Potential, Mitochondrial; Mitoxantrone; Neoplasm Invasiveness; Neoplasms, Hormone-Dependent; Prostatic Neoplasms; Quinazolines; Signal Transduction; Veratrum Alkaloids | 2007 |
Effects of gefitinib (Iressa) on mammary cancers: preventive studies with varied dosages, combinations with vorozole or targretin, and biomarker changes.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bexarotene; Biomarkers, Tumor; Carcinogens; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Mammary Neoplasms, Experimental; Methylnitrosourea; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Tetrahydronaphthalenes; Triazoles | 2008 |
The role of repair protein Rad51 in synergistic cytotoxicity and mutagenicity induced by epidermal growth factor receptor inhibitor (Gefitinib, IressaR) and benzo[a]pyrene in human lung cancer.
Topics: Antineoplastic Agents; Benzo(a)pyrene; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mutagens; Proteasome Endopeptidase Complex; Quinazolines; Rad51 Recombinase; RNA Interference | 2008 |
Does gefitinib shorten lung cancer survival? Chaos redux.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Rate; Time Factors | 2008 |
Evidence for disease control with erlotinib after gefitinib failure in typical gefitinib-sensitive Asian patients with non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2008 |
Lung adenocarcinoma with good response to erlotinib after gefitinib treatment failure and acquired T790M mutation.
Topics: Adenocarcinoma; Aged; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Tomography Scanners, X-Ray Computed; Treatment Failure | 2008 |
Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cadherins; Carcinoma, Hepatocellular; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Insulin-Like Growth Factor II; Liver Neoplasms; Mesoderm; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; STAT3 Transcription Factor; Vimentin | 2008 |
Synergistic anti-proliferative and pro-apoptotic activity of combined therapy with bortezomib, a proteasome inhibitor, with anti-epidermal growth factor receptor (EGFR) drugs in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Cell Line, Tumor; Cetuximab; Dose-Response Relationship, Drug; Drug Combinations; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Mitogen-Activated Protein Kinases; Piperidines; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Signal Transduction | 2008 |
18F-fluoro-2-deoxy-glucose uptake predicts clinical outcome in patients with gefitinib-treated non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Chromones; ErbB Receptors; Gefitinib; Humans; Lapatinib; Male; Mitogen-Activated Protein Kinases; Morpholines; Neoplasms, Hormone-Dependent; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Prostatic Neoplasms; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines | 2008 |
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Brain Neoplasms; Chemotherapy, Adjuvant; Child; Enzyme Activation; Ependymoma; ErbB Receptors; Female; Flow Cytometry; G1 Phase; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; In Situ Nick-End Labeling; Mice; Mice, Nude; Middle Aged; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Radiation-Sensitizing Agents; Radiotherapy, Adjuvant; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2008 |
Peritoneal carcinomatosis in lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Peritoneal Neoplasms; Quinazolines; Retrospective Studies; Taiwan | 2008 |
Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Immunoblotting; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Signal Transduction; Transfection | 2008 |
[A case of lung adenocarcinoma effectively treated with sivelestat and corcicosteroid for drug-induced lung disease due to gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Gefitinib; Glycine; Humans; Lung Diseases; Lung Neoplasms; Male; Prednisolone; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides | 2008 |
Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors.
Topics: Actins; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Endoplasmic Reticulum; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptors, TNF-Related Apoptosis-Inducing Ligand; Reverse Transcriptase Polymerase Chain Reaction; Sulfonamides | 2008 |
The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cells, Cultured; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Mice; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinolines | 2008 |
Epidermal growth factor receptor controls flat dysplastic aberrant crypt foci development and colon cancer progression in the rat azoxymethane model.
Topics: Animals; Azoxymethane; CCAAT-Enhancer-Binding Protein-beta; Colonic Neoplasms; Cyclin D; Cyclins; Disease Progression; ErbB Receptors; Gefitinib; Male; Precancerous Conditions; Quinazolines; Rats; Rats, Inbred F344; STAT3 Transcription Factor; Transcription Factor AP-1 | 2008 |
EGFR/KRAS mutations and gefitinib therapy in Chinese NSCLC patients.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Markers; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Treatment Outcome | 2008 |
Implications of EGFR inhibition in ovarian cancer cell proliferation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Base Sequence; Cell Growth Processes; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Humans; Molecular Sequence Data; Mutation; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGF receptor tyrosine kinase inhibitors diminish transforming growth factor-alpha-induced pulmonary fibrosis.
Topics: Animals; Bronchoalveolar Lavage Fluid; Doxycycline; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Mice; Pulmonary Fibrosis; Quinazolines; RNA, Messenger; Transforming Growth Factor alpha | 2008 |
A stable explant culture of HER2/neu invasive carcinoma supported by alpha-Smooth Muscle Actin expressing stromal cells to evaluate therapeutic agents.
Topics: Actins; Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Lobular; Cell Culture Techniques; Cell Line, Tumor; Coculture Techniques; Dose-Response Relationship, Drug; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Male; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Models, Biological; Muscle, Smooth; Quinazolines; Stromal Cells | 2008 |
Targeting EGFR activity in blood vessels is sufficient to inhibit tumor growth and is accompanied by an increase in VEGFR-2 dependence in tumor endothelial cells.
Topics: Animals; Cell Line; Cell Line, Tumor; Cell Proliferation; Cinnamates; Endothelial Cells; Endothelium, Vascular; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neuropilin-1; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transplantation, Heterologous; Tyrphostins; Vascular Endothelial Growth Factor Receptor-2 | 2008 |
Successful treatment of carcinomatous meningitis with gefitinib in a patient with lung adenocarcinoma harboring a mutated EGF receptor gene.
Topics: Adenocarcinoma; Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Meningitis; Middle Aged; Mutation; Quinazolines; Radiotherapy | 2008 |
Gefitinib-associated Propionibacterium acnes pleural empyema.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Empyema, Pleural; Female; Gefitinib; Gram-Positive Bacterial Infections; Humans; Lung Neoplasms; Middle Aged; Pleurodesis; Propionibacterium acnes; Quinazolines | 2008 |
Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.
Topics: Breast Neoplasms; Cell Proliferation; Drug Combinations; Enzyme Activation; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Indoles; Phosphorylation; Piperazines; Protein Array Analysis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Sulfonamides; Tumor Cells, Cultured | 2008 |
Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Nude; Quinazolines; Sarcoma | 2008 |
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Biopsy, Needle; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Analysis; Treatment Outcome | 2008 |
Effects of gefitinib on radiation-induced lung injury in mice.
Topics: Animals; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Lung; Mice; Mice, Inbred C57BL; Quinazolines; Radiation Injuries, Experimental | 2008 |
Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines.
Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines; Thyroid Neoplasms | 2008 |
Association of the benefit from gefitinib monotherapy with smoking status in Japanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Salvage Therapy; Smoking; Survival Analysis | 2008 |
Evidence for efficient phosphorylation of EGFR and rapid endocytosis of phosphorylated EGFR via the early/late endocytic pathway in a gefitinib-sensitive non-small cell lung cancer cell line.
Topics: Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Endocytosis; Endosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Fluorescence; Phosphorylation; Quinazolines; Signal Transduction; Sorting Nexins; Vesicular Transport Proteins | 2008 |
Mutations of epidermal growth factor receptor in colon cancer indicate susceptibility or resistance to gefitinib.
Topics: Antineoplastic Agents; Blotting, Western; Colonic Neoplasms; Disease Susceptibility; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mutagenesis, Site-Directed; Mutation; Quinazolines; Tumor Cells, Cultured | 2008 |
Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells.
Topics: Acid Anhydride Hydrolases; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; DNA-Binding Proteins; ErbB Receptors; G1 Phase; Gefitinib; Head and Neck Neoplasms; Humans; Immunoprecipitation; Inhibitory Concentration 50; Membrane Proteins; Mutation; Neoplasm Proteins; Nuclear Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Resting Phase, Cell Cycle; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Tumor Protein p73; Tumor Suppressor Protein p53; Tumor Suppressor Proteins | 2008 |
Estrogen receptor (ER) and epidermal growth factor receptor (EGFR) as targets for dual lung cancer therapy: not just a case?
Topics: Adenocarcinoma; Antineoplastic Agents; Diagnosis, Differential; Drug Therapy, Combination; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Letrozole; Lung Neoplasms; Middle Aged; Nitriles; Protein Kinase Inhibitors; Quinazolines; Receptors, Estrogen; Skin Neoplasms; Triazoles | 2008 |
From nihilism to individualism: the evolution of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Basis of acute exacerbation of idiopathic pulmonary fibrosis in Japanese patients.
Topics: Acute Disease; Asian People; Gefitinib; Genetic Predisposition to Disease; Humans; Japan; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines | 2008 |
Response of malignant thymoma to erlotinib.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Epidermal Growth Factor; Erlotinib Hydrochloride; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Protein Kinase Inhibitors; Quinazolines; Thymoma | 2008 |
EGFR polymorphism of the kinase domain in Japanese lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Polymorphism, Genetic; Prognosis; Quinazolines | 2008 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Involvement of Rad51 in cytotoxicity induced by epidermal growth factor receptor inhibitor (gefitinib, IressaR) and chemotherapeutic agents in human lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mitomycin; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; RNA, Messenger; Transfection | 2008 |
Translational research: the full cycle.
Topics: AIDS Vaccines; Animals; Biomedical Research; Child; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Genetic Therapy; Humans; Interleukin Receptor Common gamma Subunit; Leukemia; Male; Pharmacogenetics; Quinazolines; Specimen Handling; Technology Transfer; Treatment Failure; X-Linked Combined Immunodeficiency Diseases | 2008 |
Induction of lung adenocarcinoma in transgenic mice expressing activated EGFR driven by the SP-C promoter.
Topics: Adenocarcinoma; Animals; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred C57BL; Mice, Transgenic; Mutation; Peptides; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein C; Quinazolines | 2008 |
Lovastatin enhances gefitinib activity in glioblastoma cells irrespective of EGFRvIII and PTEN status.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glioblastoma; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; PTEN Phosphohydrolase; Quinazolines | 2008 |
Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Insulin Receptor Substrate Proteins; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Insulin-Like Growth Factor Binding Proteins; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2008 |
Mechanisms of resistance to ErbB-targeted cancer therapeutics.
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Mice; Mutation; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, IGF Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2008 |
Biochemical assay-based selectivity profiling of clinically relevant kinase inhibitors on mutant forms of EGF receptor.
Topics: Aminoquinolines; Aniline Compounds; Biological Assay; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Inhibitory Concentration 50; Morpholines; Mutant Proteins; Protein Kinase Inhibitors; Quinazolines; Substrate Specificity; Tyrphostins | 2008 |
Tubulointerstitial nephritis and IgA nephropathy in a patient with advanced lung cancer treated with long-term gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; Dose-Response Relationship, Drug; Female; Gefitinib; Glomerulonephritis, IGA; Humans; Kidney; Lung Neoplasms; Middle Aged; Nephritis, Interstitial; Quinazolines | 2008 |
First- or second-line therapy with gefitinib produces equal survival in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2008 |
Immunohistochemical analysis of phosphorylated epidermal growth factor receptor might provide a surrogate marker of EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
[Targeted therapy for metastatic bladder cancer].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Transitional Cell; Disease Progression; Drug Delivery Systems; Gefitinib; Humans; Lapatinib; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-2; Receptors, Growth Factor; Sorafenib; Survival Rate; Trastuzumab; Urinary Bladder Neoplasms | 2008 |
Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Epithelium; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesoderm; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor beta1 | 2009 |
Prolonged response to gefitinib in bone metastasis.
Topics: Adenocarcinoma; Antineoplastic Agents, Phytogenic; Back Pain; Carboplatin; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Spinal Neoplasms; Time Factors | 2009 |
Erlotinib and gefitinib for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a preclinical comparison.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; Cell Differentiation; Cell Line, Tumor; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Protein Kinase Inhibitors; Quinazolines | 2008 |
Sex difference in the influence of smoking status on the responsiveness to gefitinib monotherapy in adenocarcinoma of the lung: Okayama Lung Cancer Study Group experience.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Sex Factors; Smoking; Survival Rate; Treatment Outcome | 2009 |
[Successful treatment of non-small cell lung cancer by gefitinib in an elderly patient with poor performance status].
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Karnofsky Performance Status; Lung Neoplasms; Quinazolines | 2008 |
[Effect of gefinitib on airway mucus hypersecretion induced by acrolein in rats].
Topics: Acrolein; Animals; ErbB Receptors; Gefitinib; Goblet Cells; Immunohistochemistry; Male; Mucin 5AC; Mucus; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Respiratory Mucosa; Reverse Transcriptase Polymerase Chain Reaction | 2008 |
[EGFR and gefitinib (Iressa)].
Topics: Animals; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Polymorphism, Genetic; Promoter Regions, Genetic; Quinazolines; Substrate Specificity | 2008 |
Antitumor effect of gefitinib on head and neck squamous cell carcinoma enhanced by trastuzumab.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Squamous Cell; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Cells, Cultured | 2008 |
Significant cytotoxic activity in vitro of the EGFR tyrosine kinase inhibitor gefitinib in acute myeloblastic leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Apoptosis; Caspase 3; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Immunochemistry; Leukemia, Myeloid, Acute; Male; Middle Aged; Quinazolines; Tumor Cells, Cultured | 2008 |
Is vascular endothelial growth factor modulation a predictor of the therapeutic efficacy of gefitinib for bladder cancer?
Topics: Analysis of Variance; Animals; Apoptosis; Carcinoma, Transitional Cell; Cell Line, Tumor; DNA, Neoplasm; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factor A | 2008 |
Case records of the Massachusetts General Hospital. Case 23-2008. A 26-year-old man with back pain and a mass in the lung.
Topics: Adenocarcinoma; Adult; Back Pain; Diagnosis, Differential; Drug Resistance, Neoplasm; Fractures, Compression; Gefitinib; Genes, erbB-1; Humans; Lung; Lung Neoplasms; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Quinazolines; Radiography; Sequence Deletion; Spinal Fractures; Thoracic Vertebrae | 2008 |
Computed tomography-guided core-needle biopsy specimens demonstrate epidermal growth factor receptor mutations in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tomography, X-Ray Computed | 2008 |
Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Culture Media, Conditioned; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Indoles; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinazolines; Vascular Endothelial Growth Factor A | 2008 |
Somatic mutations of the tyrosine kinase domain of epidermal growth factor receptor and tyrosine kinase inhibitor response to TKIs in non-small cell lung cancer: an analytical database.
Topics: Carcinoma, Non-Small-Cell Lung; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2008 |
Erlotinib after failure of gefitinib in patients with advanced non-small cell lung cancer previously responding to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Drug interaction between complementary herbal medicines and gefitinib.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Female; Gefitinib; Herb-Drug Interactions; Herbal Medicine; Humans; Lung Neoplasms; Plants, Medicinal; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2008 |
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2008 |
Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.
Topics: Animals; Antineoplastic Agents; Base Sequence; Blotting, Western; Cell Division; Cell Line, Tumor; Cell Proliferation; DNA Primers; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression; Immunoprecipitation; Ligands; Mice; Mice, Nude; Pituitary Neoplasms; Polymerase Chain Reaction; Prolactinoma; Quinazolines; Rats | 2008 |
Promising newer molecular-targeted therapies in head and neck cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzenesulfonates; Cetuximab; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Models, Biological; Niacinamide; Panitumumab; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Sorafenib | 2008 |
Displayed correlation between gene expression profiles and submicroscopic alterations in response to cetuximab, gefitinib and EGF in human colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Cell Survival; Cetuximab; Cluster Analysis; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Microscopy, Electron, Scanning; Microvilli; Oligonucleotide Array Sequence Analysis; Quinazolines | 2008 |
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3.
Topics: Aged; Animals; Apoptosis; bcl-X Protein; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoprecipitation; Inositol 1,4,5-Trisphosphate Receptors; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Middle Aged; Mitochondria; Neoplasms; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiopharmaceuticals; Signal Transduction; Technetium Tc 99m Sestamibi | 2008 |
Pilot study of gefitinib and fulvestrant in the treatment of post-menopausal women with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Pilot Projects; Postmenopause; Prognosis; Quinazolines; Safety; Survival Rate; Treatment Outcome | 2009 |
Dual targeting of EGFR and HER-2 in colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Regression of cervical spinal cord compression in a patient with chordoma following treatment with cetuximab and gefitinib.
Topics: Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Cervical Vertebrae; Cetuximab; Chordoma; Female; Gefitinib; Humans; Middle Aged; Quinazolines; Spinal Cord Compression | 2009 |
In vitro evaluation of the effects of gefitinib on the cytotoxic activity of selected anticancer agents in a panel of human endometrial cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP-Binding Cassette Transporters; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Drug Synergism; Endometrial Neoplasms; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2009 |
N-Glycan fucosylation of epidermal growth factor receptor modulates receptor activity and sensitivity to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: ErbB Receptors; Fucosyltransferases; Gefitinib; Glycosylation; Humans; Polysaccharides; Protein Kinase Inhibitors; Quinazolines | 2008 |
Suppression of surfactant protein A by an epidermal growth factor receptor tyrosine kinase inhibitor exacerbates lung inflammation.
Topics: Adenocarcinoma; Animals; Gefitinib; Gene Expression; Humans; In Vitro Techniques; Lipopolysaccharides; Lung Diseases, Interstitial; Mice; Pneumonia; Protein Kinase Inhibitors; Pulmonary Surfactant-Associated Protein A; Quinazolines; Signal Transduction | 2008 |
Proteomics study of medullary thyroid carcinomas expressing RET germ-line mutations: identification of new signaling elements.
Topics: Animals; Antineoplastic Agents; Carcinoma, Medullary; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Germ-Line Mutation; Humans; Mice; Mice, Nude; Multiple Endocrine Neoplasia Type 2a; Multiple Endocrine Neoplasia Type 2b; Oncogene Proteins; Phosphorylation; Proteomics; Proto-Oncogene Proteins c-ret; Quinazolines; Signal Transduction; Thyroid Neoplasms; Tyrosine | 2009 |
Lung cancer response to gefitinib, then erlotinib, then gefitinib again.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography; Treatment Outcome | 2008 |
Targeting Hsp90 prevents escape of breast cancer cells from tyrosine kinase inhibition.
Topics: Animals; Apoptosis; Benzoquinones; Breast Neoplasms; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Enzyme Activation; Gefitinib; HSP90 Heat-Shock Proteins; Lactams, Macrocyclic; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins pp60(c-src); Quinazolines; Receptor, ErbB-3; Serum; Signal Transduction | 2008 |
Cytotoxic and apoptotic effects of bortezomib and gefitinib compared to alkylating agents on human glioblastoma cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Boronic Acids; Bortezomib; Brain Neoplasms; Carboplatin; Carmustine; Cell Line, Tumor; Dacarbazine; Dose-Response Relationship, Drug; ErbB Receptors; Flow Cytometry; Gefitinib; Glial Fibrillary Acidic Protein; Glioblastoma; Immunohistochemistry; Indicators and Reagents; Mice; Proteasome Inhibitors; Pyrazines; Quinazolines; Rats; Temozolomide; Tetrazolium Salts; Thiazoles | 2008 |
Synthesis and in vitro antitumor activities of novel 4-anilinoquinazoline derivatives.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Neoplasms; Phosphotransferases; Protein Structure, Tertiary; Quinazolines | 2009 |
Gefitinib maintenance in stage III non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis | 2008 |
SWOG S0023: what meets the eye may be only half the truth.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib for recurrent non-small-cell lung cancer: all things are not created equal.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2008 |
Gefitinib in advanced non-small cell lung cancer: does it deserve a second chance?
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Survival Rate | 2008 |
EGFR genetic heterogeneity of nonsmall cell lung cancers contributing to acquired gefitinib resistance.
Topics: Aged; Base Sequence; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2008 |
Epidermal growth factor receptor expression analysis in chemotherapy-naive patients with advanced non-small-cell lung cancer treated with gefitinib or placebo in combination with platinum-based chemotherapy.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Carcinoma, Non-Small-Cell Lung; Cell Division; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Lung Neoplasms; Neoplasm Staging; Placebos; Platinum Compounds; Prognosis; Quinazolines; Survival Analysis | 2009 |
Polyethylene glycol-mediated colorectal cancer chemoprevention: roles of epidermal growth factor receptor and Snail.
Topics: Animals; Azoxymethane; Cell Proliferation; Chemoprevention; Colorectal Neoplasms; Down-Regulation; Epithelial Cells; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Intestinal Mucosa; Lysosomes; Male; Models, Biological; Polyethylene Glycols; Quinazolines; Rats; Rats, Inbred F344; Repressor Proteins; Snail Family Transcription Factors; Transcription Factors; Transcription, Genetic | 2008 |
Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
Topics: Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Drug Resistance, Neoplasm; Estradiol; Estrogen Receptor alpha; Estrogens; Fulvestrant; Gefitinib; Gene Expression Profiling; Humans; Mice; Mice, Nude; Ovariectomy; Quinazolines; Receptor, ErbB-2; RNA, Messenger; Tamoxifen; Xenograft Model Antitumor Assays | 2008 |
DNA vaccination controls Her-2+ tumors that are refractory to targeted therapies.
Topics: Animals; Antibodies, Monoclonal; Cancer Vaccines; Cell Growth Processes; Female; Gefitinib; Karyotyping; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Quinazolines; Receptor, ErbB-2; Signal Transduction; T-Lymphocytes, Cytotoxic; Tyrphostins; Vaccines, DNA | 2008 |
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Treatment Outcome | 2008 |
Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cisplatin; Cyclin D1; DNA, Complementary; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Immunoblotting; Immunoprecipitation; Neoplasms; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Repressor Proteins; RNA, Small Interfering; Sequence Analysis, DNA; Signal Transduction | 2008 |
An alternative method for screening EGFR mutation using RFLP in non-small cell lung cancer patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Dinucleotide Repeats; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunoenzyme Techniques; Introns; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2008 |
Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators.
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; DNA Damage; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Inhibitory Concentration 50; Janus Kinase 2; Mice; Quinazolines; STAT3 Transcription Factor | 2008 |
Gefitinib first or gefitinib second: is timing everything in the treatment of EGFR mutant non-small cell lung cancer?
Topics: Carcinoma, Non-Small-Cell Lung; DNA, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2008 |
Antitumor activity of a new N-substituted thiourea derivative, an EGFR signaling-targeted inhibitor against a panel of human lung cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Colony-Forming Units Assay; DNA; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thiourea | 2008 |
Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats.
Topics: Administration, Oral; Animals; Biliary Tract; Camptothecin; Gefitinib; Irinotecan; Male; Quinazolines; Rats; Rats, Wistar | 2008 |
MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clinical Trials, Phase II as Topic; Cohort Studies; Disease Progression; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Dosage; Gene Expression Regulation, Neoplastic; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptors, Growth Factor; Survival Analysis | 2009 |
[Evaluation of efficacy and safety of ZD1839 as monotherapy in Chinese patients with advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Treatment Outcome | 2008 |
Impact of preexisting pulmonary fibrosis detected on chest radiograph and CT on the development of gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Risk Factors; Survival Rate; Tomography, X-Ray Computed | 2008 |
A case of advanced non-small-cell lung cancer who responded slowly to gefitinib monotherapy after long-term disease stabilization.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Src and ADAM-17-mediated shedding of transforming growth factor-alpha is a mechanism of acute resistance to TRAIL.
Topics: ADAM Proteins; ADAM17 Protein; Apoptosis; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Metalloproteases; Quinazolines; Receptor, ErbB-2; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; src-Family Kinases; TNF-Related Apoptosis-Inducing Ligand; Transforming Growth Factor alpha | 2008 |
Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.
Topics: Antineoplastic Agents; Cell Division; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Morpholines; Nerve Sheath Neoplasms; Neurofibromatosis 1; Protein-Tyrosine Kinases; Quinazolines; Receptor, ErbB-2 | 2008 |
Pharmaceutical futures: a fiendish puzzle.
Topics: Animals; Clinical Trials as Topic; Computer Simulation; Diabetes Mellitus, Type 2; Drug Industry; Gefitinib; Genomics; Glycoproteins; Humans; Models, Biological; Neoplasms; Proteome; Quinazolines; Systems Biology | 2008 |
An epidermal growth factor inhibitor, Gefitinib, induces apoptosis through a p53-dependent upregulation of pro-apoptotic molecules and downregulation of anti-apoptotic molecules in human lung adenocarcinoma A549 cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
A population-based study of gefitinib in patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Demography; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking | 2009 |
Autocrine production of amphiregulin predicts sensitivity to both gefitinib and cetuximab in EGFR wild-type cancers.
Topics: Amphiregulin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; EGF Family of Proteins; Gefitinib; Genes, erbB-1; Glycoproteins; Head and Neck Neoplasms; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
EGFR intron 1 dinucleotide repeat polymorphism is associated with the occurrence of skin rash with gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Dinucleotide Repeats; Exanthema; Female; Gefitinib; Genes, erbB-1; Humans; Inteins; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pharmacogenetics; Polymorphism, Genetic; Quinazolines; Treatment Outcome | 2009 |
Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Treatment Outcome | 2009 |
The role of targeted agents in the treatment of elderly patients with non-small cell lung cancer (NSCLC).
Topics: Age Factors; Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2008 |
Role of repair protein Rad51 in regulating the response to gefitinib in human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Proteasome Endopeptidase Complex; Quinazolines; Rad51 Recombinase; Signal Transduction; Transfection | 2008 |
[18F]Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Fluorine Radioisotopes; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; ROC Curve; Thymidine; Time; Tomography, X-Ray Computed | 2008 |
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Afatinib; Aged; Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Protein Structure, Quaternary; Quinazolines; Sequence Alignment | 2008 |
Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations.
Topics: Adenocarcinoma; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3; Receptors, Growth Factor | 2008 |
Scarring alopecia associated with use of the epidermal growth factor receptor inhibitor gefitinib.
Topics: Aged; Alopecia; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Cicatrix; Disease Progression; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Risk Assessment | 2008 |
Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; BRCA1 Protein; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cetuximab; Cisplatin; Cross-Linking Reagents; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Suppressor Protein p53; Up-Regulation | 2008 |
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Treatment Outcome | 2009 |
Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hematoma, Subdural; Humans; Lung Neoplasms; Quinazolines; Tomography, X-Ray Computed | 2009 |
Gefitinib or docetaxel in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Docetaxel; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2008 |
Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Humans; Male; Medulloblastoma; Mice; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Xenograft Model Antitumor Assays | 2009 |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2008 |
[Sequential administration of gefitinib and docetaxel as second-line therapy for advanced non-small cell lung cancer: analysis of 82 cases].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Taxoids; Treatment Outcome | 2008 |
[Efficacy of gefitinib according to smoking status in non-small cell lung cancer patients].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Male; Middle Aged; Quinazolines; Smoking; Survival Rate; Treatment Outcome | 2008 |
Erlotinib after Gefitinib failure in female never-smoker Asian patients with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Risk Factors; Smoking | 2009 |
Different response of human glioma tumor-initiating cells to epidermal growth factor receptor kinase inhibitors.
Topics: Aged; Animals; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Male; Mice; Mice, Inbred NOD; Mice, SCID; Microfilament Proteins; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplastic Stem Cells; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Tensins; Time Factors; Tumor Cells, Cultured | 2009 |
HCT116 cells deficient in p21(Waf1) are hypersensitive to tyrosine kinase inhibitors and adriamycin through a mechanism unrelated to p21 and dependent on p53.
Topics: Animals; Antibiotics, Antineoplastic; Benzamides; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Doxorubicin; Gefitinib; HCT116 Cells; Humans; Imatinib Mesylate; Mice; Piperazines; Protein Kinase Inhibitors; Protein Stability; Pyrimidines; Quinazolines; Tumor Suppressor Protein p53 | 2009 |
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Cycle; Cell Line, Tumor; Docetaxel; Dose-Response Relationship, Drug; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Inhibitory Concentration 50; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction; Taxoids | 2009 |
ErbB-3 expression is associated with E-cadherin and their coexpression restores response to gefitinib in non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cohort Studies; DNA Primers; Enzyme Inhibitors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Humans; Immunoprecipitation; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor, ErbB-3 | 2009 |
Effect of gefitinib on N-nitrosamine-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone induced lung tumorigenesis in A/J mice.
Topics: Animals; Antineoplastic Agents; Carcinogens, Environmental; Cell Growth Processes; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Gefitinib; Lung; Lung Neoplasms; Mice; Mice, Inbred Strains; Neoplasms, Experimental; Nitrosamines; Pulmonary Fibrosis; Quinazolines; Smoking; Tumor Burden | 2009 |
Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasms, Multiple Primary; Quinazolines; Sequence Deletion; Treatment Outcome | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Remission Induction; Smoking | 2009 |
The role of celecoxib in Rad51 expression and cell survival affected by gefitinib in human non-small cell lung cancer cells.
Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Survival; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Rad51 Recombinase; Sulfonamides | 2009 |
[Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromones; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Glutamates; Guanine; Humans; Integrin beta1; Lung Neoplasms; Morpholines; Pemetrexed; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Taxoids | 2008 |
Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Immunoenzyme Techniques; Incidence; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Suppressor Protein p53 | 2009 |
Identification of modulated genes by three classes of chemopreventive agents at preneoplastic stages in a p53-null mouse mammary tumor model.
Topics: Animals; Anticarcinogenic Agents; Bexarotene; Biomarkers, Tumor; Celecoxib; Cyclooxygenase Inhibitors; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Mice, Knockout; Oligonucleotide Array Sequence Analysis; Precancerous Conditions; Pyrazoles; Quinazolines; Sulfonamides; Tetrahydronaphthalenes; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Protein p53 | 2009 |
Prognostic model to predict outcomes in nonsmall cell lung cancer patients treated with gefitinib as a salvage treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Biological; Multivariate Analysis; Prognosis; Quinazolines; Reproducibility of Results; Salvage Therapy; Survival Analysis; Treatment Outcome | 2009 |
Drosophila-based in vivo assay for the validation of inhibitors of the epidermal growth factor receptor/Ras pathway.
Topics: Animals; Antineoplastic Agents; Biological Assay; Catalytic Domain; Computer Simulation; Drosophila melanogaster; ErbB Receptors; Erlotinib Hydrochloride; Eye; Gefitinib; Gene Expression Regulation; Models, Molecular; Protein Conformation; Protein Structure, Tertiary; Quinazolines; ras Proteins; Wings, Animal | 2008 |
Prolonged remission of disseminated atypical adenomatous hyperplasia under gefitinib.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Hyperplasia; Lung; Lung Neoplasms; Middle Aged; Mutation; Polymerase Chain Reaction; Quinazolines; Remission Induction; Tomography, X-Ray Computed | 2009 |
Benzo[a]pyrene promotes proliferation of human lung cancer cells by accelerating the epidermal growth factor receptor signaling pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Benzo(a)pyrene; Cell Culture Techniques; Cell Division; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; Signal Transduction | 2009 |
EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Quinazolines; Recurrence; Treatment Outcome | 2009 |
Gefitinib as targeted therapy for mucoepidermoid carcinoma of the lung: possible significance of CRTC1-MAML2 oncogene.
Topics: Carcinoma, Mucoepidermoid; DNA-Binding Proteins; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Quinazolines; Trans-Activators; Transcription Factors | 2009 |
Comprehensive analysis of EGFR signaling pathways in Japanese patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Japan; Lung Neoplasms; Male; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Treatment Outcome | 2009 |
Addition of S-1 to the epidermal growth factor receptor inhibitor gefitinib overcomes gefitinib resistance in non-small cell lung cancer cell lines with MET amplification.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Mutation; Oxonic Acid; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Tegafur; Thymidylate Synthase | 2009 |
Establishment and characterization of a model of acquired resistance to epidermal growth factor receptor targeting agents in human cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Cycle; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Immunoblotting; Mice; Mice, Nude; Models, Biological; Neovascularization, Pathologic; Protein Kinase Inhibitors; Quinazolines; Radiation Dosage; Tumor Cells, Cultured | 2009 |
Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dermatomycoses; Drug Eruptions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Perineum; Quinazolines; Scalp Dermatoses; Treatment Outcome | 2009 |
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Genes, erbB-2; Head and Neck Neoplasms; Humans; In Situ Hybridization, Fluorescence; Linear Models; Polymorphism, Genetic; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2009 |
MYC and EIF3H Coamplification significantly improve response and survival of non-small cell lung cancer patients (NSCLC) treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Eukaryotic Initiation Factor-3; Female; Gefitinib; Gene Amplification; Genes, myc; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
Gefitinib circumvents hypoxia-induced drug resistance by the modulation of HIF-1alpha.
Topics: Antineoplastic Agents; Blotting, Western; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Transfection | 2009 |
New chemotherapy strategies and biological agents in the treatment of childhood ependymoma.
Topics: Adolescent; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Child; Child, Preschool; Ependymoma; Erlotinib Hydrochloride; Gefitinib; Humans; Infant; Quinazolines; Treatment Outcome; Young Adult | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Endpoint Determination; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids | 2009 |
Gefitinib plus docetaxel in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2009 |
Cross-talk between Notch and EGFR signaling in human breast cancer cells.
Topics: Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cells, Cultured; ErbB Receptors; Female; Gefitinib; Humans; Kidney; Protein Kinase Inhibitors; Quinazolines; Receptor, Notch1; Retroviridae; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2009 |
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Piperidines; Quinazolines; Urinary Bladder Neoplasms; Vascular Endothelial Growth Factors | 2009 |
The "lazarus response" in treatment-naive, poor performance status patients with non-small-cell lung cancer and epidermal growth factor receptor mutation.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index | 2009 |
Bisphosphonate zoledronic acid enhances the inhibitory effects of gefitinib on EGFR-mutated non-small cell lung carcinoma cells.
Topics: Animals; Apoptosis; Blotting, Western; Bone Density Conservation Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Survival; Diphosphonates; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Nude; Organophosphonates; Quinazolines; Transplantation, Heterologous; Zoledronic Acid | 2009 |
Improved response by co-targeting EGFR/EGFRvIII and Src family kinases in human cancer cells.
Topics: Benzodioxoles; Cell Line, Tumor; Cell Movement; Cell Survival; ErbB Receptors; Gefitinib; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2009 |
Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Signal Transduction | 2009 |
Comparison of survival in advanced non-small cell lung cancer patients in the pre- and post-gefitinib eras.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2009 |
EGFR and HER2 genomic gain in recurrent non-small cell lung cancer after surgery: impact on outcome to treatment with gefitinib and association with EGFR and KRAS mutations in a Japanese cohort.
Topics: Aged; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Female; Gefitinib; Genes, erbB-2; Genes, ras; Genome; Humans; In Situ Hybridization, Fluorescence; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Probability; Prognosis; Quinazolines; Retrospective Studies; Sensitivity and Specificity; Statistics, Nonparametric; Survival Analysis | 2009 |
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Quinazolines; Retrospective Studies; Treatment Outcome | 2009 |
A case report of thyroid cancer showing a remarkable effect of gefitinib.
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Papillary; Female; Gefitinib; Head and Neck Neoplasms; Humans; Incidental Findings; Lung Neoplasms; Lymph Nodes; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Multiple Primary; Quinazolines; Thyroid Neoplasms; Tomography, X-Ray Computed; Treatment Outcome; Ultrasonography | 2009 |
Is erlotinib really active after failure of gefitinib in advanced non-small-cell lung cancer patients?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Salvage Therapy | 2009 |
Use of ligand based models for protein domains to predict novel molecular targets and applications to triage affinity chromatography data.
Topics: Binding Sites; Chromatography, Affinity; Drug Delivery Systems; Gefitinib; Humans; Ligands; Models, Biological; Molecular Structure; Pharmaceutical Preparations; Protein Kinase Inhibitors; Protein Kinases; Proteins; Proteomics; Quinazolines; Reproducibility of Results | 2009 |
A systems pathology model for predicting overall survival in patients with refractory, advanced non-small-cell lung cancer treated with gefitinib.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cyclin D1; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines; Survival Rate | 2009 |
Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma; Case-Control Studies; Cell Death; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Female; Forkhead Box Protein M1; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2009 |
microRNA-205 regulates HER3 in human breast cancer.
Topics: Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Combined Modality Therapy; Gefitinib; Genes, Tumor Suppressor; Genetic Therapy; Humans; Lapatinib; MicroRNAs; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Quinazolines; Receptor, ErbB-3; Transfection | 2009 |
Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Folic Acid; Gefitinib; Genotype; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Histoculture drug response assay for gefitinib in non-small-cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Smoking; Tissue Culture Techniques | 2009 |
Genistein enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitors and inhibits nuclear factor kappa B in nonsmall cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Dinoprostone; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genistein; Humans; Lung Neoplasms; NF-kappa B; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2009 |
Anti-tumor activity of a novel EGFR tyrosine kinase inhibitor against human NSCLC in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; MAP Kinase Signaling System; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Transplantation, Heterologous | 2009 |
Proteomic signatures of epidermal growth factor receptor and survival signal pathways correspond to gefitinib sensitivity in head and neck cancer.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Clinical Trials, Phase I as Topic; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Inhibitory Concentration 50; NF-kappa B; Phosphorylation; Protein Array Analysis; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2009 |
In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Brain; Carbon Radioisotopes; Gefitinib; Male; Mice; Neoplasm Proteins; Positron-Emission Tomography; Quinazolines; Radioactivity; Tetrahydroisoquinolines | 2009 |
Enediyne lidamycin enhances the effect of epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib, in epidermoid carcinoma A431 cells and lung carcinoma H460 cells.
Topics: Aminoglycosides; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Enediynes; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2009 |
Generating genome-scale candidate gene lists for pharmacogenomics.
Topics: Anticoagulants; Antineoplastic Agents; Area Under Curve; Carboplatin; Deoxycytidine; Gefitinib; Gemcitabine; Gene Expression Regulation; Genes; Genome, Human; Humans; Oligonucleotide Array Sequence Analysis; Pharmacogenetics; Quinazolines; Warfarin | 2009 |
Activated Akt prevents antitumor activity of gefitinib in renal cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Renal Cell; Drug Resistance, Neoplasm; Gefitinib; Humans; Kidney Neoplasms; Oncogene Protein v-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2009 |
Epidermal growth factor competes with EGF receptor inhibitors to induce cell death in EGFR-overexpressing tumor cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cetuximab; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Quinazolines; Signal Transduction | 2009 |
[A case of non-small cell lung cancer with EGFR mutation responding to S-1 after a therapy with gefitinib].
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oxonic Acid; Quinazolines; Tegafur; Tomography, X-Ray Computed | 2009 |
Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; China; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis | 2009 |
MRI methods for evaluating the effects of tyrosine kinase inhibitor administration used to enhance chemotherapy efficiency in a breast tumor xenograft model.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Mice; Mice, Nude; Outcome Assessment, Health Care; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Sequence dependence of cell growth inhibition by EGFR-tyrosine kinase inhibitor ZD1839, docetaxel, and cisplatin in head and neck cancer.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cisplatin; Docetaxel; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Taxoids; Tumor Cells, Cultured | 2009 |
Pharmacological interplay between breast cancer resistance protein and gefitinib in epidermal growth factor receptor signaling.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blotting, Western; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2009 |
ZD1839 (IRESSA) stabilizes p27Kip1 and enhances radiosensitivity in cholangiocarcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Blotting, Western; Cell Cycle; Cell Proliferation; Cholangiocarcinoma; Combined Modality Therapy; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Molecular Sequence Data; Mutation; Polymerase Chain Reaction; Quinazolines; Radiation Tolerance; Tumor Cells, Cultured; X-Rays | 2009 |
EGFR inhibition using gefitinib is not active in neuroblastoma cell lines.
Topics: Antineoplastic Agents; Blotting, Western; Cell Proliferation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Mutation; Neuroblastoma; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Topotecan; Tumor Cells, Cultured | 2009 |
Toward noninvasive genomic screening of lung cancer patients.
Topics: Antineoplastic Agents; Biomarkers, Tumor; DNA; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Testing; Humans; Lung Neoplasms; Mass Screening; Mutation; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Improvement of renal hemodynamics during hypertension-induced chronic renal disease: role of EGF receptor antagonism.
Topics: Animals; Arterioles; Blood Pressure; Chronic Disease; Disease Models, Animal; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Hypertension; Kidney; Kidney Diseases; Male; NG-Nitroarginine Methyl Ester; Quinazolines; Rats; Rats, Sprague-Dawley; Regional Blood Flow; Vasoconstriction | 2009 |
PUMA mediates EGFR tyrosine kinase inhibitor-induced apoptosis in head and neck cancer cells.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Head and Neck Neoplasms; Humans; Membrane Proteins; Mice; Mice, Nude; Nuclear Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Tumor Protein p73; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2009 |
Predicting differences in gene regulatory systems by state space models.
Topics: Antineoplastic Agents; Case-Control Studies; Epithelial Cells; ErbB Receptors; Gefitinib; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Genes, Regulator; Humans; Models, Genetic; Neoplasms; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Tract Neoplasms | 2008 |
Everolimus restores gefitinib sensitivity in resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Immunosuppressive Agents; Lung Neoplasms; Phosphorylation; Quinazolines; Ribosomal Protein S6 Kinases; Signal Transduction; Sirolimus | 2009 |
Effects of an epidermal growth factor receptor inhibitor on arsenic associated toxicity in the rat bladder epithelium.
Topics: Animals; Arsenites; Body Weight; Cacodylic Acid; Cell Growth Processes; Cell Line; Cell Survival; Drinking; Eating; ErbB Receptors; Female; Gefitinib; Histocytochemistry; Quinazolines; Random Allocation; Rats; Rats, Inbred F344; Urinary Bladder | 2009 |
Radiosensitizing effects of gefitinib at different administration times in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Colony-Forming Units Assay; Combined Modality Therapy; Dose-Response Relationship, Radiation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2009 |
ErbB receptor tyrosine kinases contribute to proliferation of malignant melanoma cells: inhibition by gefitinib (ZD1839).
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Melanoma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Skin Neoplasms; STAT3 Transcription Factor | 2009 |
Molecular mechanisms underlying effects of epidermal growth factor receptor inhibition on invasion, proliferation, and angiogenesis in experimental glioma.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Brain; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p16; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Mutation; Neoplasm Invasiveness; Neovascularization, Pathologic; Organ Culture Techniques; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2009 |
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; NIH 3T3 Cells; Piperidines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reverse Transcriptase Polymerase Chain Reaction; Time Factors; Transfection; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2009 |
ERBB1 and ERBB2 have distinct functions in tumor cell invasion and intravasation.
Topics: Animals; Benzothiazoles; Cell Line, Tumor; Cell Movement; ErbB Receptors; Female; Gefitinib; Humans; Lapatinib; Mammary Neoplasms, Experimental; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Metastasis; Phosphorylation; Quinazolines; Receptor, ErbB-2; Tyrphostins; Xenograft Model Antitumor Assays | 2009 |
[Potent and continuous relief of spinal bone pain due to metastasis of non-small cell lung cancer by treatment with gefitinib--a case report].
Topics: Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pain; Quinazolines; Spine; Tomography, X-Ray Computed | 2009 |
Influence of first-line chemotherapy and EGFR mutations on second-line gefitinib in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
Predictors of gefitinib outcomes in advanced non-small cell lung cancer (NSCLC): study of a comprehensive panel of molecular markers.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Introns; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2010 |
Caveolin-1 regulates EGFR signaling in MCF-7 breast cancer cells and enhances gefitinib-induced tumor cell inhibition.
Topics: Adenocarcinoma; Antineoplastic Agents; Breast Neoplasms; Caveolin 1; Cell Division; Cell Line, Tumor; Cell Movement; Enzyme Activation; Enzyme Induction; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; MAP Kinase Signaling System; Neoplasm Proteins; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2009 |
Bone scan flare phenomenon in non-small-cell lung cancer patients treated with gefitinib.
Topics: Adenocarcinoma; Aged; Artifacts; Biopsy; Bone and Bones; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Radionuclide Imaging; Retrospective Studies | 2009 |
Early prediction of response to first-line therapy using integrated 18F-FDG PET/CT for patients with advanced/metastatic non-small cell lung cancer.
Topics: Adult; Aged; Analysis of Variance; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Disease Progression; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Predictive Value of Tests; Prospective Studies; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, Emission-Computed; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; RNA, Small Interfering; src-Family Kinases | 2009 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Camptothecin; Cell Line; Cell Line, Tumor; Dogs; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Humans; Irinotecan; Mitoxantrone; Neoplasm Proteins; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Time Factors | 2010 |
Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?
Topics: Adult; Antineoplastic Agents; Drug Compounding; ErbB Receptors; Gastrointestinal Tract; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radioisotopes; Radionuclide Imaging | 2009 |
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines.
Topics: Adenosine Triphosphatases; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2010 |
Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
Topics: Animals; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Emodin; Gefitinib; Humans; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Signal Transduction | 2009 |
Demonstration of the equivalent pharmacokinetic/pharmacodynamic dosing strategy in a multiple-dose study of gefitinib.
Topics: Algorithms; Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Quinazolines; Therapeutic Equivalency; Tumor Burden; Xenograft Model Antitumor Assays | 2009 |
A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Furans; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases; Tumor Suppressor Proteins | 2009 |
Role of tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Immunoblotting; Lung Neoplasms; Pyrazines; Quinazolines; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 2009 |
Lapatinib, a dual EGFR and HER2 tyrosine kinase inhibitor, downregulates thymidylate synthase by inhibiting the nuclear translocation of EGFR and HER2.
Topics: Active Transport, Cell Nucleus; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Neoplasm Transplantation; Oligonucleotide Array Sequence Analysis; Promoter Regions, Genetic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2009 |
Detection of epidermal growth factor receptor mutations in plasma by mutant-enriched PCR assay for prediction of the response to gefitinib in patients with non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Survival Rate | 2009 |
Second-line treatments after first-line gefitinib therapy in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2010 |
[Analysis of the efficacy and safety of gefitinib in the treatment of recurrent advanced non-small cell lung cancer in an expanded access program (EAP)].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diarrhea; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2009 |
Epidermal growth factor receptor mutations and the clinical outcome in male smokers with squamous cell carcinoma of lung.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Smoking; Treatment Outcome | 2009 |
Gefitinib in combination with gemcitabine and carboplatin in never smokers with non-small cell lung carcinoma: a retrospective analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymph Nodes; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2009 |
Gefitinib and a ventriculo-peritoneal shunt to manage carcinomatous meningitis from non-small-cell lung cancer: report of two cases.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Quinazolines; Treatment Outcome; Ventriculoperitoneal Shunt | 2009 |
Compartment-specific roles of ATP-binding cassette transporters define differential topotecan distribution in brain parenchyma and cerebrospinal fluid.
Topics: Animals; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Sub-Family B Member 4; ATP-Binding Cassette Transporters; Biological Transport; Blood Proteins; Blood-Brain Barrier; Brain; Cell Line, Tumor; Gefitinib; Humans; Immunohistochemistry; Mice; Mice, Knockout; Microdialysis; Protein Binding; Quinazolines; Tissue Distribution; Topotecan | 2009 |
Age at diagnosis predicts outcomes in gefitinib-treated female patients with non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Early Detection of Cancer; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines | 2010 |
Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; DNA Damage; Dose-Response Relationship, Drug; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Microscopy, Fluorescence; Quinazolines; Radiation-Sensitizing Agents; Triazenes; Tumor Stem Cell Assay; X-Rays | 2009 |
Outpacing cancer.
Topics: Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Mutation; Piperazines; Pyrimidines; Quinazolines | 2009 |
Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Genetic Association Studies; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2010 |
The EGFR inhibitor gefitinib suppresses recruitment of pericytes and bone marrow-derived perivascular cells into tumor vessels.
Topics: Animals; Antigens; Antineoplastic Agents; Blood Vessels; Bone Marrow Cells; Cells, Cultured; Disease Models, Animal; Endothelial Cells; Endothelium, Vascular; ErbB Receptors; Gefitinib; Humans; Image Processing, Computer-Assisted; Melanoma; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Pericytes; Protein Kinase Inhibitors; Proteoglycans; Quinazolines; Skin Neoplasms | 2009 |
Gefitinib plus paclitaxel after failure of gefitinib in non-small cell lung cancer initially responding to gefitinib.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paclitaxel; Quinazolines; Survival Analysis | 2009 |
Efficacy of a lumbo-peritoneal shunt for meningeal carcinomatosis refractory to gefitinib treatment.
Topics: Antineoplastic Agents; Cerebrospinal Fluid Shunts; Female; Gefitinib; Humans; Meningeal Neoplasms; Middle Aged; Quinazolines | 2009 |
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Depression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2009 |
Distinct growth factor-induced dynamic mass redistribution (DMR) profiles for monitoring oncogenic signaling pathways in various cancer cells.
Topics: Antineoplastic Agents; Biosensing Techniques; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Neoplasms; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis.
Topics: ADAM Proteins; ADAMTS1 Protein; Animals; Bone and Bones; Bone Neoplasms; Breast Neoplasms; Cell Differentiation; Cell Line; Cell Proliferation; Epidermal Growth Factor; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Matrix Metalloproteinase 1; Mice; Mice, Nude; Osteoblasts; Osteoprotegerin; Protein Kinase Inhibitors; Quinazolines; RANK Ligand; Signal Transduction | 2009 |
Combined treatment with TNF-alpha/gefitinib alleviates the resistance to gefitinib in PC-9 cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Cycle Proteins; Cell Death; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Tumor Necrosis Factor-alpha | 2009 |
Quantitative prediction of fold resistance for inhibitors of EGFR.
Topics: Animals; Cell Line, Tumor; Computer Simulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Models, Molecular; Quinazolines | 2009 |
[Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials].
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease Progression; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2009 |
[A case of lung cancer combined with pregnancy; dramatically deteriorating condition after caesarian section].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cesarean Section; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Pregnancy; Pregnancy Complications, Neoplastic; Quinazolines | 2009 |
Using EGFR status to personalize treatment: lung cancer researchers reach a milestone.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Europe; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Treatment Failure; United States; United States Food and Drug Administration | 2009 |
Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies.
Topics: Algorithms; Antineoplastic Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Cyclodextrins; Gefitinib; Hydrogen-Ion Concentration; Quinazolines; Solubility; X-Ray Diffraction | 2009 |
Gefitinib inhibits the proliferation of pancreatic cancer cells via cell cycle arrest.
Topics: Antineoplastic Agents; Aurora Kinase B; Aurora Kinases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; G2 Phase; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Quinazolines | 2009 |
Gefitinib: phoenix from the flames.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2009 |
Nuclear Y-box binding protein-1, a predictive marker of prognosis, is correlated with expression of HER2/ErbB2 and HER3/ErbB3 in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA-Binding Proteins; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Nuclear Proteins; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Y-Box-Binding Protein 1 | 2009 |
Usefulness of cumulative smoking dose for identifying the EGFR mutation and patients with non-small-cell lung cancer for gefitinib treatment.
Topics: Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; ROC Curve; Sensitivity and Specificity; Smoking | 2009 |
Gefitinib-induced interstitial lung disease-addition of intravenous cyclophosphamide to corticosteroids is a valuable treatment option: A case report.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Drug Evaluation; Drug Therapy, Combination; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Infusions, Intravenous; Lung Diseases, Interstitial; Lung Neoplasms; Methylprednisolone; Muscular Diseases; Prednisolone; Quinazolines | 2010 |
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Smoking; Survival Analysis | 2010 |
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Genotype; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor Protein-Tyrosine Kinases; Sex Factors; Treatment Outcome | 2009 |
Fatal cystic change of brain metastasis after response to gefitinib in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Brain Diseases; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cysts; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tomography, X-Ray Computed | 2009 |
Cyclooxygenase-2 (COX-2) negatively regulates expression of epidermal growth factor receptor and causes resistance to gefitinib in COX-2-overexpressing cancer cells.
Topics: Cyclooxygenase 2; Dinoprostone; Down-Regulation; Drug Resistance, Neoplasm; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; HCT116 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Protein Biosynthesis; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Transcription, Genetic | 2009 |
Double EGFR mutants containing rare EGFR mutant types show reduced in vitro response to gefitinib compared with common activating missense mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Phosphorylation; Quinazolines; Tyrosine | 2009 |
Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Databases, Factual; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Online Systems; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Registries | 2009 |
Restoration of BRAK / CXCL14 gene expression by gefitinib is associated with antitumor efficacy of the drug in head and neck squamous cell carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemokines, CXC; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Mutation; Quinazolines; RNA, Messenger | 2009 |
Chemopreventive effects of gefitinib on nonsmoking-related lung tumorigenesis in activating epidermal growth factor receptor transgenic mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Models, Animal; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, erbB-2; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Phosphorylation; Promoter Regions, Genetic; Pulmonary Surfactant-Associated Protein C; Quinazolines; Receptor, ErbB-3; Smoking | 2009 |
Estrogen replacement in female lung cancer during gefitinib therapy.
Topics: Animals; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Estrogen Replacement Therapy; Estrogens; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Personalized medicine and inhibition of EGFR signaling in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].
Topics: Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2009 |
[A case of lung adenocarcinoma successfully treated with dose-reescalated gefitinib after resistance was acquired].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2009 |
Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Brain Neoplasms; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spinal Cord Neoplasms; Treatment Outcome | 2009 |
Gefitinib for advanced non-small-cell lung cancer and quality of life: expanding and improving treatment options.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines | 2009 |
Bronchioloalveolar carcinoma: not as easy as "BAC".
Topics: Adenocarcinoma, Bronchiolo-Alveolar; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2009 |
Effect of gefitinib on warfarin antithrombotic activity.
Topics: Aged; Anticoagulants; Antineoplastic Agents; Blood Coagulation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Female; Gefitinib; Humans; International Normalized Ratio; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Prothrombin Time; Quinazolines; Retrospective Studies; Time Factors; Warfarin | 2009 |
Insulin-like growth factor-1 receptor inhibition induces a resistance mechanism via the epidermal growth factor receptor/HER3/AKT signaling pathway: rational basis for cotargeting insulin-like growth factor-1 receptor and epidermal growth factor receptor
Topics: Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Insulin; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction; Sirolimus | 2009 |
[Epidermal growth factor receptor aberrations in malignant mesotheliomas].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mesothelioma; Quinazolines | 2009 |
I am no one. No one is perfect...Therefore I am perfect.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Survival Analysis; Taxoids | 2009 |
The drug-resistance to gefitinib in PTEN low expression cancer cells is reversed by irradiation in vitro.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasms; PTEN Phosphohydrolase; Quinazolines; Up-Regulation; X-Rays | 2009 |
Modeling glioma growth and invasion in Drosophila melanogaster.
Topics: Animals; Brain Neoplasms; Drosophila melanogaster; ErbB Receptors; Eye; Gefitinib; Glioma; Humans; Immunoenzyme Techniques; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2009 |
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sex Factors; Smoking | 2009 |
Gefitinib: a second look. Non-small cell lung cancer: still very disappointing.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Diarrhea; Docetaxel; Drug Approval; ErbB Receptors; France; Gefitinib; Humans; Lung Diseases, Interstitial; Protein Kinase Inhibitors; Quinazolines; Skin Diseases; Taxoids | 2009 |
Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Activators; Enzyme Inhibitors; Gefitinib; Humans; Hydroxylation; Intestines; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes; Quinazolines; Species Specificity; Substrate Specificity; Triazolam | 2009 |
Combination of EGFR and MEK1/2 inhibitor shows synergistic effects by suppressing EGFR/HER3-dependent AKT activation in human gastric cancer cells.
Topics: Animals; Benzimidazoles; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; In Situ Nick-End Labeling; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Stomach Neoplasms | 2009 |
Gefitinib for non-small cell lung cancer patients with liver cirrhosis.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Liver Cirrhosis; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2009 |
Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Pharmacological; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Nasopharyngeal Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
Lovastatin overcomes gefitinib resistance in human non-small cell lung cancer cells with K-Ras mutations.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lovastatin; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction | 2010 |
Induced-fit docking studies of the active and inactive states of protein tyrosine kinases.
Topics: Binding Sites; Crystallography, X-Ray; Enzyme Activation; ErbB Receptors; Gefitinib; Hydrogen Bonding; Indoles; Ligands; Models, Molecular; Oxindoles; Propionates; Protein Structure, Secondary; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-abl; Pyrroles; Quinazolines; Reproducibility of Results; Sunitinib | 2009 |
Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2010 |
[11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma.
Topics: Animals; Carbon Radioisotopes; Cell Line, Tumor; Fibrosarcoma; Gefitinib; Humans; Male; Mice; Molecular Imaging; Positron-Emission Tomography; Quinazolines; Tissue Distribution | 2010 |
Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Black or African American; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genetic Predisposition to Disease; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Probability; Quinazolines; ras Proteins; Risk Assessment; White People | 2009 |
Lessons from the lung for targeted anticancer drugs.
Topics: Antineoplastic Agents; Clinical Trials as Topic; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines | 2009 |
Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2009 |
Can treating the SYK cell cure leukemia?
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation, Leukemic; Genomics; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; Syk Kinase; Time Factors; Tyrosine | 2009 |
Proteomic and genetic approaches identify Syk as an AML target.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Differentiation; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Genomics; HL-60 Cells; Humans; Inhibitory Concentration 50; Intracellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred C57BL; Mice, Inbred NOD; Mice, SCID; Morpholines; Oxazines; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteomics; Pyridines; Pyrimidines; Quinazolines; RNA Interference; Syk Kinase; Tandem Mass Spectrometry; Time Factors; Tumor Cells, Cultured; Tyrosine; U937 Cells; Xenograft Model Antitumor Assays | 2009 |
Bioactivation of the epidermal growth factor receptor inhibitor gefitinib: implications for pulmonary and hepatic toxicities.
Topics: Animals; Antineoplastic Agents; Biotransformation; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glutathione; Hepatocytes; Humans; Lung; Lung Neoplasms; Mice; Microsomes; Microsomes, Liver; Quinazolines | 2009 |
The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mutation; Neoplasm Invasiveness; Neoplasm Metastasis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2009 |
Development of rheumatoid arthritis during the course of gefitinib therapy.
Topics: Adenocarcinoma; Antineoplastic Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Drug Interactions; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prednisolone; Quinazolines; Sulfasalazine | 2009 |
Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neuroblastoma; Pilot Projects; Prognosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Salvage Therapy; Survival Rate; Topotecan; Treatment Outcome | 2010 |
Molecular imaging of gefitinib activity in an epidermal growth factor receptor (EGFR)-bearing xenograft model.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line, Tumor; Cysteine; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunoprecipitation; Indium Radioisotopes; Mice; Mice, Nude; Molecular Imaging; Neoplasms, Glandular and Epithelial; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Technetium; Tissue Distribution; Xenograft Model Antitumor Assays | 2009 |
Amphiregulin promotes BAX inhibition and resistance to gefitinib in non-small-cell lung cancers.
Topics: Amphiregulin; Animals; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytoplasm; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mitochondria; Quinazolines | 2010 |
Amphiregulin promotes resistance to gefitinib in nonsmall cell lung cancer cells by regulating Ku70 acetylation.
Topics: Amphiregulin; Animals; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; DNA-Binding Proteins; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Histone Acetyltransferases; Humans; Hydroxamic Acids; Intercellular Signaling Peptides and Proteins; Ku Autoantigen; Lung Neoplasms; Mice; Quinazolines; Subcellular Fractions; Vorinostat | 2010 |
Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Antigens, Neoplasm; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Keratin-19; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Peptides; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2010 |
Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Stromal Cells; Xenograft Model Antitumor Assays | 2009 |
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Treatment Failure | 2009 |
Comparison of the drug-drug interactions potential of erlotinib and gefitinib via inhibition of UDP-glucuronosyltransferases.
Topics: Adolescent; Adult; Aged; Area Under Curve; Bilirubin; Binding, Competitive; Biocatalysis; Cell Line; Child; Drug Interactions; Erlotinib Hydrochloride; Female; Gefitinib; Glucuronic Acid; Glucuronosyltransferase; Humans; Hymecromone; Imipramine; Indinavir; Isoenzymes; Kinetics; Male; Microsomes, Liver; Middle Aged; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Young Adult | 2010 |
Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Receptor, ErbB-2; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2009 |
Role of epidermal growth factor inhibition in experimental pulmonary hypertension.
Topics: Animals; Antineoplastic Agents; Cell Division; Cell Survival; Disease Models, Animal; Dose-Response Relationship, Drug; Epidermal Growth Factor; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Hypertension, Pulmonary; Lapatinib; Male; Mice; Muscle, Smooth, Vascular; Polymerase Chain Reaction; Protein Kinase Inhibitors; Pulmonary Wedge Pressure; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Vascular Resistance | 2010 |
Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry.
Topics: Analytic Sample Preparation Methods; Benzamides; Calibration; Chromatography, High Pressure Liquid; Drug Monitoring; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Microchemistry; Piperazines; Pyrimidines; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2009 |
Successful treatment of lung cancer with gefitinib and EGFR mutation status determination using EBUS-TBNA samples in an extremely old patient.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Biopsy, Fine-Needle; Endosonography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2009 |
Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiotherapy Dosage; Survival Rate; Treatment Outcome | 2010 |
Inhibition of endothelial cell chemotaxis toward FGF-2 by gefitinib associates with downregulation of Fes activity.
Topics: Antineoplastic Agents; Blotting, Western; Chemotaxis; Down-Regulation; Endothelial Cells; Fibroblast Growth Factor 2; Gefitinib; Humans; Neovascularization, Pathologic; Protein Structure, Tertiary; Proto-Oncogene Proteins c-fes; Quinazolines; Vascular Endothelial Growth Factor A | 2009 |
Integrin signal masks growth-promotion activity of HB-EGF in monolayer cell cultures.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Adhesion; Cell Culture Techniques; Cell Proliferation; Cells, Cultured; Chromones; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Integrins; Intercellular Signaling Peptides and Proteins; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction | 2009 |
EGFR-TKI treatment and surgical resection for oligometastatic NSCLC?
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Down-staging of EGFR mutation-positive advanced lung carcinoma with gefitinib followed by surgical intervention: follow-up of two cases.
Topics: Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2009 |
Discovery of a novel Her-1/Her-2 dual tyrosine kinase inhibitor for the treatment of Her-1 selective inhibitor-resistant non-small cell lung cancer.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Molecular Conformation; Neoplasm Transplantation; Pyrrolidines; Quinazolines; Rats; Receptor, ErbB-2; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2009 |
Massive hematuria from the bilateral upper urinary tract in a patient treated for advanced lung cancer with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Hematuria; Humans; Lung Neoplasms; Prognosis; Quinazolines; Treatment Outcome; Urinary Tract | 2010 |
A mechanistic study on gefitinib-induced apoptosis reveals a new link between EGFR and hTERT in breast cancers.
Topics: Apoptosis; Breast Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Telomerase | 2009 |
Gefitinib induces apoptosis and decreases telomerase activity in MDA-MB-231 human breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Survival; ErbB Receptors; Female; Gefitinib; Humans; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Telomerase | 2009 |
[A case of adenocarcinoma of the lung with a long-term therapeutic effect due to S-1 administered as the sixth regimen].
Topics: Adenocarcinoma; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Docetaxel; Drug Combinations; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Oxonic Acid; Quinazolines; Taxoids; Tegafur | 2009 |
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Indicators and Reagents; Insulin-Like Growth Factor Binding Proteins; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2010 |
Effects of the combined blockade of EGFR and ErbB-2 on signal transduction and regulation of cell cycle regulatory proteins in breast cancer cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; ErbB Receptors; Female; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lapatinib; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Retinoblastoma-Like Protein p130; RNA Interference; RNA, Messenger; Signal Transduction; Time Factors; Trastuzumab | 2010 |
Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Guidelines as Topic; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Successful treatment of pyogenic granulomas following gefitinib therapy with partial matricectomy and phenolization.
Topics: Aged; Anti-Infective Agents, Local; Antineoplastic Agents; Female; Gefitinib; Granuloma, Pyogenic; Humans; Lung Neoplasms; Nails, Ingrown; Phenol; Quinazolines; Toes; Treatment Outcome | 2009 |
A novel pharmacodynamic approach to assess and predict tumor response to the epidermal growth factor receptor inhibitor gefitinib in patients with esophageal cancer.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Biopsy; Chemistry, Pharmaceutical; Drug Design; Drug Screening Assays, Antitumor; Endoscopy; ErbB Receptors; Esophageal Neoplasms; Exons; Gefitinib; Humans; Male; Middle Aged; Quinazolines | 2010 |
Combined tamoxifen and gefitinib in non-small cell lung cancer shows antiproliferative effects.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Estrogen Receptor beta; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Receptor Cross-Talk; Signal Transduction; Tamoxifen | 2010 |
[Successful gefitinib every other day administration in an advanced lung cancer patient with brain metastasis after gamma knife radiotherapy and chemotherapy].
Topics: Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; Female; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Radiosurgery | 2009 |
[A case of meningeal carcinomatosis of lung adenocarcinoma well controlled by re-treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Meningeal Neoplasms; Mutation; Paclitaxel; Quinazolines | 2009 |
New frontiers in biomarker-targeted molecular imaging.
Topics: Animals; ErbB Receptors; Gefitinib; Humans; Molecular Imaging; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Xenograft Model Antitumor Assays | 2009 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Proportional Hazards Models; Quinazolines; Survival Analysis | 2009 |
Blockade of the ERK or PI3K-Akt signaling pathway enhances the cytotoxicity of histone deacetylase inhibitors in tumor cells resistant to gefitinib or imatinib.
Topics: Analgesics; Benzamides; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Histone Deacetylase Inhibitors; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines | 2010 |
Core needle lung biopsy specimens: adequacy for EGFR and KRAS mutational analysis.
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy, Needle; Clinical Trials, Phase II as Topic; DNA Mutational Analysis; ErbB Receptors; Female; Fluoroscopy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Radiography, Interventional; ras Proteins; Tomography, X-Ray Computed | 2010 |
Are current drug development programmes realising the full potential of new agents? Tyrosine kinase inhibitors.
Topics: Animals; Breast Neoplasms; Drug Discovery; Drug Industry; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Technology, Pharmaceutical | 2009 |
[Cutaneous side effects of EGF receptor inhibitors].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Folliculitis; Gefitinib; Humans; Nail Diseases; Panitumumab; Quinazolines; Skin | 2009 |
Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
Topics: Adenocarcinoma; Adult; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA; Female; Gefitinib; Genotype; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Quinazolines | 2010 |
[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Remission Induction; Survival Rate | 2010 |
Gefitinib as first-line therapy for advanced or metastatic non-small cell lung cancer patients in southern Taiwan.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Young Adult | 2010 |
Tumor-specific cytotoxicity and type of cell death induced by gefitinib in oral squamous cell carcinoma cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Ascorbic Acid; Autophagy; Carcinoma, Squamous Cell; Caspase 3; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Drug Therapy, Combination; Gefitinib; HL-60 Cells; Humans; Methotrexate; Mitoxantrone; Mouth; Mouth Neoplasms; Phytotherapy; Plant Extracts; Quinazolines; Sodium Fluoride; Tumor Cells, Cultured | 2009 |
Treatment of lung cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Paclitaxel; Proportional Hazards Models; Quinazolines | 2009 |
Treatment of lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Survival Rate | 2009 |
Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Korea; Male; Protein Kinase Inhibitors; Quinazolines | 2010 |
Efficacy of gefitinib for elderly patients with advanced non-small cell lung cancer harboring epidermal growth factor receptor gene mutations: a retrospective analysis.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Colorectal Neoplasms; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mass Spectrometry; Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2010 |
Histology matters: individualizing treatment in non-small cell lung cancer.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; SEER Program | 2010 |
Gefitinib targets EGFR dimerization and ERK1/2 phosphorylation to inhibit pleural mesothelioma cell proliferation.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cross-Linking Reagents; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Humans; Mesothelioma; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Multimerization; Quinazolines; Tumor Cells, Cultured | 2010 |
Androgen-responsive and -unresponsive prostate cancer cell lines respond differently to stimuli inducing neuroendocrine differentiation.
Topics: Androgens; Cell Differentiation; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Male; Neuroendocrine Cells; Phosphopyruvate Hydratase; Prostatic Neoplasms; Quinazolines; Receptors, Androgen | 2010 |
Mutation detection of epidermal growth factor receptor and KRAS genes using the smart amplification process version 2 from formalin-fixed, paraffin-embedded lung cancer tissue.
Topics: Antineoplastic Agents; ErbB Receptors; Fixatives; Formaldehyde; Gefitinib; Humans; Lung Neoplasms; Mutation; Nucleic Acid Amplification Techniques; Paraffin Embedding; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA; Tissue Fixation | 2010 |
MicroRNAs reduce tumor growth and contribute to enhance cytotoxicity induced by gefitinib in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; MicroRNAs; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2010 |
Comparison of the incidence and pattern of interstitial lung disease during erlotinib and gefitinib treatment in Japanese Patients with non-small cell lung cancer: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Incidence; Japan; Logistic Models; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Risk Factors | 2010 |
Second-line therapy for elderly patients with non-small cell lung cancer who failed previous chemotherapy is as effective as for younger patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate; Young Adult | 2010 |
First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cohort Studies; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Aged; Aged, 80 and over; Biomarkers, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Chemoprevention of murine lung cancer by gefitinib in combination with prostacyclin synthase overexpression.
Topics: Adenoma; Animals; Antineoplastic Agents; Cadherins; Cytochrome P-450 Enzyme System; Dinoprostone; Epoprostenol; ErbB Receptors; Female; Gefitinib; Intramolecular Oxidoreductases; Lung Neoplasms; Male; Mice; Mice, Transgenic; Protein Kinase Inhibitors; Quinazolines; Rats; Signal Transduction | 2010 |
Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Mutation; Quinazolines; Treatment Outcome | 2010 |
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2010 |
Synergistic effect of gefitinib and rofecoxib in mesothelioma cells.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclooxygenase 2; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lactones; Mesothelioma; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sulfones | 2010 |
Lewis(y) antigen stimulates the growth of ovarian cancer cells via regulation of the epidermal growth factor receptor pathway.
Topics: Cell Line, Tumor; Cell Proliferation; Chromones; Cyclin-Dependent Kinase Inhibitor p27; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Flavonoids; Fucosyltransferases; Gefitinib; Humans; Lewis Blood Group Antigens; Morpholines; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2010 |
AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Lapatinib; Mice; Mice, Nude; Mice, SCID; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cell Survival; DNA Transposable Elements; ErbB Receptors; Female; Gefitinib; Genetic Variation; Glioblastoma; Humans; Mitochondria; Proto-Oncogene Proteins; Quinazolines; Sequence Deletion; Transplantation, Heterologous | 2010 |
[A case of complete response treated by S-1 with concurrent radiotherapy for a gefitinib-resistant non-small cell lung cancer patient].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Combinations; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Positron-Emission Tomography; Quinazolines; Remission Induction; Tegafur; Tomography, X-Ray Computed | 2010 |
Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion; Predictive Value of Tests; Quinazolines; Survival Analysis | 2010 |
Tapered dose versus constant drug exposure to anti-EGFR drugs on head-and-neck cancer xenografts. A comparison between cetuximab and gefitinib.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Mice; Mice, Nude; Quinazolines; Transplantation, Heterologous | 2010 |
Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2010 |
HER kinase axis receptor dimer partner switching occurs in response to EGFR tyrosine kinase inhibition despite failure to block cellular proliferation.
Topics: Animals; Cell Growth Processes; Cell Line, Tumor; Dimerization; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Male; Mice; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; Signal Transduction; Up-Regulation | 2010 |
Studies on the mechanism of action of dextrin-phospholipase A2 and its suitability for use in combination therapy.
Topics: Antineoplastic Agents; Cell Line, Tumor; Dextrins; Drug Therapy, Combination; ErbB Receptors; Flow Cytometry; Gefitinib; HT29 Cells; Humans; Microscopy, Confocal; Models, Biological; Molecular Structure; Phospholipases A2; Protein Kinase Inhibitors; Quinazolines | 2010 |
Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Aspirin; Cyclooxygenase Inhibitors; Disease Models, Animal; Drug Screening Assays, Antitumor; Female; Gefitinib; Naproxen; Quinazolines; Rats; Rats, Inbred F344; Research Design; Resveratrol; Stilbenes; Urinary Bladder Neoplasms | 2010 |
Cytotoxic effects induced by docetaxel, gefitinib, and cyclopamine on side population and nonside population cell fractions from human invasive prostate cancer cells.
Topics: Adenocarcinoma; Apoptosis; Cell Fractionation; Cell Line, Tumor; Cell Proliferation; Cytotoxins; Docetaxel; Drug Evaluation, Preclinical; ErbB Receptors; Gefitinib; Humans; Male; Neoplasm Invasiveness; Phosphorylation; Prostate; Prostatic Neoplasms; Quinazolines; Taxoids; Transcription Factors; Veratrum Alkaloids; Zinc Finger Protein GLI1 | 2010 |
[Two cases of non-small cell lung cancer which developed central nervous system metastases during gefitinib treatment, improving after changing to erlotinib treatment].
Topics: Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
De novo resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutation-positive patients with non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survival Rate | 2010 |
Association between gefitinib and hemorrhagic cystitis and severely contracted bladder: a case report.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cystitis; Gefitinib; Hematuria; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Urinary Bladder Diseases | 2010 |
Gefitinib-induced disseminated intravascular coagulation in a patient with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disseminated Intravascular Coagulation; Female; Gefitinib; Humans; Quinazolines | 2010 |
Osteoblastic reaction in non-small cell lung carcinoma and its association to epidermal growth factor receptor tyrosine kinase inhibitors response and prolonged survival.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Osteoblasts; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Triplet chemotherapy with cisplatin, docetaxel, and irinotecan for patients with recurrent or refractory non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Signet Ring Cell; Carcinoma, Squamous Cell; Cisplatin; Docetaxel; Female; Follow-Up Studies; Gefitinib; Humans; Irinotecan; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids | 2010 |
Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclin-Dependent Kinase Inhibitor p16; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Prevalence; Quinazolines; Retinoblastoma Protein; Reverse Transcriptase Polymerase Chain Reaction; Tumor Suppressor Protein p53 | 2010 |
Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Prognosis; Quinazolines; Retrospective Studies | 2011 |
Intestinal permeability, vitamin A absorption and serum alpha-tocopherol during therapy with gefitinib.
Topics: Adult; Aged; alpha-Tocopherol; Case-Control Studies; Female; Gefitinib; Humans; Intestinal Absorption; Intestines; Male; Middle Aged; Permeability; Quinazolines; Vitamin A | 2010 |
Enhanced antiproliferative and apoptotic response to combined treatment of gamma-tocotrienol with erlotinib or gefitinib in mammary tumor cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromans; Culture Media, Serum-Free; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Mammary Neoplasms, Animal; Mice; Quinazolines; Signal Transduction; Trastuzumab; Vitamin E | 2010 |
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cetuximab; CHO Cells; Cricetinae; Cricetulus; ErbB Receptors; Gefitinib; Humans; Ligands; Mice; Neoplasms; Neuregulin-1; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2010 |
[Gefitinib improves insulin sensitivity in Wistar diabetes rats models].
Topics: Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Gefitinib; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Male; Phosphatidylinositol 3-Kinases; Quinazolines; Rats; Rats, Wistar | 2009 |
Gefitinib enhances arsenic trioxide (AS2O3)-induced differentiation of acute promyelocytic leukemia cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Cell Differentiation; Cell Line, Tumor; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Leukemia, Promyelocytic, Acute; Oxides; Quinazolines | 2010 |
Synergistic interaction between trastuzumab and EGFR/HER-2 tyrosine kinase inhibitors in HER-2 positive breast cancer cells.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Immunoblotting; Inhibitory Concentration 50; Lapatinib; Mice; Mice, Inbred BALB C; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
The close correlation between 8-hydroxy-2'-deoxyguanosine and epidermal growth factor receptor activating mutation in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Deoxyadenosines; DNA Damage; DNA Glycosylases; DNA Repair; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Y-Box-Binding Protein 1 | 2010 |
BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Separation; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA Interference; RNA, Small Interfering | 2011 |
A state space representation of VAR models with sparse learning for dynamic gene networks.
Topics: Cells, Cultured; Computational Biology; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Regulatory Networks; Humans; Lung; Lung Neoplasms; Models, Biological; Models, Statistical; Neoplasm Proteins; Pattern Recognition, Automated; Probability; Protein Kinase Inhibitors; Quinazolines; Regression Analysis; Time Factors | 2010 |
Cytoprotective effect of the elongation factor-2 kinase-mediated autophagy in breast cancer cells subjected to growth factor inhibition.
Topics: Adenylate Kinase; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Breast Neoplasms; Calcium; Cell Line, Tumor; Elongation Factor 2 Kinase; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intercellular Signaling Peptides and Proteins; Lapatinib; Quinazolines; Signal Transduction; Trastuzumab | 2010 |
Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Topics: Adenocarcinoma; Aged; Diagnosis, Differential; DNA Mutational Analysis; Epidermal Growth Factor; Female; Gefitinib; Humans; Lung Neoplasms; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Multiple Primary; Pneumonectomy; Quinazolines; Radiography, Thoracic | 2010 |
Combined gamma-tocotrienol and erlotinib/gefitinib treatment suppresses Stat and Akt signaling in murine mammary tumor cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Proliferation; Chromans; Erlotinib Hydrochloride; Female; Gefitinib; Mammary Neoplasms, Animal; Mice; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT Transcription Factors; Vitamin E | 2010 |
[Maintenance treatment of non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2010 |
Gefitinib as an effective therapy for advanced hepatocellular carcinoma with lung metastasis?
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Somatic mutation in the ACK1 ubiquitin association domain enhances oncogenic signaling through EGFR regulation in renal cancer derived cells.
Topics: Antineoplastic Agents; Base Sequence; Carcinoma, Renal Cell; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Kidney Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction; Ubiquitin | 2010 |
Functional characterization of gefitinib uptake in non-small cell lung cancer cell lines.
Topics: Antibodies, Blocking; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrogen-Ion Concentration; Kidney; Lung Neoplasms; Octamer Transcription Factor-1; Organic Cation Transport Proteins; Organic Cation Transporter 2; Phosphorylation; Quinazolines; RNA, Messenger | 2010 |
Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Base Sequence; Benzenesulfonates; Breast Neoplasms; Calcium; Cell Division; Cell Line, Tumor; Cytosol; DNA Primers; Endoplasmic Reticulum; Flow Cytometry; Gefitinib; Humans; Lapatinib; Membrane Potentials; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sorafenib | 2010 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
Neuromedin B receptors regulate EGF receptor tyrosine phosphorylation in lung cancer cells.
Topics: Acetylcysteine; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Neurokinin B; Phosphorylation; Phosphotyrosine; Quinazolines; Reactive Oxygen Species; Receptors, Bombesin; Transcriptional Activation; Tumor Cells, Cultured | 2010 |
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
Topics: Animals; Antineoplastic Agents; Butadienes; Carcinoma, Non-Small-Cell Lung; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Mice; Mutation; Nitriles; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2010 |
Establishment and characterization of a new drug surviving cell line Am1010, derived directly from muscle metastases of a human lung adenocarcinoma patient with multi-drug-resistance to cisplatin, taxol, and gefitinib.
Topics: Adenocarcinoma; Adult; Animals; Cell Line, Tumor; Cell Proliferation; Chromosomes; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines | 2010 |
Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux.
Topics: Acridines; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Blood-Brain Barrier; Brain; Cell Line; Cell Membrane Permeability; Dogs; Gefitinib; Male; Mice; Mice, Knockout; Quinazolines; Tetrahydroisoquinolines; Tissue Distribution; Transfection | 2010 |
Inducible EGFR T790M-mediated gefitinib resistance in non-small cell lung cancer cells does not modulate sensitivity to PI103 provoked autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Furans; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Protein Serine-Threonine Kinases; Pyridines; Pyrimidines; Quinazolines; TOR Serine-Threonine Kinases | 2010 |
EGFR mutations in non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Taxoids | 2010 |
Identification of biomarkers in human head and neck tumor cell lines that predict for in vitro sensitivity to gefitinib.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; Gefitinib; Gene Dosage; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Head and Neck Neoplasms; Humans; Neoplasm Proteins; Quinazolines; RNA, Messenger | 2009 |
Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cetuximab; DNA Primers; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Transfection | 2010 |
Structure of the EGF receptor transactivation circuit integrates multiple signals with cell context.
Topics: Cell Line; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flavonoids; Gefitinib; Gene Regulatory Networks; Hepatocyte Growth Factor; Humans; Imidazoles; Ligands; Lysophospholipids; Mammary Glands, Human; Phosphorylation; Pyridines; Quinazolines; Signal Transduction; Transcriptional Activation; Transforming Growth Factor alpha | 2010 |
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Gefitinib; Glioma; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Topotecan; Xenograft Model Antitumor Assays | 2010 |
Design and synthesis of novel Gefitinib analogues with improved anti-tumor activity.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Design; ErbB Receptors; Gefitinib; Humans; Quinazolines; Receptor, ErbB-2 | 2010 |
Receptor activation and inhibition in cellular response to chemotherapeutic combinational mimicries: the concept of divergent targeting.
Topics: Analysis of Variance; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dacarbazine; DNA Damage; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; Models, Biological; Mutation; Octreotide; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Time Factors; Transfection | 2010 |
Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6.
Topics: Animals; Cell Line, Tumor; Dependovirus; ErbB Receptors; Female; Gefitinib; Gene Expression; Genetic Therapy; Genetic Vectors; Head and Neck Neoplasms; Isoantigens; Mice; Mice, Nude; Neoplasms, Experimental; Quinazolines; Receptors, Virus; Transduction, Genetic; Tyrphostins | 2010 |
Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Paclitaxel; Phosphorylation; Quinazolines; Signal Transduction | 2011 |
High efficacy of first-line gefitinib in non-Asian patients with EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chromosome Deletion; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Russia; Treatment Outcome | 2010 |
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Point Mutation; Prognosis; Quinazolines | 2010 |
Prognostic value of E-cadherin expression in non-small cell lung cancer treated with gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Cadherins; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2010 |
Gallbladder cancer with tumor thrombus in the superior vena cava.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Fibrinolytic Agents; Gallbladder Neoplasms; Gefitinib; Humans; Incidental Findings; Middle Aged; Neoplastic Cells, Circulating; Positron-Emission Tomography; Protein Kinase Inhibitors; Quinazolines; Superior Vena Cava Syndrome; Tomography, X-Ray Computed; Treatment Outcome; Vena Cava, Superior | 2010 |
Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
Topics: Afatinib; Amino Acid Substitution; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; Drug Synergism; E2F1 Transcription Factor; ErbB Receptors; Fluorouracil; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Mice; Mutation; Oxonic Acid; Pemetrexed; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Mas; Quinazolines; Tegafur; Thymidylate Synthase; Xenograft Model Antitumor Assays | 2010 |
Emerging role of gefitinib in the treatment of non-small-cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib.
Topics: Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Purpura; Quinazolines; Vasculitis, Leukocytoclastic, Cutaneous | 2010 |
The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2011 |
Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.
Topics: Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Luteolin; Male; Prostatic Neoplasms; Quinazolines; Signal Transduction | 2010 |
[Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2010 |
Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Recurrence; Retreatment; Retrospective Studies; Treatment Failure | 2010 |
Surgical resection of lung adenocarcinoma without EGFR mutation after neoadjuvant gefitinib treatment.
Topics: Adenocarcinoma; Aged; Biopsy, Needle; Chemotherapy, Adjuvant; Female; Gefitinib; Genes, erbB-1; Humans; Infant; Lung Neoplasms; Mutation; Neoadjuvant Therapy; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2010 |
Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Antineoplastic Agents; Benzodiazepinones; Breast Neoplasms; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Dipeptides; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Notch; Signal Transduction; Xenograft Model Antitumor Assays | 2010 |
Immunohistochemical detection of EGFR mutation using mutation-specific antibodies in lung cancer.
Topics: Antibodies; Antibody Specificity; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Gene Amplification; Gene Deletion; Humans; Immunohistochemistry; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Denaturing capillary electrophoresis for automated detection of L858R mutation in exon 21 of the epidermal growth factor receptor gene in prediction of the outcome of lung cancer therapy.
Topics: Adenocarcinoma; Automation; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Electrophoresis, Capillary; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Nucleic Acid Denaturation; Pharmacogenetics; Point Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship; Treatment Outcome | 2010 |
Successful treatment with erlotinib after gefitinib-induced severe interstitial lung disease.
Topics: Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Successful erlotinib rechallenge after gefitinib-induced acute interstitial pneumonia.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Middle Aged; Quinazolines; Survival Rate; Tomography, X-Ray Computed; Treatment Outcome | 2010 |
Epidermal growth factor receptor tyrosine kinase inhibitors induce CCL2 and CCL5 via reduction in IL-1R2 in keratinocytes.
Topics: Acneiform Eruptions; Adolescent; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cell Line; Enzyme Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-1; Keratinocytes; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptors, Interleukin-1; Receptors, Interleukin-1 Type II; RNA, Messenger; Signal Transduction | 2010 |
Targeted therapies: Importance of patient selection for EGFR TKIs in lung cancer.
Topics: Clinical Trials as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2010 |
Predictors of skeletal-related events in non-small cell lung cancer patients with bone metastases.
Topics: Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Diphosphonates; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2011 |
A new A431/cell membrane chromatography and online high performance liquid chromatography/mass spectrometry method for screening epidermal growth factor receptor antagonists from Radix sophorae flavescentis.
Topics: Alkaloids; Binding, Competitive; Cell Fractionation; Cell Line, Tumor; Cell Membrane; Cell Proliferation; Chromatography, High Pressure Liquid; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Humans; Mass Spectrometry; Matrines; Plant Roots; Protein Kinase Inhibitors; Quinazolines; Quinolizines; Reproducibility of Results; Sophora | 2010 |
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Pyrazines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Epidermal growth factor receptor polymorphisms and risk for toxicity in paediatric patients treated with gefitinib.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Clinical Trials as Topic; Diarrhea; Drug Eruptions; ErbB Receptors; Exanthema; Gefitinib; Germ-Line Mutation; Humans; Infant; Neoplasms; Polymorphism, Genetic; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Young Adult | 2010 |
Ozarelix, a fourth generation GnRH antagonist, induces apoptosis in hormone refractory androgen receptor negative prostate cancer cells modulating expression and activity of death receptors.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Cycle; Cell Division; Drug Synergism; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gonadotropin-Releasing Hormone; Humans; Male; p38 Mitogen-Activated Protein Kinases; Prostatic Neoplasms; Quinazolines; Tumor Cells, Cultured | 2010 |
Sprouty2 protein enhances the response to gefitinib through epidermal growth factor receptor in colon cancer cells.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Survival; Cetuximab; Colonic Neoplasms; ErbB Receptors; Female; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Immunoblotting; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Xenograft Model Antitumor Assays | 2010 |
Use of cetuximab after failure of gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Remission Induction; Salvage Therapy; Survival Rate; Treatment Failure; Treatment Outcome | 2010 |
A simple procedure for the derivation of electron density based surfaces of drug-receptor complexes from a combination of X-ray data and theoretical calculations.
Topics: Antineoplastic Agents; Coronavirus; Coronavirus 3C Proteases; Crystallography, X-Ray; Cysteine Endopeptidases; Electrons; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Protein Kinase Inhibitors; Quinazolines; Viral Proteins | 2010 |
[Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Quinazolines | 2010 |
[Lung cancer].
Topics: Administration, Oral; Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials, Phase III as Topic; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2010 |
Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Trastuzumab | 2011 |
Steroid receptor coactivator-3 expression in lung cancer and its role in the regulation of cancer cell survival and proliferation.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cell Survival; Cetuximab; Disease-Free Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Dosage; Gene Knockdown Techniques; Humans; Immunohistochemistry; Lung Neoplasms; Nuclear Receptor Coactivator 3; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction | 2010 |
[Application of epidermal growth factor receptor tyrosine kinase inhibitor as the first-line therapy in patients with advanced non-small cell lung cancer].
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Quinazolines; Retrospective Studies; Young Adult | 2010 |
Salvage surgery for advanced non-small cell lung cancer after response to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy; Time Factors; Treatment Outcome | 2010 |
Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Genes, ras; Humans; Immunohistochemistry; Lung Neoplasms; Male; Mesoderm; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2010 |
[A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib].
Topics: Antineoplastic Agents; Diagnosis, Differential; Exanthema; Female; Gefitinib; Humans; IgA Vasculitis; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Effect of gefitinib on the survival of patients with recurrence of lung adenocarcinoma after surgery: a retrospective case-matching cohort study.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2010 |
Targeted therapy at the end of life for patients with lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Delivery Systems; Drug Utilization; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Patient Selection; Practice Patterns, Physicians'; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Singapore; Sirolimus; Terminal Care; Time Factors; Treatment Outcome | 2010 |
TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer.
Topics: Animals; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Interleukin-6; Lung Neoplasms; Mesoderm; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transforming Growth Factor beta | 2010 |
TAK-701, a humanized monoclonal antibody to hepatocyte growth factor, reverses gefitinib resistance induced by tumor-derived HGF in non-small cell lung cancer with an EGFR mutation.
Topics: Animals; Antibodies, Monoclonal; Base Sequence; Carcinoma, Non-Small-Cell Lung; DNA Primers; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.
Topics: Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Cycle Proteins; Cell Line, Tumor; DNA-Binding Proteins; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Protein Serine-Threonine Kinases; Quinazolines; Radiation-Sensitizing Agents; Tumor Suppressor Proteins | 2010 |
Gefitinib. Still no convincing results in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Clinical impact of amphiregulin expression in patients with epidermal growth factor receptor (EGFR) wild-type nonsmall cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; EGF Family of Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glycoproteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2011 |
[A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2010 |
Complex mutations in the epidermal growth factor receptor gene in non-small cell lung cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines; Sequence Deletion | 2010 |
Successful treatment of two lung cancer patients with erlotinib following gefitinib-induced hepatotoxicity.
Topics: Aged, 80 and over; Aspartate Aminotransferases; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Gefitinib; Green Fluorescent Proteins; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Monitoring, Physiologic; Neoplasm Metastasis; Quinazolines; Recurrence | 2010 |
Gefitinib attenuates murine pulmonary fibrosis induced by bleomycin.
Topics: Animals; Bleomycin; Blotting, Western; Collagen Type I; Collagen Type III; ErbB Receptors; Gefitinib; Male; Mice; Mice, Inbred C57BL; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
Favorable response to gefitinib treatment of lung adenocarcinoma with coexisting germline and somatic epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Base Sequence; Chemotherapy, Adjuvant; Cholecystitis; Cisplatin; Combined Modality Therapy; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; Genetic Predisposition to Disease; Humans; Incidental Findings; Lung Neoplasms; Mutation; Neoplasm Staging; Pedigree; Pneumonectomy; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Vinblastine; Vinorelbine | 2010 |
Single-agent gefitinib with concurrent radiotherapy for locally advanced non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Feasibility Studies; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Radiotherapy; Withholding Treatment | 2011 |
Comparison of gefitinib and erlotinib in advanced NSCLC and the effect of EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Survival Analysis | 2011 |
Small-cell carcinoma with an epidermal growth factor receptor mutation in a never-smoker with gefitinib-responsive adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Mutation; Quinazolines | 2010 |
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2010 |
Restoration of gefitinib efficacy following chemotherapy in a patient with metastatic non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines; Treatment Outcome | 2010 |
Lovastatin inhibits VEGFR and AKT activation: synergistic cytotoxicity in combination with VEGFR inhibitors.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lovastatin; Proto-Oncogene Proteins c-akt; Quinazolines; Transcriptional Activation; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Time Factors; Treatment Outcome | 2010 |
Gefitinib-induced epidermal growth factor receptor-independent keratinocyte apoptosis is mediated by the JNK activation pathway.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Quinazolines; Signal Transduction | 2011 |
IGFBP-3 can either inhibit or enhance EGF-mediated growth of breast epithelial cells dependent upon the presence of fibronectin.
Topics: Biotinylation; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Fibronectins; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Laminin; MAP Kinase Signaling System; Phosphorylation; Quinazolines; Radioimmunoassay; rho-Associated Kinases | 2010 |
[Feasibility of erlotinib after gefitinib failure in patients with advanced pulmonary adenocarcinoma previously responding to gefitinib].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Tolerance; Erlotinib Hydrochloride; Feasibility Studies; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2010 |
A pilot study of preoperative gefitinib for early-stage lung cancer to assess intratumor drug concentration and pathways mediating primary resistance.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Blotting, Western; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Phosphorylation; Pilot Projects; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Survival Rate; Tissue Distribution; Tyrosine | 2010 |
Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Quinazolines; Tomography, X-Ray Computed | 2011 |
Mitochondrially localized EGFR is independent of its endocytosis and associates with cell viability.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line; Cell Line, Tumor; Cell Survival; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Etoposide; Gefitinib; Green Fluorescent Proteins; Humans; Immunoblotting; Microscopy, Immunoelectron; Mitochondria; Mitochondrial Proteins; Mutation; Protein Transport; Quinazolines | 2010 |
Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cluster Analysis; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Paclitaxel; Phenotype; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2 | 2010 |
EGFR tyrosine kinase inhibition worsens acute lung injury in mice with repairing airway epithelium.
Topics: Acute Lung Injury; Airway Remodeling; Animals; Bronchoalveolar Lavage Fluid; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression; Mice; Mice, Inbred C57BL; Naphthalenes; Protein Kinase Inhibitors; Quinazolines; Respiratory Mucosa; Treatment Outcome | 2011 |
Interstitial lung disease and gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Product Surveillance, Postmarketing; Quinazolines | 2010 |
The transforming growth factor-beta (TGF-β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells.
Topics: Antigens, CD; Apoptosis; Apoptosis Regulatory Proteins; Cadherins; Carcinoma, Hepatocellular; Cell Proliferation; Cell Transdifferentiation; Cells, Cultured; ErbB Receptors; Gefitinib; Gene Expression Regulation; Hepatocytes; Humans; Liver; Liver Neoplasms; Mesenchymal Stem Cells; Neoplasm Invasiveness; Phenotype; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1 | 2011 |
[Re-treatment with epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)for lung adenocarcinoma].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2010 |
Interstitial lung disease and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Incidence; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Quinazolines | 2010 |
The prostaglandin E2 receptor, EP2, stimulates keratinocyte proliferation in mouse skin by G protein-dependent and {beta}-arrestin1-dependent signaling pathways.
Topics: Alprostadil; Animals; Arrestins; beta-Arrestins; Cell Proliferation; Cyclic AMP-Dependent Protein Kinases; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; GTP-Binding Proteins; Keratinocytes; Mice; Mitogen-Activated Protein Kinase 3; Multiprotein Complexes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Prostaglandin E, EP2 Subtype; Signal Transduction; Skin; src-Family Kinases; STAT3 Transcription Factor; Tyrphostins | 2010 |
Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Tumor Cells, Cultured | 2010 |
Design and synthesis of tetrahydropyridothieno[2,3-d]pyrimidine scaffold based epidermal growth factor receptor (EGFR) kinase inhibitors: the role of side chain chirality and Michael acceptor group for maximal potency.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Male; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous | 2010 |
Predictive biomarkers in the management of EGFR mutant lung cancer.
Topics: Adenocarcinoma; Aged; Apoptosis; BRCA1 Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genetic Therapy; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; White People | 2010 |
ILD during erlotinib and gefitinib treatment in Japanese patients with non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asian People; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Prognosis; Quinazolines | 2010 |
Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2010 |
Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome | 2010 |
Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockout Techniques; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
DTI assessment of the brainstem white matter tracts in pediatric BSG before and after therapy: a report from the Pediatric Brain Tumor Consortium.
Topics: Adolescent; Anisotropy; Antineoplastic Agents; Brain Stem; Brain Stem Neoplasms; Child; Child, Preschool; Clinical Trials, Phase II as Topic; Combined Modality Therapy; Diffusion Tensor Imaging; Gefitinib; Glioma; Humans; Image Interpretation, Computer-Assisted; Male; Nerve Fibers, Myelinated; Quinazolines; Quinolones; Radiotherapy | 2011 |
Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Integrin beta1; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Sequence Analysis, DNA | 2010 |
[Analysis of prognostic factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines | 2010 |
Chemoprevention of pancreatic cancer: ready for the clinic?
Topics: Animals; Antineoplastic Agents; Chemoprevention; ErbB Receptors; Gefitinib; Humans; Mice; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
The epidermal growth factor receptor inhibitor gefitinib prevents the progression of pancreatic lesions to carcinoma in a conditional LSL-KrasG12D/+ transgenic mouse model.
Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma in Situ; Carcinoma, Pancreatic Ductal; Disease Models, Animal; Disease Progression; ErbB Receptors; Fluorescent Antibody Technique; Gefitinib; Immunohistochemistry; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Research Design; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
Inhibition of poxvirus spreading by the anti-tumor drug Gefitinib (Iressa).
Topics: Antiviral Agents; Cell Line; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Microbial Sensitivity Tests; Oxazines; Quinazolines; Vaccinia virus; Viral Plaque Assay; Xanthenes | 2011 |
Good response to gefitinib in lung adenocarcinoma harboring coexisting EML4-ALK fusion gene and EGFR mutation.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogene Proteins, Fusion; Quinazolines | 2010 |
HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lactotrophs; Lapatinib; Molecular Targeted Therapy; Prolactin; Prolactinoma; Quinazolines; Rats; Receptor, ErbB-2; RNA, Messenger; Signal Transduction | 2011 |
Different efficacies of erlotinib and gefitinib in taiwanese patients with advanced non-small cell lung cancer: a retrospective multicenter study.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan | 2011 |
A novel hybrid peptide targeting EGFR-expressing cancers.
Topics: Animals; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Mutant Chimeric Proteins; Neoplasm Transplantation; Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Transplantation, Heterologous | 2011 |
One patient with metastastic colorectal cancer successfully treated by combination of targeted agents after failure of chemotherapy.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Capecitabine; Catheter Ablation; Cetuximab; Cytokine-Induced Killer Cells; Deoxycytidine; Disease-Free Survival; Drug Delivery Systems; ErbB Receptors; Fluorouracil; Gefitinib; Humans; Immunotherapy, Adoptive; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Oxaloacetates; Positron-Emission Tomography; Quality of Life; Quinazolines; Sigmoid Neoplasms; Tomography, X-Ray Computed | 2010 |
Inhibition of RIP2's tyrosine kinase activity limits NOD2-driven cytokine responses.
Topics: Acetylmuramyl-Alanyl-Isoglutamine; Animals; Cells, Cultured; Cytokines; Enzyme Activation; Erlotinib Hydrochloride; Gefitinib; Gene Knockout Techniques; HEK293 Cells; HT29 Cells; Humans; Mice; Nod2 Signaling Adaptor Protein; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Tyrosine; Ubiquitin-Protein Ligases; Ubiquitination | 2010 |
Estrogen receptor β exerts tumor repressive functions in human malignant pleural mesothelioma via EGFR inactivation and affects response to gefitinib.
Topics: Blotting, Western; Caveolin 1; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Estrogen Receptor beta; Gefitinib; Humans; Immunoprecipitation; Mesothelioma; Microscopy, Confocal; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Pleural Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference | 2010 |
Targeted therapy for non-small-cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asia; Carboplatin; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Multicenter Studies as Topic; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Treatment Outcome | 2010 |
The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antibody Specificity; ErbB Receptors; Female; Gefitinib; Genetic Association Studies; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Point Mutation; Quinazolines; Sequence Deletion | 2011 |
Warfarin therapy: how the less interesting half just got interesting.
Topics: Acetaminophen; Anticoagulants; Azithromycin; Cimetidine; Cytochrome P-450 Enzyme System; Drug Interactions; Gefitinib; Humans; Omeprazole; Quinazolines; Stereoisomerism; Substrate Specificity; Warfarin | 2010 |
The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; DNA Methylation; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Triazenes | 2011 |
Traditional Chinese medicine herbal treatment may have a relevant impact on the prognosis of patients with stage IV adenocarcinoma of the lung treated with platinum-based chemotherapy or combined targeted therapy and chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carboplatin; Cisplatin; Combined Modality Therapy; Deoxycytidine; Docetaxel; Drug Therapy, Combination; Drugs, Chinese Herbal; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Medicine, Chinese Traditional; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Organoplatinum Compounds; Outpatients; Paclitaxel; Platinum Compounds; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Taxoids; Treatment Outcome; Vinblastine; Vinorelbine | 2011 |
Oncogenic Kras promotes chemotherapy-induced growth factor shedding via ADAM17.
Topics: ADAM Proteins; ADAM17 Protein; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Gefitinib; Genes, ras; HCT116 Cells; HT29 Cells; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Mice; Mice, Inbred BALB C; Mice, SCID; Point Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Transforming Growth Factor alpha | 2011 |
Necrotizing vasculitis triggered by gefitinib: an unusual clinical presentation.
Topics: Antineoplastic Agents; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lower Extremity; Lung Neoplasms; Male; Middle Aged; Necrosis; Neoplasm Invasiveness; Neoplasm Staging; Prednisolone; Quinazolines; Risk Assessment; Skin Diseases, Vascular; Treatment Outcome; Vasculitis | 2011 |
Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prospective Studies; Quinazolines; Survival Rate; Treatment Outcome | 2011 |
Rapidly acquired resistance to EGFR tyrosine kinase inhibitors in NSCLC cell lines through de-repression of FGFR2 and FGFR3 expression.
Topics: Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblast Growth Factor 2; Fibroblast Growth Factor 7; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2010 |
Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, erbB-1; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Membrane Proteins; Microtubule-Associated Proteins; Mutation; Oncogene Protein v-akt; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Survivin | 2010 |
Lung cancer: recent advances.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2010 |
Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Acinar Cell; Cell Line, Tumor; Cell Movement; Cell Shape; Deoxycytidine; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Gene Expression Profiling; Humans; Lung Neoplasms; Middle Aged; Neoplasm Invasiveness; Pancreatic Neoplasms; Quinazolines; Sequence Deletion | 2011 |
[Gefitinib inhibits α-smooth muscle actin expression in mice with bleomycin-induced lung fibrosis].
Topics: Actins; Animals; Bleomycin; ErbB Receptors; Gefitinib; Lung; Male; Mice; Mice, Inbred BALB C; Pulmonary Fibrosis; Quinazolines; RNA, Messenger | 2010 |
Recurrent myocardial infarction associated with gefitinib therapy.
Topics: Antineoplastic Agents; Carcinoid Tumor; Gefitinib; Humans; Male; Middle Aged; Myocardial Infarction; Neoplasm Metastasis; Quinazolines | 2011 |
Inhibition of L-type amino acid transporter 1 has antitumor activity in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acids, Cyclic; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; ErbB Receptors; Fusion Regulatory Protein-1; Gefitinib; Humans; Immunohistochemistry; Large Neutral Amino Acid-Transporter 1; Leucine; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases | 2010 |
Tumour response to gefitinib is associated with EGF- and gefitinib- but not radiation-modulated EGFR expression.
Topics: Antineoplastic Agents; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Melanoma; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2010 |
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2011 |
AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity.
Topics: Animals; Benzylamines; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Therapy, Combination; Feedback, Physiological; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mechanistic Target of Rapamycin Complex 1; Mice; Mice, Nude; Models, Biological; Multiprotein Complexes; Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Quinoxalines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, IGF Type 1; Receptor, Insulin; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Up-Regulation; Xenograft Model Antitumor Assays | 2011 |
Aurora-A promotes gefitinib resistance via a NF-κB signaling pathway in p53 knockdown lung cancer cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Aurora Kinases; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; I-kappa B Proteins; Lung Neoplasms; Mutation; NF-kappa B; NF-KappaB Inhibitor alpha; Protein Serine-Threonine Kinases; Quinazolines; Transcriptional Activation; Tumor Suppressor Protein p53 | 2011 |
Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer.
Topics: Animals; Apoptosis; Blotting, Western; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Furans; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Prospective study of second-line chemotherapy for non-small cell lung cancer selected according to EGFR gene status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2010 |
Rapid and accurate ranking of binding affinities of epidermal growth factor receptor sequences with selected lung cancer drugs.
Topics: Computer Simulation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Purines; Quinazolines | 2011 |
Targeted inhibition of multiple receptor tyrosine kinases in mesothelioma.
Topics: Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Benzoquinones; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Interactions; Enzyme Activation; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Indoles; Lactams, Macrocyclic; Mesothelioma; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Sulfones | 2011 |
The epidermal growth factor receptor-L861Q mutation increases kinase activity without leading to enhanced sensitivity toward epidermal growth factor receptor kinase inhibitors.
Topics: Animals; Blotting, Western; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Kidney; Mice; Mutation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Quinazolines | 2011 |
Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Paclitaxel; Quinazolines; Signal Transduction; Transforming Growth Factor alpha | 2011 |
Antagonism between gefitinib and cisplatin in non-small cell lung cancer cells: why randomized trials failed?
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Clinical Trials, Phase III as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; Mutation; Paclitaxel; Quinazolines; Randomized Controlled Trials as Topic; Treatment Failure; Tumor Cells, Cultured | 2011 |
MGMT is a molecular determinant for potency of the DNA-EGFR-combi-molecule ZRS1.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Dacarbazine; Diazonium Compounds; DNA Methylation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; O(6)-Methylguanine-DNA Methyltransferase; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Tumor Suppressor Protein p53 | 2011 |
Effectiveness of erlotinib against recurrent pulmonary adenocarcinoma unresponsive to gefitinib: report of a case.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Quinazolines | 2011 |
DNA repair gene polymorphisms and benefit from gefitinib in never-smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; DNA-Binding Proteins; Endonucleases; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Genetic; Quinazolines; Smoking; X-ray Repair Cross Complementing Protein 1 | 2011 |
KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lapatinib; Lung Neoplasms; Membrane Potential, Mitochondrial; Mutation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Tumor Cells, Cultured; Vorinostat | 2011 |
Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2011 |
Duration of prior gefitinib treatment predicts survival potential in patients with lung adenocarcinoma receiving subsequent erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Quinazolines; Retrospective Studies; Time Factors; Treatment Failure | 2011 |
Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines | 2011 |
An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Docetaxel; Gefitinib; Humans; Lung Neoplasms; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Taxoids | 2011 |
Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Quinazolines | 2011 |
Could HBx protein expression affect signal pathway inhibition by gefitinib or selumetinib, a MEK inhibitor, in hepatocellular carcinoma cell lines?
Topics: Animals; Antineoplastic Agents; Benzimidazoles; beta Catenin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Liver Neoplasms; Mitogen-Activated Protein Kinase Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Trans-Activators; Viral Regulatory and Accessory Proteins | 2011 |
Is FISH floating or still swimming in the lung cancer ocean?
Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome | 2011 |
MRI as a central component of clinical trials analysis in brainstem glioma: a report from the Pediatric Brain Tumor Consortium (PBTC).
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Diffusion; Female; Gefitinib; Glioma; Humans; Magnetic Resonance Imaging; Male; Quinazolines; Quinolones; Radiotherapy Dosage; Research Design; Survival Rate; Treatment Outcome | 2011 |
Targeting epidermal growth factor receptor to optimize chemoradiotherapy in locally advanced head and neck cancer: has biology been taken into account?
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Chemotherapy, Adjuvant; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiotherapy, Adjuvant; Treatment Outcome | 2011 |
Comparing the epidermal growth factor interaction with four different cell lines: intriguing effects imply strong dependency of cellular context.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Kinetics; Protein Binding; Quinazolines; Signal Transduction | 2011 |
Knockdown of oncogenic KRAS in non-small cell lung cancers suppresses tumor growth and sensitizes tumor cells to targeted therapy.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Genetic Vectors; Humans; Mice; Mice, Nude; Mutation; p38 Mitogen-Activated Protein Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retroviridae; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2011 |
Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Transformation, Neoplastic; Chlorocebus aethiops; Disease Progression; Female; Gefitinib; Humans; Lapatinib; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT1 Transcription Factor; Transplantation, Heterologous | 2011 |
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; Drug Discovery; Drug Industry; Gefitinib; Humans; Lung Neoplasms; Politics; Quinazolines; United States; United States Food and Drug Administration | 2011 |
Expression of selected gene for acquired drug resistance to EGFR-TKI in lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Cadherins; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Fibronectins; gamma Catenin; Gefitinib; Gene Expression Regulation; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); PTEN Phosphohydrolase; Quinazolines; ras Proteins | 2011 |
Screening for EGFR mutations in lung cancer, a report from India.
Topics: Age Factors; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; India; Lung Neoplasms; Middle Aged; Mutation, Missense; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Sequence Deletion; Sex Factors | 2011 |
Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Diarrhea; Female; Gefitinib; Genome-Wide Association Study; Genotype; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Polymorphism, Genetic; Precision Medicine; Quinazolines; Treatment Outcome | 2011 |
Epidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.
Topics: Adaptor Proteins, Signal Transducing; Blotting, Western; Cell Line, Tumor; Computational Biology; DNA Primers; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Gefitinib; Humans; Models, Biological; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Proteins | 2011 |
Prospective study of epidermal growth factor receptor tyrosine kinase inhibitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prospective Studies; Quinazolines; Radiation Injuries; Radiotherapy Dosage; Tumor Burden | 2011 |
Density of Demodex folliculorum in patients receiving epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Animals; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mite Infestations; Mites; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Rosacea; Skin | 2011 |
NSCLC drug targets acquire new visibility.
Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome | 2011 |
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; Drug Synergism; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines | 2011 |
[Limitation of apoptosis induced by gefitinib in a long-surviving postoperative recurrent lung cancer case].
Topics: Aged; Apoptosis; Female; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Time Factors; Tomography, X-Ray Computed | 2011 |
[A case of lung adenocarcinoma with postoperative recurrence maintaining complete remission by treatment with gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Clinical Trials as Topic; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence; Remission Induction; Tomography, X-Ray Computed | 2011 |
Efficacy of the EGFr inhibitor Iressa on development of chemically-induced urinary bladder cancers: dose dependency and modulation of biomarkers.
Topics: Animals; Antineoplastic Agents; Biomarkers; Butylhydroxybutylnitrosamine; Cluster Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Models, Biological; Quinazolines; Rats; Signal Transduction; Urinary Bladder Neoplasms | 2011 |
Heat shock protein 90-sheltered overexpression of insulin-like growth factor 1 receptor contributes to malignancy of thymic epithelial tumors.
Topics: Aged; Apoptosis; Benzoquinones; Blotting, Western; Cell Cycle; Cell Line, Tumor; Cell Survival; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Immunohistochemistry; Infant; Infant, Newborn; Lactams, Macrocyclic; Male; Middle Aged; Neoplasms, Glandular and Epithelial; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Thymus Neoplasms | 2011 |
Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Diarrhea; Drug Dosage Calculations; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver Function Tests; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Population Groups; Quinazolines; Retrospective Studies; Skin Diseases; Treatment Failure | 2011 |
EGFR and EGFRvIII undergo stress- and EGFR kinase inhibitor-induced mitochondrial translocalization: a potential mechanism of EGFR-driven antagonism of apoptosis.
Topics: Amino Acid Motifs; Amino Acid Sequence; Amino Acid Substitution; Apoptosis; Cell Line, Tumor; Conserved Sequence; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Mitochondria; Molecular Sequence Data; Mutant Proteins; Protein Kinase Inhibitors; Protein Transport; Quinazolines | 2011 |
[Survival-related clinical factors of patients with advanced non-small cell lung cancer after 2000].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Survival Rate | 2011 |
Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pyridines; Quinazolines; RNA Interference; STAT3 Transcription Factor; Tumor Suppressor Protein p53; Tyrphostins | 2011 |
Constitutively active Harvey Ras confers resistance to epidermal growth factor receptor-targeted therapy with cetuximab and gefitinib.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Genes, ras; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Models, Biological; Phosphorylation; Quinazolines; ras Proteins; Vulvar Neoplasms | 2011 |
Good response to gefitinib in a lung adenocarcinoma harboring a heterozygous complex mutation of L833V and H835L in epidermal growth factor receptor gene.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Base Sequence; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Salvage Therapy | 2011 |
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines | 2011 |
Clinical significance of pretreatment C-reactive protein in patients with advanced nonsquamous, non-small cell lung cancer who received gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; C-Reactive Protein; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Quinazolines | 2010 |
Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2011 |
Drug localization in different lung cancer phenotypes by MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tandem Mass Spectrometry | 2011 |
Focal leptomeningeal metastasis following curative surgery for lung cancer: case report.
Topics: Adenocarcinoma; Antineoplastic Agents; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Neoplasms, Multiple Primary; Quinazolines | 2011 |
Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Topics: Adult; Aged; Antibodies, Monoclonal; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; DNA; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Pleural Effusion, Malignant; Polymerase Chain Reaction; Quinazolines; Recurrence; Sensitivity and Specificity; Sequence Deletion | 2011 |
Interstitial lung disease induced by gefitinib and toll-like receptor ligands is mediated by Fra-1.
Topics: Animals; Chemokine CCL2; Female; Gefitinib; Humans; Ligands; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages, Alveolar; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred ICR; Mice, Transgenic; Proto-Oncogene Proteins c-fos; Quinazolines; Toll-Like Receptors | 2011 |
Studies on the inhibition of feline EGFR in squamous cell carcinoma: enhancement of radiosensitivity and rescue of resistance to small molecule inhibitors.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cats; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Conserved Sequence; Disease Models, Animal; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Quinazolines; Radiation Tolerance; RNA Interference; Signal Transduction | 2011 |
Malignant pleural effusion from lung adenocarcinoma treated by gefitinib.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Apoptosis; Drainage; Gefitinib; Humans; Lung Neoplasms; Male; Pleural Effusion, Malignant; Quinazolines; Treatment Outcome | 2011 |
β1 integrin controls EGFR signaling and tumorigenic properties of lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Membrane Proteins; Mice; Mice, SCID; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transplantation, Heterologous | 2011 |
Phosphorylated insulin-like growth factor 1 receptor is implicated in resistance to the cytostatic effect of gefitinib in colorectal cancer cells.
Topics: Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Cross-Talk; Receptor, IGF Type 1; Signal Transduction; Tyrphostins | 2011 |
Nuclear translocation of epidermal growth factor receptor by Akt-dependent phosphorylation enhances breast cancer-resistant protein expression in gefitinib-resistant cells.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines | 2011 |
The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Female; Gefitinib; Humans; Liver Diseases; Male; Middle Aged; Quinazolines | 2011 |
"Un-slugging" resistance to epidermal growth factor receptor inhibition. A positive outlook for the future of lung cancer therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Snail Family Transcription Factors; Transcription Factors | 2011 |
EGFR inhibitors enhanced the susceptibility to NK cell-mediated lysis of lung cancer cells.
Topics: Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Lung Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcription Factor AP-2 | 2011 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Tyrosine kinase inhibitors and epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer: to test or not to test?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Lung Neoplasms; Mutation; Pharmacogenetics; Protein-Tyrosine Kinases; Quinazolines; Taiwan; Treatment Outcome | 2011 |
Gefitinib therapy in patients with advanced non-small cell lung cancer with or without testing for epidermal growth factor receptor (EGFR) mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Genetic Testing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pharmacogenetics; Quinazolines; Retrospective Studies; Taiwan; Treatment Outcome | 2011 |
Adaptive informatics for multifactorial and high-content biological data.
Topics: Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Data Interpretation, Statistical; Database Management Systems; Databases, Factual; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Microscopy; Programming Languages; Quinazolines; Software | 2011 |
VEGF inhibitor (Iressa) arrests histone deacetylase expression: single-cell cotransfection imaging cytometry for multi-target-multi-drug analysis.
Topics: Drug Discovery; Gefitinib; HEK293 Cells; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Image Cytometry; Phenylbutyrates; Protein Kinase Inhibitors; Quinazolines; Transfection; Vascular Endothelial Growth Factors | 2011 |
Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration.
Topics: Adult; Aged; Aged, 80 and over; Analysis of Variance; Antineoplastic Agents; Biopsy, Fine-Needle; Carboplatin; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Cisplatin; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, p53; Genes, ras; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Quinazolines; Retrospective Studies; Ultrasonography, Interventional | 2011 |
Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Insurance Benefits; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Patient Selection; Prognosis; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2011 |
Effectiveness of tyrosine kinase inhibitors on "uncommon" epidermal growth factor receptor mutations of unknown clinical significance in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2011 |
Characterization of a serum protein pattern from NSCLC patients treated with Gefitinib.
Topics: Aged; Algorithms; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease Progression; Electrophoresis, Polyacrylamide Gel; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2011 |
Regulation of cigarette smoke-mediated mucin expression by hypoxia-inducible factor-1α via epidermal growth factor receptor-mediated signaling pathways.
Topics: Cells, Cultured; Epithelial Cells; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mitogen-Activated Protein Kinase 3; Mucin 5AC; Nicotiana; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Signal Transduction; Smoke; Smoking; Up-Regulation | 2012 |
First- or second-line gefitinib therapy in unknown epidermal growth factor receptor mutants of non-small-cell lung cancer patients treated in Taiwan.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Taiwan; Treatment Outcome | 2011 |
An early event of EGFR mutation in pleomorphic carcinoma of the lung.
Topics: Antineoplastic Agents; Carcinoma; Cell Transformation, Neoplastic; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Design, synthesis of novel quinazolone alkaloids derivatives as potential antitumor agents.
Topics: Alkaloids; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Humans; Male; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Structure-Activity Relationship | 2011 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and signal protein expression of human lung adenocarcinoma cell SPC-A1].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Taxoids | 2011 |
[Factors affecting the sensitivity of EGFR-TKI treatment in advanced non-small cell lung cancer].
Topics: Adult; Aged; Antineoplastic Agents; Bone Neoplasms; Brain Neoplasms; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking | 2011 |
[A case of adenocarcinoma of the lung with a pulmonary thromboembolism which improved with gefitinib].
Topics: Adenocarcinoma; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Pulmonary Embolism; Quinazolines | 2011 |
Two cases of leptomeningeal metastases from lung adenocarcinoma which progressed during gefitinib therapy but responded to erlotinib.
Topics: Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Neoplasms; Middle Aged; Quinazolines | 2012 |
Epithelial to mesenchymal transition in an epidermal growth factor receptor-mutant lung cancer cell line with acquired resistance to erlotinib.
Topics: Adenocarcinoma; Biomarkers, Tumor; Blotting, Western; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Proliferation; DNA, Neoplasm; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mutation; Oligonucleotide Array Sequence Analysis; Protein Array Analysis; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Neoplasm; RNA, Small Interfering; Tumor Cells, Cultured | 2011 |
[Histology-based algorithm in the molecular diagnosis of mutations of the Epidernal Growth Factor Receptor (EGFR) in non-small cell lung cancer].
Topics: Adenocarcinoma; Algorithms; Austria; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Delivery Systems; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR upregulates inflammatory and proliferative responses in human lung adenocarcinoma cell line (A549), induced by lower dose of cadmium chloride.
Topics: Adenocarcinoma; Antineoplastic Agents; Cadmium Chloride; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cyclin D1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Environmental Pollutants; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Ki-67 Antigen; Lethal Dose 50; Lung Neoplasms; Microscopy, Acoustic; Proliferating Cell Nuclear Antigen; Quinazolines; Up-Regulation | 2011 |
The use of optical technology to monitor the antiangiogenic effects of gefitinib treatment for advanced head and neck squamous cell carcinoma: a brief report.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Squamous Cell; Endoscopy; Gefitinib; Head and Neck Neoplasms; Humans; Male; Middle Aged; Mouth Mucosa; Optics and Photonics; Quinazolines | 2012 |
P21 (waf1/cip1) is required for non-small cell lung cancer sensitive to Gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Oncogene Protein v-akt; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection; Tumor Suppressor Protein p53 | 2011 |
Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells.
Topics: Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Hepatocyte Growth Factor; Humans; Mice; Mice, SCID; Mitogen-Activated Protein Kinases; Neoplasm Invasiveness; Neoplasms, Squamous Cell; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Transforming Growth Factor alpha; Wound Healing; Xenograft Model Antitumor Assays | 2011 |
Long-term survival in a smoking caucasian male patient treated with gefitinib for spinal cord compression secondary to lung cancer.
Topics: Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Smoking; Spinal Cord Compression; Survivors; Treatment Outcome | 2011 |
The influence of intracellular epidermal growth factor receptor (EGFR) signal activation on the outcome of EGFR tyrosine kinase inhibitor treatment for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Mas; Quinazolines; Signal Transduction | 2011 |
[Antitumor effects of gefitinib for metastatic brain tumors from lung carcinomas with EGFR mutation].
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2011 |
[Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2011 |
KL-6 and CEA levels in epithelial lining fluid microsamples predict response to gefitinib in patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Quinazolines | 2011 |
EGFR tyrosine kinase inhibitors activate autophagy as a cytoprotective response in human lung cancer cells.
Topics: Autophagy; Autophagy-Related Protein 5; Autophagy-Related Protein 7; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Microscopy, Confocal; Microscopy, Electron; Microtubule-Associated Proteins; Phagosomes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Ribosomal Protein S6 Kinases, 70-kDa; RNA Interference; Signal Transduction; Time Factors; TOR Serine-Threonine Kinases; Ubiquitin-Activating Enzymes | 2011 |
EGFR inhibition fails to suppress vascular proliferation and tumor growth in a Ewing's sarcoma model.
Topics: Angiography; Animals; Antineoplastic Agents; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Humans; In Vitro Techniques; Mice; Mice, Nude; Neovascularization, Pathologic; Quinazolines; Sarcoma, Ewing; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2012 |
Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Atorvastatin; Benzylamines; beta-Cyclodextrins; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholesterol; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heptanoic Acids; Humans; Lovastatin; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Pyrroles; Quinazolines; Thiophenes | 2011 |
HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; RNA, Messenger; Ubiquitination; Vorinostat | 2011 |
Molecular selection trumps clinical selection.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Paclitaxel; Precision Medicine; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Survival Rate; Time Factors; Treatment Outcome | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lung.
Topics: Brain Neoplasms; Breath Tests; Carcinoma, Squamous Cell; DNA Mutational Analysis; ErbB Receptors; Exhalation; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Remission Induction; Sequence Deletion; Smoking | 2011 |
[Gefitinib enhances the radiosensitivity of nasopharyngeal carcinoma cell line CNE2 in vitro].
Topics: Apoptosis; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Flow Cytometry; Gefitinib; Humans; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Quinazolines; Radiation Tolerance | 2011 |
Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry.
Topics: Antineoplastic Agents; Chromatography, Liquid; Drug Stability; Gefitinib; Humans; Least-Squares Analysis; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
Ileal perforation induced by acute radiation injury under gefitinib treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Enteritis; ErbB Receptors; Female; Gefitinib; Humans; Intestinal Mucosa; Intestine, Small; Lung Neoplasms; Peritonitis; Quinazolines; Radiation Injuries; Radiotherapy; Wound Healing | 2011 |
Tumor-to-tumor metastasis: lung adenocarcinoma metastasizing to a follicular variant of papillary thyroid carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Combined Modality Therapy; DNA Mutational Analysis; DNA, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Thyroid Cancer, Papillary; Thyroid Neoplasms; Treatment Outcome | 2011 |
Surgical resection of locally advanced pulmonary adenocarcinoma after gefitinib therapy.
Topics: Adenocarcinoma; Administration, Oral; Biopsy, Needle; Female; Follow-Up Studies; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Staging; Pneumonectomy; Positron-Emission Tomography; Quinazolines; Risk Assessment; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Quinazolines; RNA | 2012 |
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Glioblastoma; Histone Deacetylase Inhibitors; Humans; Models, Biological; Phenylbutyrates; Piperidines; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Stem Cell Assay | 2011 |
Elevated BCRP/ABCG2 expression confers acquired resistance to gefitinib in wild-type EGFR-expressing cells.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Neoplasm Proteins; Quinazolines; RNA, Small Interfering | 2011 |
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Evolution, Molecular; Female; Gefitinib; Genes, erbB-1; Humans; Mice; Mice, Nude; Models, Theoretical; Mutation; Neoplasm Transplantation; Protein Kinase Inhibitors; Quinazolines | 2011 |
A simple HPLC-UV method for the simultaneous quantification of gefitinib and erlotinib in human plasma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Spectrophotometry, Ultraviolet | 2011 |
DARPP-32 increases interactions between epidermal growth factor receptor and ERBB3 to promote tumor resistance to gefitinib.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Disease Models, Animal; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-3; Signal Transduction; Stomach Neoplasms | 2011 |
Gefitinib induces apoptosis in human glioma cells by targeting Bad phosphorylation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; bcl-Associated Death Protein; Blotting, Western; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Cyclic AMP-Dependent Protein Kinases; Gefitinib; Glioma; Humans; Immunoprecipitation; Membrane Potential, Mitochondrial; Phosphorylation; Quinazolines; RNA, Small Interfering; Transfection | 2011 |
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Sorafenib; Xenograft Model Antitumor Assays | 2011 |
Marsdenia tenacissima extract restored gefitinib sensitivity in resistant non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Marsdenia; Mutation; Phosphorylation; Plant Extracts; Proteasome Endopeptidase Complex; Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2012 |
Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells.
Topics: Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Mass Spectrometry; Peptide Mapping; Protein Isoforms; Proteomics; Quinazolines; Software; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Two-Dimensional Difference Gel Electrophoresis; Vorinostat | 2011 |
The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mutation; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
[Inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase: similarity and differences].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[What choice of first-line treatment?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Translocation, Genetic | 2011 |
[What is the best sequence of treatment for patients with EGFR mutations?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome | 2011 |
[Management of patients with resistance to EGFR-TKI].
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Treatment Outcome | 2011 |
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Medical Oncology; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2011 |
Clinical significance of serum hepatocyte growth factor and epidermal growth factor gene somatic mutations in patients with non-squamous non-small cell lung cancer receiving gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Epidermal Growth Factor; Erlotinib Hydrochloride; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proportional Hazards Models; Quinazolines | 2012 |
Interstitial lung disease in gefitinib-treated Japanese patients with non-small-cell lung cancer: genome-wide analysis of genetic data.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Gefitinib; Genome-Wide Association Study; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2011 |
Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2011 |
Proteomic biomarkers for acute interstitial lung disease in gefitinib-treated Japanese lung cancer patients.
Topics: Asian People; Biomarkers; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Databases, Protein; Discriminant Analysis; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Peptides; Phenotype; Proteomics; Quality Control; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2011 |
Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apc(min/+) mouse.
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Down-Regulation; Drug Evaluation, Preclinical; Drug Synergism; ErbB Receptors; Gefitinib; Genes, APC; Intestinal Neoplasms; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; Tumor Burden | 2011 |
Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications.
Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lapatinib; Morpholines; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Quinolines; Receptor, ErbB-2; Trastuzumab | 2012 |
Maintained sensitivity to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer recurring after adjuvant erlotinib or gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy, Adjuvant; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Recurrence | 2011 |
Activity of epidermal growth factor receptor-tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring rare epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Review Literature as Topic; Treatment Outcome | 2011 |
[A case of alveolar hemorrhage caused by gefitinib].
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Hemorrhage; Humans; Lung Diseases; Lung Neoplasms; Pulmonary Alveoli; Quinazolines | 2011 |
Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Withholding Treatment | 2011 |
Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Curcumin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Intestinal Mucosa; Intestines; Lung Neoplasms; Mice; Mice, SCID; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Quinazolines; Ubiquitination; Xenograft Model Antitumor Assays | 2011 |
[Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib
in Patients with Non-small Cell Lung Cancer].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Quinazolines; Treatment Outcome | 2011 |
Osteosclerotic lesions in patients treated with gefitinib for lung adenocarcinomas: a sign of favorable therapeutic response.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteosclerosis; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
EGFR mutant lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Quinolines | 2012 |
Prediction of synergistic antitumour effect of gefitinib and radiation in vitro.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Melanoma; Phosphorylation; Quinazolines; Radiation, Ionizing; Skin Neoplasms | 2011 |
Basic clinical parameters predict gefitinib efficacy in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines | 2011 |
[Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy].
Topics: Adult; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; Disease-Free Survival; Docetaxel; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Neoplasm Staging; Neutropenia; Platinum; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids | 2011 |
[Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Remission Induction; Survival Rate | 2011 |
[Value of serum carcinoembryonic antigen in prediction of chemotherapy efficacy and prognosis in patients with advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor].
Topics: Aged; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Survival Rate | 2011 |
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding.
Topics: Binding Sites; ErbB Receptors; Gefitinib; Humans; Lapatinib; Models, Biological; Pharmaceutical Preparations; Phosphorylation; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Tumor Cells, Cultured | 2011 |
The critical role of the epidermal growth factor receptor in endochondral ossification.
Topics: Animals; Bone and Bones; Calcification, Physiologic; Cartilage; Cell Differentiation; Cell Proliferation; Cells, Cultured; Chondrocytes; ErbB Receptors; Gefitinib; Growth Plate; Hypertrophy; Matrix Metalloproteinases; Mice; Neovascularization, Physiologic; Osteoclasts; Osteogenesis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction | 2011 |
Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Docetaxel; Drug Combinations; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Oxonic Acid; Quinazolines; Retrospective Studies; Taxoids; Tegafur; Treatment Outcome | 2012 |
Association of the expression of mutant epidermal growth factor receptor protein as determined with mutation-specific antibodies in non-small cell lung cancer with progression-free survival after gefitinib treatment.
Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Design, synthesis, and in vitro antitumor activity evaluation of novel 4-pyrrylamino quinazoline derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Design; ErbB Receptors; Gefitinib; Humans; Quinazolines; Structure-Activity Relationship | 2011 |
Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Topics: Animals; Antibiotics, Antineoplastic; Brain; Cell Line; Cell Line, Tumor; Cell Proliferation; Cell Survival; Doxorubicin; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioblastoma; Humans; Immunoblotting; Mice; Mice, Nude; Mice, SCID; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor Cross-Talk; Receptors, Urokinase Plasminogen Activator; RNA Interference; STAT5 Transcription Factor; Transplantation, Heterologous; Tyrosine | 2011 |
MEMS microwell and microcolumn arrays: novel methods for high-throughput cell-based assays.
Topics: Cell Line, Tumor; Drug Evaluation, Preclinical; ErbB Receptors; Fluorescent Dyes; Gefitinib; Green Fluorescent Proteins; High-Throughput Screening Assays; Humans; Micro-Electrical-Mechanical Systems; Quinazolines; RNA Interference; RNA, Small Interfering | 2011 |
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5'-DFUR, the bioactive metabolite of Xeloda.
Topics: Antineoplastic Agents; Breast Neoplasms; Capecitabine; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deoxycytidine; Drug Synergism; ErbB Receptors; Female; Floxuridine; Fluorouracil; Gefitinib; Gene Expression Regulation, Enzymologic; Humans; Inhibitory Concentration 50; Methotrexate; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Thymidine Phosphorylase; Thymidylate Synthase | 2012 |
Successful pregnancy with epidermal growth factor receptor tyrosine kinase inhibitor treatment of metastatic lung adenocarcinoma presenting with respiratory failure.
Topics: Adenocarcinoma; Adult; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphangitis; Lymphatic Metastasis; Neoplasm Staging; Pleural Effusion, Malignant; Pregnancy; Pregnancy Complications, Neoplastic; Pregnancy Trimester, Third; Quinazolines; Remission Induction; Respiratory Insufficiency; Sequence Deletion; Term Birth | 2011 |
A noninvasive system for monitoring resistance to epidermal growth factor receptor tyrosine kinase inhibitors with plasma DNA.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Case-Control Studies; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity; Survival Rate; Treatment Outcome; Tumor Cells, Cultured | 2011 |
Using the Skindex-16 and Common Terminology Criteria for Adverse Events to assess rash symptoms: results of a pooled-analysis (N0993).
Topics: Algorithms; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Male; Middle Aged; Mometasone Furoate; Neoplasms; Pregnadienediols; Protein Kinase Inhibitors; Protein Synthesis Inhibitors; Quinazolines; Radiodermatitis; Randomized Controlled Trials as Topic; Severity of Illness Index; Sunscreening Agents; Surveys and Questionnaires; Terminology as Topic; Tetracycline | 2012 |
[Classification and regression tree analysis of clinical patterns that predict survival in 127 Chinese patients with advanced non-small cell lung cancer treated by gefitinib who failed to previous chemotherapy].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Regression Analysis; Retrospective Studies; Survival Analysis; Young Adult | 2011 |
Gefitinib attenuates transforming growth factor-β1-activated mitogen-activated protein kinases and mitogenesis in NRK-49F cells.
Topics: Animals; Benzamides; Cell Line; Collagen; Cyclin D1; Dioxoles; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Flavonoids; Gefitinib; Imidazoles; Kidney; MAP Kinase Signaling System; Mice; Mitosis; Models, Biological; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyridines; Quinazolines; Rats; Receptors, Transforming Growth Factor beta; Smad Proteins; Transforming Growth Factor beta1; Translational Research, Biomedical | 2011 |
Gefitinib induces epidermal growth factor receptor dimers which alters the interaction characteristics with ¹²⁵I-EGF.
Topics: Antineoplastic Agents; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Iodine Radioisotopes; Protein Binding; Protein Multimerization; Quinazolines | 2011 |
Erlotinib as a salvage treatment for patients with advanced non-small cell lung cancer after failure of gefitinib treatment.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Colorectal cancer.
Topics: Antineoplastic Agents; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genetic Therapy; Humans; Interferon-alpha; Quinazolines | 2011 |
The effect of combining interferon-alpha and gefitinib in human colon cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Interferon-alpha; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Quinazolines | 2011 |
Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.
Topics: Blotting, Western; Chromatin Immunoprecipitation; Colonic Neoplasms; Cytotoxicity, Immunologic; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; GPI-Linked Proteins; Humans; Intracellular Signaling Peptides and Proteins; Killer Cells, Natural; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Up-Regulation | 2012 |
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation | 2012 |
EGFR inhibitors sensitize non-small cell lung cancer cells to TRAIL-induced apoptosis.
Topics: Adenoviridae; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Genetic Vectors; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Recombinant Proteins; Signal Transduction; TNF-Related Apoptosis-Inducing Ligand; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2011 |
Gefitinib resistance in HCC mahlavu cells: upregulation of CD133 expression, activation of IGF-1R signaling pathway, and enhancement of IGF-1R nuclear translocation.
Topics: AC133 Antigen; Active Transport, Cell Nucleus; Antigens, CD; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycoproteins; Humans; Liver Neoplasms; Neoplastic Stem Cells; Peptides; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Up-Regulation | 2012 |
Investigation of acquired resistance to EGFR-targeted therapies in lung cancer using cDNA microarrays.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2012 |
Imaging patterns and prognosis of patients with gefitinib-related interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Radiography, Thoracic; Retrospective Studies; Tomography, X-Ray Computed | 2011 |
The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Trastuzumab; Xenograft Model Antitumor Assays | 2011 |
Allosteric modulation by protein kinase Cε leads to modified responses of EGF receptor towards tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Dimerization; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Immunoprecipitation; Lapatinib; Plasmids; Protein Conformation; Protein Kinase C-epsilon; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Transfection | 2012 |
Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Heparitin Sulfate; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Failure | 2011 |
Changes in plasma mass-spectral profile in course of treatment of non-small cell lung cancer patients with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Adult; Aged; Aged, 80 and over; Blood Proteins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2012 |
Differential impact of EGFR-targeted therapies on hypoxia responses: implications for treatment sensitivity in triple-negative metastatic breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Survival; Cetuximab; DNA; Drug Screening Assays, Antitumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, Reporter; Green Fluorescent Proteins; Humans; Hypoxia; Hypoxia-Inducible Factor 1; Lapatinib; Molecular Sequence Data; Neoplasm Metastasis; Quinazolines; Transcription, Genetic | 2011 |
Automated synthesis of [18F]gefitinib on a modular system.
Topics: Chromatography, High Pressure Liquid; Equipment Design; Fluorine Radioisotopes; Gefitinib; Isotope Labeling; Quinazolines; Radiopharmaceuticals; Robotics | 2012 |
Modulation of gene expression and cell-cycle signaling pathways by the EGFR inhibitor gefitinib (Iressa) in rat urinary bladder cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Blotting, Western; Cell Cycle; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Rats; Rats, Inbred F344; Real-Time Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Urinary Bladder Neoplasms | 2012 |
Rapid symptomatic improvement in gefitinib-treated patients with EGFR-mutated lung cancer: possible role of downregulation of inflammatory molecules?
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; DNA Mutational Analysis; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Inflammation Mediators; Lung Neoplasms; Lymphatic Metastasis; Neoadjuvant Therapy; Neoplasm Staging; Quinazolines; Tomography, X-Ray Computed | 2011 |
Chronic activation of wild-type epidermal growth factor receptor and loss of Cdkn2a cause mouse glioblastoma formation.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cyclin-Dependent Kinase Inhibitor p16; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Ligands; Membrane Proteins; Mice; Mitogen-Activated Protein Kinase Kinases; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction | 2011 |
EGFR protein expression in non-small cell lung cancer predicts response to an EGFR tyrosine kinase inhibitor--a novel antibody for immunohistochemistry or AQUA technology.
Topics: Adult; Aged; Aged, 80 and over; Binding Sites; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Fluorescent Antibody Technique; Gefitinib; Humans; Image Processing, Computer-Assisted; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Tissue Array Analysis | 2011 |
An EGFR inhibitor enhances the efficacy of SN38, an active metabolite of irinotecan, in SN38-refractory gastric carcinoma cells.
Topics: Animals; Apoptosis; Camptothecin; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Genes, erbB-2; Humans; Irinotecan; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Stomach Neoplasms | 2011 |
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Benzenesulfonates; Cardiotoxins; Cell Survival; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Indoles; Male; Models, Animal; Myocytes, Cardiac; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-raf; Pyridines; Pyrroles; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Sorafenib; Sunitinib; Zebrafish | 2011 |
Comparison of ROCK and EGFR activation pathways in the progression of glomerular injuries in AngII-infused rats.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Angiotensin II; Animals; Disease Progression; ErbB Receptors; Gefitinib; Kidney Diseases; Kidney Glomerulus; Male; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Wistar; rho-Associated Kinases; Signal Transduction | 2011 |
Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multimodal Imaging; Mutation; Positron-Emission Tomography; Prognosis; Quinazolines; Radiopharmaceuticals; Survival Rate; Tomography, X-Ray Computed | 2012 |
Multi-agent concurrent chemoradiotherapy for locally advanced head and neck squamous cell cancer in the elderly.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Squamous Cell; Chemoradiotherapy; Cisplatin; Enteral Nutrition; Female; Fluorouracil; Gefitinib; Head and Neck Neoplasms; Hospitalization; Humans; Male; Middle Aged; Neutropenia; Quinazolines; Radiotherapy Dosage; Registries; Retrospective Studies | 2012 |
Neonatal lethality in knockout mice expressing the kinase-dead form of the gefitinib target GAK is caused by pulmonary dysfunction.
Topics: Amino Acid Sequence; Animals; Animals, Newborn; Cadherins; Cell Membrane; Cesarean Section; Embryo, Mammalian; ErbB Receptors; Fibroblasts; Gefitinib; Gene Knockdown Techniques; Lung; Mice; Mice, Knockout; Molecular Sequence Data; Phenotype; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein Transport; Quinazolines | 2011 |
Evaluation of antitumor activity of gefitinib in pediatric glioblastoma and neuroblastoma cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Glioblastoma; Humans; Neuroblastoma; Phosphorylation; Quinazolines; Receptor, ErbB-2 | 2011 |
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Morpholines; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2011 |
Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
Topics: Aged; Antineoplastic Agents; Base Sequence; Carcinoma, Large Cell; Carcinoma, Neuroendocrine; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Sequence Data; Mutation; Neoplasm Metastasis; Protein Kinase Inhibitors; Quinazolines | 2011 |
Endocrine therapy, new biologicals, and new study designs for presurgical studies in breast cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ki-67 Antigen; Lapatinib; Molecular Targeted Therapy; Multicenter Studies as Topic; Neoadjuvant Therapy; Nitriles; Predictive Value of Tests; Preoperative Period; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Tamoxifen; Treatment Outcome; Triazoles | 2011 |
Clinical implications of high MET gene dosage in non-small cell lung cancer patients without previous tyrosine kinase inhibitor treatment.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Amplification; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Real-Time Polymerase Chain Reaction | 2011 |
Hepatocyte growth factor expression in EGFR mutant lung cancer with intrinsic and acquired resistance to tyrosine kinase inhibitors in a Japanese cohort.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Amplification; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2011 |
MK-2206, a novel allosteric inhibitor of Akt, synergizes with gefitinib against malignant glioma via modulating both autophagy and apoptosis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Bcl-2-Like Protein 11; Beclin-1; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Heterocyclic Compounds, 3-Ring; Humans; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Microtubule-Associated Proteins; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; RNA, Small Interfering | 2012 |
Collocation-based sparse estimation for constructing dynamic gene networks.
Topics: Algorithms; Antineoplastic Agents; Computer Simulation; Epithelial Cells; False Positive Reactions; Gefitinib; Gene Expression Regulation; Gene Regulatory Networks; Humans; Models, Theoretical; Oligonucleotide Array Sequence Analysis; Quinazolines; ROC Curve; Stochastic Processes; Time Factors; Transcription, Genetic | 2010 |
Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Analysis | 2011 |
PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Lung Neoplasms; Male; Middle Aged; Phosphatidylinositol 3-Kinases; PTEN Phosphohydrolase; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2011 |
Suppression of expression of heat shock protein 70 by gefitinib and its contribution to pulmonary fibrosis.
Topics: Animals; Cell Line, Tumor; ErbB Receptors; Gefitinib; HSP70 Heat-Shock Proteins; Humans; Immunoblotting; Lung Diseases, Interstitial; Mice; Mice, Transgenic; MicroRNAs; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Real-Time Polymerase Chain Reaction | 2011 |
[Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; X-Rays | 2011 |
A new medical therapy for Cushing disease?
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Animals; ErbB Receptors; Gefitinib; Humans; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines | 2011 |
EGFR as a therapeutic target for human, canine, and mouse ACTH-secreting pituitary adenomas.
Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Adrenocorticotropic Hormone; Animals; Cell Line, Tumor; Corticosterone; Dog Diseases; Dogs; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Molecular Targeted Therapy; Neoplasm Transplantation; Pituitary ACTH Hypersecretion; Pro-Opiomelanocortin; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Secretory Rate; Tumor Burden | 2011 |
Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines | 2011 |
Dual phosphoproteomics and chemical proteomics analysis of erlotinib and gefitinib interference in acute myeloid leukemia cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Leukemic; Gene Expression Regulation, Neoplastic; Humans; Leukemia, Myeloid, Acute; Mass Spectrometry; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction | 2012 |
Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Proliferation; Child; Ependymoma; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Immunoenzyme Techniques; In Vitro Techniques; Mice; Neoplastic Stem Cells; Purines; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
EML4-ALK translocation predicts better outcome in lung adenocarcinoma patients with wild-type EGFR.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Cell Cycle Proteins; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Microtubule-Associated Proteins; Middle Aged; Multivariate Analysis; Mutation Rate; Oncogene Proteins, Fusion; Pleural Effusion, Malignant; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases; Smoking; Translocation, Genetic | 2012 |
[Complete remission of multiple brain metastases of non-small cell lung cancer induced by gefitinib monotherapy].
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Brain Neoplasms; Cranial Irradiation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Neoplasm Staging; Quinazolines; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted | 2011 |
Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mutation; Prognosis; Quinazolines; Small Cell Lung Carcinoma | 2012 |
Protein expression signatures for inhibition of epidermal growth factor receptor-mediated signaling.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cetuximab; Chromatography, Liquid; Colorectal Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gastritis, Hypertrophic; Gefitinib; Humans; Mice; Neoplasms; Neoplasms, Glandular and Epithelial; Phosphorylation; Prospective Studies; Proteomics; Quinazolines; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Transplantation, Heterologous | 2012 |
Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2011 |
Pharmacogenetic predictors for EGFR-inhibitor-associated skin toxicity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Association Studies; Haplotypes; Humans; Male; Middle Aged; Neoplasms; Panitumumab; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines | 2013 |
Synergistic inhibitory effects by the combination of gefitinib and genistein on NSCLC with acquired drug-resistance in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genistein; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Pneumatosis cystoides intestinalis after gefitinib therapy for pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Radiography | 2012 |
Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anoikis; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Receptor, Notch1; RNA, Small Interfering; Signal Transduction; Tumor Stem Cell Assay | 2012 |
Gefitinib resistance of cancer cells correlated with TM4SF5-mediated epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin-Dependent Kinase Inhibitor p27; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Membrane Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2012 |
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Afatinib; Aged; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutagenesis, Insertional; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Male; MAP Kinase Signaling System; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-pim-1; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Tumor Suppressor Proteins | 2011 |
Systems biology modeling reveals a possible mechanism of the tumor cell death upon oncogene inactivation in EGFR addicted cancers.
Topics: Ascorbic Acid; Cell Death; Cell Line, Tumor; Computer Simulation; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Silencing; Humans; Models, Biological; Neoplasms; Oncogenes; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Reproducibility of Results; Signal Transduction; Systems Biology | 2011 |
Overexpressed HER2 in NSCLC is a possible therapeutic target of EGFR inhibitors.
Topics: Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Mice; Mutation; Neoplasm Transplantation; Quinazolines; Receptor, ErbB-2; Treatment Outcome | 2011 |
Continuous administration of EGFR-TKIs following radiotherapy after disease progression in bone lesions for non-small cell lung cancer.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Treatment Outcome | 2011 |
A high-throughput cell-based screening for L858R/T790M mutant epidermal growth factor receptor inhibitors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2012 |
[Clinical response to gefitinib retreatment of lung adenocarcinoma patients who benefited from an initial gefitinib therapy: a retrospective analysis].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2012 |
Lack of EGFR mutations benefiting gefitinib treatment in adenocarcinoma of esophagogastric junction.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; ErbB Receptors; Esophageal Neoplasms; Esophagogastric Junction; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Stomach Neoplasms; Survival Rate | 2012 |
The major vault protein mediates resistance to epidermal growth factor receptor inhibition in human hepatoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytokines; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Vault Ribonucleoprotein Particles | 2012 |
Sialylation of epidermal growth factor receptor regulates receptor activity and chemosensitivity to gefitinib in colon cancer cells.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Proliferation; Cell Survival; Colonic Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HT29 Cells; Humans; Immunoblotting; Immunoprecipitation; In Situ Nick-End Labeling; Mice; Mice, Nude; Phosphorylation; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Sialic Acids; Sialyltransferases; Transfection; Xenograft Model Antitumor Assays | 2012 |
Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Line, Tumor; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Epitopes; ErbB Receptors; Gefitinib; Humans; Mutation, Missense; Panitumumab; Quinazolines | 2012 |
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Feedback, Physiological; Female; Gefitinib; HEK293 Cells; Humans; Indoles; Melanoma; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; RNA Interference; Sulfonamides; Vemurafenib; Xenograft Model Antitumor Assays | 2012 |
Characterization and response of newly developed high-grade glioma cultures to the tyrosine kinase inhibitors, erlotinib, gefitinib and imatinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Brain Neoplasms; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Glioma; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-kit; PTEN Phosphohydrolase; Pyrimidines; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Survival Rate; Tumor Cells, Cultured; Young Adult | 2012 |
Erlotinib after failure of gefitinib treatment of more than 6 months in advanced non-small cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2012 |
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 months.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Drug Therapy, Combination; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
Lack of AKT activation in lung cancer cells with EGFR mutation is a novel marker of cetuximab sensitivity.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Dosage; Genes, ras; Humans; Lung Neoplasms; Mutation; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2012 |
Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cisplatin; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Ovarian Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Signal Transduction | 2012 |
Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Phenotype; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors | 2012 |
Severe bronchorrhea in a patient with bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Biopsy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sputum; Tomography, X-Ray Computed | 2012 |
Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
SKLB1206, a novel orally available multikinase inhibitor targeting EGFR activating and T790M mutants, ErbB2, ErbB4, and VEGFR2, displays potent antitumor activity both in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Mutation; Phosphorylation; Protein Kinase Inhibitors; Purines; Quinazolines; Random Allocation; Rats; Rats, Sprague-Dawley; Receptor, ErbB-2; Receptor, ErbB-4; Signal Transduction; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays; Zebrafish | 2012 |
Crotoxin enhances the antitumor activity of gefinitib (Iressa) in SK-MES-1 human lung squamous carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Caspase 3; Cell Cycle; Cell Line, Tumor; Crotoxin; Drug Synergism; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Increased activation of fibrocytes in patients with chronic obstructive asthma through an epidermal growth factor receptor-dependent pathway.
Topics: Acetylcysteine; ADAM Proteins; ADAM17 Protein; Adult; Antigens, CD34; Asthma; Blood Cells; Cell Proliferation; Cell Transformation, Neoplastic; Cells, Cultured; Collagen Type I; ErbB Receptors; Female; Fibroblasts; Follow-Up Studies; Gefitinib; Humans; Hydrogen Peroxide; Leukocyte Common Antigens; Male; Middle Aged; Oxidative Stress; Pulmonary Disease, Chronic Obstructive; Quinazolines; Respiratory Function Tests; Signal Transduction; Stem Cells; Tyrphostins | 2012 |
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Evaluating the short-term effect of gefitinib in advanced lung adenocarcinoma with positive EGFR-mutant by dual source volume perfusion CT].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Cone-Beam Computed Tomography; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2011 |
Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Methionine; Mice; Mice, Nude; Mice, SCID; Molecular Conformation; Mutation; Neoplasm Transplantation; Pyrimidines; Quinazolines; Structure-Activity Relationship; Threonine; Transplantation, Heterologous | 2012 |
Manifestation of leukoencephalopathy in a patient with advanced non-small cell lung cancer following treatment with gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Leukoencephalopathies; Lung Neoplasms; Middle Aged; Quinazolines | 2011 |
Identification of tumour initiating cells in feline head and neck squamous cell carcinoma and evidence for gefitinib induced epithelial to mesenchymal transition.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Squamous Cell; Cat Diseases; Cats; Cell Line, Tumor; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Glycoproteins; Head and Neck Neoplasms; Humans; Neoplastic Stem Cells; Peptides; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2012 |
Effect of κ-opioid receptor agonist on the growth of non-small cell lung cancer (NSCLC) cells.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Glycogen Synthase Kinase 3; Glycogen Synthase Kinase 3 beta; Humans; Mutation, Missense; Naltrexone; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Opioid, kappa; Signal Transduction; STAT3 Transcription Factor | 2012 |
Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Conformation; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Benzimidazoles; Cell Line; Cetuximab; Chromones; Dose-Response Relationship, Drug; Drug Resistance, Multiple; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Morpholines; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phosphatidylinositol 3-Kinases; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Signal Transduction; Tyrphostins | 2012 |
Identifying regulational alterations in gene regulatory networks by state space representation of vector autoregressive models and variational annealing.
Topics: Computational Biology; ErbB Receptors; Gefitinib; Gene Regulatory Networks; Humans; Lung; Models, Statistical; Models, Theoretical; Quinazolines | 2012 |
Cost-utility and budget impact analyses of gefitinib in second-line treatment for advanced non-small cell lung cancer from Thai payer perspective.
Topics: Antineoplastic Combined Chemotherapy Protocols; Budgets; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Models, Economic; Pemetrexed; Quality-Adjusted Life Years; Quinazolines; Randomized Controlled Trials as Topic; Survival Rate; Taxoids; Thailand; Treatment Outcome | 2012 |
EGFR kinase promotes acquisition of stem cell-like properties: a potential therapeutic target in head and neck squamous cell carcinoma stem cells.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cisplatin; ErbB Receptors; Flow Cytometry; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplasm Invasiveness; Neoplastic Stem Cells; Quinazolines; Signal Transduction | 2012 |
Differential efficacy of gefitinib across age groups in treatment of advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aging; Antineoplastic Agents; Disease Progression; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Logistic Models; Lung Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Quinazolines; Retrospective Studies; Software; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Pneumatosis intestinalis and portal venous gas secondary to Gefitinib therapy for lung adenocarcinoma.
Topics: Adenocarcinoma; Aged; Embolism, Air; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Portal Vein; Protein Kinase Inhibitors; Quinazolines | 2012 |
Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proteome; Proteomics; Quinazolines; Reproducibility of Results; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Animals; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Hepatocellular; Cell Division; Drug Resistance, Neoplasm; EGF Family of Proteins; ErbB Receptors; Female; Gefitinib; Glycoproteins; Hep G2 Cells; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms, Experimental; Male; MAP Kinase Signaling System; Mice; Mice, Nude; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Quinazolines; Receptor, ErbB-3; Sorafenib; Xenograft Model Antitumor Assays | 2012 |
[Sequence-dependent effect of docetaxel with gefitinib on the proliferation and apoptosis of lung adenocarcinoma cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Caspase 3; Caspase 8; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Taxoids | 2012 |
Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Caspase 7; Cell Line, Tumor; Cell Proliferation; Cetuximab; Down-Regulation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Phenotype; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Transfection | 2012 |
Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2012 |
FoxM1 mediated resistance to gefitinib in non-small-cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Mucoepidermoid; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Flow Cytometry; Forkhead Box Protein M1; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Time Factors | 2012 |
Gefitinib for a poor performance status patient with squamous cell carcinoma of the lung harboring EGFR mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Squamous Cell; Combined Modality Therapy; Docetaxel; ErbB Receptors; Fatal Outcome; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Severity of Illness Index; Smoking; Taxoids; Tomography, X-Ray Computed | 2012 |
Epidermal growth factor receptor-tyrosine kinase inhibitor (gefitinib) augments pneumonitis, but attenuates lung fibrosis in response to radiation injury in rats.
Topics: Animals; Disease Models, Animal; ErbB Receptors; Gefitinib; Male; Protein Kinase Inhibitors; Pulmonary Fibrosis; Quinazolines; Radiation Pneumonitis; Rats; Rats, Wistar | 2012 |
Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Treatment Failure; Treatment Outcome | 2012 |
Influence of precursor solvent properties on matrix crystallinity and drug release rates from nanoparticle aerosol lipid matrices.
Topics: Acetates; Aerosols; Antineoplastic Agents; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Chloroform; Crystallization; Crystallography, X-Ray; Delayed-Action Preparations; Drug Carriers; Drug Compounding; Gefitinib; Hydrogen-Ion Concentration; Kinetics; Methylene Chloride; Microscopy, Electron, Transmission; Nanoparticles; Nanotechnology; Particle Size; Quinazolines; Solubility; Solvents; Stearic Acids; Technology, Pharmaceutical; Vapor Pressure | 2012 |
The endothelin A receptor and epidermal growth factor receptor signaling converge on β-catenin to promote ovarian cancer metastasis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; beta Catenin; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Matrix Metalloproteinases; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Phosphorylation; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2012 |
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP).
Topics: AC133 Antigen; Antigens, CD; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Mutation; Neoplasm Proteins; Neoplastic Stem Cells; Peptides; Proto-Oncogene Mas; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Survivors | 2012 |
Clinical outcome in patients with leptomeningeal metastasis from non-small cell lung cancer: Okayama Lung Cancer Study Group.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Severity of Illness Index; Treatment Outcome | 2012 |
[Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Mutation; Proto-Oncogene Mas; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2012 |
Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2012 |
Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Male; Quinazolines | 2012 |
Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Carcinoma, Non-Small-Cell Lung; Exanthema; Female; Gefitinib; Gene Frequency; Genetic Predisposition to Disease; Genotype; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Proteins; Phenotype; Polymorphism, Single Nucleotide; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Assessment; Risk Factors; Treatment Outcome | 2012 |
Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; DNA Breaks, Double-Stranded; DNA-Activated Protein Kinase; ErbB Receptors; Gefitinib; Glioma; Histones; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Neuroglia; Phosphorylation; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Tumor Stem Cell Assay | 2012 |
Frequent EGFR mutations in nonsmall cell lung cancer presenting with miliary intrapulmonary carcinomatosis.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Time Factors; Treatment Outcome | 2013 |
[Inhibitory effect of gefitinib and lapatinib on proliferation of HEL cells].
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Janus Kinase 2; Lapatinib; Mutation; Myeloproliferative Disorders; Protein Kinase Inhibitors; Quinazolines | 2012 |
Gutter method: noninvasive management of ingrown nails caused by epidermal growth factor inhibitor treatment.
Topics: Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Nails, Ingrown; Plastics; Protein Kinase Inhibitors; Quinazolines; Splints | 2012 |
Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance.
Topics: Aminoquinolines; Aniline Compounds; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Neoplasm Proteins; Piperidines; Protein Binding; Quinazolines; Quinolines | 2012 |
Comprehensive two-dimensional HepG2/cell membrane chromatography/monolithic column/time-of-flight mass spectrometry system for screening anti-tumor components from herbal medicines.
Topics: Alkaloids; Antineoplastic Agents; Berberine; Berberine Alkaloids; Cell Proliferation; Chromatography, Liquid; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Hep G2 Cells; Humans; Mass Spectrometry; Matrines; Quinazolines; Quinolizines; Reproducibility of Results | 2012 |
Combine therapy of gefitinib and fulvestrant enhances antitumor effects on NSCLC cell lines with acquired resistance to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Receptors, Estrogen; Signal Transduction; Up-Regulation | 2012 |
[Mutation testing for non-small-cell lung cancer].
Topics: Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mutation; Point Mutation; Polymerase Chain Reaction; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2012 |
Activity of the MEK inhibitor selumetinib (AZD6244; ARRY-142886) in nasopharyngeal cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Cell Survival; Cisplatin; Drug Synergism; Gefitinib; Humans; Mitogen-Activated Protein Kinase Kinases; Nasopharyngeal Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines | 2013 |
Quantitative immunohistochemistry for evaluating the distribution of Ki67 and other biomarkers in tumor sections and use of the method to study repopulation in xenografts after treatment with paclitaxel.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Female; Gefitinib; Humans; Immunohistochemistry; Ki-67 Antigen; Mice; Mice, Nude; Neoplasms, Experimental; Paclitaxel; Quinazolines; Xenograft Model Antitumor Assays | 2012 |
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.
Topics: Amino Acid Sequence; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Dynamics Simulation; Molecular Sequence Data; Neoplasms; Point Mutation; Protein Folding; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines; Sequence Alignment; Signal Transduction | 2012 |
Physicochemical properties of epidermal growth factor receptor inhibitors and development of a nanoliposomal formulation of gefitinib.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Liposomes; Neoplasms; Protein Kinase Inhibitors; Quinazolines; Rats; Spectrometry, Fluorescence | 2012 |
Amplification of CRKL induces transformation and epidermal growth factor receptor inhibitor resistance in human non-small cell lung cancers.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenocarcinoma of Lung; Cell Death; Cell Line, Tumor; Cell Transformation, Neoplastic; Chromosomes, Human, Pair 22; Epithelial Cells; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Amplification; Humans; Lung Neoplasms; Mutation; Neurofibromin 1; Nuclear Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; raf Kinases; Shelterin Complex; Signal Transduction; SOS1 Protein; Telomere-Binding Proteins | 2011 |
Design, synthesis and antiproliferative activity of novel 2-substituted-4-amino-6-halogenquinolines.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Humans; Inhibitory Concentration 50; Quinazolines; Quinolines; Structure-Activity Relationship | 2012 |
T-Cadherin is an auxiliary negative regulator of EGFR pathway activity in cutaneous squamous cell carcinoma: impact on cell motility.
Topics: Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lapatinib; Membrane Microdomains; Quinazolines; rho GTP-Binding Proteins; Signal Transduction; Skin Neoplasms | 2012 |
Utility of insulin-like growth factor receptor-1 expression in gefitinib-treated patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; Immunohistochemistry; Lung Neoplasms; Male; Quinazolines; Receptor, IGF Type 1; Signal Transduction | 2012 |
Gefitinib-related interstitial lung disease in Taiwanese patients with non-small-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cough; Dyspnea; Female; Gefitinib; Hospital Mortality; Humans; Hypoxia; Incidence; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Taiwan | 2013 |
Epidermal growth factor receptor signaling pathway involved in progestin-resistance of human endometrial carcinoma: In a mouse model.
Topics: Animals; Antineoplastic Agents, Hormonal; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Therapy, Combination; Endometrial Neoplasms; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Medroxyprogesterone Acetate; Mice; Mice, Inbred BALB C; Phosphorylation; Quinazolines; Receptors, Progesterone; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
[Selected arterial infusion chemotherapy combined with target drugs for non-small cell lung cancer with multiple brain metastase].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Deoxycytidine; Drug Administration Schedule; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Infusions, Intra-Arterial; Leukopenia; Lung Neoplasms; Male; Middle Aged; Nimustine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Skin Diseases; Survival Analysis; Treatment Outcome | 2012 |
A transformation in the mechanism by which the urokinase receptor signals provides a selection advantage for estrogen receptor-expressing breast cancer cells in the absence of estrogen.
Topics: Animals; Breast Neoplasms; Erlotinib Hydrochloride; Estrogen Receptor alpha; Estrogens; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Mice; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Tumor Cells, Cultured | 2012 |
Saracatinib (AZD0530) is a potent modulator of ABCB1-mediated multidrug resistance in vitro and in vivo.
Topics: Adenosine Triphosphatases; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodioxoles; Cell Line, Tumor; Doxorubicin; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; HEK293 Cells; HeLa Cells; HL-60 Cells; Humans; MCF-7 Cells; Mice; Mice, Nude; Paclitaxel; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rho-Associated Kinases | 2013 |
Gefitinib alone or with concomitant whole brain radiotherapy for patients with brain metastasis from non-small-cell lung cancer: a retrospective study.
Topics: Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
[Multidisciplinary treatment of leptomeningeal metastasis in patients with lung adenocarcinoma: the triple modality combination of EGFR-TKI, VP shunt and irradiation].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Combined Modality Therapy; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate; Ventriculoperitoneal Shunt | 2012 |
Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib.
Topics: Apoptosis; Cell Differentiation; Cell Proliferation; Down-Regulation; Drug Delivery Systems; Drug Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Time Factors; Tyrosine | 2012 |
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Genes, MDR; Humans; Lung Neoplasms; Microtubules; Mutation; Paclitaxel; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tubulin Modulators | 2012 |
Long-term survival of a patient with carcinomatous meningitis due to non-small cell lung cancer treated with erlotinib following gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Spinal Puncture | 2011 |
[Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Nucleus; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lung Neoplasms; Quinazolines; Radiation Tolerance; Survival Analysis | 2012 |
[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Cross-Sectional Studies; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Public Health Practice; Quality of Life; Quinazolines; Retrospective Studies; Safety; Survivors; Time Factors; Treatment Outcome | 2012 |
Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Topics: Androgens; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Betacellulin; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Intercellular Signaling Peptides and Proteins; Male; Neuregulin-1; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger | 2012 |
A targeted enzyme approach to sensitization of tyrosine kinase inhibitor-resistant breast cancer cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Catalase; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2012 |
Salvage surgery for a super-responder by gefitinib therapy for advanced lung cancer.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Nodes; Neoplasm, Residual; Quinazolines; Salvage Therapy | 2012 |
Design, synthesis and cytotoxicity of novel 2-arylvinyl-4-aminoquinoline derivatives.
Topics: Aminoquinolines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; Gefitinib; Hep G2 Cells; HT29 Cells; Humans; Quinazolines; Structure-Activity Relationship | 2012 |
EGFR S1166 phosphorylation induced by a combination of EGF and gefitinib has a potentially negative impact on lung cancer cell growth.
Topics: Amino Acid Motifs; Amino Acid Sequence; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Sequence Data; Peptide Fragments; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Serine; Tandem Mass Spectrometry; Tyrosine | 2012 |
Encouragement to submit data of clinical response to EGFR-TKIs in patients with uncommon EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation, Missense; Quinazolines | 2012 |
Rare and novel epidermal growth factor receptor mutations in non-small-cell lung cancer and lack of clinical response to gefitinib in two cases.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Survival Rate; Tomography, X-Ray Computed | 2012 |
MET increases the sensitivity of gefitinib-resistant cells to SN-38, an active metabolite of irinotecan, by up-regulating the topoisomerase I activity.
Topics: Antineoplastic Agents; Blotting, Western; Camptothecin; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; DNA Topoisomerases, Type I; Drug Resistance, Neoplasm; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Irinotecan; Lung Neoplasms; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Topoisomerase I Inhibitors; Tumor Cells, Cultured | 2012 |
Detecting the effect of targeted anti-cancer medicines on single cancer cells using a poly-silicon wire ion sensor integrated with a confined sensitive window.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Biosensing Techniques; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Delivery Systems; Gefitinib; Humans; Ions; Lung Neoplasms; Propylamines; Quinazolines; Silanes; Silicon; Single-Cell Analysis; Staurosporine | 2012 |
The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Recurrence; Risk Factors | 2012 |
On Bayesian methods of exploring qualitative interactions for targeted treatment.
Topics: Adenocarcinoma; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bayes Theorem; Carboplatin; Cetuximab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Computer Simulation; ErbB Receptors; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Mutation; Paclitaxel; Pharmacogenetics; Quinazolines; Regression Analysis; Survival Analysis | 2012 |
Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Signal Transduction; Tankyrases; Wnt Proteins; Xenograft Model Antitumor Assays | 2012 |
MiR-23a regulates TGF-β-induced epithelial-mesenchymal transition by targeting E-cadherin in lung cancer cells.
Topics: Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Transforming Growth Factor beta | 2012 |
Novel liposomal gefitinib (L-GEF) formulations.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; beta-Cyclodextrins; Cell Line, Tumor; Drug Stability; Gefitinib; Humans; Liposomes; Lung Neoplasms; Mice; Mice, Inbred ICR; Particle Size; Quinazolines | 2012 |
Efficacy of EGFR tyrosine kinase inhibitors for non-adenocarcinoma NSCLC patients with EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies | 2012 |
Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Linear Models; Lung Neoplasms; Multivariate Analysis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Diminished functional role and altered localization of SHP2 in non-small cell lung cancer cells with EGFR-activating mutations.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Membrane; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines | 2013 |
Micellar delivery of cyclopamine and gefitinib for treating pancreatic cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Gefitinib; Humans; Male; Mice; Mice, Nude; Micelles; Pancreatic Neoplasms; Quinazolines; Veratrum Alkaloids | 2012 |
[Effect of gefitinib on the migration of triple-negative breast cancer cell line MDA-MB-231 cells].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cytoskeleton; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Signal Transduction | 2012 |
[Comparison of the efficacy of second line EGFR TKIs followed by third line pemetrexed or the reverse sequence in the treatment of advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Survival Rate | 2012 |
Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met.
Topics: Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Coculture Techniques; Culture Media, Conditioned; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression; Hepatocyte Growth Factor; Humans; Paracrine Communication; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Triple Negative Breast Neoplasms | 2012 |
Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer.
Topics: Aminopyridines; Animals; Antibodies; Antibody Specificity; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Models, Biological; Mutation; Neovascularization, Pathologic; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2012 |
A critical role for p130Cas in the progression of pulmonary hypertension in humans and rodents.
Topics: Animals; Benzamides; Benzimidazoles; Case-Control Studies; Crk-Associated Substrate Protein; Disease Models, Animal; Endothelial Cells; Epidermal Growth Factor; Familial Primary Pulmonary Hypertension; Fibroblast Growth Factor 2; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Mice; Monocrotaline; Myocytes, Smooth Muscle; Piperazines; Platelet-Derived Growth Factor; Protein Kinase Inhibitors; Pulmonary Artery; Pyrimidines; Quinazolines; Quinolones; Rats; Signal Transduction | 2012 |
HGFK1 is associated with a better prognosis and reverses inhibition by gefitinib in NSCLC cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Kaplan-Meier Estimate; Kringles; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Phosphorylation; Proportional Hazards Models; Quinazolines; STAT5 Transcription Factor; Tumor Burden | 2012 |
Tamoxifen-induced epigenetic silencing of oestrogen-regulated genes in anti-hormone resistant breast cancer.
Topics: Apoptosis; Azacitidine; Breast Neoplasms; Cell Proliferation; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Silencing; Genes, Neoplasm; Growth Differentiation Factor 15; Humans; MCF-7 Cells; Quinazolines; Receptors, Estrogen; Receptors, Progesterone; Recombinant Proteins; Tamoxifen; Trefoil Factor-1; Tumor Suppressor Proteins | 2012 |
Loss of activating EGFR mutant gene contributes to acquired resistance to EGFR tyrosine kinase inhibitors in lung cancer cells.
Topics: Alleles; Cell Line, Tumor; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Polymorphism, Single-Stranded Conformational; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Signal Transduction | 2012 |
Anti-proliferative effect of cytohesin inhibition in gefitinib-resistant lung cancer cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Guanine Nucleotide Exchange Factors; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Receptor, IGF Type 1; Signal Transduction; Triazoles | 2012 |
Cutaneous side-effects of epidermal growth factor receptor-tyrosine kinase inhibitor (TKI) in the treatment of lung cancer: description and its management.
Topics: Adenocarcinoma; Adult; Disease Progression; Drug Eruptions; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Analysis of bypass signaling in EGFR pathway and profiling of bypass genes for predicting response to anticancer EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Lung Neoplasms; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Support Vector Machine | 2012 |
Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
Cerebrospinal fluid concentrations of gefitinib in patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Tandem Mass Spectrometry | 2013 |
ATP serves as an endogenous inhibitor of UDP-glucuronosyltransferase (UGT): a new insight into the latency of UGT.
Topics: Adenine; Adenosine Monophosphate; Adenosine Triphosphate; Alamethicin; Animals; Catalytic Domain; Cetomacrogol; Endoplasmic Reticulum; Gefitinib; Glucuronosyltransferase; Humans; Male; Microsomes, Liver; NADP; Quinazolines; Rats; Rats, Sprague-Dawley; UDP-Glucuronosyltransferase 1A9 | 2012 |
Silencing of SNX1 by siRNA stimulates the ligand-induced endocytosis of EGFR and increases EGFR phosphorylation in gefitinib-resistant human lung cancer cell lines.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Endocytosis; Endosomes; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lysosomes; Phosphorylation; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorting Nexins | 2012 |
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Transforming Growth Factor alpha; Up-Regulation | 2012 |
Mechanism of drug efficacy within the EGF receptor revealed by microsecond molecular dynamics simulation.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Binding Sites; Enzyme Stability; ErbB Receptors; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Principal Component Analysis; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines; Time Factors | 2012 |
Analytical approach to characterize the intratumoral pharmacokinetics and pharmacodynamics of gefitinib in a glioblastoma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Chromatography, Liquid; Gefitinib; Glioblastoma; Mice; Models, Biological; Quinazolines; Tandem Mass Spectrometry | 2012 |
Role of GRB2-associated binder 1 in epidermal growth factor receptor-induced signaling in head and neck squamous cell carcinoma.
Topics: Adaptor Proteins, Signal Transducing; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; Head and Neck Neoplasms; Humans; Mitogen-Activated Protein Kinase Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
Prognostic and predictive value of carcinoembryonic antigen and cytokeratin-19 fragments levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Keratin-19; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Sex Factors | 2012 |
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting].
Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines | 2012 |
MicroRNA-133b inhibits the growth of non-small-cell lung cancer by targeting the epidermal growth factor receptor.
Topics: 3' Untranslated Regions; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; In Situ Hybridization; Lung Neoplasms; Lymphatic Metastasis; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction | 2012 |
[Correlation between the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors and EGFR mutations in advanced squamous cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2012 |
FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-raf; Quinazolines; RNA Interference; Signal Transduction; Tyrphostins; Xenograft Model Antitumor Assays | 2012 |
[Pharmacoeconomic analysis of gefitinib therapy in patients with non-cell cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Female; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Russia; Survival Analysis; Treatment Outcome | 2012 |
Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Malaysia; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2012 |
Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Proportional Hazards Models; Quinazolines; Salvage Therapy | 2013 |
[Cancer of unknown primary site with epidermal growth factor receptor mutation for which gefitinib proved effective].
Topics: Adenocarcinoma; Antineoplastic Agents; Biopsy; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasms, Unknown Primary; Quinazolines; Tomography, X-Ray Computed | 2012 |
Reversal of multidrug resistance by gefitinib via RAF1/ERK pathway in pancreatic cancer cell line.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Line, Tumor; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-raf; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2012 |
[EGFR mutations in patients with advanced NSCLC].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2012 |
Inhibition of the AKT/mTOR and erbB pathways by gefitinib, perifosine and analogs of gonadotropin-releasing hormone I and II to overcome tamoxifen resistance in breast cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Comparative Genomic Hybridization; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gonadotropin-Releasing Hormone; Humans; MCF-7 Cells; Phosphatidylinositol 3-Kinases; Phosphorylcholine; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Receptors, LHRH; Signal Transduction; Tamoxifen; TOR Serine-Threonine Kinases | 2012 |
Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase-2
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Catechin; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase Inhibitors; Mouth Neoplasms; Neoplasm Metastasis; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Wound Healing | 2012 |
EGF signalling pathway regulates colon cancer stem cell proliferation and apoptosis.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Proliferation; Colonic Neoplasms; Epidermal Growth Factor; Gefitinib; Gene Expression Regulation, Neoplastic; HCT116 Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplastic Stem Cells; Quinazolines; Signal Transduction | 2012 |
[Gefitinib in patients with advanced non-small-cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Poland; Quinazolines | 2012 |
The effect of monoclonal antibody cetuximab (C225) in combination with tyrosine kinase inhibitor gefitinib (ZD1839) on colon cancer cell lines.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cetuximab; Colonic Neoplasms; Dose-Response Relationship, Drug; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2012 |
Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus | 2012 |
Stearoyl-CoA desaturase activity modulates the activation of epidermal growth factor receptor in human lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Stearoyl-CoA Desaturase; TOR Serine-Threonine Kinases | 2012 |
Computational study of EGFR inhibition: molecular dynamics studies on the active and inactive protein conformations.
Topics: Adenosine Triphosphate; Binding Sites; Drug Design; ErbB Receptors; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Kinetics; Lapatinib; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines; Static Electricity; Structure-Activity Relationship; Thermodynamics | 2013 |
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinase 1; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, ErbB-2 | 2012 |
Mechanisms involved in PGE2-induced transactivation of the epidermal growth factor receptor in MH1C1 hepatocarcinoma cells.
Topics: Animals; Carcinoma, Hepatocellular; Cell Line, Tumor; Dinoprostone; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocytes; Humans; Liver Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction | 2012 |
The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Estrogen Receptor alpha; Estrogen Receptor beta; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Lung Neoplasms; MAP Kinase Signaling System; Nitriles; Protein Kinase Inhibitors; Protein Transport; Proto-Oncogene Proteins c-akt; Quinazolines; Triazoles | 2012 |
Gefitinib-induced paronychia: response to autologous platelet-rich plasma.
Topics: Aged; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Paronychia; Platelet-Rich Plasma; Quinazolines | 2012 |
A pilot study for the early assessment of the effects of BMS-754807 plus gefitinib in an H292 tumor model by [(18)F]fluorothymidine-positron emission tomography.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fluorine Radioisotopes; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Pilot Projects; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Receptor, IGF Type 1; Thymidine; Triazines; Tumor Burden | 2013 |
Epidermal growth factor receptor (EGFR) inhibitors and derived treatments.
Topics: Afatinib; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Quinolines; Translational Research, Biomedical; Treatment Outcome | 2012 |
Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor.
Topics: Animals; Binding Sites; Blotting, Western; Cell Line; Cross-Linking Reagents; Disulfides; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Microscopy, Electron; Mutation; Phosphotransferases; Protein Conformation; Protein Kinase Inhibitors; Protein Multimerization; Protein Structure, Tertiary; Quinazolines | 2012 |
[EGFR gene mutation statuses in advanced non-small cell lung cancer patients and their influence on effect of gefitinib].
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Young Adult | 2012 |
Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate; Treatment Outcome | 2012 |
Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Amplification; Gene Expression; Hepatocyte Growth Factor; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies | 2012 |
[Timing the change of chemotherapy for non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2012 |
[Efficacy of erlotinib after gefitinib administration in patients with non-small cell lung cancer].
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2012 |
Treatment of epidermal growth factor receptor inhibitor-induced acneiform eruption with topical recombinant human epidermal growth factor.
Topics: Acneiform Eruptions; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2012 |
Gefitinib-induced hepatotoxicity in patients treated for non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Liver Neoplasms; Middle Aged; Quinazolines; Treatment Outcome | 2012 |
Outcomes of phase II clinical trials with single-agent therapies in advanced/metastatic non-small cell lung cancer published between 2000 and 2009.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multicenter Studies as Topic; Multivariate Analysis; Quinazolines; Treatment Outcome | 2012 |
Survival of lung adenocarcinoma patients with malignant pleural effusion.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pleural Effusion, Malignant; Prospective Studies; Quinazolines; Sequence Analysis, DNA; Time Factors; Treatment Outcome | 2013 |
Epidermal growth factor receptor is a preferred target for treating amyloid-β-induced memory loss.
Topics: Amyloid beta-Peptides; Animals; Animals, Genetically Modified; Blotting, Western; Chlorocebus aethiops; COS Cells; Drosophila; Drosophila Proteins; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Maze Learning; Memantine; Memory; Memory Disorders; Mice; Mice, Transgenic; Molecular Structure; Peptide Fragments; Protein Kinase Inhibitors; Quinazolines | 2012 |
Miliary brain metastases in 2 cases with advanced non-small cell lung cancer harboring EGFR mutation during gefitinib treatment.
Topics: Adult; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines | 2012 |
Trifluoperazine, an antipsychotic agent, inhibits cancer stem cell growth and overcomes drug resistance of lung cancer.
Topics: Animals; Antipsychotic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; Gefitinib; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Neoplastic Stem Cells; Quinazolines; Random Allocation; Sensitivity and Specificity; Trifluoperazine; Tumor Cells, Cultured | 2012 |
Epidermal growth factor receptor tyrosine kinase defines critical prognostic genes of stage I lung adenocarcinoma.
Topics: Adenocarcinoma; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Staging; Prognosis; Quinazolines; Reproducibility of Results | 2012 |
Lovastatin induces multiple stress pathways including LKB1/AMPK activation that regulate its cytotoxic effects in squamous cell carcinoma cells.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line; Cell Line, Tumor; Drug Synergism; Fibroblasts; Gefitinib; Gene Deletion; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lovastatin; Metformin; Mice; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction | 2012 |
Flare phenomenon following gefitinib treatment of lung adenocarcinoma with bone metastasis.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Alkaline Phosphatase; Antineoplastic Agents; Bone and Bones; Bone Neoplasms; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polyphosphates; Quinazolines; Radionuclide Imaging; Technetium Compounds; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
The long-term survival of a patient with adenosquamous lung carcinoma harboring EGFR-activating mutations who was treated with gefitinib.
Topics: Amino Acid Substitution; Antineoplastic Agents; Carcinoma, Adenosquamous; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Middle Aged; Mutation; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2012 |
Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Crk-Associated Substrate Protein; Disease-Free Survival; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Integrins; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Multivariate Analysis; Neoplasm Transplantation; Phosphoproteins; Phosphorylation; Proportional Hazards Models; Protein Processing, Post-Translational; Quinazolines; Receptor Cross-Talk; Retrospective Studies; RNA, Small Interfering; Signal Transduction | 2012 |
A CD44high/EGFRlow subpopulation within head and neck cancer cell lines shows an epithelial-mesenchymal transition phenotype and resistance to treatment.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Lineage; Cell Proliferation; Cell Shape; Cetuximab; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Flow Cytometry; Gamma Rays; Gefitinib; Gene Expression; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Neoplastic Stem Cells; Oligonucleotide Array Sequence Analysis; Organ Specificity; Quinazolines | 2012 |
Evaluation of tyrosine kinase inhibitor combinations for glioblastoma therapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Synergism; Female; Gefitinib; Glioblastoma; Humans; Immunoblotting; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrroles; Quinazolines; Rats, Inbred F344; Spheroids, Cellular; Sunitinib; Treatment Outcome; Xenograft Model Antitumor Assays | 2012 |
EGFR inhibition abrogates leiomyosarcoma cell chemoresistance through inactivation of survival pathways and impairment of CSC potential.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Humans; Leiomyosarcoma; Mice; Neoplasm Grading; Neoplastic Stem Cells; Phenotype; Phosphoproteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vincristine; Xenograft Model Antitumor Assays | 2012 |
Grape polyphenols inhibit Akt/mammalian target of rapamycin signaling and potentiate the effects of gefitinib in breast cancer.
Topics: Adenylate Kinase; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Catechin; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation; Humans; Mice; Mice, SCID; Polyphenols; Proto-Oncogene Proteins c-akt; Quercetin; Quinazolines; Resveratrol; Signal Transduction; Sirolimus; Stilbenes; TOR Serine-Threonine Kinases; Vitis; Xenograft Model Antitumor Assays | 2012 |
Prolonged response using gefitinib followed by sirolimus for advanced cutaneous squamous cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; ErbB Receptors; Gefitinib; Humans; Lymphatic Metastasis; Male; Quinazolines; Sirolimus; Skin Neoplasms; Skin Ulcer; TOR Serine-Threonine Kinases | 2012 |
The pharmacokinetics and long-term therapeutic effects of gefitinib in patients with lung adenocarcinoma harboring the epidermal growth factor receptor(EGFR)mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies | 2012 |
Prognostic significance of NSE mRNA in advanced NSCLC treated with gefitinib.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Phosphopyruvate Hydratase; Prognosis; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2013 |
Positron emission tomography and circulating tumor cells to monitor a dramatic response to gefitinib.
Topics: Adenocarcinoma; Adult; Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplastic Cells, Circulating; Positron-Emission Tomography; Prognosis; Quinazolines | 2012 |
Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.
Topics: Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2012 |
Clinical modes of EGFR tyrosine kinase inhibitor failure and subsequent management in advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Proto-Oncogene Proteins c-met; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure; Tumor Burden | 2013 |
Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.
Topics: Adult; Aged; Aged, 80 and over; Alleles; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Cytochrome P-450 CYP2D6; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2012 |
Erlotinib antagonizes ABC transporters in acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antigens, CD34; Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Neoplastic Stem Cells; Quinazolines | 2012 |
Tissue culture correlational study of genetic cholangiopathy of autosomal recessive polycystic kidney disease.
Topics: Animals; Basement Membrane; Bile Ducts; Blotting, Western; Cell Culture Techniques; Cell Proliferation; Collagen Type IV; Epithelial Cells; Fibrinolysin; Gefitinib; Humans; Matrix Metalloproteinases; Phenotype; Polycystic Kidney, Autosomal Recessive; Quinazolines; Rats; Tissue Culture Techniques; Transforming Growth Factor beta1 | 2013 |
Carcinoembryonic antigen-related cell adhesion molecules as surrogate markers for EGFR inhibitor sensitivity in human lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Biomarkers, Tumor; Carcinoembryonic Antigen; Cell Adhesion; Cell Adhesion Molecules; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2012 |
[The TULUNG clinical registry].
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Czech Republic; Erlotinib Hydrochloride; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Quinazolines; Registries | 2012 |
MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib.
Topics: Animals; Benzimidazoles; Blotting, Western; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; GTP Phosphohydrolases; Humans; Lung Neoplasms; Male; Membrane Proteins; Mice; Mice, Inbred BALB C; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Xenograft Model Antitumor Assays | 2013 |
Activation of the insulin-like growth factor-1 receptor alters p27 regulation by the epidermal growth factor receptor in oral squamous carcinoma cells.
Topics: Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Nucleus; Cyclin D; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin-Like Growth Factor I; Mouth Neoplasms; Oncogene Protein v-akt; Peptide Fragments; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, IGF Type 1; S Phase; Subcellular Fractions | 2013 |
Apoptosis induced by benzyl isothiocyanate in gefitinib-resistant lung cancer cells is associated with Akt/MAPK pathways and generation of reactive oxygen species.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Expression Regulation, Neoplastic; Glutathione; Humans; Isothiocyanates; MAP Kinase Signaling System; NF-kappa B; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Transcription Factor AP-1; Transcriptional Activation | 2013 |
Norcantharidin suppresses cell growth and migration with enhanced anticancer activity of gefitinib and cisplatin in human non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Cycle; Cell Movement; Cell Proliferation; Cisplatin; Epidermal Growth Factor; ErbB Receptors; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Quinazolines; Signal Transduction; Tumor Cells, Cultured | 2013 |
Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chemotherapy, Adjuvant; Disease-Free Survival; DNA Mutational Analysis; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymph Nodes; Magnetic Resonance Imaging; Male; Meningeal Carcinomatosis; Middle Aged; Mutation, Missense; Neoplasm Invasiveness; Neoplasm Staging; Pemetrexed; Pneumonectomy; Quinazolines; Radiotherapy, Adjuvant; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Multiple analyses of G-protein coupled receptor (GPCR) expression in the development of gefitinib-resistance in transforming non-small-cell lung cancer.
Topics: Adenosine A2 Receptor Antagonists; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cells, Cultured; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Humans; Lung; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Pyrimidines; Quinazolines; Receptor, Adenosine A2A; Receptors, G-Protein-Coupled; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Transcriptome; Triazoles | 2012 |
Induction of mitotic cell death by overriding G2/M checkpoint in endometrial cancer cells with non-functional p53.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Endometrial Neoplasms; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; M Phase Cell Cycle Checkpoints; Mice; Mice, Nude; Mitosis; Paclitaxel; Pteridines; Quinazolines; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
Spectrum of ocular toxicities from epidermal growth factor receptor inhibitors and their intermediate-term follow-up: a five-year review.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cetuximab; Chicago; ErbB Receptors; Erlotinib Hydrochloride; Eye Diseases; Female; Follow-Up Studies; Gefitinib; Humans; Male; Medical Audit; Neoplasms; Panitumumab; Quinazolines; Retrospective Studies | 2013 |
Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Retrospective Studies; Survival Rate; Young Adult | 2012 |
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Cytoskeletal Proteins; Female; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Proteins, Fusion; Phosphorylation; Piperidines; Proto-Oncogene Proteins c-ret; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Transplantation, Heterologous; Tumor Cells, Cultured | 2012 |
Interaction of radiation and gefitinib on a human lung cancer cell line with mutant EGFR gene in vitro.
Topics: Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Chemoradiotherapy; Flow Cytometry; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction | 2012 |
[Lung injury].
Topics: Antineoplastic Agents; Erlotinib Hydrochloride; Everolimus; Gefitinib; Humans; Lung Diseases; Quinazolines; Sirolimus | 2012 |
[Effects of icotinib hydrochloride on the proliferation and apoptosis of human lung cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Crown Ethers; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin | 2012 |
Gastric perforation secondary to regression of lung adenocarcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; Gefitinib; Humans; Lung Neoplasms; Male; Prognosis; Quinazolines; Remission Induction; Stomach Rupture; Tomography, X-Ray Computed | 2013 |
The role of insulin-like growth factor binding protein-3 in the breast cancer cell response to DNA-damaging agents.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Nucleus; Cell Survival; DNA Damage; DNA Repair; DNA-Activated Protein Kinase; Doxorubicin; ErbB Receptors; Etoposide; Female; Gefitinib; Humans; Insulin-Like Growth Factor Binding Protein 3; Membrane Microdomains; Phosphorylation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines | 2014 |
Proposal for a novel methodology to screen and score cost versus survival for anticancer drugs in metastatic disease: could cost weigh in evaluation?
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Health Care Costs; Humans; Lung Neoplasms; Pemetrexed; Quinazolines | 2012 |
Gefitinib analogue V1801 induces apoptosis of T790M EGFR-harboring lung cancer cells by up-regulation of the BH-3 only protein Noxa.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Quinazolines; Treatment Outcome; Up-Regulation; Xenograft Model Antitumor Assays | 2012 |
In-vitro growth inhibition of chemotherapy and molecular targeted agents in hepatocellular carcinoma.
Topics: Alanine; alpha-Fetoproteins; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Hepatocellular; Cetuximab; Dasatinib; Doxorubicin; Drug Screening Assays, Antitumor; Epothilones; Gefitinib; Humans; Indoles; Inhibitory Concentration 50; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Pyridones; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thiazoles; Triazines | 2013 |
Gefitinib inhibits the cross-talk between mesenchymal stem cells and prostate cancer cells leading to tumor cell proliferation and inhibition of docetaxel activity.
Topics: Cell Communication; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Chemokine CCL5; Chemotaxis; Culture Media, Conditioned; Docetaxel; ErbB Receptors; Gefitinib; Humans; Male; Mesenchymal Stem Cells; Osteoblasts; Osteoclasts; Osteogenesis; Phosphorylation; Prostatic Neoplasms; Quinazolines; Subcellular Fractions; Taxoids | 2013 |
Molecular phenotype predicts sensitivity of squamous cell carcinoma of the head and neck to epidermal growth factor receptor inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Humans; Mice; Mice, Nude; Mutation; Phenotype; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2013 |
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 1. Recent treatments and progress in malignant tumors--chemotherapy and molecular targeting agents. Antibody therapy; 3) Non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines | 2012 |
Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Genetic Predisposition to Disease; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Odds Ratio; Polymorphism, Single Nucleotide; Quinazolines; Real-Time Polymerase Chain Reaction | 2012 |
Heterogeneity of the EGFR mutation status between the primary tumor and metastatic lymph node and the sensitivity to EGFR tyrosine kinase inhibitor in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Frequency-modulated pulses of ERK activity transmit quantitative proliferation signals.
Topics: Benzamides; Cell Line; Cell Proliferation; Diphenylamine; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Microscopy, Fluorescence; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; S Phase Cell Cycle Checkpoints; Time-Lapse Imaging | 2013 |
Gefitinib and gemcitabine coordinately inhibited the proliferation of cholangiocarcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Cholangiocarcinoma; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Hep G2 Cells; Humans; Liver Neoplasms; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Random Allocation; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |
Effects of voltage-gated K+ channel blockers in gefitinib-resistant H460 non-small cell lung cancer cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Kv1.1 Potassium Channel; Lung Neoplasms; Male; Mice; Mice, Nude; Peptides; Quinazolines; RNA, Messenger; Xenograft Model Antitumor Assays | 2012 |
The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Survival Rate | 2013 |
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Topics: Aged; Aged, 80 and over; Base Sequence; Carcinoma, Squamous Cell; Confidence Intervals; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2013 |
EGFR activity is required for renal tubular cell dedifferentiation and proliferation in a murine model of folic acid-induced acute kidney injury.
Topics: Acute Kidney Injury; Animals; Apoptosis; Cell Dedifferentiation; Cell Proliferation; Creatinine; ErbB Receptors; Folic Acid; Gefitinib; Kidney Tubules; Mice; Mice, Inbred C57BL; PAX2 Transcription Factor; Phosphatidylinositol 3-Kinases; Phosphorylation; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2013 |
Continued treatment with gefitinib beyond progressive disease benefits patients with activating EGFR mutations.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Failure | 2013 |
Comparison of adverse events and efficacy between gefitinib and erlotinib in patients with non-small-cell lung cancer: a retrospective analysis.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Gefitinib-resistance is related to BIM expression in non-small cell lung cancer cell lines.
Topics: Adenocarcinoma; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Inhibitors; Flow Cytometry; Gefitinib; Humans; Immunoenzyme Techniques; Lung Neoplasms; MAP Kinase Kinase Kinases; Membrane Proteins; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Small Interfering; Tumor Cells, Cultured | 2013 |
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma.
Topics: Animals; Anoikis; Antineoplastic Agents; Apoptosis; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Salivary Gland Neoplasms; Snail Family Transcription Factors; Transcription Factors | 2012 |
Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Catalytic Domain; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Models, Molecular; Mutation, Missense; Phosphorylation; Protein Binding; Protein Processing, Post-Translational; Protein Stability; Protein Structure, Secondary; Quinazolines; Quinazolinones; Sf9 Cells; Spodoptera | 2013 |
PXR-mediated P-glycoprotein induction by small molecule tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Humans; Niacinamide; Phenylurea Compounds; Piperidines; Pregnane X Receptor; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Receptors, Steroid; Sorafenib | 2013 |
Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
Topics: Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Keratin-7; Lung; Lung Neoplasms; Middle Aged; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Thyroid Nuclear Factor 1; Time Factors; Transcription Factors; Treatment Outcome | 2013 |
[Efficacy of erlotinib after the failure of gefitinib in patients with metastasis of non-small cell lung cancer with unknown EGFR mutation status].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate | 2012 |
[Efficacy and safety of docetaxol, pemetrexed and EGFR-TKIs as second-line treatment for patients with advanced non-small-cell lung cancer].
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Neoplasm Staging; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Taxoids | 2012 |
ErbBs inhibition by lapatinib blocks tumor growth in an orthotopic model of human testicular germ cell tumor.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Blotting, Western; Carcinoma, Embryonal; Cell Survival; Cetuximab; Choriocarcinoma; Endodermal Sinus Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoprecipitation; Lapatinib; Male; Mice; Mice, Nude; Neoplasms, Experimental; Neoplasms, Germ Cell and Embryonal; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; Receptor, ErbB-3; Teratocarcinoma; Testicular Neoplasms; Transplantation, Heterologous | 2013 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 12; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genetic Predisposition to Disease; Humans; Lapatinib; Mice; Mice, Nude; Molecular Targeted Therapy; Oligonucleotide Array Sequence Analysis; Phenotype; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, ErbB-2; RNA Interference; Small Ubiquitin-Related Modifier Proteins; Time Factors; Transfection; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2012 |
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden | 2013 |
Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Haplotypes; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymorphism, Single Nucleotide; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Clinical outcomes in elderly patients administered gefitinib as first-line treatment in epidermal growth factor receptor-mutated non-small-cell lung cancer: retrospective analysis in a Nagano Lung Cancer Research Group study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Mutation; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Gefitinib, but not erlotinib, is a possible inducer of Fra-1-mediated interstitial lung disease.
Topics: Animals; Antineoplastic Agents; Chemokine CCL2; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Lipopolysaccharides; Lung Diseases, Interstitial; Macrophages; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-fos; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha | 2012 |
[The mechanism of gefitinib resistance induced by hepatocyte growth factor in sensitive non-small cell lung cancer cells in vitro].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; Chemoradiotherapy; Cisplatin; Cyclin-Dependent Kinase Inhibitor p16; Disease-Free Survival; DNA, Viral; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Panitumumab; Proportional Hazards Models; Quinazolines; Retrospective Studies | 2013 |
Caspase-independent cell death is involved in the negative effect of EGF receptor inhibitors on cisplatin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Death; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Forkhead Box Protein O3; Forkhead Transcription Factors; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2013 |
Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Inflammation; Quinazolines; Tumor Necrosis Factor-alpha | 2013 |
Molecular mechanisms underlying the antitumor activity of 3-aminopropanamide irreversible inhibitors of the epidermal growth factor receptor in non-small cell lung cancer.
Topics: Adenocarcinoma; Amides; Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Gene-guided gefitinib switch maintenance therapy for patients with advanced EGFR mutation-positive non-small cell lung cancer: an economic analysis.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; Decision Support Techniques; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Life Expectancy; Lung Neoplasms; Markov Chains; Medical Assistance; Models, Economic; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Survival Analysis; Time Factors; Treatment Outcome; Uncertainty | 2013 |
Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lysosomes; Membrane Transport Proteins; Molecular Targeted Therapy; Mutation; Protein Transport; Proto-Oncogene Proteins c-met; Quinazolines; Sorting Nexins | 2013 |
A mathematical model for microRNA in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer Simulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Genetic; Mutation; Oncogene Protein p21(ras); Proto-Oncogene Proteins c-myc; Quinazolines; Signal Transduction | 2013 |
T-cadherin loss promotes experimental metastasis of squamous cell carcinoma.
Topics: Animals; Cadherins; Carcinoma, Squamous Cell; Cell Adhesion; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Endothelial Cells; ErbB Receptors; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Immunoblotting; Keratinocytes; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Confocal; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Skin Neoplasms; Transendothelial and Transepithelial Migration; Transplantation, Heterologous | 2013 |
Quantitative chemical proteomics profiling differentiates erlotinib from gefitinib in EGFR wild-type non-small cell lung carcinoma cell lines.
Topics: Adaptor Proteins, Signal Transducing; Adenosine Triphosphate; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; LIM Domain Proteins; Lung Neoplasms; Membrane Proteins; Microfilament Proteins; Molecular Conformation; Molecular Docking Simulation; Protein Binding; Protein Serine-Threonine Kinases; Proteomics; Quinazolines; Signal Transduction | 2013 |
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Lung Neoplasms; Male; Membrane Proteins; Mice; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Tumor Burden; Vorinostat; Xenograft Model Antitumor Assays | 2013 |
p300/CBP dependent hyperacetylation of histone potentiates anticancer activity of gefitinib nanoparticles.
Topics: Acetylation; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; E1A-Associated p300 Protein; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Histone Acetyltransferases; Histones; Humans; Nanoparticles; Quinazolines | 2013 |
Sensitivity and kinase activity of epidermal growth factor receptor (EGFR) exon 19 and others to EGFR-tyrosine kinase inhibitors.
Topics: Afatinib; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; MCF-7 Cells; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2013 |
Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Synergism; ErbB Receptors; Estradiol; Estrogen Receptor Modulators; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptors, Estrogen; Receptors, Progesterone; Tumor Cells, Cultured | 2013 |
High-resolution computed tomography findings for patients with drug-induced pulmonary toxicity, with special reference to hypersensitivity pneumonitis-like patterns in gemcitabine-induced cases.
Topics: Adult; Aged; Aged, 80 and over; Alveolitis, Extrinsic Allergic; Antineoplastic Agents; Biopsy; Docetaxel; Female; Gefitinib; Granuloma; Humans; Lung; Male; Middle Aged; Neoplasms; Quinazolines; Retrospective Studies; Taxoids; Thoracic Surgery, Video-Assisted; Tomography, X-Ray Computed | 2013 |
A novel mechanism of PPAR gamma induction via EGFR signalling constitutes rational for combination therapy in bladder cancer.
Topics: Animals; Antineoplastic Agents; CCAAT-Enhancer-Binding Protein-beta; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Mice; PPAR gamma; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tumor Burden; Urinary Bladder Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
Topics: Adenocarcinoma; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Meningeal Carcinomatosis; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2013 |
Cross-talk between EGFR and T-cadherin: EGFR activation promotes T-cadherin localization to intercellular contacts.
Topics: Cadherins; Cell Communication; Cell Line, Tumor; Cytoskeleton; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction | 2013 |
Analysis of treatment outcomes of intraventricular chemotherapy in 105 patients for leptomeningeal carcinomatosis from non-small-cell lung cancer.
Topics: Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cranial Nerve Diseases; Cytarabine; Erlotinib Hydrochloride; Female; Gefitinib; Headache; Humans; Hydrocortisone; Infusions, Intraventricular; Intracranial Pressure; Karnofsky Performance Status; Lung Neoplasms; Male; Meningeal Carcinomatosis; Mental Disorders; Methotrexate; Middle Aged; Nausea; Palliative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Vomiting | 2013 |
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2013 |
[About new treatments in thoracic oncology].
Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2013 |
Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Azacitidine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; CpG Islands; Decitabine; DNA Methylation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines | 2013 |
Afatinib prolongs survival compared with gefitinib in an epidermal growth factor receptor-driven lung cancer model.
Topics: Afatinib; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; ErbB Receptors; Exons; Female; Gefitinib; Heterografts; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2 | 2013 |
Cancer stem-like cell properties are regulated by EGFR/AKT/β-catenin signaling and preferentially inhibited by gefitinib in nasopharyngeal carcinoma.
Topics: Animals; Antineoplastic Agents; beta Catenin; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cell Transformation, Neoplastic; Cisplatin; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Homeodomain Proteins; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Nanog Homeobox Protein; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Neoplasm Transplantation; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Quinazolines; Side-Population Cells; Signal Transduction; Spheroids, Cellular; Xenograft Model Antitumor Assays | 2013 |
Gefitinib enhances the efficacy of photodynamic therapy using 5-aminolevulinic acid in malignant brain tumor cells.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Glioma; Humans; Photochemotherapy; Photosensitizing Agents; Quinazolines; Treatment Outcome | 2013 |
Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Biopsy; CD56 Antigen; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Kaplan-Meier Estimate; Ki-67 Antigen; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-2 | 2013 |
Two rare exon 21 EGFR mutations in patients treated with gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Successful treatment with erlotinib of severe neutropenia induced by gefitinib in a patient with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Mutation; Neutropenia; Protein Kinase Inhibitors; Quinazolines | 2013 |
[Primary lateral sclerosis and lung adenocarcinoma].
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Causality; Diagnosis, Differential; Dysarthria; Electromyography; Fatal Outcome; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Lymphatic Metastasis; Middle Aged; Motor Neuron Disease; Motor Neurons; Multimodal Imaging; Paraneoplastic Syndromes, Nervous System; Pemetrexed; Pleural Effusion, Malignant; Positron-Emission Tomography; Quadriplegia; Quinazolines; Tomography, X-Ray Computed | 2013 |
Both gefitinib and erlotinib induced drug-related interstitial lung disease in a patient with pulmonary adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2013 |
α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells.
Topics: Antioxidants; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Quinazolines; Reactive Oxygen Species; Receptor, ErbB-2; Thioctic Acid | 2013 |
Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Lactams, Macrocyclic; Lung Neoplasms; Mice; Mice, Nude; Mutation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Sulfonamides; Xenograft Model Antitumor Assays | 2013 |
Pressure sore-like ulcers on acneiform papules caused by EGFR inhibitors.
Topics: Acneiform Eruptions; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Neoplasm Recurrence, Local; Pressure Ulcer; Quinazolines; Wound Healing | 2014 |
Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Topics: Adenocarcinoma; Administration, Oral; Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Drug Eruptions; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Prognosis; Quinazolines; Retreatment; Retrospective Studies; Sex Factors; Treatment Outcome | 2012 |
Evidence of securin-mediated resistance to gefitinib-induced apoptosis in human cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Caspase 3; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Membrane Potential, Mitochondrial; Neoplasm Proteins; Poly(ADP-ribose) Polymerases; Protein Stability; Proteolysis; Proto-Oncogene Mas; Quinazolines; Securin; Signal Transduction | 2013 |
Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Topics: Afatinib; Analysis of Variance; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Fluorometry; Gefitinib; Humans; Indoles; Microscopy, Fluorescence; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Signal Transduction; Spectrophotometry; Sulfonamides | 2013 |
Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Topics: Apoptosis; Autocrine Communication; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clone Cells; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Models, Biological; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; RNA, Small Interfering; Signal Transduction | 2013 |
Chemosensitization potential of P-glycoprotein inhibitors in malaria parasites.
Topics: Antimalarials; Artemisinins; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzamides; Boron Compounds; Chloroquine; Chlorpheniramine; Dibenzocycloheptenes; Drug Interactions; Drug Resistance, Multiple; Erythrocytes; Fluorescent Dyes; Gefitinib; Humans; Imatinib Mesylate; Mefloquine; Piperazines; Plasmodium falciparum; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Quinolines | 2013 |
Acquired resistance to EGFR inhibitors is associated with a manifestation of stem cell-like properties in cancer cells.
Topics: Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Genotype; Humans; MicroRNAs; Neoplasms; Neoplastic Stem Cells; Quinazolines; Retinal Dehydrogenase; Transcriptome | 2013 |
Molecular profiling for druggable genetic abnormalities in carcinoma of unknown primary.
Topics: Antineoplastic Combined Chemotherapy Protocols; Arginine; Biopsy; Carboplatin; Carcinoma; Deoxycytidine; Disease-Free Survival; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Immunohistochemistry; Leucine; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Unknown Primary; Point Mutation; Quinazolines; Tomography, X-Ray Computed | 2013 |
Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Patho
Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Patient Selection; Protein Kinase Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Systematic Reviews as Topic | 2013 |
Thyroid cancer cell resistance to gefitinib depends on the constitutive oncogenic activation of the ERK pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Genes, ras; Humans; MAP Kinase Signaling System; Mutation; Neoplasm Invasiveness; Phosphorylation; Proto-Oncogene Proteins B-raf; Quinazolines; Thyroid Neoplasms | 2013 |
Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis Regulatory Proteins; Base Sequence; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Transdifferentiation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Sequence Analysis, DNA; Sequence Deletion | 2013 |
Influence of gefitinib and erlotinib on apoptosis and c-MYC expression in H23 lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Erlotinib Hydrochloride; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-myc; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured | 2013 |
Cisplatin influences acquisition of resistance to molecular-targeted agents through epithelial-mesenchymal transition-like changes.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cisplatin; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2013 |
Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemokine CCL5; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inflammation; Interleukin-10; Interleukin-8; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Treatment Outcome | 2013 |
Update: NCCN non-small cell lung cancer clinical practice guidelines.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemotherapy, Adjuvant; Gefitinib; Humans; Lung Neoplasms; Neoplasm Micrometastasis; Neoplasm Staging; Positron-Emission Tomography; Practice Guidelines as Topic; Quinazolines | 2004 |
A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance.
Topics: AC133 Antigen; Adolescent; Adult; Animals; Antigens, CD; Antineoplastic Agents; Brain Neoplasms; Drug Resistance; Drug Resistance, Neoplasm; ErbB Receptors; Female; Flow Cytometry; Fluorescent Antibody Technique; Gefitinib; Glioblastoma; Glycoproteins; Humans; Immunohistochemistry; Immunomagnetic Separation; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Neoplasm Transplantation; Peptides; Quinazolines; Real-Time Polymerase Chain Reaction; Stem Cells; Young Adult | 2013 |
Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Genes, bcl-2; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; RNA Interference; RNA, Small Interfering | 2013 |
Cytokeratin 19 fragment predicts the efficacy of epidermal growth factor receptor-tyrosine kinase inhibitor in non-small-cell lung cancer harboring EGFR mutation.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Keratin-19; Luminescent Measurements; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Epidermal growth factor receptor tyrosine kinase inhibition up-regulates interleukin-6 in cancer cells and induces subsequent development of interstitial pneumonia.
Topics: Antibodies, Neutralizing; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Lung Diseases, Interstitial; Neoplasms, Experimental; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tyrphostins; Up-Regulation | 2013 |
mTOR inhibitors radiosensitize PTEN-deficient non-small-cell lung cancer cells harboring an EGFR activating mutation by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mutation, Missense; PTEN Phosphohydrolase; Quinazolines; Radiation Tolerance; RNA, Small Interfering; Sirolimus; TOR Serine-Threonine Kinases | 2013 |
Inhibition of the PI3K/AKT pathway potentiates cytotoxicity of EGFR kinase inhibitors in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Caspases; Cell Death; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Furans; Gefitinib; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Quinazolines; Signal Transduction | 2013 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzimidazoles; Benzylamines; Bone Marrow Cells; Chemokine CXCL12; Combined Modality Therapy; Cyclams; Dose Fractionation, Radiation; ErbB Receptors; Gefitinib; Green Fluorescent Proteins; Heterocyclic Compounds; Luminescent Agents; Male; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Pericytes; Prostatic Neoplasms; Quinazolines; Receptors, CXCR4; Tumor Microenvironment | 2013 |
Spontaneous hemothorax as a presenting form of bronchogenic carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Large Cell; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Hemothorax; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Proteins; Pleural Effusion, Malignant; Pulmonary Atelectasis; Quinazolines; Rupture, Spontaneous; Solitary Pulmonary Nodule; Tomography, X-Ray Computed | 2013 |
Insulin-like growth factor-1 receptor (IGF-1R) as a biomarker for resistance to the tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; HEK293 Cells; Humans; Immunoblotting; Immunohistochemistry; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA Interference; Signal Transduction; Tissue Array Analysis | 2013 |
Correlation between EGFR mutations and serum tumor markers in lung adenocarcinoma patients.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antigens, Tumor-Associated, Carbohydrate; Antineoplastic Agents; Biomarkers, Tumor; CA-125 Antigen; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
ErbB inhibitors ameliorate behavioral impairments of an animal model for schizophrenia: implication of their dopamine-modulatory actions.
Topics: Animals; Antipsychotic Agents; Brain Chemistry; Disease Models, Animal; Dopaminergic Neurons; Dose-Response Relationship, Drug; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Male; Motor Activity; Quinazolines; Rats; Rats, Sprague-Dawley; Reflex, Startle; Schizophrenia; Schizophrenic Psychology | 2013 |
Multitargeted low-dose GLAD combination chemoprevention: a novel and promising approach to combat colon carcinogenesis.
Topics: Adenomatous Polyps; Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Carcinogenesis; Cell Proliferation; Chemoprevention; Colon; Colonic Neoplasms; Cytokines; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Eflornithine; Female; Gefitinib; Heptanoic Acids; Intestine, Small; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Pyrroles; Quinazolines | 2013 |
Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Case-Control Studies; Cytochrome P-450 CYP2D6; Female; Follow-Up Studies; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymorphism, Genetic; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
ZD1839 and cisplatin alone or in combination for treatment of a nasopharyngeal carcinoma cell line and Xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cisplatin; Drug Synergism; Female; Flow Cytometry; Gefitinib; Heterografts; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Nasopharyngeal Neoplasms; Quinazolines; Tumor Cells, Cultured | 2013 |
Coexistence of EGFR mutation and ALK translocation in NSCLC: literature review and case report of response to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Middle Aged; Mutation; Quinazolines; Receptor Protein-Tyrosine Kinases; Serine Endopeptidases | 2013 |
Synergistic effects of metformin treatment in combination with gefitinib, a selective EGFR tyrosine kinase inhibitor, in LKB1 wild-type NSCLC cell lines.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Metformin; Mice; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Tumor Burden; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays | 2013 |
β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Quinazolines; Signal Transduction | 2014 |
[Small molecule inhibitor SB203580 enhances the antitumor effect of gefitinib in PC-9 and A549 lung cancer cell lines].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme Inhibitors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Signal Transduction | 2013 |
Severe refractory scarring alopecia associated with combinational use of ficlatuzumab (AV-299) and gefitinib.
Topics: Aged; Alopecia; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Cicatrix; Female; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Risk Assessment; Severity of Illness Index | 2013 |
Detection of epidermal growth factor receptor T790M mutation in plasma DNA from patients refractory to epidermal growth factor receptor tyrosine kinase inhibitor.
Topics: Adult; Aged; Alleles; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sensitivity and Specificity | 2013 |
Synergistic inhibition of survival, proliferation, and migration of U87 cells with a combination of LY341495 and Iressa.
Topics: Amino Acids; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Glioblastoma; Glutamic Acid; Humans; Quinazolines; Riluzole; Xanthenes | 2013 |
Studying protein-ligand interactions using X-ray crystallography.
Topics: Binding Sites; Crystallization; Crystallography, X-Ray; ErbB Receptors; Gefitinib; Humans; Kinetics; Ligands; Molecular Docking Simulation; Neoplasm Proteins; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Quinazolines; Software; Tamoxifen | 2013 |
Parallel RNA interference screens identify EGFR activation as an escape mechanism in FGFR3-mutant cancer.
Topics: Animals; Cell Line, Tumor; Dasatinib; ErbB Receptors; Gefitinib; Heterografts; High-Throughput Screening Assays; Humans; MAP Kinase Signaling System; Mice; Neoplasm Transplantation; Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor, Fibroblast Growth Factor, Type 3; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiazoles | 2013 |
USP8 is a novel target for overcoming gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Endopeptidases; Endosomal Sorting Complexes Required for Transport; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Protease Inhibitors; Quinazolines; Receptor Protein-Tyrosine Kinases; Ubiquitin Thiolesterase; Xenograft Model Antitumor Assays | 2013 |
Significant increase in hEGF uptake is correlated with formation of EGFR dimers induced by the EGFR tyrosine kinase inhibitor gefitinib.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cross-Linking Reagents; Dimerization; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Glyceraldehyde-3-Phosphate Dehydrogenases; Humans; Iodine Radioisotopes; Isotope Labeling; Panitumumab; Phosphorylation; Protein-Tyrosine Kinases; Quinazolines | 2013 |
Routine EGFR molecular analysis in non-small-cell lung cancer patients is feasible: exons 18-21 sequencing results of 753 patients and subsequent clinical outcomes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Exons; Feasibility Studies; Female; France; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA; Survival Rate; Treatment Outcome | 2013 |
Gefitinib selectively inhibits tumor cell migration in EGFR-amplified human glioblastoma.
Topics: Cell Movement; Cell Proliferation; Cohort Studies; ErbB Receptors; Gefitinib; Gene Amplification; Glioblastoma; Humans; In Situ Hybridization, Fluorescence; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2013 |
Antitumor impact of p14ARF on gefitinib-resistant non-small cell lung cancers.
Topics: Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Intracellular Space; Lung Neoplasms; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Tumor Suppressor Protein p14ARF | 2013 |
EGFR-SGLT1 interaction does not respond to EGFR modulators, but inhibition of SGLT1 sensitizes prostate cancer cells to EGFR tyrosine kinase inhibitors.
Topics: Cell Line, Tumor; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Male; Phosphorylation; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Purines; Quinazolines; Sodium-Glucose Transporter 1 | 2013 |
[A case report of patient with advanced non-small cell lung cancer by five times EGFR-TKIs therapy].
Topics: Carcinoma, Non-Small-Cell Lung; Drug Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Therapeutic efficacy of gefitinib and erlotinib in patients with advanced lung adenosquamous carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Adenosquamous; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Activity of gefitinib in a non-small-cell lung cancer patient with both activating and resistance EGFR mutations.
Topics: Aged; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Neoplasm Metastasis; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2013 |
Epidermal growth factor receptor in lung cancer: the amazing interplay of molecular testing and cytopathology.
Topics: Carcinoma, Non-Small-Cell Lung; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Quinazolines | 2013 |
EGFR mutations detected on cytology samples by a centralized laboratory reliably predict response to gefitinib in non-small cell lung carcinoma patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cytodiagnosis; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Recurrence patterns of advanced non-small cell lung cancer treated with gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
Hepatic myofibroblasts promote the progression of human cholangiocarcinoma through activation of epidermal growth factor receptor.
Topics: Animals; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Cell Line, Tumor; Cholangiocarcinoma; Disease Progression; ErbB Receptors; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Liver Neoplasms; Mice; Myofibroblasts; Quinazolines; Signal Transduction; Stromal Cells | 2013 |
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome | 2013 |
RECIST 1.1 in NSCLC patients with EGFR mutations treated with EGFR tyrosine kinase inhibitors: comparison with RECIST 1.0.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Statistics, Nonparametric; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Individualized treatment of NSCLC: from research to clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Transcriptome | 2013 |
Nitric oxide donating anilinopyrimidines: synthesis and biological evaluation as EGFR inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Free Radical Scavengers; Gefitinib; Humans; Nitric Oxide; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Signal Transduction | 2013 |
IL-33/IL-31 axis: a new pathological mechanisms for EGFR tyrosine kinase inhibitors-associated skin toxicity.
Topics: Drug-Related Side Effects and Adverse Reactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Interleukin-33; Interleukins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Skin | 2013 |
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma.
Topics: Animals; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Capillary Permeability; Cell Line, Tumor; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Glioblastoma; Humans; Male; Mice; Mice, Nude; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Differences in epidermal growth factor receptor gene mutations and relationship with clinicopathological features in NSCLC between Uygur and Han ethnic groups.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; ErbB Receptors; Ethnicity; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion | 2013 |
Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
Topics: Adult; Aged; Blood-Brain Barrier; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
DISSECT Method Using PNA-LNA Clamp Improves Detection of EGFR T790m Mutation.
Topics: Alleles; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Oligonucleotides; Peptide Nucleic Acids; Polymerase Chain Reaction; Quinazolines; Sequence Analysis, DNA | 2013 |
Impact of physical size on gefitinib efficacy in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Size; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2013 |
Establishment of patient-derived non-small cell lung cancer xenograft models with genetic aberrations within EGFR, KRAS and FGFR1: useful tools for preclinical studies of targeted therapies.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Genes, ras; Genetic Variation; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Mutation; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Quinazolines; ras Proteins; Receptor, Fibroblast Growth Factor, Type 1; Xenograft Model Antitumor Assays | 2013 |
6-Aryl and heterocycle quinazoline derivatives as potent EGFR inhibitors with improved activity toward gefitinib-sensitive and -resistant tumor cell lines.
Topics: Binding Sites; Catalytic Domain; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Heterocyclic Compounds; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Evidence of epidermal growth factor receptor expression in uveal melanoma: inhibition of epidermal growth factor-mediated signalling by Gefitinib and Cetuximab triggered antibody-dependent cellular cytotoxicity.
Topics: Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Cell Line, Tumor; Cell Proliferation; Cetuximab; ErbB Receptors; Gefitinib; Humans; Melanoma; Quinazolines; Signal Transduction; Transcriptome; Uveal Neoplasms | 2013 |
Scheduling of paclitaxel and gefitinib to inhibit repopulation for optimal treatment of human cancer cells and xenografts that overexpress the epidermal growth factor receptor.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Nude; Neoplasms; Paclitaxel; Quinazolines; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2013 |
Tumor reoxygenation following administration of the EGFR inhibitor, gefitinib, in experimental tumors.
Topics: Animals; Cell Hypoxia; Electron Spin Resonance Spectroscopy; ErbB Receptors; Fibrosarcoma; Gefitinib; Liver Neoplasms, Experimental; Mice; Mice, Inbred C3H; Oximetry; Oxygen; Oxygen Consumption; Quinazolines | 2013 |
[How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Choice Behavior; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies; Treatment Outcome | 2013 |
5-aminolaevulinic acid/photo-dynamic therapy and gefitinib in non-small cell lung cancer cell lines: a potential strategy to improve gefitinib therapeutic efficacy.
Topics: Aminolevulinic Acid; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Death; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; NF-kappa B; Photochemotherapy; Photosensitizing Agents; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic | 2013 |
Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.
Topics: Animals; Chemoradiotherapy; Combined Modality Therapy; Dose Fractionation, Radiation; ErbB Receptors; Female; Gefitinib; Humans; Immunoassay; Immunohistochemistry; Mice; Oligodendroglioma; Phosphoproteins; Quinazolines; Signal Transduction; Statistics, Nonparametric; Treatment Outcome; Xenograft Model Antitumor Assays | 2013 |
Highly sensitive and noninvasive detection of epidermal growth factor receptor T790M mutation in non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2013 |
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Canada; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Financing, Government; Follow-Up Studies; Gefitinib; Health Plan Implementation; Health Services; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Practice Guidelines as Topic; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2013 |
Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Oncogene Protein v-akt; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Receptor, ErbB-3; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Separation and estimation of process-related impurities of gefitinib by reverse-phase high-performance liquid chromatography.
Topics: Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Drug Contamination; Gefitinib; Quinazolines; Reproducibility of Results | 2014 |
Cyclopamine increases the radiosensitivity of human pancreatic cancer cells by regulating the DNA repair signal pathway through an epidermal growth factor receptor‑dependent pathway.
Topics: Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Gefitinib; Histones; Humans; Pancreatic Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Signal Transduction; Veratrum Alkaloids | 2013 |
Reaction of plasma adiponectin level in non-small cell lung cancer patients treated with EGFR-TKIs.
Topics: Adiponectin; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Insulin; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Outcome | 2013 |
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines | 2014 |
The role of epithelial-mesenchymal transition and IGF-1R expression in prediction of gefitinib activity as the second-line treatment for advanced nonsmall-cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epithelial-Mesenchymal Transition; Female; Gefitinib; Genes, erbB-1; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Receptor, IGF Type 1; Treatment Outcome | 2013 |
Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pressure Liquid; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Meglumine; Mice; Mice, Inbred NOD; Plant Extracts; Protein Kinase Inhibitors; Quinazolines; Seeds; Silybin; Silybum marianum; Silymarin; Tandem Mass Spectrometry; Xenograft Model Antitumor Assays | 2013 |
Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dipeptides; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Receptor, Notch1; RNA Interference; Signal Transduction; Time Factors; Transfection; Xenograft Model Antitumor Assays | 2013 |
[Long survival case of resected lung cancer after chemotherapy with gefitinib].
Topics: Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Combined Modality Therapy; Disease-Free Survival; Gefitinib; Humans; Lung Neoplasms; Male; Mediastinum; Pneumonectomy; Quinazolines; Time Factors | 2013 |
Gefitinib enhances the effects of combined radiotherapy and 5-fluorouracil in a colorectal cancer cell line.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Chemoradiotherapy; Colorectal Neoplasms; Combined Modality Therapy; Fluorouracil; Gefitinib; Humans; Quinazolines; Real-Time Polymerase Chain Reaction | 2014 |
Combination therapy with gefitinib and doxorubicin inhibits tumor growth in transgenic mice with adrenal neuroblastoma.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Disease Models, Animal; Doxorubicin; Gefitinib; Humans; Mice; Mice, Inbred C57BL; Mice, Transgenic; Neuroblastoma; Polyethylene Glycols; Quinazolines; Transcriptome | 2013 |
The relative expression of Mig6 and EGFR is associated with resistance to EGFR kinase inhibitors.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Immunoblotting; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Mice; Middle Aged; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Signal Transduction; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays | 2013 |
Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
Topics: Autophagy; Cell Communication; Cell Degranulation; Cell Line, Tumor; Cytotoxicity, Immunologic; ErbB Receptors; Gefitinib; Histocompatibility Antigens Class I; Humans; Immunomodulation; Interferon-gamma; Killer Cells, Natural; Ligands; Lung Neoplasms; Mutation; NK Cell Lectin-Like Receptor Subfamily K; Quinazolines; Receptor, IGF Type 2; STAT3 Transcription Factor | 2013 |
Icotinib: kick-starting the Chinese anticancer drug industry.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Female; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2013 |
RIP2/RICK-dependent cytokine production upon Yersinia enterocolitica infection in macrophages with TLR4 deficiency.
Topics: Animals; Enzyme Inhibitors; Gefitinib; Imidazoles; Interleukin-10; Interleukin-6; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Nod1 Signaling Adaptor Protein; Nod2 Signaling Adaptor Protein; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Quinazolines; Receptor-Interacting Protein Serine-Threonine Kinase 2; Receptor-Interacting Protein Serine-Threonine Kinases; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha; Yersinia enterocolitica; Yersinia Infections | 2013 |
"Arrow" sign: a rapid microscopic diagnosis of hair change associated with epidermal growth factor receptor inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hair; Humans; Male; Microscopy; Middle Aged; Quinazolines; Scalp Dermatoses | 2013 |
Effects of pemetrexed, gefitinib, and their combination on human colorectal cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Colorectal Neoplasms; Drug Synergism; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Mutation; Pemetrexed; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Thymidylate Synthase | 2013 |
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mutation; Pyrazoles; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Skinflammation and drug toxicity--a delicate balance.
Topics: Animals; Antineoplastic Agents; ErbB Receptors; Exanthema; Female; Gefitinib; Humans; Male; Quinazolines; Skin | 2013 |
Four-membered heterocycles-containing 4-anilino-quinazoline derivatives as epidermal growth factor receptor (EGFR) kinase inhibitors.
Topics: Aza Compounds; Azetidines; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Heterocyclic Compounds; Humans; Molecular Structure; Quinazolines | 2013 |
Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Treatment Outcome | 2013 |
[A case of lung adenocarcinoma wtih exon19 and T790M mutations in EGFR having good response to erlotinib after gefitinib treatment failure].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Salvage Therapy | 2013 |
Serum CEA level change and its significance before and after Gefitinib therapy on patients with advanced non-small cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoembryonic Antigen; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Prognosis; Quinazolines; Survival Rate | 2013 |
Nutlin-3 inhibits epithelial-mesenchymal transition by interfering with canonical transforming growth factor-β1-Smad-Snail/Slug axis.
Topics: Antigens, CD; Antineoplastic Agents; Cadherins; Cell Line, Tumor; Cell Movement; Drug Evaluation, Preclinical; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression; Humans; Imidazoles; Lapatinib; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Quinazolines; RNA, Messenger; Signal Transduction; Smad Proteins; Snail Family Transcription Factors; Transcription Factors; Transforming Growth Factor beta1; Up-Regulation | 2014 |
Pharmacokinetic and pharmacodynamic study of Gefitinib in a mouse model of non-small-cell lung carcinoma with brain metastasis.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line; Disease Models, Animal; Dose-Response Relationship, Drug; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Kinase Inhibitors; Quinazolines | 2013 |
A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Treatment Outcome; Young Adult | 2013 |
Targeting EGFR and PI3K pathways in ovarian cancer.
Topics: Antibiotics, Antineoplastic; Cell Proliferation; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Sirolimus; Triazines; Tumor Cells, Cultured | 2013 |
Scalp pustules in a patient receiving chemotherapy.
Topics: Acneiform Eruptions; Aged; Aged, 80 and over; Biopsy; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Scalp | 2013 |
Lower gefitinib dose led to earlier resistance acquisition before emergence of T790M mutation in epidermal growth factor receptor-mutated lung cancer model.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, Transgenic; Mutation, Missense; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
[c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Hepatocyte Growth Factor; Humans; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2013 |
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2014 |
Targeting SHP2 for EGFR inhibitor resistant non-small cell lung carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Discovery of pteridin-7(8H)-one-based irreversible inhibitors targeting the epidermal growth factor receptor (EGFR) kinase T790M/L858R mutant.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Computational Biology; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mice, SCID; Models, Chemical; Molecular Structure; Mutation; Protein Kinase Inhibitors; Pteridines; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Combined epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor and chemotherapy in non-small-cell lung cancer: chemo-refractoriness of cells harboring sensitizing-EGFR mutations in the presence of gefitinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cause of Death; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies | 2013 |
Dual inhibition of MEK1/2 and EGFR synergistically induces caspase-3-dependent apoptosis in EGFR inhibitor-resistant lung cancer cells via BIM upregulation.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lapatinib; Lung Neoplasms; MAP Kinase Kinase 1; MAP Kinase Kinase 2; Membrane Proteins; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyridones; Quinazolines; Sulfonamides | 2013 |
Atorvastatin overcomes gefitinib resistance in KRAS mutant human non-small cell lung carcinoma cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Atorvastatin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Class I Phosphatidylinositol 3-Kinases; Drug Resistance, Neoplasm; Drug Synergism; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Heptanoic Acids; Humans; Lung Neoplasms; Mice; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-raf; Proto-Oncogene Proteins p21(ras); Pyrroles; Quinazolines; ras Proteins; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Medical treatment of ectopic pregnancy: is there something new?
Topics: Abortifacient Agents, Nonsteroidal; Animals; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Methotrexate; Placenta; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2013 |
Effects of gefitinib, an epidermal growth factor receptor inhibitor, on human placental cell growth.
Topics: Abortifacient Agents, Nonsteroidal; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Evaluation, Preclinical; Drug Therapy, Combination; ErbB Receptors; Female; Gefitinib; Humans; Methotrexate; Mice; Mice, SCID; Placenta; Pregnancy; Pregnancy Trimester, First; Pregnancy, Ectopic; Quinazolines | 2013 |
High SIRT1 expression is a negative prognosticator in pancreatic ductal adenocarcinoma.
Topics: Aged; Aged, 80 and over; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Follow-Up Studies; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Middle Aged; Naphthalenes; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Niacinamide; Pancreatic Neoplasms; Prognosis; Pyrimidinones; Quinazolines; Sirtuin 1 | 2013 |
Treatment with gefitinib or lapatinib induces drug resistance through downregulation of topoisomerase IIα expression.
Topics: Amsacrine; Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; DNA Breaks, Double-Stranded; DNA Topoisomerases, Type II; DNA-Binding Proteins; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Gefitinib; Gene Expression Regulation, Neoplastic; Histones; Humans; Lapatinib; Protein Kinase Inhibitors; Quinazolines | 2013 |
The economic evaluation of personalised oncology medicines: ethical challenges.
Topics: Antineoplastic Agents; Australia; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Neoplasms; Precision Medicine; Quinazolines; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Effect of metformin on residual cells after chemotherapy in a human lung adenocarcinoma cell line.
Topics: AC133 Antigen; Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antigens, CD; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; CD24 Antigen; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Glycoproteins; Humans; Hyaluronan Receptors; Hypoglycemic Agents; Lung Neoplasms; Metformin; Mice; Mice, SCID; Neoplasm Transplantation; Peptides; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2013 |
Comparative drug pair screening across multiple glioblastoma cell lines reveals novel drug-drug interactions.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carbazoles; Cell Line, Tumor; Drug Interactions; Gefitinib; Glioblastoma; Humans; Quinazolines; Sertraline; Stilbenes | 2013 |
[Progressive patterns of gifitinib treating advanced non-small cell lung cancer after obtained resistance].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2013 |
[Local treatment combined with EGFR-TKIs for advanced non-small cell lung cancer with solitary progression during EGFR-TKI treatment].
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2013 |
Successful treatment with a combination of electrocautery using wire snares and gefitinib in patients with EGFR-mutant lung cancer and central airway obstruction.
Topics: Aged; Aged, 80 and over; Airway Obstruction; Antineoplastic Agents; Combined Modality Therapy; Electrocoagulation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Treatment Outcome | 2013 |
Experimental models to study drug distributions in tissue using MALDI mass spectrometry imaging.
Topics: Adenocarcinoma; Animals; Biological Transport; Cholinergic Antagonists; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Microtomy; Neoplasms, Experimental; Protein Kinase Inhibitors; Quinazolines; Scopolamine Derivatives; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tiotropium Bromide; Tissue Culture Techniques; Tumor Microenvironment | 2013 |
Statistical and practical considerations for clinical evaluation of predictive biomarkers.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Dacarbazine; DNA Modification Methylases; DNA Repair Enzymes; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Indazoles; Interleukin-6; Kidney Neoplasms; Lung Neoplasms; Methylation; Molecular Targeted Therapy; Mutation; Neoplasms; Precision Medicine; Predictive Value of Tests; Pyrimidines; Quinazolines; Radiotherapy, Adjuvant; Randomized Controlled Trials as Topic; Sample Size; Sulfonamides; Temozolomide; Tumor Suppressor Proteins | 2013 |
Inhibition of p38 MAPK-dependent MutS homologue-2 (MSH2) expression by metformin enhances gefitinib-induced cytotoxicity in human squamous lung cancer cells.
Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chemotherapy, Adjuvant; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lung Neoplasms; MAP Kinase Kinase 3; MAP Kinase Kinase 6; Metformin; Mutation; MutS Homolog 2 Protein; p38 Mitogen-Activated Protein Kinases; Pyridines; Quinazolines; RNA, Small Interfering; Signal Transduction; Transgenes | 2013 |
Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Humans; Male; Middle Aged; Parotid Neoplasms; Quinazolines; Vitiligo | 2013 |
Induction of autophagy is an early response to gefitinib and a potential therapeutic target in breast cancer.
Topics: Adenine; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Protein 7; Beclin-1; Breast Neoplasms; Cadaverine; Cell Line, Tumor; Cell Survival; Cytoplasmic Vesicles; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Gene Silencing; Humans; Hydroxychloroquine; Membrane Proteins; Mice; Phagosomes; Quinazolines; RNA, Small Interfering; Signal Transduction; Staining and Labeling; Tamoxifen; Treatment Outcome; Ubiquitin-Activating Enzymes; Xenograft Model Antitumor Assays | 2013 |
Combined inhibition of epidermal growth factor receptor and cyclooxygenase-2 leads to greater anti-tumor activity of docetaxel in advanced prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Proliferation; Cyclooxygenase 2; Docetaxel; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Staging; NF-kappa B; Nitrobenzenes; Prostatic Neoplasms; Quinazolines; Sulfonamides; Taxoids; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2013 |
Marsdenia tenacissima extract inhibits gefitinib metabolism in vitro by interfering with human hepatic CYP3A4 and CYP2D6 enzymes.
Topics: Antineoplastic Agents; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Gefitinib; Gene Expression Regulation, Enzymologic; Hep G2 Cells; Herb-Drug Interactions; Humans; Marsdenia; Plant Extracts; Quinazolines; Recombinant Proteins | 2014 |
Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Topics: Antimetabolites, Antineoplastic; Biological Transport; Cell Line, Tumor; Cell Survival; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Erlotinib Hydrochloride; Gefitinib; Gemcitabine; Humans; Inhibitory Concentration 50; Nucleoside Transport Proteins; Piperidines; Quinazolines; Saccharomyces cerevisiae; Uridine | 2014 |
A multicenter blinded study evaluating EGFR and KRAS mutation testing methods in the clinical non-small cell lung cancer setting--IFCT/ERMETIC2 Project Part 1: Comparison of testing methods in 20 French molecular genetic National Cancer Institute platform
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; False Positive Reactions; Gefitinib; Genotype; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Nucleic Acid Amplification Techniques; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Sequence Analysis, DNA | 2014 |
Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Ki-67 Antigen; Mice; Neoplasms; Phosphorylation; Quinazolines; Radiopharmaceuticals; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
microRNA expression profiles associated with survival, disease progression, and response to gefitinib in completely resected non-small-cell lung cancer with EGFR mutation.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Analysis | 2013 |
Liquid chromatography-tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma.
Topics: Acetonitriles; Animals; Area Under Curve; Calibration; Chromatography, Liquid; Edetic Acid; Female; Gefitinib; Indoles; Mice; Poly(ADP-ribose) Polymerase Inhibitors; Protein Kinase Inhibitors; Quality Control; Quinazolines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2014 |
Lapatinib-induced NF-kappaB activation sensitizes triple-negative breast cancer cells to proteasome inhibitors.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; I-kappa B Kinase; Lapatinib; Mice, SCID; NF-kappa B; Phosphorylation; Proteasome Inhibitors; Pyrazines; Quinazolines; Receptor, ErbB-2; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2013 |
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance status.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2013 |
Clinical significance of erlotinib monotherapy for gefitinib-resistant non-small cell lung cancer with EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Rate | 2013 |
EGFR T790M mutation as a possible target for immunotherapy; identification of HLA-A*0201-restricted T cell epitopes derived from the EGFR T790M mutation.
Topics: Aged; Amino Acid Sequence; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epitopes, T-Lymphocyte; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HLA-A2 Antigen; Humans; Immunotherapy; Leukocytes, Mononuclear; Lung Neoplasms; Lymphocyte Activation; Male; Middle Aged; Molecular Sequence Data; Mutation; Peptides; Protein Kinase Inhibitors; Quinazolines | 2013 |
Pro-MMP-9 upregulation in HT1080 cells expressing CD9 is regulated by epidermal growth factor receptor.
Topics: Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Quinazolines; Tetraspanin 29; Up-Regulation | 2013 |
[Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].
Topics: Antineoplastic Agents; Apoptosis; beta Catenin; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; Wnt Signaling Pathway | 2013 |
Gefitinib and erlotinib for non-small cell lung cancer patients who fail to respond to radiotherapy for brain metastases.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Treatment Failure | 2014 |
MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Guanylate Kinases; Humans; Lung Neoplasms; Membrane Proteins; MicroRNAs; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Transforming Growth Factor beta1 | 2014 |
Post-progression survival in patients with non-small cell lung cancer with clinically acquired resistance to gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival; Treatment Outcome | 2013 |
Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression.
Topics: Antineoplastic Agents; Antineoplastic Agents, Hormonal; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Estradiol; Fulvestrant; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transfection; Up-Regulation | 2014 |
Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2013 |
Effectiveness and cost-effectiveness of erlotinib versus gefitinib in first-line treatment of epidermal growth factor receptor-activating mutation-positive non-small-cell lung cancer patients in Hong Kong.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Cost-Benefit Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
miR-30b and miR-30c expression predicted response to tyrosine kinase inhibitors as first line treatment in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Reverse Transcriptase Polymerase Chain Reaction | 2013 |
Linking γ-aminobutyric acid A receptor to epidermal growth factor receptor pathways activation in human prostate cancer.
Topics: Autocrine Communication; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; GABA Agonists; GABA Antagonists; gamma-Aminobutyric Acid; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Isonicotinic Acids; Male; Paracrine Communication; Phosphorylation; Picrotoxin; Prostate; Prostatic Neoplasms; Protein Kinase Inhibitors; Quinazolines; Receptors, GABA-A; Signal Transduction; src-Family Kinases | 2014 |
Evidence that depletion of the sorting nexin 1 by siRNA promotes HGF-induced MET endocytosis and MET phosphorylation in a gefitinib-resistant human lung cancer cell line.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Endocytosis; Endosomes; Gefitinib; Gene Silencing; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Microscopy, Fluorescence; Phosphorylation; Protein Transport; Proto-Oncogene Proteins c-met; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; RNA, Small Interfering; Signal Transduction; Sorting Nexins; Tumor Cells, Cultured | 2014 |
Biological characteristics and epidermal growth factor receptor tyrosine kinase inhibitors efficacy of EGFR mutation and its subtypes in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Young Adult | 2014 |
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2.
Topics: 3T3 Cells; Adenosine; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Blood-Brain Barrier; Cell Line, Tumor; Diketopiperazines; Endothelial Cells; Firefly Luciferin; Gefitinib; Gene Expression; HEK293 Cells; Heterocyclic Compounds, 4 or More Rings; Humans; Luciferases, Firefly; Luminescent Agents; Luminescent Measurements; Mice; Mice, Transgenic; Neoplasm Proteins; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenobiotics | 2013 |
EpCAM expression in the prostate cancer makes the difference in the response to growth factors.
Topics: AMP-Activated Protein Kinases; Antigens, Neoplasm; Biomarkers, Tumor; Cell Adhesion Molecules; Cell Line, Tumor; Epidermal Growth Factor; Epithelial Cell Adhesion Molecule; ErbB Receptors; Gefitinib; Humans; Large Neutral Amino Acid-Transporter 1; Male; Neoplastic Stem Cells; Prostatic Neoplasms; Quinazolines; Signal Transduction; Tumor Microenvironment | 2014 |
Clinical characteristics of non-small cell lung cancer patients who experienced acquired resistance during gefitinib treatment.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Risk Factors; Sex Factors; Survival Analysis | 2014 |
[Effect of bufalin combined gefitinib on lung cancer H1975 cells and its mechanisms research].
Topics: Bufanolides; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2013 |
MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA-Binding Proteins; Transgenes; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Inhibition of insulin-like growth factor-binding protein-3 signaling through sphingosine kinase-1 sensitizes triple-negative breast cancer cells to EGF receptor blockade.
Topics: Animals; Blotting, Western; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Thiazoles; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Effects of PI3K inhibitor NVP-BKM120 on acquired resistance to gefitinib of human lung adenocarcinoma H1975 cells.
Topics: Adenocarcinoma; Aminopyridines; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lung Neoplasms; Matrix Metalloproteinase 9; Morpholines; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; RNA, Messenger; Vascular Endothelial Growth Factor A | 2013 |
Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Proportional Hazards Models; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Regression Analysis; Retrospective Studies; Treatment Outcome | 2014 |
Role of IGF-binding protein 3 in the resistance of EGFR mutant lung cancer cells to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Insulin-Like Growth Factor Binding Protein 3; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2013 |
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Topics: Amino Acid Sequence; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crystallography, X-Ray; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Models, Molecular; Molecular Sequence Data; Mutagenesis, Insertional; Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Structural Homology, Protein; Translational Research, Biomedical | 2013 |
Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation, Missense; Prognosis; Quinazolines; Republic of Korea; Retrospective Studies; Sequence Deletion; Survival Analysis; Treatment Outcome | 2013 |
The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
Topics: Acetylation; Adenocarcinoma; Adenocarcinoma, Mucinous; Adult; Aged; Aged, 80 and over; Antigens, Nuclear; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Blotting, Western; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Histone Deacetylase 1; Humans; Immunoenzyme Techniques; Immunoprecipitation; Ku Autoantigen; Lung Neoplasms; Male; Middle Aged; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Neoplasm Metastasis; Phosphatidylinositol 3-Kinase; Phosphorylation; Prognosis; Prospective Studies; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, IGF Type 1; Tumor Cells, Cultured | 2014 |
Silencing of reversion-inducing cysteine-rich protein with Kazal motifs stimulates hyperplastic phenotypes through activation of epidermal growth factor receptor and hypoxia-inducible factor-2α.
Topics: Animals; Basic Helix-Loop-Helix Transcription Factors; Cell Hypoxia; Colony-Forming Units Assay; ErbB Receptors; Gefitinib; Gene Expression Regulation; Gene Knockdown Techniques; GPI-Linked Proteins; Hyperplasia; Mice; Mice, Nude; Phenotype; Quinazolines; RNA, Small Interfering | 2013 |
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Salvage Therapy | 2013 |
BCRP/ABCG2 inhibition sensitizes hepatocellular carcinoma cells to sorafenib.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport, Active; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Liver Neoplasms; MAP Kinase Signaling System; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Sorafenib | 2013 |
Topoisomerase I as a target of erlotinib and gefitinib: efficacy of combined treatments with camptothecin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Camptothecin; DNA Topoisomerases, Type I; Erlotinib Hydrochloride; Female; Gefitinib; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Processing, Post-Translational; Quinazolines | 2014 |
TPCA-1 is a direct dual inhibitor of STAT3 and NF-κB and regresses mutant EGFR-associated human non-small cell lung cancers.
Topics: Amides; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; I-kappa B Proteins; Mutation; NF-kappa B; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Thiophenes | 2014 |
Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retreatment; Retrospective Studies; Smoking; Treatment Outcome | 2014 |
Complete metabolic remission with Gefitinib in a hemodialysis patient with bone metastases from non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Feasibility Studies; Gefitinib; Humans; Kidney Failure, Chronic; Lung Neoplasms; Male; Positron-Emission Tomography; Prognosis; Quinazolines; Remission Induction; Renal Dialysis; Tomography, X-Ray Computed | 2014 |
Factors associated with early progression of non-small-cell lung cancer treated by epidermal growth factor receptor tyrosine-kinase inhibitors.
Topics: Aged; Aged, 80 and over; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Overcoming resistance to first generation EGFR TKIs with cetuximab in combination with chemotherapy in an EGFR mutated advanced stage NSCLC patient.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Remission Induction; Vinblastine; Vinorelbine | 2014 |
A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Diarrhea; Drug Monitoring; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; ROC Curve; Sensitivity and Specificity; Specimen Handling; Time Factors | 2014 |
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome | 2014 |
Survival outcome assessed according to tumor response and shrinkage pattern in patients with EGFR mutation-positive non-small-cell lung cancer treated with gefitinib or erlotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2014 |
EGFR exon 19 insertions show good response to gefitinib, but short time to progression in Japanese patients.
Topics: Adenocarcinoma; Aged; Bone Neoplasms; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2014 |
Gefitinib and non-small cell lunt cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Docetaxel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Taxoids | 2013 |
Src mediates ERK reactivation in gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Nitrosamines; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins pp60(c-src); Quinazolines | 2014 |
Integrin beta 1 enhances the epithelial-mesenchymal transition in association with gefitinib resistance of non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Integrin beta1; Lung Neoplasms; Mice; Mice, Nude; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2013 |
Clinical predictors of response to EGFR tyrosine kinase inhibitors in patients with EGFR-mutant non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Proportional Hazards Models; Quinazolines; Retrospective Studies; Treatment Outcome | 2014 |
Gefitinib enhances the antitumor activity of CPT-11 in vitro and in vivo by inhibiting ABCG2 but not ABCB1: a new clue to circumvent gastrointestinal toxicity risk.
Topics: Administration, Oral; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Camptothecin; Cell Line, Tumor; Cell Survival; Diarrhea; Drug Synergism; Drug Therapy, Combination; Female; Gefitinib; HEK293 Cells; Humans; Irinotecan; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Proteins; Quinazolines; RNA, Messenger; Transplantation, Heterologous | 2013 |
In vitro-in vivo correlation of the effect of supersaturation on the intestinal absorption of BCS Class 2 drugs.
Topics: Administration, Oral; Albendazole; Animals; Antineoplastic Agents; Calorimetry, Differential Scanning; Cytochrome P-450 CYP3A Inhibitors; Dipyridamole; Drug Stability; Gefitinib; In Vitro Techniques; Intestinal Absorption; Ketoconazole; Male; Quinazolines; Rats; Rats, Sprague-Dawley; Solubility; Solvents; Tubulin Modulators; Vasodilator Agents | 2014 |
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Agents; Basic Helix-Loop-Helix Transcription Factors; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Niacinamide; Phenylurea Compounds; Quinazolines; Signal Transduction; Sorafenib; Transforming Growth Factor alpha; Up-Regulation | 2014 |
Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Topics: AC133 Antigen; Animals; Antigens, CD; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Hypoxia; Cell Line, Tumor; Cell Separation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycoproteins; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin-Like Growth Factor I; Lung Neoplasms; Mice, Inbred NOD; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Quinazolines; Receptor, IGF Type 1; Spheroids, Cellular; Up-Regulation | 2014 |
Does gefitinib have effects on EGFR mutation-positive thymoma? -Case report of thymoma recurrence.
Topics: Antineoplastic Agents; Combined Modality Therapy; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Quinazolines; Reoperation; Thoracic Surgery, Video-Assisted; Thymoma; Thymus Neoplasms | 2014 |
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha | 2014 |
Humoral immune responses to EGFR-derived peptides predict progression-free and overall survival of non-small cell lung cancer patients receiving gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Immunity, Humoral; Immunoglobulin G; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Oligopeptides; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Quinazolines | 2014 |
EGFR, HER2 and HER3 dimerization patterns guide targeted inhibition in two histotypes of esophageal cancer.
Topics: Adenocarcinoma; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Esophageal Neoplasms; Fluorescent Antibody Technique; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoenzyme Techniques; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Tumor Cells, Cultured | 2014 |
Structural bioinformatics-based identification of EGFR inhibitor gefitinib as a putative lead compound for BACE.
Topics: Amyloid beta-Protein Precursor; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Binding Sites; Cell Line, Tumor; Cell Survival; Computational Biology; ErbB Receptors; Gefitinib; Humans; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines | 2014 |
PANC-1 pancreatic cancer cell growth inhibited by cucurmosin alone and in combination with an epidermal growth factor receptor-targeted drug.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Caspases; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Pancreatic Neoplasms; Phosphatidylinositol 3-Kinases; Plant Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Ribosome Inactivating Proteins, Type 1; Signal Transduction; Time Factors; Xenograft Model Antitumor Assays | 2014 |
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
Topics: Animals; Apoptosis; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Female; Fulvestrant; Gefitinib; Humans; Lapatinib; MCF-7 Cells; Mice; Mice, Nude; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptors, Estrogen; Signal Transduction; Tamoxifen; Up-Regulation; Xenograft Model Antitumor Assays | 2014 |
Pneumonectomy after response to gefitinib treatment for lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biopsy; Chemotherapy, Adjuvant; Empyema, Pleural; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Lymph Node Excision; Mutation; Neoadjuvant Therapy; Neoplasm, Residual; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome; Tumor Burden | 2013 |
Adenomatous polyposis coli determines sensitivity to the EGFR tyrosine kinase inhibitor gefitinib in colorectal cancer cells.
Topics: Adenomatous Polyposis Coli Protein; Antineoplastic Agents; Blotting, Western; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction | 2014 |
[Development and biochemical characterization of EGFR/c-Met dual inhibitors].
Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines | 2013 |
EGFR gene mutations in patients with adenosquamous lung carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Adenosquamous; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Poland; Polymerase Chain Reaction; Quinazolines; Remission Induction; Smoking | 2014 |
miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Receptors, G-Protein-Coupled; RNA, Messenger; RNA, Neoplasm | 2014 |
Monitoring of gefitinib sensitivity with radioiodinated PHY based on EGFR expression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, Emission-Computed, Single-Photon | 2014 |
Economic outcomes of maintenance gefitinib for locally advanced/metastatic non-small-cell lung cancer with unknown EGFR mutations: a semi-Markov model analysis.
Topics: Carcinoma, Non-Small-Cell Lung; China; Cost-Benefit Analysis; Delivery of Health Care; Drug Costs; Gefitinib; Humans; Maintenance Chemotherapy; Models, Economic; Quality-Adjusted Life Years; Quinazolines | 2014 |
MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2014 |
Short-course treatment with gefitinib enhances curative potential of radiation therapy in a mouse model of human non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Combined Modality Therapy; Disease Models, Animal; ErbB Receptors; Gefitinib; Genes, erbB-1; Heterografts; Histones; Humans; Lung Neoplasms; Mice; Mitogen-Activated Protein Kinase Kinases; Poly(ADP-ribose) Polymerases; Proto-Oncogene Proteins c-akt; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
Synthesis and evaluation of 2-anilinopyrimidines bearing 3-aminopropamides as potential epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Molecular Structure; Nitric Oxide; Oxadiazoles; Pyrimidines; Quinazolines; Signal Transduction; Structure-Activity Relationship | 2014 |
Synergistic anti-tumor effects of a novel phosphatidyl inositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Quinolines; Signal Transduction; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2014 |
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Agents; Ascitic Fluid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Small Cell Lung Carcinoma; Tomography, X-Ray Computed | 2014 |
Successful gefitinib treatment administration via gastrostomy tube in a patient with non-small cell lung cancer with dysphagia.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deglutition Disorders; Drug Administration Routes; Female; Gastrostomy; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Metabolite characterization of anti-cancer agent gefitinib in human hepatocytes.
Topics: Antineoplastic Agents; Biotransformation; Chromatography, High Pressure Liquid; Dealkylation; Gefitinib; Glutathione; Halogenation; Hepatocytes; Humans; Male; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Oxidation-Reduction; Protein Kinase Inhibitors; Quinazolines; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2014 |
Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation, Missense; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2014 |
Autophagy facilitates the EGFR-TKI acquired resistance of non-small-cell lung cancer cells.
Topics: Antineoplastic Agents; Autophagy; Benzamides; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Effect of simvastatin on the resistance to EGFR tyrosine kinase inhibitors in a non-small cell lung cancer with the T790M mutation of EGFR.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Catenins; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Mutation, Missense; Protein Kinase Inhibitors; Quinazolines; Simvastatin; Survivin | 2014 |
Novel ruthenium complexes ligated with 4-anilinoquinazoline derivatives: synthesis, characterisation and preliminary evaluation of biological activity.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Cell Proliferation; Cell Survival; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; MCF-7 Cells; Models, Molecular; Molecular Structure; Organometallic Compounds; Quinazolines; Ruthenium; Structure-Activity Relationship | 2014 |
Early assessment of tumor response to gefitinib treatment by noninvasive optical imaging of tumor vascular endothelial growth factor expression in animal models.
Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; Female; Gefitinib; Human Umbilical Vein Endothelial Cells; Humans; Ki-67 Antigen; Mice; Mice, Inbred BALB C; Microscopy, Fluorescence; Models, Animal; Molecular Imaging; Neoplasm Transplantation; Neoplasms; Optics and Photonics; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Time Factors; Vascular Endothelial Growth Factor A | 2014 |
Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Interleukin-6; Kaplan-Meier Estimate; Lung Neoplasms; Metformin; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Learning from errors: response to gefitinib in kidney urothelial carcinoma with EGFR mutations.
Topics: Antineoplastic Agents; Carboplatin; Carcinoma, Squamous Cell; Deoxycytidine; ErbB Receptors; Female; Gefitinib; Gemcitabine; Humans; Kidney; Kidney Neoplasms; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Urothelium | 2014 |
EGFR endocytosis is a novel therapeutic target in lung cancer with wild-type EGFR.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Dynamins; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Humans; Hydrazones; Lung Neoplasms; Male; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; rab GTP-Binding Proteins; Signal Transduction | 2014 |
Celastrol induces apoptosis in gefitinib-resistant non-small cell lung cancer cells via caspases-dependent pathways and Hsp90 client protein degradation.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mitochondria; Pentacyclic Triterpenes; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Signal Transduction; Triterpenes | 2014 |
Changes in symptom severity in Taiwanese lung cancer patients after gefitinib treatment: a pilot study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Quinazolines; Severity of Illness Index; Symptom Assessment; Taiwan; Treatment Outcome | 2014 |
Antitumor activity of combination treatment with gefitinib and docetaxel in EGFR-TKI-sensitive, primary resistant and acquired resistant human non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Taxoids | 2014 |
T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines | 2014 |
Reossification of osteolytic metastases at the acetabulum following gefitinib and multidisciplinary treatment for lung cancer: a case report with autopsy findings.
Topics: Acetabulum; Adenocarcinoma; Administration, Oral; Antineoplastic Agents; Autopsy; Biopsy; Bone Neoplasms; Disease Progression; ErbB Receptors; Fatal Outcome; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Ossification, Heterotopic; Quinazolines; Tomography, X-Ray Computed | 2015 |
An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Autophagy; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Microtubule-Associated Proteins; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Nanoimmunoassay to Detect Responses in Head and Neck Cancer: Feasibility in a Mouse Model.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Feasibility Studies; Gefitinib; Head and Neck Neoplasms; Heterografts; Immunoassay; In Vitro Techniques; Mice; Nanotechnology; Quinazolines | 2014 |
Suppression of Dicer increases sensitivity to gefitinib in human lung cancer cells.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Quinazolines; Retrospective Studies; Ribonuclease III; RNA, Messenger | 2014 |
Schedule-dependent synergistic interaction between docetaxel and gefitinib in NSCLC cell lines regardless of the mutation status of EGFR and KRAS and its molecular mechanisms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Docetaxel; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Taxoids; Tumor Cells, Cultured | 2014 |
Combined therapeutic potential of nuclear receptors with receptor tyrosine kinase inhibitors in lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cyclin B; Cyclin D1; ErbB Receptors; Gefitinib; Humans; Hydrocarbons, Fluorinated; Indoles; Liver X Receptors; Lung Neoplasms; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Quinazolines; Receptors, Cytoplasmic and Nuclear; Sulfonamides; Sulfones | 2014 |
Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2014 |
Lung carcinomas with EGFR exon 19 insertions are sensitive to gefitinib treatment.
Topics: Adenocarcinoma; Amino Acid Sequence; Base Sequence; Carcinoma, Large Cell; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Molecular Sequence Data; Mutagenesis, Insertional; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2014 |
Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian People; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Methionine; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Republic of Korea; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Threonine; Treatment Outcome; Tumor Cells, Cultured | 2014 |
Combined treatment with Epimedium koreanum Nakai extract and gefitinib overcomes drug resistance caused by T790M mutation in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Combined Modality Therapy; Drug Resistance, Neoplasm; Drug Synergism; Endothelial Cells; Epimedium; ErbB Receptors; Gefitinib; Humans; Mice, Nude; Mutation; Phosphatidylinositol 3-Kinases; Plant Extracts; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Erlotinib or gefitinib as first-choice therapy for bronchorrhea in bronchioloalveolar carcinoma.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Aged; Bronchi; Bronchial Diseases; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines; Radiography, Thoracic | 2014 |
RAC1 inhibition as a therapeutic target for gefitinib-resistant non-small-cell lung cancer.
Topics: Aminoquinolines; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Mice; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; rac1 GTP-Binding Protein; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Everolimus prolonged survival in transgenic mice with EGFR-driven lung tumors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Transgenic; Mutant Proteins; Mutation; Neovascularization, Pathologic; Phosphorylation; Quinazolines; Ribosomal Protein S6; Sirolimus; TOR Serine-Threonine Kinases | 2014 |
Hepassocin activates the EGFR/ERK cascade and induces proliferation of L02 cells through the Src-dependent pathway.
Topics: Cell Line; Cell Proliferation; Down-Regulation; Epidermal Growth Factor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Fibrinogen; Gefitinib; Humans; Neoplasm Proteins; Phosphorylation; Quinazolines; Recombinant Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Transcriptional Activation | 2014 |
Cytoplasmic YAP expression is associated with prolonged survival in patients with lung adenocarcinomas and epidermal growth factor receptor tyrosine kinase inhibitor treatment.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adult; Aged; Aged, 80 and over; Cytoplasm; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Phosphoproteins; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Survival Rate; Transcription Factors; YAP-Signaling Proteins; Young Adult | 2014 |
Hsp90 inhibition by WK88-1 potently suppresses the growth of gefitinib-resistant H1975 cells harboring the T790M mutation in EGFR.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2014 |
In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth fact
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; In Vitro Techniques; Membrane Proteins; Polymerase Chain Reaction; Predictive Value of Tests; Proto-Oncogene Proteins; Quinazolines; Sensitivity and Specificity; Signal Transduction; Vascular Endothelial Growth Factor A | 2015 |
Combination gefitinib and methotrexate treatment for non-tubal ectopic pregnancies: a case series.
Topics: Abortifacient Agents, Nonsteroidal; Acneiform Eruptions; Adult; Cesarean Section; Chorionic Gonadotropin; Fallopian Tubes; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy Outcome; Pregnancy, Ectopic; Quinazolines; Ultrasonography, Prenatal; Young Adult | 2014 |
Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy.
Topics: Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nitriles; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Sequence Analysis, RNA | 2014 |
Targeting EGFL7 expression through RNA interference suppresses renal cell carcinoma growth by inhibiting angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Calcium-Binding Proteins; Carcinoma, Renal Cell; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation; EGF Family of Proteins; Endothelial Growth Factors; ErbB Receptors; Female; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Kidney Neoplasms; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays | 2014 |
A complex deletion/insertion on exon 19 of the EGFR gene predicts response to gefitinib.
Topics: Adenocarcinoma; Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Exons; Female; Gefitinib; Humans; INDEL Mutation; Lung Neoplasms; Quinazolines | 2014 |
Epidermal growth factor receptor inhibitors selectively inhibit the expressions of human β-defensins induced by Staphylococcus epidermidis.
Topics: beta-Defensins; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Host-Pathogen Interactions; Humans; Immunity, Innate; Keratinocytes; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Staphylococcus aureus; Staphylococcus epidermidis; Time Factors | 2014 |
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cyclin B1; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; HEK293 Cells; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Invasiveness; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases; RNA Interference; Time Factors; Transfection; Tumor Burden; Wnt Proteins; Wnt-5a Protein; Xenograft Model Antitumor Assays | 2014 |
EGFR activation suppresses respiratory virus-induced IRF1-dependent CXCL10 production.
Topics: Bronchi; Cell Line; Cell Movement; Chemokine CXCL10; Epithelial Cells; ErbB Receptors; Female; Gefitinib; Humans; Influenza A Virus, H1N1 Subtype; Interferon Regulatory Factor-1; Interleukin-8; Killer Cells, Natural; Quinazolines; Respiratory Syncytial Viruses; Rhinovirus; Signal Transduction; Virus Diseases | 2014 |
Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; G1 Phase Cell Cycle Checkpoints; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Ten lessons from EGFR.
Topics: Afatinib; Antineoplastic Agents; Clinical Trials as Topic; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Precision Medicine; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Efficacy of gefitinib for young patients with unknown EGFR gene mutation
in advanced lung adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Antineoplastic Agents; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2014 |
News products to avoid.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Azacitidine; Decitabine; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Everolimus; Ferrosoferric Oxide; Gefitinib; Hematinics; Humans; Imidazoles; Indazoles; Oxonic Acid; Pyridines; Quinazolines; Risk Assessment; Risk Factors; Sirolimus; Tegafur | 2014 |
Clinical trials: More trials, fewer tribulations.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size | 2014 |
Combination of gefitinib and DNA methylation inhibitor decitabine exerts synergistic anti-cancer activity in colon cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azacitidine; Cell Line, Tumor; Cell Survival; Colonic Neoplasms; Decitabine; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Gefitinib; Humans; Intracellular Signaling Peptides and Proteins; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Autophagy contributes to gefitinib-induced glioma cell growth inhibition.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinases; Animals; Apoptosis Regulatory Proteins; Autophagy; Cell Line, Tumor; Gefitinib; Glioma; Growth Inhibitors; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Ribonucleotides; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Marsdenia; Phosphatidylinositol 3-Kinases; Phytotherapy; Plant Extracts; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases | 2014 |
Fibroblasts weaken the anti-tumor effect of gefitinib on co-cultured non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Epithelial-Mesenchymal Transition; Fibroblasts; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression; Humans; Immunoconjugates; Lung Neoplasms; Maytansine; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
β-adrenergic receptor-dependent alterations in murine cardiac transcript expression are differentially regulated by gefitinib in vivo.
Topics: Adrenergic beta-Agonists; Animals; Down-Regulation; Female; Gefitinib; Gene Expression Profiling; Gene Regulatory Networks; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Myocardium; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Adrenergic, beta; Up-Regulation | 2014 |
An in vitro one-dimensional assay to study growth factor-regulated tumor cell-macrophage interaction.
Topics: Animals; Biological Assay; Cell Communication; Cell Line, Tumor; Cell Movement; Coculture Techniques; Collagen Type I; Epidermal Growth Factor; Extracellular Matrix; Female; Fibronectins; Gefitinib; Humans; Macrophages; Mammary Glands, Human; Mice; Molecular Imaging; Quinazolines; Signal Transduction; Time-Lapse Imaging; Tyrphostins | 2014 |
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; GPI-Linked Proteins; Homeodomain Proteins; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases; Transcription Factors; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2014 |
Comparison is beyond IPASS and OPTIMAL.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
[Long-term survival with complete response by gefitinib treatment followed by noncurative operation for lung cancer].
Topics: Antineoplastic Agents; Combined Modality Therapy; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Time Factors; Vena Cava, Superior | 2014 |
Primary and secondary resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2014 |
Gefitinib and afatinib treatment in an advanced non-small cell lung cancer (NSCLC) patient undergoing hemodialysis.
Topics: Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prognosis; Quinazolines; Renal Dialysis | 2014 |
Antitumor activity of selective MEK1/2 inhibitor AZD6244 in combination with PI3K/mTOR inhibitor BEZ235 in gefitinib-resistant NSCLC xenograft models.
Topics: Animals; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Female; Gefitinib; Humans; Imidazoles; Ki-67 Antigen; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Endothelial Cell Adhesion Molecule-1; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Quinolines; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Extracellular vesicles shed from gefitinib-resistant nonsmall cell lung cancer regulate the tumor microenvironment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Matrix; Gefitinib; Humans; Lung; Lung Neoplasms; Point Mutation; Protein Kinase Inhibitors; Proteomics; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2014 |
Combining AKT inhibition with chloroquine and gefitinib prevents compensatory autophagy and induces cell death in EGFR mutated NSCLC cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chloroquine; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proto-Oncogene Proteins c-akt; Quinazolines; RNA Interference; Xenograft Model Antitumor Assays | 2014 |
Gefitinib for oesophageal cancer: a cog in need of a wheel?
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Quinazolines | 2014 |
Multivariate signaling regulation by SHP2 differentially controls proliferation and therapeutic response in glioma cells.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Glioblastoma; Humans; Indoles; MAP Kinase Signaling System; Mice, Nude; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins c-met; Quinazolines; STAT3 Transcription Factor; Sulfones | 2014 |
management of nonhematologic toxicities associated with different EGFR-TKIs in advanced NSCLC: a comparison analysis.
Topics: Afatinib; Anti-Bacterial Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Feeding Behavior; Gefitinib; Humans; Incidence; Lung Neoplasms; Mucositis; Neoplasm Metastasis; Neoplasm Staging; Quinazolines; Withholding Treatment | 2014 |
Synthesis and evaluation of salicylanilide derivatives as potential epidermal growth factor receptor inhibitors.
Topics: Antineoplastic Agents; Benzamides; Binding Sites; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperidines; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Salicylanilides; Thermodynamics | 2015 |
AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2014 |
Activity of EGFR, mTOR and PI3K inhibitors in an isogenic breast cell line model.
Topics: Breast; Cell Line; Cell Survival; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mutation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triazines | 2014 |
An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Autophagy; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Heterografts; Humans; Indoles; Lamin Type A; Liver Neoplasms; Methylation; Mice, SCID; Oncogene Protein p21(ras); Protein Methyltransferases; Protein Prenylation; Pyrimidines; Quinazolines | 2014 |
Gefitinib and luteolin cause growth arrest of human prostate cancer PC-3 cells via inhibition of cyclin G-associated kinase and induction of miR-630.
Topics: Active Transport, Cell Nucleus; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Luteolin; Male; MicroRNAs; Models, Biological; Neoplasm Grading; Phosphorylation; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Transport; Quinazolines; Signal Transduction | 2014 |
More trials, fewer tribulations.
Topics: Antineoplastic Agents; Bayes Theorem; Clinical Trials as Topic; Drug Approval; Gefitinib; Humans; Mutation; National Cancer Institute (U.S.); Neoplasms; Quinazolines; Transcriptome; United States | 2014 |
Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Nude; Molecular Docking Simulation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET.
Topics: 3' Untranslated Regions; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Proto-Oncogene Proteins c-met; Quinazolines; Random Allocation; Transfection; Xenograft Model Antitumor Assays | 2014 |
CMV-induced pathology: pathway and gene-gene interaction analysis.
Topics: Animals; Carcinoma, Mucoepidermoid; Cytomegalovirus; Cytomegalovirus Infections; Epistasis, Genetic; Female; Gefitinib; Gene Expression Regulation; Gene Regulatory Networks; Humans; Mice; Mice, Inbred C57BL; Models, Theoretical; Organ Culture Techniques; Protein Kinase Inhibitors; Quinazolines; Salivary Gland Neoplasms; Salivary Glands; Signal Transduction; Tumor Microenvironment | 2014 |
Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chromatography, Liquid; Cisplatin; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Mutation; Pemetrexed; Quinazolines; Retrospective Studies; Tandem Mass Spectrometry | 2015 |
Renal cortical hexokinase and pentose phosphate pathway activation through the EGFR/Akt signaling pathway in endotoxin-induced acute kidney injury.
Topics: Acute Kidney Injury; Animals; Enzyme Activation; ErbB Receptors; Gefitinib; Glucosephosphate Dehydrogenase; Glycolysis; Heterocyclic Compounds, 3-Ring; Hexokinase; Kidney Cortex; Lipopolysaccharides; Male; Mice; Pentose Phosphate Pathway; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines | 2014 |
Increased INR after gefitinib and acenocoumarol co-administration.
Topics: Acenocoumarol; Adenocarcinoma; Aged; Anticoagulants; Antineoplastic Agents; Atrial Fibrillation; Carcinoma, Non-Small-Cell Lung; Drug Interactions; Gefitinib; Heart Failure; Humans; International Normalized Ratio; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2014 |
The gefitinib dose reduction on survival outcomes in epidermal growth factor receptor mutant non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
The reverse effect of X-ray irradiation on acquired gefitinib resistance in non-small cell lung cancer cell line NCI-H1975 in vitro.
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Vimentin; X-Rays | 2014 |
[Gefitinib treatment in lung cancer -- rebiopsy, retreatment, remission].
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bronchial Neoplasms; Disease Progression; Docetaxel; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Genes, erbB-1; Humans; Molecular Targeted Therapy; Quinazolines; Remission Induction; Retreatment; Taxoids; Treatment Outcome | 2014 |
Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivation.
Topics: ADAM Proteins; ADAM10 Protein; ADAM17 Protein; Amyloid Precursor Protein Secretases; Antibodies; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; Membrane Proteins; Phosphorylation; Quinazolines; Signal Transduction | 2014 |
Deficient HER3 expression in poorly-differentiated colorectal cancer cells enhances gefitinib sensitivity.
Topics: Animals; Antineoplastic Agents; Butyric Acid; Cell Cycle; Cell Differentiation; Cell Line, Tumor; Colorectal Neoplasms; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Xenograft Model Antitumor Assays | 2014 |
Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Point Mutation; Quinazolines; Retrospective Studies; Sequence Deletion; Treatment Outcome | 2014 |
Detection of mutations by fill-in ligation reaction with enzyme-linked immunosorbent assay for rapid medical diagnosis.
Topics: Base Sequence; DNA Mutational Analysis; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Exons; Gefitinib; Genotyping Techniques; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Plasmids; Polymorphism, Single Nucleotide; Quinazolines; Time Factors; Treatment Outcome | 2014 |
Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Lung Neoplasms; Male; MAP Kinase Signaling System; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Survival Analysis | 2014 |
Esophageal carcinoma cell line with high EGFR polysomy is responsive to gefitinib.
Topics: Adenocarcinoma; Cell Line, Tumor; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Male; Middle Aged; Quinazolines | 2014 |
Structural signature of the G719S-T790M double mutation in the EGFR kinase domain and its response to inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Ligands; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Mutation; Neoplasm Proteins; Principal Component Analysis; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein Structure, Tertiary; Quinazolines | 2014 |
Hinokitiol induces DNA damage and autophagy followed by cell cycle arrest and senescence in gefitinib-resistant lung adenocarcinoma cells.
Topics: Acridine Orange; Adenocarcinoma; Adenocarcinoma of Lung; Annexin A5; Antineoplastic Agents, Phytogenic; Autophagy; Blotting, Western; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cupressaceae; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Gas Chromatography-Mass Spectrometry; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Monoterpenes; Oils, Volatile; Quinazolines; Real-Time Polymerase Chain Reaction; Taiwan; Tropolone; Tumor Stem Cell Assay | 2014 |
Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzoquinones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Lactams, Macrocyclic; Lung Neoplasms; Male; Mice, Inbred BALB C; Mice, Inbred C57BL; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, ErbB-3 | 2014 |
3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Aurora Kinase A; Aurora Kinase B; Carcinoma, Non-Small-Cell Lung; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Flavonoids; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Burden | 2014 |
FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; ErbB Receptors; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; MAP Kinase Signaling System; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Mice; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; RNA, Small Interfering; Transfection; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Abrogating phosphorylation of eIF4B is required for EGFR and mTOR inhibitor synergy in triple-negative breast cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Synergism; ErbB Receptors; Eukaryotic Initiation Factors; Female; Gefitinib; HEK293 Cells; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2014 |
Efficacy analysis of tyrosine kinase inhibitors on rare non-small cell lung cancer patients harboring complex EGFR mutations.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2014 |
Epidermal growth factor receptor (EGFR) exon 20 mutations in non-small-cell lung cancer and resistance to EGFR-tyrosine kinase inhibitors.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2014 |
Spatiotemporal T790M heterogeneity in a patient with EGFR-mutant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Lung Neoplasms; Mutation; Quinazolines; Spatio-Temporal Analysis | 2014 |
Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Body Surface Area; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Time Factors; Treatment Outcome | 2014 |
Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Female; Fibronectins; Gefitinib; Humans; MCF-7 Cells; Phosphorylation; Quinazolines; Signal Transduction; Silybin; Silymarin; Triple Negative Breast Neoplasms; Tyrphostins | 2014 |
Design, synthesis and biological evaluation of quinoxalin-2(1H)-one derivatives as EGFR tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Quinoxalines | 2015 |
Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Paclitaxel; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Treatment Failure; Tumor Burden; Xenograft Model Antitumor Assays | 2014 |
Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Melatonin; Mutation; Phosphorylation; Quinazolines | 2014 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Polyoxypregnane steroids from the stems of Marsdenia tenacissima.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Gefitinib; Glycosides; Humans; Marsdenia; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Pregnanes; Quinazolines | 2014 |
Recombinant expression of different mutant K-ras gene in pancreatic cancer Bxpc-3 cells and its effects on chemotherapy sensitivity.
Topics: Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Screening Assays, Antitumor; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, ras; Green Fluorescent Proteins; Humans; Mutation; Pancreas; Pancreatic Neoplasms; Plasmids; Quinazolines; ras Proteins; Recombinant Proteins | 2014 |
Colloidal gold nanoparticle conjugates of gefitinib.
Topics: Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Gold Colloid; Humans; Membranes, Artificial; Metal Nanoparticles; Quinazolines; Serum Albumin, Bovine; Spectrum Analysis, Raman | 2014 |
Tyrosine kinase inhibitors enhance ciprofloxacin-induced phototoxicity by inhibiting ABCG2.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Blotting, Western; Ciprofloxacin; Dermatitis, Phototoxic; Drug Synergism; Flow Cytometry; Gefitinib; Gene Expression Regulation; HEK293 Cells; Humans; Imatinib Mesylate; Neoplasm Proteins; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Quinazolines; Risk Factors | 2014 |
Gefitinib induces cytoplasmic translocation of the CDK inhibitor p27 and its binding to a cleaved intermediate of caspase 8 in non-small cell lung cancer cells.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Caspase 8; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p27; Cytoplasm; Dose-Response Relationship, Drug; Enzyme Activation; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Microscopy, Confocal; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Transport; Quinazolines | 2014 |
Experience with afatinib in patients with non-small cell lung cancer progressing after clinical benefit from gefitinib and erlotinib.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Compassionate Use Trials; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Failure | 2014 |
Molecular diagnostics and therapeutics for ectopic pregnancy.
Topics: Animals; Biomarkers; Female; Gefitinib; Humans; Methotrexate; Pregnancy; Pregnancy, Ectopic; Quinazolines | 2015 |
Plasticity of mammary cell boundaries governed by EGF and actin remodeling.
Topics: Actin Cytoskeleton; Actins; Cadherins; Cell Differentiation; Cell Line; Desmosomes; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Humans; Mammary Glands, Human; Protein Kinase Inhibitors; Quinazolines; Shear Strength; Signal Transduction | 2014 |
Gefitinib inhibits the growth of Toxoplasma gondii in HeLa cells.
Topics: Antiprotozoal Agents; Dose-Response Relationship, Drug; Drug Repositioning; Gefitinib; HeLa Cells; Humans; Parasitic Sensitivity Tests; Quinazolines; Toxoplasma | 2014 |
Gefitinib targets ZAP-70-expressing chronic lymphocytic leukemia cells and inhibits B-cell receptor signaling.
Topics: Cell Survival; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Protein Kinase Inhibitors; Quinazolines; Receptors, Antigen, B-Cell; Signal Transduction; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2014 |
The role of BIM-EL and BCL2-α on the efficacy of erlotinib and gefitinib in lung cancer.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Membrane Proteins; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Real-Time Polymerase Chain Reaction; RNA, Messenger | 2015 |
The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signaling.
Topics: Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Epidermal Growth Factor; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Receptor-Like Protein Tyrosine Phosphatases, Class 3; RNA, Messenger; Signal Transduction; src-Family Kinases | 2014 |
Optimization of gefitinib analogues with potent anticancer activity.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Piperazines; Quinazolines | 2014 |
Crotoxin suppresses the tumorigenic properties and enhances the antitumor activity of Iressa® (gefinitib) in human lung adenocarcinoma SPCA‑1 cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinogenesis; Cell Line, Tumor; Crotoxin; ErbB Receptors; G1 Phase Cell Cycle Checkpoints; Gefitinib; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Neovascularization, Pathologic; Quinazolines | 2014 |
SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Proto-Oncogene Mas; Proto-Oncogene Proteins c-met; Pulsatilla; Quinazolines; Saponins; Signal Transduction | 2014 |
Inhaled tyrosine kinase inhibitors for pulmonary hypertension: a possible future treatment.
Topics: Administration, Inhalation; Benzamides; Erlotinib Hydrochloride; Gefitinib; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2014 |
Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Carcinoma, Hepatocellular; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrazines; Quinazolines; Reactive Oxygen Species; Signal Transduction; src-Family Kinases | 2015 |
Estrogen adversely affects the prognosis of patients with lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; ErbB Receptors; Estradiol; Estrogen Receptor beta; Estrogens; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; MAP Kinase Signaling System; Middle Aged; Osteopontin; Pleural Effusion, Malignant; Prognosis; Prospective Studies; Quinazolines; Transcriptional Activation | 2015 |
MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Computational Biology; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results | 2015 |
Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Eukaryotic Initiation Factor-4E; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Staging; Protein Biosynthesis; Proto-Oncogene Mas; Proto-Oncogene Proteins c-pim-1; Quinazolines; Transcription, Genetic | 2014 |
The effect of gefitinib in patients with postoperative recurrent non-small cell lung cancer harboring mutations of the epidermal growth factor receptor.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Quinazolines; Retrospective Studies | 2015 |
Neutralizing the EGF receptor in glioblastoma cells stimulates cell migration by activating uPAR-initiated cell signaling.
Topics: Animals; Brain Neoplasms; Cell Movement; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Nude; Phosphorylation; Quinazolines; Receptors, Urokinase Plasminogen Activator; RNA, Small Interfering; Signal Transduction; src-Family Kinases; Tumor Cells, Cultured | 2015 |
Long‑term exposure to gefitinib induces acquired resistance through DNA methylation changes in the EGFR‑mutant PC9 lung cancer cell line.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Quinazolines; Time Factors | 2015 |
Gefitinib loaded folate decorated bovine serum albumin conjugated carboxymethyl-beta-cyclodextrin nanoparticles enhance drug delivery and attenuate autophagy in folate receptor-positive cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Autophagy; beta-Cyclodextrins; Cell Survival; Drug Delivery Systems; Folate Receptors, GPI-Anchored; Folic Acid; Gefitinib; HeLa Cells; Humans; Molecular Targeted Therapy; Nanoparticles; Quinazolines; Serum Albumin, Bovine; Spectroscopy, Fourier Transform Infrared | 2014 |
Elevated neutrophil-to-lymphocyte ratio predicts poor outcome in patients with advanced non-small-cell lung cancer receiving first-line gefitinib or erlotinib treatment.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Lymphocytes; Male; Neutrophils; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Treatment Outcome | 2017 |
Long-term survival of non-small-cell lung cancer patients with EGFR inhibitor treatment.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2014 |
Gefitinib inhibits sodium phosphate co-transporter III isoform 1 in a model of human malignant glioma.
Topics: Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Proliferation; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Neoplasm Grading; Phosphates; Protein Isoforms; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sodium-Phosphate Cotransporter Proteins, Type III; Tumor Cells, Cultured | 2014 |
EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin.
Topics: Cadherins; Cell Line, Tumor; Cell Movement; Cell Nucleus; Cell Survival; Collagen; Drug Combinations; ErbB Receptors; Gefitinib; Gene Silencing; Golgi Apparatus; Humans; Laminin; Male; Neoplasm Invasiveness; Phenotype; Phosphorylation; Prostate; Prostatic Neoplasms; Proteoglycans; Pyrimidines; Pyrroles; Quinazolines; Receptor, IGF Type 1 | 2015 |
ProKinO: a unified resource for mining the cancer kinome.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Data Mining; Gefitinib; Gene Ontology; Humans; Hydrophobic and Hydrophilic Interactions; Knowledge Bases; Models, Molecular; Neoplasms; Protein Kinase Inhibitors; Protein Kinases; Quinazolines; Sequence Alignment; Software | 2015 |
Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Fibroblasts; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Male; Membrane Glycoproteins; Middle Aged; Mutation; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Quinazolines; Risk Factors; Treatment Outcome; Tumor Microenvironment | 2015 |
Downregulation of c-Met expression does not enhance the sensitivity of gastric cancer cell line MKN-45 to gefitinib.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Down-Regulation; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Silencing; Humans; Inhibitory Concentration 50; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; RNA, Messenger; Signal Transduction; Stomach Neoplasms; Transfection | 2015 |
Mig-6 overcomes gefitinib resistance by inhibiting EGFR/ERK pathway in non-small cell lung cancer cell lines.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Suppressor Proteins | 2014 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic | 2015 |
Phospholipids of tumor extracellular vesicles stratify gefitinib-resistant nonsmall cell lung cancer cells from gefitinib-sensitive cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Extracts; Cell Line, Tumor; Cytoplasmic Vesicles; Drug Resistance, Neoplasm; Extracellular Space; Gefitinib; Humans; Phospholipids; Quinazolines | 2015 |
Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mucin-1; Mutation; Neoplasm Staging; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Risk Factors; RNA, Messenger; Treatment Outcome; Vascular Endothelial Growth Factor A | 2014 |
Toxic epidermal necrolysis related to AP (pemetrexed plus cisplatin) and gefitinib combination therapy in a patient with metastatic non-small cell lung cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Female; Gefitinib; Glutamates; Guanine; Humans; Lung Neoplasms; Neoplasm Metastasis; Pemetrexed; Quinazolines; Stevens-Johnson Syndrome | 2015 |
Is the evidence of the Supreme Court Ruling of gefitinib litigation in Japan scientific?
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Labeling; Drug Packaging; Gefitinib; Humans; Japan; Lung Diseases, Interstitial; Lung Neoplasms; Product Surveillance, Postmarketing; Quinazolines | 2014 |
New therapy targets resistant non-small-cell lung cancers.
Topics: Afatinib; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cetuximab; Clinical Trials as Topic; Drug Combinations; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; National Cancer Institute (U.S.); Quinazolines; United States | 2014 |
A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma.
Topics: Animals; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Brain Neoplasms; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Glioblastoma; Heterografts; Humans; Membrane Proteins; Mice; Mice, Nude; Proto-Oncogene Proteins; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction | 2015 |
EGFR inhibitor-driven endoplasmic reticulum stress-mediated injury on intestinal epithelial cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Cell Line; Crown Ethers; Diarrhea; Endoplasmic Reticulum Stress; ErbB Receptors; Gefitinib; Intestinal Mucosa; Protein Kinase Inhibitors; Quinazolines; Rats | 2014 |
Current status and study activity of lung cancer in Japan.
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Research | 2014 |
Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Disease-Free Survival; Drugs, Chinese Herbal; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies | 2014 |
Identification of novel 4-anilinoquinazoline derivatives as potent EGFR inhibitors both under normoxia and hypoxia.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Binding Sites; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HT29 Cells; Humans; Molecular Docking Simulation; NADP; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2014 |
EGFR inhibitor Gefitinib attenuates posterior capsule opacification in vitro and in the ex vivo human capsular bag model.
Topics: Adult; Aged; Capsule Opacification; Cell Line; Cell Movement; Cell Proliferation; Epithelial Cells; ErbB Receptors; Gefitinib; Humans; Lens, Crystalline; Materials Testing; Middle Aged; Neuroglia; Posterior Capsule of the Lens; Protein Kinase Inhibitors; Quinazolines; Retinal Pigment Epithelium | 2015 |
Modification of topoisomerases in mammospheres derived from breast cancer cell line: clinical implications for combined treatments with tyrosine kinase inhibitors.
Topics: Animals; Antigens, Surface; Breast Neoplasms; Camptothecin; Cell Line, Tumor; Cell Survival; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Synergism; Enzyme Activation; Etoposide; Female; Gefitinib; Humans; Immunophenotyping; MCF-7 Cells; Mice; Neoplastic Stem Cells; Quinazolines; Spheroids, Cellular; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2014 |
Sequence-dependent antiproliferative effects of gefitinib and docetaxel on non-small cell lung cancer (NSCLC) cells and the possible mechanism.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Administration Schedule; ErbB Receptors; Gefitinib; Genes, ras; Humans; Lung Neoplasms; MAP Kinase Signaling System; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2014 |
Biomarkers for predicting response to tyrosine kinase inhibitors in drug-sensitive and drug-resistant human bladder cancer cells.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Biomarkers, Tumor; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Genes, p53; Humans; Lapatinib; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Mutation; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Urinary Bladder Neoplasms | 2015 |
Establishment and biological characteristics of acquired gefitinib resistance in cell line NCI-H1975/gefinitib-resistant with epidermal growth factor receptor T790M mutation.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; ras Proteins | 2015 |
Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Chemokine CCL2; ErbB Receptors; Fibrosis; Gefitinib; Heart Ventricles; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Myocardial Contraction; Myocytes, Cardiac; Myofibroblasts; Quinazolines; RNA, Messenger; Tumor Necrosis Factor-alpha; Ventricular Remodeling | 2015 |
Amelioration of hypercholesterolemia by an EGFR tyrosine kinase inhibitor in mice with liver-specific knockout of Mig-6.
Topics: Animals; Blotting, Western; Cells, Cultured; Cholesterol; ErbB Receptors; Gefitinib; Hypercholesterolemia; Integrases; Intracellular Signaling Peptides and Proteins; Lipids; Liver; Male; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Triglycerides | 2014 |
Autophagosome-mediated EGFR down-regulation induced by the CK2 inhibitor enhances the efficacy of EGFR-TKI on EGFR-mutant lung cancer cells with resistance by T790M.
Topics: Apoptosis; Autophagy; Casein Kinase II; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Naphthyridines; Phagosomes; Phenazines; Protein Kinase Inhibitors; Quinazolines | 2014 |
Enoxaparin sensitizes human non-small-cell lung carcinomas to gefitinib by inhibiting DOCK1 expression, vimentin phosphorylation, and Akt activation.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Enoxaparin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; rac GTP-Binding Proteins; Vimentin; Xenograft Model Antitumor Assays | 2015 |
Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genetic Vectors; Humans; Mice; Phosphatidylinositol 3-Kinase; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2015 |
Acquired resistance to EGFR tyrosine kinase inhibitor in A431 squamous cell carcinoma xenografts is mediated by c-Kit pathway transduction.
Topics: Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-kit; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Breast Neoplasms; Calcitriol; Caspase 3; Cell Cycle; Cell Proliferation; Drug Synergism; Female; Gefitinib; Humans; Membrane Proteins; Proto-Oncogene Proteins; Quinazolines; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Vitamins | 2015 |
Long-term outcome of surgical resection for residual or regrown advanced non-small cell lung carcinomas following EGFR-TKI treatment: report of four cases.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Neoplasm, Residual; Pneumonectomy; Quinazolines | 2016 |
Effect of KRAS exon 2 mutations on antitumor activity of afatinib and gefitinib.
Topics: Afatinib; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Colorectal Neoplasms; ErbB Receptors; Exons; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Mutation; Phosphorylation; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor, ErbB-2; Receptor, ErbB-3 | 2015 |
Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Quinazolines; RNA, Small Interfering; Signal Transduction | 2015 |
The scaffolding protein NHERF1 sensitizes EGFR-dependent tumor growth, motility and invadopodia function to gefitinib treatment in breast cancer cells.
Topics: Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Neoplasm Invasiveness; Phosphoproteins; Plakins; Protein Transport; Pseudopodia; Quinazolines; Sodium-Hydrogen Exchangers; Triple Negative Breast Neoplasms; Tumor Cells, Cultured | 2015 |
A peptide antigen derived from EGFR T790M is immunogenic in non‑small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HLA-A2 Antigen; Humans; Immunotherapy; Mutation; Peptides; Quinazolines | 2015 |
EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Colonic Neoplasms; Drug Synergism; Enhancer of Zeste Homolog 2 Protein; ErbB Receptors; Gefitinib; Gene Expression; Humans; Phosphorylation; Polycomb Repressive Complex 2; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering | 2014 |
Histologic evolution from adenocarcinoma to squamous cell carcinoma after gefitinib treatment.
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Quinazolines | 2015 |
Can EGFR mutation status be reliably determined in pre-operative needle biopsies from adenocarcinomas of the lung?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Preoperative Care; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Analysis, DNA | 2015 |
γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Topics: Amyloid Precursor Protein Secretases; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred BALB C; Oxadiazoles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Sulfonamides | 2015 |
Differential Effects of Tyrosine Kinase Inhibitors on Normal and Oncogenic EGFR Signaling and Downstream Effectors.
Topics: Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-cbl; Quinazolines; Signal Transduction; STAT5 Transcription Factor | 2015 |
Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Epidemiologic Methods; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
Gefitinib extends survival in some esophageal cancers.
Topics: Antineoplastic Agents; Clinical Trials, Phase III as Topic; ErbB Receptors; Esophageal Neoplasms; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2015 |
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway.
Topics: Apoptosis; Cell Line, Tumor; Cell Survival; Chromones; Drug Interactions; ErbB Receptors; Female; Gefitinib; Humans; Oligopeptides; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor, ErbB-2; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2015 |
Des-gamma-carboxy prothrombin (DCP) antagonizes the effects of gefitinib on human hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers; Carcinoma, Hepatocellular; Caspases; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Gefitinib; Hep G2 Cells; Hepatocyte Growth Factor; Humans; Liver Neoplasms; Protein Precursors; Prothrombin; Proto-Oncogene Proteins c-met; Quinazolines; Up-Regulation | 2015 |
DUSP1 expression induced by HDAC1 inhibition mediates gefitinib sensitivity in non-small cell lung cancers.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Dual Specificity Phosphatase 1; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Histone Deacetylase 1; Histone Deacetylase Inhibitors; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice, Inbred BALB C; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
A kinase-independent role for EGF receptor in autophagy initiation.
Topics: Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Proteins; Beclin-1; Cell Line, Tumor; Endosomes; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Intracellular Signaling Peptides and Proteins; Membrane Proteins; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines; Vesicular Transport Proteins | 2015 |
Tyrosine 370 phosphorylation of ATM positively regulates DNA damage response.
Topics: Amino Acid Sequence; Ataxia Telangiectasia Mutated Proteins; Cell Line, Tumor; Checkpoint Kinase 2; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Gefitinib; HeLa Cells; Humans; Phosphorylation; Quinazolines; Radiation, Ionizing; RNA Interference; RNA, Small Interfering; Signal Transduction; Tyrosine | 2015 |
Efficacy and survival-associated factors with gefitinib combined with cisplatin and gemcitabine for advanced non- small cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cisplatin; Deoxycytidine; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Survival Rate; Young Adult | 2014 |
Hsp90 inhibitor NVP-AUY922 enhances the radiation sensitivity of lung cancer cell lines with acquired resistance to EGFR-tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; DNA End-Joining Repair; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Protein Kinase Inhibitors; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Resorcinols | 2015 |
The evidence of glioblastoma heterogeneity.
Topics: Animals; Antigens, CD; Brain Neoplasms; Collagen Type I; Collagen Type I, alpha 1 Chain; Disease Models, Animal; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin-Like Growth Factor Binding Proteins; Kaplan-Meier Estimate; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transplantation, Heterologous; Tumor Cells, Cultured | 2015 |
[Effect of recombinant human p53 adenovirus (Ad-p53) combined with EGFR inhibitor gefitinib on the sensitivity of breast cancer MDA-MB-468 cells].
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Caspase 3; Caspase 9; Cell Line, Tumor; Down-Regulation; Gefitinib; Genes, p53; Humans; Mice; Mice, Nude; Phosphatidylinositol 3-Kinases; Quinazolines | 2014 |
Radiation myelitis after hypofractionated radiotherapy with concomitant gefitinib.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Dose Fractionation, Radiation; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Myelitis; Palliative Care; Quinazolines; Radiation Injuries; Spinal Neoplasms; Thoracic Vertebrae | 2015 |
AURKA upregulation plays a role in fibroblast-reduced gefitinib sensitivity in the NSCLC cell line HCC827.
Topics: Antineoplastic Agents; Aurora Kinase A; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Coculture Techniques; Drug Resistance, Neoplasm; Enzyme Induction; ErbB Receptors; Fibroblasts; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Genes, erbB-1; Humans; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-mdm2; Quinazolines; Recombinant Fusion Proteins; RNA Interference; RNA, Small Interfering; Signal Transduction; Stromal Cells; Tumor Suppressor Protein p53; Up-Regulation | 2015 |
Gender-based impact of epidermal growth factor receptor mutation in patients with nonsmall cell lung cancer and previous tuberculosis.
Topics: Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sex Factors; Taiwan; Tuberculosis, Pulmonary | 2015 |
CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Topics: Antineoplastic Agents; Cell Line, Tumor; CpG Islands; Cyclin D1; DNA Methylation; Drug Resistance, Neoplasm; Early Growth Response Protein 1; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Humans; Intercellular Adhesion Molecule-1; Lung Neoplasms; Phosphorylation; Promoter Regions, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines | 2015 |
Ets1 identified as a novel molecular target of RNA aptamer selected against metastatic cells for targeted delivery of nano-formulation.
Topics: Animals; Antineoplastic Agents; Aptamers, Nucleotide; Cell Line, Tumor; Cell Membrane Permeability; Drug Carriers; Female; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Mice, Nude; Nanoparticles; Neoplasm Metastasis; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Proto-Oncogene Protein c-ets-1; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Estrogen Receptor beta; Female; Gefitinib; Humans; MAP Kinase Kinase 1; MAP Kinase Kinase 2; MCF-7 Cells; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Phosphorylation; Quinazolines; RNA, Messenger; Signal Transduction; Tamoxifen; Up-Regulation | 2015 |
Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2.
Topics: Adenocarcinoma; Antineoplastic Agents; Autophagy; Cell Survival; Cytoplasm; Enzyme Activation; Extracellular Fluid; Gefitinib; HMGB1 Protein; Humans; MAP Kinase Signaling System; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor for Advanced Glycation End Products; RNA Interference; RNA, Small Interfering; Stomach Neoplasms; Transfection | 2015 |
EGF‑stimulated AKT activation is mediated by EGFR recycling via an early endocytic pathway in a gefitinib‑resistant human lung cancer cell line.
Topics: Cell Line, Tumor; Cell Membrane; Drug Resistance, Neoplasm; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Monensin; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Sorting Nexins | 2015 |
SMARCE1 suppresses EGFR expression and controls responses to MET and ALK inhibitors in lung cancer.
Topics: Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosomal Proteins, Non-Histone; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Polycomb Repressive Complex 1; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction | 2015 |
Target modulation by a kinase inhibitor engineered to induce a tandem blockade of the epidermal growth factor receptor (EGFR) and c-Src: the concept of type III combi-targeting.
Topics: Animals; Apoptosis; Binding Sites; Cell Line, Tumor; Cell Movement; Cell Proliferation; CSK Tyrosine-Protein Kinase; Dasatinib; Drug Design; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Molecular Dynamics Simulation; Neoplasms; NIH 3T3 Cells; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; src-Family Kinases; Thiazoles; Transplantation, Heterologous | 2015 |
Down-regulation of ERK1/2 and AKT-mediated X-ray repair cross-complement group 1 protein (XRCC1) expression by Hsp90 inhibition enhances the gefitinib-induced cytotoxicity in human lung cancer cells.
Topics: Antineoplastic Agents; Cell Proliferation; DNA-Binding Proteins; Dose-Response Relationship, Drug; Down-Regulation; Drug Screening Assays, Antitumor; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger; Signal Transduction; Structure-Activity Relationship; Tumor Cells, Cultured; X-ray Repair Cross Complementing Protein 1 | 2015 |
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Treatment Outcome | 2015 |
Adaptive Upregulation of EGFR Limits Attenuation of Tumor Growth by Neutralizing IL6 Antibodies, with Implications for Combined Therapy in Ovarian Cancer.
Topics: Animals; Antibodies, Neutralizing; Antineoplastic Combined Chemotherapy Protocols; Cell Nucleus; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-6; MAP Kinase Signaling System; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Protein Transport; Quinazolines; STAT3 Transcription Factor; Tumor Burden; Up-Regulation; Xenograft Model Antitumor Assays | 2015 |
Recurrent gain-of-function USP8 mutations in Cushing's disease.
Topics: 14-3-3 Proteins; ACTH-Secreting Pituitary Adenoma; Adolescent; Adrenocorticotropic Hormone; Adult; Base Sequence; Cushing Syndrome; Endopeptidases; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Exome; Female; Gefitinib; Humans; Male; Middle Aged; Pro-Opiomelanocortin; Protein Binding; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Sequence Analysis, DNA; Ubiquitin Thiolesterase; Young Adult | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
Gefitinib-mediated reactive oxygen specie (ROS) instigates mitochondrial dysfunction and drug resistance in lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Mitochondria; Quinazolines; Reactive Oxygen Species | 2015 |
Hypermethylation of the CpG dinucleotide in epidermal growth factor receptor codon 790: implications for a mutational hotspot leading to the T790M mutation in non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; CpG Islands; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; MCF-7 Cells; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA | 2015 |
Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glycosylation; Humans; Metabolic Engineering; Pancreatic Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; STAT Transcription Factors | 2015 |
Statins augment efficacy of EGFR-TKIs in patients with advanced-stage non-small cell lung cancer harbouring KRAS mutation.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins | 2015 |
Preclinical evaluation of (99m)Tc labeled gefitinib as a potential scintigraphic probe for the detection of tumors expressing epidermal growth factor receptors.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cell Line, Tumor; Contrast Media; ErbB Receptors; Gefitinib; Humans; Isotope Labeling; Metabolic Clearance Rate; Mice; Mice, Inbred BALB C; Molecular Probe Techniques; Molecular Probes; Quinazolines; Rabbits; Radionuclide Imaging; Reproducibility of Results; Sensitivity and Specificity; Technetium; Tissue Distribution | 2015 |
Chronic nicotine exposure mediates resistance to EGFR-TKI in EGFR-mutated lung cancer via an EGFR signal.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Nicotine; Quinazolines; Receptors, Nicotinic; Signal Transduction; Smoking | 2015 |
Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
Topics: Afatinib; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Mutation; Quinazolines; Radiation-Sensitizing Agents; Random Allocation; Xenograft Model Antitumor Assays | 2015 |
Factors associated with a poor response to gefitinib in the NEJ002 study: smoking and the L858R mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Smoking; Treatment Outcome | 2015 |
Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carbolines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Molecular Docking Simulation; Molecular Targeted Therapy; Mutation; Phosphorylation; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Disease flare after gefitinib discontinuation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease Progression; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Withholding Treatment | 2015 |
Liver metastasis predicts poorer prognosis in stage IV lung adenocarcinoma patients receiving first-line gefitinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides | 2015 |
Targeting the degradation of AXL receptor tyrosine kinase to overcome resistance in gefitinib-resistant non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Random Allocation; Receptor Protein-Tyrosine Kinases; Xenograft Model Antitumor Assays | 2015 |
Effects of cytokines on CYP3A4 expression and reversal of the effects by anti-cytokine agents in the three-dimensionally cultured human hepatoma cell line FLC-4.
Topics: Antibodies, Monoclonal, Humanized; Blotting, Western; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Down-Regulation; Gefitinib; Humans; Interleukin-1beta; Interleukin-6; Paclitaxel; Quinazolines; Receptors, Interleukin-1; Substrate Specificity; Tumor Necrosis Factor-alpha | 2015 |
Gefitinib-Induced Interstitial Lung Disease in Korean Lung Cancer Patients.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Quinazolines; Retrospective Studies; Seoul | 2016 |
CI-988 Inhibits EGFR Transactivation and Proliferation Caused by Addition of CCK/Gastrin to Lung Cancer Cells.
Topics: 1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dipeptides; ErbB Receptors; Gastrins; Gefitinib; Hormone Antagonists; Humans; Indoles; Lung Neoplasms; Meglumine; Pyrimidines; Quinazolines | 2015 |
AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
Topics: Animals; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Cell Movement; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, SCID; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Receptor Protein-Tyrosine Kinases; Resorcinols; Xenograft Model Antitumor Assays | 2015 |
TPN-associated intestinal epithelial cell atrophy is modulated by TLR4/EGF signaling pathways.
Topics: Animals; Apoptosis; Atrophy; Cell Proliferation; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Interferon-gamma; Intestinal Mucosa; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Parenteral Nutrition, Total; Quinazolines; RNA, Messenger; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Galectin-3 knockdown increases gefitinib sensitivity to the inhibition of EGFR endocytosis in gefitinib-insensitive esophageal squamous cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Cycle; Cell Movement; Cell Proliferation; Endocytosis; ErbB Receptors; Esophageal Neoplasms; Galectin 3; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphorylation; Quinazolines; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Blood-brain barrier permeability of gefitinib in patients with brain metastases from non-small-cell lung cancer before and during whole brain radiation therapy.
Topics: Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Prognosis; Quinazolines; Young Adult | 2015 |
EGF Receptor Inhibition Alleviates Hyperuricemic Nephropathy.
Topics: Animals; Chemokines; Cytokines; Disease Progression; ErbB Receptors; Fibroblasts; Fibrosis; Gefitinib; Hyperuricemia; Inflammation; Kidney; Kidney Diseases; Male; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Risk Factors; Signal Transduction; Transforming Growth Factor beta; Transforming Growth Factor beta1; Uric Acid | 2015 |
Synthesis, reactivity, and biological activity of gold(I) complexes modified with thiourea-functionalized tyrosine kinase inhibitors.
Topics: Afatinib; Cell Line; Cell Line, Tumor; Cell Proliferation; Coordination Complexes; Dose-Response Relationship, Drug; Gefitinib; Gold; Humans; Inhibitory Concentration 50; Protein Kinase Inhibitors; Quinazolines; Thiourea | 2015 |
Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells.
Topics: Adenine; Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chloroquine; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2015 |
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms.
Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured | 2015 |
ANO1/TMEM16A interacts with EGFR and correlates with sensitivity to EGFR-targeting therapy in head and neck cancer.
Topics: Anoctamin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Chloride Channels; ErbB Receptors; Fusion Regulatory Protein 1, Heavy Chain; Gefitinib; Head and Neck Neoplasms; HEK293 Cells; Humans; Multiprotein Complexes; Mutation; Neoplasm Proteins; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Squamous Cell Carcinoma of Head and Neck | 2015 |
Minimal change nephrotic syndrome associated with gefitinib and a successful switch to erlotinib.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Neoplasm Recurrence, Local; Nephrosis, Lipoid; Protein Kinase Inhibitors; Quinazolines | 2015 |
Combined treatment with silibinin and either sorafenib or gefitinib enhances their growth-inhibiting effects in hepatocellular carcinoma cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Liver Neoplasms; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Silybin; Silymarin; Sorafenib | 2015 |
Characterization of interaction of calf thymus DNA with gefitinib: spectroscopic methods and molecular docking.
Topics: Animals; Binding, Competitive; Cattle; Circular Dichroism; DNA; Gefitinib; Hydrogen Bonding; Molecular Docking Simulation; Nucleic Acid Conformation; Osmolar Concentration; Quinazolines; Spectrophotometry, Ultraviolet; Thermodynamics; Viscosity | 2015 |
Variation in transplacental transfer of tyrosine kinase inhibitors in the human perfused cotyledon model.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Fetus; Gefitinib; Humans; Imatinib Mesylate; Lung Neoplasms; Maternal-Fetal Exchange; Mutation; Perfusion; Placenta; Pregnancy; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Discovery of 2',4'-dimethoxychalcone as a Hsp90 inhibitor and its effect on iressa-resistant non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chalcones; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
EGFR-independent autophagy induction with gefitinib and enhancement of its cytotoxic effect by targeting autophagy with clarithromycin in non-small cell lung cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Clarithromycin; Drug Synergism; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Treatment Outcome | 2015 |
An Integrative Analysis of the Putative Gefitinib-resistance Related Genes in a Lung Cancer Cell Line Model System.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromosome Mapping; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Signal Transduction | 2015 |
Current two EGFR mutations in lung adenocarcinoma - case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Radiography | 2015 |
10-year long-term survival of a metastatic EGFR-mutated nonsmall cell lung cancer patient.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Metastasis; Protein-Tyrosine Kinases; Quinazolines; Treatment Outcome | 2015 |
MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Proto-Oncogene Proteins c-met; Quinazolines | 2015 |
EGFR Mutant Structural Database: computationally predicted 3D structures and the corresponding binding free energies with gefitinib and erlotinib.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Protein; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; ROC Curve; Tissue Distribution; Tomography, X-Ray Computed; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2015 |
Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway.
Topics: 6-Aminonicotinamide; Afatinib; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Glucose; Humans; Metabolome; Multiple Myeloma; Oxygen; Pentose Phosphate Pathway; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; ras Proteins; Receptor, ErbB-2; RNA, Small Interfering; TOR Serine-Threonine Kinases | 2015 |
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; DNA Mutational Analysis; Drug Resistance, Neoplasm; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Mutation; Proportional Hazards Models; Quinazolines; Sequence Analysis, DNA | 2015 |
Inhibition of SN-38 glucuronidation by gefitinib and its metabolite.
Topics: Antineoplastic Agents, Phytogenic; Area Under Curve; Camptothecin; Drug Combinations; Drug Interactions; Gefitinib; Glucuronosyltransferase; Humans; Irinotecan; Microsomes, Liver; Quinazolines | 2015 |
The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Down-Regulation; Drug Resistance, Neoplasm; Female; Flow Cytometry; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; RNA, Long Noncoding; Transfection; Xenograft Model Antitumor Assays | 2015 |
Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Humans; Janus Kinases; Mice; Ovarian Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Small Molecule Libraries; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
Non small cell carcinoma of lung with metachronous breast metastasis and cardiac tamponade: Unusual presentation of a common cancer.
Topics: Adult; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Ductal, Breast; Carcinoma, Non-Small-Cell Lung; Cardiac Tamponade; Deoxycytidine; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Neoplasms, Second Primary; Quinazolines; Radiography | 2015 |
[Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; DNA Methylation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines | 2015 |
The Effects and Molecular Mechanisms of MiR-106a in Multidrug Resistance Reversal in Human Glioma U87/DDP and U251/G Cell Lines.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cisplatin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Glioma; Humans; MicroRNAs; Quinazolines | 2015 |
Primary TKI resistance in advanced non-small cell lung cancer with EGFR mutation: an open question.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Tomography, X-Ray Computed | 2015 |
Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenosquamous; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Time Factors; Treatment Outcome | 2015 |
Dual inhibition of EGFR and MET induces synthetic lethality in triple-negative breast cancer cells through downregulation of ribosomal protein S6.
Topics: Cell Line, Tumor; Cell Survival; Down-Regulation; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Indoles; Peptide Library; Piperazines; Proto-Oncogene Proteins c-met; Quinazolines; Ribosomal Protein S6; Sulfonamides; Triple Negative Breast Neoplasms | 2015 |
EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Topics: Apoptosis; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Kinase Kinases; MAP Kinase Signaling System; Oncogene Protein v-akt; Protein Kinase Inhibitors; Quinazolines; Triple Negative Breast Neoplasms | 2015 |
Chemical Proteomics Uncovers EPHA2 as a Mechanism of Acquired Resistance to Small Molecule EGFR Kinase Inhibition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Proteomics; Quinazolines; Receptor, EphA2 | 2015 |
Using the MCF10A/MCF10CA1a Breast Cancer Progression Cell Line Model to Investigate the Effect of Active, Mutant Forms of EGFR in Breast Cancer Development and Treatment Using Gefitinib.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Class I Phosphatidylinositol 3-Kinases; DNA Copy Number Variations; Drug Resistance, Neoplasm; ErbB Receptors; Exome; Female; Gefitinib; Gene Expression; Humans; Mice; Mice, Nude; Models, Biological; Mutation; Phosphatidylinositol 3-Kinases; Plasmids; Protein Kinase Inhibitors; Quinazolines; Transfection; Xenograft Model Antitumor Assays | 2015 |
Effect of sialylation on EGFR phosphorylation and resistance to tyrosine kinase inhibition.
Topics: Cell Line, Tumor; Dimerization; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Mutation, Missense; Neuraminidase; Phosphorylation; Protein Binding; Protein-Tyrosine Kinases; Quinazolines | 2015 |
ROS1 amplification mediates resistance to gefitinib in glioblastoma cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Drug Synergism; Gefitinib; Gene Amplification; Glioblastoma; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Quinazolines; S Phase | 2015 |
Autophagy Inhibition Overcomes the Antagonistic Effect Between Gefitinib and Cisplatin in Epidermal Growth Factor Receptor Mutant Non--Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chloroquine; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2015 |
Combined effects of EGFR tyrosine kinase inhibitors and vATPase inhibitors in NSCLC cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Lapatinib; Lung Neoplasms; Macrolides; Membrane Proteins; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; RNA Interference; Transfection; Vacuolar Proton-Translocating ATPases | 2015 |
Marsdenia tenacissima extract enhances gefitinib efficacy in non-small cell lung cancer xenografts.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Synergism; Drugs, Chinese Herbal; Gefitinib; Male; Marsdenia; Mice, Inbred BALB C; Mice, Nude; Plant Extracts; Quinazolines; Xenograft Model Antitumor Assays | 2015 |
Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cisplatin; Deoxycytidine; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Paclitaxel; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2015 |
Contribution of EGFR and ErbB-3 Heterodimerization to the EGFR Mutation-Induced Gefitinib- and Erlotinib-Resistance in Non-Small-Cell Lung Carcinoma Treatments.
Topics: Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Dynamics Simulation; Mutant Proteins; Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Multimerization; Quinazolines; Receptor, ErbB-3; Regression Analysis; Signal Transduction; Structural Homology, Protein; Thermodynamics | 2015 |
Interference of STAT 5b expression enhances the chemo-sensitivity of gastric cancer cells to gefitinib by promoting mitochondrial pathway-mediated cell apoptosis.
Topics: Aged; Aged, 80 and over; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Mitochondria; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Signal Transduction; STAT5 Transcription Factor; Stomach Neoplasms | 2015 |
The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non-Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors.
Topics: Aged; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Retrospective Studies | 2015 |
Highly sensitive HPLC-DAD method for the assay of gefitinib in patient plasma and cerebrospinal fluid: application to a blood-brain barrier penetration study.
Topics: Blood-Brain Barrier; Brain Neoplasms; Chromatography, High Pressure Liquid; Gefitinib; Humans; Linear Models; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Solid Phase Extraction | 2015 |
An important role for peroxiredoxin II in survival of A549 lung cancer cells resistant to gefitinib.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Oxidative Stress; Peroxiredoxins; Quinazolines; Reactive Oxygen Species | 2015 |
Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Body Surface Area; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Quinazolines; Survival Rate | 2015 |
Exon 19 deletion was associated with better survival outcomes in advanced lung adenocarcinoma with mutant EGFR treated with EGFR-TKIs as second-line therapy after first-line chemotherapy: a retrospective analysis of 128 patients.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion; Survival Rate | 2015 |
Increased survival with the combination of stereotactic radiosurgery and gefitinib for non-small cell lung cancer brain metastasis patients: a nationwide study in Taiwan.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Comorbidity; Female; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Quinazolines; Radiosurgery; Retrospective Studies; Taiwan; Treatment Outcome | 2015 |
Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Heterografts; Humans; Lung Neoplasms; Mice, SCID; Mutation; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2015 |
Modern Treatments in Advanced Non-Small-Cell Lung Cancer: Temporal Trends and Effect on Survival. A French Population-Based Study.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Follow-Up Studies; France; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Staging; Platinum Compounds; Population Groups; Quinazolines; Survival Analysis; Treatment Outcome | 2015 |
Sequential use of vinorelbine followed by gefitinib enhances the antitumor effect in NSCLC cell lines poorly responsive to reversible EGFR tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Radionuclide Imaging; Radiopharmaceuticals; Signal Transduction; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays | 2015 |
TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Focal Adhesion Protein-Tyrosine Kinases; Gefitinib; Humans; Lung Neoplasms; Mice; Morpholines; Mutation; Protein Binding; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Xenograft Model Antitumor Assays | 2015 |
ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations.
Topics: 3T3 Cells; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; China; Drug Resistance, Neoplasm; ErbB Receptors; Estradiol; Estrogen Receptor Antagonists; Estrogen Receptor beta; Female; Fulvestrant; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Male; MCF-7 Cells; Mice; Middle Aged; Protein Kinase Inhibitors; Quinazolines | 2015 |
Decision to adopt medical technology under the National Health Insurance System in Taiwan: case study of new molecular targeted drugs among non-small cell lung cancer patients.
Topics: Adult; Age Factors; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Databases, Factual; Decision Making; Drug Utilization; Erlotinib Hydrochloride; Female; Gefitinib; Hospital Administration; Humans; Logistic Models; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; National Health Programs; Ownership; Quinazolines; Residence Characteristics; Taiwan | 2015 |
[Molecular targeted therapies and cytotoxics: Friends or foes?].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Molecular Targeted Therapy; Quinazolines | 2015 |
t-Darpp Promotes Enhanced EGFR Activation and New Drug Synergies in Her2-Positive Breast Cancer Cells.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dopamine and cAMP-Regulated Phosphoprotein 32; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Quinazolines; Receptor, ErbB-2; Trastuzumab; Tyrphostins | 2015 |
MMP9, Cyclin D1 and β-Catenin Are Useful Markers of p16-positive Squamous Cell Carcinoma in Therapeutic EGFR Inhibition In Vitro.
Topics: Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Cyclin D1; Epigenesis, Genetic; ErbB Receptors; Gefitinib; Human papillomavirus 16; Humans; Lapatinib; Matrix Metalloproteinase 9; Quinazolines; Vimentin | 2015 |
Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Retrospective Studies; Sequence Deletion | 2015 |
The therapy of gefitinib towards breast cancer partially through reversing breast cancer biomarker arginine.
Topics: Adult; Antineoplastic Agents; Area Under Curve; Arginine; Breast Neoplasms; Case-Control Studies; Female; Gefitinib; Humans; Mass Spectrometry; Metabolomics; Predictive Value of Tests; Quinazolines; ROC Curve; Sensitivity and Specificity | 2015 |
Relevance of E-cadherin expression to EGFR-TKI molecular targeted therapy sensitivity/resistance and its clinical significance.
Topics: Breast Neoplasms; Cadherins; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2015 |
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function.
Topics: Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Cyclins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MAP Kinase Signaling System; Membrane Proteins; Models, Biological; Mutation; Neoplasm Proteins; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Protein c-ets-1; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; ras Proteins; RNA, Messenger; src-Family Kinases | 2015 |
Lovastatin overcomes gefitinib resistance through TNF-α signaling in human cholangiocarcinomas with different LKB1 statuses in vitro and in vivo.
Topics: AMP-Activated Protein Kinase Kinases; Animals; Antineoplastic Agents; Apoptosis; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cholangiocarcinoma; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Lung Neoplasms; Male; Mice; Mice, Inbred ICR; Protein Serine-Threonine Kinases; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Tumor Necrosis Factor-alpha; Xenograft Model Antitumor Assays | 2015 |
Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells.
Topics: Apoptosis; Breast Neoplasms; Cell Proliferation; Cell Survival; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Estrogen Receptor alpha; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Poly (ADP-Ribose) Polymerase-1; Poly(ADP-ribose) Polymerases; Quinazolines; Quinolines; Receptor, ErbB-2; Tamoxifen | 2015 |
Homoharringtonine induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal pathway in Gefitinib-resistant lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Docetaxel; Drug Resistance, Neoplasm; Drug Synergism; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Gefitinib; Harringtonines; Homoharringtonine; Humans; Interleukin-6; Janus Kinase 1; Lung Neoplasms; Male; Mice; Mice, Nude; Mitochondria; Phosphorylation; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Taxoids; Transplantation, Heterologous | 2015 |
Continuation of epidermal growth factor receptor tyrosine kinase inhibitor treatment prolongs disease control in non-small-cell lung cancers with acquired resistance to EGFR tyrosine kinase inhibitors.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Disease Progression; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Outcome Assessment, Health Care; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Time Factors | 2015 |
Treatment with cucurbitacin B alone and in combination with gefitinib induces cell cycle inhibition and apoptosis via EGFR and JAK/STAT pathway in human colorectal cancer cell lines.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Cell Cycle; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Janus Kinases; Microscopy, Fluorescence; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction; STAT Transcription Factors; Triterpenes | 2016 |
MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration, Invasion, and Gefitinib Resistance in Non-Small Cell Lung Cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Base Sequence; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Neoplasm Invasiveness; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference | 2015 |
Bidirectional signaling between TM4SF5 and IGF1R promotes resistance to EGFR kinase inhibitors.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Spheroids, Cellular | 2015 |
[A Case of Pneumatosis Cystoides Intestinalis Secondary to Gefitinib Therapy for Lung Adenocarcinoma].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Diarrhea; Gefitinib; Humans; Lung Neoplasms; Male; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed; Vomiting | 2015 |
Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non-Small-Cell Lung Cancer with Activating EGFR Mutation.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Glycolysis; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Positron-Emission Tomography; Predictive Value of Tests; Quinazolines; Survival Rate | 2015 |
Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.
Topics: Aniline Compounds; Cell Cycle Proteins; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; Heterocyclic Compounds, 2-Ring; Humans; Models, Molecular; Molecular Structure; Neoplasms; Point Mutation; Protein Binding; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein Structure, Tertiary; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines | 2015 |
Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Communication; Cell Line, Tumor; Chromones; Connexin 26; Connexins; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Female; Gap Junctions; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Nude; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2015 |
First Reported Case of Unexpected Response to an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the I744M Uncommon EGFR Mutation.
Topics: Aged; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; Diarrhea; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Respiratory Sounds; Treatment Outcome | 2015 |
An unusual bowel complication during molecularly-targeted therapy.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Emphysema; Female; Gefitinib; Humans; Intestinal Diseases; Lung Neoplasms; Pneumoperitoneum; Quinazolines; Tomography, X-Ray Computed | 2015 |
Metabolomics reveals the formation of aldehydes and iminium in gefitinib metabolism.
Topics: Aldehydes; Animals; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; ErbB Receptors; Gefitinib; Humans; Imines; Isoenzymes; Membrane Proteins; Metabolic Detoxication, Phase I; Metabolic Detoxication, Phase II; Metabolomics; Mice; Mice, Knockout; Microsomes, Liver; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Recombinant Proteins | 2015 |
The Dissociation of Gefitinib Trough Concentration and Clinical Outcome in NSCLC Patients with EGFR Sensitive Mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Disease-Free Survival; Dose-Response Relationship, Drug; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Tandem Mass Spectrometry; Treatment Outcome | 2015 |
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.
Topics: Antineoplastic Agents; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Molecular Docking Simulation; Quinazolines; Receptor, ErbB-2; Retrospective Studies | 2015 |
Gefitinib Approved for EGFR-Mutated NSCLC.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Approval; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; United States; United States Food and Drug Administration | 2015 |
Novel quinazoline derivatives exhibit antitumor activity by inhibiting JAK2/STAT3.
Topics: Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Janus Kinase 2; Mice; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2015 |
First-line gefitinib treatment in elderly patients (aged ≥75 years) with non-small cell lung cancer harboring EGFR mutations.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Drug Monitoring; ErbB Receptors; Feasibility Studies; Female; Follow-Up Studies; Gefitinib; Humans; Incidence; Japan; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Severity of Illness Index; Survival Analysis | 2015 |
Copper improves the anti-angiogenic activity of disulfiram through the EGFR/Src/VEGF pathway in gliomas.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Disulfiram; Drug Synergism; ErbB Receptors; Gefitinib; Glioma; Gluconates; Human Umbilical Vein Endothelial Cells; Humans; Male; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Signal Transduction; src-Family Kinases; Tumor Burden; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor Assays | 2015 |
Cost-effectiveness analysis of EGFR mutation testing and gefitinib as first-line therapy for non-small cell lung cancer.
Topics: Administration, Intravenous; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Decision Support Techniques; DNA Mutational Analysis; Economics, Pharmaceutical; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Markov Chains; Mutation; Paclitaxel; Precision Medicine; Protein Kinase Inhibitors; Quinazolines; Young Adult | 2015 |
PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Topics: Acridines; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Cell Line, Tumor; Drug Interactions; Fluorine Radioisotopes; Gefitinib; Humans; Male; Mice; Positron-Emission Tomography; Quinazolines; Tetrahydroisoquinolines; Tissue Distribution; Tomography, X-Ray Computed | 2015 |
Antitumoral activity of tyrosine kinase inhibitors in patients with non-small cell lung cancer harbouring rare epidermal growth factor receptor mutations.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2015 |
Elevated β-catenin pathway as a novel target for patients with resistance to EGF receptor targeting drugs.
Topics: Adenocarcinoma; Antineoplastic Agents; Base Sequence; beta Catenin; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Sequence Data; Molecular Targeted Therapy; Mutation, Missense; Protein Transport; Quinazolines; Transcription, Genetic; Transcriptional Activation; Up-Regulation; Wnt Signaling Pathway | 2015 |
[Targeted therapy for solid tumors in the elderly].
Topics: Aged; Aged, 80 and over; Aging; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Trastuzumab | 2015 |
Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Mice; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad Proteins; Transforming Growth Factor beta1 | 2015 |
Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Caco-2 Cells; Carcinoma, Squamous Cell; Cell Line, Tumor; Chemistry, Pharmaceutical; Excipients; Gefitinib; Humans; Mice, Nude; Proteomics; Quinazolines; Rats; Rats, Sprague-Dawley; Skin Neoplasms; Solubility; Survival Analysis; Xenograft Model Antitumor Assays | 2016 |
Src and epidermal growth factor receptor mediate the pro-invasive activity of Bcl-w.
Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-X Protein; Cell Line, Tumor; Cell Movement; Disease Progression; ErbB Receptors; Gefitinib; Humans; Neoplasm Invasiveness; Phosphatidylinositol 3-Kinases; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Reactive Oxygen Species; src-Family Kinases | 2016 |
Gefitinib and Erlotinib Lead to Phosphorylation of Eukaryotic Initiation Factor 2 Alpha Independent of Epidermal Growth Factor Receptor in A549 Cells.
Topics: Antineoplastic Agents; Cell Line; Cell Proliferation; Cyclin D1; Endoplasmic Reticulum Stress; ErbB Receptors; Erlotinib Hydrochloride; Eukaryotic Initiation Factor-2; Gefitinib; Humans; Lung Diseases, Interstitial; Phosphorylation; Pulmonary Alveoli; Quinazolines; Signal Transduction; Taurochenodeoxycholic Acid | 2015 |
Gli1-Mediated Regulation of Sox2 Facilitates Self-Renewal of Stem-Like Cells and Confers Resistance to EGFR Inhibitors in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Promoter Regions, Genetic; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; SOXB1 Transcription Factors; Spheroids, Cellular; Stem Cells; Transcription Factors; Tumor Cells, Cultured; Zinc Finger Protein GLI1 | 2015 |
Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antigens; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Membrane Proteins; Proteomics; Quinazolines; Receptors, Progesterone; RNA, Small Interfering; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2015 |
Whole-brain radiation fails to boost intracerebral gefitinib concentration in patients with brain metastatic non-small cell lung cancer: a self-controlled, pilot study.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Agents; Blood-Brain Barrier; Brain; Brain Neoplasms; Capillary Permeability; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neurons; Pilot Projects; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Tissue Distribution | 2015 |
Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Anthracyclines; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Movement; Cell Proliferation; Computer-Aided Design; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Mice, SCID; Molecular Docking Simulation; Molecular Structure; Molecular Targeted Therapy; Neoplasm Invasiveness; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; Structure-Activity Relationship; Time Factors; Xenograft Model Antitumor Assays | 2015 |
Impact of single nucleotide polymorphisms on severe hepatotoxicity induced by EGFR tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring EGFR mutations.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Young Adult | 2015 |
Impact of Smoking History on the Efficacy of Gefitinib in Patients with Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2015 |
Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin-paclitaxel.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Female; Gefitinib; Genes, erbB-1; Humans; Latin America; Lung Neoplasms; Male; Mexico; Models, Econometric; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines | 2016 |
EGFR mutation L747P led to gefitinib resistance and accelerated liver metastases in a Chinese patient with lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; China; Disease Progression; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Genetic Predisposition to Disease; Humans; Immunohistochemistry; Liver Neoplasms; Lung Neoplasms; Male; Molecular Sequence Data; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Time Factors; Tomography, X-Ray Computed; Treatment Outcome | 2015 |
EGFR kinase activity is required for TLR4 signaling and the septic shock response.
Topics: Animals; ErbB Receptors; Gefitinib; Interferon Regulatory Factors; Interferon-beta; Lipopolysaccharides; Mice; Microarray Analysis; Myeloid Cells; NF-kappa B; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; RAW 264.7 Cells; Shock, Septic; Signal Transduction; Toll-Like Receptor 4; Tumor Necrosis Factor-alpha | 2015 |
Synergistic effects of metformin in combination with EGFR-TKI in the treatment of patients with advanced non-small cell lung cancer and type 2 diabetes.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diabetes Mellitus, Type 2; Disease-Free Survival; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Metformin; Middle Aged; Neoplasm Staging; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2015 |
Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells.
Topics: Antineoplastic Agents; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Insulin; Lung Neoplasms; Mutation; Nuclear Proteins; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Receptor, IGF Type 1; RNA, Messenger; Signal Transduction | 2015 |
EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Amino Acid Substitution; Angiogenesis Inhibitors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Biopsy; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2015 |
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers.
Topics: Antibodies, Monoclonal; Cell Line, Tumor; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Up-Regulation | 2015 |
[Clinical Experience of Gefitinib in the Treatment of 32 Lung Adenocarcinoma Patients with Brain Metastases].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Brain Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate; Treatment Outcome | 2015 |
Lysophosphatidic acid induces both EGFR-dependent and EGFR-independent effects on DNA synthesis and migration in pancreatic and colorectal carcinoma cells.
Topics: Carcinoma; Cell Line, Tumor; Cell Movement; Cell Proliferation; Colorectal Neoplasms; DNA; ErbB Receptors; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Lysophospholipids; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transcriptional Activation | 2016 |
Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance.
Topics: Adenosine Triphosphate; Annexin A5; Apoptosis; Blotting, Western; Cell Line, Tumor; Cell Survival; Chitosan; Chloroquine; Drug Delivery Systems; Drug Resistance, Neoplasm; Endocytosis; Fluorescein-5-isothiocyanate; Gefitinib; Humans; Intracellular Space; Nanoparticles; Necrosis; Quinazolines | 2015 |
Vorinostat synergizes with EGFR inhibitors in NSCLC cells by increasing ROS via up-regulation of the major mitochondrial porin VDAC1 and modulation of the c-Myc-NRF2-KEAP1 pathway.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Intracellular Signaling Peptides and Proteins; Kelch-Like ECH-Associated Protein 1; Lung Neoplasms; NF-E2-Related Factor 2; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-myc; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured; Voltage-Dependent Anion Channel 1; Vorinostat | 2015 |
Drug-Drug Molecular Salt Hydrate of an Anticancer Drug Gefitinib and a Loop Diuretic Drug Furosemide: An Alternative for Multidrug Treatment.
Topics: Antineoplastic Agents; Furosemide; Gefitinib; Hydrogen Bonding; Molecular Structure; Quinazolines; Sodium Chloride; Sodium Potassium Chloride Symporter Inhibitors; Solubility; Water | 2015 |
EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Separation; Cell Survival; DNA Breaks, Double-Stranded; DNA Repair; ErbB Receptors; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Microscopy, Fluorescence; Quinazolines; Radiation Tolerance; Signal Transduction; X-Rays | 2015 |
Simultaneous targeting of 5-LOX-COX and EGFR blocks progression of pancreatic ductal adenocarcinoma.
Topics: Animals; Antineoplastic Agents; Arachidonate 5-Lipoxygenase; Carcinoma, Pancreatic Ductal; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Synergism; ErbB Receptors; Female; Gefitinib; Lipoxygenase Inhibitors; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Pancreatic Neoplasms; Pyrroles; Quinazolines; Signal Transduction | 2015 |
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cytotoxicity, Immunologic; Deoxycytidine; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Killer Cells, Natural; Lung Neoplasms; NK Cell Lectin-Like Receptor Subfamily K; Protein Kinase Inhibitors; Quinazolines | 2015 |
Drug response to HER2 gatekeeper T798M mutation in HER2-positive breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydroxybutyrates; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Purines; Quinazolines; Receptor, ErbB-2; Staurosporine | 2016 |
The usage of a three-compartment model to investigate the metabolic differences between hepatic reductase null and wild-type mice.
Topics: Angiogenesis Inhibitors; Animals; Cytochrome P-450 Enzyme System; Disease Models, Animal; GABA Modulators; Gefitinib; Liver; Mice; Mice, Transgenic; Midazolam; Models, Biological; NADPH-Ferrihemoprotein Reductase; Protein Kinase Inhibitors; Quinazolines; Thalidomide | 2017 |
Effects of epidermal growth factor receptor inhibitor on proliferative cholangitis in hepatolithiasis.
Topics: Adult; Aged; Bile Ducts; Cholangitis; Collagen Type I; Endoscopy, Digestive System; Epithelium; ErbB Receptors; Female; Gefitinib; Gene Expression; Glucuronidase; Humans; Hyperplasia; Ki-67 Antigen; Lithiasis; Liver Diseases; Male; Middle Aged; Mucin-3; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Quinazolines | 2015 |
Synergistic induction of apoptosis by salinomycin and gefitinib through lysosomal and mitochondrial dependent pathway overcomes gefitinib resistance in colorectal cancer.
Topics: Animals; Apoptosis; Cathepsin B; Cathepsin D; Cell Line, Tumor; Cell Survival; Colorectal Neoplasms; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Lysosomes; Membrane Potential, Mitochondrial; Mice; Mice, Nude; Mitochondria; Pyrans; Quinazolines; Reactive Oxygen Species; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Aptamer targeting EGFRvIII mutant hampers its constitutive autophosphorylation and affects migration, invasion and proliferation of glioblastoma cells.
Topics: Antineoplastic Agents; Apoptosis; Aptamers, Nucleotide; Blotting, Western; Brain Neoplasms; Cell Adhesion; Cell Movement; Cell Proliferation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Immunoenzyme Techniques; Molecular Targeted Therapy; Mutation; Neoplasm Invasiveness; Phosphorylation; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Signal Transduction; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tumor Cells, Cultured | 2015 |
Ultrasmall dual-modality silica nanoparticle drug conjugates: Design, synthesis, and characterization.
Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; Drug Carriers; Drug Design; ErbB Receptors; Gefitinib; Humans; Nanoparticles; Peptide Hydrolases; Phosphorylation; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Silicon Dioxide | 2015 |
Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Celecoxib; Cell Line, Tumor; Cell Proliferation; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Quinazolines | 2015 |
[An Elderly Patient with Non-Small Cell Lung Cancer Who Responded to Salvage S-1 Monotherapy after Gefitinib Therapy].
Topics: Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Combinations; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Oxonic Acid; Quinazolines; Salvage Therapy; Tegafur | 2015 |
LXR ligands sensitize EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt activation.
Topics: Adenocarcinoma; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; In Vitro Techniques; Ligands; Liver X Receptors; Lung Neoplasms; Mutation; Orphan Nuclear Receptors; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2015 |
Overexpression of Cathepsin L is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cathepsin L; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
MicroRNA-221 targets PTEN to reduce the sensitivity of cervical cancer cells to gefitinib through the PI3K/Akt signaling pathway.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Survival; Chromones; Enzyme Inhibitors; Female; Gefitinib; HeLa Cells; Humans; MicroRNAs; Morpholines; Phosphatidylinositol 3-Kinase; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Uterine Cervical Neoplasms | 2016 |
c-Myc alterations confer therapeutic response and acquired resistance to c-Met inhibitors in MET-addicted cancers.
Topics: Animals; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Proto-Oncogene Proteins c-myc; Pyridazines; Quinazolines; RNA Interference; RNA, Small Interfering; Triazoles; Xenograft Model Antitumor Assays | 2015 |
[Sequence-dependent Effect of Triptolide with Gefitinib on the Proliferation
and Apoptosis of Lung Adenocarcinoma Cell H1975].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Diterpenes; Epoxy Compounds; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phenanthrenes; Protein Kinase Inhibitors; Quinazolines | 2015 |
Valproic acid sensitizes human glioma cells to gefitinib-induced autophagy.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Autophagy; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Activation; Gefitinib; Glioma; Humans; Oxidative Stress; Quinazolines; Reactive Oxygen Species; Valproic Acid | 2015 |
Metformin attenuates gefitinib-induced exacerbation of pulmonary fibrosis by inhibition of TGF-β signaling pathway.
Topics: Animals; Antineoplastic Agents; Bleomycin; Blotting, Western; Epithelial-Mesenchymal Transition; Flow Cytometry; Gefitinib; Humans; Immunohistochemistry; Lung Diseases, Interstitial; Male; Metformin; Pulmonary Fibrosis; Quinazolines; Rats; Rats, Sprague-Dawley; Signal Transduction; Transforming Growth Factor beta | 2015 |
Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study.
Topics: Adult; Aged; Antineoplastic Agents; Base Sequence; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; DNA Mutational Analysis; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Genes, erbB-1; Hospitals; Humans; Lung Neoplasms; Male; Middle Aged; Prognosis; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Smoking | 2015 |
244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice, Nude; Mice, SCID; Molecular Dynamics Simulation; Mutation; Phenols; Phosphorylation; Protein Binding; Protein Conformation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Signal Transduction; Time Factors; Tumor Burden; Xenograft Model Antitumor Assays | 2015 |
Binding mode of the breakthrough inhibitor AZD9291 to epidermal growth factor receptor revealed.
Topics: Acrylamides; Aniline Compounds; Antineoplastic Agents; Crystallography, X-Ray; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2015 |
Simultaneous and rapid determination of gefitinib, erlotinib and afatinib plasma levels using liquid chromatography/tandem mass spectrometry in patients with non-small-cell lung cancer.
Topics: Afatinib; Calibration; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Erlotinib Hydrochloride; Gefitinib; Humans; Limit of Detection; Lung Neoplasms; Quinazolines; Tandem Mass Spectrometry | 2016 |
EGFR is not a major driver for osteosarcoma cell growth in vitro but contributes to starvation and chemotherapy resistance.
Topics: Antineoplastic Agents; Apoptosis; Bone Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Osteosarcoma; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
Topics: Animals; Apoptosis; Benzophenanthridines; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Humans; Isoquinolines; Lung Neoplasms; Membrane Glycoproteins; Membrane Proteins; Methionine; Mice; Models, Biological; Models, Molecular; Molecular Conformation; NADPH Oxidase 2; NADPH Oxidases; Oxidation-Reduction; Protein Binding; Protein Kinase Inhibitors; Proteolysis; Quinazolines; Reactive Oxygen Species; Xenograft Model Antitumor Assays | 2016 |
Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines.
Topics: ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chromatography, High Pressure Liquid; ErbB Receptors; Gefitinib; Gene Expression Regulation; HEK293 Cells; Humans; Indoles; Lung Neoplasms; Neoplasm Proteins; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering; Tandem Mass Spectrometry | 2015 |
(Z)3,4,5,4'-trans-tetramethoxystilbene, a new analogue of resveratrol, inhibits gefitinb-resistant non-small cell lung cancer via selectively elevating intracellular calcium level.
Topics: Adenylate Kinase; Antineoplastic Agents; Apoptosis; Calcium; Cell Line, Tumor; Endoplasmic Reticulum Stress; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Quinazolines; Stilbenes | 2015 |
Nuclear PKM2 contributes to gefitinib resistance via upregulation of STAT3 activation in colorectal cancer.
Topics: Antineoplastic Agents; Carrier Proteins; Cell Line; Cell Line, Tumor; Cell Nucleus; Colorectal Neoplasms; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HCT116 Cells; HEK293 Cells; HT29 Cells; Humans; Membrane Proteins; Protein Kinase Inhibitors; Quinazolines; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones; Transcriptional Activation; Up-Regulation | 2015 |
Health-related quality of life after first-line anti-cancer treatments for advanced non-small cell lung cancer in clinical practice.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Erlotinib Hydrochloride; Female; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Pemetrexed; Platinum; Prospective Studies; Quality of Life; Quinazolines; Sickness Impact Profile; Surveys and Questionnaires; World Health Organization | 2016 |
[Gefitineb inhibits the growth and induces the apoptosis of mouse I-10 Leydig testicular cancer cells in vitro].
Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Proliferation; Cell Survival; Gefitinib; Leydig Cell Tumor; Male; Mice; Neoplasm Proteins; Neoplasms, Germ Cell and Embryonal; Quinazolines; Testicular Neoplasms | 2015 |
Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hospitals, University; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Republic of Korea; Retrospective Studies; Risk Factors; Salvage Therapy; Time Factors; Treatment Failure | 2015 |
Spectroscopic and molecular docking studies of binding interaction of gefitinib, lapatinib and sunitinib with bovine serum albumin (BSA).
Topics: Animals; Binding Sites; Cattle; Circular Dichroism; Fluorescence Resonance Energy Transfer; Gefitinib; Indoles; Lapatinib; Molecular Docking Simulation; Protein Binding; Protein Structure, Tertiary; Pyrroles; Quinazolines; Serum Albumin, Bovine; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared; Sunitinib; Thermodynamics | 2015 |
A Whole-Body Physiologically Based Pharmacokinetic Model of Gefitinib in Mice and Scale-Up to Humans.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Area Under Curve; Blood Proteins; Gefitinib; Healthy Volunteers; Humans; Infusions, Intravenous; Male; Mice; Models, Statistical; Neoplasms; Pharmacokinetics; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Species Specificity; Tissue Distribution | 2016 |
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Insulin; Insulin-Like Growth Factor I; Mice; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Receptor, Insulin; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
[Gefitinib therapy in advanced non-small cell lung cancer in patients with EGFR mutations: cost-effectiveness analysis].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Disease-Free Survival; Drug Costs; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Gene Deletion; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Point Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quality of Life; Quinazolines; Retrospective Studies; Russia; Treatment Outcome | 2015 |
An Apoferritin-based Drug Delivery System for the Tyrosine Kinase Inhibitor Gefitinib.
Topics: Apoferritins; Cell Line, Tumor; Drug Delivery Systems; Endocytosis; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines | 2015 |
Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy.
Topics: Adult; Age Distribution; Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Genetic Markers; Humans; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Prevalence; Quinazolines; Retrospective Studies; Risk Factors; Sex Distribution; Smoking; Switzerland; Treatment Outcome | 2015 |
RECIST progression patterns during EGFR tyrosine kinase inhibitor treatment of advanced non-small cell lung cancer patients harboring an EGFR mutation.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Response Evaluation Criteria in Solid Tumors; Retrospective Studies; Treatment Outcome | 2015 |
Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; Crown Ethers; Diphosphonates; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Imidazoles; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Pamidronate; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome; Zoledronic Acid | 2016 |
Overexpression of Sphk2 is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering | 2016 |
Observation of hepatotoxicity during long-term gefitinib administration in patients with non-small-cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Time Factors | 2016 |
Resveratrol overcomes gefitinib resistance by increasing the intracellular gefitinib concentration and triggering apoptosis, autophagy and senescence in PC9/G NSCLC cells.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cellular Senescence; Cytochrome P-450 CYP1A1; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Neoplasm Proteins; Quinazolines; Resveratrol; Stilbenes | 2015 |
BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Lung Neoplasms; Male; Membrane Proteins; Middle Aged; Mutation; Proto-Oncogene Proteins; Quinazolines; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2015 |
Different EGFR Gene Mutations in Exon 18, 19 and 21 as Prognostic and Predictive Markers in NSCLC: A Single Institution Analysis.
Topics: Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Gemcitabine; Gene Deletion; Genetic Markers; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Pemetrexed; Prognosis; Proportional Hazards Models; Quinazolines; Retrospective Studies; Taxoids | 2016 |
Pancreatic Tumor Progression Associated With CD133 Overexpression: Involvement of Increased TERT Expression and Epidermal Growth Factor Receptor-Dependent Akt Activation.
Topics: AC133 Antigen; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell Survival; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Mice, SCID; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Telomerase; Transplantation, Heterologous | 2016 |
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance.
Topics: Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Chitosan; Deoxyribonuclease I; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Electrophoresis, Agar Gel; Endocytosis; Flow Cytometry; Gefitinib; HeLa Cells; Humans; Intracellular Space; Nanoparticles; Neoplasms; Particle Size; Quinazolines; RNA, Small Interfering; Transfection | 2015 |
Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non-Small Cell Lung Cancer.
Topics: Acneiform Eruptions; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Compassionate Use Trials; Cross-Sectional Studies; Drug Eruptions; Erlotinib Hydrochloride; Gefitinib; Humans; Ichthyosis; Lung Neoplasms; Paronychia; Pruritus; Quinazolines; Retrospective Studies | 2016 |
Anti-Tumor Activity of Yuanhuacine by Regulating AMPK/mTOR Signaling Pathway and Actin Cytoskeleton Organization in Non-Small Cell Lung Cancer Cells.
Topics: Actin Cytoskeleton; AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Diterpenes; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Quinazolines; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2015 |
Inhibition of EGF Receptor Blocks the Development and Progression of Peritoneal Fibrosis.
Topics: Animals; Disease Progression; ErbB Receptors; Gefitinib; Male; Peritoneal Fibrosis; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Time Factors; Transforming Growth Factor beta1 | 2016 |
Synthesis and Anti-Tumor Activities of 4-Anilinoquinoline Derivatives.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; HeLa Cells; Humans; Quinazolines; Quinolines; Structure-Activity Relationship | 2015 |
Change in PD-L1 Expression After Acquiring Resistance to Gefitinib in EGFR-Mutant Non-Small-Cell Lung Cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; B7-H1 Antigen; Biomarkers, Pharmacological; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Quinazolines; Survival Analysis; Treatment Outcome | 2016 |
Heterogeneity in resistance mechanisms causes shorter duration of epidermal growth factor receptor kinase inhibitor treatment in lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Genes, erbB-1; Genetic Heterogeneity; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis; Time-to-Treatment; Treatment Failure | 2016 |
Acid-Base Interactions of Polystyrene Sulfonic Acid in Amorphous Solid Dispersions Using a Combined UV/FTIR/XPS/ssNMR Study.
Topics: Acid-Base Equilibrium; Antineoplastic Agents; Calorimetry, Differential Scanning; Crystallization; Drug Carriers; Drug Compounding; Drug Stability; Excipients; Gefitinib; Lapatinib; Magnetic Resonance Spectroscopy; Photoelectron Spectroscopy; Polystyrenes; Quinazolines; Solubility; Spectrophotometry, Ultraviolet; Spectroscopy, Fourier Transform Infrared | 2016 |
Diagnostic significance of cerebrospinal fluid EGFR mutation analysis for leptomeningeal metastasis in non-small-cell lung cancer patients harboring an active EGFR mutation following gefitinib therapy failure.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Retrospective Studies; Time Factors; Treatment Failure; Treatment Outcome | 2016 |
Macrolides sensitize EGFR-TKI-induced non-apoptotic cell death via blocking autophagy flux in pancreatic cancer cell lines.
Topics: Apoptosis; Autophagy; Azithromycin; Cell Line, Tumor; Clarithromycin; Drug Synergism; ErbB Receptors; Erythromycin; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Macrolides; Pancreatic Neoplasms; Quinazolines | 2016 |
Overexpression of BRCA1 attenuates the sensitivity of PC9 cells to gefitinib.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; BRCA1 Protein; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Lung Neoplasms; Phosphorylation; Quinazolines; Signal Transduction | 2015 |
5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Azacitidine; Blotting, Western; Cell Line, Tumor; Death-Associated Protein Kinases; DNA Methylation; Drug Resistance, Neoplasm; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Polymerase Chain Reaction; Promoter Regions, Genetic; Quinazolines | 2015 |
Total regression of brain metastases in non-small cell lung cancer patients harboring EGFR mutations treated with gefitinib without radiotherapy: two case reports.
Topics: Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Magnetic Resonance Imaging; Middle Aged; Mutation; Quinazolines; Radiography, Thoracic; Remission Induction | 2016 |
Inhibition of epidermal growth factor receptor induces tumor necrosis factor-α via activation of peroxisome proliferator-activated receptor-γ and nuclear factor-κB in sebocytes: A possible pathogenesis of papulopustular rash.
Topics: Cell Line; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; NF-kappa B; PPAR gamma; Protein Kinase Inhibitors; Quinazolines; Sebaceous Glands; Signal Transduction; Skin Diseases, Papulosquamous; Time Factors; Tumor Necrosis Factor-alpha; Up-Regulation | 2016 |
TOPK promotes lung cancer resistance to EGFR tyrosine kinase inhibitors by phosphorylating and activating c-Jun.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Enzyme Activation; ErbB Receptors; Gefitinib; Heterografts; Humans; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase Kinases; Models, Molecular; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Random Allocation; Transfection | 2016 |
Gefitinib Synergizes with Irinotecan to Suppress Hepatocellular Carcinoma via Antagonizing Rad51-Mediated DNA-Repair.
Topics: Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Camptothecin; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; DNA Repair; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Hep G2 Cells; Humans; Irinotecan; Liver Neoplasms; Mice; Mice, Nude; Neoplasm Transplantation; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Topoisomerase I Inhibitors | 2016 |
Prolyl isomerase Pin1 promotes survival in EGFR-mutant lung adenocarcinoma cells with an epithelial-mesenchymal transition phenotype.
Topics: Acrylamides; Adenocarcinoma; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Lung Neoplasms; Mutation; NIMA-Interacting Peptidylprolyl Isomerase; Peptidylprolyl Isomerase; Phenotype; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference | 2016 |
The apoptotic effect of simvastatin via the upregulation of BIM in nonsmall cell lung cancer cells.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Quinazolines; Simvastatin; Up-Regulation | 2016 |
Mutation analysis of EGFR and its correlation with the HPV in Indian cervical cancer patients.
Topics: Adult; Aged; Antineoplastic Agents; Cell Line, Tumor; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; HeLa Cells; Human papillomavirus 16; Human papillomavirus 18; Humans; India; Middle Aged; Mutation; Papillomavirus Infections; Protein Kinase Inhibitors; Quinazolines; Uterine Cervical Neoplasms | 2016 |
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic | 2015 |
Case Report: Bazex Syndrome Associated With Pulmonary Adenocarcinoma.
Topics: Acitretin; Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Biopsy, Needle; Bone Neoplasms; Carcinoma, Basal Cell; Dexamethasone; Drug Therapy, Combination; Follow-Up Studies; Gefitinib; Humans; Hypotrichosis; Immunohistochemistry; Lung Neoplasms; Lymph Nodes; Male; Paraneoplastic Syndromes; Quinazolines; Radiography; Rare Diseases; Risk Assessment; Skin Neoplasms; Treatment Outcome | 2016 |
Volumetric Tumor Response and Progression in EGFR-mutant NSCLC Patients Treated with Erlotinib or Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Remission Induction; Retrospective Studies; Survival Rate; Tomography, X-Ray Computed; Tumor Burden; Young Adult | 2016 |
miR-200/ZEB axis regulates sensitivity to nintedanib in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Profiling; Humans; Indoles; Inhibitory Concentration 50; Lung Neoplasms; MicroRNAs; Phenotype; Quinazolines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Receptors, Vascular Endothelial Growth Factor; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
The Chronic and Short-Term Effects of Gefinitib on Airway Remodeling and Inflammation in a Mouse Model of Asthma.
Topics: Airway Remodeling; Animals; Asthma; bcl-2-Associated X Protein; Bronchoalveolar Lavage Fluid; Disease Models, Animal; Down-Regulation; Eosinophils; ErbB Receptors; Gefitinib; Inflammation; Interferon-gamma; Interleukin-13; Leukocyte Count; Male; Mice; Mice, Inbred BALB C; Mucin 5AC; Ovalbumin; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2016 |
An unusual cause of early aortic bioprosthetic valve failure.
Topics: Adenocarcinoma; Antineoplastic Agents; Aortic Valve; Aortic Valve Stenosis; Bioprosthesis; Echocardiography; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Prosthesis Failure; Quinazolines | 2016 |
Simultaneous determination of gefitinib and its major metabolites in mouse plasma by HPLC-MS/MS and its application to a pharmacokinetics study.
Topics: Animals; Chromatography, High Pressure Liquid; Drug Stability; Female; Gefitinib; Linear Models; Mice; Mice, Nude; Quinazolines; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry | 2016 |
[Mechanism of TRIM24 to Regulate Resistance of Gefitinib in NSCLC cells].
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-akt; Quinazolines | 2016 |
[Successful Treatment of Non-Small Cell Lung Cancer with Afatinib after Gefitinib-Induced Hepatotoxicity].
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Gefitinib; Humans; Liver Diseases; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2016 |
The P21-activated kinase expression pattern is different in non-small cell lung cancer and affects lung cancer cell sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; p21-Activated Kinases; Protein Kinase Inhibitors; Quinazolines | 2016 |
Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Morpholines; Mutation; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction | 2016 |
Oncogenic activation of the PI3K/Akt pathway promotes cellular glucose uptake by downregulating the expression of thioredoxin-interacting protein.
Topics: Animals; Carrier Proteins; Cell Line; Cell Line, Tumor; Down-Regulation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation; Glucose; Glucose Transporter Type 1; Humans; Insulin; Intercellular Signaling Peptides and Proteins; Oncogene Proteins; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Response Elements; RNA, Messenger; Signal Transduction; TOR Serine-Threonine Kinases; Transcription, Genetic | 2016 |
Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition.
Topics: Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger | 2016 |
Novel 4-anilinoquinazoline derivatives featuring an 1-adamantyl moiety as potent EGFR inhibitors with enhanced activity against NSCLC cell lines.
Topics: Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Quinazolines | 2016 |
Oncogene swap as a novel mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor in lung cancer.
Topics: Acrylamides; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Oncogenes; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines | 2016 |
Paris Saponins enhance radiosensitivity in a gefitinib-resistant lung adenocarcinoma cell line by inducing apoptosis and G2/M cell cycle phase arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Diosgenin; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; G2 Phase Cell Cycle Checkpoints; Gefitinib; Humans; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Radiation Tolerance; Radiation-Sensitizing Agents; Saponins | 2016 |
Transtinib, a potent tyrosine kinase inhibitor inhibits L858R/T790M mutant NSCLC cell lines and xenografts.
Topics: Acrylamides; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Inhibitory Concentration 50; Lung Neoplasms; Mice; Mice, Nude; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
High mannose-binding Pseudomonas fluorescens lectin (PFL) downregulates cell surface integrin/EGFR and induces autophagy in gastric cancer cells.
Topics: Animals; Autophagy; Cell Line, Tumor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Integrins; Mannose-Binding Lectin; Mice; Pseudomonas fluorescens; Quinazolines; RNA, Small Interfering; Stomach Neoplasms; Xenograft Model Antitumor Assays | 2016 |
Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Benzothiazoles; Biological Transport; Blood-Brain Barrier; Blotting, Western; Cells, Cultured; Choriocarcinoma; Female; Flow Cytometry; Gefitinib; Image Processing, Computer-Assisted; Luciferases, Firefly; Luminescent Agents; Luminescent Measurements; Male; Mice; Mice, Transgenic; Placenta; Pregnancy; Quinazolines; Tissue Distribution | 2016 |
Identification of drugs that restore primary cilium expression in cancer cells.
Topics: A549 Cells; Antineoplastic Agents; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cilia; Drug Screening Assays, Antitumor; Gefitinib; Humans; Microscopy, Confocal; Neoplasms; Pancreatic Neoplasms; Quinazolines; Reproducibility of Results | 2016 |
Ten Years of Complete Remission of Pulmonary Metastasis after Post-Cystectomy Palliative Cisplatin-Gemcitabine Chemotherapy with Gefitinib for Muscle Invasive Bladder Cancer: A Case Report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cystectomy; Deoxycytidine; Gefitinib; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Invasiveness; Quinazolines; Urinary Bladder Neoplasms | 2016 |
miR-217 and CAGE form feedback loop and regulates the response to anti-cancer drugs through EGFR and HER2.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Neovascularization, Pathologic; Paclitaxel; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab | 2016 |
Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Topics: Adenine Nucleotide Translocator 2; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Molecular Targeted Therapy; Promoter Regions, Genetic; Quinazolines; RNA, Small Interfering; Up-Regulation | 2016 |
therascreen® EGFR RGQ PCR Kit: A Companion Diagnostic for Afatinib and Gefitinib in Non-Small Cell Lung Cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; DNA Mutational Analysis; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity | 2016 |
Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Alleles; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Grading; Neoplasm Staging; Pharmacogenetics; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma.
Topics: Aminosalicylic Acids; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Sarcoma; Signal Transduction; STAT3 Transcription Factor; Treatment Outcome; Xenograft Model Antitumor Assays | 2016 |
Flipped script for gefitinib: A reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; United States; United States Food and Drug Administration | 2017 |
Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2016 |
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck | 2016 |
Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Topics: Antigens, CD; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biomarkers, Tumor; Cadherins; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Hedgehog Proteins; Humans; Immunohistochemistry; Inhibitory Concentration 50; Lung Neoplasms; Neoplasm Proteins; Neoplastic Stem Cells; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Snail Family Transcription Factors; Transcription Factors; Up-Regulation | 2016 |
Clinical Impact of Gastric Acid-Suppressing Medication Use on the Efficacy of Erlotinib and Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastric Acid; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Epidermal Growth Factor Receptor Kinase Inhibitors Synergize with TCDD to Induce CYP1A1/1A2 in Human Breast Epithelial MCF10A Cells.
Topics: Benzamides; Breast; Cell Line; Cytochrome P-450 CYP1A1; Cytochrome P-450 CYP1A2; Drug Synergism; Epithelial Cells; ErbB Receptors; Gefitinib; Humans; MAP Kinase Kinase 1; Morpholines; Polychlorinated Dibenzodioxins; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Tyrphostins | 2016 |
Midkine Deteriorates Cardiac Remodeling via Epidermal Growth Factor Receptor Signaling in Chronic Kidney Disease.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Cytokines; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Mice, Knockout; Midkine; Myocytes, Cardiac; Nephrectomy; Phosphorylation; Quinazolines; Rats; Rats, Sprague-Dawley; Renal Insufficiency, Chronic; Sensitivity and Specificity; Signal Transduction; Ventricular Remodeling | 2016 |
Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2016 |
Ephedrae herba stimulates hepatocyte growth factor-induced MET endocytosis and downregulation via early/late endocytic pathways in gefitinib-resistant human lung cancer cells.
Topics: Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Endocytosis; Ephedra; Gefitinib; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Phosphorylation; Plant Extracts; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction | 2016 |
Drug resistance originating from a TGF-β/FGF-2-driven epithelial-to-mesenchymal transition and its reversion in human lung adenocarcinoma cell lines harboring an EGFR mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; B7-H1 Antigen; Cell Line, Tumor; Cell Survival; Cisplatin; Dimethyl Sulfoxide; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Indoles; Lung Neoplasms; Metformin; Mutation; Purines; Quinazolines; Transforming Growth Factor beta | 2016 |
Genetic Association of Curative and Adverse Reactions to Tyrosine Kinase Inhibitors in Chinese advanced Non-Small Cell Lung Cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; China; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Treatment Outcome | 2016 |
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Topics: AC133 Antigen; Animals; Antigens, CD; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Female; Gefitinib; Gene Deletion; Glycoproteins; Humans; Hypoxia; Immunohistochemistry; Lung Neoplasms; Mice; Mice, Inbred NOD; Microscopy, Fluorescence; Mutation; Neoplasm Transplantation; Neoplastic Stem Cells; Octamer Transcription Factor-3; Peptides; Phenotype; Quinazolines; Real-Time Polymerase Chain Reaction | 2016 |
Partial Remission of Hepatic Metastatic Lesion but Complicated with Secondary and Refractory Fever Lead by Nivolumab in a Patient with Lung Adenocarcinoma Presenting Gefitinib Acquired Resistance.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antibodies, Monoclonal; Drug Resistance, Neoplasm; Female; Fever; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Middle Aged; Nivolumab; Quinazolines | 2016 |
Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation.
Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cardiac Glycosides; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Digitoxin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Medicine, Chinese Traditional; Microtubules; Mutation; Quinazolines; Tubulin | 2016 |
Combination of Gefitinib and Pemetrexed Prevents the Acquisition of TKI Resistance in NSCLC Cell Lines Carrying EGFR-Activating Mutation.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines | 2016 |
Molecular Dynamics Analysis of Binding of Kinase Inhibitors to WT EGFR and the T790M Mutant.
Topics: Catalytic Domain; ErbB Receptors; Gefitinib; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Point Mutation; Protein Conformation; Protein Kinase Inhibitors; Quinazolines; Thermodynamics | 2016 |
Trial-Based Cost-Utility Analysis of Icotinib versus Gefitinib as Second-Line Therapy for Advanced Non-Small Cell Lung Cancer in China.
Topics: Carcinoma, Non-Small-Cell Lung; China; Clinical Trials as Topic; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Male; Markov Chains; Mutation; Quinazolines | 2016 |
Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Antineoplastic Agents; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Multivariate Analysis; Mutation; Nutrition Assessment; Nutritional Status; Phenotype; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2016 |
Exosomes derived from gefitinib-treated EGFR-mutant lung cancer cells alter cisplatin sensitivity via up-regulating autophagy.
Topics: Antineoplastic Agents; Autophagy; Cisplatin; ErbB Receptors; Exosomes; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines; Up-Regulation | 2016 |
Inequalities in lung cancer: a world of EGFR.
Topics: Afatinib; Crown Ethers; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Geography; Global Health; Health Care Costs; Health Equity; Health Services Accessibility; Healthcare Disparities; Humans; Lung Neoplasms; Medical Oncology; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Surveys and Questionnaires; United States | 2016 |
Gastrointestinal toxicities of first and second-generation small molecule human epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Diarrhea; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Quinazolinones | 2016 |
Safe and successful treatment with afatinib in three postoperative non-small cell lung cancer patients with recurrences following gefitinib/erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Erlotinib Hydrochloride; Female; Gefitinib; Genes, erbB-1; Humans; Liver; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Tomography, X-Ray Computed | 2016 |
Analysis of a single-codon E746 deletion in exon 19 of the epidermal growth factor receptor.
Topics: Animals; Cell Line, Tumor; Codon; ErbB Receptors; Exons; Gefitinib; Gene Deletion; Lung Neoplasms; Mice; Molecular Docking Simulation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Treatment Outcome | 2016 |
Rapid assessment of drug resistance of cancer cells to gefitinib and carboplatin using optical imaging.
Topics: Antineoplastic Agents; Breast Neoplasms; Carboplatin; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gefitinib; Humans; Optical Imaging; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured; Urinary Bladder Neoplasms | 2016 |
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme-Linked Immunosorbent Assay; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Imaging, Three-Dimensional; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Swine; Tissue Engineering; Transforming Growth Factor beta1 | 2016 |
Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Topics: A549 Cells; Animals; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 12; Membrane Proteins; Mice; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cardiomegaly; Cardiotoxicity; Caspase 3; Cell Line; Dose-Response Relationship, Drug; Gefitinib; Gene Expression Regulation; Heme Oxygenase (Decyclizing); Male; Myocytes, Cardiac; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Rats, Wistar; Reactive Oxygen Species; Signal Transduction; Tumor Suppressor Protein p53 | 2016 |
Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genotype; Humans; Lung Neoplasms; Male; Membrane Transport Proteins; Middle Aged; Mutation; Pharmacogenomic Testing; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines | 2017 |
NF-κB-driven suppression of FOXO3a contributes to EGFR mutation-independent gefitinib resistance.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Drug; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Forkhead Box Protein O3; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplastic Stem Cells; NF-kappa B; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Tumor Cells, Cultured | 2016 |
Synthesis, Characterization, and in Vitro Antitumor Activity of Ruthenium(II) Polypyridyl Complexes Tethering EGFR-Inhibiting 4-Anilinoquinazolines.
Topics: 2,2'-Dipyridyl; Aniline Compounds; Antineoplastic Agents; Apoptosis; Benzimidazoles; Cell Line, Tumor; Cisplatin; Coordination Complexes; DNA; ErbB Receptors; Fluorescent Dyes; Gefitinib; Humans; Hydrolysis; Ligands; Membrane Proteins; Phenanthrolines; Quinazolines; Ruthenium | 2016 |
Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.
Topics: A549 Cells; Antineoplastic Agents; Azurin; Bacterial Proteins; Cell Adhesion; Cell Membrane; Cell Movement; Cell Proliferation; Drug Synergism; Elastic Modulus; ErbB Receptors; Erlotinib Hydrochloride; Extracellular Matrix; Gefitinib; Gene Expression; Humans; Integrin beta1; Microscopy, Atomic Force; Quinazolines; Surface Properties | 2016 |
Clinical, Pathological, and Molecular Features of Lung Adenocarcinomas with AXL Expression.
Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Cadherins; Down-Regulation; ErbB Receptors; Female; Gefitinib; Humans; Hyaluronan Receptors; Immunohistochemistry; Kaplan-Meier Estimate; Lung; Lung Neoplasms; Male; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Prognosis; Proportional Hazards Models; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
EGFR inhibitors identified as a potential treatment for chordoma in a focused compound screen.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Chordoma; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mice; Quinazolines; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
Combined treatment with vitamin E and gefitinib has synergistic effects to inhibit TGF-β1-induced renal fibroblast proliferation.
Topics: Animals; Cell Line; Cell Proliferation; Drug Synergism; Fibroblasts; Gefitinib; Gene Expression Regulation; Kidney; MAP Kinase Signaling System; Quinazolines; Rats; Transforming Growth Factor beta1; Vitamin E | 2016 |
Zoledronic acid increases the antitumor effect of gefitinib treatment for non-small cell lung cancer with EGFR mutations.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Diphosphonates; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mutation; Quinazolines; STAT3 Transcription Factor; Zoledronic Acid | 2016 |
Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium).
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prospective Studies; Protein Kinase Inhibitors; Quinazolines; Sequence Analysis, DNA; Treatment Outcome | 2016 |
Systemic therapy for recurrent meningioma.
Topics: Gefitinib; Humans; Kruppel-Like Factor 4; Meningeal Neoplasms; Meningioma; Prospective Studies; Quinazolines; Vascular Endothelial Growth Factor A | 2016 |
Anticancer Effects of Paris Saponins by Apoptosis and PI3K/AKT Pathway in Gefitinib-Resistant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Inhibitory Concentration 50; Liliaceae; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Signal Transduction | 2016 |
Study of Gefitinib and Pemetrexed as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutation.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
[The combination of dasatinib and gefitinib enhances the killing effect of gefitinib on HCC827 lung cancer cells].
Topics: Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Cell Proliferation; Dasatinib; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; src-Family Kinases | 2016 |
StructMAn: annotation of single-nucleotide polymorphisms in the structural context.
Topics: Amino Acid Sequence; Amino Acids; Animals; Bacteria; Benchmarking; Disease; Drug Resistance; ErbB Receptors; Gefitinib; Humans; Imaging, Three-Dimensional; Internet; Ligands; Models, Molecular; Molecular Sequence Annotation; Phenotype; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Proteins; Quinazolines; Software | 2016 |
Cetuximab-modified mesoporous silica nano-medicine specifically targets EGFR-mutant lung cancer and overcomes drug resistance.
Topics: Animals; Antineoplastic Agents, Immunological; Cell Line, Tumor; Cetuximab; Disease Models, Animal; Doxorubicin; Drug Carriers; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Heterografts; Humans; Lung Neoplasms; Nanomedicine; Quinazolines; Silicon Dioxide; Treatment Outcome | 2016 |
Inhibition of DHHC20-Mediated EGFR Palmitoylation Creates a Dependence on EGFR Signaling.
Topics: Acyltransferases; Animals; Antineoplastic Agents; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cysteine; Endocytosis; Epidermal Growth Factor; ErbB Receptors; Gefitinib; GRB2 Adaptor Protein; HEK293 Cells; Humans; Lipoylation; Mass Spectrometry; Mice; Mutation; NIH 3T3 Cells; Protein Conformation; Protein Kinase Inhibitors; Protein Processing, Post-Translational; Protein Transport; Proteolysis; Quinazolines; RNA Interference; Signal Transduction; Structure-Activity Relationship; Transfection | 2016 |
Effects of polymorphisms in CYP2D6 and ABC transporters and side effects induced by gefitinib on the pharmacokinetics of the gefitinib metabolite, O-desmethyl gefitinib.
Topics: Aged; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily G, Member 2; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Female; Gefitinib; Humans; Lung Neoplasms; Male; Multivariate Analysis; Neoplasm Proteins; Polymorphism, Single Nucleotide; Prospective Studies; Quinazolines | 2016 |
Synthesis of new 4-anilinoquinazoline analogues and evaluation of their EGFR inhibitor activity.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Inhibitory Concentration 50; Phosphorylation; Quinazolines | 2015 |
Overexpression of PAD4 suppresses drug resistance of NSCLC cell lines to gefitinib through inhibiting Elk1-mediated epithelial-mesenchymal transition.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ets-Domain Protein Elk-1; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hydrolases; Lung Neoplasms; Protein-Arginine Deiminase Type 4; Protein-Arginine Deiminases; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Epidermal growth factor receptor inhibitor cancer drug gefitinib modulates cell growth and differentiation of acute myeloid leukemia cells via histamine receptors.
Topics: Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Cyclic AMP; ErbB Receptors; Gefitinib; Gene Expression Regulation, Leukemic; Humans; Leukemia, Myeloid, Acute; MAP Kinase Signaling System; Phosphorylation; Protein Binding; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, G-Protein-Coupled; Receptors, Histamine; Receptors, Histamine H2; Receptors, Histamine H4 | 2016 |
Are TKIs favourable for the elderly with non-small-cell lung cancer?
Topics: Age Factors; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quality of Life; Quinazolines; Retrospective Studies; Treatment Outcome | 2016 |
HDAC6 promotes cell proliferation and confers resistance to gefitinib in lung adenocarcinoma.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2016 |
Necrolytic Migratory Erythema-like Skin Lesion During Gefitinib Treatment: A Rare Cutaneous Adverse Reaction.
Topics: Biopsy, Needle; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; Follow-Up Studies; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Male; Middle Aged; Necrolytic Migratory Erythema; Protein Kinase Inhibitors; Quinazolines; Rare Diseases; Risk Assessment; Withholding Treatment | 2016 |
IL-8 signaling is involved in resistance of lung carcinoma cells to erlotinib.
Topics: A549 Cells; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Interleukin-8; Lung Neoplasms; Mice; Mice, Nude; Mutation; Neoplasm Transplantation; p38 Mitogen-Activated Protein Kinases; Phenotype; Quinazolines; Signal Transduction; Up-Regulation | 2016 |
Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cyclosporine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; NFATC Transcription Factors; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; STAT3 Transcription Factor; Time Factors; Transfection; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Dihydrouracil Dehydrogenase (NADP); Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Plicamycin; Quinazolines; Signal Transduction; Sp1 Transcription Factor | 2016 |
The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Culture Techniques; Cell Line, Tumor; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Gain of Function Mutation; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2016 |
PA-MSHA in combination with EGFR tyrosine kinase inhibitor: A new strategy to overcome the drug resistance of non-small cell lung cancer cells.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Caspases; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fimbriae Proteins; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction | 2016 |
miR-26a desensitizes non-small cell lung cancer cells to tyrosine kinase inhibitors by targeting PTPN13.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; MicroRNAs; Protein Kinase Inhibitors; Protein Tyrosine Phosphatase, Non-Receptor Type 13; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2016 |
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; Female; Gefitinib; Gene Expression Regulation, Neoplastic; HEK293 Cells; Humans; Hydroxychloroquine; Lung Neoplasms; Lymphatic Metastasis; Mice; MicroRNAs; Neoplastic Stem Cells; Oligonucleotides; Quinazolines; Signal Transduction; Survival Analysis; Tumor Burden; Xenograft Model Antitumor Assays | 2016 |
Metformin and gefitinib cooperate to inhibit bladder cancer growth via both AMPK and EGFR pathways joining at Akt and Erk.
Topics: Administration, Intravesical; Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Metformin; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Urinary Bladder Neoplasms | 2016 |
[Effect of autophagy inhibitor combined with EGFR inhibitor on triple-negative breast cancer MDA-MB-468 and MDA-MB-231 cells].
Topics: Adenine; Antineoplastic Agents; Autophagy; Autophagy-Related Proteins; Caspase 3; Caspase 9; Cell Line, Tumor; Cell Proliferation; Gefitinib; Humans; Macrolides; MCF-7 Cells; Microtubule-Associated Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Triple Negative Breast Neoplasms | 2016 |
Drug repurposing for chronic myeloid leukemia: in silico and in vitro investigation of DrugBank database for allosteric Bcr-Abl inhibitors.
Topics: Allosteric Site; Antineoplastic Agents; Binding Sites; Catalytic Domain; Cell Proliferation; Dasatinib; Databases, Chemical; Drug Combinations; Drug Repositioning; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Fusion Proteins, bcr-abl; Gefitinib; Humans; Imatinib Mesylate; K562 Cells; Molecular Dynamics Simulation; Protein Binding; Protein Conformation, alpha-Helical; Protein Conformation, beta-Strand; Protein Interaction Domains and Motifs; Protein Kinase Inhibitors; Quinazolines; Thermodynamics | 2017 |
TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
Topics: Animals; Anthraquinones; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Proteolysis; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Stem Cell Assay; Ubiquitin; Ubiquitination | 2016 |
Comparative analysis of the interaction of capecitabine and gefitinib with human serum albumin using (19)F nuclear magnetic resonance-based approach.
Topics: Binding Sites; Capecitabine; Fluorine-19 Magnetic Resonance Imaging; Gefitinib; Humans; Protein Binding; Protein Structure, Secondary; Quinazolines; Serum Albumin | 2016 |
Overexpression of mutant EGFR protein indicates a better survival benefit from EGFR-TKI therapy in non-small cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Outcome Assessment, Health Care; Protein Kinase Inhibitors; Quinazolines | 2016 |
Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gallic Acid; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor; Xenograft Model Antitumor Assays | 2016 |
Co-targeting ALK and EGFR parallel signaling in oral squamous cell carcinoma.
Topics: Anaplastic Lymphoma Kinase; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Humans; Mice, Nude; Mouth Neoplasms; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Xenograft Model Antitumor Assays | 2016 |
AT-101 enhances gefitinib sensitivity in non-small cell lung cancer with EGFR T790M mutations.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gossypol; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Myeloid Cell Leukemia Sequence 1 Protein; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines | 2016 |
Amphiregulin Confers Regulatory T Cell Suppressive Function and Tumor Invasion via the EGFR/GSK-3β/Foxp3 Axis.
Topics: Amphiregulin; beta-Transducin Repeat-Containing Proteins; ErbB Receptors; Female; Forkhead Transcription Factors; Gefitinib; Gene Expression Regulation, Neoplastic; Glycogen Synthase Kinase 3 beta; HeLa Cells; Humans; Male; Neoplasms; Quinazolines; Signal Transduction; T-Lymphocytes, Regulatory | 2016 |
Inhibition of the EGFR/STAT3/CEBPD Axis Reverses Cisplatin Cross-resistance with Paclitaxel in the Urothelial Carcinoma of the Urinary Bladder.
Topics: Aminosalicylic Acids; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carcinoma; CCAAT-Enhancer-Binding Protein-delta; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Multidrug Resistance-Associated Protein 2; Paclitaxel; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Urinary Bladder Neoplasms; Urothelium | 2017 |
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity.
Topics: Acrylamides; Afatinib; Aniline Compounds; Animals; Antineoplastic Agents; Biological Transport; Blood-Brain Barrier; Brain Neoplasms; Caco-2 Cells; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Dogs; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Madin Darby Canine Kidney Cells; Male; Mice; Mice, SCID; Middle Aged; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Rats; Xenograft Model Antitumor Assays | 2016 |
Financial consequences of a payment-by-results scheme in Catalonia: gefitinib in advanced EGFR-mutation positive non-small-cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Drug Costs; ErbB Receptors; Female; Gefitinib; Humans; Interviews as Topic; Male; Middle Aged; Mutation; Qualitative Research; Quinazolines; Reimbursement, Incentive; Spain | 2017 |
Inhibition of SREBP increases gefitinib sensitivity in non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Humans; Hydroxycholesterols; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Microtubule-Associated Proteins; Protein Kinase Inhibitors; Pyridines; Quinazolines; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Thiazoles; Triterpenes; Xenograft Model Antitumor Assays | 2016 |
ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
Topics: Amino Acid Transport System ASC; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cetuximab; Dichloroacetic Acid; Down-Regulation; Endocytosis; ErbB Receptors; Gefitinib; Glutamine; Glutathione; Head and Neck Neoplasms; Humans; Minor Histocompatibility Antigens; Oxidative Stress; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Quinazolines; Reactive Oxygen Species; RNA Interference; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Time Factors; Transfection | 2016 |
Elaboration of tetra-orthogonally-substituted aromatic scaffolds towards novel EGFR-kinase inhibitors.
Topics: Amination; Animals; Catalysis; CHO Cells; Cricetulus; Drug Discovery; ErbB Receptors; Gefitinib; Humans; Molecular Docking Simulation; Molecular Structure; Palladium; Protein Kinase Inhibitors; Quinazolines; Small Molecule Libraries; Stereoisomerism; Structure-Activity Relationship | 2016 |
A genetic cell context-dependent role for ZEB1 in lung cancer.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Male; Mice, Nude; MicroRNAs; Promoter Regions, Genetic; Proto-Oncogene Proteins p21(ras); Quinazolines; Receptor, ErbB-3; Receptor, Notch1; Reproducibility of Results; Smoking; Xenograft Model Antitumor Assays; Zinc Finger E-box-Binding Homeobox 1 | 2016 |
IL-17E synergizes with EGF and confers in vitro resistance to EGFR-targeted therapies in TNBC cells.
Topics: Cell Line, Tumor; Cell Nucleus; Drug Resistance, Neoplasm; Drug Synergism; Epidermal Growth Factor; ErbB Receptors; Female; Gefitinib; Humans; Interleukin-17; Phosphorylation; Protein Kinase Inhibitors; Protein Transport; Quinazolines; Signal Transduction; STAT3 Transcription Factor; Triple Negative Breast Neoplasms | 2016 |
EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Male; Middle Aged; Polymerase Chain Reaction; Prospective Studies; Quinazolines | 2016 |
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer.
Topics: Adult; Aged; Aged, 80 and over; Androstadienes; Animals; Breast Neoplasms; Chromones; Class I Phosphatidylinositol 3-Kinases; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Mice; Middle Aged; Morpholines; Mutation; Phosphoric Monoester Hydrolases; Polyethylene Glycols; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Tissue Array Analysis; Xenograft Model Antitumor Assays | 2016 |
FOXM1 confers resistance to gefitinib in lung adenocarcinoma via a MET/AKT-dependent positive feedback loop.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Line, Tumor; Chromones; Drug Resistance, Neoplasm; Feedback, Physiological; Forkhead Box Protein M1; Gefitinib; Humans; Indoles; Lung Neoplasms; Morpholines; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA, Small Interfering; Signal Transduction; Sulfones | 2016 |
Optimal tumor shrinkage predicts long-term outcome in advanced nonsmall cell lung cancer (NSCLC) treated with target therapy: Result from 3 clinical trials of advanced NSCLC by 1 institution.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; China; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Invasiveness; Neoplasm Staging; Predictive Value of Tests; Quinazolines; Response Evaluation Criteria in Solid Tumors; ROC Curve; Survival Analysis; Time Factors; Treatment Outcome | 2016 |
Pneumatosis intestinalis after gefitinib therapy for pulmonary adenocarcinoma: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Female; Gefitinib; Humans; Lung Neoplasms; Pneumatosis Cystoides Intestinalis; Quinazolines; Tomography, X-Ray Computed | 2016 |
Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol.
Topics: Antineoplastic Agents; Autophagy; Blotting, Western; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; Pentacyclic Triterpenes; Proteolysis; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Triterpenes; Tumor Cells, Cultured | 2016 |
β-Elemene enhances the efficacy of gefitinib on glioblastoma multiforme cells through the inhibition of the EGFR signaling pathway.
Topics: Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Humans; Quinazolines; Sesquiterpenes; Signal Transduction | 2016 |
Human Organotypic Lung Tumor Models: Suitable For Preclinical 18F-FDG PET-Imaging.
Topics: Animals; Antineoplastic Agents; Drug Evaluation, Preclinical; Fluorodeoxyglucose F18; Gefitinib; Humans; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Lung; Lung Neoplasms; Organ Culture Techniques; Positron-Emission Tomography; Quinazolines; Radiopharmaceuticals; Rats; Rats, Inbred Lew | 2016 |
Cell autonomous or systemic EGFR blockade alters the immune-environment in squamous cell carcinomas.
Topics: Animals; Carcinoma, Squamous Cell; ErbB Receptors; Gefitinib; Immunocompetence; Keratinocytes; Mice; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms | 2016 |
Synthesis and biological evaluation of novel tricyclic oxazine and oxazepine fused quinazolines. Part 2: Gefitinib analogs.
Topics: Cell Line; ErbB Receptors; Gefitinib; Humans; Phosphorylation; Quinazolines | 2016 |
Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown.
Topics: A549 Cells; Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Cell Death; Cell Line, Tumor; Cetuximab; Class Ia Phosphatidylinositol 3-Kinase; Drug Delivery Systems; Gefitinib; Gelatin; Gene Expression Regulation, Neoplastic; Humans; Nanoconjugates; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Proto-Oncogene Proteins p21(ras); Quinazolines; Respiratory Mucosa; RNA, Small Interfering; Signal Transduction | 2016 |
Gefitinib, an EGFR Tyrosine Kinase inhibitor, Prevents Smoke-Mediated Ciliated Airway Epithelial Cell Loss and Promotes Their Recovery.
Topics: Cell Differentiation; Cell Survival; Cells, Cultured; Cilia; Epithelial Cells; ErbB Receptors; Forkhead Transcription Factors; Gefitinib; Humans; MAP Kinase Signaling System; Protein Kinase Inhibitors; Quinazolines; Respiratory Mucosa; Signal Transduction; Smoke; Smoking | 2016 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Down-regulation of SerpinB2 is associated with gefitinib resistance in non-small cell lung cancer and enhances invadopodia-like structure protrusions.
Topics: Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Neoplasm Proteins; Plasminogen Activator Inhibitor 2; Pseudopodia; Quinazolines | 2016 |
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; ErbB Receptors; Gefitinib; Glucuronosyltransferase; Humans; Lung Neoplasms; Middle Aged; Mutation; Pharmacogenetics; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Protein Kinase Inhibitors; Quinazolines; Retreatment; Treatment Outcome | 2016 |
Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; beta-Transducin Repeat-Containing Proteins; Breast; Breast Neoplasms; Cell Line, Tumor; Epidermal Growth Factor; Female; Gefitinib; Glycogen Synthase Kinase 3 beta; Glycosylation; Humans; Immunologic Surveillance; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Phosphorylation; Programmed Cell Death 1 Receptor; Protein Stability; Quinazolines; T-Lymphocytes; Tumor Escape; Ubiquitination; Xenograft Model Antitumor Assays | 2016 |
Colossolactone H, a new Ganoderma triterpenoid exhibits cytotoxicity and potentiates drug efficacy of gefitinib in lung cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; DNA Damage; Down-Regulation; Ganoderma; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Molecular Structure; Quinazolines; Reactive Oxygen Species; Triterpenes; Tumor Suppressor Protein p53; Up-Regulation; Xenograft Model Antitumor Assays | 2016 |
A decrease in D-dimer concentration and an occurrence of skin rash as iatrogenic events and complementary predictors of survival in lung cancer patients treated with EGFR tyrosine kinase inhibitors.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Fibrin Fibrinogen Degradation Products; Gefitinib; Humans; Iatrogenic Disease; Lung Neoplasms; Male; Middle Aged; Pilot Projects; Predictive Value of Tests; Protein Kinase Inhibitors; Quinazolines; Survival Rate | 2016 |
A novel application of E1A in combination therapy with EGFR-TKI treatment in breast cancer.
Topics: Adenovirus E1A Proteins; Animals; Apoptosis; Axl Receptor Tyrosine Kinase; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Disease Progression; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Genetic Therapy; Humans; Kaplan-Meier Estimate; Lapatinib; Mice; Mice, SCID; Neoplasm Transplantation; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Receptor Protein-Tyrosine Kinases | 2016 |
Potential influence of being overweight on the development of hepatic dysfunction in Japanese patients with EGFR-mutated non-small cell lung cancer undergoing gefitinib monotherapy: the Okayama Lung Cancer Study Group experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Body Mass Index; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Female; Gefitinib; Humans; Liver Function Tests; Lung Neoplasms; Male; Middle Aged; Mutation; Overweight; Quinazolines; Retrospective Studies; Risk Factors | 2016 |
Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Amplification; Gene Expression Regulation, Neoplastic; HSP90 Heat-Shock Proteins; Humans; Insulin-Like Growth Factor Binding Protein 2; Insulin-Like Growth Factor Binding Protein 3; Insulin-Like Growth Factor Binding Protein 4; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Receptor, IGF Type 1; Receptors, Death Domain; Receptors, Somatomedin; Signal Transduction; Smad2 Protein; Smad3 Protein; Somatomedins | 2016 |
Targeting Hsp90 with FS-108 circumvents gefitinib resistance in EGFR mutant non-small cell lung cancer cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heterografts; HSP90 Heat-Shock Proteins; Humans; Isoxazoles; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Neoplasm Transplantation; Oxazoles; Quinazolines; Resorcinols | 2016 |
Gefitinib enhances human colon cancer cells to TRAIL-induced apoptosis of via autophagy- and JNK-mediated death receptors upregulation.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Colonic Neoplasms; Gefitinib; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Quinazolines; Receptors, Death Domain; Receptors, TNF-Related Apoptosis-Inducing Ligand; TNF-Related Apoptosis-Inducing Ligand; Up-Regulation | 2016 |
Combining Nonclinical Experiments with Translational PKPD Modeling to Differentiate Erlotinib and Gefitinib.
Topics: Algorithms; Animals; Antineoplastic Agents; Biomarkers; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Mice; Models, Biological; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the B-Raf inhibitor encorafenib, the EGFR inhibitors afatinib, erlotinib and gefitinib and the O-desmethyl metabolites of erlotinib and gefitinib in human plasma.
Topics: Administration, Oral; Adult; Afatinib; Aged; Aged, 80 and over; Calibration; Carbamates; Chromatography, Liquid; Drug Monitoring; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Quinazolines; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry | 2016 |
Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Topics: Adolescent; Adult; Aged; Annexin A2; Antineoplastic Agents; Brain; Cell Movement; Cell Proliferation; Child; Child, Preschool; Cohort Studies; Craniopharyngioma; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Male; Middle Aged; Oncogene Protein v-akt; Pituitary Neoplasms; Prognosis; Quinazolines; Signal Transduction; Tumor Cells, Cultured; Young Adult | 2017 |
Neighbors' death is required for surviving human adenocarcinoma PC-9 cells in an early stage of gefitinib treatment.
Topics: Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Quinazolines; Receptors, Fibroblast Growth Factor; Signal Transduction; Treatment Outcome | 2016 |
AZ1366: An Inhibitor of Tankyrase and the Canonical Wnt Pathway that Limits the Persistence of Non-Small Cell Lung Cancer Cells Following EGFR Inhibition.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Mice; Neoplasm Recurrence, Local; Quinazolines; Tankyrases; Wnt Signaling Pathway; Xenograft Model Antitumor Assays | 2017 |
The Epidermal Growth Factor Receptor (EGFR) Inhibitor Gefitinib Reduces but Does Not Prevent Tumorigenesis in Chemical and Hormonal Induced Hepatocarcinogenesis Rat Models.
Topics: Animals; Cell Proliferation; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Islets of Langerhans Transplantation; Liver Neoplasms, Experimental; Male; Nitrosamines; Protein Kinase Inhibitors; Quinazolines; ras Proteins; Rats; Rats, Inbred Lew; Sodium-Glucose Transporter 1; Thyroid Epithelial Cells; TOR Serine-Threonine Kinases; Transforming Growth Factor alpha | 2016 |
Developments for Personalized Medicine of Lung Cancer Subtypes: Mass Spectrometry-Based Clinical Proteogenomic Analysis of Oncogenic Mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Asian People; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression; Humans; Lung Neoplasms; Mass Spectrometry; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Precision Medicine; Protein Interaction Mapping; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-ret; Quinazolines; Receptor, ErbB-2; White People | 2016 |
Case-specific potentiation of glioblastoma drugs by pterostilbene.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cell Cycle; Cell Line, Tumor; Cell Proliferation; DNA Copy Number Variations; Drug Synergism; Female; Gefitinib; Gene Expression Profiling; Gene Knockdown Techniques; Glioblastoma; Humans; Male; MAP Kinase Signaling System; Middle Aged; Mutation; Phenotype; Protein Kinase Inhibitors; Quinazolines; Stilbenes; Transcriptome | 2016 |
MiR-128 reverses the gefitinib resistance of the lung cancer stem cells by inhibiting the c-met/PI3K/AKT pathway.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; MicroRNAs; Models, Biological; Neoplastic Stem Cells; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; Signal Transduction | 2016 |
Anexelekto (AXL) Increases Resistance to EGFR-TKI and Activation of AKT and ERK1/2 in Non-Small Cell Lung Cancer Cells.
Topics: Antineoplastic Agents; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor Protein-Tyrosine Kinases; Transfection | 2016 |
Plexin A1 signaling confers malignant phenotypes in lung cancer cells.
Topics: Animals; Apoptosis; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Proliferation; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glucose; Mice; Nerve Tissue Proteins; Protein Kinase Inhibitors; Quinazolines; Receptors, Cell Surface; RNA, Small Interfering; Semaphorin-3A; Signal Transduction | 2016 |
Gefitinib enhances oxaliplatin-induced apoptosis mediated by Src and PKC-modulated gap junction function.
Topics: Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Caspase 9; Cell Line, Tumor; Connexin 43; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; Gap Junctions; Gefitinib; Humans; Organoplatinum Compounds; Oxaliplatin; Phosphorylation; Protein Kinase C; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-bcl-2; Quinazolines; src-Family Kinases | 2016 |
Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case.
Topics: Arm; Carcinoma, Squamous Cell; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Quinazolines; Soft Tissue Neoplasms; Treatment Outcome | 2016 |
Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2016 |
miR-543 is up-regulated in gefitinib-resistant non-small cell lung cancer and promotes cell proliferation and invasion via phosphatase and tensin homolog.
Topics: A549 Cells; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Enzyme Activation; Female; Gefitinib; Humans; Lung Neoplasms; Male; MicroRNAs; Middle Aged; Neoplasm Invasiveness; PTEN Phosphohydrolase; Quinazolines | 2016 |
EGFR mutation status of paired cerebrospinal fluid and plasma samples in EGFR mutant non-small cell lung cancer with leptomeningeal metastases.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Neoplasms; Middle Aged; Mutation; Quinazolines | 2016 |
Chalcone-templated Hsp90 inhibitors and their effects on gefitinib resistance in non-small cell lung cancer (NSCLC).
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Survival; Chalcone; Crystallography, X-Ray; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Structure, Secondary; Quinazolines | 2017 |
Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Topics: Animals; Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Drug Synergism; Endosomal Sorting Complexes Required for Transport; ErbB Receptors; Female; Fluorescent Antibody Technique; Focal Adhesion Kinase 2; Gefitinib; Humans; Immunoblotting; Immunohistochemistry; Immunoprecipitation; Intracellular Signaling Peptides and Proteins; Mice; Nedd4 Ubiquitin Protein Ligases; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-3; Signal Transduction; Triple Negative Breast Neoplasms; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2017 |
Phosphoproteome Profiling Reveals Molecular Mechanisms of Growth-Factor-Mediated Kinase Inhibitor Resistance in EGFR-Overexpressing Cancer Cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Fibroblast Growth Factor 2; Gefitinib; Humans; Neoplasms; Phosphoinositide-3 Kinase Inhibitors; Phosphopeptides; Protein Kinase Inhibitors; Proteome; Proteomics; Pyridones; Pyrimidinones; Quinazolines | 2016 |
Heterogeneity of the resistance to gefitinib treatment in a non-small cell lung cancer patient with active epidermal growth factor receptor mutation.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Heterogeneity; Humans; Liver Neoplasms; Lung Neoplasms; Male; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Treatment Outcome | 2017 |
Overexpression of OCT4 is associated with gefitinib resistance in non-small cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mutation; Octamer Transcription Factor-3; Protein Kinase Inhibitors; Quinazolines; RNA Interference; RNA, Small Interfering | 2016 |
Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles.
Topics: Antineoplastic Agents; Biomarkers, Tumor; Biopsy; Chemotherapy, Adjuvant; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genetic Predisposition to Disease; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Phenotype; Pneumonectomy; Protein Kinase Inhibitors; PTEN Phosphohydrolase; Quinazolines; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase 4; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Piperazines; Protein Kinase Inhibitors; Pyridines; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Bufalin inhibits gefitinib resistant NCI-H460 human lung cancer cell migration and invasion in vitro.
Topics: Antineoplastic Agents; Bufanolides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Lung Neoplasms; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Quinazolines; rhoA GTP-Binding Protein; Signal Transduction; SOS1 Protein | 2016 |
Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Glucocorticoids; Humans; Lung Neoplasms; Male; Mice; Middle Aged; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
Construction of a novel cell-based assay for the evaluation of anti-EGFR drug efficacy against EGFR mutation.
Topics: Afatinib; Antineoplastic Agents; Cell Culture Techniques; Cells, Cultured; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Transfection | 2017 |
Shikonin inhibits gefitinib-resistant non-small cell lung cancer by inhibiting TrxR and activating the EGFR proteasomal degradation pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; High-Throughput Screening Assays; Humans; Lung Neoplasms; Mutation; Naphthoquinones; Neoplasm Recurrence, Local; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Thioredoxin-Disulfide Reductase | 2017 |
Pyogenic Granuloma in a Patient on Gefitinib.
Topics: Antineoplastic Agents; Female; Fingers; Gefitinib; Granuloma, Pyogenic; Humans; Middle Aged; Quinazolines | 2016 |
miR-127 promotes EMT and stem-like traits in lung cancer through a feed-forward regulatory loop.
Topics: 3' Untranslated Regions; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Cell Movement; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Models, Biological; Neoplastic Stem Cells; NF-kappa B; Quinazolines; RNA Interference; Signal Transduction; Tumor Necrosis Factor alpha-Induced Protein 3 | 2017 |
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.
Topics: Adenocarcinoma; Cell Line, Tumor; Cetuximab; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; fms-Like Tyrosine Kinase 3; Gefitinib; Gene Rearrangement; Hepatocyte Growth Factor; Humans; Indoles; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Mas; Proto-Oncogene Proteins c-ret; Pyrroles; Quinazolines; RNA, Small Interfering; Signal Transduction; Sorafenib; Sunitinib | 2017 |
EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chi-Square Distribution; Databases, Factual; Disease Progression; Disease-Free Survival; Drug Interactions; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Karnofsky Performance Status; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Proportional Hazards Models; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Risk Assessment; Risk Factors; Singapore; Time Factors; Treatment Outcome | 2016 |
EGFR Mutation Subtypes Influence Survival Outcomes following First-Line Gefitinib Therapy in Advanced Asian NSCLC Patients.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Asian People; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.
Topics: Blood-Brain Barrier; Cell Line, Tumor; Cell Survival; Cell-Penetrating Peptides; Gefitinib; Glutathione; Humans; Liposomes; Lung Neoplasms; Microscopy, Confocal; Microscopy, Electron, Transmission; Polysorbates; Quinazolines | 2016 |
miR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer.
Topics: 3' Untranslated Regions; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Snail Family Transcription Factors; STAT3 Transcription Factor | 2016 |
miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation; Gene Silencing; Humans; Mice; Mice, Nude; MicroRNAs; Neoplasms, Experimental; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
Computational and Experimental Characterization of Patient Derived Mutations Reveal an Unusual Mode of Regulatory Spine Assembly and Drug Sensitivity in EGFR Kinase.
Topics: Allosteric Regulation; Amino Acid Motifs; Animals; Catalytic Domain; CHO Cells; Cricetinae; Cricetulus; Drug Resistance; Enzyme Activation; Epidermal Growth Factor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrophobic and Hydrophilic Interactions; Immunoblotting; Lapatinib; Molecular Dynamics Simulation; Mutation; Protein Kinase Inhibitors; Protein Structure, Secondary; Quinazolines | 2017 |
17β-estradiol-induced growth of triple-negative breast cancer cells is prevented by the reduction of GPER expression after treatment with gefitinib.
Topics: Antineoplastic Agents; Aromatase; Cell Line, Tumor; Cell Proliferation; CSK Tyrosine-Protein Kinase; Cyclin D1; ErbB Receptors; Estradiol; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genes, fos; Humans; Phosphorylation; Quinazolines; Receptors, Estrogen; Receptors, G-Protein-Coupled; src-Family Kinases; Triple Negative Breast Neoplasms | 2017 |
Effect of Particle Size on Drug Loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres.
Topics: Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Gefitinib; Kinetics; Lactic Acid; Microscopy, Electron, Scanning; Microspheres; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Solvents; X-Ray Diffraction | 2017 |
Chinese herbal medicine Fuzheng Kang-Ai decoction sensitized the effect of gefitinib on inhibition of human lung cancer cells through inactivating PI3-K/Akt -mediated suppressing MUC1 expression.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drugs, Chinese Herbal; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucin-1; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; RNA, Messenger | 2016 |
MicroRNA-30e reduces cell growth and enhances drug sensitivity to gefitinib in lung carcinoma.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Homeodomain Proteins; Humans; Lung Neoplasms; Mice; MicroRNAs; Neoplasm Transplantation; Quinazolines; Transcription Factors | 2017 |
Design, synthesis, and biological evaluation of novel 1-oxo-1,2,3,4-tetrahydropyrazino[1,2-a]indole-3-carboxamide analogs in MCF-7 and MDA-MB-468 breast cancer cell lines.
Topics: Amides; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Design; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Indoles; MCF-7 Cells; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Structure-Activity Relationship | 2017 |
Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.
Topics: Anti-HIV Agents; Antineoplastic Agents; Computer Simulation; Drug Interactions; Erlotinib Hydrochloride; Gefitinib; HIV Infections; Humans; Models, Biological; Quinazolines | 2017 |
The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis; Treatment Outcome | 2017 |
A Comparison of ddPCR and ARMS for detecting EGFR T790M status in ctDNA from advanced NSCLC patients with acquired EGFR-TKI resistance.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Polymerase Chain Reaction; Precision Medicine; Prognosis; Quinazolines; Reagent Kits, Diagnostic; Sensitivity and Specificity; Treatment Outcome | 2017 |
Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3.
Topics: Crizotinib; Drug Interactions; Gefitinib; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines | 2018 |
Synchronous occurrence of squamous-cell carcinoma "transformation" and EGFR exon 20 S768I mutation as a novel mechanism of resistance in EGFR-mutated lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Fatal Outcome; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
Topics: Adult; Afatinib; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Magnetic Resonance Imaging; Meningeal Carcinomatosis; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Treatment Outcome | 2017 |
Remarkable bone formation following gefitinib for extensive lytic bone metastasis: a report of two cases.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Bone Neoplasms; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Osteogenesis; Pelvic Bones; Quinazolines; Spine | 2016 |
Cost-effectiveness of gefitinib, icotinib, and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; China; Computer Simulation; Cost-Benefit Analysis; Crown Ethers; Disease-Free Survival; Drug Costs; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Models, Economic; Molecular Targeted Therapy; Mutation; Pemetrexed; Precision Medicine; Protein Kinase Inhibitors; Quality-Adjusted Life Years; Quinazolines; Time Factors; Treatment Outcome | 2017 |
Transcriptome analysis of EGFR tyrosine kinase inhibitors resistance associated long noncoding RNA in non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Profiling; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Long Noncoding | 2017 |
Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2017 |
Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Disease-Free Survival; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Meningeal Carcinomatosis; Middle Aged; Prognosis; Quinazolines; Retrospective Studies | 2017 |
Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Cell Line; Cell Line, Tumor; Cell Movement; Choline Kinase; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Hep G2 Cells; Humans; Immunoblotting; Immunohistochemistry; Liver Neoplasms; Mechanistic Target of Rapamycin Complex 2; Mice; Multiprotein Complexes; Neoplasm Invasiveness; Neoplasm Transplantation; Quinazolines; RNA, Messenger; TOR Serine-Threonine Kinases; Wound Healing; Xenograft Model Antitumor Assays | 2017 |
Norcantharidin Inhibits cell growth by suppressing the expression and phosphorylation of both EGFR and c-Met in human colon cancer cells.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; ErbB Receptors; G2 Phase Cell Cycle Checkpoints; Gefitinib; HCT116 Cells; HT29 Cells; Humans; Phosphorylation; Proto-Oncogene Proteins c-met; Quinazolines | 2017 |
EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.
Topics: Acrylamides; Adenocarcinoma; Afatinib; Alleles; Aniline Compounds; Animals; Antineoplastic Agents; Cell Proliferation; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Middle Aged; NIH 3T3 Cells; Phosphorylation; Piperazines; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Cells, Cultured | 2017 |
Polyphyllin II Restores Sensitization of the Resistance of PC-9/ZD Cells to Gefitinib by a Negative Regulation of the PI3K/Akt/mTOR Signaling Pathway.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Saponins; Steroids; TOR Serine-Threonine Kinases; Xenograft Model Antitumor Assays | 2017 |
Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis.
Topics: Algorithms; Antineoplastic Agents; Bortezomib; Commerce; Cost-Benefit Analysis; Dasatinib; Drug Costs; Drugs, Generic; England; Everolimus; Gefitinib; Humans; Neoplasms; Quinazolines | 2017 |
Distinct Benefit of Overall Survival between Patients with Non-Small-Cell Lung Cancer Harboring EGFR Exon 19 Deletion and Exon 21 L858R Substitution.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Multivariate Analysis; Mutation; Odds Ratio; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Sequence Deletion | 2017 |
Repression of Smad3 by Stat3 and c-Ski/SnoN induces gefitinib resistance in lung adenocarcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mutation; Proto-Oncogene Proteins; Quinazolines; Signal Transduction; Smad3 Protein; STAT3 Transcription Factor | 2017 |
Impact of EGFR-Tyrosine Kinase Inhibitors on Postoperative Recurrent Non-Small-Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Recurrence, Local; Postoperative Period; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Oncogenes Activate an Autonomous Transcriptional Regulatory Circuit That Drives Glioblastoma.
Topics: Animals; Astrocytes; Brain; Brain Neoplasms; Cell Proliferation; Cells, Cultured; Disease Models, Animal; Down-Regulation; ErbB Receptors; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasm Grading; Oligodendrocyte Transcription Factor 2; Plasmids; Plicamycin; Quinazolines; Receptor, Platelet-Derived Growth Factor alpha; RNA Interference; SOXB1 Transcription Factors; Zinc Finger E-box-Binding Homeobox 1 | 2017 |
An unexpected response to second line EGFR inhibitor in relapsing leptomeningeal carcinomatosis from lung adenocarcinoma raises questions on differential mechanisms of action of these agents.
Topics: Adenocarcinoma; Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Middle Aged; Quinazolines | 2017 |
Synthesis and antitumor activity evaluation of novel oleanolic acid derivatives.
Topics: A549 Cells; Antineoplastic Agents; Cell Proliferation; Drug Screening Assays, Antitumor; Gefitinib; HeLa Cells; Humans; Molecular Docking Simulation; Molecular Structure; Oleanolic Acid; Pentacyclic Triterpenes; Proto-Oncogene Proteins c-kit; Quinazolines; Structure-Activity Relationship | 2017 |
Endothelin causes transactivation of the EGFR and HER2 in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Endothelins; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Peptides, Cyclic; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Receptor, Endothelin A; Receptor, Endothelin B; Receptor, ErbB-2; Transcriptional Activation | 2017 |
Epidermal Growth Factor Receptor (EGFR) Mutation in Exon 19 (p.E749Q) Confers Resistance to Gefitinib in One Patient With Lung Adenocarcinoma.
Topics: Adenocarcinoma; Aged; DNA Mutational Analysis; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Dyspnea; ErbB Receptors; Exons; Gefitinib; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Mutation; Pleural Effusion; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib or Erlotinib for Previously Treated Lung Adenocarcinoma: Which Is Superior?
Topics: Adenocarcinoma of Lung; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2017 |
Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Topics: Antineoplastic Agents; Apoptosis; Benzoates; Benzylamines; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Immunohistochemistry; Liver X Receptors; Lung Neoplasms; NF-kappa B; Proto-Oncogene Proteins c-akt; Quinazolines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction | 2017 |
Gefitinib/gefitinib microspheres loaded polyurethane constructs as drug-eluting stent coating.
Topics: Delayed-Action Preparations; Drug Liberation; Drug-Eluting Stents; Excipients; Gefitinib; Humans; Lactic Acid; Microspheres; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Polyurethanes; Quinazolines | 2017 |
Protein kinase CK2 is important for the function of glioblastoma brain tumor initiating cells.
Topics: AC133 Antigen; Animals; Brain Neoplasms; Casein Kinase II; Cell Line, Tumor; Cell Proliferation; Embryo, Mammalian; Enzyme Inhibitors; Female; Gefitinib; Glioblastoma; Humans; Mice; Mice, Inbred C57BL; Mice, Nude; Naphthyridines; Neoplastic Stem Cells; Phenazines; Pregnancy; Quinazolines; RNA, Small Interfering; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Retrospective Analysis of Different Treatment Schemes After Gefitinib Resistance in Advanced Non-small Cell Lung Cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Quinazolines; Retrospective Studies; Survival Rate | 2017 |
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
Topics: Adenocarcinoma; Aged; Biomarkers; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
[Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
[Precision first-line therapy for advanced non-small-cell lung cancer patients harboring EGFR mutation].
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Regulation of voltage-gated potassium channels attenuates resistance of side-population cells to gefitinib in the human lung cancer cell line NCI-H460.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Potassium Channels, Voltage-Gated; Quinazolines; Side-Population Cells | 2017 |
Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines | 2017 |
Gefitinib single drug in treatment of advanced esophageal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Disease Progression; Esophageal Neoplasms; Female; Follow-Up Studies; Gefitinib; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2016 |
Synthesis and in vitro biological evaluation of novel quinazoline derivatives.
Topics: Aniline Compounds; Antineoplastic Agents; Cell Line, Tumor; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lapatinib; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction | 2017 |
Patient response to use of tyrosine kinase inhibitors in lung cancer: a retrospective audit during funding changes.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; Erlotinib Hydrochloride; Female; Financing, Government; Gefitinib; Genes, erbB-1; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Medical Audit; Middle Aged; New Zealand; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Gefitinib enhances radiotherapeutic effects of
Topics: Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Transformation, Neoplastic; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Iodine Radioisotopes; Mice; Mice, Nude; Protein Transport; Quinazolines; Radiation Tolerance; Radiochemistry; Tissue Distribution | 2017 |
Outcome in advanced non-small cell lung cancer patients with successful rechallenge after recovery from epidermal growth factor receptor tyrosine kinase inhibitor-induced interstitial lung disease.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Middle Aged; Mutation; Prednisolone; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Survival Analysis; Tomography, X-Ray Computed; Treatment Outcome | 2017 |
DDX17 nucleocytoplasmic shuttling promotes acquired gefitinib resistance in non-small cell lung cancer cells via activation of β-catenin.
Topics: A549 Cells; Active Transport, Cell Nucleus; Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Non-Small-Cell Lung; DEAD-box RNA Helicases; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nuclear Export Signals; Nuclear Localization Signals; Protein Binding; Protein Kinase Inhibitors; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transfection | 2017 |
Piccolo mediates EGFR signaling and acts as a prognostic biomarker in esophageal squamous cell carcinoma.
Topics: Animals; Antibodies, Monoclonal; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cytoskeletal Proteins; Disease-Free Survival; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Expression; Humans; Inhibitory Concentration 50; Kaplan-Meier Estimate; Lymphatic Metastasis; Male; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Mutation; Neoplasm Transplantation; Neuropeptides; Prognosis; Proportional Hazards Models; Protein Stability; Protein Transport; Quinazolines; Signal Transduction | 2017 |
A fluorescent light-up aggregation-induced emission probe for screening gefitinib-sensitive non-small cell lung carcinoma.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Screening Assays, Antitumor; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Optical Imaging; Peptides; Protein Kinase Inhibitors; Quinazolines; Stilbenes | 2017 |
Chronic myelomonocytic leukemia blast crisis in a patient with advanced non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors.
Topics: Afatinib; Agranulocytosis; Blast Crisis; Carcinoma, Non-Small-Cell Lung; Female; Gefitinib; Genes, erbB-1; Humans; Leukemia, Myelomonocytic, Chronic; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells.
Topics: Anoikis; Antineoplastic Agents; Brain Neoplasms; Cell Adhesion; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Gefitinib; Glioblastoma; Humans; Neovascularization, Pathologic; Phenylurea Compounds; Quinazolines; Quinolines; Receptors, Vascular Endothelial Growth Factor | 2017 |
Phosphoproteomics Reveals HMGA1, a CK2 Substrate, as a Drug-Resistant Target in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HMGA1a Protein; Humans; Lung Neoplasms; Phosphorylation; Protein Interaction Maps; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2017 |
Neutrophil elastase inhibitor sivelestat ameliorates gefitinib-naphthalene-induced acute pneumonitis in mice.
Topics: Acute Disease; Animals; Bronchoalveolar Lavage Fluid; Female; Gefitinib; Glycine; Humans; Kaplan-Meier Estimate; Leukocyte Count; Leukocyte Elastase; Lung; Mice, Inbred C57BL; Naphthalenes; Neutrophils; Pneumonia; Quinazolines; Serine Proteinase Inhibitors; Sulfonamides; Weight Loss | 2017 |
Epidermal growth factor receptor (EGFR) structure-based bioactive pharmacophore models for identifying next-generation inhibitors against clinically relevant EGFR mutations.
Topics: Antineoplastic Agents; Computer-Aided Design; Databases, Pharmaceutical; Drug Design; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydroxamic Acids; Molecular Docking Simulation; Mutation; Protein Kinase Inhibitors; Quantitative Structure-Activity Relationship; Quinazolines; Small Molecule Libraries | 2017 |
Clinical Response to Everolimus of EGFR-Mutation-Positive NSCLC With Primary Resistance to EGFR TKIs.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; DNA Mutational Analysis; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Everolimus; Gefitinib; Genes, erbB-1; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Male; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Caspase 3; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Oligonucleotide Array Sequence Analysis; Quinazolines; Real-Time Polymerase Chain Reaction | 2017 |
Exosome production and its regulation of EGFR during wound healing in renal tubular cells.
Topics: Aniline Compounds; Animals; Benzylidene Compounds; Cell Line; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Exosomes; Gefitinib; Kidney Tubules; Mice; Polyenes; Polyunsaturated Alkamides; Quinazolines; Signal Transduction; Time Factors; Wound Healing | 2017 |
BCL6 promotes glioma and serves as a therapeutic target.
Topics: Animals; Axl Receptor Tyrosine Kinase; Brain Neoplasms; Cell Line, Tumor; Gefitinib; Gene Expression Regulation, Neoplastic; Glioblastoma; Glioma; Humans; MAP Kinase Kinase Kinases; Mice, Mutant Strains; Molecular Targeted Therapy; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-6; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2017 |
Triggering of Suicidal Erythrocyte Death by Gefitinib.
Topics: Calcium; Calcium Signaling; Cell Death; Erythrocyte Membrane; Female; Gefitinib; Humans; Male; Oxidative Stress; Phospholipids; Quinazolines; Reactive Oxygen Species | 2017 |
Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.
Topics: A549 Cells; Antineoplastic Agents; Binding Sites; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Design; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HT29 Cells; Humans; Lung Neoplasms; Molecular Docking Simulation; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Structure-Activity Relationship | 2017 |
Central nervous system progression in advanced non-small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study.
Topics: Adult; Aged; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Central Nervous System Neoplasms; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Prognosis; Quality of Life; Quinazolines | 2017 |
Low plasma concentration of gefitinib in patients with EGFR exon 21 L858R point mutations shortens progression-free survival.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed | 2017 |
Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung; Lung Neoplasms; Mice; Models, Molecular; Morpholines; Point Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays | 2017 |
Acquired
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Middle Aged; Mutation; NIH 3T3 Cells; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Regulation of miR-21 expression in human melanoma via UV-ray-induced melanin pigmentation.
Topics: alpha-MSH; Animals; Cell Line, Tumor; Down-Regulation; ErbB Receptors; Gefitinib; Humans; Melanins; Melanoma; Melanoma, Experimental; Mice; MicroRNAs; Phosphorylation; Pigmentation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Skin Neoplasms; Ultraviolet Rays | 2017 |
Chitosan nanoparticle-mediated co-delivery of shAtg-5 and gefitinib synergistically promoted the efficacy of chemotherapeutics through the modulation of autophagy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chitosan; Drug Delivery Systems; Female; Gefitinib; Gene Silencing; Humans; Mice, Inbred BALB C; Mice, Nude; Nanomedicine; Nanoparticles; Neoplasms, Experimental; Quinazolines; RNA, Small Interfering; Transfection | 2017 |
Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFR.
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cetuximab; Drug Administration Schedule; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Hedgehog Proteins; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Treatment Outcome; Xenograft Model Antitumor Assays | 2017 |
Generation of lung cancer cell lines harboring EGFR T790M mutation by CRISPR/Cas9-mediated genome editing.
Topics: Amino Acid Substitution; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; CRISPR-Cas Systems; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Editing; Gene Expression; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2017 |
Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6.
Topics: A549 Cells; Apoptosis; Astragalus propinquus; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Quinazolines; Saponins; Sirtuins; Triterpenes | 2017 |
Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Flow Cytometry; Gefitinib; Glucose; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Neoplastic Stem Cells; Phloretin; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Withanolides; Xenograft Model Antitumor Assays | 2017 |
Dasatinib + Gefitinib, a non platinum-based combination with enhanced growth inhibitory, anti-migratory and anti-invasive potency against human ovarian cancer cells.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Movement; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Drug Synergism; ErbB Receptors; Female; Gefitinib; Humans; MAP Kinase Signaling System; Molecular Targeted Therapy; Neoplasm Invasiveness; Ovarian Neoplasms; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; src-Family Kinases; Tumor Cells, Cultured | 2017 |
Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
Topics: Adult; Aged; Aged, 80 and over; Amphiregulin; Biomarkers, Tumor; Calcifediol; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Male; Middle Aged; Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Signal Transduction; Survival Analysis | 2017 |
Functional characterization of wild-type and 24 CYP2D6 allelic variants on gefitinib metabolism in vitro.
Topics: Alleles; Antineoplastic Agents; Cytochrome P-450 CYP2D6; Gefitinib; Genetic Variation; Humans; Quinazolines | 2017 |
Selective targeting of point-mutated KRAS through artificial microRNAs.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Mice; Mice, Nude; MicroRNAs; Neoplasm Transplantation; Polymorphism, Single Nucleotide; Proto-Oncogene Proteins p21(ras); Quinazolines; RNA Interference; RNA, Small Interfering; Transplantation, Heterologous | 2017 |
The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Salvage Therapy | 2017 |
Epithelial growth factor receptor expression influences 5-ALA induced glioblastoma fluorescence.
Topics: Aminolevulinic Acid; Astrocytes; Cell Line, Tumor; Epidermal Growth Factor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Gene Expression; Glioblastoma; Heme Oxygenase-1; Humans; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger | 2017 |
Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gain of Function Mutation; Gefitinib; Hepatitis C, Chronic; Humans; Liver Neoplasms; Lung; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Smoking; Taiwan | 2017 |
Autophagy inhibitor facilitates gefitinib sensitivity in vitro and in vivo by activating mitochondrial apoptosis in triple negative breast cancer.
Topics: Adenine; Animals; Autophagy; Caspase 3; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Survival; Cytochromes c; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; In Vitro Techniques; Macrolides; Mice; Mice, Nude; Mitochondria; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Successful Treatment with Gefitinib in Advanced Non-Small Cell Lung Cancer after Acquired Resistance to Osimertinib.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Piperazines; Prognosis; Quinazolines; Remission Induction | 2017 |
Gefitinib Delays NSCLC Recurrence After Surgery.
Topics: Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase III as Topic; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Mutation; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines | 2017 |
The Tyrosine Kinase Inhibitor Gefitinib Restricts Mycobacterium tuberculosis Growth through Increased Lysosomal Biogenesis and Modulation of Cytokine Signaling.
Topics: Animals; Antitubercular Agents; Bone Marrow Cells; Cytokines; ErbB Receptors; Gefitinib; Gene Expression Regulation; Lysosomes; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Mycobacterium tuberculosis; Organelle Biogenesis; Phosphoproteins; Primary Cell Culture; Protein Kinase Inhibitors; Proteomics; Quinazolines; Signal Transduction; STAT3 Transcription Factor | 2017 |
Gefitinib and EGFR Gene Copy Number Aberrations in Esophageal Cancer.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Class I Phosphatidylinositol 3-Kinases; Clinical Trials, Phase III as Topic; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Gene Amplification; Gene Dosage; Genes, erbB-1; Humans; In Situ Hybridization, Fluorescence; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins p21(ras); Quinazolines; Randomized Controlled Trials as Topic; Response Evaluation Criteria in Solid Tumors; Signal Transduction; Single-Blind Method; Survival Rate | 2017 |
Interaction of glycosphingolipids GD3 and GD2 with growth factor receptors maintains breast cancer stem cell phenotype.
Topics: Aldehyde Dehydrogenase 1 Family; Animals; Biomarkers; Breast Neoplasms; Cell Adhesion; Cell Line, Tumor; Cell Movement; Clonal Evolution; Disease Models, Animal; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Knockdown Techniques; Glycosphingolipids; Humans; Isoenzymes; Mice; Neoplastic Stem Cells; Phenotype; Quinazolines; Receptors, Growth Factor; Retinal Dehydrogenase; Sialyltransferases; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Purpuric Drug Eruptions Caused by Epidermal Growth Factor Receptor Inhibitors for Non-Small Cell Lung Cancer: A Clinicopathologic Study of 32 Cases.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug Eruptions; ErbB Receptors; Erlotinib Hydrochloride; Female; Filaggrin Proteins; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Prospective Studies; Quinazolines | 2017 |
Synergistic Activity of an Antimetabolite Drug and Tyrosine Kinase Inhibitors against Breast Cancer Cells.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Cycle; Cell Proliferation; Cell Survival; Cladribine; Dasatinib; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Humans; MCF-7 Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship | 2017 |
Impact of Small Molecules on β-Catenin and E-Cadherin Expression in HPV16-positive and -negative Squamous Cell Carcinomas.
Topics: Antigens, CD; Antineoplastic Agents; beta Catenin; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Dasatinib; Erlotinib Hydrochloride; Gefitinib; Head and Neck Neoplasms; Human papillomavirus 16; Humans; Protein Kinase Inhibitors; Pyrimidines; Quinazolines | 2017 |
Corneal edema with a systemic epidermal growth factor receptor inhibitor.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Corneal Edema; Dose-Response Relationship, Drug; Drug Substitution; Epithelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Quinazolines | 2017 |
Cigarette smoke extract induces EGFR-TKI resistance via promoting EGFR signaling pathway and ROS generation in NSCLC cell lines.
Topics: A549 Cells; Acetylcysteine; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cigarette Smoking; Drug Resistance, Neoplasm; ErbB Receptors; Free Radical Scavengers; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2017 |
Effects of Histamine 2-receptor Antagonists and Proton Pump Inhibitors on the Pharmacokinetics of Gefitinib in Patients With Non-small-cell Lung Cancer.
Topics: Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2C19; Drug Interactions; Female; Gefitinib; Genotype; Histamine H2 Antagonists; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Proton Pump Inhibitors; Quinazolines; Retrospective Studies | 2017 |
Construction of EGFR peptide gefitinib/quantum dots long circulating polymeric liposomes for treatment and detection of nasopharyngeal carcinoma.
Topics: Antineoplastic Agents; Carcinoma; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Gefitinib; Humans; Liposomes; Nasopharyngeal Carcinoma; Nasopharyngeal Neoplasms; Peptides; Polymers; Quantum Dots; Quinazolines; Structure-Activity Relationship; Tumor Cells, Cultured | 2017 |
Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Droplet digital PCR improved the EGFR mutation diagnosis with pleural fluid samples in non-small-cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crown Ethers; DNA, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Particle Size; Pleural Effusion; Polymerase Chain Reaction; Quinazolines | 2017 |
Trisubstituted Pyridinylimidazoles as Potent Inhibitors of the Clinically Resistant L858R/T790M/C797S EGFR Mutant: Targeting of Both Hydrophobic Regions and the Phosphate Binding Site.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imidazoles; Lung Neoplasms; Molecular Docking Simulation; Point Mutation; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2017 |
Aucklandia lappa DC. extract enhances gefitinib efficacy in gefitinib-resistance secondary epidermal growth factor receptor mutations.
Topics: Animals; Animals, Genetically Modified; Antineoplastic Agents; Asteraceae; Caenorhabditis elegans; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Mutation; Plant Extracts; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction | 2017 |
The MET/AXL/FGFR Inhibitor S49076 Impairs Aurora B Activity and Improves the Antitumor Efficacy of Radiotherapy.
Topics: Aurora Kinase B; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Quinazolines; Radiation Tolerance; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Signal Transduction; Xenograft Model Antitumor Assays | 2017 |
Fabrication of β-cyclodextrin-mediated single bimolecular inclusion complex: characterization, molecular docking, in-vitro release and bioavailability studies for gefitinib and simvastatin conjugate.
Topics: Animals; Anticholesteremic Agents; Antineoplastic Agents; beta-Cyclodextrins; Biological Availability; Drug Carriers; Drug Compounding; Drug Liberation; Female; Gefitinib; Male; Mice; Molecular Docking Simulation; Quinazolines; Rats, Wistar; Simvastatin; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2017 |
Gefitinib or erlotinib in previously treated non-small-cell lung cancer patients: a cohort study in Taiwan.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cohort Studies; Comorbidity; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Prognosis; Propensity Score; Proportional Hazards Models; Protein Kinase Inhibitors; Quinazolines; Registries; Retreatment; Severity of Illness Index; Taiwan; Treatment Outcome | 2017 |
Induction of CYP1A1 increases gefitinib-induced oxidative stress and apoptosis in A549 cells.
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Cytochrome P-450 CYP1A1; Enzyme Induction; Gefitinib; Humans; Membrane Potential, Mitochondrial; Oxidative Stress; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species; RNA, Small Interfering | 2017 |
Suppression of Lipogenesis via Reactive Oxygen Species-AMPK Signaling for Treating Malignant and Proliferative Diseases.
Topics: AMP-Activated Protein Kinases; Arthritis, Rheumatoid; Berberine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Fibroblasts; Gefitinib; Gene Expression Regulation; Humans; Lipogenesis; Oxidation-Reduction; Quinazolines; Reactive Oxygen Species; Signal Transduction; Sterol Regulatory Element Binding Protein 1; Synovial Fluid | 2018 |
HB-EGF Is a Promising Therapeutic Target for Lung Cancer with Secondary Mutation of
Topics: Animals; Antineoplastic Agents; Apoptosis; Bacterial Proteins; Cell Line, Tumor; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Tumor Burden | 2017 |
Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; DNA Mutational Analysis; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Retrospective Studies; Treatment Outcome | 2017 |
Reverse epithelial-mesenchymal transition contributes to the regain of drug sensitivity in tyrosine kinase inhibitor-resistant non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial Cells; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mutation; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Snail Family Transcription Factors | 2017 |
Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; B7-H1 Antigen; Binding Sites; Cell Line, Tumor; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Nuclear Proteins; Phosphoproteins; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Respiratory Mucosa; RNA, Messenger; RNA, Small Interfering; Signal Transduction; TEA Domain Transcription Factors; Transcription Factors; YAP-Signaling Proteins | 2017 |
Liposomal honokiol induced lysosomal degradation of Hsp90 client proteins and protective autophagy in both gefitinib-sensitive and gefitinib-resistant NSCLC cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Biphenyl Compounds; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Female; Gefitinib; HSP90 Heat-Shock Proteins; Humans; Lignans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Quinazolines; Signal Transduction | 2017 |
The EGFR/miR-338-3p/EYA2 axis controls breast tumor growth and lung metastasis.
Topics: Adult; Aged; Aged, 80 and over; Animals; Breast Neoplasms; Cell Line, Tumor; Down-Regulation; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Mice; Mice, Inbred BALB C; MicroRNAs; Middle Aged; Nuclear Proteins; Protein Tyrosine Phosphatases; Quinazolines; Signal Transduction; Transplantation, Homologous | 2017 |
Induction of ABCG2/BCRP restricts the distribution of zidovudine to the fetal brain in rats.
Topics: Animals; Anti-HIV Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Biological Availability; Brain; Female; Fetus; Gefitinib; Lipid Peroxidation; Mitochondria; Pregnancy; Quinazolines; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Inhibitors; Zidovudine | 2017 |
Role for ZAP-70 Signaling in the Differential Effector Functions of Rituximab and Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia B Cells.
Topics: Adenine; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; B-Lymphocytes; Cell Adhesion; Cell Adhesion Molecules; Gefitinib; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Monocytes; Piperidines; Pyrazoles; Pyrimidines; Quinazolines; Receptors, IgG; Rituximab; Signal Transduction; ZAP-70 Protein-Tyrosine Kinase | 2017 |
Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ.
Topics: A549 Cells; Acyltransferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Hydroxamic Acids; Indoles; Mice; Panobinostat; Proto-Oncogene Proteins p21(ras); Quinazolines; Transcription Factors | 2017 |
Dihydroartemisinin and gefitinib synergistically inhibit NSCLC cell growth and promote apoptosis via the Akt/mTOR/STAT3 pathway.
Topics: Apoptosis; Artemisinins; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; CDC2 Protein Kinase; Cell Cycle; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Cyclin B1; Down-Regulation; Drug Synergism; Gefitinib; Humans; Lung Neoplasms; Neoplasm Invasiveness; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; STAT3 Transcription Factor; TOR Serine-Threonine Kinases; Up-Regulation | 2017 |
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2017 |
Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.
Topics: Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lymphocyte Count; Lymphocytes; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Neutrophils; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2017 |
Therapeutic Role of MiR-140-5p for the Treatment of Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cisplatin; Disease Progression; Down-Regulation; Drug Screening Assays, Antitumor; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; MicroRNAs; Pyrazoles; Quinazolines; Quinolines; Signal Transduction; Up-Regulation | 2017 |
Simultaneous quantification of volitinib and gefitinib in rat plasma by HPLC-MS/MS for application to a pharmacokinetic study in rats.
Topics: Animals; Chromatography, High Pressure Liquid; Gefitinib; Pyrazines; Quinazolines; Rats; Tandem Mass Spectrometry; Triazines | 2017 |
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Cost-Benefit Analysis; Gefitinib; Humans; Lung Neoplasms; Quinazolines; Radiation-Sensitizing Agents | 2017 |
Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Drug Resistance, Neoplasm; Drug Synergism; G1 Phase; Gefitinib; Humans; Lung Neoplasms; Phytotherapy; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Saponins; Signal Transduction | 2017 |
Tumor-Stroma Crosstalk in Bone Tissue: The Osteoclastogenic Potential of a Breast Cancer Cell Line in a Co-Culture System and the Role of EGFR Inhibition.
Topics: Breast Neoplasms; Cell Communication; Cell Line, Tumor; Coculture Techniques; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Monocytes; Neoplasm Metastasis; Neoplasm Proteins; Osteoclasts; Quinazolines; Signal Transduction | 2017 |
Continued EGFR-TKI with concurrent radiotherapy to improve time to progression (TTP) in patients with locally progressive non-small cell lung cancer (NSCLC) after front-line EGFR-TKI treatment.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Chemoradiotherapy; Crown Ethers; Disease Progression; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy | 2018 |
Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade.
Topics: Animals; Caspase 3; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Fingolimod Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Insulin-Like Growth Factor Binding Protein 3; Mice; Phosphotransferases (Alcohol Group Acceptor); Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Mutation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Retrospective Studies; Signal Transduction; Time Factors; Treatment Outcome; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2017 |
The EGFR Inhibitor Gefitinib Enhanced the Response of Human Oral Squamous Cell Carcinoma to Cisplatin In Vitro.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Mouth Neoplasms; Quinazolines | 2017 |
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Sulfones | 2017 |
Combination Osimertinib and Gefitinib in C797S and T790M EGFR-Mutated Non-Small Cell Lung Cancer.
Topics: Acrylamides; Adult; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Piperazines; Quinazolines | 2017 |
Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; Forkhead Box Protein M1; Gefitinib; Gene Silencing; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Neoplastic Stem Cells; Niacinamide; Phenotype; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; RNA, Neoplasm; Signal Transduction; Sorafenib; Stathmin; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
Topics: ADAMTS Proteins; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Calcium-Binding Proteins; Calponins; Carcinoma, Non-Small-Cell Lung; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exome; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Genome-Wide Association Study; Humans; Lung Neoplasms; Male; Microfilament Proteins; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Tumor Suppressor Protein p53; Wnt Proteins | 2017 |
Gefitinib-loaded DSPE-PEG2000 nanomicelles with CD133 aptamers target lung cancer stem cells.
Topics: A549 Cells; AC133 Antigen; Animals; Antineoplastic Agents; Aptamers, Peptide; Drug Carriers; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, SCID; Nanoparticles; Neoplastic Stem Cells; Phosphatidylethanolamines; Polyethylene Glycols; Quinazolines; Xenograft Model Antitumor Assays | 2017 |
Pharmacological synergism of 2,2-dichloroacetophenone and EGFR-TKi to overcome TKi-induced resistance in NSCLC cells.
Topics: Acetophenones; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib Enhances Mitochondrial Biological Functions in NSCLCs with
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Aggregation; Cell Count; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Mutation; Quinazolines; Succinate Dehydrogenase | 2017 |
Effects of an Alkaline Diet on EGFR-TKI Therapy in EGFR Mutation-positive NSCLC.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Urine | 2017 |
Phenotype-driven precision oncology as a guide for clinical decisions one patient at a time.
Topics: Adaptor Proteins, Signal Transducing; Animals; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cisplatin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Head and Neck Neoplasms; Humans; Mice, Inbred NOD; Mouth Neoplasms; Phenotype; Phosphoproteins; Precision Medicine; Quinazolines; Transcription Factors; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2017 |
An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Topics: A549 Cells; Animals; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; B7-H1 Antigen; Bcl-2-Like Protein 11; Carcinoma, Non-Small-Cell Lung; CCAAT-Enhancer-Binding Protein-beta; Cell Movement; Disease-Free Survival; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Promoter Regions, Genetic; Protein Binding; Protein Kinase Inhibitors; Protein Stability; Quinazolines; RNA Interference; Signal Transduction; Time Factors; Transcription Factors; Transcription, Genetic; Transfection; Up-Regulation; Xenograft Model Antitumor Assays | 2017 |
Dual effects of a CpG-DNAzyme targeting mutant EGFR transcripts in lung cancer cells: TLR9 activation and EGFR downregulation.
Topics: Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; CpG Islands; DNA, Catalytic; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mutation; Quinazolines; RNA, Messenger; Toll-Like Receptor 9 | 2018 |
Induced sensitivity to EGFR inhibitors is mediated by palmitoylated cysteine 1025 of EGFR and requires oncogenic Kras.
Topics: Antineoplastic Agents; Apoptosis; Cocarcinogenesis; Cysteine; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lipoylation; MCF-7 Cells; Membrane Proteins; Mutation; Neoplasms, Experimental; Proto-Oncogene Proteins p21(ras); Quinazolines | 2017 |
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Quinazolines | 2017 |
Long noncoding RNA EGFR-AS1 mediates epidermal growth factor receptor addiction and modulates treatment response in squamous cell carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Gene Knockdown Techniques; Head and Neck Neoplasms; Humans; In Vitro Techniques; Male; Middle Aged; Molecular Targeted Therapy; Mouth Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA Isoforms; RNA Splicing; RNA, Long Noncoding; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2017 |
Design of gefitinib-loaded poly (l-lactic acid) microspheres via a supercritical anti-solvent process for dry powder inhalation.
Topics: A549 Cells; Administration, Inhalation; Drug Carriers; Drug Compounding; Dry Powder Inhalers; Gefitinib; Humans; Microspheres; Particle Size; Polyesters; Powders; Quinazolines; Solvents; Spectroscopy, Fourier Transform Infrared | 2017 |
Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Cycle Checkpoints; Cell Survival; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; Epithelial-Mesenchymal Transition; ErbB Receptors; Fatty Acids, Unsaturated; Flow Cytometry; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Survivin; Time Factors | 2017 |
Synthesis, in vitro antitumour activity, and molecular docking study of novel 2-substituted mercapto-3-(3,4,5-trimethoxybenzyl)-4(3H)-quinazolinone analogues.
Topics: Acetamides; Amides; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Models, Molecular; Molecular Docking Simulation; Molecular Structure; Protein Binding; Quinazolines; Quinazolinones | 2017 |
In vitro and in vivo antitumor effect of gefitinib nanoparticles on human lung cancer.
Topics: Cell Line, Tumor; Gefitinib; Humans; Lung Neoplasms; Nanoparticles; Quinazolines | 2017 |
EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents.
Topics: A549 Cells; Antineoplastic Agents; Antioxidants; Binding Sites; Cell Line, Tumor; Cell Survival; Drug Design; ErbB Receptors; Gefitinib; HEK293 Cells; HeLa Cells; Humans; Hydrogen Bonding; Imidazoles; Molecular Docking Simulation; Morpholines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Receptor, ErbB-2; Structure-Activity Relationship; Thermodynamics | 2017 |
mAb MDR1-modified chitosan nanoparticles overcome acquired EGFR-TKI resistance through two potential therapeutic targets modulation of MDR1 and autophagy.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Autophagy; Cell Line, Tumor; Chitosan; Chloroquine; Drug Delivery Systems; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Nanoparticles; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2017 |
Gefitinib inhibits M2-like polarization of tumor-associated macrophages in Lewis lung cancer by targeting the STAT6 signaling pathway.
Topics: Animals; Antineoplastic Agents; Carcinoma, Lewis Lung; Cell Line, Tumor; Cell Movement; Cell Plasticity; Cell Proliferation; Dose-Response Relationship, Drug; Gefitinib; Interleukin-13; Macrophages; Mice; Mice, Inbred C57BL; Neoplasm Invasiveness; Phenotype; Protein Kinase Inhibitors; Quinazolines; RAW 264.7 Cells; Signal Transduction; STAT6 Transcription Factor | 2017 |
Gefitinib and pyrrolidine dithiocarbamate decrease viral replication and cytokine production in dengue virus infected human monocyte cultures.
Topics: Adult; Animals; Antiviral Agents; Cell Line; Cells, Cultured; Culicidae; Cytokines; Dengue; Dengue Virus; ErbB Receptors; Gefitinib; Humans; Male; Monocytes; NF-kappa B; Nod2 Signaling Adaptor Protein; Protein Kinase Inhibitors; Pyrrolidines; Quinazolines; Thiocarbamates; Virus Replication | 2017 |
Delayed Sequential Co-Delivery of Gefitinib and Doxorubicin for Targeted Combination Chemotherapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Doxorubicin; ErbB Receptors; Female; Gefitinib; Humans; Hydrogen-Ion Concentration; Inhibitory Concentration 50; Lactates; Mice; Nanocapsules; Polyethylene Glycols; Quinazolines; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
PPARγ agonist efatutazone and gefitinib synergistically inhibit the proliferation of EGFR-TKI-resistant lung adenocarcinoma cells via the PPARγ/PTEN/Akt pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Differentiation; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Signal Transduction; Survival Analysis; Thiazolidinediones | 2017 |
Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associated NEU3.
Topics: Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Membrane; Electrophoresis, Polyacrylamide Gel; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Neuraminidase; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Signal Transduction | 2017 |
Adverse Prognostic CT Findings for Patients With Advanced Lung Adenocarcinoma Receiving First-Line Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapy.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Pleural Effusion; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Tomography, X-Ray Computed; Young Adult | 2018 |
A Targetable EGFR-Dependent Tumor-Initiating Program in Breast Cancer.
Topics: Animals; BRCA1 Protein; ErbB Receptors; Female; Gefitinib; Humans; Mesenchymal Stem Cells; Mice; Mice, Inbred NOD; Mice, SCID; Microscopy, Fluorescence; Protein Kinase Inhibitors; Quinazolines; RNA, Neoplasm; Sequence Analysis, RNA; Triple Negative Breast Neoplasms; Xenograft Model Antitumor Assays | 2017 |
Design, synthesis and evaluation of alkylphosphocholine-gefitinib conjugates as multitarget anticancer agents.
Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Molecular Structure; Phosphorylation; Phosphorylcholine; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2018 |
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine | 2017 |
Potential influence of interleukin-6 on the therapeutic effect of gefitinib in patients with advanced non-small cell lung cancer harbouring EGFR mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Genetic Predisposition to Disease; Humans; Interleukin-6; Japan; Lung Neoplasms; Male; Middle Aged; Mutation; Prevalence; Quinazolines; Risk Factors; Survival Rate; Treatment Outcome | 2018 |
Suppressors for Human Epidermal Growth Factor Receptor 2/4 (HER2/4): A New Family of Anti-Toxoplasmic Agents in ARPE-19 Cells.
Topics: Afatinib; Aminoquinolines; Aniline Compounds; Animals; Cell Line; Gefitinib; Humans; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; Quinazolinones; Quinolines; Receptor, ErbB-2; Toxoplasma; Tyrphostins | 2017 |
Bioisostere Identification by Determining the Amino Acid Binding Preferences of Common Chemical Fragments.
Topics: Amino Acids; Animals; Binding Sites; Cluster Analysis; Computer-Aided Design; Databases, Pharmaceutical; Databases, Protein; Drug Design; ErbB Receptors; Gefitinib; Humans; Hydrogen Bonding; Ligands; Models, Molecular; Protein Conformation; Proteins; Quinazolines | 2017 |
A method of high-throughput functional evaluation of
Topics: 3T3 Cells; Animals; Antineoplastic Agents; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; HEK293 Cells; Humans; Mice; Mutation; Quinazolines | 2017 |
Combined SN-38 and gefitinib treatment promotes CD44 degradation in head and neck squamous cell carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Squamous Cell; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gefitinib; Head and Neck Neoplasms; Humans; Hyaluronan Receptors; Irinotecan; Lysosomes; Mice; Proteolysis; Quinazolines; Squamous Cell Carcinoma of Head and Neck; Xenograft Model Antitumor Assays | 2018 |
Up-regulation of YPEL1 and YPEL5 and down-regulation of ITGA2 in erlotinib-treated EGFR-mutant non-small cell lung cancer: A bioinformatic analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; China; Computational Biology; Down-Regulation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Nuclear Proteins; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Transcriptional Activation; Up-Regulation | 2018 |
Elevation of sensitivity to anticancer agents of human lung adenocarcinoma A549 cells by knockdown of claudin-2 expression in monolayer and spheroid culture models.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Cell Nucleus; Cell Proliferation; Cisplatin; Claudin-2; Doxorubicin; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Quinazolines; Spheroids, Cellular | 2018 |
MiR-181a contributes gefitinib resistance in non-small cell lung cancer cells by targeting GAS7.
Topics: Biomarkers, Tumor; China; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; MicroRNAs; Nerve Tissue Proteins; Protein Kinase Inhibitors; Quinazolines; Risk Factors; Survival Rate | 2018 |
Utilization of Molecular Testing and Survival Outcomes of Treatment with First- or Second-line Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer in a Dutch Population.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Diagnostic Techniques; Netherlands; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Downregulation of MicroRNA-135 Promotes Sensitivity of Non-Small Cell Lung Cancer to Gefitinib by Targeting TRIM16.
Topics: Antineoplastic Agents; Apoptosis; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; DNA-Binding Proteins; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; MicroRNAs; Quinazolines; Transcription Factors; Tripartite Motif Proteins; Tumor Cells, Cultured; Ubiquitin-Protein Ligases; Xenograft Model Antitumor Assays | 2018 |
A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.
Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2018 |
Alterations of Gefitinib Pharmacokinetics by Co-administration of Herbal Medications in Rats.
Topics: Animals; Chromatography, Liquid; Dose-Response Relationship, Drug; Drugs, Chinese Herbal; Gefitinib; Male; Quinazolines; Rats, Sprague-Dawley; Tandem Mass Spectrometry; Time Factors | 2018 |
Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell Survival; Down-Regulation; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Drug Synergism; ErbB Receptors; Female; Gefitinib; Gene Knockdown Techniques; Heterocyclic Compounds, 3-Ring; Humans; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Regulatory-Associated Protein of mTOR; Ribosomal Protein S6; RNA, Small Interfering; Signal Transduction; TOR Serine-Threonine Kinases; Triple Negative Breast Neoplasms | 2018 |
[Clinical Observation of Gefitinib with Pericardial Perfusion for
Advanced Non-small Cell Lung Cancer].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Perfusion; Pericardial Effusion; Pericardium; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
Multiple single cell screening and DNA MDA amplification chip for oncogenic mutation profiling.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; DNA Mutational Analysis; DNA, Neoplasm; Drug Screening Assays, Antitumor; Gefitinib; HEK293 Cells; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred C57BL; Microfluidic Analytical Techniques; Mutation; Nucleic Acid Amplification Techniques; Oligonucleotide Array Sequence Analysis; Polymerase Chain Reaction; Quinazolines; Single-Cell Analysis | 2018 |
Investigation of the binding characteristics between ligands and epidermal growth factor receptor by cell membrane chromatography.
Topics: Afatinib; Cell Membrane; Chromatography; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; HEK293 Cells; Humans; Ligands; Molecular Docking Simulation; Morpholines; Piperidines; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Computational screening, ensemble docking and pharmacophore analysis of potential gefitinib analogues against epidermal growth factor receptor.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Ligands; Molecular Docking Simulation; Mutation; Protein Binding; Protein Kinase Inhibitors; Quinazolines | 2018 |
Prognostic Significance of NSCLC and Response to EGFR-TKIs of EGFR-Mutated NSCLC Based on PD-L1 Expression.
Topics: Aged; B7-H1 Antigen; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2018 |
Global named patient use program of afatinib in advanced non-small-cell lung carcinoma patients who progressed following prior therapies.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Selection; Program Evaluation; Protein Kinase Inhibitors; Quinazolines; Time Factors; Treatment Failure | 2018 |
PPARgamma agonists sensitize PTEN-deficient resistant lung cancer cells to EGFR tyrosine kinase inhibitors by inducing autophagy.
Topics: Antineoplastic Agents; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; PPAR gamma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; Rosiglitazone; Thiazolidinediones | 2018 |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain.
Topics: Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Spain; Treatment Outcome | 2018 |
Sensitivity to chemotherapeutics of NSCLC cells with acquired resistance to EGFR-TKIs is mediated by T790M mutation or epithelial-mesenchymal transition.
Topics: Biomarkers, Tumor; Bridged-Ring Compounds; Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Gene Knockdown Techniques; Humans; Mutation; Neoplastic Stem Cells; Paclitaxel; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2018 |
Losmapimod Overcomes Gefitinib Resistance in Non-small Cell Lung Cancer by Preventing Tetraploidization.
Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cyclopropanes; Drug Resistance, Neoplasm; Enzyme Activation; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Mice; p38 Mitogen-Activated Protein Kinases; Phosphoproteins; Phosphorylation; Pyridines; Quinazolines; Tetraploidy; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death.
Topics: Antineoplastic Agents; Apoptosis; beta-D-Galactoside alpha 2-6-Sialyltransferase; Cell Line, Tumor; Drug Resistance, Neoplasm; Epidermal Growth Factor; ErbB Receptors; Gefitinib; Gene Expression; Gene Knockdown Techniques; Humans; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proteome; Proteomics; Quinazolines; Sialyltransferases; Signal Transduction | 2018 |
Vinorelbine Potently Induces Placental Cell Death, Does Not Harm Fertility and is a Potential Treatment for Ectopic Pregnancy.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Death; Cell Line; Cell Proliferation; Cell Survival; Disease Models, Animal; Female; Fertility; Gefitinib; Heterografts; Humans; Methotrexate; Mice; Microtubules; Miosis; Placenta; Pregnancy; Pregnancy, Ectopic; Quinazolines; Trophoblasts; Vinblastine; Vinorelbine | 2018 |
The clinical features of squamous cell lung carcinoma with sensitive EGFR mutations.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Squamous Cell; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
Adenocarcinoma of the lung with rare insertion mutation in EGFR exon 19 that had partial response to gefitinib: a case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Biopsy; DNA Mutational Analysis; ErbB Receptors; Exons; Female; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutagenesis, Insertional; Polymerase Chain Reaction; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Tomography, X-Ray Computed | 2017 |
Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis.
Topics: Amino Acids; Antineoplastic Agents; Cell Culture Techniques; Cell Death; Cell Line, Tumor; ErbB Receptors; Gefitinib; Humans; Quinazolines | 2018 |
Molecular Modeling, Docking, Dynamics and Simulation of Gefitinib and its Derivatives with EGFR in Non-small Cell Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computer-Aided Design; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Dynamics Simulation; Protein Kinase Inhibitors; Quinazolines; Software | 2018 |
Prediction of sensitivity to gefitinib/erlotinib for EGFR mutations in NSCLC based on structural interaction fingerprints and multilinear principal component analysis.
Topics: Carcinoma, Non-Small-Cell Lung; Computer Simulation; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Principal Component Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Detection of epidermal growth factor receptor mutation in the peripheral blood of patients with esophageal carcinoma to guide epidermal growth factor receptor-tyrosine kinase inhibitor treatment.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carcinoma; Disease Progression; DNA Mutational Analysis; ErbB Receptors; Esophageal Neoplasms; Female; Gefitinib; Humans; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Treatment Outcome | 2018 |
FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1 | 2018 |
Gefitinib inhibits retina angiogenesis by affecting VEGF signaling pathway.
Topics: Angiogenesis Inhibitors; Animals; Animals, Newborn; Cyclin E; Cyclin-Dependent Kinase 2; Disease Models, Animal; Gefitinib; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Oxygen; Platelet Endothelial Cell Adhesion Molecule-1; Quinazolines; Retinal Diseases; Retinal Vessels; Vascular Endothelial Growth Factor A | 2018 |
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.
Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cardiotonic Agents; Cardiovascular Diseases; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Nebivolol; Piperazines; Protein Kinase Inhibitors; Quinazolines; Ramipril | 2018 |
Daily or weekly dosing with EGFR inhibitors, gefitinib and lapatinib, and AKt inhibitor MK2206 in mammary cancer models.
Topics: Animals; Disease Models, Animal; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Heterocyclic Compounds, 3-Ring; Lapatinib; Male; Mammary Neoplasms, Experimental; Mice; Mice, Knockout; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; Triazoles | 2018 |
Comparative studies on the human serum albumin binding of the clinically approved EGFR inhibitors gefitinib, erlotinib, afatinib, osimertinib and the investigational inhibitor KP2187.
Topics: Acrylamides; Afatinib; Aniline Compounds; Binding Sites; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Hydrogen Bonding; Molecular Docking Simulation; Piperazines; Protein Binding; Protein Kinase Inhibitors; Quinazolines; Serum Albumin, Human; Solvents; Spectrometry, Fluorescence | 2018 |
Gefitinib inhibits malignant melanoma cells through the VEGF/AKT signaling pathway.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Movement; Cell Proliferation; Gefitinib; Humans; Melanoma; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Vascular Endothelial Growth Factor A | 2018 |
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines | 2018 |
Polymer nanofiber-based microchips for EGFR mutation analysis of circulating tumor cells in lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Count; Cell Line, Tumor; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Exons; Gefitinib; Humans; Lactic Acid; Lung Neoplasms; Male; Microarray Analysis; Middle Aged; Mutation; Nanofibers; Neoplastic Cells, Circulating; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Quinazolines; Reproducibility of Results | 2018 |
Phenethyl Isothiocyanate Induces Apoptotic Cell Death Through the Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells
Topics: Apoptosis; Calcium Signaling; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2018 |
Krüppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Gene Amplification; Humans; Kruppel-Like Factor 4; Kruppel-Like Transcription Factors; Lung Neoplasms; Male; Mice, Nude; Proto-Oncogene Proteins c-met; Quinazolines; RNA Interference; Tumor Burden; Xenograft Model Antitumor Assays | 2018 |
TW37 enhances the pro-apoptosis and anti-migration ability of gefitinib in Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzamides; Cell Line, Tumor; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Respiratory Mucosa; Signal Transduction; Sulfones | 2018 |
Mandibular metastasis as the first clinical indication of occult lung adenocarcinoma with multiple metastases: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Biopsy; Bone Density Conservation Agents; Diagnosis, Differential; Diphosphonates; Female; Gefitinib; Humans; Imidazoles; Immunohistochemistry; Lung; Lung Neoplasms; Mandible; Mandibular Neoplasms; Neoplasm Grading; Neoplasm Staging; Quinazolines; Thyroid Neoplasms; Treatment Outcome; Zoledronic Acid | 2018 |
A blood biomarker for monitoring response to anti-EGFR therapy.
Topics: Animals; Antineoplastic Agents; Biomarkers; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mice; Peroxiredoxin VI; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome; Xenograft Model Antitumor Assays | 2018 |
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Smoking; Treatment Outcome | 2018 |
MEF2C promotes gefitinib resistance in hepatic cancer cells through regulating MIG6 transcription.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Liver Neoplasms; MEF2 Transcription Factors; Mice; Mice, Nude; Promoter Regions, Genetic; Protein Kinase Inhibitors; Quinazolines; Transcription, Genetic; Tumor Suppressor Proteins; Up-Regulation | 2018 |
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma | 2018 |
Shikonin enhances sensitization of gefitinib against wild-type EGFR non-small cell lung cancer via inhibition PKM2/stat3/cyclinD1 signal pathway.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Carcinoma, Non-Small-Cell Lung; Carrier Proteins; Cell Line, Tumor; Cell Survival; Cyclin D1; Drug Synergism; ErbB Receptors; Gefitinib; Humans; Immunohistochemistry; Lung Neoplasms; Membrane Proteins; Mice; Mice, Nude; Naphthoquinones; Quinazolines; Signal Transduction; Sincalide; STAT3 Transcription Factor; Thyroid Hormone-Binding Proteins; Thyroid Hormones | 2018 |
Systematic bioinformatic approaches reveal novel gene expression signatures associated with acquired resistance to EGFR targeted therapy in lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Computational Biology; Databases, Genetic; Drug Resistance, Neoplasm; ELAV-Like Protein 1; ErbB Receptors; Erlotinib Hydrochloride; Estrogen Receptor alpha; Gefitinib; Gene Expression Regulation, Neoplastic; Gene Regulatory Networks; Humans; Lung Neoplasms; Oligonucleotide Array Sequence Analysis; Protein Kinase Inhibitors; Quinazolines | 2018 |
PD-L1 mRNA expression in EGFR-mutant lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Apoptosis; B7-H1 Antigen; Bcl-2-Like Protein 11; Biomarkers, Tumor; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Proteins; Neoplasm Recurrence, Local; Quinazolines; Vascular Endothelial Growth Factor A | 2018 |
Knockdown of annexin A5 restores gefitinib sensitivity by promoting G2/M cell cycle arrest.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Annexin A5; Antineoplastic Agents; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Quinazolines | 2018 |
Characteristics and outcomes of patients with EGFR-mutation positive non-small-cell lung cancer receiving gefitinib beyond radiological progression.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease Progression; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proportional Hazards Models; Prospective Studies; Quinazolines; Survival Rate | 2018 |
Gefitinib for Epidermal Growth Factor Receptor Activated Osteoarthritis Subpopulation Treatment.
Topics: Animals; Cartilage, Articular; Collagen Type II; Disease Models, Animal; ErbB Receptors; Gefitinib; Humans; Mice; Mice, Transgenic; Osteoarthritis; Precision Medicine; Quinazolines; Signal Transduction | 2018 |
Preliminary mechanisms of regulating PD‑L1 expression in non‑small cell lung cancer during the EMT process.
Topics: A549 Cells; Animals; B7-H1 Antigen; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Epithelial-Mesenchymal Transition; Female; Fibroblast Growth Factor 2; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Transforming Growth Factor beta1 | 2018 |
Relationship between Paronychia and Drug Concentrations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Topics: Afatinib; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Paronychia; Protein Kinase Inhibitors; Quinazolines | 2018 |
A novel strategy of EGFR‑TKI combined chemotherapy in the treatment of human lung cancer with EGFR‑sensitive mutation.
Topics: A549 Cells; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Drug Synergism; ErbB Receptors; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Mutation; Paclitaxel; Protein Kinase Inhibitors; Quinazolines | 2018 |
[The efficacy of TKIs in treatment of human primary small cell lung cancer xenograft model in vivo].
Topics: Afatinib; Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; Protein Kinase Inhibitors; Quinazolines; Xenograft Model Antitumor Assays | 2016 |
[Expression of Acetaldehyde Dehydrogenase in Gefitinib-resistant Human Lung Adenocarcinoma HCC-827/GR Cells].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aldehyde Oxidoreductases; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Quinazolines | 2018 |
Exposure to EGF and 17β‑estradiol irreversibly affects the proliferation and transformation of MCF7 cells but is not sufficient to promote tumor growth in a xenograft mouse model upon withdrawal of exposure.
Topics: Animals; Benzamides; Carcinogenesis; Cell Proliferation; Cell Transformation, Neoplastic; Dioxoles; Epidermal Growth Factor; Estradiol; Female; Gefitinib; Humans; MCF-7 Cells; Mice, SCID; Models, Biological; Neoplastic Stem Cells; Phenotype; Quinazolines; Spheroids, Cellular; Tamoxifen; Xenograft Model Antitumor Assays | 2018 |
PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Proto-Oncogene Proteins c-akt; Quinazolines; Receptors, Urokinase Plasminogen Activator; Signal Transduction; Survivin | 2018 |
An exosomal- and interfacial-biosensing based strategy for remote monitoring of aberrantly phosphorylated proteins in lung cancer cells.
Topics: Adsorption; Cell Line, Tumor; ErbB Receptors; Exosomes; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gold; Humans; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Quinazolines | 2018 |
HOTAIR, a long noncoding RNA, is a marker of abnormal cell cycle regulation in lung cancer.
Topics: Animals; Antineoplastic Agents; beta Catenin; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; E2F Transcription Factors; Epithelial-Mesenchymal Transition; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Quinazolines; Retinoblastoma Protein; RNA, Long Noncoding; Transplantation, Heterologous | 2018 |
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays | 2018 |
Synthesis, Biological Evaluation and Molecular Docking of Novel Indole-Aminoquinazoline Hybrids for Anticancer Properties.
Topics: A549 Cells; Aminoquinolines; Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; ErbB Receptors; Gefitinib; HeLa Cells; Humans; Indoles; MCF-7 Cells; Molecular Docking Simulation; Molecular Structure; Quinazolines; Structure-Activity Relationship | 2018 |
Efficacy of gefitinib‑celecoxib combination therapy in docetaxel‑resistant prostate cancer.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Celecoxib; Cell Proliferation; Cyclooxygenase 2 Inhibitors; Docetaxel; Drug Resistance, Neoplasm; Gefitinib; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Prostatic Neoplasms; Quinazolines; Taxoids; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
Discovery of 4,5-Dihydro-1
Topics: A549 Cells; ErbB Receptors; Gefitinib; Hep G2 Cells; Humans; Inhibitory Concentration 50; Molecular Docking Simulation; Protein Kinase Inhibitors; Pyrazoles; Quinazolines | 2018 |
Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticholesteremic Agents; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Cetuximab; Colorectal Neoplasms; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Phosphoproteins; Polyisoprenyl Phosphates; Protein Kinase Inhibitors; Quinazolines; Signal Transduction; Simvastatin; Transcription Factors; Tumor Cells, Cultured; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2018 |
Calpain 2 knockdown promotes cell apoptosis and restores gefitinib sensitivity through epidermal growth factor receptor/protein kinase B/survivin signaling.
Topics: Animals; Apoptosis; Biomarkers, Tumor; Calpain; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Movement; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Survivin; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |
EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice.
Topics: Animals; Cells, Cultured; Diabetes Mellitus, Experimental; Diabetic Cardiomyopathies; ErbB Receptors; Gefitinib; Mice; Mice, Inbred C57BL; Myocardium; Protein Kinase Inhibitors; Quinazolines; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium-Calcium Exchanger | 2018 |
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
Topics: Aged; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Meningeal Carcinomatosis; Pneumatosis Cystoides Intestinalis; Protein Kinase Inhibitors; Quinazolines | 2018 |
Novel β-phenylacrylic acid derivatives exert anti-cancer activity by inducing Src-mediated apoptosis in wild-type KRAS colon cancer.
Topics: Antineoplastic Agents; Apoptosis; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; ErbB Receptors; Gefitinib; Genes, src; HCT116 Cells; HT29 Cells; Humans; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins p21(ras); Quinazolines; Signal Transduction; src-Family Kinases | 2018 |
[112th Scientific Meeting of the Japanese Society of Internal Medicine: Presidential Lecture: Panel discussion: Preemptive Medicine from the Perspective of Physicians: Lung Cancer].
Topics: Antineoplastic Agents; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Benzyl Isothiocyanate Induces Apoptotic Cell Death Through Mitochondria-dependent Pathway in Gefitinib-resistant NCI-H460 Human Lung Cancer Cells
Topics: Apoptosis Regulatory Proteins; Caspases; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Lung Neoplasms; Membrane Potential, Mitochondrial; Mitochondria; Quinazolines; Reactive Oxygen Species; Signal Transduction | 2018 |
Leukocyte Telomere Length and Clinical Outcomes of Advanced Lung Adenocarcinoma Patients with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Agents; Biomarkers, Pharmacological; Cohort Studies; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Expression; Humans; Leukocytes; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Quinazolines; Survival Analysis; Telomere | 2018 |
An observational study of the epidermal growth factor receptor-tyrosine kinase inhibitor resistance mechanism in epidermal growth factor receptor gene mutation-positive non-small cell lung cancer.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Prospective Studies; Protein Kinase Inhibitors; Proteomics; Quinazolines; Research Design | 2018 |
Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations.
Topics: Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Consolidation Chemotherapy; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Pneumonectomy; Protein Kinase Inhibitors; Quinazolines; Radiosurgery; Retrospective Studies; Survival Analysis | 2019 |
[Effect of Fuzheng Kang'ai Recipe Combined Gefitinib on Lung Cancer A549 Cells and Its Mecha- nism Research].
Topics: A549 Cells; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drugs, Chinese Herbal; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Quinazolines | 2016 |
[Efficacy and Safety of Gefitinib as First-Line Chemotherapy for Elderly Patients with Advanced Non-Small Cell Lung Cancer(NSCLC)].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2019 |
Glycerol kinase 5 confers gefitinib resistance through SREBP1/SCD1 signaling pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Glycerol Kinase; Humans; Lung Neoplasms; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred BALB C; Protein Kinase Inhibitors; Quinazolines; RNA, Messenger; Signal Transduction; Stearoyl-CoA Desaturase; Sterol Regulatory Element Binding Protein 1; Up-Regulation | 2019 |
Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Design; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Molecular Docking Simulation; Molecular Structure; Protein Kinase Inhibitors; Quinazolines; Structure-Activity Relationship | 2019 |
Rationale for Using Irreversible Epidermal Growth Factor Receptor Inhibitors in Combination with Phosphatidylinositol 3-Kinase Inhibitors for Advanced Head and Neck Squamous Cell Carcinoma.
Topics: Afatinib; Cell Line, Tumor; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Head and Neck Neoplasms; Humans; Phosphoinositide-3 Kinase Inhibitors; Protein Kinase Inhibitors; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; Squamous Cell Carcinoma of Head and Neck; Sulfonamides | 2019 |
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult | 2019 |
Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Cycle Proteins; Cell Line, Tumor; Cisplatin; Crown Ethers; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; G2 Phase Cell Cycle Checkpoints; Gefitinib; Gemcitabine; Humans; Lung Neoplasms; Male; Middle Aged; Protein-Tyrosine Kinases; Quinazolines; RNA, Small Interfering | 2019 |
Yiqi Chutan Tang Reduces Gefitinib-Induced Drug Resistance in Non-Small-Cell Lung Cancer by Targeting Apoptosis and Autophagy.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2020 |
Sequential Administration of EGFR-TKI and Pemetrexed Achieved a Long Duration of Response in Advanced NSCLC Patients with EGFR-mutant Tumours.
Topics: Adenocarcinoma of Lung; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Prognosis; Quinazolines; Retrospective Studies; Survival Rate | 2019 |
Dual inhibition of EGFR and MET by Echinatin retards cell growth and induces apoptosis of lung cancer cells sensitive or resistant to gefitinib.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chalcones; Drug Resistance, Neoplasm; Endoplasmic Reticulum Chaperone BiP; ErbB Receptors; Gefitinib; Glycyrrhiza; Humans; Lung Neoplasms; Molecular Docking Simulation; Plant Roots; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines | 2020 |
Novel conjugates of endoperoxide and 4-anilinoquinazoline induce myeloma cell apoptosis by inhibiting the IGF1-R/AKT/mTOR signaling pathway.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Artemisinins; Cell Line, Tumor; Gefitinib; Humans; Multiple Myeloma; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Receptor, IGF Type 1; Signal Transduction; TOR Serine-Threonine Kinases | 2020 |
Overexpression of AGR2 Is Associated With Drug Resistance in Mutant Non-small Cell Lung Cancers.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Movement; Cell Proliferation; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mucoproteins; Mutation; Neoplasm Invasiveness; Oncogene Proteins; Protein Kinase Inhibitors; Quinazolines | 2020 |
Reduced expression of CYLD promotes cell survival and inflammation in gefitinib-treated NSCLC PC-9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Deubiquitinating Enzyme CYLD; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Genes, Tumor Suppressor; Humans; Inflammation; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2020 |
Gefitinib induced severe hyponatremia: A case report.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Hyponatremia; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines | 2021 |
Continued gefitinib retreatment beyond progression in patients with advanced non-small cell lung cancer harboring sensitive
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Middle Aged; Mutation; Protein Kinase Inhibitors; Quinazolines; Retreatment; Retrospective Studies | 2020 |
Comprehensive genomic profile of Chinese lung cancer patients and mutation characteristics of individuals resistant to icotinib/gefitinib.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Asian People; Biomarkers, Tumor; China; Crown Ethers; Drug Resistance, Neoplasm; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines | 2020 |
Survival analysis for older patients with epidermal growth factor receptor mutation-positive advanced non-small cell lung cancer after progression of first-line gefitinib.
Topics: Age Factors; Aged; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Survival Analysis | 2022 |
The Pharmacokinetics of Gefitinib in a Chinese Cancer Population Group: A Virtual Clinical Trials Population Study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; China; Gefitinib; Humans; Lung Neoplasms; Mutation; Population Groups; Quinazolines | 2021 |
Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L.
Topics: Aged; Disease-Free Survival; ErbB Receptors; Gefitinib; Humans; Japan; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Recurrence, Local; Prospective Studies; Protein Kinase Inhibitors; Quinazolines | 2021 |
A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Small Cell Lung Carcinoma; Survivin; Xenograft Model Antitumor Assays | 2021 |
Rhabdomyolysis Caused by Gefitinib Overdose.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Rhabdomyolysis | 2022 |
Simultaneous quantitative detection of afatinib, erlotinib, gefitinib, icotinib, osimertinib and their metabolites in plasma samples of patients with non-small cell lung cancer using liquid chromatography-tandem mass spectrometry.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromatography, Liquid; Crown Ethers; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Reproducibility of Results; Tandem Mass Spectrometry | 2022 |
Uncovering Molecular Mechanisms of Drug Resistance via Network-Constrained Common Structure Identification.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Black phosphorus nanoparticles for dual therapy of non-small cell lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Nanoparticles; Phosphorus; Protein Kinase Inhibitors; Quinazolines | 2022 |
Sulforaphane overcomes T790M-mediated gefitinib resistance in vitro through epithelial-mesenchymal transition.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; Isothiocyanates; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Sulfoxides | 2021 |
A Transcriptomic Approach to Elucidate the Mechanisms of Gefitinib-Induced Toxicity in Healthy Human Intestinal Organoids.
Topics: Aged; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Intestines; Male; Organoids; Quinazolines; Signal Transduction; Transcriptome; Tumor Suppressor Protein p53 | 2022 |
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
Topics: Afatinib; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Exons; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies | 2023 |
Proton pump inhibitors reduce the survival of advanced lung cancer patients with therapy of gefitinib or erlotinib.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Histamine H2 Antagonists; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines | 2022 |
Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer.
Topics: Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment; Vascular Endothelial Growth Factor A | 2023 |
Uncovering the Molecular Basis for the Better Gefitinib Sensitivity of EGFR with Complex Mutations over Single Rare Mutation: Insights from Molecular Simulations.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Targeted Co-Delivery of Gefitinib and Rapamycin by Aptamer-Modified Nanoparticles Overcomes EGFR-TKI Resistance in NSCLC via Promoting Autophagy.
Topics: Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Combinations; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nanoparticles; Protein Kinase Inhibitors; Quinazolines; Sirolimus | 2022 |
Activation of the HSP27-AKT axis contributes to gefitinib resistance in non-small cell lung cancer cells independent of EGFR mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; HSP27 Heat-Shock Proteins; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2022 |
Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Nucleotides; Polymorphism, Single Nucleotide; Quinazolines; Retrospective Studies | 2022 |
Chlorpromazine cooperatively induces apoptosis with tyrosine kinase inhibitors in EGFR-mutated lung cancer cell lines and restores the sensitivity to gefitinib in T790M-harboring resistant cells.
Topics: Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorpromazine; Drug Resistance, Neoplasm; ErbB Receptors; Everolimus; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Plasma exosomal DOK3 reflects immunological states in lung tumor and predicts prognosis of gefitinib treatment.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; CD8-Positive T-Lymphocytes; ErbB Receptors; Exosomes; Gefitinib; Humans; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Proteomics; Quinazolines | 2022 |
SH005S7 Overcomes Primary and Acquired Resistance of Non-Small Cell Lung Cancer by Combined MET/EGFR/HER3 Inhibition.
Topics: Animals; Apoptosis; Bromodeoxyuridine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Ki-67 Antigen; Lung Neoplasms; Matrix Metalloproteinase 9; Mice; Mice, Nude; Proliferating Cell Nuclear Antigen; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; Quinazolines; Tumor Necrosis Factor-alpha; Vimentin | 2022 |
Role of allogeneic natural killer T cells in the treatment of a patient with gefitinib-sensitive lung adenocarcinoma.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Hematopoietic Stem Cell Transplantation; Humans; Lung Neoplasms; Mutation; Natural Killer T-Cells; Protein Kinase Inhibitors; Quinazolines | 2022 |
Gefitinib enhances the anti‑tumor immune response against EGFR‑mutated NSCLC by upregulating B7H5 expression and activating T cells via CD28H.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Immunity; Leukocytes, Mononuclear; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; T-Lymphocytes | 2022 |
The Effect of Gefitinib on Treatment Necessity and Prognosis of NSCLC Patients with Early EGFR Mutations.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Quinazolines | 2022 |
Raloxifene potentiates the effect of gefitinib in triple-negative breast cancer cell lines.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Endothelial Cells; Gefitinib; Humans; Protein Kinase Inhibitors; Quinazolines; Raloxifene Hydrochloride; Triple Negative Breast Neoplasms | 2022 |
Macrophage renewal modes affect acquired resistance to gefitinib in EGFR‑mutant lung cancer PC‑9 cells.
Topics: Antineoplastic Agents; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Macrophages; Protein Kinase Inhibitors; Quinazolines; Tumor Microenvironment | 2023 |
Osteosclerotic change as a therapeutic response to gefitinib in symptomatic non-small cell lung cancer bone metastasis.
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2022 |
Ultrasound-mediated mesoporous silica nanoparticles loaded with PDLIM5 siRNA inhibit gefitinib resistance in NSCLC cells by attenuating EMT.
Topics: Adaptor Proteins, Signal Transducing; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gefitinib; Humans; LIM Domain Proteins; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; RNA, Small Interfering; Ultrasonography | 2023 |
Study on the hepatotoxicity and potential mechanism of gefitinib based on CYP450 in mice and AML12 cells.
Topics: Animals; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP1A1; Drug-Related Side Effects and Adverse Reactions; Gefitinib; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Quinazolines; RNA, Messenger | 2023 |
Clinical impact of tetracyclines and/or proton pump inhibitors on the efficacy of epidermal growth factor receptor inhibitors in non-small cell lung cancer: a retrospective cohort study.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proton Pump Inhibitors; Quinazolines; Retrospective Studies; Tetracyclines | 2023 |
[Gefitinib Monotherapy Afforded Long-Term Survival of an Octogenarian Patient with a Postoperative Recurrence of a Pulmonary Adenocarcinoma-A Case Report].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Octogenarians; Quinazolines | 2023 |
Dihydroartemisinin enhances gefitinib cytotoxicity against lung adenocarcinoma cells by inducing ROS-dependent apoptosis and ferroptosis.
Topics: Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Ferroptosis; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Methyltransferases; NLR Family, Pyrin Domain-Containing 3 Protein; Protein Kinase Inhibitors; Pyroptosis; Quinazolines; RNA, Long Noncoding | 2023 |
The Underlying Mechanism Involved in Gefitinib Resistance and Corresponding Experiment Validation in Lung Cancer.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; TOR Serine-Threonine Kinases; Tumor Microenvironment | 2023 |
Pemetrexed induces ROS generation and cellular senescence by attenuating TS-mediated thymidylate metabolism to reverse gefitinib resistance in NSCLC.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cellular Senescence; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Reactive Oxygen Species | 2023 |
Methylseleninic acid overcomes gefitinib resistance through asparagine-MET-TOPK signaling axis in non-small cell lung cancer cells.
Topics: Antineoplastic Agents; Asparagine; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2023 |
BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Phosphatidylinositol 3-Kinase; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines | 2023 |
RAGE potentiates EGFR signaling and interferes with the anticancer effect of gefitinib on NSCLC cells.
Topics: Carcinogenesis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Humans; Ligands; Lung Neoplasms; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Receptor for Advanced Glycation End Products | 2023 |
Gefitinib, an effective treatment option for patients with pulmonary enteric adenocarcinoma harboring compound EGFR L858R and A871G mutation.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2023 |
Targeting MET endocytosis or degradation to overcome HGF-induced gefitinib resistance in EGFR-sensitive mutant lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; Endocytosis; ErbB Receptors; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2023 |
Design, synthesis and biological evaluation of small molecule fluorescent probes targeting EGFR for tumor detection and treatment.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; ErbB Receptors; Fluorescent Dyes; Gefitinib; Humans; Lung Neoplasms; Mice; Neoplasms; Quinazolines | 2023 |